ID AAMP_HUMAN Reviewed; 434 AA. AC Q13685; Q8WUJ9; Q96H92; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 26-APR-2005, sequence version 2. DT 28-JAN-2026, entry version 196. DE RecName: Full=Angio-associated migratory cell protein; GN Name=AAMP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=7743515; RA Beckner M.E., Krutzsch H.C., Stracke M.L., Williams S.T., Gallardo J.A., RA Liotta L.A.; RT "Identification of a new immunoglobulin superfamily protein expressed in RT blood vessels with a heparin-binding consensus sequence."; RL Cancer Res. 55:2140-2149(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Ovary, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10329261; DOI=10.1006/mvre.1999.2144; RA Beckner M.E., Peterson V.A., Moul D.E.; RT "Angio-associated migratory cell protein is expressed as an extracellular RT protein by blood-vessel-associated mesenchymal cells."; RL Microvasc. Res. 57:347-352(1999). RN [5] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18634987; DOI=10.1016/j.jacc.2008.03.055; RA Vogt F., Zernecke A., Beckner M., Krott N., Bosserhoff A.-K., Hoffmann R., RA Zandvoort M.A.M.J., Jahnke T., Kelm M., Weber C., Blindt R.; RT "Blockade of angio-associated migratory cell protein inhibits smooth muscle RT cell migration and neointima formation in accelerated atherosclerosis."; RL J. Am. Coll. Cardiol. 52:302-311(2008). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Plays a role in angiogenesis and cell migration. In smooth CC muscle cell migration, may act through the RhoA pathway. CC {ECO:0000269|PubMed:10329261, ECO:0000269|PubMed:18634987}. CC -!- INTERACTION: CC Q13685; Q8WTP8: AEN; NbExp=2; IntAct=EBI-727274, EBI-8637627; CC Q13685; Q8WTP8-2: AEN; NbExp=4; IntAct=EBI-727274, EBI-12119298; CC -!- SUBCELLULAR LOCATION: Cell membrane. Cytoplasm. CC -!- TISSUE SPECIFICITY: Expressed in metastatic melanoma, liver, skin, CC kidney, heart, lung, lymph node, skeletal muscle and brain, and also in CC A2058 melanoma cells and activated T-cells (at protein level). CC Expressed in blood vessels. Strongly expressed in endothelial cells, CC cytotrophoblasts, and poorly differentiated. colon adenocarcinoma cells CC found in lymphatics. {ECO:0000269|PubMed:10329261, CC ECO:0000269|PubMed:7743515}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA68889.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=CAG33036.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/533/AAMP"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95627; AAA68889.1; ALT_INIT; mRNA. DR EMBL; CR456755; CAG33036.1; ALT_INIT; mRNA. DR EMBL; BC008809; AAH08809.2; -; mRNA. DR EMBL; BC020244; AAH20244.1; -; mRNA. DR EMBL; BC039866; AAH39866.2; -; mRNA. DR CCDS; CCDS33378.1; -. DR PIR; I39383; I39383. DR RefSeq; NP_001078.2; NM_001087.5. DR AlphaFoldDB; Q13685; -. DR SMR; Q13685; -. DR BioGRID; 106532; 80. DR FunCoup; Q13685; 1643. DR IntAct; Q13685; 35. DR MINT; Q13685; -. DR STRING; 9606.ENSP00000403343; -. DR GlyGen; Q13685; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13685; -. DR PhosphoSitePlus; Q13685; -. DR BioMuta; AAMP; -. DR DMDM; 62906874; -. DR jPOST; Q13685; -. DR MassIVE; Q13685; -. DR PaxDb; 9606-ENSP00000248450; -. DR PeptideAtlas; Q13685; -. DR ProteomicsDB; 59660; -. DR Pumba; Q13685; -. DR Antibodypedia; 34259; 171 antibodies from 30 providers. DR DNASU; 14; -. DR Ensembl; ENST00000248450.9; ENSP00000248450.4; ENSG00000127837.11. DR GeneID; 14; -. DR KEGG; hsa:14; -. DR MANE-Select; ENST00000248450.9; ENSP00000248450.4; NM_001087.5; NP_001078.2. DR UCSC; uc002vhk.4; human. DR AGR; HGNC:18; -. DR ClinPGx; PA24365; -. DR CTD; 14; -. DR DisGeNET; 14; -. DR GeneCards; AAMP; -. DR HGNC; HGNC:18; AAMP. DR HPA; ENSG00000127837; Low tissue specificity. DR MalaCards; AAMP; -. DR MIM; 603488; gene. DR OpenTargets; ENSG00000127837; -. DR VEuPathDB; HostDB:ENSG00000127837; -. DR eggNOG; KOG0296; Eukaryota. DR GeneTree; ENSGT00940000153648; -. DR HOGENOM; CLU_000288_57_9_1; -. DR InParanoid; Q13685; -. DR OMA; GPDEVMW; -. DR OrthoDB; 10261640at2759; -. DR PAN-GO; Q13685; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q13685; -. DR PathwayCommons; Q13685; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-177929; Signaling by EGFR. DR Reactome; R-HSA-194138; Signaling by VEGF. DR Reactome; R-HSA-428930; Thromboxane signalling through TP receptor. DR SignaLink; Q13685; -. DR Agora; ENSG00000127837; -. DR BioGRID-ORCS; 14; 753 hits in 1174 CRISPR screens. DR ChiTaRS; AAMP; human. DR GeneWiki; AAMP_(gene); -. DR GenomeRNAi; 14; -. DR Pharos; Q13685; Tbio. DR PRO; PR:Q13685; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q13685; protein. DR Bgee; ENSG00000127837; Expressed in body of stomach and 200 other cell types or tissues. DR ExpressionAtlas; Q13685; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0045171; C:intercellular bridge; IDA:HPA. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0008201; F:heparin binding; IDA:GO_Central. DR GO; GO:0001525; P:angiogenesis; NAS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB. DR GO; GO:0014909; P:smooth muscle cell migration; IEP:UniProtKB. DR CDD; cd00200; WD40; 1. DR FunFam; 2.130.10.10:FF:000074; Angio-associated migratory cell protein-like protein; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR InterPro; IPR019775; WD40_repeat_CS. DR InterPro; IPR036322; WD40_repeat_dom_sf. DR InterPro; IPR001680; WD40_rpt. DR InterPro; IPR051179; WD_repeat_multifunction. DR PANTHER; PTHR19857:SF8; ANGIO-ASSOCIATED MIGRATORY CELL PROTEIN; 1. DR PANTHER; PTHR19857; MITOCHONDRIAL DIVISION PROTEIN 1-RELATED; 1. DR Pfam; PF00400; WD40; 6. DR SMART; SM00320; WD40; 8. DR SUPFAM; SSF50978; WD40 repeat-like; 1. DR PROSITE; PS00678; WD_REPEATS_1; 1. DR PROSITE; PS50082; WD_REPEATS_2; 6. DR PROSITE; PS50294; WD_REPEATS_REGION; 1. PE 1: Evidence at protein level; KW Angiogenesis; Cell membrane; Cytoplasm; Developmental protein; KW Differentiation; Direct protein sequencing; Membrane; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; WD repeat. FT CHAIN 1..434 FT /note="Angio-associated migratory cell protein" FT /id="PRO_0000050832" FT REPEAT 89..129 FT /note="WD 1" FT REPEAT 132..171 FT /note="WD 2" FT REPEAT 173..212 FT /note="WD 3" FT REPEAT 214..254 FT /note="WD 4" FT REPEAT 258..299 FT /note="WD 5" FT REPEAT 315..354 FT /note="WD 6" FT REPEAT 356..395 FT /note="WD 7" FT REPEAT 398..433 FT /note="WD 8" FT REGION 1..63 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 39..62 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 20 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT VARIANT 250 FT /note="I -> V (in dbSNP:rs2305835)" FT /id="VAR_037061" SQ SEQUENCE 434 AA; 46751 MW; A7B8314442EBAF15 CRC64; MESESESGAA ADTPPLETLS FHGDEEIIEV VELDPGPPDP DDLAQEMEDV DFEEEEEEEG NEEGWVLEPQ EGVVGSMEGP DDSEVTFALH SASVFCVSLD PKTNTLAVTG GEDDKAFVWR LSDGELLFEC AGHKDSVTCA GFSHDSTLVA TGDMSGLLKV WQVDTKEEVW SFEAGDLEWM EWHPRAPVLL AGTADGNTWM WKVPNGDCKT FQGPNCPATC GRVLPDGKRA VVGYEDGTIR IWDLKQGSPI HVLKGTEGHQ GPLTCVAANQ DGSLILTGSV DCQAKLVSAT TGKVVGVFRP ETVASQPSLG EGEESESNSV ESLGFCSVMP LAAVGYLDGT LAIYDLATQT LRHQCQHQSG IVQLLWEAGT AVVYTCSLDG IVRLWDARTG RLLTDYRGHT AEILDFALSK DASLVVTTSG DHKAKVFCVQ RPDR // ID ABCB5_HUMAN Reviewed; 1257 AA. AC Q2M3G0; A4D131; A7BKA4; B5MD19; B7WPL1; F8QQP8; F8QQP9; J3KQ04; Q2M3I5; AC Q5I5Q7; Q5I5Q8; Q6KG50; Q6XFQ5; Q8IXA1; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2014, sequence version 4. DT 28-JAN-2026, entry version 160. DE RecName: Full=ATP-binding cassette sub-family B member 5 {ECO:0000305}; DE AltName: Full=ABCB5 P-gp; DE AltName: Full=P-glycoprotein ABCB5; DE EC=7.6.2.2 {ECO:0000269|PubMed:22306008}; GN Name=ABCB5 {ECO:0000312|HGNC:HGNC:46}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND VARIANT LYS-970. RC TISSUE=Melanocyte, and Melanoma; RX PubMed=12960149; DOI=10.1074/jbc.m308700200; RA Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D., Doeing C., RA Sayegh M.H., Frank M.H.; RT "Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel RT human ATP-binding cassette transporter."; RL J. Biol. Chem. 278:47156-47165(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANTS GLU-560 AND RP LYS-970, AND TISSUE SPECIFICITY. RC TISSUE=Melanoma; RX PubMed=15760339; DOI=10.1111/j.1600-0749.2005.00214.x; RA Chen K.G., Szakacs G., Annereau J.-P., Rouzaud F., Liang X.-J., RA Valencia J.C., Nagineni C.N., Hooks J.J., Hearing V.J., Gottesman M.M.; RT "Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of RT the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and RT melanocytes."; RL Pigment Cell Res. 18:102-112(2005). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Colon adenocarcinoma; RX PubMed=21652540; DOI=10.1158/0008-5472.can-11-0221; RA Wilson B.J., Schatton T., Zhan Q., Gasser M., Ma J., Saab K.R., RA Schanche R., Waaga-Gasser A.M., Gold J.S., Huang Q., Murphy G.F., RA Frank M.H., Frank N.Y.; RT "ABCB5 identifies a therapy-refractory tumor cell population in colorectal RT cancer patients."; RL Cancer Res. 71:5307-5316(2011). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, VARIANT LYS-970, AND RP CATALYTIC ACTIVITY. RC TISSUE=Prostate, and Testis; RX PubMed=22306008; DOI=10.1016/j.bbrc.2012.01.090; RA Kawanobe T., Kogure S., Nakamura S., Sato M., Katayama K., Mitsuhashi J., RA Noguchi K., Sugimoto Y.; RT "Expression of human ABCB5 confers resistance to taxanes and RT anthracyclines."; RL Biochem. Biophys. Res. Commun. 418:736-741(2012). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT LYS-970. RA Meij I.C., van Aubel R., Tammur J., Dean M., Russel F.G., Allikmets R., RA Cremers F.P.M.; RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LYS-970. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Melanoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP FUNCTION. RX PubMed=15205344; DOI=10.1158/0008-5472.can-03-3884; RA Huang Y., Anderle P., Bussey K.J., Barbacioru C., Shankavaram U., Dai Z., RA Reinhold W.C., Papp A., Weinstein J.N., Sadee W.; RT "Membrane transporters and channels: role of the transportome in cancer RT chemosensitivity and chemoresistance."; RL Cancer Res. 64:4294-4301(2004). RN [11] RP FUNCTION. RX PubMed=15899824; DOI=10.1158/0008-5472.can-04-3327; RA Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M., RA Gasser M., Sayegh M.H., Sadee W., Frank M.H.; RT "ABCB5-mediated doxorubicin transport and chemoresistance in human RT malignant melanoma."; RL Cancer Res. 65:4320-4333(2005). RN [12] RP TISSUE SPECIFICITY. RX PubMed=22784549; DOI=10.1016/j.ejca.2012.05.027; RA Grimm M., Krimmel M., Polligkeit J., Alexander D., Munz A., Kluba S., RA Keutel C., Hoffmann J., Reinert S., Hoefert S.; RT "ABCB5 expression and cancer stem cell hypothesis in oral squamous cell RT carcinoma."; RL Eur. J. Cancer 48:3186-3197(2012). RN [13] RP TISSUE SPECIFICITY. RX PubMed=22044138; DOI=10.3109/10428194.2011.637214; RA Yang M., Li W., Fan D., Yan Y., Zhang X., Zhang Y., Xiong D.; RT "Expression of ABCB5 gene in hematological malignances and its RT significance."; RL Leuk. Lymphoma 53:1211-1215(2012). RN [14] RP TISSUE SPECIFICITY. RX PubMed=22675422; DOI=10.1371/journal.pone.0036762; RA Chartrain M., Riond J., Stennevin A., Vandenberghe I., Gomes B., Lamant L., RA Meyer N., Gairin J.E., Guilbaud N., Annereau J.P.; RT "Melanoma chemotherapy leads to the selection of ABCB5-expressing cells."; RL PLoS ONE 7:E36762-E36762(2012). RN [15] RP TISSUE SPECIFICITY. RX PubMed=23770371; DOI=10.1016/j.bbrc.2013.06.006; RA Lin J.Y., Zhang M., Schatton T., Wilson B.J., Alloo A., Ma J., RA Qureshi A.A., Frank N.Y., Han J., Frank M.H.; RT "Genetically determined ABCB5 functionality correlates with pigmentation RT phenotype and melanoma risk."; RL Biochem. Biophys. Res. Commun. 436:536-542(2013). RN [16] RP TISSUE SPECIFICITY. RX PubMed=24934811; DOI=10.1158/0008-5472.can-14-0582; RA Wilson B.J., Saab K.R., Ma J., Schatton T., Putz P., Zhan Q., Murphy G.F., RA Gasser M., Waaga-Gasser A.M., Frank N.Y., Frank M.H.; RT "ABCB5 maintains melanoma-initiating cells through a pro-inflammatory RT cytokine signaling circuit."; RL Cancer Res. 74:4196-4207(2014). RN [17] RP VARIANT [LARGE SCALE ANALYSIS] VAL-675. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [18] RP VARIANT [LARGE SCALE ANALYSIS] THR-880. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). RN [19] RP TISSUE SPECIFICITY. RX PubMed=25030174; DOI=10.1038/nature13426; RA Ksander B.R., Kolovou P.E., Wilson B.J., Saab K.R., Guo Q., Ma J., RA McGuire S.P., Gregory M.S., Vincent W.J., Perez V.L., Cruz-Guilloty F., RA Kao W.W., Call M.K., Tucker B.A., Zhan Q., Murphy G.F., Lathrop K.L., RA Alt C., Mortensen L.J., Lin C.P., Zieske J.D., Frank M.H., Frank N.Y.; RT "ABCB5 is a limbal stem cell gene required for corneal development and RT repair."; RL Nature 511:353-357(2014). CC -!- FUNCTION: Energy-dependent efflux transporter responsible for decreased CC drug accumulation in multidrug-resistant cells (PubMed:12960149, CC PubMed:15205344, PubMed:15899824, PubMed:22306008). Specifically CC present in limbal stem cells, where it plays a key role in corneal CC development and repair (By similarity). {ECO:0000250|UniProtKB:B5X0E4, CC ECO:0000269|PubMed:12960149, ECO:0000269|PubMed:15205344, CC ECO:0000269|PubMed:15899824, ECO:0000269|PubMed:22306008}. CC -!- CATALYTIC ACTIVITY: CC Reaction=daunorubicin(in) + ATP + H2O = daunorubicin(out) + ADP + CC phosphate + H(+); Xref=Rhea:RHEA:33147, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:64677, ChEBI:CHEBI:456216; EC=7.6.2.2; CC Evidence={ECO:0000269|PubMed:22306008}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33148; CC Evidence={ECO:0000269|PubMed:22306008}; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12960149}; CC Multi-pass membrane protein {ECO:0000255|PROSITE-ProRule:PRU00441, CC ECO:0000269|PubMed:12960149}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=4; CC IsoId=Q2M3G0-4; Sequence=Displayed; CC Name=2; Synonyms=ABCB5alpha; CC IsoId=Q2M3G0-2; Sequence=VSP_056752, VSP_056753, VSP_056756; CC Name=3; CC IsoId=Q2M3G0-3; Sequence=VSP_056752, VSP_056754, VSP_056755; CC Name=1; Synonyms=ABCB5beta; CC IsoId=Q2M3G0-1; Sequence=VSP_056752; CC -!- TISSUE SPECIFICITY: Expressed by CD133-expressing progenitor cells CC among epidermal melanocytes (at protein level). Widely expressed with CC specific expression in pigment cells. Highly expressed in several CC malignant tissues: highly expressed in clinical melanomas, with low CC expression in normal skin. In melanoma, marks malignant melanoma- CC initiating cells (MMIC), in which clinical virulence resides as a CC consequence of unlimited self-renewal capacity, resulting in inexorable CC tumor progression and metastasis. Also highly expressed in a number of CC leukemia cells. Expressed in basal limbal epithelium. CC {ECO:0000269|PubMed:12960149, ECO:0000269|PubMed:15760339, CC ECO:0000269|PubMed:22044138, ECO:0000269|PubMed:22675422, CC ECO:0000269|PubMed:22784549, ECO:0000269|PubMed:23770371, CC ECO:0000269|PubMed:24934811, ECO:0000269|PubMed:25030174}. CC -!- MISCELLANEOUS: Acts as a marker of stem-like cells (CSC) in a number of CC malignancies (PubMed:24934811). Associated with clinical drug CC resistance, tumor progression and disease recurrence in malignant CC melanoma and acute leukemias. Responsible for the resistance to CC doxorubicin of a subset of malignant melanomas. ABCB5-expressing cells CC selectively survive when exposed to dacarbazine drug, the reference CC treatment of metastatic melanoma, vemurafenib and other various CC chemotherapeutic drugs, suggesting that anti-melanoma chemotherapy CC participates in the chemoresistance acquisition by selecting tumor cell CC subpopulations expressing ABCB5 (PubMed:22044138, PubMed:22675422, CC PubMed:22784549, PubMed:23770371, PubMed:24934811). Present in CC melanoma-initiating cells that acts as an enhancer of tumor growth by CC promoting CSC maintenance and tumor growth by controlling IL-1beta CC (IL1B) secretion to maintain slow-cycling, chemoresistant cells through CC an IL-1beta (IL1B)/IL8/CXCR1 cytokine signaling circuit CC (PubMed:24934811). {ECO:0000305|PubMed:22044138, CC ECO:0000305|PubMed:22675422, ECO:0000305|PubMed:22784549, CC ECO:0000305|PubMed:23770371, ECO:0000305|PubMed:24934811}. CC -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB family. CC Multidrug resistance exporter (TC 3.A.1.201) subfamily. {ECO:0000305}. CC -!- CAUTION: Was named ABCB1 by some authors. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAN76500.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAQ03033.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44305/ABCB5"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF319622; AAN76500.1; ALT_INIT; mRNA. DR EMBL; AF399931; AAQ03033.1; ALT_INIT; mRNA. DR EMBL; AY090613; AAM09027.1; -; mRNA. DR EMBL; AY234788; AAO73470.1; -; mRNA. DR EMBL; AY851364; AAW31629.1; -; mRNA. DR EMBL; AY851365; AAW31630.1; -; mRNA. DR EMBL; GU437216; ADV32636.1; -; mRNA. DR EMBL; GU437217; ADV32637.1; -; mRNA. DR EMBL; AB353947; BAF75364.1; -; mRNA. DR EMBL; AY230001; AAP55848.1; -; mRNA. DR EMBL; AC002486; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005060; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH236948; EAL24273.1; -; Genomic_DNA. DR EMBL; CH471073; EAW93726.1; -; Genomic_DNA. DR EMBL; BC104894; AAI04895.2; -; mRNA. DR EMBL; BC104920; AAI04921.1; -; mRNA. DR EMBL; BC110370; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS5371.1; -. [Q2M3G0-1] DR CCDS; CCDS55090.1; -. [Q2M3G0-4] DR CCDS; CCDS55091.1; -. [Q2M3G0-2] DR CCDS; CCDS55092.1; -. [Q2M3G0-3] DR RefSeq; NP_001157413.1; NM_001163941.2. [Q2M3G0-4] DR RefSeq; NP_001157414.1; NM_001163942.2. [Q2M3G0-2] DR RefSeq; NP_001157465.1; NM_001163993.3. [Q2M3G0-3] DR RefSeq; NP_848654.3; NM_178559.5. [Q2M3G0-1] DR AlphaFoldDB; Q2M3G0; -. DR SMR; Q2M3G0; -. DR BioGRID; 131028; 23. DR FunCoup; Q2M3G0; 77. DR IntAct; Q2M3G0; 5. DR STRING; 9606.ENSP00000384881; -. DR ChEMBL; CHEMBL1772928; -. DR DrugBank; DB06263; Amrubicin. DR DrugBank; DB11591; Bilastine. DR DrugBank; DB04851; Biricodar. DR DrugBank; DB08870; Brentuximab vedotin. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB09183; Dasabuvir. DR DrugBank; DB11943; Delafloxacin. DR DrugBank; DB14067; Dofequidar. DR DrugBank; DB00254; Doxycycline. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15275; Inavolisib. DR DrugBank; DB00598; Labetalol. DR DrugBank; DB04948; Lofexidine. DR DrugBank; DB11691; Naldemedine. DR DrugBank; DB11641; Vinflunine. DR TCDB; 3.A.1.201.13; the atp-binding cassette (abc) superfamily. DR TCDB; 3.A.1.201.50; the atp-binding cassette (abc) superfamily. DR GlyCosmos; Q2M3G0; 11 sites, No reported glycans. DR GlyGen; Q2M3G0; 11 sites, 1 N-linked glycan (1 site). DR iPTMnet; Q2M3G0; -. DR PhosphoSitePlus; Q2M3G0; -. DR BioMuta; ABCB5; -. DR DMDM; 308153645; -. DR jPOST; Q2M3G0; -. DR MassIVE; Q2M3G0; -. DR PaxDb; 9606-ENSP00000384881; -. DR PeptideAtlas; Q2M3G0; -. DR ProteomicsDB; 61374; -. [Q2M3G0-4] DR ProteomicsDB; 61375; -. [Q2M3G0-2] DR ProteomicsDB; 6148; -. DR Antibodypedia; 11940; 408 antibodies from 39 providers. DR DNASU; 340273; -. DR Ensembl; ENST00000258738.10; ENSP00000258738.6; ENSG00000004846.17. [Q2M3G0-1] DR Ensembl; ENST00000404938.7; ENSP00000384881.2; ENSG00000004846.17. [Q2M3G0-4] DR Ensembl; ENST00000406935.5; ENSP00000383899.1; ENSG00000004846.17. [Q2M3G0-3] DR Ensembl; ENST00000443026.6; ENSP00000406730.2; ENSG00000004846.17. [Q2M3G0-2] DR GeneID; 340273; -. DR KEGG; hsa:340273; -. DR MANE-Select; ENST00000404938.7; ENSP00000384881.2; NM_001163941.2; NP_001157413.1. DR UCSC; uc003suv.4; human. [Q2M3G0-4] DR AGR; HGNC:46; -. DR ClinPGx; PA24387; -. DR CTD; 340273; -. DR DisGeNET; 340273; -. DR GeneCards; ABCB5; -. DR HGNC; HGNC:46; ABCB5. DR HPA; ENSG00000004846; Tissue enriched (epididymis). DR MalaCards; ABCB5; -. DR MIM; 611785; gene. DR OpenTargets; ENSG00000004846; -. DR VEuPathDB; HostDB:ENSG00000004846; -. DR eggNOG; KOG0055; Eukaryota. DR GeneTree; ENSGT00940000161340; -. DR HOGENOM; CLU_000604_1_9_1; -. DR InParanoid; Q2M3G0; -. DR OMA; WAFQSWV; -. DR OrthoDB; 6500128at2759; -. DR PAN-GO; Q2M3G0; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q2M3G0; -. DR BRENDA; 7.6.2.2; 2681. DR PathwayCommons; Q2M3G0; -. DR Reactome; R-HSA-382556; ABC-family proteins mediated transport. DR SignaLink; Q2M3G0; -. DR Agora; ENSG00000004846; -. DR BioGRID-ORCS; 340273; 13 hits in 1142 CRISPR screens. DR ChiTaRS; ABCB5; human. DR GeneWiki; ABCB5; -. DR GenomeRNAi; 340273; -. DR Pharos; Q2M3G0; Tbio. DR PRO; PR:Q2M3G0; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q2M3G0; protein. DR Bgee; ENSG00000004846; Expressed in cauda epididymis and 81 other cell types or tissues. DR ExpressionAtlas; Q2M3G0; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0008559; F:ABC-type xenobiotic transporter activity; IEA:UniProtKB-EC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro. DR GO; GO:0042626; F:ATPase-coupled transmembrane transporter activity; IBA:GO_Central. DR GO; GO:0015562; F:efflux transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0001654; P:eye development; ISS:UniProtKB. DR GO; GO:0042391; P:regulation of membrane potential; IDA:UniProtKB. DR GO; GO:0055085; P:transmembrane transport; IDA:UniProtKB. DR CDD; cd18577; ABC_6TM_Pgp_ABCB1_D1_like; 1. DR CDD; cd18578; ABC_6TM_Pgp_ABCB1_D2_like; 1. DR CDD; cd03249; ABC_MTABC3_MDL1_MDL2; 2. DR FunFam; 1.20.1560.10:FF:000018; ATP-binding cassette subfamily B member 11; 1. DR FunFam; 1.20.1560.10:FF:000046; ATP-binding cassette subfamily B member 11; 1. DR FunFam; 3.40.50.300:FF:000302; ATP-binding cassette subfamily B member 5; 2. DR Gene3D; 1.20.1560.10; ABC transporter type 1, transmembrane domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR InterPro; IPR003593; AAA+_ATPase. DR InterPro; IPR011527; ABC1_TM_dom. DR InterPro; IPR036640; ABC1_TM_sf. DR InterPro; IPR003439; ABC_transporter-like_ATP-bd. DR InterPro; IPR017871; ABC_transporter-like_CS. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR039421; Type_1_exporter. DR PANTHER; PTHR43394; ATP-DEPENDENT PERMEASE MDL1, MITOCHONDRIAL; 1. DR PANTHER; PTHR43394:SF27; ATP-DEPENDENT TRANSLOCASE ABCB1-LIKE; 1. DR Pfam; PF00664; ABC_membrane; 2. DR Pfam; PF00005; ABC_tran; 2. DR SMART; SM00382; AAA; 2. DR SUPFAM; SSF90123; ABC transporter transmembrane region; 2. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2. DR PROSITE; PS50929; ABC_TM1F; 2. DR PROSITE; PS00211; ABC_TRANSPORTER_1; 2. DR PROSITE; PS50893; ABC_TRANSPORTER_2; 2. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell membrane; Differentiation; KW Glycoprotein; Membrane; Nucleotide-binding; Proteomics identification; KW Reference proteome; Repeat; Translocase; Transmembrane; KW Transmembrane helix; Transport. FT CHAIN 1..1257 FT /note="ATP-binding cassette sub-family B member 5" FT /id="PRO_0000253575" FT TRANSMEM 49..69 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 110..130 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 181..201 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 203..223 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 294..314 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 322..342 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 693..713 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 737..757 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 827..847 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 917..937 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT TRANSMEM 954..974 FT /note="Helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT DOMAIN 49..350 FT /note="ABC transmembrane type-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT DOMAIN 386..622 FT /note="ABC transporter 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT DOMAIN 693..980 FT /note="ABC transmembrane type-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00441" FT DOMAIN 1015..1253 FT /note="ABC transporter 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT REGION 1..24 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 421..428 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT BINDING 1050..1057 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT CARBOHYD 17 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 85 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 91 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 371 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 390 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 423 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 789 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 819 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 910 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1188 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..445 FT /note="Missing (in isoform 1, isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:12960149, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:15760339, FT ECO:0000303|PubMed:21652540" FT /id="VSP_056752" FT VAR_SEQ 570..576 FT /note="ASKGRTT -> DTPRYSF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15760339" FT /id="VSP_056753" FT VAR_SEQ 570..571 FT /note="AS -> KK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_056754" FT VAR_SEQ 572..1257 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_056755" FT VAR_SEQ 577..1257 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15760339" FT /id="VSP_056756" FT VARIANT 560 FT /note="K -> E (in dbSNP:rs2301641)" FT /evidence="ECO:0000269|PubMed:15760339" FT /id="VAR_028387" FT VARIANT 669 FT /note="K -> R (in dbSNP:rs13222448)" FT /id="VAR_028388" FT VARIANT 675 FT /note="E -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035731" FT VARIANT 880 FT /note="A -> T (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation; dbSNP:rs1187237313)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062662" FT VARIANT 905 FT /note="Q -> H (in dbSNP:rs35885925)" FT /id="VAR_033456" FT VARIANT 915 FT /note="A -> T (in dbSNP:rs17143304)" FT /id="VAR_028389" FT VARIANT 970 FT /note="E -> K (in dbSNP:rs6461515)" FT /evidence="ECO:0000269|PubMed:12960149, FT ECO:0000269|PubMed:15760339, ECO:0000269|PubMed:22306008, FT ECO:0000269|Ref.5, ECO:0000269|Ref.8" FT /id="VAR_028390" FT CONFLICT 577 FT /note="I -> M (in Ref. 1; AAN76500)" FT /evidence="ECO:0000305" FT CONFLICT 1141 FT /note="L -> P (in Ref. 2; AAW31630)" FT /evidence="ECO:0000305" FT CONFLICT 1186 FT /note="L -> I (in Ref. 3; ADV32637)" FT /evidence="ECO:0000305" SQ SEQUENCE 1257 AA; 138641 MW; A4521B83E0D234CF CRC64; MENSERAEEM QENYQRNGTA EEQPKLRKEA VGSIEIFRFA DGLDITLMIL GILASLVNGA CLPLMPLVLG EMSDNLISGC LVQTNTTNYQ NCTQSQEKLN EDMTLLTLYY VGIGVAALIF GYIQISLWII TAARQTKRIR KQFFHSVLAQ DIGWFDSCDI GELNTRMTDD IDKISDGIGD KIALLFQNMS TFSIGLAVGL VKGWKLTLVT LSTSPLIMAS AAACSRMVIS LTSKELSAYS KAGAVAEEVL SSIRTVIAFR AQEKELQRYT QNLKDAKDFG IKRTIASKVS LGAVYFFMNG TYGLAFWYGT SLILNGEPGY TIGTVLAVFF SVIHSSYCIG AAVPHFETFA IARGAAFHIF QVIDKKPSID NFSTAGYKPE SIEGTVEFKN VSFNYPSRPS IKILKGLNLR IKSGETVALV GLNGSGKSTV VQLLQRLYDP DDGFIMVDEN DIRALNVRHY RDHIGVVSQE PVLFGTTISN NIKYGRDDVT DEEMERAARE ANAYDFIMEF PNKFNTLVGE KGAQMSGGQK QRIAIARALV RNPKILILDE ATSALDSESK SAVQAALEKA SKGRTTIVVA HRLSTIRSAD LIVTLKDGML AEKGAHAELM AKRGLYYSLV MSQDIKKADE QMESMTYSTE RKTNSLPLHS VKSIKSDFID KAEESTQSKE ISLPEVSLLK ILKLNKPEWP FVVLGTLASV LNGTVHPVFS IIFAKIITMF GNNDKTTLKH DAEIYSMIFV ILGVICFVSY FMQGLFYGRA GEILTMRLRH LAFKAMLYQD IAWFDEKENS TGGLTTILAI DIAQIQGATG SRIGVLTQNA TNMGLSVIIS FIYGWEMTFL ILSIAPVLAV TGMIETAAMT GFANKDKQEL KHAGKIATEA LENIRTIVSL TREKAFEQMY EEMLQTQHRN TSKKAQIIGS CYAFSHAFIY FAYAAGFRFG AYLIQAGRMT PEGMFIVFTA IAYGAMAIGE TLVLAPEYSK AKSGAAHLFA LLEKKPNIDS RSQEGKKPDT CEGNLEFREV SFFYPCRPDV FILRGLSLSI ERGKTVAFVG SSGCGKSTSV QLLQRLYDPV QGQVLFDGVD AKELNVQWLR SQIAIVPQEP VLFNCSIAEN IAYGDNSRVV PLDEIKEAAN AANIHSFIEG LPEKYNTQVG LKGAQLSGGQ KQRLAIARAL LQKPKILLLD EATSALDNDS EKVVQHALDK ARTGRTCLVV THRLSAIQNA DLIVVLHNGK IKEQGTHQEL LRNRDIYFKL VNAQSVQ // ID AURKA_HUMAN Reviewed; 403 AA. AC O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5; DT 27-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 3. DT 28-JAN-2026, entry version 254. DE RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393}; DE EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; DE AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084}; DE AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231}; DE Short=ARK-1 {ECO:0000303|PubMed:9153231}; DE Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916}; DE AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771}; DE AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}; DE AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714}; DE AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241}; GN Name=AURKA {ECO:0000312|HGNC:HGNC:11393}; GN Synonyms=AIK {ECO:0000303|PubMed:9153231}, GN AIRK1 {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393}, GN AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1 {ECO:0000250|UniProtKB:P97477}, GN BTAK {ECO:0000303|PubMed:9771714}, IAK1 {ECO:0000250|UniProtKB:P97477}, GN STK15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, GN STK6 {ECO:0000303|PubMed:9771714}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT RP VAL-57. RC TISSUE=Blood; RX PubMed=9153231; DOI=10.1074/jbc.272.21.13766; RA Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K., RA Okano Y.; RT "Cell cycle-dependent expression and spindle pole localization of a novel RT human protein kinase, Aik, related to Aurora of Drosophila and yeast RT Ipl1."; RL J. Biol. Chem. 272:13766-13771(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57. RX PubMed=9514916; DOI=10.1006/bbrc.1998.8250; RA Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J., RA Jenkins N.A., Copeland N.G., Yagita H., Okumura K.; RT "cDNA cloning, expression, subcellular localization, and chromosomal RT assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 RT and 2."; RL Biochem. Biophys. Res. Commun. 244:285-292(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57. RC TISSUE=Mammary gland; RX PubMed=9771714; DOI=10.1038/2496; RA Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R., RA Sen S.; RT "Tumour amplified kinase STK15/BTAK induces centrosome amplification, RT aneuploidy and transformation."; RL Nat. Genet. 20:189-193(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang L., Thibodeau S.N.; RT "Mutational analysis of the STK15 gene in human tumors."; RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57. RC TISSUE=Cervix, Colon, Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, AND SUBCELLULAR LOCATION. RX PubMed=9606188; DOI=10.1093/emboj/17.11.3052; RA Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., RA Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., RA Novotny M., Slamon D.J., Plowman G.D.; RT "A homologue of Drosophila aurora kinase is oncogenic and amplified in RT human colorectal cancers."; RL EMBO J. 17:3052-3065(1998). RN [9] RP UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205. RX PubMed=10851084; DOI=10.1038/sj.onc.1203609; RA Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., RA Furukawa K., Urano T.; RT "Degradation of human Aurora2 protein kinase by the anaphase-promoting RT complex-ubiquitin-proteasome pathway."; RL Oncogene 19:2812-2819(2000). RN [10] RP FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288, RP UBIQUITINATION, AND ACTIVITY REGULATION. RX PubMed=11039908; DOI=10.1038/sj.onc.1203847; RA Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.; RT "The mitotic serine/threonine kinase Aurora2/AIK is regulated by RT phosphorylation and degradation."; RL Oncogene 19:4906-4916(2000). RN [11] RP FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF RP PHE-165 AND PHE-346, AND PHOSPHORYLATION. RX PubMed=11551964; DOI=10.1074/jbc.m107540200; RA Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.; RT "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and RT protein phosphatase 1 through mitotic cell division cycle."; RL J. Biol. Chem. 276:46219-46224(2001). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=12576638; DOI=10.1247/csf.27.457; RA Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M., RA Dotsu M.; RT "Molecular dynamics of Aurora-A kinase in living mitotic cells RT simultaneously visualized with histone H3 and nuclear membrane protein RT importinalpha."; RL Cell Struct. Funct. 27:457-467(2002). RN [13] RP FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x; RA Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., RA Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., RA Saya H.; RT "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian RT cells."; RL Genes Cells 7:1173-1182(2002). RN [14] RP INDUCTION. RX PubMed=11790771; DOI=10.1074/jbc.m108252200; RA Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S., RA Ishigatsubo Y.; RT "Cell-cycle-dependent regulation of human aurora A transcription is RT mediated by periodic repression of E4TF1."; RL J. Biol. Chem. 277:10719-10726(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288. RX PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1; RA Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., RA Hatakeyama K., Saya H.; RT "Aurora-A and an interacting activator, the LIM protein Ajuba, are required RT for mitotic commitment in human cells."; RL Cell 114:585-598(2003). RN [16] RP FUNCTION. RX PubMed=14523000; DOI=10.1074/jbc.m306275200; RA Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.; RT "Aurora-A kinase maintains the fidelity of early and late mitotic events in RT HeLa cells."; RL J. Biol. Chem. 278:51786-51795(2003). RN [17] RP INTERACTION WITH TACC1. RX PubMed=14603251; DOI=10.1038/sj.onc.1206972; RA Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., RA Prigent C., Seraphin B., Jacquemier J., Birnbaum D.; RT "TACC1-chTOG-Aurora A protein complex in breast cancer."; RL Oncogene 22:8102-8116(2003). RN [18] RP FUNCTION. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [19] RP RETRACTED PAPER. RX PubMed=14990569; DOI=10.1074/jbc.m311780200; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RT "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M RT transition."; RL J. Biol. Chem. 279:19643-19648(2004). RN [20] RP RETRACTION NOTICE OF PUBMED:14990569. RX PubMed=26341884; DOI=10.1074/jbc.a115.311780; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RL J. Biol. Chem. 290:22311-22311(2015). RN [21] RP FUNCTION. RX PubMed=15128871; DOI=10.1242/jcs.01108; RA Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., RA Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., RA Prigent C., Ducommun B.; RT "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the RT G2-M transition."; RL J. Cell Sci. 117:2523-2531(2004). RN [22] RP FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [23] RP INTERACTION WITH CPEB1. RX PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x; RA Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E., RA Saya H., Hirota T.; RT "Over-expression of Aurora-A targets cytoplasmic polyadenylation element RT binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1."; RL Genes Cells 10:627-638(2005). RN [24] RP PHOSPHORYLATION AT THR-288 AND SER-342. RX PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035; RA Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.; RT "The GIT-associated kinase PAK targets to the centrosome and regulates RT Aurora-A."; RL Mol. Cell 20:237-249(2005). RN [25] RP INDUCTION, AND FUNCTION. RX PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005; RA Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.; RT "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP RT as a transforming target of Aurora-A."; RL Mol. Cell. Biol. 25:5789-5800(2005). RN [26] RP INTERACTION WITH BORA. RX PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002; RA Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., RA Knoblich J.A.; RT "Mitotic activation of the kinase Aurora-A requires its binding partner RT Bora."; RL Dev. Cell 11:147-157(2006). RN [27] RP FUNCTION. RX PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578; RA Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.; RT "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of RT centrosome-dependent microtubule nucleation."; RL Cancer Res. 67:11186-11194(2007). RN [28] RP FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP ASP-274 AND THR-288. RX PubMed=17604723; DOI=10.1016/j.cell.2007.04.035; RA Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.; RT "HEF1-dependent Aurora A activation induces disassembly of the primary RT cilium."; RL Cell 129:1351-1363(2007). RN [29] RP INTERACTION WITH ARHGEF2. RX PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014; RA Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.; RT "GEF-H1 modulates localized RhoA activation during cytokinesis under the RT control of mitotic kinases."; RL Dev. Cell 12:699-712(2007). RN [30] RP SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT RP SER-51. RX PubMed=17229885; DOI=10.1091/mbc.e06-12-1152; RA Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.; RT "Functional interaction of Aurora-A and PP2A during mitosis."; RL Mol. Biol. Cell 18:1233-1241(2007). RN [31] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=17726514; DOI=10.1371/journal.pone.0000784; RA North B.J., Verdin E.; RT "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during RT mitosis."; RL PLoS ONE 2:E784-E784(2007). RN [32] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=17360485; DOI=10.1073/pnas.0608798104; RA Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., RA Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., RA Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., RA Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.; RT "Antitumor activity of MLN8054, an orally active small-molecule inhibitor RT of Aurora A kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [34] RP FUNCTION. RX PubMed=18615013; DOI=10.1038/nature07185; RA Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., RA Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.; RT "Polo-like kinase-1 is activated by aurora A to promote checkpoint RT recovery."; RL Nature 455:119-123(2008). RN [35] RP FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3. RX PubMed=19812038; DOI=10.1074/jbc.m109.055897; RA Khazaei M.R., Puschel A.W.; RT "Phosphorylation of the par polarity complex protein Par3 at serine 962 is RT mediated by aurora A and regulates its function in neuronal polarity."; RL J. Biol. Chem. 284:33571-33579(2009). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A. RX PubMed=19351716; DOI=10.1242/jcs.044321; RA Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.; RT "Plk1 and Aurora A regulate the depolymerase activity and the cellular RT localization of Kif2a."; RL J. Cell Sci. 122:1334-1341(2009). RN [37] RP FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288, RP AND MUTAGENESIS OF THR-287. RX PubMed=19668197; DOI=10.1038/ncb1919; RA Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S., RA Saya H., Wynshaw-Boris A., Hirotsune S.; RT "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation RT by modulation of microtubule dynamics."; RL Nat. Cell Biol. 11:1057-1068(2009). RN [38] RP INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION. RX PubMed=19357306; DOI=10.1073/pnas.0900833106; RA Fu J., Bian M., Liu J., Jiang Q., Zhang C.; RT "A single amino acid change converts Aurora-A into Aurora-B-like kinase in RT terms of partner specificity and cellular function."; RL Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009). RN [39] RP FUNCTION, INTERACTION WITH CIMAP3, AND ACTIVATION BY CIMAP3. RX PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005; RA Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B., RA Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.; RT "Pitchfork regulates primary cilia disassembly and left-right asymmetry."; RL Dev. Cell 19:66-77(2010). RN [40] RP IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN. RX PubMed=20596670; DOI=10.3892/ijo_00000691; RA Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y., RA Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.; RT "Functional characterization of AIBp, a novel Aurora-A binding protein in RT centrosome structure and spindle formation."; RL Int. J. Oncol. 37:429-436(2010). RN [41] RP INTERACTION WITH GADD45A. RX PubMed=20460379; DOI=10.1074/jbc.m109.069344; RA Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., RA Montoya G., Campos-Olivas R., Blanco F.J.; RT "Solution structure of human growth arrest and DNA damage 45alpha RT (Gadd45alpha) and its interactions with proliferating cell nuclear antigen RT (PCNA) and Aurora A kinase."; RL J. Biol. Chem. 285:22196-22201(2010). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [44] RP REVIEW ON FUNCTION. RX PubMed=14625535; DOI=10.1038/nrm1245; RA Carmena M., Earnshaw W.C.; RT "The cellular geography of aurora kinases."; RL Nat. Rev. Mol. Cell Biol. 4:842-854(2003). RN [45] RP REVIEW ON FUNCTION. RX PubMed=19774610; DOI=10.1002/em.20533; RA Lukasiewicz K.B., Lingle W.L.; RT "Aurora A, centrosome structure, and the centrosome cycle."; RL Environ. Mol. Mutagen. 50:602-619(2009). RN [46] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004; RA Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C., RA Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I., RA Gius D., Deng C.X.; RT "SIRT2 maintains genome integrity and suppresses tumorigenesis through RT regulating APC/C activity."; RL Cancer Cell 20:487-499(2011). RN [47] RP INTERACTION WITH HNRNPU. RX PubMed=21242313; DOI=10.1242/jcs.063347; RA Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S., RA Fukui K.; RT "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule RT attachment and contributes to the targeting of Aurora-A to mitotic RT spindles."; RL J. Cell Sci. 124:394-404(2011). RN [48] RP INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=23213400; DOI=10.1242/bio.2011018; RA Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.; RT "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora- RT A."; RL Biol. Open 1:82-91(2012). RN [49] RP INTERACTION WITH FRY. RX PubMed=22753416; DOI=10.1074/jbc.m112.378968; RA Ikeda M., Chiba S., Ohashi K., Mizuno K.; RT "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation."; RL J. Biol. Chem. 287:27670-27681(2012). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=25657325; DOI=10.1091/mbc.e14-09-1366; RA Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.; RT "CENP-32 is required to maintain centrosomal dominance in bipolar spindle RT assembly."; RL Mol. Biol. Cell 26:1225-1237(2015). RN [51] RP INTERACTION WITH HNRNPU. RX PubMed=25986610; DOI=10.1128/mcb.01312-14; RA Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L., RA Lees-Miller S.P.; RT "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is RT required for mitosis."; RL Mol. Cell. Biol. 35:2699-2713(2015). RN [52] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=27192185; DOI=10.1080/15384101.2016.1187342; RA Meunier S., Timon K., Vernos I.; RT "Aurora-A regulates MCRS1 function during mitosis."; RL Cell Cycle 15:1779-1786(2016). RN [53] RP FUNCTION. RX PubMed=27335426; DOI=10.1242/jcs.184416; RA Kotak S., Afshar K., Busso C., Goenczy P.; RT "Aurora A kinase regulates proper spindle positioning in C. elegans and in RT human cells."; RL J. Cell Sci. 129:3015-3025(2016). RN [54] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [55] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP FOXP1. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=30538148; DOI=10.1261/rna.069773.118; RA Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D., RA Pellman D., Kennedy S., Slack F.J.; RT "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing RT factor."; RL RNA 25:352-363(2019). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE, RP AND CATALYTIC ACTIVITY. RX PubMed=12237287; DOI=10.1074/jbc.c200426200; RA Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., RA Lippke J.A., Austen D.A.; RT "Crystal structure of aurora-2, an oncogenic serine/threonine kinase."; RL J. Biol. Chem. 277:42419-42422(2002). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2, RP MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND RP THR-288, AND REGION ACTIVATION SEGMENT. RX PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7; RA Bayliss R., Sardon T., Vernos I., Conti E.; RT "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle."; RL Mol. Cell 12:851-862(2003). RN [60] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP RP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053; RA Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., RA Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., RA Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.; RT "SAR and inhibitor complex structure determination of a novel class of RT potent and specific Aurora kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 16:1320-1323(2006). RN [61] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH RP SYNTHETIC INHIBITORS, AND FUNCTION. RX PubMed=17125279; DOI=10.1021/jm060897w; RA Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., RA Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., RA Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., RA Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., RA Vianello P.; RT "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent RT aurora kinase inhibitor with a favorable antitumor kinase inhibition RT profile."; RL J. Med. Chem. 49:7247-7251(2006). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND RP TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBUNIT. RX PubMed=18662907; DOI=10.1110/ps.036590.108; RA Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., RA Kirkpatrick R.B., Lai Z.; RT "Modulation of kinase-inhibitor interactions by auxiliary protein binding: RT crystallography studies on Aurora A interactions with VX-680 and with RT TPX2."; RL Protein Sci. 17:1791-1797(2008). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP, RP CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH RP TPX2. RX PubMed=19801554; DOI=10.1074/jbc.m109.032722; RA Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., RA Bayliss R., Linardopoulos S.; RT "A cancer-associated aurora A mutant is mislocalized and misregulated due RT to loss of interaction with TPX2."; RL J. Biol. Chem. 284:33177-33184(2009). RN [64] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19140666; DOI=10.1021/jm801270e; RA Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H., RA Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y., RA Hsieh H.P.; RT "Structure-based drug design of novel Aurora kinase A inhibitors: RT structural basis for potency and specificity."; RL J. Med. Chem. 52:1050-1062(2009). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19402633; DOI=10.1021/jm9000314; RA Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J., RA Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J., RA Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L., RA Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.; RT "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually RT high selectivity against Aurora B."; RL J. Med. Chem. 52:3300-3307(2009). RN [66] RP X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND RP ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF RP CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY. RX PubMed=27837025; DOI=10.1073/pnas.1610626113; RA Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L., RA Bayliss R.; RT "Structural basis of N-Myc binding by Aurora-A and its destabilization by RT kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016). RN [67] RP VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57. RX PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149; RA Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., RA Nagase H.; RT "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) RT coordinately increase esophageal cancer risk."; RL Cancer Res. 65:3548-3554(2005). RN [68] RP VARIANTS ILE-31 AND VAL-57. RX PubMed=16011022; RA Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M., RA Zhang X.; RT "Linkage disequilibrium and haplotype analysis of two single nucleotide RT polymorphisms in STK15 in Chinese."; RL Yi Chuan Xue Bao 32:331-336(2005). RN [69] RP VARIANT ILE-31. RX PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002; RA Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., RA Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., RA Burwinkel B.; RT "Aurora kinases A and B and familial breast cancer risk."; RL Cancer Lett. 247:266-272(2007). RN [70] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174 RP AND VAL-373. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [71] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN. RX PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654; RA Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C., RA Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.; RT "NEDD9 regulates actin dynamics through cortactin deacetylation in an RT AURKA/HDAC6-dependent manner."; RL Mol. Cancer Res. 12:681-693(2014). RN [72] RP FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-288. RX PubMed=26246606; DOI=10.1091/mbc.e15-02-0113; RA Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A., RA Koehler K., Huebner A., Griffis E.R.; RT "The nucleoporin ALADIN regulates Aurora A localization to ensure robust RT mitotic spindle formation."; RL Mol. Biol. Cell 26:3424-3438(2015). CC -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the CC regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, CC PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). CC Associates with the centrosome and the spindle microtubules during CC mitosis and plays a critical role in various mitotic events including CC the establishment of mitotic spindle, centrosome duplication, CC centrosome separation as well as maturation, chromosomal alignment, CC spindle assembly checkpoint, and cytokinesis (PubMed:14523000, CC PubMed:26246606). Required for normal spindle positioning during CC mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex CC during metaphase (PubMed:27335426). Required for initial activation of CC CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates CC numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, CC DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, CC p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, CC PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, CC PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1- CC mediated kinetochore fiber assembly and mitotic progression CC (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity CC (PubMed:19351716). Important for microtubule formation and/or CC stabilization (PubMed:18056443). Required for normal axon formation CC (PubMed:19812038). Plays a role in microtubule remodeling during CC neurite extension (PubMed:19668197). Also acts as a key regulatory CC component of the p53/TP53 pathway, and particularly the checkpoint- CC response pathways critical for oncogenic transformation of cells, by CC phosphorylating and destabilizing p53/TP53 (PubMed:14702041). CC Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) CC isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia CC outgrowth (By similarity). Required for cilia disassembly via CC phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin CC (PubMed:17604723, PubMed:20643351). Regulates protein levels of the CC anti-apoptosis protein BIRC5 by suppressing the expression of the CC SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through CC the phosphorylation of the transcription factor FOXP1 CC (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724, CC ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279, CC ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723, CC ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27192185, CC ECO:0000269|PubMed:27335426, ECO:0000269|PubMed:28218735}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; CC -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream CC event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2 CC act also as activators. Inactivated by the G2 checkpoint. Inhibited by CC GADD45A and p53/TP53, and through dephosphorylation by protein CC phosphatase type 1 (PP1). MLN8054 is also a potent and selective CC inhibitor. Activated during the early phase of cilia disassembly in the CC presence of CIMAP3. Inhibited by the small molecule inhibitor VX-680 CC (PubMed:28218735). {ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within CC the complex NEDD9 acts as a scaffold protein and is required for CC complex formation (PubMed:24574519). Identified in a complex with AUNIP CC and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity). CC Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the CC protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC CC (PubMed:11551964, PubMed:14580337, PubMed:14603251, PubMed:15966895, CC PubMed:17229885, PubMed:18662907, PubMed:19357306, PubMed:19668197, CC PubMed:19801554, PubMed:21225229, PubMed:27837025). Also interacts with CC its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53 CC (PubMed:14702041, PubMed:16890155, PubMed:17488622, PubMed:19351716, CC PubMed:19812038). Interaction with BORA promotes phosphorylation of CC PLK1 (By similarity). Interacts with CIMAP3 (PubMed:20643351). CC Interacts with GADD45A, competing with its oligomerization CC (PubMed:20460379). Interacts (via C-terminus) with AUNIP (via C- CC terminus) (PubMed:20596670). Interacts with FRY; this interaction CC facilitates AURKA-mediated PLK1 phosphorylation (PubMed:22753416). CC Interacts with SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with CC MYCN; interaction is phospho-independent and triggers AURKA activation; CC AURKA competes with FBXW7 for binding to unphosphorylated MYCN but not CC for binding to phosphorylated MYCN (PubMed:27837025). Interacts with CC HNRNPU (PubMed:21242313, PubMed:25986610). Interacts with AAAS CC (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400). CC Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA- CC mediated phosphorylation of HDAC6 promotes deacetylation of alpha- CC tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287, CC ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337, CC ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622, CC ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038, CC ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670, CC ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400, CC ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}. CC -!- INTERACTION: CC O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665; CC O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823; CC O14965; Q6PGQ7: BORA; NbExp=3; IntAct=EBI-448680, EBI-719836; CC O14965; P15056: BRAF; NbExp=5; IntAct=EBI-448680, EBI-365980; CC O14965; P00533: EGFR; NbExp=5; IntAct=EBI-448680, EBI-297353; CC O14965; P06730: EIF4E; NbExp=2; IntAct=EBI-448680, EBI-73440; CC O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185; CC O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456; CC O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266; CC O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907; CC O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972; CC O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369; CC O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579; CC O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768; CC O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990; CC O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317; CC O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606; CC O14965; Q9ULW0: TPX2; NbExp=10; IntAct=EBI-448680, EBI-1037322; CC O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm, CC cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231, CC ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome, centriole CC {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection CC {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium CC {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane CC {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in CC developing neurons (By similarity). Localizes at the centrosome in CC mitotic cells from early prophase until telophase, but also localizes CC to the spindle pole MTs from prophase to anaphase (PubMed:17229885, CC PubMed:21225229, PubMed:9606188). Colocalized with SIRT2 at centrosome CC (PubMed:22014574). Moves to the midbody during both telophase and CC cytokinesis (PubMed:17726514). Associates with both the pericentriolar CC material (PCM) and centrioles (PubMed:22014574). The localization to CC the spindle poles is regulated by AAAS (PubMed:26246606). CC {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606, CC ECO:0000269|PubMed:9606188}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal CC muscle, thymus and spleen. Also highly expressed in colon, ovarian, CC prostate, neuroblastoma, breast and cervical cancer cell lines. CC -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates CC during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997, CC ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}. CC -!- PTM: Activated by phosphorylation at Thr-288; this brings about a CC change in the conformation of the activation segment. Phosphorylation CC at Thr-288 varies during the cell cycle and is highest during M phase. CC Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be CC phosphorylated by several kinases, including PAK and PKA. Protein CC phosphatase type 1 (PP1) binds AURKA and inhibits its activity by CC dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342 CC decreases the kinase activity. PPP2CA controls degradation by CC dephosphorylating Ser-51 at the end of mitosis. CC {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907, CC ECO:0000269|PubMed:19668197}. CC -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex CC SCF(FBXL7) during mitosis, leading to its degradation by the proteasome CC (By similarity). Ubiquitinated by CHFR, leading to its degradation by CC the proteasome (By similarity). Ubiquitinated by the anaphase-promoting CC complex (APC), leading to its degradation by the proteasome CC (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18 CC ligase leading to its activation at the centrosome which is required CC for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated CC by CUL3-KLHL18 ligase does not lead to its degradation by the CC proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:23213400}. CC -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are CC uncoupled, and this amplification is associated with cancer and with an CC increase in the levels of chromosomal instability. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2 CC different proteins (PubMed:9771714). It is clear that they are the same CC protein. {ECO:0000305|PubMed:9771714}. CC -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation CC of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M CC transition was withdrawn due to data manipulation of flow cytometry CC data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/730/AURKA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA. DR EMBL; AF008551; AAC12708.1; -; mRNA. DR EMBL; AF011467; AAC23448.1; -; Genomic_DNA. DR EMBL; AF011468; AAC63902.1; -; mRNA. DR EMBL; AF195947; AAF29508.1; -; Genomic_DNA. DR EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75550.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75551.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75552.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75553.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75554.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75555.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75556.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75557.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75558.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75559.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75561.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75562.1; -; Genomic_DNA. DR EMBL; BC001280; AAH01280.1; -; mRNA. DR EMBL; BC002499; AAH02499.1; -; mRNA. DR EMBL; BC006423; AAH06423.1; -; mRNA. DR EMBL; BC027464; AAH27464.1; -; mRNA. DR CCDS; CCDS13451.1; -. DR PIR; JC5974; JC5974. DR RefSeq; NP_001310232.1; NM_001323303.2. DR RefSeq; NP_001310233.1; NM_001323304.2. DR RefSeq; NP_001310234.1; NM_001323305.2. DR RefSeq; NP_001411346.1; NM_001424417.1. DR RefSeq; NP_003591.2; NM_003600.3. DR RefSeq; NP_940835.1; NM_198433.3. DR RefSeq; NP_940836.1; NM_198434.3. DR RefSeq; NP_940837.1; NM_198435.3. DR RefSeq; NP_940838.1; NM_198436.3. DR RefSeq; NP_940839.1; NM_198437.3. DR PDB; 1MQ4; X-ray; 1.90 A; A=125-391. DR PDB; 1MUO; X-ray; 2.90 A; A=107-403. DR PDB; 1OL5; X-ray; 2.50 A; A=122-403. DR PDB; 1OL6; X-ray; 3.00 A; A=122-403. DR PDB; 1OL7; X-ray; 2.75 A; A=122-403. DR PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403. DR PDB; 2C6D; X-ray; 2.20 A; A=124-398. DR PDB; 2C6E; X-ray; 2.10 A; A/B=123-401. DR PDB; 2DWB; X-ray; 2.50 A; A=122-403. DR PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403. DR PDB; 2J50; X-ray; 3.00 A; A/B=126-403. DR PDB; 2NP8; X-ray; 2.25 A; A=125-391. DR PDB; 2W1C; X-ray; 3.24 A; A=122-389. DR PDB; 2W1D; X-ray; 2.97 A; A=122-389. DR PDB; 2W1E; X-ray; 2.93 A; A=122-389. DR PDB; 2W1F; X-ray; 2.85 A; A=122-389. DR PDB; 2W1G; X-ray; 2.71 A; A=122-389. DR PDB; 2WQE; X-ray; 2.50 A; A=127-388. DR PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403. DR PDB; 2WTW; X-ray; 3.30 A; A=122-403. DR PDB; 2X6D; X-ray; 2.80 A; A=122-403. DR PDB; 2X6E; X-ray; 3.35 A; A=122-403. DR PDB; 2X81; X-ray; 2.91 A; A=126-391. DR PDB; 2XNE; X-ray; 2.80 A; A=122-392. DR PDB; 2XNG; X-ray; 2.60 A; A=122-403. DR PDB; 2XRU; X-ray; 2.90 A; A=126-403. DR PDB; 3COH; X-ray; 2.70 A; A/B=124-391. DR PDB; 3E5A; X-ray; 2.30 A; A=125-391. DR PDB; 3EFW; X-ray; 2.29 A; A/B=125-391. DR PDB; 3FDN; X-ray; 1.90 A; A=123-401. DR PDB; 3H0Y; X-ray; 2.50 A; A=124-391. DR PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391. DR PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391. DR PDB; 3HA6; X-ray; 2.36 A; A=125-391. DR PDB; 3K5U; X-ray; 2.35 A; A=123-401. DR PDB; 3LAU; X-ray; 2.10 A; A=125-399. DR PDB; 3M11; X-ray; 2.75 A; A=123-401. DR PDB; 3MYG; X-ray; 2.40 A; A=125-391. DR PDB; 3NRM; X-ray; 3.05 A; A=126-403. DR PDB; 3O50; X-ray; 2.00 A; A/B=125-391. DR PDB; 3O51; X-ray; 3.20 A; A=125-391. DR PDB; 3P9J; X-ray; 2.80 A; A=125-391. DR PDB; 3QBN; X-ray; 3.50 A; A=124-403. DR PDB; 3R21; X-ray; 2.90 A; A=126-391. DR PDB; 3R22; X-ray; 2.90 A; A=126-391. DR PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UO4; X-ray; 2.45 A; A=123-401. DR PDB; 3UO5; X-ray; 2.70 A; A=123-401. DR PDB; 3UO6; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOD; X-ray; 2.50 A; A=123-401. DR PDB; 3UOH; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401. DR PDB; 3UOK; X-ray; 2.95 A; A/B=123-401. DR PDB; 3UOL; X-ray; 2.40 A; A/B=123-401. DR PDB; 3UP2; X-ray; 2.30 A; A=123-401. DR PDB; 3UP7; X-ray; 3.05 A; A=123-401. DR PDB; 3VAP; X-ray; 2.66 A; A=125-391. DR PDB; 3W10; X-ray; 2.70 A; A=126-403. DR PDB; 3W16; X-ray; 2.80 A; A=126-403. DR PDB; 3W18; X-ray; 2.50 A; A/B=126-403. DR PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388. DR PDB; 4B0G; X-ray; 2.50 A; A=122-403. DR PDB; 4BN1; X-ray; 2.50 A; A=122-403. DR PDB; 4BYI; X-ray; 2.60 A; A=122-403. DR PDB; 4BYJ; X-ray; 2.75 A; A=122-403. DR PDB; 4C3P; X-ray; 2.69 A; A/D=122-403. DR PDB; 4C3R; X-ray; 2.79 A; A=122-403. DR PDB; 4CEG; X-ray; 2.10 A; A=122-403. DR PDB; 4DEA; X-ray; 2.45 A; A=123-401. DR PDB; 4DEB; X-ray; 3.05 A; A=123-401. DR PDB; 4DED; X-ray; 3.05 A; A=123-401. DR PDB; 4DEE; X-ray; 2.30 A; A=123-401. DR PDB; 4DHF; X-ray; 2.80 A; A/B=126-391. DR PDB; 4J8M; X-ray; 1.85 A; A=123-401. DR PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401. DR PDB; 4JAI; X-ray; 3.20 A; A=122-396. DR PDB; 4JAJ; X-ray; 2.70 A; A=122-396. DR PDB; 4JBO; X-ray; 2.49 A; A=123-401. DR PDB; 4JBP; X-ray; 2.45 A; A=123-401. DR PDB; 4JBQ; X-ray; 2.30 A; A=123-401. DR PDB; 4O0S; X-ray; 2.50 A; A=122-403. DR PDB; 4O0U; X-ray; 2.60 A; A=122-403. DR PDB; 4O0W; X-ray; 2.60 A; A=122-403. DR PDB; 4PRJ; X-ray; 2.80 A; A=124-391. DR PDB; 4UYN; X-ray; 1.90 A; A=125-399. DR PDB; 4UZD; X-ray; 3.20 A; A/B=125-399. DR PDB; 4UZH; X-ray; 2.00 A; A=125-399. DR PDB; 4ZS0; X-ray; 3.00 A; A=122-403. DR PDB; 4ZTQ; X-ray; 2.80 A; A=122-403. DR PDB; 4ZTR; X-ray; 2.85 A; A=122-403. DR PDB; 4ZTS; X-ray; 2.90 A; A=122-403. DR PDB; 5AAD; X-ray; 3.10 A; A=122-403. DR PDB; 5AAE; X-ray; 3.11 A; A=122-403. DR PDB; 5AAF; X-ray; 2.78 A; A=122-403. DR PDB; 5AAG; X-ray; 2.85 A; A=122-403. DR PDB; 5DN3; X-ray; 2.05 A; A=125-391. DR PDB; 5DNR; X-ray; 1.95 A; A=125-391. DR PDB; 5DOS; X-ray; 2.98 A; A=126-390. DR PDB; 5DPV; X-ray; 2.29 A; A=126-390. DR PDB; 5DR2; X-ray; 2.46 A; A=128-390. DR PDB; 5DR6; X-ray; 2.53 A; A=126-390. DR PDB; 5DR9; X-ray; 2.47 A; A=126-390. DR PDB; 5DRD; X-ray; 2.13 A; A=126-390. DR PDB; 5DT0; X-ray; 2.15 A; A=126-390. DR PDB; 5DT3; X-ray; 2.33 A; A=126-390. DR PDB; 5DT4; X-ray; 2.86 A; A=126-390. DR PDB; 5EW9; X-ray; 2.18 A; A=123-390. DR PDB; 5G15; X-ray; 2.06 A; A=122-403. DR PDB; 5G1X; X-ray; 1.72 A; A=122-403. DR PDB; 5L8J; X-ray; 1.68 A; A=122-403. DR PDB; 5L8K; X-ray; 1.79 A; A=122-403. DR PDB; 5L8L; X-ray; 1.67 A; A=122-403. DR PDB; 5LXM; X-ray; 2.08 A; A=122-403. DR PDB; 5OBJ; X-ray; 2.90 A; A=125-391. DR PDB; 5OBR; X-ray; 2.62 A; A=125-391. DR PDB; 5ODT; X-ray; 2.02 A; A=122-403. DR PDB; 5ONE; X-ray; 2.60 A; A=122-403. DR PDB; 5ORL; X-ray; 1.69 A; A=127-391. DR PDB; 5ORN; X-ray; 2.19 A; A=127-391. DR PDB; 5ORO; X-ray; 2.12 A; A=127-391. DR PDB; 5ORP; X-ray; 2.19 A; A=127-391. DR PDB; 5ORR; X-ray; 2.09 A; A=127-391. DR PDB; 5ORS; X-ray; 1.98 A; A=127-391. DR PDB; 5ORT; X-ray; 2.56 A; A=127-391. DR PDB; 5ORV; X-ray; 1.88 A; A=127-391. DR PDB; 5ORW; X-ray; 2.00 A; A=127-391. DR PDB; 5ORX; X-ray; 1.88 A; A=127-391. DR PDB; 5ORY; X-ray; 1.99 A; A=127-391. DR PDB; 5ORZ; X-ray; 1.92 A; A=127-391. DR PDB; 5OS0; X-ray; 1.74 A; A=127-391. DR PDB; 5OS1; X-ray; 1.90 A; A=127-391. DR PDB; 5OS2; X-ray; 1.92 A; A=127-391. DR PDB; 5OS3; X-ray; 1.81 A; A=127-391. DR PDB; 5OS4; X-ray; 1.88 A; A=127-391. DR PDB; 5OS5; X-ray; 1.74 A; A=125-392. DR PDB; 5OS6; X-ray; 2.20 A; A=127-391. DR PDB; 5OSD; X-ray; 1.99 A; A=125-391. DR PDB; 5OSE; X-ray; 1.90 A; A=127-391. DR PDB; 5OSF; X-ray; 1.89 A; A=127-391. DR PDB; 5ZAN; X-ray; 2.85 A; A=123-403. DR PDB; 6C2R; X-ray; 1.96 A; A=125-391. DR PDB; 6C2T; X-ray; 1.73 A; A=125-391. DR PDB; 6C83; X-ray; 2.55 A; A/B=122-403. DR PDB; 6CPE; X-ray; 2.45 A; A=122-403. DR PDB; 6CPF; X-ray; 2.30 A; A=122-403. DR PDB; 6CPG; X-ray; 2.80 A; A/D=122-403. DR PDB; 6GRA; X-ray; 2.60 A; A=122-403. DR PDB; 6HJJ; X-ray; 2.13 A; A=122-403. DR PDB; 6HJK; X-ray; 2.40 A; A=122-403. DR PDB; 6I2U; X-ray; 2.50 A; A=122-403. DR PDB; 6R49; X-ray; 2.21 A; A=122-403. DR PDB; 6R4A; X-ray; 1.94 A; A=122-403. DR PDB; 6R4B; X-ray; 2.15 A; A=122-403. DR PDB; 6R4C; X-ray; 2.04 A; A=122-403. DR PDB; 6R4D; X-ray; 2.01 A; A=122-403. DR PDB; 6VPG; X-ray; 2.64 A; A=117-389. DR PDB; 6VPH; X-ray; 2.14 A; A=117-389. DR PDB; 6VPI; X-ray; 2.00 A; A=117-389. DR PDB; 6VPJ; X-ray; 2.10 A; A=117-389. DR PDB; 6VPL; X-ray; 1.86 A; A/B=117-389. DR PDB; 6VPM; X-ray; 1.58 A; A/B=117-389. DR PDB; 6XKA; X-ray; 2.65 A; A=117-389. DR PDB; 6Z4Y; X-ray; 2.25 A; A=122-403. DR PDB; 7AYH; X-ray; 2.80 A; A=122-403. DR PDB; 7AYI; X-ray; 2.86 A; A=122-403. DR PDB; 7FIC; X-ray; 2.32 A; A=127-391. DR PDB; 7O2V; X-ray; 3.10 A; A=116-403. DR PDB; 7ZTL; X-ray; 1.90 A; A=122-403. DR PDB; 8C14; X-ray; 1.93 A; A=125-391. DR PDB; 8C15; X-ray; 2.41 A; A=126-388. DR PDB; 8C1D; X-ray; 2.12 A; A=126-388. DR PDB; 8C1E; X-ray; 2.80 A; A=125-391. DR PDB; 8C1F; X-ray; 1.92 A; A=126-388. DR PDB; 8C1G; X-ray; 1.96 A; A=126-388. DR PDB; 8C1H; X-ray; 2.23 A; A=126-388. DR PDB; 8C1I; X-ray; 2.81 A; A=126-388. DR PDB; 8C1K; X-ray; 2.43 A; A=126-390. DR PDB; 8C1M; X-ray; 2.84 A; A=125-391. DR PDB; 8GUW; X-ray; 2.70 A; A/B/C=123-403. DR PDB; 8JF4; X-ray; 2.89 A; A=127-389. DR PDB; 8JG8; X-ray; 2.90 A; A=127-389. DR PDB; 8JMX; X-ray; 2.95 A; A=127-389. DR PDB; 8OF5; X-ray; 1.97 A; A=122-403. DR PDB; 8PR7; X-ray; 2.76 A; A/D=122-403. DR PDB; 8SSO; X-ray; 1.97 A; A/D=122-403. DR PDB; 8SSP; X-ray; 2.60 A; A=122-403. DR PDB; 9BZG; X-ray; 1.80 A; A=122-403. DR PDB; 9BZL; X-ray; 1.81 A; B=122-403. DR PDBsum; 1MQ4; -. DR PDBsum; 1MUO; -. DR PDBsum; 1OL5; -. DR PDBsum; 1OL6; -. DR PDBsum; 1OL7; -. DR PDBsum; 2BMC; -. DR PDBsum; 2C6D; -. DR PDBsum; 2C6E; -. DR PDBsum; 2DWB; -. DR PDBsum; 2J4Z; -. DR PDBsum; 2J50; -. DR PDBsum; 2NP8; -. DR PDBsum; 2W1C; -. DR PDBsum; 2W1D; -. DR PDBsum; 2W1E; -. DR PDBsum; 2W1F; -. DR PDBsum; 2W1G; -. DR PDBsum; 2WQE; -. DR PDBsum; 2WTV; -. DR PDBsum; 2WTW; -. DR PDBsum; 2X6D; -. DR PDBsum; 2X6E; -. DR PDBsum; 2X81; -. DR PDBsum; 2XNE; -. DR PDBsum; 2XNG; -. DR PDBsum; 2XRU; -. DR PDBsum; 3COH; -. DR PDBsum; 3E5A; -. DR PDBsum; 3EFW; -. DR PDBsum; 3FDN; -. DR PDBsum; 3H0Y; -. DR PDBsum; 3H0Z; -. DR PDBsum; 3H10; -. DR PDBsum; 3HA6; -. DR PDBsum; 3K5U; -. DR PDBsum; 3LAU; -. DR PDBsum; 3M11; -. DR PDBsum; 3MYG; -. DR PDBsum; 3NRM; -. DR PDBsum; 3O50; -. DR PDBsum; 3O51; -. DR PDBsum; 3P9J; -. DR PDBsum; 3QBN; -. DR PDBsum; 3R21; -. DR PDBsum; 3R22; -. DR PDBsum; 3UNZ; -. DR PDBsum; 3UO4; -. DR PDBsum; 3UO5; -. DR PDBsum; 3UO6; -. DR PDBsum; 3UOD; -. DR PDBsum; 3UOH; -. DR PDBsum; 3UOJ; -. DR PDBsum; 3UOK; -. DR PDBsum; 3UOL; -. DR PDBsum; 3UP2; -. DR PDBsum; 3UP7; -. DR PDBsum; 3VAP; -. DR PDBsum; 3W10; -. DR PDBsum; 3W16; -. DR PDBsum; 3W18; -. DR PDBsum; 3W2C; -. DR PDBsum; 4B0G; -. DR PDBsum; 4BN1; -. DR PDBsum; 4BYI; -. DR PDBsum; 4BYJ; -. DR PDBsum; 4C3P; -. DR PDBsum; 4C3R; -. DR PDBsum; 4CEG; -. DR PDBsum; 4DEA; -. DR PDBsum; 4DEB; -. DR PDBsum; 4DED; -. DR PDBsum; 4DEE; -. DR PDBsum; 4DHF; -. DR PDBsum; 4J8M; -. DR PDBsum; 4J8N; -. DR PDBsum; 4JAI; -. DR PDBsum; 4JAJ; -. DR PDBsum; 4JBO; -. DR PDBsum; 4JBP; -. DR PDBsum; 4JBQ; -. DR PDBsum; 4O0S; -. DR PDBsum; 4O0U; -. DR PDBsum; 4O0W; -. DR PDBsum; 4PRJ; -. DR PDBsum; 4UYN; -. DR PDBsum; 4UZD; -. DR PDBsum; 4UZH; -. DR PDBsum; 4ZS0; -. DR PDBsum; 4ZTQ; -. DR PDBsum; 4ZTR; -. DR PDBsum; 4ZTS; -. DR PDBsum; 5AAD; -. DR PDBsum; 5AAE; -. DR PDBsum; 5AAF; -. DR PDBsum; 5AAG; -. DR PDBsum; 5DN3; -. DR PDBsum; 5DNR; -. DR PDBsum; 5DOS; -. DR PDBsum; 5DPV; -. DR PDBsum; 5DR2; -. DR PDBsum; 5DR6; -. DR PDBsum; 5DR9; -. DR PDBsum; 5DRD; -. DR PDBsum; 5DT0; -. DR PDBsum; 5DT3; -. DR PDBsum; 5DT4; -. DR PDBsum; 5EW9; -. DR PDBsum; 5G15; -. DR PDBsum; 5G1X; -. DR PDBsum; 5L8J; -. DR PDBsum; 5L8K; -. DR PDBsum; 5L8L; -. DR PDBsum; 5LXM; -. DR PDBsum; 5OBJ; -. DR PDBsum; 5OBR; -. DR PDBsum; 5ODT; -. DR PDBsum; 5ONE; -. DR PDBsum; 5ORL; -. DR PDBsum; 5ORN; -. DR PDBsum; 5ORO; -. DR PDBsum; 5ORP; -. DR PDBsum; 5ORR; -. DR PDBsum; 5ORS; -. DR PDBsum; 5ORT; -. DR PDBsum; 5ORV; -. DR PDBsum; 5ORW; -. DR PDBsum; 5ORX; -. DR PDBsum; 5ORY; -. DR PDBsum; 5ORZ; -. DR PDBsum; 5OS0; -. DR PDBsum; 5OS1; -. DR PDBsum; 5OS2; -. DR PDBsum; 5OS3; -. DR PDBsum; 5OS4; -. DR PDBsum; 5OS5; -. DR PDBsum; 5OS6; -. DR PDBsum; 5OSD; -. DR PDBsum; 5OSE; -. DR PDBsum; 5OSF; -. DR PDBsum; 5ZAN; -. DR PDBsum; 6C2R; -. DR PDBsum; 6C2T; -. DR PDBsum; 6C83; -. DR PDBsum; 6CPE; -. DR PDBsum; 6CPF; -. DR PDBsum; 6CPG; -. DR PDBsum; 6GRA; -. DR PDBsum; 6HJJ; -. DR PDBsum; 6HJK; -. DR PDBsum; 6I2U; -. DR PDBsum; 6R49; -. DR PDBsum; 6R4A; -. DR PDBsum; 6R4B; -. DR PDBsum; 6R4C; -. DR PDBsum; 6R4D; -. DR PDBsum; 6VPG; -. DR PDBsum; 6VPH; -. DR PDBsum; 6VPI; -. DR PDBsum; 6VPJ; -. DR PDBsum; 6VPL; -. DR PDBsum; 6VPM; -. DR PDBsum; 6XKA; -. DR PDBsum; 6Z4Y; -. DR PDBsum; 7AYH; -. DR PDBsum; 7AYI; -. DR PDBsum; 7FIC; -. DR PDBsum; 7O2V; -. DR PDBsum; 7ZTL; -. DR PDBsum; 8C14; -. DR PDBsum; 8C15; -. DR PDBsum; 8C1D; -. DR PDBsum; 8C1E; -. DR PDBsum; 8C1F; -. DR PDBsum; 8C1G; -. DR PDBsum; 8C1H; -. DR PDBsum; 8C1I; -. DR PDBsum; 8C1K; -. DR PDBsum; 8C1M; -. DR PDBsum; 8GUW; -. DR PDBsum; 8JF4; -. DR PDBsum; 8JG8; -. DR PDBsum; 8JMX; -. DR PDBsum; 8OF5; -. DR PDBsum; 8PR7; -. DR PDBsum; 8SSO; -. DR PDBsum; 8SSP; -. DR PDBsum; 9BZG; -. DR PDBsum; 9BZL; -. DR AlphaFoldDB; O14965; -. DR SMR; O14965; -. DR BioGRID; 112666; 697. DR CORUM; O14965; -. DR DIP; DIP-33068N; -. DR ELM; O14965; -. DR FunCoup; O14965; 1695. DR IntAct; O14965; 219. DR MINT; O14965; -. DR STRING; 9606.ENSP00000216911; -. DR BindingDB; O14965; -. DR ChEMBL; CHEMBL4722; -. DR DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole. DR DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE. DR DrugBank; DB07266; AKI-001. DR DrugBank; DB05220; Alisertib. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB05169; AT9283. DR DrugBank; DB06347; Cenisertib. DR DrugBank; DB05198; CYC116. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB16891; ENMD-981693. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB18019; Erbumine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB12556; MK-5108. DR DrugBank; DB13061; MLN8054. DR DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE. DR DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB13059; PF-03814735. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB06134; SNS-314. DR DrugCentral; O14965; -. DR GuidetoPHARMACOLOGY; 1936; -. DR GlyGen; O14965; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14965; -. DR PhosphoSitePlus; O14965; -. DR BioMuta; AURKA; -. DR CPTAC; CPTAC-1341; -. DR CPTAC; CPTAC-3083; -. DR CPTAC; CPTAC-3084; -. DR jPOST; O14965; -. DR MassIVE; O14965; -. DR PaxDb; 9606-ENSP00000216911; -. DR PeptideAtlas; O14965; -. DR ProteomicsDB; 48339; -. DR Pumba; O14965; -. DR ABCD; O14965; 7 sequenced antibodies. DR Antibodypedia; 1129; 1084 antibodies from 47 providers. DR DNASU; 6790; -. DR Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.19. DR Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.19. DR Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.19. DR Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.19. DR Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.19. DR Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.19. DR Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.19. DR GeneID; 6790; -. DR KEGG; hsa:6790; -. DR MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1. DR UCSC; uc002xxe.1; human. DR AGR; HGNC:11393; -. DR CIViC; 6790; 8 evidence items across 3 molecular profiles. DR ClinPGx; PA36201; -. DR CTD; 6790; -. DR DisGeNET; 6790; -. DR GeneCards; AURKA; -. DR HGNC; HGNC:11393; AURKA. DR HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; AURKA; -. DR MIM; 603072; gene. DR OpenTargets; ENSG00000087586; -. DR VEuPathDB; HostDB:ENSG00000087586; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000154900; -. DR InParanoid; O14965; -. DR OMA; KIMNLMF; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; O14965; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14965; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O14965; -. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA. DR SignaLink; O14965; -. DR SIGNOR; O14965; -. DR Agora; ENSG00000087586; -. DR BioGRID-ORCS; 6790; 713 hits in 1214 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; AURKA; human. DR EvolutionaryTrace; O14965; -. DR GeneWiki; Aurora_A_kinase; -. DR GenomeRNAi; 6790; -. DR Pharos; O14965; Tchem. DR PRO; PR:O14965; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; O14965; protein. DR Bgee; ENSG00000087586; Expressed in oocyte and 159 other cell types or tissues. DR ExpressionAtlas; O14965; baseline and differential. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB. DR GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0042585; C:germinal vesicle; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:HPA. DR GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0045120; C:pronucleus; IEA:Ensembl. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035175; F:histone H3S10 kinase activity; IEA:Ensembl. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051642; P:centrosome localization; IEA:Ensembl. DR GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0097421; P:liver regeneration; IDA:MGI. DR GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc. DR GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0009611; P:response to wounding; IDA:MGI. DR GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl. DR GO; GO:0007051; P:spindle organization; IMP:UniProtKB. DR CDD; cd14116; STKc_Aurora-A; 1. DR DisProt; DP03125; -. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000235; Serine/threonine-protein kinase ark1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR030611; AURKA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane; KW Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm; KW Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..403 FT /note="Aurora kinase A" FT /id="PRO_0000086692" FT DOMAIN 133..383 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..125 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 280..293 FT /note="Activation segment" FT /evidence="ECO:0000269|PubMed:14580337" FT COMPBIAS 27..83 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 91..101 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 114..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 256 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027, FT ECO:0000269|PubMed:14580337" FT BINDING 143 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 162 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 211..213 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 260..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 274 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 51 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17229885" FT MOD_RES 287 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:19668197" FT MOD_RES 288 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11039908, FT ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907, FT ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606" FT MOD_RES 342 FT /note="Phosphoserine; by PKA and PAK" FT /evidence="ECO:0000269|PubMed:16246726" FT CROSSLNK 258 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 11 FT /note="G -> R (in dbSNP:rs6069717)" FT /id="VAR_030840" FT VARIANT 31 FT /note="F -> I (in dbSNP:rs2273535)" FT /evidence="ECO:0000269|PubMed:15867347, FT ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714" FT /id="VAR_030841" FT VARIANT 50 FT /note="P -> L (in dbSNP:rs34572020)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041127" FT VARIANT 57 FT /note="I -> V (increased kinase activity; dbSNP:rs1047972)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, FT ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714" FT /id="VAR_030842" FT VARIANT 104 FT /note="S -> L (in dbSNP:rs2230743)" FT /id="VAR_061745" FT VARIANT 155 FT /note="S -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; reduces interaction with TPX2)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041128" FT VARIANT 174 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; constitutively enhanced kinase activity)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041129" FT VARIANT 373 FT /note="M -> V (in dbSNP:rs33923703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041130" FT MUTAGEN 162 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14702041" FT MUTAGEN 165 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 198 FT /note="G->N: Reduces interaction with TPX2. Reduces kinase FT activity tenfold. Promotes interaction with the AURKB FT binding partners INCENP and BIRC5 that are normally not FT bound by AURKA." FT /evidence="ECO:0000269|PubMed:19357306" FT MUTAGEN 205 FT /note="R->A: Reduces ubiquitination and proteasomal FT degradation." FT /evidence="ECO:0000269|PubMed:10851084" FT MUTAGEN 274 FT /note="D->N: Abolishes cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:17604723" FT MUTAGEN 287 FT /note="T->A: No direct effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 287 FT /note="T->E: Enhances interaction with TPX2." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 288 FT /note="T->A: Reduces cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:17604723" FT MUTAGEN 288 FT /note="T->D: Mimics phosphorylation state and increases FT kinase activity." FT /evidence="ECO:0000269|PubMed:11039908" FT MUTAGEN 290 FT /note="C->A: Enhances stability; when associated with A- FT 393." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 334 FT /note="Y->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 335 FT /note="Q->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 346 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 393 FT /note="C->A: Enhances stability; when associated with A- FT 290." FT /evidence="ECO:0000269|PubMed:27837025" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 133..141 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 143..152 FT /evidence="ECO:0007829|PDB:6VPM" FT TURN 153..156 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 157..165 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 166..172 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 175..185 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:3UO6" FT STRAND 196..201 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:2J50" FT HELIX 218..225 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 230..249 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6XKA" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:3UOL" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:5ORL" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:5L8L" FT HELIX 288..291 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:5L8J" FT HELIX 298..302 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 304..306 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:6C2T" FT HELIX 310..324 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 334..342 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 350..352 FT /evidence="ECO:0007829|PDB:8JF4" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 368..370 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 374..378 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 381..386 FT /evidence="ECO:0007829|PDB:6VPM" SQ SEQUENCE 403 AA; 45823 MW; 7C2E7B438D969187 CRC64; MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS // ID BAP1_HUMAN Reviewed; 729 AA. AC Q92560; A8K993; Q6LEM0; Q7Z5E8; DT 05-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1998, sequence version 2. DT 28-JAN-2026, entry version 194. DE RecName: Full=Ubiquitin carboxyl-terminal hydrolase BAP1 {ECO:0000305}; DE EC=3.4.19.12 {ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:9528852}; DE AltName: Full=BRCA1-associated protein 1 {ECO:0000303|PubMed:9528852}; DE AltName: Full=Cerebral protein 6 {ECO:0000303|Ref.2}; GN Name=BAP1 {ECO:0000303|PubMed:9528852, ECO:0000312|HGNC:HGNC:950}; GN Synonyms=KIAA0272 {ECO:0000303|PubMed:9039502}; GN ORFNames=hucep-6 {ECO:0000303|Ref.2}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, MUTAGENESIS OF CYS-91 AND RP LEU-691, INTERACTION WITH BRCA1, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, RP AND MISCELLANEOUS. RC TISSUE=B-cell; RX PubMed=9528852; DOI=10.1038/sj.onc.1201861; RA Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., RA Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minna J., Borodovsky A., RA Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S., RA Prendergast G.C., Rauscher F.J. III; RT "BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and RT enhances BRCA1-mediated cell growth suppression."; RL Oncogene 16:1097-1112(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RA Yoshimoto M., Yazaki M., Takayama K., Matsumoto K.; RT "Biological functions of a novel human gene, hucep-6, which is specifically RT expressed in the central nervous system."; RL Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=9039502; DOI=10.1093/dnares/3.5.321; RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O., RA Tanaka A., Kotani H., Miyajima N., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. VI. The RT coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of RT cDNA clones from cell line KG-1 and brain."; RL DNA Res. 3:321-329(1996). RN [4] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 164-729. RC TISSUE=Medulloblastoma; RX PubMed=12800201; DOI=10.1002/ijc.11208; RA Behrends U., Schneider I., Roessler S., Frauenknecht H., Golbeck A., RA Lechner B., Eigenstetter G., Zobywalski C., Mueller-Weihrich S., RA Graubner U., Schmid I., Sackerer D., Spaeth M., Goetz C., Prantl F., RA Asmuss H.-P., Bise K., Mautner J.; RT "Novel tumor antigens identified by autologous antibody screening of RT childhood medulloblastoma cDNA libraries."; RL Int. J. Cancer 106:244-251(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-369; SER-521; RP SER-537; SER-585 AND SER-597, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS ASP-95 AND VAL-178. RX PubMed=10546591; DOI=10.1016/s0304-3835(99)90004-6; RA Jensen D.E., Rauscher F.J. III; RT "Defining biochemical functions for the BRCA1 tumor suppressor protein: RT analysis of the BRCA1 binding protein BAP1."; RL Cancer Lett. 143:S13-S17(1999). RN [16] RP FUNCTION. RX PubMed=12485996; DOI=10.1093/emboj/cdf691; RA Mallery D.L., Vandenberg C.J., Hiom K.; RT "Activation of the E3 ligase function of the BRCA1/BARD1 complex by RT polyubiquitin chains."; RL EMBO J. 21:6755-6762(2002). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, MUTAGENESIS OF RP CYS-91; 656-LYS--ARG-661 AND 717-ARG--ARG-722, AND CHARACTERIZATION OF RP VARIANTS ASP-95 AND VAL-178. RX PubMed=18757409; DOI=10.1158/0008-5472.can-08-0365; RA Ventii K.H., Devi N.S., Friedrich K.L., Chernova T.A., Tighiouart M., RA Van Meir E.G., Wilkinson K.D.; RT "BRCA1-associated protein-1 is a tumor suppressor that requires RT deubiquitinating activity and nuclear localization."; RL Cancer Res. 68:6953-6962(2008). RN [18] RP FUNCTION, INTERACTION WITH BARD1 AND BRCA1, AND CHARACTERIZATION OF VARIANT RP KURIS SER-91. RX PubMed=19117993; DOI=10.1158/0008-5472.can-08-3355; RA Nishikawa H., Wu W., Koike A., Kojima R., Gomi H., Fukuda M., Ohta T.; RT "BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer RT activity."; RL Cancer Res. 69:111-119(2009). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, MUTAGENESIS OF RP 363-ASN--TYR-366, AND CHARACTERIZATION OF VARIANT KURIS SER-91. RX PubMed=19815555; DOI=10.1074/jbc.m109.046755; RA Machida Y.J., Machida Y., Vashisht A.A., Wohlschlegel J.A., Dutta A.; RT "The deubiquitinating enzyme BAP1 regulates cell growth via interaction RT with HCF-1."; RL J. Biol. Chem. 284:34179-34188(2009). RN [20] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, AND MUTAGENESIS OF RP CYS-91 AND 363-ASN--TYR-366. RX PubMed=19188440; DOI=10.1128/mcb.01517-08; RA Misaghi S., Ottosen S., Izrael-Tomasevic A., Arnott D., Lamkanfi M., RA Lee J., Liu J., O'Rourke K., Dixit V.M., Wilson A.C.; RT "Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 RT with cell cycle regulator host cell factor 1."; RL Mol. Cell. Biol. 29:2181-2192(2009). RN [21] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, INTERACTION WITH YY1 AND RP HCFC1, IDENTIFICATION BY MASS SPECTROMETRY, AND CHARACTERIZATION OF VARIANT RP KURIS SER-91. RX PubMed=20805357; DOI=10.1128/mcb.00396-10; RA Yu H., Mashtalir N., Daou S., Hammond-Martel I., Ross J., Sui G., RA Hart G.W., Rauscher F.J. III, Drobetsky E., Milot E., Shi Y., Affar el B.; RT "The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and RT HCF-1 and is a critical regulator of gene expression."; RL Mol. Cell. Biol. 30:5071-5085(2010). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE PR-DUB COMPLEX, AND RP INTERACTION WITH ASXL1. RX PubMed=20436459; DOI=10.1038/nature08966; RA Scheuermann J.C., de Ayala Alonso A.G., Oktaba K., Ly-Hartig N., RA McGinty R.K., Fraterman S., Wilm M., Muir T.W., Muller J.; RT "Histone H2A deubiquitinase activity of the Polycomb repressive complex PR- RT DUB."; RL Nature 465:243-247(2010). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF 691-LEU--LYS-711. RX PubMed=24703950; DOI=10.1016/j.molcel.2014.03.002; RA Mashtalir N., Daou S., Barbour H., Sen N.N., Gagnon J., Hammond-Martel I., RA Dar H.H., Therrien M., Affar E.B.; RT "Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic RT sequestration mediated by the atypical ubiquitin ligase UBE2O."; RL Mol. Cell 54:392-406(2014). RN [24] RP SUBCELLULAR LOCATION, AND INTERACTION WITH FOXK2. RX PubMed=24748658; DOI=10.1093/nar/gku274; RA Ji Z., Mohammed H., Webber A., Ridsdale J., Han N., Carroll J.S., RA Sharrocks A.D.; RT "The forkhead transcription factor FOXK2 acts as a chromatin targeting RT factor for the BAP1-containing histone deubiquitinase complex."; RL Nucleic Acids Res. 42:6232-6242(2014). RN [25] RP IDENTIFICATION IN THE PR-DUB COMPLEX, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=24634419; DOI=10.1002/pmic.201400013; RA Baymaz H.I., Fournier A., Laget S., Ji Z., Jansen P.W., Smits A.H., RA Ferry L., Mensinga A., Poser I., Sharrocks A., Defossez P.A., Vermeulen M.; RT "MBD5 and MBD6 interact with the human PR-DUB complex through their methyl- RT CpG-binding domain."; RL Proteomics 14:2179-2189(2014). RN [26] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, DOMAIN, AND RP MUTAGENESIS OF ASN-251; LEU-635 AND 713-ARG--GLN-729. RX PubMed=30258054; DOI=10.1038/s41467-018-06186-1; RA Foglizzo M., Middleton A.J., Burgess A.E., Crowther J.M., Dobson R.C.J., RA Murphy J.M., Day C.L., Mace P.D.; RT "A bidentate Polycomb Repressive-Deubiquitinase complex is required for RT efficient activity on nucleosomes."; RL Nat. Commun. 9:3932-3932(2018). RN [27] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, SUBCELLULAR LOCATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=30664650; DOI=10.1038/s41467-018-08255-x; RA Campagne A., Lee M.K., Zielinski D., Michaud A., Le Corre S., Dingli F., RA Chen H., Shahidian L.Z., Vassilev I., Servant N., Loew D., Pasmant E., RA Postel-Vinay S., Wassef M., Margueron R.; RT "BAP1 complex promotes transcription by opposing PRC1-mediated H2A RT ubiquitylation."; RL Nat. Commun. 10:348-348(2019). RN [28] RP FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=34170818; DOI=10.7554/elife.63254; RA Perez-Garcia V., Lea G., Lopez-Jimenez P., Okkenhaug H., Burton G.J., RA Moffett A., Turco M.Y., Hemberger M.; RT "BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition RT during trophoblast differentiation and invasion."; RL Elife 10:0-0(2021). RN [29] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, INTERACTION WITH ASXL1, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=36180891; DOI=10.1186/s13059-022-02776-x; RA Tsuboyama N., Szczepanski A.P., Zhao Z., Wang L.; RT "MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent RT cancer."; RL Genome Biol. 23:206-206(2022). RN [30] {ECO:0007744|PDB:7VPW} RP X-RAY CRYSTALLOGRAPHY (3.76 ANGSTROMS) OF 706-724, SUBUNIT, INTERACTION RP WITH TNPO1; KPNA1 AND KPNA2, SUBCELLULAR LOCATION, DOMAIN NLS, RP UBIQUITINATION, MUTAGENESIS OF 684-GLN--GLN-729, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=35446349; DOI=10.1083/jcb.202201094; RA Yang T.J., Li T.N., Huang R.S., Pan M.Y., Lin S.Y., Lin S., Wu K.P., RA Wang L.H., Hsu S.D.; RT "Tumor suppressor BAP1 nuclear import is governed by transportin-1."; RL J. Cell Biol. 221:0-0(2022). RN [31] {ECO:0007744|PDB:8H1T} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) IN COMPLEX WITH ASXL1; RP UBB AND THE CHROMATOSOME COMPLEX, INTERACTION WITH ASXL1 AND CHROMATOSOME RP COMPLEX, DOMAIN C-TERMINAL TAIL AND UCH, AND MUTAGENESIS OF 56-ARG--ARG-60; RP 697-SER--GLN-729; 699-ARG--GLN-702; ARG-699; ARG-700; ARG-701; GLN-702; RP GLY-703; ARG-708; 711-LYS--ARG-718; 711-LYS--GLN-729; ARG-713 AND RP 718-ARG--GLN-729. RX PubMed=36991118; DOI=10.1038/s41586-023-05841-y; RA Ge W., Yu C., Li J., Yu Z., Li X., Zhang Y., Liu C.P., Li Y., Tian C., RA Zhang X., Li G., Zhu B., Xu R.M.; RT "Basis of the H2AK119specificity of the Polycomb repressive RT deubiquitinase."; RL Nature 616:176-182(2023). RN [32] {ECO:0007744|PDB:8SVF} RP STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN COMPLEX WITH ASXL1; RP UBC AND THE XENOPUS NUCLEOSOME COMPLEX, INTERACTION WITH ASXL1 AND THE RP NUCLEOSOME COMPLEX, DOMAIN UCH AND ARG-FINGER, AND MUTAGENESIS OF RP 56-ARG--ARG-60; ARG-56; ARG-59; 699-ARG--ARG-701; 699-ARG-ARG-700; ARG-699 RP AND ARG-701. RX PubMed=37556531; DOI=10.1126/sciadv.adg9832; RA Thomas J.F., Valencia-Sanchez M.I., Tamburri S., Gloor S.L., RA Rustichelli S., Godinez-Lopez V., De Ioannes P., Lee R., Abini-Agbomson S., RA Gretarsson K., Burg J.M., Hickman A.R., Sun L., Gopinath S., Taylor H.F., RA Sun Z.W., Ezell R.J., Vaidya A., Meiners M.J., Cheek M.A., Rice W.J., RA Svetlov V., Nudler E., Lu C., Keogh M.C., Pasini D., Armache K.J.; RT "Structural basis of histone H2A lysine 119 deubiquitination by Polycomb RT repressive deubiquitinase BAP1/ASXL1."; RL Sci. Adv. 9:eadg9832-eadg9832(2023). RN [33] RP VARIANT TPDS1 267-GLN--GLN-729 DEL, AND INVOLVEMENT IN TPDS1. RX PubMed=21941004; DOI=10.1136/jmedgenet-2011-100156; RA Abdel-Rahman M.H., Pilarski R., Cebulla C.M., Massengill J.B., RA Christopher B.N., Boru G., Hovland P., Davidorf F.H.; RT "Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, RT meningioma, and other cancers."; RL J. Med. Genet. 48:856-859(2011). RN [34] RP INVOLVEMENT IN MESOM, AND VARIANTS CYS-63; VAL-81; TRP-91; ASP-95; ALA-315 RP AND VAL-685. RX PubMed=21642991; DOI=10.1038/ng.855; RA Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., RA Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S., RA Zhou Q., Shen R., Olshen A., Rusch V., Ladanyi M.; RT "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic RT mutations and 3p21.1 losses in malignant pleural mesothelioma."; RL Nat. Genet. 43:668-672(2011). RN [35] RP INVOLVEMENT IN TPDS1. RX PubMed=21874003; DOI=10.1038/ng.910; RA Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P., RA Windpassinger C., Wackernagel W., Loy S., Wolf I., Viale A., Lash A.E., RA Pirun M., Socci N.D., Rutten A., Palmedo G., Abramson D., Offit K., Ott A., RA Becker J.C., Cerroni L., Kutzner H., Bastian B.C., Speicher M.R.; RT "Germline mutations in BAP1 predispose to melanocytic tumors."; RL Nat. Genet. 43:1018-1021(2011). RN [36] RP INVOLVEMENT IN TPDS1 AND MESOM. RX PubMed=21874000; DOI=10.1038/ng.912; RA Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., RA Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A., RA Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M.; RT "Germline BAP1 mutations predispose to malignant mesothelioma."; RL Nat. Genet. 43:1022-1025(2011). RN [37] RP VARIANT TPDS1 ALA-93. RX PubMed=23684012; DOI=10.1016/j.ajhg.2013.04.012; RA Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., RA Dubois-d'Enghien C., Richaudeau B., Renaudin X., Sellers J., Nicolas A., RA Sastre-Garau X., Desjardins L., Gyapay G., Raynal V., Sinilnikova O.M., RA Andrieu N., Manie E., de Pauw A., Gesta P., Bonadona V., Maugard C.M., RA Penet C., Avril M.F., Barillot E., Cabaret O., Delattre O., Richard S., RA Caron O., Benfodda M., Hu H.H., Soufir N., Bressac-de Paillerets B., RA Stoppa-Lyonnet D., Stern M.H.; RT "Germline BAP1 mutations predispose to renal cell carcinomas."; RL Am. J. Hum. Genet. 92:974-980(2013). RN [38] RP VARIANT PHE-47. RX PubMed=25080371; DOI=10.1111/cge.12472; RA de la Fouchardiere A., Cabaret O., Savin L., Combemale P., Schvartz H., RA Penet C., Bonadona V., Soufir N., Bressac-de Paillerets B.; RT "Germline BAP1 mutations predispose also to multiple basal cell RT carcinomas."; RL Clin. Genet. 88:273-277(2015). RN [39] RP FUNCTION, INTERACTION WITH FOXK1 AND FOXK2, PHOSPHORYLATION AT THR-493, RP MUTAGENESIS OF SER-489; SER-492; THR-493 AND THR-495, AND CHARACTERIZATION RP OF VARIANT KURIS SER-91. RX PubMed=25451922; DOI=10.1074/jbc.m114.609834; RA Okino Y., Machida Y., Frankland-Searby S., Machida Y.J.; RT "BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the RT ubiquitin-mediated activation of FoxK2 target genes."; RL J. Biol. Chem. 290:1580-1591(2015). RN [40] RP INVOLVEMENT IN UVM2. RX PubMed=25687217; DOI=10.3109/13816810.2015.1010734; RA Cebulla C.M., Binkley E.M., Pilarski R., Massengill J.B., Rai K., RA Liebner D.A., Marino M.J., Singh A.D., Abdel-Rahman M.H.; RT "Analysis of BAP1 Germline gene mutation in young uveal melanoma RT patients."; RL Ophthalmic Genet. 36:126-131(2015). RN [41] RP CHARACTERIZATION OF VARIANTS PHE-47; VAL-81; ASP-95 AND VAL-178. RX PubMed=26680512; DOI=10.1038/srep18462; RA Bhattacharya S., Hanpude P., Maiti T.K.; RT "Cancer associated missense mutations in BAP1 catalytic domain induce RT amyloidogenic aggregation: A new insight in enzymatic inactivation."; RL Sci. Rep. 5:18462-18462(2015). RN [42] RP INVOLVEMENT IN UVM2. RX PubMed=32002398; DOI=10.1159/000499570; RA Yu M.D., Masoomian B., Shields J.A., Shields C.L.; RT "BAP1 germline mutation associated with bilateral primary uveal melanoma."; RL Ocul. Oncol. Pathol. 6:10-14(2020). RN [43] RP VARIANTS KURIS ALA-12; THR-12; LYS-31; PRO-49; ARG-91; GLY-91; SER-91; RP ARG-169 AND GLN-718, CHARACTERIZATION OF VARIANTS KURIS THR-12; ARG-91; RP SER-91; ARG-169 AND GLN-718, INVOLVEMENT IN KURIS, FUNCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=35051358; DOI=10.1016/j.ajhg.2021.12.011; RG Undiagnosed Diseases Network; RA Kuery S., Ebstein F., Molle A., Besnard T., Lee M.K., Vignard V., Hery T., RA Nizon M., Mancini G.M.S., Giltay J.C., Cogne B., McWalter K., Deb W., RA Mor-Shaked H., Li H., Schnur R.E., Wentzensen I.M., Denomme-Pichon A.S., RA Fourgeux C., Verheijen F.W., Faurie E., Schot R., Stevens C.A., Smits D.J., RA Barr E., Sheffer R., Bernstein J.A., Stimach C.L., Kovitch E., Shashi V., RA Schoch K., Smith W., van Jaarsveld R.H., Hurst A.C.E., Smith K., RA Baugh E.H., Bohm S.G., Vyhnalkova E., Ryba L., Delnatte C., Neira J., RA Bonneau D., Toutain A., Rosenfeld J.A., Audebert-Bellanger S., RA Gilbert-Dussardier B., Odent S., Laumonnier F., Berger S.I., Smith A.C.M., RA Bourdeaut F., Stern M.H., Redon R., Krueger E., Margueron R., Bezieau S., RA Poschmann J., Isidor B.; RT "Rare germline heterozygous missense variants in BRCA1-associated protein RT 1, BAP1, cause a syndromic neurodevelopmental disorder."; RL Am. J. Hum. Genet. 109:361-372(2022). CC -!- FUNCTION: Deubiquitinating enzyme that plays a key role in chromatin by CC mediating deubiquitination of histone H2A and HCFC1 (PubMed:12485996, CC PubMed:18757409, PubMed:20436459, PubMed:25451922, PubMed:35051358). CC Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) CC complex, a complex that specifically mediates deubiquitination of CC histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1) CC (PubMed:20436459, PubMed:25451922, PubMed:30664650, PubMed:35051358). CC Does not deubiquitinate monoubiquitinated histone H2B (PubMed:20436459, CC PubMed:30664650). The PR-DUB complex is an epigenetic regulator of gene CC expression and acts as a transcriptional coactivator, affecting genes CC involved in development, cell communication, signaling, cell CC proliferation and cell viability (PubMed:20805357, PubMed:30664650, CC PubMed:36180891). Antagonizes PRC1 mediated H2AK119ub1 CC monoubiquitination (PubMed:30664650). As part of the PR-DUB complex, CC associates with chromatin enriched in histone marks H3K4me1, H3K4me3, CC and H3K27Ac, but not in H3K27me3 (PubMed:36180891). Recruited to CC specific gene-regulatory regions by YY1 (PubMed:20805357). Acts as a CC regulator of cell growth by mediating deubiquitination of HCFC1 N- CC terminal and C-terminal chains, with some specificity toward 'Lys-48'- CC linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin CC chains (PubMed:19188440, PubMed:19815555). Deubiquitination of HCFC1 CC does not lead to increase stability of HCFC1 (PubMed:19188440, CC PubMed:19815555). Interferes with the BRCA1 and BARD1 heterodimer CC activity by inhibiting their ability to mediate ubiquitination and CC autoubiquitination (PubMed:19117993). It however does not mediate CC deubiquitination of BRCA1 and BARD1 (PubMed:19117993). Able to mediate CC autodeubiquitination via intramolecular interactions to counteract CC monoubiquitination at the nuclear localization signal (NLS), thereby CC protecting it from cytoplasmic sequestration (PubMed:24703950). CC Negatively regulates epithelial-mesenchymal transition (EMT) of CC trophoblast stem cells during placental development by regulating genes CC involved in epithelial cell integrity, cell adhesion and cytoskeletal CC organization (PubMed:34170818). {ECO:0000269|PubMed:12485996, CC ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:20805357, CC ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:25451922, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:34170818, CC ECO:0000269|PubMed:35051358, ECO:0000269|PubMed:36180891}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide CC and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76- CC residue protein attached to proteins as an intracellular targeting CC signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:20436459, CC ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:9528852}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=4.7 uM for ubiquitin-7-amido-4-methylcoumarin (UB-AMC) CC {ECO:0000269|PubMed:30258054}; CC -!- SUBUNIT: Core component of the polycomb repressive deubiquitinase (PR- CC DUB) complex, at least composed of BAP1, one of ASXL1, ASXL2 or CC (probably) ASXL3, and one of MBD5 or MBD6 (PubMed:20436459, CC PubMed:24634419, PubMed:30664650, PubMed:36180891). The PR-DUB core CC associates with a number of accessory proteins, including FOXK1, FOXK2, CC KDM1B, HCFC1, YY1 and OGT; KDM1B specifically associates with ASXL2 PR- CC DUB complexes (Probable) (PubMed:20805357, PubMed:30664650). The BAP1 CC deubiquitinase activity is not required for PR-DUB assembly CC (PubMed:20805357). Homodimerizes (via coiled-coil hinge-region between CC the UCH and ULD domains) to mediate assembly of 2 copies of the BAP1- CC ASXL heterodimer into a bisymmetric tetramer; dimerization enhances CC association with nucleosomes (PubMed:30258054, PubMed:35446349). The CC PR-DUB complex associates with nucleosomes to mediate deubiquitination CC of 'lys-120' of histone H2AK118ub1 substrates; the association requires CC the positively charged C-terminal tail of BAP1 (PubMed:30258054, CC PubMed:36991118, PubMed:37556531). Interacts (via ULD domain) with CC ASXL1 (via DEUBAD domain); the interaction is direct and forms a CC ubiquitin binding cleft (PubMed:36180891, PubMed:36991118, CC PubMed:37556531). The interaction with ASXL1 stabilizes BAP1 but is not CC required for nucleosome binding (PubMed:36180891). Associates (via C- CC terminus) with nucleosome and chromatosome complexes through direct CC interaction with DNA and the histone3/4 dimer; this association CC displaces the histone-2A C-terminal tail, extending and orienting the CC H2AK118ub1 substrate towards the BAP1 deubiquitinase active site CC (PubMed:36991118, PubMed:37556531). Also interacts (via arginine CC finger) directly with the histone H2A-H2B acidic patch; this CC interaction is not critical for nucleosome-chromatosome association but CC may play a role in orienting the H2AK118ub1 substrate towards the PR- CC DUB complex active site (PubMed:36991118). Interacts with BRCA1 (via CC the RING finger) (PubMed:19117993, PubMed:9528852). Interacts (via HBM- CC like motif) with HCFC1 (PubMed:19188440, PubMed:19815555, CC PubMed:20805357). Interacts (via a C-terminal region overlapping the CC ULD domain) with YY1; the interaction is direct and requires the CC interaction with HCFC1 (PubMed:20805357). Interacts (when CC phosphorylated at Thr-493) with FOXK1 (PubMed:25451922). Interacts CC (when phosphorylated at Thr-493) with FOXK2; leading to recruitment of CC the PR-DUB complex and repression of FOXK2 target genes CC (PubMed:24748658, PubMed:25451922). Interacts (via non-classical PY- CC NLS) with TNPO1/transportin-1 (via HEAT repeats 8-12); the interaction CC is direct, mediates BAP1 nuclear localization and disrupts BAP1 CC homodimerization (PubMed:35446349). Interacts (via C-terminus) with CC KPNA1/importin alpha5 and KPNA2/importin alpha1; these interactions can CC contribute to BAP1 nuclear localization but are less important than the CC interaction with TNPO1/transportin-1 (PubMed:35446349). The interaction CC with TNPO1/transportin-1 disrupts homodimerization and blocks CC ubiquitination by UBE2O (PubMed:35446349). CC {ECO:0000269|PubMed:19117993, ECO:0000269|PubMed:19188440, CC ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20436459, CC ECO:0000269|PubMed:20805357, ECO:0000269|PubMed:24634419, CC ECO:0000269|PubMed:24748658, ECO:0000269|PubMed:25451922, CC ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:30664650, CC ECO:0000269|PubMed:35446349, ECO:0000269|PubMed:36180891, CC ECO:0000269|PubMed:36991118, ECO:0000269|PubMed:37556531, CC ECO:0000269|PubMed:9528852, ECO:0000305|PubMed:24634419}. CC -!- INTERACTION: CC Q92560; Q8IXJ9: ASXL1; NbExp=9; IntAct=EBI-1791447, EBI-1646500; CC Q92560; P15056: BRAF; NbExp=4; IntAct=EBI-1791447, EBI-365980; CC Q92560; P38398: BRCA1; NbExp=3; IntAct=EBI-1791447, EBI-349905; CC Q92560; P38398-5: BRCA1; NbExp=2; IntAct=EBI-1791447, EBI-2015072; CC Q92560; P51610: HCFC1; NbExp=6; IntAct=EBI-1791447, EBI-396176; CC Q92560; Q14573: ITPR3; NbExp=12; IntAct=EBI-1791447, EBI-351055; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18757409, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:24703950}. Nucleus {ECO:0000269|PubMed:18757409, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:24748658, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:35051358, CC ECO:0000269|PubMed:35446349, ECO:0000269|PubMed:9528852}. Chromosome CC {ECO:0000269|PubMed:30664650}. Note=Mainly nuclear (PubMed:24703950, CC PubMed:30664650). Binds to chromatin (PubMed:30664650). Localizes to CC the cytoplasm when monoubiquitinated by the E2/E3 hybrid ubiquitin- CC protein ligase UBE2O (PubMed:24703950). Recruitment to chromatin is CC dependent on ASXL1/2/3 and recruitment to specific genes on FOXK1/2 (By CC similarity). Nuclear localization is redundantly mediated by the CC importin and transportin systems; TNPO1/transportin-1 is the major CC mediator of nuclear localization (PubMed:35446349). CC {ECO:0000250|UniProtKB:Q99PU7, ECO:0000269|PubMed:24703950, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:35446349}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis, placenta and ovary CC (PubMed:9528852). Expressed in breast (PubMed:9528852). levels in the CC placenta increase over the course of pregnancy (PubMed:34170818). CC {ECO:0000269|PubMed:34170818, ECO:0000269|PubMed:9528852}. CC -!- DEVELOPMENTAL STAGE: Expressed in trophoblast stem cells during CC placenta development (at protein levels) (PubMed:34170818). Decreased CC expression levels correlate with epithelial-mesenchymal transition CC (EMT) during trophoblast cell differentiation (at protein level) CC (PubMed:34170818). {ECO:0000269|PubMed:34170818}. CC -!- DOMAIN: Possesses 2 overlapping nuclear localization sequences (NLS), a CC classic bipartite NLS and a non-classical PY-NLS (PubMed:35446349). The CC classical NLS probably mediates import via the importin alpha/beta CC system while the PY-NLS mediates nuclear import via the transportin CC system (PubMed:35446349). {ECO:0000269|PubMed:35446349}. CC -!- DOMAIN: The positively charged C-terminal tail stabilizes the CC interaction with nucleosomes/chromatosomes through interaction with the CC DNA backbone (PubMed:30258054, PubMed:36991118). Binding of ASXL1 just CC upstream of the positively charged C-terminal tail may stabilize its CC orientation to align the PR-DUB with its H2AK118ub1 substrate CC (PubMed:36991118). {ECO:0000269|PubMed:30258054, CC ECO:0000269|PubMed:36991118}. CC -!- DOMAIN: The ubiquitin C-terminal hydrolase (UCH) domain, together with CC the DEUBAD domain of ASXL1, forms the ubiquitin binding cleft of the CC PR-DUB complex. {ECO:0000269|PubMed:36991118, CC ECO:0000269|PubMed:37556531}. CC -!- DOMAIN: The positively charged Arg-finger motif mediates interaction CC with the histone H2A-H2B acidic patch; this interaction is critical for CC nucleosomal H2AK119ub1 deubiquitination activity but not nucleosomal CC binding. {ECO:0000269|PubMed:37556531}. CC -!- PTM: Ubiquitinated: monoubiquitinated at multiple sites within its CC nuclear localization signal (NLS) BY UBE2O, leading to cytoplasmic CC retention (PubMed:24703950). Able to mediate autodeubiquitination via CC intramolecular interactions to counteract cytoplasmic retention CC (PubMed:24703950). Monoubiquitinated on at least 4 sites near or within CC its PY-NLS (PubMed:35446349). {ECO:0000269|PubMed:24703950, CC ECO:0000269|PubMed:35446349}. CC -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive CC neoplasm of the serosal lining of the chest. It appears as broad sheets CC of cells, with some regions containing spindle-shaped, sarcoma-like CC cells and other regions showing adenomatous patterns. Pleural CC mesotheliomas have been linked to exposure to asbestos. CC {ECO:0000269|PubMed:21642991, ECO:0000269|PubMed:21874000}. Note=The CC gene represented in this entry is involved in disease pathogenesis. CC -!- DISEASE: Tumor predisposition syndrome 1 (TPDS1) [MIM:614327]: An CC autosomal dominant condition characterized by predisposition to develop CC a variety of tumors, including benign melanocytic tumors as well as CC several malignant tumors, including uveal melanoma, cutaneous melanoma, CC malignant mesothelioma on exposure to asbestos, lung adenocarcinoma and CC meningioma. {ECO:0000269|PubMed:21874000, ECO:0000269|PubMed:21874003, CC ECO:0000269|PubMed:21941004, ECO:0000269|PubMed:23684012}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Melanoma, uveal, 2 (UVM2) [MIM:606661]: Most common CC intraocular malignancy, arising from melanocytes in the iris, ciliary CC body, or choroid. Metastases develop in more than 30% of case patients, CC almost invariably in the liver, with poor prognosis. CC {ECO:0000269|PubMed:25687217, ECO:0000269|PubMed:32002398}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Kury-Isidor syndrome (KURIS) [MIM:619762]: An autosomal CC dominant neurodevelopmental disorder characterized mainly by mild CC global developmental delay apparent from infancy or early childhood, CC and behavioral problems, including autism in most patients. CC Intellectual development may be mildly delayed, borderline, or even CC normal. Additional variable systemic features may include poor overall CC growth, hypotonia, distal skeletal anomalies, seizures, and non- CC specific dysmorphic facial features. {ECO:0000269|PubMed:19117993, CC ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, CC ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:35051358}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: May act as a tumor suppressor. CC {ECO:0000269|PubMed:9528852}. CC -!- SIMILARITY: Belongs to the peptidase C12 family. BAP1 subfamily. CC {ECO:0000305}. CC -!- CAUTION: According to a report, interaction with FOXK2 is not dependent CC on phosphorylation of BAP1 (PubMed:24748658). However, it was later CC shown that phosphorylation at Thr-493 promotes interaction with FOXK2 CC (PubMed:25451922). {ECO:0000269|PubMed:24748658, CC ECO:0000269|PubMed:25451922}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA13401.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/755/BAP1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045581; AAC15970.1; -; mRNA. DR EMBL; D88812; BAB46921.1; -; mRNA. DR EMBL; D87462; BAA13401.2; ALT_INIT; mRNA. DR EMBL; AK292608; BAF85297.1; -; mRNA. DR EMBL; CH471055; EAW65220.1; -; Genomic_DNA. DR EMBL; BC001596; AAH01596.1; -; mRNA. DR EMBL; AY130008; AAN05092.1; -; mRNA. DR CCDS; CCDS2853.1; -. DR RefSeq; NP_004647.1; NM_004656.4. DR PDB; 7VPW; X-ray; 3.76 A; B=706-724. DR PDB; 8H1T; EM; 3.00 A; L=1-729. DR PDB; 8SVF; EM; 3.20 A; K=1-729. DR PDBsum; 7VPW; -. DR PDBsum; 8H1T; -. DR PDBsum; 8SVF; -. DR AlphaFoldDB; Q92560; -. DR EMDB; EMD-34431; -. DR EMDB; EMD-40789; -. DR SMR; Q92560; -. DR BioGRID; 113911; 1328. DR ComplexPortal; CPX-414; PR-DUB complex. DR CORUM; Q92560; -. DR DIP; DIP-47004N; -. DR FunCoup; Q92560; 3418. DR IntAct; Q92560; 113. DR MINT; Q92560; -. DR STRING; 9606.ENSP00000417132; -. DR BindingDB; Q92560; -. DR ChEMBL; CHEMBL1293314; -. DR MEROPS; C12.004; -. DR GlyGen; Q92560; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q92560; -. DR MetOSite; Q92560; -. DR PhosphoSitePlus; Q92560; -. DR BioMuta; BAP1; -. DR DMDM; 68565074; -. DR jPOST; Q92560; -. DR MassIVE; Q92560; -. DR PaxDb; 9606-ENSP00000417132; -. DR PeptideAtlas; Q92560; -. DR ProteomicsDB; 75316; -. DR Pumba; Q92560; -. DR Antibodypedia; 3812; 492 antibodies from 39 providers. DR DNASU; 8314; -. DR Ensembl; ENST00000460680.6; ENSP00000417132.1; ENSG00000163930.10. DR GeneID; 8314; -. DR KEGG; hsa:8314; -. DR MANE-Select; ENST00000460680.6; ENSP00000417132.1; NM_004656.4; NP_004647.1. DR UCSC; uc003ddx.5; human. DR AGR; HGNC:950; -. DR CIViC; 8314; 18 evidence items across 13 molecular profiles. DR ClinPGx; PA25254; -. DR CTD; 8314; -. DR DisGeNET; 8314; -. DR GeneCards; BAP1; -. DR GeneReviews; BAP1; -. DR HGNC; HGNC:950; BAP1. DR HPA; ENSG00000163930; Low tissue specificity. DR MalaCards; BAP1; -. DR MIM; 156240; phenotype. DR MIM; 603089; gene. DR MIM; 606661; phenotype. DR MIM; 614327; phenotype. DR MIM; 619762; phenotype. DR OpenTargets; ENSG00000163930; -. DR Orphanet; 289539; BAP1-related tumor predisposition syndrome. DR Orphanet; 618; Familial melanoma. DR Orphanet; 2495; Meningioma. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR Orphanet; 50251; Pleural mesothelioma. DR Orphanet; 39044; Uveal melanoma. DR VEuPathDB; HostDB:ENSG00000163930; -. DR eggNOG; KOG2778; Eukaryota. DR GeneTree; ENSGT00940000156388; -. DR HOGENOM; CLU_018316_5_0_1; -. DR InParanoid; Q92560; -. DR OMA; RIAYEQK; -. DR OrthoDB; 1924260at2759; -. DR PAN-GO; Q92560; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q92560; -. DR BRENDA; 3.4.19.12; 2681. DR PathwayCommons; Q92560; -. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR SignaLink; Q92560; -. DR SIGNOR; Q92560; -. DR Agora; ENSG00000163930; -. DR BioGRID-ORCS; 8314; 488 hits in 1221 CRISPR screens. DR ChiTaRS; BAP1; human. DR GeneWiki; BAP1; -. DR GenomeRNAi; 8314; -. DR Pharos; Q92560; Tbio. DR PRO; PR:Q92560; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q92560; protein. DR Bgee; ENSG00000163930; Expressed in left testis and 164 other cell types or tissues. DR ExpressionAtlas; Q92560; baseline and differential. DR GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0035517; C:PR-DUB complex; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl. DR GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB. DR GO; GO:0140950; F:histone H2A deubiquitinase activity; IMP:UniProtKB. DR GO; GO:0008233; F:peptidase activity; NAS:UniProtKB. DR GO; GO:0035726; P:common myeloid progenitor cell proliferation; IEA:Ensembl. DR GO; GO:0043249; P:erythrocyte maturation; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0061484; P:hematopoietic stem cell homeostasis; IEA:Ensembl. DR GO; GO:0031507; P:heterochromatin formation; IBA:GO_Central. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0070661; P:leukocyte proliferation; IEA:Ensembl. DR GO; GO:0061519; P:macrophage homeostasis; IEA:Ensembl. DR GO; GO:0000278; P:mitotic cell cycle; IEA:Ensembl. DR GO; GO:0035520; P:monoubiquitinated protein deubiquitination; IDA:UniProtKB. DR GO; GO:0033028; P:myeloid cell apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0070050; P:neuron cellular homeostasis; IEA:Ensembl. DR GO; GO:0030223; P:neutrophil differentiation; IEA:Ensembl. DR GO; GO:0043363; P:nucleate erythrocyte differentiation; IEA:Ensembl. DR GO; GO:0036344; P:platelet morphogenesis; IEA:Ensembl. DR GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL. DR GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB. DR GO; GO:0071108; P:protein K48-linked deubiquitination; IMP:UniProtKB. DR GO; GO:0036211; P:protein modification process; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IMP:UniProtKB. DR GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl. DR GO; GO:0002574; P:thrombocyte differentiation; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro. DR CDD; cd09617; Peptidase_C12_UCH37_BAP1; 1. DR FunFam; 1.20.58.860:FF:000002; Ubiquitin carboxyl-terminal hydrolase; 1. DR FunFam; 3.40.532.10:FF:000002; Ubiquitin carboxyl-terminal hydrolase; 1. DR Gene3D; 1.20.58.860; -; 1. DR Gene3D; 3.40.532.10; Peptidase C12, ubiquitin carboxyl-terminal hydrolase; 1. DR InterPro; IPR038765; Papain-like_cys_pep_sf. DR InterPro; IPR001578; Peptidase_C12_UCH. DR InterPro; IPR036959; Peptidase_C12_UCH_sf. DR InterPro; IPR041507; UCH_C. DR PANTHER; PTHR10589; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1. DR PANTHER; PTHR10589:SF28; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE BAP1; 1. DR Pfam; PF01088; Peptidase_C12; 1. DR Pfam; PF18031; UCH_C; 1. DR PRINTS; PR00707; UBCTHYDRLASE. DR SUPFAM; SSF54001; Cysteine proteinases; 1. DR PROSITE; PS52048; UCH_DOMAIN; 1. DR PROSITE; PS52049; ULD; 1. PE 1: Evidence at protein level; KW 3D-structure; Chromatin regulator; Chromosome; Coiled coil; Cytoplasm; KW Developmental protein; Differentiation; Disease variant; Hydrolase; KW Intellectual disability; Nucleus; Phosphoprotein; Protease; KW Proteomics identification; Reference proteome; Thiol protease; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..729 FT /note="Ubiquitin carboxyl-terminal hydrolase BAP1" FT /id="PRO_0000211069" FT DOMAIN 4..235 FT /note="UCH catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT DOMAIN 670..698 FT /note="ULD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01394" FT REGION 301..351 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 372..435 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 464..524 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 575..623 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 596..721 FT /note="Interaction with BRCA1" FT REGION 642..686 FT /note="Interaction with YY1" FT /evidence="ECO:0000269|PubMed:20805357" FT REGION 699..701 FT /note="Interaction with nucleosomal DNA forming a DNA clamp FT with ASXL1" FT /evidence="ECO:0000269|PubMed:37556531" FT REGION 703..729 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 713..729 FT /note="Positively charged C-terminal extension (CTE)" FT /evidence="ECO:0000269|PubMed:30258054, FT ECO:0000269|PubMed:36991118" FT COILED 636..656 FT /evidence="ECO:0000255" FT MOTIF 56..60 FT /note="Arg-finger motif" FT /evidence="ECO:0000269|PubMed:37556531" FT MOTIF 363..366 FT /note="HBM-like motif" FT /evidence="ECO:0000269|PubMed:19188440, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, FT ECO:0000269|PubMed:25451922" FT MOTIF 699..722 FT /note="Classical bipartite Nuclear localization signal FT (NLS)" FT /evidence="ECO:0000269|PubMed:18757409, FT ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:35446349" FT MOTIF 717..724 FT /note="Non-classical PY-nuclear localization signal (PY- FT NLS)" FT /evidence="ECO:0000269|PubMed:35446349" FT COMPBIAS 395..409 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 480..524 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 582..598 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 599..614 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 91 FT /note="Nucleophile" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, FT ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, FT ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:9528852" FT ACT_SITE 169 FT /note="Proton donor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT SITE 85 FT /note="Transition state stabilizer" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT SITE 184 FT /note="Important for enzyme activity" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT MOD_RES 292 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 369 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99PU7" FT MOD_RES 493 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:25451922" FT MOD_RES 521 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 585 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 597 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 12 FT /note="P -> A (in KURIS; dbSNP:rs2153228682)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086937" FT VARIANT 12 FT /note="P -> T (in KURIS; loss-of-function variant; FT increased steady-state levels of ubiquitinated H2A are FT found in patient cells; unable to rescue impaired H2AK119ub FT deubiquitination when expressed in BAP1-deficient cells; FT does not affect localization to the nucleus; FT dbSNP:rs2153228682)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086938" FT VARIANT 31 FT /note="E -> K (in KURIS; uncertain significance; FT dbSNP:rs2153228535)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086939" FT VARIANT 47 FT /note="I -> F (found in a primary uveal melanoma; somatic FT mutation; induces cytoplasmic accumulation; loss of FT deubiquitinase activity; up-regulates heat shock response; FT induces formation of amyloid-beta aggregates; FT dbSNP:rs2153228345)" FT /evidence="ECO:0000269|PubMed:25080371, FT ECO:0000269|PubMed:26680512" FT /id="VAR_075251" FT VARIANT 49 FT /note="L -> P (in KURIS; uncertain significance; FT dbSNP:rs2153228340)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086940" FT VARIANT 63 FT /note="S -> C (found in a malignant pleural mesothelioma FT sample; somatic mutation; dbSNP:rs747311942)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065976" FT VARIANT 81 FT /note="F -> V (found in a malignant pleural mesothelioma FT sample; somatic mutation; induces cytoplasmic accumulation; FT loss of deubiquitinase activity; up-regulates heat shock FT response; induces formation of amyloid-beta aggregates)" FT /evidence="ECO:0000269|PubMed:21642991, FT ECO:0000269|PubMed:26680512" FT /id="VAR_065977" FT VARIANT 91 FT /note="C -> G (in KURIS; dbSNP:rs1705222655)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086941" FT VARIANT 91 FT /note="C -> R (in KURIS; loss-of-function variant; unable FT to rescue impaired H2AK119ub deubiquitination when FT expressed in BAP1-deficient cells; does not affect FT localization to the nucleus; dbSNP:rs1705222655)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086942" FT VARIANT 91 FT /note="C -> S (in KURIS; loss-of-function variant; FT increased steady-state level of ubiquitinated H2A are found FT in patient cells; unable to rescue impaired H2AK119ub FT deubiquitination when expressed in BAP1-deficient cells; FT abolishes deubiquitinase activity; does not affect its FT ability to interfere with BRCA1 E3 ligase activity; does FT not affect localization to the nucleus; has a dominant FT negative effect on cell growth; does not affect interaction FT with FOXK1 and FOXK2; has no effect on PR-DUB complex FT assembly; unable to activate transcription; FT dbSNP:rs1559591264)" FT /evidence="ECO:0000269|PubMed:19117993, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, FT ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:35051358" FT /id="VAR_086943" FT VARIANT 91 FT /note="C -> W (found in a malignant pleural mesothelioma FT sample; dbSNP:rs2153228144)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065978" FT VARIANT 93 FT /note="T -> A (in TPDS1; significantly increased risk for FT renal cell carcinoma; dbSNP:rs375129361)" FT /evidence="ECO:0000269|PubMed:23684012" FT /id="VAR_087531" FT VARIANT 95 FT /note="A -> D (in a lung cancer sample; also found in a FT malignant pleural mesothelioma cell line; induces FT cytoplasmic accumulation; loss of deubiquitinase activity; FT up-regulates heat shock response; induces formation of FT amyloid-beta aggregates)" FT /evidence="ECO:0000269|PubMed:10546591, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:21642991, FT ECO:0000269|PubMed:26680512" FT /id="VAR_063498" FT VARIANT 169 FT /note="H -> R (in KURIS; loss-of-function variant; unable FT to rescue impaired H2AK119ub deubiquitination when FT expressed in BAP1-deficient cells; does not affect FT localization to the nucleus; dbSNP:rs2153227828)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086944" FT VARIANT 178 FT /note="G -> V (in a lung cancer sample; induces cytoplasmic FT accumulation; impairs deubiquitinase activity; up-regulates FT heat shock response; induces formation of beta-amyloid FT aggregates; dbSNP:rs2153227803)" FT /evidence="ECO:0000269|PubMed:10546591, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:26680512" FT /id="VAR_063499" FT VARIANT 267..729 FT /note="Missing (in TPDS1)" FT /evidence="ECO:0000269|PubMed:21941004" FT /id="VAR_087532" FT VARIANT 315 FT /note="E -> A (found in a malignant pleural mesothelioma FT sample; dbSNP:rs149974450)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065979" FT VARIANT 616 FT /note="V -> E (in dbSNP:rs35353781)" FT /id="VAR_051517" FT VARIANT 685 FT /note="E -> V (found in a malignant pleural mesothelioma FT cell line)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065980" FT VARIANT 718 FT /note="R -> Q (in KURIS; uncertain significance; able to FT rescue impaired H2AK119ub deubiquitination when expressed FT in BAP1-deficient cells; does not affect localization to FT the nucleus; dbSNP:rs1440748203)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086945" FT MUTAGEN 56..60 FT /note="RRSRR->AASAA: Probably disrupts interaction with the FT histone H2A-H2B acidic patch. Severely attenuates FT deubiquitination of histone H2AK119ub1 substrates in the FT context of the nucleosome but does not disrupt nucleosome FT interaction." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 56 FT /note="R->C: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 59 FT /note="R->W: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 91 FT /note="C->A: Abolishes deubiquitinase activity. Has no FT effect on interaction with HCFC1." FT /evidence="ECO:0000269|PubMed:18757409, FT ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:9528852" FT MUTAGEN 251 FT /note="N->R: Severely attenuates deubiquitination of FT histone H2AK119ub1 substrates, possibly due to disruption FT of homodimerization." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 363..366 FT /note="NHNY->AAAA: Abolishes interaction with HCFC1 without FT affecting interaction with FOXK1 and FOXK2." FT /evidence="ECO:0000269|PubMed:19188440, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922" FT MUTAGEN 489 FT /note="S->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 492 FT /note="S->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 493 FT /note="T->A,L: Abolished interaction with FOXK1 and FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 495 FT /note="T->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 635 FT /note="L->A: Severely attenuated deubiquitination of FT histone H2AK119ub1 substrates, possibly due to disruption FT of homodimerization. No effect on intrinsic catalytic FT activity." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 656..661 FT /note="KRKKFK->AAAAAA: Does not affect nuclear FT localization." FT /evidence="ECO:0000269|PubMed:18757409" FT MUTAGEN 684..729 FT /note="Missing: Predominantly localizes to the cytosol." FT /evidence="ECO:0000269|PubMed:35446349" FT MUTAGEN 691..711 FT /note="Missing: Abolishes ubiquitination by UBE2O." FT /evidence="ECO:0000269|PubMed:24703950" FT MUTAGEN 691 FT /note="L->P: Abolishes interaction with BRCA1." FT /evidence="ECO:0000269|PubMed:9528852" FT MUTAGEN 697..729 FT /note="Missing: Abolishes deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome, FT probably due to disruption of nucleosome interaction. Does FT not affect deubiquitination of H2AK119ub1 on free FT histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 699..702 FT /note="Missing: Severely reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome but only mildly disrupts nucleosome FT interaction." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 699..701 FT /note="RRR->AAA: Reduced nucleosomal binding." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 699..700 FT /note="RR->DD: Reduced nucleosomal binding." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 699 FT /note="R->W: Slight or no reduction of deubiquitination FT efficiency towards H2AK119ub1 substrates in the context of FT the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 700 FT /note="R->Q: Slightly reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 701 FT /note="R->C: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 702 FT /note="Missing: Slightly reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 703 FT /note="G->P,R: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 708 FT /note="R->A: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 711..729 FT /note="Missing: Disrupts nucleosome interaction and FT abolishes deubiquitination activity towards H2AK119ub1 FT substrates in the context of the nucleosome. Does not FT affect deubiquitination of H2AK119ub1 on free histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 711..718 FT /note="Missing: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome, FT probably due to disruption of nucleosome interaction. Does FT not affect deubiquitination of H2AK119ub1 on free FT histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 713..729 FT /note="Missing: Impairs deubiquitination activity of FT histone H2AK118ub1 substrates, probably due to disruption FT of nucleosome association." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 713 FT /note="R->A: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 717..722 FT /note="RRKRSR->AAAAAA: Abolishes nuclear localization." FT /evidence="ECO:0000269|PubMed:18757409" FT MUTAGEN 718..729 FT /note="Missing: Disrupts nucleosome interaction and reduces FT deubiquitination activity towards H2AK119ub1 substrates in FT the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT HELIX 12..22 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 46..52 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 55..59 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 68..70 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 91..101 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:8SVF" FT HELIX 110..119 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:8SVF" FT HELIX 124..132 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 135..143 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 148..151 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 167..175 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 178..186 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 191..195 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 203..217 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 228..234 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 237..242 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 648..667 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 672..685 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 688..694 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 700..703 FT /evidence="ECO:0007829|PDB:8H1T" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:8SVF" SQ SEQUENCE 729 AA; 80362 MW; 031DA03AE1841D85 CRC64; MNKGWLELES DPGLFTLLVE DFGVKGVQVE EIYDLQSKCQ GPVYGFIFLF KWIEERRSRR KVSTLVDDTS VIDDDIVNNM FFAHQLIPNS CATHALLSVL LNCSSVDLGP TLSRMKDFTK GFSPESKGYA IGNAPELAKA HNSHARPEPR HLPEKQNGLS AVRTMEAFHF VSYVPITGRL FELDGLKVYP IDHGPWGEDE EWTDKARRVI MERIGLATAG EPYHDIRFNL MAVVPDRRIK YEARLHVLKV NRQTVLEALQ QLIRVTQPEL IQTHKSQESQ LPEESKSASN KSPLVLEANR APAASEGNHT DGAEEAAGSC AQAPSHSPPN KPKLVVKPPG SSLNGVHPNP TPIVQRLPAF LDNHNYAKSP MQEEEDLAAG VGRSRVPVRP PQQYSDDEDD YEDDEEDDVQ NTNSALRYKG KGTGKPGALS GSADGQLSVL QPNTINVLAE KLKESQKDLS IPLSIKTSSG AGSPAVAVPT HSQPSPTPSN ESTDTASEIG SAFNSPLRSP IRSANPTRPS SPVTSHISKV LFGEDDSLLR VDCIRYNRAV RDLGPVISTG LLHLAEDGVL SPLALTEGGK GSSPSIRPIQ GSQGSSSPVE KEVVEATDSR EKTGMVRPGE PLSGEKYSPK ELLALLKCVE AEIANYEACL KEEVEKRKKF KIDDQRRTHN YDEFICTFIS MLAQEGMLAN LVEQNISVRR RQGVSIGRLH KQRKPDRRKR SRPYKAKRQ // ID BMR1B_HUMAN Reviewed; 502 AA. AC O00238; B2R953; B4DSV1; P78366; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1997, sequence version 1. DT 28-JAN-2026, entry version 235. DE RecName: Full=Bone morphogenetic protein receptor type-1B; DE Short=BMP type-1B receptor; DE Short=BMPR-1B; DE EC=2.7.11.30 {ECO:0000250|UniProtKB:P36898}; DE AltName: CD_antigen=CDw293; DE Flags: Precursor; GN Name=BMPR1B; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Prostate; RX PubMed=9178898; DOI=10.1038/sj.onc.1200964; RA Ide H., Katoh M., Sasaki H., Yoshida T., Aoki K., Nawa Y., Osada Y., RA Sugimura T., Terada M.; RT "Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and RT its expression in prostate cancer in comparison with other BMPRs."; RL Oncogene 14:1377-1382(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Ovary; RX PubMed=10051328; DOI=10.1007/s003359900990; RA Astroem A.-K., Jin D.F., Imamura T., Roijer E., Rosenzweig B., Miyazono K., RA ten Dijke P., Stenman G.; RT "Chromosomal localization of three human genes encoding bone morphogenetic RT protein receptors."; RL Mamm. Genome 10:299-302(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=PNS; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH TGFBR3, AND SUBCELLULAR LOCATION. RX PubMed=19726563; DOI=10.1091/mbc.e09-07-0539; RA Lee N.Y., Kirkbride K.C., Sheu R.D., Blobe G.C.; RT "The transforming growth factor-beta type III receptor mediates distinct RT subcellular trafficking and downstream signaling of activin-like kinase RT (ALK)3 and ALK6 receptors."; RL Mol. Biol. Cell 20:4362-4370(2009). RN [8] RP INTERACTION WITH TSC22D1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [9] RP INTERACTION WITH GDF5. RX PubMed=24098149; DOI=10.1371/journal.pgen.1003846; RA Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C., Nickel J., RA Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T., Mundlos S., RA Doelken S.C., Seemann P.; RT "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2."; RL PLoS Genet. 9:E1003846-E1003846(2013). RN [10] RP INTERACTION WITH SCUBE3. RX PubMed=33308444; DOI=10.1016/j.ajhg.2020.11.015; RG Genomics England Research Consortium; RA Lin Y.C., Niceta M., Muto V., Vona B., Pagnamenta A.T., Maroofian R., RA Beetz C., van Duyvenvoorde H., Dentici M.L., Lauffer P., Vallian S., RA Ciolfi A., Pizzi S., Bauer P., Gruening N.M., Bellacchio E., RA Del Fattore A., Petrini S., Shaheen R., Tiosano D., Halloun R., RA Pode-Shakked B., Albayrak H.M., Isik E., Wit J.M., Dittrich M., RA Freire B.L., Bertola D.R., Jorge A.A.L., Barel O., Sabir A.H., RA Al Tenaiji A.M.J., Taji S.M., Al-Sannaa N., Al-Abdulwahed H., Digilio M.C., RA Irving M., Anikster Y., Bhavani G.S.L., Girisha K.M., Haaf T., Taylor J.C., RA Dallapiccola B., Alkuraya F.S., Yang R.B., Tartaglia M.; RT "SCUBE3 loss-of-function causes a recognizable recessive developmental RT disorder due to defective bone morphogenetic protein signaling."; RL Am. J. Hum. Genet. 108:115-133(2021). RN [11] RP VARIANTS BDA2 LYS-200 AND TRP-486, AND CHARACTERIZATION OF VARIANTS BDA2 RP LYS-200 AND TRP-486. RX PubMed=14523231; DOI=10.1073/pnas.2133476100; RA Lehmann K., Seemann P., Stricker S., Sammar M., Meyer B., Suering K., RA Majewski F., Tinschert S., Grzeschik K.-H., Mueller D., Knaus P., RA Nuernberg P., Mundlos S.; RT "Mutations in bone morphogenetic protein receptor 1B cause brachydactyly RT type A2."; RL Proc. Natl. Acad. Sci. U.S.A. 100:12277-12282(2003). RN [12] RP INVOLVEMENT IN AMD3. RX PubMed=15805157; DOI=10.1136/jmg.2004.023564; RA Demirhan O., Tuerkmen S., Schwabe G.C., Soyupak S., Akguel E., Tastemir D., RA Karahan D., Mundlos S., Lehmann K.; RT "A homozygous BMPR1B mutation causes a new subtype of acromesomelic RT chondrodysplasia with genital anomalies."; RL J. Med. Genet. 42:314-317(2005). RN [13] RP VARIANT BRACHYDACTYLY TYPE C/BDA2 GLN-486. RX PubMed=16957682; DOI=10.1038/sj.ejhg.5201708; RA Lehmann K., Seemann P., Boergermann J., Morin G., Reif S., Knaus P., RA Mundlos S.; RT "A novel R486Q mutation in BMPR1B resulting in either a brachydactyly type RT C/symphalangism-like phenotype or brachydactyly type A2."; RL Eur. J. Hum. Genet. 14:1248-1254(2006). RN [14] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-31; TRP-149; HIS-224; ASN-297 AND RP GLN-371. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [15] RP VARIANT AMD3 ARG-53, AND CHARACTERIZATION OF VARIANT AMD3 ARG-53. RX PubMed=24129431; DOI=10.1038/ejhg.2013.222; RA Graul-Neumann L.M., Deichsel A., Wille U., Kakar N., Koll R., Bassir C., RA Ahmad J., Cormier-Daire V., Mundlos S., Kubisch C., Borck G., Klopocki E., RA Mueller T.D., Doelken S.C., Seemann P.; RT "Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic RT chondrodysplasia-type Grebe."; RL Eur. J. Hum. Genet. 22:726-733(2014). RN [16] RP INVOLVEMENT IN BDA1D, VARIANT BDA1D ASN-325, AND CHARACTERIZATION OF RP VARIANT BDA1D ASN-325. RX PubMed=25758993; DOI=10.1038/ejhg.2015.38; RA Racacho L., Byrnes A.M., MacDonald H., Dranse H.J., Nikkel S.M., RA Allanson J., Rosser E., Underhill T.M., Bulman D.E.; RT "Two novel disease-causing variants in BMPR1B are associated with RT brachydactyly type A1."; RL Eur. J. Hum. Genet. 23:1640-1645(2015). RN [17] RP VARIANT AMD3 CYS-31, AND CHARACTERIZATION OF VARIANT AMD3 CYS-31. RX PubMed=26105076; DOI=10.1186/s13023-015-0299-5; RA Stange K., Desir J., Kakar N., Mueller T.D., Budde B.S., Gordon C.T., RA Horn D., Seemann P., Borck G.; RT "A hypomorphic BMPR1B mutation causes du Pan acromesomelic dysplasia."; RL Orphanet J. Rare Dis. 10:84-84(2015). CC -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two CC type II and two type I transmembrane serine/threonine kinases. Type II CC receptors phosphorylate and activate type I receptors which CC autophosphorylate, then bind and activate SMAD transcriptional CC regulators. Receptor for BMP7/OP-1 and GDF5. Positively regulates CC chondrocyte differentiation through GDF5 interaction. CC {ECO:0000250|UniProtKB:P36898}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44881; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18674; CC Evidence={ECO:0000250|UniProtKB:P36898}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with high affinity with GDF5; positively regulates CC chondrocyte differentiation (PubMed:24098149). Interacts with SCUBE3 CC (PubMed:33308444). Interacts with TSC22D1/TSC-22 (PubMed:21791611). CC Interacts with TGFBR3 (PubMed:19726563). {ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:24098149, ECO:0000269|PubMed:33308444}. CC -!- INTERACTION: CC O00238; P12643: BMP2; NbExp=3; IntAct=EBI-7527193, EBI-1029262; CC O00238; P43026: GDF5; NbExp=7; IntAct=EBI-7527193, EBI-8571476; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19726563}; CC Single-pass type I membrane protein {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O00238-1; Sequence=Displayed; CC Name=2; CC IsoId=O00238-2; Sequence=VSP_045100; CC -!- PTM: Autophosphorylated. {ECO:0000250|UniProtKB:P36898}. CC -!- DISEASE: Acromesomelic dysplasia 3 (AMD3) [MIM:609441]: A form of CC acromesomelic dysplasia, a skeletal disorder characterized by short CC stature, very short limbs and hand/foot malformations. The severity of CC limb abnormalities increases from proximal to distal with profoundly CC affected hands and feet showing brachydactyly and/or rudimentary CC fingers (knob-like fingers). AMD3 is an autosomal recessive form CC characterized by bilateral aplasia of the fibula, severe brachydactyly, CC and fusion of carpal and tarsal bones. {ECO:0000269|PubMed:15805157, CC ECO:0000269|PubMed:24129431, ECO:0000269|PubMed:26105076}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Brachydactyly A2 (BDA2) [MIM:112600]: A form of brachydactyly. CC Brachydactyly defines a group of inherited malformations characterized CC by shortening of the digits due to abnormal development of the CC phalanges and/or the metacarpals. In brachydactyly type A2 shortening CC of the middle phalanges is confined to the index finger and the second CC toe, all other digits being more or less normal. Because of a rhomboid CC or triangular shape of the affected middle phalanx, the end of the CC second finger usually deviates radially. {ECO:0000269|PubMed:14523231, CC ECO:0000269|PubMed:16957682}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Brachydactyly A1, D (BDA1D) [MIM:616849]: A form of CC brachydactyly type A1. Brachydactyly defines a group of inherited CC malformations characterized by shortening of the digits due to abnormal CC development of the phalanges and/or the metacarpals. Brachydactyly type CC A1 is characterized by middle phalanges of all the digits rudimentary CC or fused with the terminal phalanges. The proximal phalanges of the CC thumbs and big toes are short. BDA1D inheritance is autosomal dominant. CC {ECO:0000269|PubMed:25758993}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D89675; BAA19765.1; -; mRNA. DR EMBL; U89326; AAC28131.1; -; mRNA. DR EMBL; AK299930; BAG61763.1; -; mRNA. DR EMBL; AK313642; BAG36400.1; -; mRNA. DR EMBL; AC004061; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092609; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC093634; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC105395; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471057; EAX06060.1; -; Genomic_DNA. DR EMBL; BC047773; AAH47773.1; -; mRNA. DR EMBL; BC069796; AAH69796.1; -; mRNA. DR EMBL; BC069803; AAH69803.1; -; mRNA. DR CCDS; CCDS3642.1; -. [O00238-1] DR CCDS; CCDS58919.1; -. [O00238-2] DR RefSeq; NP_001194.1; NM_001203.3. [O00238-1] DR RefSeq; NP_001243721.1; NM_001256792.2. [O00238-1] DR RefSeq; NP_001243722.1; NM_001256793.2. [O00238-2] DR RefSeq; NP_001243723.1; NM_001256794.1. [O00238-1] DR RefSeq; XP_011530503.1; XM_011532201.3. [O00238-1] DR RefSeq; XP_016864047.1; XM_017008558.2. [O00238-1] DR RefSeq; XP_016864048.1; XM_017008559.2. [O00238-1] DR RefSeq; XP_016864049.1; XM_017008560.2. [O00238-1] DR RefSeq; XP_047272047.1; XM_047416091.1. [O00238-1] DR RefSeq; XP_047272049.1; XM_047416093.1. [O00238-1] DR RefSeq; XP_047272050.1; XM_047416094.1. [O00238-1] DR RefSeq; XP_047272051.1; XM_047416095.1. [O00238-1] DR RefSeq; XP_054206712.1; XM_054350737.1. [O00238-1] DR RefSeq; XP_054206713.1; XM_054350738.1. [O00238-1] DR RefSeq; XP_054206714.1; XM_054350739.1. [O00238-1] DR RefSeq; XP_054206715.1; XM_054350740.1. [O00238-1] DR RefSeq; XP_054206716.1; XM_054350741.1. [O00238-1] DR RefSeq; XP_054206717.1; XM_054350742.1. [O00238-1] DR RefSeq; XP_054206718.1; XM_054350743.1. [O00238-1] DR PDB; 3MDY; X-ray; 2.05 A; A/C=168-502. DR PDBsum; 3MDY; -. DR AlphaFoldDB; O00238; -. DR SMR; O00238; -. DR BioGRID; 107126; 80. DR FunCoup; O00238; 929. DR IntAct; O00238; 15. DR MINT; O00238; -. DR STRING; 9606.ENSP00000401907; -. DR BindingDB; O00238; -. DR ChEMBL; CHEMBL5476; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O00238; -. DR GuidetoPHARMACOLOGY; 1789; -. DR GlyGen; O00238; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O00238; -. DR PhosphoSitePlus; O00238; -. DR BioMuta; BMPR1B; -. DR CPTAC; CPTAC-2846; -. DR CPTAC; CPTAC-2847; -. DR jPOST; O00238; -. DR MassIVE; O00238; -. DR PaxDb; 9606-ENSP00000401907; -. DR PeptideAtlas; O00238; -. DR ProteomicsDB; 47802; -. [O00238-1] DR Antibodypedia; 4045; 661 antibodies from 36 providers. DR DNASU; 658; -. DR Ensembl; ENST00000264568.8; ENSP00000264568.4; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000394931.1; ENSP00000378389.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000440890.7; ENSP00000401907.2; ENSG00000138696.12. [O00238-2] DR Ensembl; ENST00000509540.6; ENSP00000421671.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000512312.5; ENSP00000425444.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000515059.6; ENSP00000426617.1; ENSG00000138696.12. [O00238-1] DR Ensembl; ENST00000672698.1; ENSP00000500035.1; ENSG00000138696.12. [O00238-1] DR GeneID; 658; -. DR KEGG; hsa:658; -. DR MANE-Select; ENST00000515059.6; ENSP00000426617.1; NM_001203.3; NP_001194.1. DR UCSC; uc003htm.5; human. [O00238-1] DR AGR; HGNC:1077; -. DR ClinPGx; PA25387; -. DR CTD; 658; -. DR DisGeNET; 658; -. DR GeneCards; BMPR1B; -. DR GeneReviews; BMPR1B; -. DR HGNC; HGNC:1077; BMPR1B. DR HPA; ENSG00000138696; Tissue enhanced (cervix, prostate). DR MalaCards; BMPR1B; -. DR MIM; 112600; phenotype. DR MIM; 603248; gene. DR MIM; 609441; phenotype. DR MIM; 616849; phenotype. DR OpenTargets; ENSG00000138696; -. DR Orphanet; 2098; Acromesomelic dysplasia, Grebe type. DR Orphanet; 93388; Brachydactyly type A1. DR Orphanet; 93396; Brachydactyly type A2. DR Orphanet; 93384; Brachydactyly type C. DR Orphanet; 2639; Fibular aplasia-complex brachydactyly syndrome. DR VEuPathDB; HostDB:ENSG00000138696; -. DR eggNOG; KOG2052; Eukaryota. DR GeneTree; ENSGT00940000155919; -. DR HOGENOM; CLU_000288_8_1_1; -. DR InParanoid; O00238; -. DR OMA; RRTIACC; -. DR OrthoDB; 69842at2759; -. DR PAN-GO; O00238; 8 GO annotations based on evolutionary models. DR PhylomeDB; O00238; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; O00238; -. DR Reactome; R-HSA-201451; Signaling by BMP. DR SignaLink; O00238; -. DR SIGNOR; O00238; -. DR Agora; ENSG00000138696; -. DR BioGRID-ORCS; 658; 17 hits in 1178 CRISPR screens. DR ChiTaRS; BMPR1B; human. DR EvolutionaryTrace; O00238; -. DR GeneWiki; BMPR1B; -. DR GenomeRNAi; 658; -. DR Pharos; O00238; Tchem. DR PRO; PR:O00238; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; O00238; protein. DR Bgee; ENSG00000138696; Expressed in calcaneal tendon and 160 other cell types or tissues. DR ExpressionAtlas; O00238; baseline and differential. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL. DR GO; GO:0036122; F:BMP binding; IPI:BHF-UCL. DR GO; GO:0098821; F:BMP receptor activity; IDA:ARUK-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL. DR GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL. DR GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IBA:GO_Central. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0030509; P:BMP signaling pathway; IDA:HGNC-UCL. DR GO; GO:0001502; P:cartilage condensation; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0002063; P:chondrocyte development; ISS:AgBase. DR GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central. DR GO; GO:0060350; P:endochondral bone morphogenesis; ISS:AgBase. DR GO; GO:0001654; P:eye development; ISS:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:1902731; P:negative regulation of chondrocyte proliferation; ISS:AgBase. DR GO; GO:0001649; P:osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0001550; P:ovarian cumulus expansion; ISS:UniProtKB. DR GO; GO:0042698; P:ovulation cycle; ISS:UniProtKB. DR GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL. DR GO; GO:0061036; P:positive regulation of cartilage development; ISS:AgBase. DR GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISS:UniProtKB. DR GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0030166; P:proteoglycan biosynthetic process; ISS:AgBase. DR GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR CDD; cd14219; STKc_BMPR1b; 1. DR CDD; cd23613; TFP_LU_ECD_BMPR1B; 1. DR FunFam; 1.10.510.10:FF:000018; Receptor protein serine/threonine kinase; 1. DR FunFam; 2.10.60.10:FF:000001; Receptor protein serine/threonine kinase; 1. DR FunFam; 3.30.200.20:FF:000055; Receptor protein serine/threonine kinase; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000472; Activin_recp. DR InterPro; IPR003605; GS_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR PANTHER; PTHR23255:SF62; BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF01064; Activin_recp; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF08515; TGF_beta_GS; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00467; GS; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS51256; GS; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Chondrogenesis; Disease variant; Disulfide bond; Dwarfism; Kinase; KW Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding; KW Proteomics identification; Receptor; Reference proteome; KW Serine/threonine-protein kinase; Signal; Transferase; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..13 FT /evidence="ECO:0000255" FT CHAIN 14..502 FT /note="Bone morphogenetic protein receptor type-1B" FT /id="PRO_0000024412" FT TOPO_DOM 14..126 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 127..148 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 149..502 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 174..203 FT /note="GS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00585" FT DOMAIN 204..494 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..25 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 332 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 210..218 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DISULFID 32..53 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 34..38 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 47..71 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 81..95 FT /evidence="ECO:0000250|UniProtKB:P36898" FT DISULFID 96..102 FT /evidence="ECO:0000250|UniProtKB:P36898" FT VAR_SEQ 1 FT /note="M -> MGWLEELNWQLHIFLLILLSMHTRANFLDNM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045100" FT VARIANT 31 FT /note="R -> C (in AMD3; uncertain significance; mouse FT BMPR1B construct containing this mutation shows reduced FT GDF5-dependent receptor activation, mouse BMPR1B construct FT containing this mutation shows no loss of cell membrane FT localization; dbSNP:rs745854387)" FT /evidence="ECO:0000269|PubMed:26105076" FT /id="VAR_075520" FT VARIANT 31 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs200035802)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041401" FT VARIANT 53 FT /note="C -> R (in AMD3; mouse BMPR1B construct containing FT this mutation shows loss of GDF5-dependent receptor FT activation, chicken BMPR1B construct containing this FT mutation does not show reduced chondrocyte differentiation, FT mouse BMPR1B construct containing this mutation shows no FT loss of cell membrane localization; dbSNP:rs863225041)" FT /evidence="ECO:0000269|PubMed:24129431" FT /id="VAR_075521" FT VARIANT 149 FT /note="R -> W (in dbSNP:rs34231464)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041402" FT VARIANT 200 FT /note="I -> K (in BDA2; in animal models loss of kinase FT activity and loss of positive regulation of chondrocyte FT differentiation; dbSNP:rs121434417)" FT /evidence="ECO:0000269|PubMed:14523231" FT /id="VAR_023819" FT VARIANT 224 FT /note="R -> H (in dbSNP:rs35973133)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041403" FT VARIANT 297 FT /note="D -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041404" FT VARIANT 325 FT /note="K -> N (in BDA1D; acts in a dominant-negative FT manner; dbSNP:rs869025614)" FT /evidence="ECO:0000269|PubMed:25758993" FT /id="VAR_076406" FT VARIANT 371 FT /note="R -> Q (in dbSNP:rs34970181)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041405" FT VARIANT 486 FT /note="R -> Q (in brachydactyly type C and BDA2; with also FT additional features of symphalangism-1; dbSNP:rs121434419)" FT /evidence="ECO:0000269|PubMed:16957682" FT /id="VAR_037967" FT VARIANT 486 FT /note="R -> W (in BDA2; in animal models no effect on FT kinase activity but strongly decreased positive regulation FT of chondrocyte differentiation; dbSNP:rs121434418)" FT /evidence="ECO:0000269|PubMed:14523231" FT /id="VAR_023820" FT HELIX 176..186 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 194..197 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 200..203 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 205..213 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 216..223 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 226..234 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 235..237 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 238..248 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 261..268 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 270..272 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 274..279 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 287..293 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 298..316 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 337..340 FT /evidence="ECO:0007829|PDB:3MDY" FT STRAND 346..348 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 375..377 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 380..383 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 393..411 FT /evidence="ECO:0007829|PDB:3MDY" FT TURN 426..430 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 437..444 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 455..459 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 461..473 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:3MDY" FT HELIX 484..496 FT /evidence="ECO:0007829|PDB:3MDY" FT TURN 497..499 FT /evidence="ECO:0007829|PDB:3MDY" SQ SEQUENCE 502 AA; 56930 MW; B283D9BF45535C79 CRC64; MLLRSAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DSVNNICSTD GYCFTMIEED DSGLPVVTSG CLGLEGSDFQ CRDTPIPHQR RSIECCTERN ECNKDLHPTL PPLKNRDFVD GPIHHRALLI SVTVCSLLLV LIILFCYFRY KRQETRPRYS IGLEQDETYI PPGESLRDLI EQSQSSGSGS GLPLLVQRTI AKQIQMVKQI GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDY LKSTTLDAKS MLKLAYSSVS GLCHLHTEIF STQGKPAIAH RDLKSKNILV KKNGTCCIAD LGLAVKFISD TNEVDIPPNT RVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV ARRCVSGGIV EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS RLTALRVKKT LAKMSESQDI KL // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID BRDT_HUMAN Reviewed; 947 AA. AC Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1; AC Q7Z4A6; Q8IWI6; DT 30-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 4. DT 28-JAN-2026, entry version 165. DE RecName: Full=Bromodomain testis-specific protein; DE AltName: Full=Cancer/testis antigen 9; DE Short=CT9; DE AltName: Full=RING3-like protein; GN Name=BRDT; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP VARIANTS LYS-62 AND LEU-696. RX PubMed=9367677; DOI=10.1006/geno.1997.5000; RA Jones M.H., Numata M., Shimane M.; RT "Identification and characterization of BRDT: a testis-specific gene RT related to the bromodomain genes RING3 and Drosophila fsh."; RL Genomics 45:529-534(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ALTERNATIVE SPLICING, RP TISSUE SPECIFICITY, AND VARIANTS LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=15647849; RA Zheng Y., Yuan W., Zhou Z., Xu M., Sha J.-H.; RT "Molecular cloning and expression of a novel alternative splice variant of RT BRDT gene."; RL Int. J. Mol. Med. 15:315-321(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANTS RP LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS LYS-62 AND RP LEU-696. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-462 (ISOFORM 1), AND VARIANTS RP LYS-62; ASN-238 AND LYS-410. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP TISSUE SPECIFICITY, AND IDENTIFICATION AS A CANCER/TESTIS ANTIGEN. RX PubMed=10704737; DOI=10.1016/s0304-3835(99)00385-7; RA Scanlan M.J., Altorki N.K., Gure A.O., Williamson B., Jungbluth A., RA Chen Y.-T., Old L.J.; RT "Expression of cancer-testis antigens in lung cancer: definition of RT bromodomain testis-specific gene (BRDT) as a new CT gene, CT9."; RL Cancer Lett. 150:155-164(2000). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-2; GLN-6; VAL-89; ASN-238; TYR-288; RP LYS-357; LYS-410 AND ALA-542. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=20538714; DOI=10.1530/rep-10-0139; RA Steilmann C., Cavalcanti M.C., Bartkuhn M., Pons-Kuhnemann J., RA Schuppe H.C., Weidner W., Steger K., Paradowska A.; RT "The interaction of modified histones with the bromodomain testis-specific RT (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile RT men."; RL Reproduction 140:435-443(2010). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF NUCLEAR LOCALIZATION SIGNAL. RX PubMed=22971749; DOI=10.1248/bpb.b12-00527; RA Fukazawa H., Masumi A.; RT "The conserved 12-amino acid stretch in the inter-bromodomain region of BET RT family proteins functions as a nuclear localization signal."; RL Biol. Pharm. Bull. 35:2064-2068(2012). RN [11] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [12] {ECO:0007744|PDB:2RFJ} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 21-137, FUNCTION, SUBUNIT, AND RP DOMAIN. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [13] {ECO:0007744|PDB:4FLP} RP X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 21-137 IN COMPLEX WITH JQ1, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=22901802; DOI=10.1016/j.cell.2012.06.045; RA Matzuk M.M., McKeown M.R., Filippakopoulos P., Li Q., Ma L., Agno J.E., RA Lemieux M.E., Picaud S., Yu R.N., Qi J., Knapp S., Bradner J.E.; RT "Small-molecule inhibition of BRDT for male contraception."; RL Cell 150:673-684(2012). RN [14] RP VARIANT SPGF21 ASP-928, AND CHARACTERIZATION OF VARIANT SPGF21 ASP-928. RX PubMed=28199965; DOI=10.18632/oncotarget.15251; RA Li L., Sha Y., Wang X., Li P., Wang J., Kee K., Wang B.; RT "Whole-exome sequencing identified a homozygous BRDT mutation in a patient RT with acephalic spermatozoa."; RL Oncotarget 8:19914-19922(2017). CC -!- FUNCTION: Testis-specific chromatin protein that specifically binds CC histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, CC respectively) and plays a key role in spermatogenesis (PubMed:22464331, CC PubMed:22901802). Required in late pachytene spermatocytes: plays a CC role in meiotic and post-meiotic cells by binding to acetylated CC histones at the promoter of specific meiotic and post-meiotic genes, CC facilitating their activation at the appropriate time CC (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds CC to hyperacetylated histones and participates in their general removal CC from DNA (PubMed:22901802). Also recognizes and binds a subset of CC butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' CC (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' CC (H4K5ac) (By similarity). Also acts as a component of the splicing CC machinery in pachytene spermatocytes and round spermatids and CC participates in 3'-UTR truncation of specific mRNAs in post-meiotic CC spermatids (By similarity). Required for chromocenter organization, a CC structure comprised of peri-centromeric heterochromatin. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:22901802, CC ECO:0000269|PubMed:9367677}. CC -!- SUBUNIT: Interacts with mRNA splicing machinery proteins SRSF2, DDX5, CC HNRNPK and TARDBP. Interacts with the acetylated N-terminus of histone CC H1, H2, H3 and H4. Interacts with P-TEFb components CDK9 and CC CCNT1/cyclin-T1. Interacts with SMARCE1 (By similarity). Interacts with CC the acetylated N-terminus of histone H1.4, H2A, H2B, H3 and H4. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20538714, CC ECO:0000269|PubMed:22901802, ECO:0000269|PubMed:22971749, CC ECO:0000269|PubMed:25593309}. Note=Detected on chromatin. CC {ECO:0000250|UniProtKB:Q91Y44}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=Q58F21-1; Sequence=Displayed; CC Name=2; Synonyms=BRDT-NY; CC IsoId=Q58F21-2; Sequence=VSP_019118; CC Name=3; CC IsoId=Q58F21-3; Sequence=VSP_044511; CC Name=4; CC IsoId=Q58F21-4; Sequence=VSP_044510; CC Name=5; CC IsoId=Q58F21-5; Sequence=VSP_044509; CC -!- TISSUE SPECIFICITY: Testis-specific. A 3-fold higher expression is seen CC in adult testis than in embryo testis. Expression seems to be CC correlated with histone H4 hyperacetylation during the haploid phase of CC spermatogenesis (spermiogenesis). No expression, or very low expression CC is seen in patients' testes with abnormal spermatogenesis. Expressed in CC cancers such as non-small cell lung cancer and squamous cell carcinomas CC of the head and neck as well as of esophagus, but not in melanoma or in CC cancers of the colon, breast, kidney and bladder. CC {ECO:0000269|PubMed:10704737, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:9367677}. CC -!- DEVELOPMENTAL STAGE: Expressed in embryo testis. CC -!- DOMAIN: Bromo domains mediate interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). CC Bromo domain 1 mediates binding with histone H4 acetylated at 'Lys-5' CC and 'Lys-8' (H4K5ac and H4K8ac, respectively) (PubMed:22901802). The CC bromo domains also recognize and bind a subset of butyrylated histones: CC able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is CC not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity). CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- PTM: Ubiquitinated in a SPOP-dependent manner, leading to proteasomal CC degradation. {ECO:0000250|UniProtKB:Q91Y44}. CC -!- DISEASE: Spermatogenic failure 21 (SPGF21) [MIM:617644]: An infertility CC disorder caused by spermatogenesis defects and characterized by CC acephalic spermatozoa in the semen of affected individuals. SPGF21 CC inheritance is autosomal recessive. {ECO:0000269|PubMed:28199965}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: BRDT is a promising target for male contraception. CC Inhibition by thienodiazepine inhibitor (+)-JQ1 that binds Asn-109, CC prevents recognition of acetylated histone H4, causing a complete and CC reversible contraceptive effect in male mice (PubMed:22901802). CC {ECO:0000305|PubMed:22901802}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH05281.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH47900.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH62700.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=Asking life to be patient CC - Issue 144 of November 2012; CC URL="https://www.proteinspotlight.org/back_issues/144"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF019085; AAB87862.1; -; mRNA. DR EMBL; AY338951; AAQ16198.1; -; mRNA. DR EMBL; AK303008; BAH13876.1; -; mRNA. DR EMBL; AK302758; BAH13797.1; -; mRNA. DR EMBL; AK316442; BAH14813.1; -; mRNA. DR EMBL; AC114486; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471097; EAW73106.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73107.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73108.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73110.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73111.1; -; Genomic_DNA. DR EMBL; BC005281; AAH05281.1; ALT_SEQ; mRNA. DR EMBL; BC017582; AAH17582.1; -; mRNA. DR EMBL; BC047900; AAH47900.1; ALT_SEQ; mRNA. DR EMBL; BC062700; AAH62700.1; ALT_SEQ; mRNA. DR CCDS; CCDS55615.1; -. [Q58F21-4] DR CCDS; CCDS55616.1; -. [Q58F21-5] DR CCDS; CCDS735.1; -. [Q58F21-1] DR RefSeq; NP_001229734.2; NM_001242805.2. [Q58F21-1] DR RefSeq; NP_001229735.2; NM_001242806.2. [Q58F21-3] DR RefSeq; NP_001229736.2; NM_001242807.2. [Q58F21-4] DR RefSeq; NP_001229737.2; NM_001242808.2. [Q58F21-4] DR RefSeq; NP_001229739.2; NM_001242810.2. [Q58F21-5] DR RefSeq; NP_001717.3; NM_001726.4. [Q58F21-1] DR RefSeq; NP_997072.2; NM_207189.4. [Q58F21-1] DR RefSeq; XP_006710918.1; XM_006710855.5. [Q58F21-1] DR RefSeq; XP_006710919.1; XM_006710856.5. [Q58F21-1] DR RefSeq; XP_011540334.1; XM_011542032.4. [Q58F21-1] DR RefSeq; XP_011540336.1; XM_011542034.4. [Q58F21-1] DR RefSeq; XP_011540337.1; XM_011542035.4. [Q58F21-1] DR RefSeq; XP_011540338.1; XM_011542036.4. [Q58F21-1] DR RefSeq; XP_047284905.1; XM_047428949.1. [Q58F21-1] DR RefSeq; XP_047284911.1; XM_047428955.1. [Q58F21-1] DR RefSeq; XP_047284923.1; XM_047428967.1. [Q58F21-1] DR PDB; 2RFJ; X-ray; 2.05 A; A/B/C=21-137. DR PDB; 4FLP; X-ray; 2.23 A; A/B=21-137. DR PDB; 4KCX; X-ray; 2.00 A; A/B=21-137. DR PDB; 5VBQ; X-ray; 1.65 A; A/B=29-137. DR PDB; 5VBR; X-ray; 1.90 A; A/B=29-137. DR PDB; 7BJY; X-ray; 2.22 A; A/B=29-137. DR PDB; 7L73; X-ray; 1.46 A; A=29-137. DR PDB; 7L99; X-ray; 1.90 A; A/B/C/D=269-380. DR PDB; 7L9A; X-ray; 2.27 A; A/B=269-380. DR PDB; 7LEJ; X-ray; 1.73 A; A=266-378. DR PDB; 7LEK; X-ray; 2.75 A; A/B/C/D=266-378. DR PDB; 7LEL; X-ray; 2.15 A; A/B/C/D=266-378. DR PDB; 7LEM; X-ray; 1.89 A; A/B=29-137. DR PDB; 7MRC; X-ray; 1.55 A; A/B=29-137. DR PDB; 7MRD; X-ray; 1.39 A; A/B=29-137. DR PDB; 7MRG; X-ray; 1.99 A; A/B=29-137. DR PDB; 7MRH; X-ray; 1.98 A; A/B=29-137. DR PDB; 7UBO; X-ray; 1.82 A; A/B/C/D=29-137. DR PDB; 7UUU; X-ray; 1.52 A; A=29-137. DR PDB; 8CZA; X-ray; 2.96 A; A/B/C/D/E/F=29-137. DR PDB; 8YHS; X-ray; 1.50 A; A=21-137. DR PDBsum; 2RFJ; -. DR PDBsum; 4FLP; -. DR PDBsum; 4KCX; -. DR PDBsum; 5VBQ; -. DR PDBsum; 5VBR; -. DR PDBsum; 7BJY; -. DR PDBsum; 7L73; -. DR PDBsum; 7L99; -. DR PDBsum; 7L9A; -. DR PDBsum; 7LEJ; -. DR PDBsum; 7LEK; -. DR PDBsum; 7LEL; -. DR PDBsum; 7LEM; -. DR PDBsum; 7MRC; -. DR PDBsum; 7MRD; -. DR PDBsum; 7MRG; -. DR PDBsum; 7MRH; -. DR PDBsum; 7UBO; -. DR PDBsum; 7UUU; -. DR PDBsum; 8CZA; -. DR PDBsum; 8YHS; -. DR AlphaFoldDB; Q58F21; -. DR SASBDB; Q58F21; -. DR SMR; Q58F21; -. DR BioGRID; 107143; 78. DR FunCoup; Q58F21; 517. DR IntAct; Q58F21; 2. DR STRING; 9606.ENSP00000387822; -. DR BindingDB; Q58F21; -. DR ChEMBL; CHEMBL1795185; -. DR DrugBank; DB17021; JQ1. DR DrugCentral; Q58F21; -. DR GuidetoPHARMACOLOGY; 2729; -. DR GlyGen; Q58F21; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q58F21; -. DR PhosphoSitePlus; Q58F21; -. DR BioMuta; BRDT; -. DR DMDM; 226694198; -. DR jPOST; Q58F21; -. DR MassIVE; Q58F21; -. DR PaxDb; 9606-ENSP00000387822; -. DR PeptideAtlas; Q58F21; -. DR ProteomicsDB; 1029; -. DR ProteomicsDB; 62618; -. [Q58F21-1] DR ProteomicsDB; 62619; -. [Q58F21-2] DR Antibodypedia; 3212; 136 antibodies from 22 providers. DR DNASU; 676; -. DR Ensembl; ENST00000362005.7; ENSP00000354568.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000370389.6; ENSP00000359416.2; ENSG00000137948.19. [Q58F21-5] DR Ensembl; ENST00000394530.7; ENSP00000378038.3; ENSG00000137948.19. [Q58F21-4] DR Ensembl; ENST00000399546.7; ENSP00000387822.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000402388.1; ENSP00000384051.1; ENSG00000137948.19. [Q58F21-1] DR GeneID; 676; -. DR KEGG; hsa:676; -. DR MANE-Select; ENST00000399546.7; ENSP00000387822.3; NM_207189.4; NP_997072.2. DR UCSC; uc001dol.5; human. [Q58F21-1] DR AGR; HGNC:1105; -. DR ClinPGx; PA25418; -. DR CTD; 676; -. DR DisGeNET; 676; -. DR GeneCards; BRDT; -. DR HGNC; HGNC:1105; BRDT. DR HPA; ENSG00000137948; Tissue enriched (testis). DR MalaCards; BRDT; -. DR MIM; 602144; gene. DR MIM; 617644; phenotype. DR OpenTargets; ENSG00000137948; -. DR VEuPathDB; HostDB:ENSG00000137948; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000154549; -. DR HOGENOM; CLU_001499_0_0_1; -. DR InParanoid; Q58F21; -. DR OMA; DFKTMFL; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; Q58F21; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q58F21; -. DR PathwayCommons; Q58F21; -. DR SignaLink; Q58F21; -. DR SIGNOR; Q58F21; -. DR Agora; ENSG00000137948; -. DR BioGRID-ORCS; 676; 15 hits in 1166 CRISPR screens. DR ChiTaRS; BRDT; human. DR EvolutionaryTrace; Q58F21; -. DR GeneWiki; BRDT; -. DR GenomeRNAi; 676; -. DR Pharos; Q58F21; Tchem. DR PRO; PR:Q58F21; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q58F21; protein. DR Bgee; ENSG00000137948; Expressed in left testis and 97 other cell types or tissues. DR ExpressionAtlas; Q58F21; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0140008; F:histone H4 reader activity; IEA:Ensembl. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0007141; P:male meiosis I; ISS:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0043484; P:regulation of RNA splicing; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW. DR GO; GO:0035092; P:sperm DNA condensation; ISS:UniProtKB. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR DisProt; DP03058; -. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR031354; BRD4_CDT. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF175; BROMODOMAIN TESTIS-SPECIFIC PROTEIN; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF17105; BRD4_CDT; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Bromodomain; KW Chromatin regulator; Coiled coil; Differentiation; Disease variant; KW Meiosis; mRNA processing; mRNA splicing; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Spermatogenesis; KW Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..947 FT /note="Bromodomain testis-specific protein" FT /id="PRO_0000239225" FT DOMAIN 27..133 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 267..376 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 500..582 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 202..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 395..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 444..511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 610..698 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 882..924 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 417..470 FT /evidence="ECO:0000255" FT COILED 591..621 FT /evidence="ECO:0000255" FT MOTIF 209..220 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22971749" FT COMPBIAS 217..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..462 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 470..481 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 482..494 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..662 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 674..692 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 885..924 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 109 FT /ligand="JQ1" FT /ligand_id="ChEBI:CHEBI:137113" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:22901802, FT ECO:0007744|PDB:4FLP" FT SITE 109 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT SITE 114 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT MOD_RES 187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT VAR_SEQ 1..73 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_044509" FT VAR_SEQ 1 FT /note="M -> MTCTCRQDSKQLRM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15647849" FT /id="VSP_019118" FT VAR_SEQ 65..110 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044510" FT VAR_SEQ 148 FT /note="K -> KGKAG (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044511" FT VARIANT 2 FT /note="S -> F (in dbSNP:rs55806733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041924" FT VARIANT 6 FT /note="R -> Q (in dbSNP:rs56273490)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041925" FT VARIANT 62 FT /note="Q -> K (in dbSNP:rs10783071)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15647849, FT ECO:0000269|PubMed:9367677, ECO:0000269|Ref.5" FT /id="VAR_026584" FT VARIANT 89 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs781375003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041926" FT VARIANT 238 FT /note="K -> N (in dbSNP:rs1156281)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026585" FT VARIANT 288 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041927" FT VARIANT 336 FT /note="K -> T (in dbSNP:rs1064567)" FT /id="VAR_047327" FT VARIANT 357 FT /note="E -> K (in dbSNP:rs34674879)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041928" FT VARIANT 410 FT /note="N -> K (in dbSNP:rs3088232)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026586" FT VARIANT 542 FT /note="P -> A (in dbSNP:rs55912588)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041929" FT VARIANT 605 FT /note="R -> Q (in dbSNP:rs35327986)" FT /id="VAR_047328" FT VARIANT 696 FT /note="P -> L (in dbSNP:rs10747493)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15647849, ECO:0000269|PubMed:9367677, FT ECO:0000269|Ref.5" FT /id="VAR_047329" FT VARIANT 928 FT /note="G -> D (in SPGF21; uncertain significance; no effect FT on protein expression; dbSNP:rs754258809)" FT /evidence="ECO:0000269|PubMed:28199965" FT /id="VAR_079306" FT CONFLICT 42 FT /note="D -> N (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="P -> S (in Ref. 6; AAH05281)" FT /evidence="ECO:0000305" FT CONFLICT 80 FT /note="K -> I (in Ref. 6; AAH62700)" FT /evidence="ECO:0000305" FT CONFLICT 265 FT /note="K -> E (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="K -> S (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 462 FT /note="E -> K (in Ref. 6; AAH17582)" FT /evidence="ECO:0000305" FT CONFLICT 477 FT /note="Q -> R (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 552 FT /note="I -> M (in Ref. 2; AAQ16198)" FT /evidence="ECO:0000305" FT CONFLICT 686 FT /note="N -> H (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 893 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 915 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT HELIX 29..37 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 39..45 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:7MRD" FT STRAND 53..55 FT /evidence="ECO:0007829|PDB:2RFJ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 66..69 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 76..84 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 91..108 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 114..131 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 266..284 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 289..292 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:7LEJ" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7L99" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 319..327 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 334..351 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 357..373 FT /evidence="ECO:0007829|PDB:7LEJ" SQ SEQUENCE 947 AA; 107954 MW; 09C0FD8690E217BB CRC64; MSLPSRQTAI IVNPPPPEYI NTKKNGRLTN QLQYLQKVVL KDLWKHSFSW PFQRPVDAVK LQLPDYYTII KNPMDLNTIK KRLENKYYAK ASECIEDFNT MFSNCYLYNK PGDDIVLMAQ ALEKLFMQKL SQMPQEEQVV GVKERIKKGT QQNIAVSSAK EKSSPSATEK VFKQQEIPSV FPKTSISPLN VVQGASVNSS SQTAAQVTKG VKRKADTTTP ATSAVKASSE FSPTFTEKSV ALPPIKENMP KNVLPDSQQQ YNVVKTVKVT EQLRHCSEIL KEMLAKKHFS YAWPFYNPVD VNALGLHNYY DVVKNPMDLG TIKEKMDNQE YKDAYKFAAD VRLMFMNCYK YNPPDHEVVT MARMLQDVFE THFSKIPIEP VESMPLCYIK TDITETTGRE NTNEASSEGN SSDDSEDERV KRLAKLQEQL KAVHQQLQVL SQVPFRKLNK KKEKSKKEKK KEKVNNSNEN PRKMCEQMRL KEKSKRNQPK KRKQQFIGLK SEDEDNAKPM NYDEKRQLSL NINKLPGDKL GRVVHIIQSR EPSLSNSNPD EIEIDFETLK ASTLRELEKY VSACLRKRPL KPPAKKIMMS KEELHSQKKQ ELEKRLLDVN NQLNSRKRQT KSDKTQPSKA VENVSRLSES SSSSSSSSES ESSSSDLSSS DSSDSESEMF PKFTEVKPND SPSKENVKKM KNECIPPEGR TGVTQIGYCV QDTTSANTTL VHQTTPSHVM PPNHHQLAFN YQELEHLQTV KNISPLQILP PSGDSEQLSN GITVMHPSGD SDTTMLESEC QAPVQKDIKI KNADSWKSLG KPVKPSGVMK SSDELFNQFR KAAIEKEVKA RTQELIRKHL EQNTKELKAS QENQRDLGNG LTVESFSNKI QNKCSGEEQK EHQQSSEAQD KSKLWLLKDR DLARQKEQER RRREAMVGTI DMTLQSDIMT MFENNFD // ID BRSK1_HUMAN Reviewed; 778 AA. AC Q8TDC3; F1DG44; Q5J5B5; Q8NDD0; Q8NDR4; Q8TDC2; Q96AV4; Q96JL4; DT 29-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 21-SEP-2011, sequence version 2. DT 28-JAN-2026, entry version 200. DE RecName: Full=Serine/threonine-protein kinase BRSK1; DE EC=2.7.11.1; DE AltName: Full=Brain-selective kinase 1; DE EC=2.7.11.26; DE AltName: Full=Brain-specific serine/threonine-protein kinase 1; DE Short=BR serine/threonine-protein kinase 1; DE AltName: Full=Serine/threonine-protein kinase SAD-B; DE AltName: Full=Synapses of Amphids Defective homolog 1; DE Short=SAD1 homolog; DE Short=hSAD1; GN Name=BRSK1; Synonyms=KIAA1811, SAD1, SADB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF THR-189. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-59. RC TISSUE=Testis; RX PubMed=15150265; DOI=10.1074/jbc.m404728200; RA Lu R., Niida H., Nakanishi M.; RT "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint RT function."; RL J. Biol. Chem. 279:31164-31170(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=16630837; DOI=10.1016/j.neuron.2006.03.018; RA Inoue E., Mochida S., Takagi H., Higa S., Deguchi-Tawarada M., RA Takao-Rikitsu E., Inoue M., Yao I., Takeuchi K., Kitajima I., Setou M., RA Ohtsuka T., Takai Y.; RT "SAD: a presynaptic kinase associated with synaptic vesicles and the active RT zone cytomatrix that regulates neurotransmitter release."; RL Neuron 50:261-275(2006). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RX PubMed=19648910; DOI=10.1038/ncb1921; RA Alvarado-Kristensson M., Rodriguez M.J., Silio V., Valpuesta J.M., RA Carrera A.C.; RT "SADB phosphorylation of gamma-tubulin regulates centrosome duplication."; RL Nat. Cell Biol. 11:1081-1092(2009). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RA She X.Y., Yu L., Guo J.H.; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 35-778. RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 64-778. RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 287-778. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF GLY-327. RX PubMed=18339622; DOI=10.1074/jbc.m710381200; RA Bright N.J., Carling D., Thornton C.; RT "Investigating the regulation of brain-specific kinases 1 and 2 by RT phosphorylation."; RL J. Biol. Chem. 283:14946-14954(2008). RN [11] RP PHOSPHORYLATION. RX PubMed=19958286; DOI=10.1042/bj20091372; RA Fogarty S., Hawley S.A., Green K.A., Saner N., Mustard K.J., Hardie D.G.; RT "Calmodulin-dependent protein kinase kinase-beta activates AMPK without RT forming a stable complex: synergistic effects of Ca2+ and AMP."; RL Biochem. J. 426:109-118(2010). RN [12] RP FUNCTION. RX PubMed=20026642; DOI=10.1242/jcs.058230; RA Muller M., Lutter D., Puschel A.W.; RT "Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB- RT deficient neurons disrupts neuronal polarity."; RL J. Cell Sci. 123:286-294(2010). RN [13] RP CATALYTIC ACTIVITY, AND FUNCTION IN MAPT PHOSPHORYLATION. RX PubMed=21985311; DOI=10.1111/j.1471-4159.2011.07523.x; RA Yoshida H., Goedert M.; RT "Phosphorylation of microtubule-associated protein tau by AMPK-related RT kinases."; RL J. Neurochem. 120:165-176(2012). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-508, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-303; ILE-319; GLU-391; ASN-531; SER-749 RP AND ALA-764. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that plays a key role in CC polarization of neurons and centrosome duplication. Phosphorylates CC CDC25B, CDC25C, MAPT/TAU, RIMS1, TUBG1, TUBG2 and WEE1. Following CC phosphorylation and activation by STK11/LKB1, acts as a key regulator CC of polarization of cortical neurons, probably by mediating CC phosphorylation of microtubule-associated proteins such as MAPT/TAU at CC 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by CC mediating phosphorylation of WEE1 at 'Ser-642' in postmitotic neurons, CC leading to down-regulate WEE1 activity in polarized neurons. In CC neurons, localizes to synaptic vesicles and plays a role in CC neurotransmitter release, possibly by phosphorylating RIMS1. Also acts CC as a positive regulator of centrosome duplication by mediating CC phosphorylation of gamma-tubulin (TUBG1 and TUBG2) at 'Ser-131', CC leading to translocation of gamma-tubulin and its associated proteins CC to the centrosome. Involved in the UV-induced DNA damage checkpoint CC response, probably by inhibiting CDK1 activity through phosphorylation CC and activation of WEE1, and inhibition of CDC25B and CDC25C. CC {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15150265, CC ECO:0000269|PubMed:20026642, ECO:0000269|PubMed:21985311}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; Evidence={ECO:0000269|PubMed:21985311}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-189 by CC STK11/LKB1. {ECO:0000269|PubMed:14976552}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15150265}. Nucleus CC {ECO:0000269|PubMed:15150265}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250}. Synapse CC {ECO:0000250|UniProtKB:B2DD29}. Presynaptic active zone CC {ECO:0000250|UniProtKB:B2DD29}. Cytoplasmic vesicle, secretory vesicle, CC synaptic vesicle {ECO:0000250|UniProtKB:B2DD29}. Note=Nuclear in the CC absence of DNA damage. Translocated to the nucleus in response to CC UV- or MMS-induced DNA damage (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=SADB-Long, L; CC IsoId=Q8TDC3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8TDC3-2; Sequence=VSP_008158; CC Name=3; Synonyms=SADB-short, S; CC IsoId=Q8TDC3-3; Sequence=VSP_041742; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in brain and CC testis. Protein levels remain constant throughout the cell cycle. CC {ECO:0000269|PubMed:15150265}. CC -!- PTM: Phosphorylated at Thr-189 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Not CC phosphorylated at Thr-189 by CaMKK2. In contrast, it is phosphorylated CC and activated by CaMKK1. May be inactivated via dephosphorylation of CC Thr-189 by PP2C. {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:19958286}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16681.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY458602; AAS10354.1; -; mRNA. DR EMBL; AY505124; AAS86442.1; -; mRNA. DR EMBL; HQ830199; ADX95745.1; -; mRNA. DR EMBL; AF479826; AAL87697.1; -; mRNA. DR EMBL; AF479827; AAL87698.1; -; mRNA. DR EMBL; AC008974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC020922; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL831945; CAD38595.1; -; mRNA. DR EMBL; AL834275; CAD38950.2; -; mRNA. DR EMBL; AB058714; BAB47440.1; -; mRNA. DR EMBL; BC016681; AAH16681.1; ALT_INIT; mRNA. DR CCDS; CCDS12921.1; -. [Q8TDC3-1] DR RefSeq; NP_115806.1; NM_032430.2. [Q8TDC3-1] DR AlphaFoldDB; Q8TDC3; -. DR SMR; Q8TDC3; -. DR BioGRID; 124084; 36. DR FunCoup; Q8TDC3; 1370. DR IntAct; Q8TDC3; 29. DR MINT; Q8TDC3; -. DR STRING; 9606.ENSP00000310649; -. DR BindingDB; Q8TDC3; -. DR ChEMBL; CHEMBL5650; -. DR DrugCentral; Q8TDC3; -. DR GlyGen; Q8TDC3; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q8TDC3; -. DR PhosphoSitePlus; Q8TDC3; -. DR SwissPalm; Q8TDC3; -. DR BioMuta; BRSK1; -. DR DMDM; 347595639; -. DR jPOST; Q8TDC3; -. DR MassIVE; Q8TDC3; -. DR PaxDb; 9606-ENSP00000310649; -. DR PeptideAtlas; Q8TDC3; -. DR ProteomicsDB; 74264; -. [Q8TDC3-1] DR ProteomicsDB; 74265; -. [Q8TDC3-2] DR ProteomicsDB; 74266; -. [Q8TDC3-3] DR Antibodypedia; 19545; 448 antibodies from 37 providers. DR DNASU; 84446; -. DR Ensembl; ENST00000309383.6; ENSP00000310649.1; ENSG00000160469.17. [Q8TDC3-1] DR Ensembl; ENST00000585418.1; ENSP00000467357.1; ENSG00000160469.17. [Q8TDC3-3] DR Ensembl; ENST00000590333.5; ENSP00000468190.1; ENSG00000160469.17. [Q8TDC3-2] DR GeneID; 84446; -. DR KEGG; hsa:84446; -. DR MANE-Select; ENST00000309383.6; ENSP00000310649.1; NM_032430.2; NP_115806.1. DR UCSC; uc002qkf.4; human. [Q8TDC3-1] DR AGR; HGNC:18994; -. DR ClinPGx; PA134888976; -. DR CTD; 84446; -. DR DisGeNET; 84446; -. DR GeneCards; BRSK1; -. DR HGNC; HGNC:18994; BRSK1. DR HPA; ENSG00000160469; Group enriched (brain, pituitary gland). DR MalaCards; BRSK1; -. DR MIM; 609235; gene. DR OpenTargets; ENSG00000160469; -. DR VEuPathDB; HostDB:ENSG00000160469; -. DR eggNOG; KOG0588; Eukaryota. DR GeneTree; ENSGT00940000161254; -. DR HOGENOM; CLU_000288_156_2_1; -. DR InParanoid; Q8TDC3; -. DR OMA; QHSQRNR; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q8TDC3; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q8TDC3; -. DR PathwayCommons; Q8TDC3; -. DR SignaLink; Q8TDC3; -. DR SIGNOR; Q8TDC3; -. DR Agora; ENSG00000160469; -. DR BioGRID-ORCS; 84446; 8 hits in 1189 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; BRSK1; human. DR GeneWiki; BRSK1; -. DR GenomeRNAi; 84446; -. DR Pharos; Q8TDC3; Tchem. DR PRO; PR:Q8TDC3; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8TDC3; protein. DR Bgee; ENSG00000160469; Expressed in right frontal lobe and 121 other cell types or tissues. DR ExpressionAtlas; Q8TDC3; baseline and differential. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0098981; C:cholinergic synapse; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0150034; C:distal axon; ISS:ARUK-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0048786; C:presynaptic active zone; TAS:ARUK-UCL. DR GO; GO:0008021; C:synaptic vesicle; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IC:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0008306; P:associative learning; ISS:ARUK-UCL. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0051298; P:centrosome duplication; ISS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:MGI. DR GO; GO:0090176; P:microtubule cytoskeleton organization involved in establishment of planar polarity; ISS:ARUK-UCL. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0007269; P:neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:MGI. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050770; P:regulation of axonogenesis; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:2000807; P:regulation of synaptic vesicle clustering; TAS:ARUK-UCL. DR GO; GO:0010807; P:regulation of synaptic vesicle priming; IEA:Ensembl. DR GO; GO:0009411; P:response to UV; IDA:UniProtKB. DR GO; GO:0099504; P:synaptic vesicle cycle; ISS:ARUK-UCL. DR CDD; cd14081; STKc_BRSK1_2; 1. DR CDD; cd14340; UBA_BRSK; 1. DR FunFam; 1.10.510.10:FF:000064; BR serine/threonine-protein kinase 2; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR048622; BRSK1_2-like_UBA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF36; SERINE_THREONINE-PROTEIN KINASE BRSK1 ISOFORM X1-RELATED; 1. DR Pfam; PF21122; KA1_BRSK; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF21115; UBA_BRSK; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Cell projection; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; DNA damage; Kinase; Magnesium; KW Metal-binding; Methylation; Neurogenesis; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..778 FT /note="Serine/threonine-protein kinase BRSK1" FT /id="PRO_0000085669" FT DOMAIN 34..285 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 314..356 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 362..548 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 719..778 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 362..383 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 430..457 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 491..508 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 509..533 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 156 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 189 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:18339622" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 443 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 450 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 466 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 481 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 484 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 498 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 508 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 525 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 529 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 535 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 550 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 583 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 586 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 587 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 601 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT VAR_SEQ 1..26 FT /note="MSSGAKEGGGGSPAYHLPHPHPHPPQ -> MVAGLTLGKGPESPDGDVSVPE FT RKDEVAGGGGEEEEAEERGR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14976552, ECO:0000303|Ref.5" FT /id="VSP_008158" FT VAR_SEQ 344..778 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:19648910" FT /id="VSP_041742" FT VARIANT 303 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs144130246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040394" FT VARIANT 319 FT /note="V -> I (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs2088591390)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040395" FT VARIANT 391 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040396" FT VARIANT 531 FT /note="T -> N (in dbSNP:rs55892637)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040397" FT VARIANT 749 FT /note="G -> S (in dbSNP:rs12978445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040398" FT VARIANT 764 FT /note="P -> A (in dbSNP:rs55796422)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040399" FT MUTAGEN 59 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15150265" FT MUTAGEN 189 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 327 FT /note="G->A: Abolishes activation of kinase activity." FT /evidence="ECO:0000269|PubMed:18339622" FT CONFLICT 762 FT /note="G -> A (in Ref. 9; AAH16681)" FT /evidence="ECO:0000305" SQ SEQUENCE 778 AA; 85087 MW; 8D1818D4E54398BB CRC64; MSSGAKEGGG GSPAYHLPHP HPHPPQHAQY VGPYRLEKTL GKGQTGLVKL GVHCITGQKV AIKIVNREKL SESVLMKVER EIAILKLIEH PHVLKLHDVY ENKKYLYLVL EHVSGGELFD YLVKKGRLTP KEARKFFRQI VSALDFCHSY SICHRDLKPE NLLLDEKNNI RIADFGMASL QVGDSLLETS CGSPHYACPE VIKGEKYDGR RADMWSCGVI LFALLVGALP FDDDNLRQLL EKVKRGVFHM PHFIPPDCQS LLRGMIEVEP EKRLSLEQIQ KHPWYLGGKH EPDPCLEPAP GRRVAMRSLP SNGELDPDVL ESMASLGCFR DRERLHRELR SEEENQEKMI YYLLLDRKER YPSCEDQDLP PRNDVDPPRK RVDSPMLSRH GKRRPERKSM EVLSITDAGG GGSPVPTRRA LEMAQHSQRS RSVSGASTGL SSSPLSSPRS PVFSFSPEPG AGDEARGGGS PTSKTQTLPS RGPRGGGAGE QPPPPSARST PLPGPPGSPR SSGGTPLHSP LHTPRASPTG TPGTTPPPSP GGGVGGAAWR SRLNSIRNSF LGSPRFHRRK MQVPTAEEMS SLTPESSPEL AKRSWFGNFI SLDKEEQIFL VLKDKPLSSI KADIVHAFLS IPSLSHSVLS QTSFRAEYKA SGGPSVFQKP VRFQVDISSS EGPEPSPRRD GSGGGGIYSV TFTLISGPSR RFKRVVETIQ AQLLSTHDQP SVQALADEKN GAQTRPAGAP PRSLQPPPGR PDPELSSSPR RGPPKDKKLL ATNGTPLP // ID DEDD2_HUMAN Reviewed; 326 AA. AC Q8WXF8; Q8NBR2; Q8NES1; Q8TAA8; Q96D35; DT 10-MAY-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2002, sequence version 1. DT 28-JAN-2026, entry version 176. DE RecName: Full=DNA-binding death effector domain-containing protein 2; DE AltName: Full=DED-containing protein FLAME-3; DE AltName: Full=FADD-like anti-apoptotic molecule 3; GN Name=DEDD2; Synonyms=FLAME3; ORFNames=PSEC0004; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INTERACTION RP WITH CASP8. RX PubMed=11741985; DOI=10.1074/jbc.m110749200; RA Roth W., Stenner-Liewen F., Pawlowski K., Godzik A., Reed J.C.; RT "Identification and characterization of DEDD2, a death effector domain- RT containing protein."; RL J. Biol. Chem. 277:7501-7508(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INTERACTION WITH CASP8 AND GTF3C3. RX PubMed=11965497; DOI=10.1038/sj.cdd.4401038; RA Zhan Y., Hegde R., Srinivasula S.M., Fernandes-Alnemri T., Alnemri E.S.; RT "Death effector domain-containing proteins DEDD and FLAME-3 form nuclear RT complexes with the TFIIIC102 subunit of human transcription factor IIIC."; RL Cell Death Differ. 9:439-447(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=12235123; DOI=10.1083/jcb.200112124; RA Lee J.C., Schickling O., Stegh A.H., Oshima R.G., Dinsdale D., Cohen G.M., RA Peter M.E.; RT "DEDD regulates degradation of intermediate filaments during apoptosis."; RL J. Cell Biol. 158:1051-1066(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INTERACTION WITH CASP8 AND CASP10. RX PubMed=12527898; DOI=10.1038/sj.onc.1206099; RA Alcivar A., Hu S., Tang J., Yang X.; RT "DEDD and DEDD2 associate with caspase-8/10 and signal cell death."; RL Oncogene 22:291-297(2003). CC -!- FUNCTION: May play a critical role in death receptor-induced apoptosis CC and may target CASP8 and CASP10 to the nucleus. May regulate CC degradation of intermediate filaments during apoptosis. May play a role CC in the general transcription machinery in the nucleus and might be an CC important regulator of the activity of GTF3C3. CC -!- SUBUNIT: Interacts with CASP8, CASP10 and GTF3C3. Homodimerizes and CC heterodimerizes with DEDD. {ECO:0000269|PubMed:11741985, CC ECO:0000269|PubMed:11965497, ECO:0000269|PubMed:12527898}. CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:11965497}. CC Note=Nuclear, accumulated in subnuclear structures resembling nucleoli. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WXF8-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WXF8-2; Sequence=VSP_010312; CC -!- TISSUE SPECIFICITY: Expressed in most tissues. High levels were found CC in liver, kidney, heart, ovary, spleen, testes, skeletal muscle and CC peripheral blood leukocytes. Expression was absent or low in colon and CC small intestine. Expression is relatively high in the tumor cell lines CC chronic myologenous leukemia K-562 and the colorectal adenocarcinoma CC SW480. Expression is moderate in the cervical carcinoma HeLa, the CC Burkitt's lymphoma Raji, the lung carcinoma A-549, and the melanoma G- CC 361. In contrast, two leukemia cell lines, HL-60 (promyelocytic CC leukemia) and MOLT-4 (lymphoblastic leukemia), show relatively low CC levels. {ECO:0000269|PubMed:11741985, ECO:0000269|PubMed:11965497}. CC -!- DOMAIN: Interactions with CASP8 and CASP10 are mediated by the DED CC domain. CC -!- SEQUENCE CAUTION: CC Sequence=AAH13372.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF443591; AAL48220.1; -; mRNA. DR EMBL; AF457575; AAM10835.1; -; mRNA. DR EMBL; AY125488; AAM95240.1; -; mRNA. DR EMBL; AK075328; BAC11551.1; -; mRNA. DR EMBL; BC013372; AAH13372.2; ALT_FRAME; mRNA. DR EMBL; BC027930; AAH27930.1; -; mRNA. DR CCDS; CCDS12597.1; -. [Q8WXF8-1] DR CCDS; CCDS59391.1; -. [Q8WXF8-2] DR RefSeq; NP_001257543.1; NM_001270614.2. [Q8WXF8-1] DR RefSeq; NP_001257544.1; NM_001270615.2. [Q8WXF8-2] DR RefSeq; NP_579874.1; NM_133328.4. [Q8WXF8-1] DR RefSeq; XP_047294269.1; XM_047438313.1. [Q8WXF8-1] DR RefSeq; XP_054176029.1; XM_054320054.1. [Q8WXF8-1] DR AlphaFoldDB; Q8WXF8; -. DR SMR; Q8WXF8; -. DR BioGRID; 127838; 17. DR FunCoup; Q8WXF8; 1017. DR IntAct; Q8WXF8; 8. DR MINT; Q8WXF8; -. DR STRING; 9606.ENSP00000471512; -. DR iPTMnet; Q8WXF8; -. DR PhosphoSitePlus; Q8WXF8; -. DR BioMuta; DEDD2; -. DR DMDM; 47116024; -. DR MassIVE; Q8WXF8; -. DR PaxDb; 9606-ENSP00000470082; -. DR PeptideAtlas; Q8WXF8; -. DR ProteomicsDB; 75029; -. [Q8WXF8-1] DR ProteomicsDB; 75030; -. [Q8WXF8-2] DR Antibodypedia; 17411; 201 antibodies from 30 providers. DR DNASU; 162989; -. DR Ensembl; ENST00000336034.8; ENSP00000336972.4; ENSG00000160570.15. [Q8WXF8-2] DR Ensembl; ENST00000595337.5; ENSP00000470082.1; ENSG00000160570.15. [Q8WXF8-1] DR Ensembl; ENST00000596251.6; ENSP00000471512.1; ENSG00000160570.15. [Q8WXF8-1] DR GeneID; 162989; -. DR KEGG; hsa:162989; -. DR MANE-Select; ENST00000596251.6; ENSP00000471512.1; NM_133328.4; NP_579874.1. DR UCSC; uc002osu.3; human. [Q8WXF8-1] DR AGR; HGNC:24450; -. DR ClinPGx; PA134912744; -. DR CTD; 162989; -. DR DisGeNET; 162989; -. DR GeneCards; DEDD2; -. DR HGNC; HGNC:24450; DEDD2. DR HPA; ENSG00000160570; Low tissue specificity. DR OpenTargets; ENSG00000160570; -. DR VEuPathDB; HostDB:ENSG00000160570; -. DR eggNOG; ENOG502QQKR; Eukaryota. DR GeneTree; ENSGT00390000008714; -. DR HOGENOM; CLU_053869_0_0_1; -. DR InParanoid; Q8WXF8; -. DR OMA; GHPETHW; -. DR OrthoDB; 6422954at2759; -. DR PAN-GO; Q8WXF8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8WXF8; -. DR PathwayCommons; Q8WXF8; -. DR SignaLink; Q8WXF8; -. DR Agora; ENSG00000160570; -. DR BioGRID-ORCS; 162989; 13 hits in 1164 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; DEDD2; human. DR GenomeRNAi; 162989; -. DR Pharos; Q8WXF8; Tbio. DR PRO; PR:Q8WXF8; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8WXF8; protein. DR Bgee; ENSG00000160570; Expressed in granulocyte and 184 other cell types or tissues. DR ExpressionAtlas; Q8WXF8; baseline and differential. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0003677; F:DNA binding; IBA:GO_Central. DR GO; GO:0030159; F:signaling receptor complex adaptor activity; NAS:UniProtKB. DR GO; GO:0030262; P:apoptotic nuclear changes; IDA:UniProtKB. DR GO; GO:0019725; P:cellular homeostasis; NAS:UniProtKB. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0006396; P:RNA processing; NAS:UniProtKB. DR GO; GO:0016075; P:rRNA catabolic process; NAS:UniProtKB. DR FunFam; 1.10.533.10:FF:000023; DNA-binding death effector domain-containing protein 2; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR001875; DED_dom. DR InterPro; IPR038856; DEDD/DEDD2. DR InterPro; IPR049341; TRADD-like_N. DR PANTHER; PTHR15205; DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR15205:SF1; DNA-BINDING DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN 2; 1. DR Pfam; PF01335; DED; 1. DR Pfam; PF20694; TRADD-like_N; 1. DR SMART; SM00031; DED; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR PROSITE; PS50168; DED; 1. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; DNA-binding; Nucleus; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..326 FT /note="DNA-binding death effector domain-containing protein FT 2" FT /id="PRO_0000191277" FT DOMAIN 25..104 FT /note="DED" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT REGION 104..194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 104..109 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOTIF 155..173 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 136..146 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 155..174 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 175..191 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 145..149 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12235123, FT ECO:0000303|PubMed:15489334" FT /id="VSP_010312" FT CONFLICT 27 FT /note="H -> N (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="A -> G (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 79 FT /note="D -> G (in Ref. 4; BAC11551)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="C -> R (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 230 FT /note="Missing (in Ref. 5; AAH13372)" FT /evidence="ECO:0000305" SQ SEQUENCE 326 AA; 36179 MW; 3F7B0B307CC870CD CRC64; MALSGSTPAP CWEEDECLDY YGMLSLHRMF EVVGGQLTEC ELELLAFLLD EAPGAAGGLA RARSGLELLL ELERRGQCDE SNLRLLGQLL RVLARHDLLP HLARKRRRPV SPERYSYGTS SSSKRTEGSC RRRRQSSSSA NSQQGQWETG SPPTKRQRRS RGRPSGGARR RRRGAPAAPQ QQSEPARPSS EGKVTCDIRL RVRAEYCEHG PALEQGVASR RPQALARQLD VFGQATAVLR SRDLGSVVCD IKFSELSYLD AFWGDYLSGA LLQALRGVFL TEALREAVGR EAVRLLVSVD EADYEAGRRR LLLMEEEGGR RPTEAS // ID DSE_HUMAN Reviewed; 958 AA. AC Q9UL01; Q5R3K6; DT 07-FEB-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 175. DE RecName: Full=Dermatan-sulfate epimerase; DE Short=DS epimerase; DE EC=5.1.3.19 {ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}; DE AltName: Full=Chondroitin-glucuronate 5-epimerase; DE AltName: Full=Squamous cell carcinoma antigen recognized by T-cells 2; DE Short=SART-2; DE Flags: Precursor; GN Name=DSE; Synonyms=SART2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10679095; DOI=10.4049/jimmunol.164.5.2565; RA Nakao M., Shichijo S., Imaizumi T., Inoue Y., Matsunaga K., Yamada A., RA Kikuchi M., Tsuda N., Ohta K., Takamori S., Yamana H., Fujita H., Itoh K.; RT "Identification of a gene coding for a new squamous cell carcinoma antigen RT recognized by the CTL."; RL J. Immunol. 164:2565-2574(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, RP PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=7092807; DOI=10.1042/bj2010489; RA Malmstroem A., Aberg L.; RT "Biosynthesis of dermatan sulphate. Assay and properties of the uronosyl C- RT 5 epimerase."; RL Biochem. J. 201:489-493(1982). RN [5] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=16505484; DOI=10.1074/jbc.m513373200; RA Maccarana M., Olander B., Malmstroem J., Tiedemann K., Aebersold R., RA Lindahl U., Li J.-P., Malmstroem A.; RT "Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is RT identical to SART2."; RL J. Biol. Chem. 281:11560-11568(2006). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, GLYCOSYLATION AT RP ASN-183; ASN-336; ASN-642 AND ASN-648, AND MUTAGENESIS OF HIS-203; HIS-205; RP TYR-256; TYR-261; LYS-331 AND HIS-450. RX PubMed=19004833; DOI=10.1074/jbc.m805479200; RA Pacheco B., Maccarana M., Goodlett D.R., Malmstroem A., Malmstroem L.; RT "Identification of the active site of DS-epimerase 1 and requirement of N- RT glycosylation for enzyme function."; RL J. Biol. Chem. 284:1741-1747(2009). RN [7] {ECO:0007744|PDB:6HZN} RP X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 23-775 IN COMPLEX WITH MANGANESE RP IONS, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, GLYCOSYLATION AT RP ASN-183; ASN-336; ASN-411; ASN-642 AND ASN-648, AND MUTAGENESIS OF TRP-98; RP ASP-147; PRO-383; HIS-452; GLU-470 AND TYR-473. RX DOI=10.1039/D0SC05971D; RA Hasan M., Khakzad H., Happonen L., Sundin A., Unge J., Mueller U., RA Malmstrom J., Westergren-Thorsson G., Malmstrom L., Ellervik U., RA Malmstrom A., Tykesson E.; RT "The structure of human dermatan sulfate epimerase 1 emphasizes the RT importance of C5-epimerization of glucuronic acid in higher organisms."; RL Chem. Sci. 11:0-0(2020). RN [8] RP VARIANT EDSMC2 LEU-268, AND CHARACTERIZATION OF VARIANT EDSMC2 LEU-268. RX PubMed=23704329; DOI=10.1093/hmg/ddt227; RA Mueller T., Mizumoto S., Suresh I., Komatsu Y., Vodopiutz J., Dundar M., RA Straub V., Lingenhel A., Melmer A., Lechner S., Zschocke J., Sugahara K., RA Janecke A.R.; RT "Loss of dermatan sulfate epimerase (DSE) function results in RT musculocontractural Ehlers-Danlos syndrome."; RL Hum. Mol. Genet. 22:3761-3772(2013). CC -!- FUNCTION: Converts D-glucuronic acid to L-iduronic acid (IdoUA) CC residues. Plays an important role in the biosynthesis of the CC glycosaminoglycan/mucopolysaccharide dermatan sulfate. CC {ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, CC ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}. CC -!- CATALYTIC ACTIVITY: CC Reaction=chondroitin 4'-sulfate = dermatan 4'-sulfate; CC Xref=Rhea:RHEA:21084, Rhea:RHEA-COMP:9829, Rhea:RHEA-COMP:9965, CC ChEBI:CHEBI:58422, ChEBI:CHEBI:58465; EC=5.1.3.19; CC Evidence={ECO:0000269|PubMed:16505484, ECO:0000269|PubMed:19004833, CC ECO:0000269|PubMed:7092807, ECO:0000269|Ref.7}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:7092807}; CC Note=Also has weak activity in the presence of Mg(2+) or Ca(2+) ions. CC {ECO:0000269|PubMed:7092807}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=0.12 mM for chondroitin {ECO:0000269|PubMed:7092807}; CC pH dependence: CC Optimum pH is 5.5. {ECO:0000269|PubMed:7092807}; CC -!- PATHWAY: Glycan metabolism; chondroitin sulfate biosynthesis. CC {ECO:0000305|PubMed:16505484, ECO:0000305|PubMed:19004833, CC ECO:0000305|PubMed:7092807, ECO:0000305|Ref.7}. CC -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis. CC {ECO:0000305|PubMed:16505484, ECO:0000305|PubMed:19004833, CC ECO:0000305|PubMed:7092807, ECO:0000305|Ref.7}. CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:10679095, ECO:0000305|PubMed:7092807}; Multi-pass CC membrane protein {ECO:0000305}. Golgi apparatus membrane CC {ECO:0000269|PubMed:10679095}; Multi-pass membrane protein CC {ECO:0000305}. Cytoplasmic vesicle membrane CC {ECO:0000269|PubMed:10679095}; Multi-pass membrane protein CC {ECO:0000305}. Microsome membrane {ECO:0000269|PubMed:7092807}; Multi- CC pass membrane protein {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Ubiquitously expressed with higher expression in CC kidney and ovary and lower expression in brain, colon and thymus. Also CC expressed in renal cell carcinomas, brain tumors, and in a part of CC melanomas and adenocarcinomas from organs other than the breast. CC Expressed in squamous cell carcinomas (SCC), glioma, and some CC adenocarcinoma cell lines, but not in breast cancer cell lines or any CC normal tissues (at protein level). {ECO:0000269|PubMed:10679095}. CC -!- PTM: N-glycosylated (PubMed:19004833, Ref.7). Glycosylation is CC important for enzymatic activity (PubMed:19004833). CC {ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7}. CC -!- DISEASE: Ehlers-Danlos syndrome, musculocontractural type 2 (EDSMC2) CC [MIM:615539]: A form of Ehlers-Danlos syndrome characterized by CC progressive multisystem manifestations, including joint dislocations CC and deformities, skin hyperextensibility, skin bruisability and CC fragility with recurrent large subcutaneous hematomas, cardiac CC valvular, respiratory, gastrointestinal, and ophthalmologic CC complications. Motor developmental delay is associated with muscle CC hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in CC histology in adulthood. {ECO:0000269|PubMed:23704329}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the dermatan-sulfate isomerase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF098066; AAF00087.1; -; mRNA. DR EMBL; Z84488; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039245; AAH39245.1; -; mRNA. DR CCDS; CCDS5107.1; -. DR RefSeq; NP_001074445.1; NM_001080976.3. DR RefSeq; NP_001309866.1; NM_001322937.2. DR RefSeq; NP_001309867.1; NM_001322938.2. DR RefSeq; NP_001309868.1; NM_001322939.1. DR RefSeq; NP_001309869.1; NM_001322940.1. DR RefSeq; NP_001309870.1; NM_001322941.1. DR RefSeq; NP_001309872.1; NM_001322943.1. DR RefSeq; NP_001309873.1; NM_001322944.1. DR RefSeq; NP_037484.1; NM_013352.4. DR PDB; 6HZN; X-ray; 2.41 A; A=23-775. DR PDBsum; 6HZN; -. DR AlphaFoldDB; Q9UL01; -. DR SMR; Q9UL01; -. DR BioGRID; 118977; 39. DR FunCoup; Q9UL01; 1086. DR IntAct; Q9UL01; 32. DR MINT; Q9UL01; -. DR STRING; 9606.ENSP00000494147; -. DR GlyCosmos; Q9UL01; 5 sites, No reported glycans. DR GlyGen; Q9UL01; 6 sites, 2 N-linked glycans (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q9UL01; -. DR PhosphoSitePlus; Q9UL01; -. DR BioMuta; DSE; -. DR DMDM; 74762778; -. DR jPOST; Q9UL01; -. DR MassIVE; Q9UL01; -. DR PaxDb; 9606-ENSP00000332151; -. DR PeptideAtlas; Q9UL01; -. DR ProteomicsDB; 84921; -. DR Antibodypedia; 3106; 80 antibodies from 20 providers. DR DNASU; 29940; -. DR Ensembl; ENST00000331677.7; ENSP00000332151.2; ENSG00000111817.20. DR Ensembl; ENST00000452085.7; ENSP00000404049.2; ENSG00000111817.20. DR Ensembl; ENST00000644252.3; ENSP00000494147.2; ENSG00000111817.20. DR GeneID; 29940; -. DR KEGG; hsa:29940; -. DR MANE-Select; ENST00000644252.3; ENSP00000494147.2; NM_013352.4; NP_037484.1. DR UCSC; uc003pws.5; human. DR AGR; HGNC:21144; -. DR ClinPGx; PA162384080; -. DR CTD; 29940; -. DR DisGeNET; 29940; -. DR GeneCards; DSE; -. DR GeneReviews; DSE; -. DR HGNC; HGNC:21144; DSE. DR HPA; ENSG00000111817; Low tissue specificity. DR MalaCards; DSE; -. DR MIM; 605942; gene. DR MIM; 615539; phenotype. DR OpenTargets; ENSG00000111817; -. DR Orphanet; 2953; Musculocontractural Ehlers-Danlos syndrome. DR VEuPathDB; HostDB:ENSG00000111817; -. DR eggNOG; ENOG502QPWZ; Eukaryota. DR GeneTree; ENSGT00390000006522; -. DR HOGENOM; CLU_308813_0_0_1; -. DR InParanoid; Q9UL01; -. DR OMA; FFIHAVC; -. DR OrthoDB; 5946629at2759; -. DR PAN-GO; Q9UL01; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UL01; -. DR BioCyc; MetaCyc:HS03472-MONOMER; -. DR BRENDA; 5.1.3.19; 2681. DR PathwayCommons; Q9UL01; -. DR Reactome; R-HSA-2022923; DS-GAG biosynthesis. DR SignaLink; Q9UL01; -. DR UniPathway; UPA00755; -. DR UniPathway; UPA00756; -. DR Agora; ENSG00000111817; -. DR BioGRID-ORCS; 29940; 10 hits in 1149 CRISPR screens. DR ChiTaRS; DSE; human. DR GeneWiki; DSE_(gene); -. DR GenomeRNAi; 29940; -. DR Pharos; Q9UL01; Tbio. DR PRO; PR:Q9UL01; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q9UL01; protein. DR Bgee; ENSG00000111817; Expressed in parietal pleura and 198 other cell types or tissues. DR ExpressionAtlas; Q9UL01; baseline and differential. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC-UCL. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:HGNC-UCL. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0047757; F:chondroitin-glucuronate 5-epimerase activity; IDA:HGNC-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0050654; P:chondroitin sulfate proteoglycan metabolic process; IBA:GO_Central. DR GO; GO:0050651; P:dermatan sulfate proteoglycan biosynthetic process; IDA:UniProtKB. DR GO; GO:0050655; P:dermatan sulfate proteoglycan metabolic process; IBA:GO_Central. DR GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IEA:UniProtKB-UniPathway. DR FunFam; 1.50.10.100:FF:000001; dermatan-sulfate epimerase isoform X1; 1. DR FunFam; 2.70.98.70:FF:000001; dermatan-sulfate epimerase isoform X1; 1. DR Gene3D; 2.70.98.70; -; 1. DR Gene3D; 1.50.10.100; Chondroitin AC/alginate lyase; 1. DR InterPro; IPR008929; Chondroitin_lyas. DR InterPro; IPR052447; Dermatan-Sulfate_Isomerase. DR PANTHER; PTHR15532; -; 1. DR PANTHER; PTHR15532:SF3; DERMATAN-SULFATE EPIMERASE; 1. DR SUPFAM; SSF48230; Chondroitin AC/alginate lyase; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasmic vesicle; Disease variant; Ehlers-Danlos syndrome; KW Endoplasmic reticulum; Glycoprotein; Golgi apparatus; Isomerase; Manganese; KW Membrane; Metal-binding; Microsome; Proteomics identification; KW Reference proteome; Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..958 FT /note="Dermatan-sulfate epimerase" FT /id="PRO_0000223311" FT TOPO_DOM 23..902 FT /note="Lumenal" FT /evidence="ECO:0000305" FT TRANSMEM 903..923 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 924..933 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 934..954 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 955..958 FT /note="Lumenal" FT /evidence="ECO:0000305" FT ACT_SITE 205 FT /note="Proton donor" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT ACT_SITE 261 FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT ACT_SITE 473 FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7" FT BINDING 452 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT BINDING 470 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT BINDING 481 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT SITE 450 FT /note="Critical for catalysis" FT /evidence="ECO:0000269|PubMed:19004833" FT CARBOHYD 183 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 411 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|Ref.7, ECO:0007744|PDB:6HZN" FT CARBOHYD 642 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT CARBOHYD 648 FT /note="N-linked (GlcNAc...) (paucimannose) asparagine" FT /evidence="ECO:0000269|PubMed:19004833, ECO:0000269|Ref.7, FT ECO:0007744|PDB:6HZN" FT VARIANT 25 FT /note="T -> I (in dbSNP:rs10485183)" FT /id="VAR_034481" FT VARIANT 34 FT /note="P -> L (in dbSNP:rs35548455)" FT /id="VAR_053833" FT VARIANT 268 FT /note="S -> L (in EDSMC2; shows a loss of epimerase FT activity towards partially desulfated dermatan sulfate; FT patient-derived fibroblasts show also a significant FT reduction in activity; dbSNP:rs398122361)" FT /evidence="ECO:0000269|PubMed:23704329" FT /id="VAR_070911" FT VARIANT 282 FT /note="I -> V (in dbSNP:rs34994230)" FT /id="VAR_053834" FT MUTAGEN 98 FT /note="W->A: Severely impairs catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 147 FT /note="D->A: Impairs catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 203 FT /note="H->A,N: Severely impairs catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 205 FT /note="H->A,N: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 256 FT /note="Y->A: Moderately reduced catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 261 FT /note="Y->A,F: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 331 FT /note="K->A: No significant effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 383 FT /note="P->A: Very low levels of protein expression and no FT detectable catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 450 FT /note="H->A,N: Abolishes catalytic activity." FT /evidence="ECO:0000269|PubMed:19004833" FT MUTAGEN 452 FT /note="H->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 470 FT /note="E->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT MUTAGEN 473 FT /note="Y->A: Abolishes catalytic activity." FT /evidence="ECO:0000269|Ref.7" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 53..61 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 65..80 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 82..85 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 91..94 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 101..115 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 120..134 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 149..165 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 171..191 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 192..194 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 196..198 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 205..222 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 226..247 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 258..280 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 288..298 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 323..332 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 338..349 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 352..354 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 360..366 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 367..373 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 384..387 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 391..394 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 395..398 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 399..403 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 414..418 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 424..432 FT /evidence="ECO:0007829|PDB:6HZN" FT TURN 437..439 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 442..445 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 457..461 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 484..488 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 515..518 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 524..531 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 534..540 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 542..544 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 547..549 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 551..562 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 565..574 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 582..592 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 602..609 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 612..620 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 629..633 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 639..641 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 644..652 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 655..665 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 671..678 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 680..691 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 693..701 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 704..707 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 709..713 FT /evidence="ECO:0007829|PDB:6HZN" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 723..725 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 738..746 FT /evidence="ECO:0007829|PDB:6HZN" FT HELIX 750..765 FT /evidence="ECO:0007829|PDB:6HZN" SQ SEQUENCE 958 AA; 109773 MW; A3D05C6194B4D2F9 CRC64; MRTHTRGAPS VFFIYLLCFV SAYITDENPE VMIPFTNANY DSHPMLYFSR AEVAELQLRA ASSHEHIAAR LTEAVHTMLS SPLEYLPPWD PKDYSARWNE IFGNNLGALA MFCVLYPENI EARDMAKDYM ERMAAQPSWL VKDAPWDEVP LAHSLVGFAT AYDFLYNYLS KTQQEKFLEV IANASGYMYE TSYRRGWGFQ YLHNHQPTNC MALLTGSLVL MNQGYLQEAY LWTKQVLTIM EKSLVLLREV TDGSLYEGVA YGSYTTRSLF QYMFLVQRHF NINHFGHPWL KQHFAFMYRT ILPGFQRTVA IADSNYNWFY GPESQLVFLD KFVMRNGSGN WLADQIRRNR VVEGPGTPSK GQRWCTLHTE FLWYDGSLKS VPPPDFGTPT LHYFEDWGVV TYGSALPAEI NRSFLSFKSG KLGGRAIYDI VHRNKYKDWI KGWRNFNAGH EHPDQNSFTF APNGVPFITE ALYGPKYTFF NNVLMFSPAV SKSCFSPWVG QVTEDCSSKW SKYKHDLAAS CQGRVVAAEE KNGVVFIRGE GVGAYNPQLN LKNVQRNLIL LHPQLLLLVD QIHLGEESPL ETAASFFHNV DVPFEETVVD GVHGAFIRQR DGLYKMYWMD DTGYSEKATF ASVTYPRGYP YNGTNYVNVT MHLRSPITRA AYLFIGPSID VQSFTVHGDS QQLDVFIATS KHAYATYLWT GEATGQSAFA QVIADRHKIL FDRNSAIKSS IVPEVKDYAA IVEQNLQHFK PVFQLLEKQI LSRVRNTASF RKTAERLLRF SDKRQTEEAI DRIFAISQQQ QQQSKSKKNR RAGKRYKFVD AVPDIFAQIE VNEKKIRQKA QILAQKELPI DEDEEMKDLL DFADVTYEKH KNGGLIKGRF GQARMVTTTH SRAPSLSASY TRLFLILNIA IFFVMLAMQL TYFQRAQSLH GQRCLYAVLL IDSCILLWLY SSCSQSQC // ID E2AK2_HUMAN Reviewed; 551 AA. AC P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4; DT 01-FEB-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 2. DT 28-JAN-2026, entry version 260. DE RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase; DE EC=2.7.11.1; DE AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2; DE Short=eIF-2A protein kinase 2; DE AltName: Full=Interferon-inducible RNA-dependent protein kinase; DE AltName: Full=P1/eIF-2A protein kinase; DE AltName: Full=Protein kinase RNA-activated; DE Short=PKR; DE Short=Protein kinase R {ECO:0000303|PubMed:11438532}; DE AltName: Full=Tyrosine-protein kinase EIF2AK2; DE EC=2.7.10.2; DE AltName: Full=p68 kinase; GN Name=EIF2AK2; Synonyms=PKR, PRKR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118 AND RP 309-325, AND INDUCTION. RX PubMed=1695551; DOI=10.1016/0092-8674(90)90374-n; RA Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M., Williams B.R.G., RA Hovanessian A.G.; RT "Molecular cloning and characterization of the human double-stranded RNA- RT activated protein kinase induced by interferon."; RL Cell 62:379-390(1990). RN [2] RP SEQUENCE REVISION. RA Meurs E.; RL Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5; RA Thomis D.C., Doohan J.P., Samuel C.E.; RT "Mechanism of interferon action: cDNA structure, expression, and regulation RT of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from RT human cells."; RL Virology 188:33-46(1992). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RX PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9; RA Kuhen K.L., Shen X., Samuel C.E.; RT "Mechanism of interferon action sequence of the human interferon-inducible RT RNA-dependent protein kinase (PKR) deduced from genomic clones."; RL Gene 178:191-193(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8812437; DOI=10.1006/geno.1996.0446; RA Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G., RA Tanaka H., Samuel C.E.; RT "Structural organization of the human gene (PKR) encoding an interferon- RT inducible RNA-dependent protein kinase (PKR) and differences from its mouse RT homolog."; RL Genomics 36:197-201(1996). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9726442; DOI=10.1089/jir.1998.18.609; RA Xu Z., Williams B.R.; RT "Genomic features of human PKR: alternative splicing and a polymorphic CGG RT repeat in the 5'-untranslated region."; RL J. Interferon Cytokine Res. 18:609-616(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Prostatic carcinoma; RA Bienvenut W.V., Gao M., Leug H.; RL Submitted (JUN-2009) to UniProtKB. RN [14] RP INTERACTION WITH DNAJC3. RX PubMed=8576172; DOI=10.1074/jbc.271.3.1702; RA Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.; RT "The P58 cellular inhibitor complexes with the interferon-induced, double- RT stranded RNA-dependent protein kinase, PKR, to regulate its RT autophosphorylation and activity."; RL J. Biol. Chem. 271:1702-1707(1996). RN [15] RP INTERACTION WITH HIV-1 TAT. RX PubMed=9079663; DOI=10.1074/jbc.272.13.8388; RA Brand S.R., Kobayashi R., Mathews M.B.; RT "The Tat protein of human immunodeficiency virus type 1 is a substrate and RT inhibitor of the interferon-induced, virally activated protein kinase, RT PKR."; RL J. Biol. Chem. 272:8388-8395(1997). RN [16] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9143277; DOI=10.1006/viro.1997.8493; RA Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E., RA Polyak S.J., Gretch D.R., Katze M.G.; RT "Evidence that hepatitis C virus resistance to interferon is mediated RT through repression of the PKR protein kinase by the nonstructural 5A RT protein."; RL Virology 230:217-227(1997). RN [17] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9710605; DOI=10.1128/mcb.18.9.5208; RA Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M., RA Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.; RT "Control of PKR protein kinase by hepatitis C virus nonstructural 5A RT protein: molecular mechanisms of kinase regulation."; RL Mol. Cell. Biol. 18:5208-5218(1998). RN [18] RP INTERACTION WITH INFLUENZA A NS1 PROTEIN. RX PubMed=9781815; DOI=10.1089/jir.1998.18.757; RA Tan S.L., Katze M.G.; RT "Biochemical and genetic evidence for complex formation between the RT influenza A virus NS1 protein and the interferon-induced PKR protein RT kinase."; RL J. Interferon Cytokine Res. 18:757-766(1998). RN [19] RP INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION). RX PubMed=10390359; DOI=10.1126/science.285.5424.107; RA Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.; RT "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 RT protein."; RL Science 285:107-110(1999). RN [20] RP FUNCTION, AND INTERACTION WITH IKBKB. RX PubMed=10848580; DOI=10.1128/mcb.20.13.4532-4542.2000; RA Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.; RT "PKR stimulates NF-kappaB irrespective of its kinase function by RT interacting with the IkappaB kinase complex."; RL Mol. Cell. Biol. 20:4532-4542(2000). RN [21] RP INTERACTION WITH TARBP2. RX PubMed=11438532; DOI=10.1074/jbc.m103584200; RA Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S., RA Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F., RA Gatignol A.; RT "Two dimerization domains in the trans-activation response RNA-binding RT protein (TRBP) individually reverse the protein kinase R inhibition of HIV- RT 1 long terminal repeat expression."; RL J. Biol. Chem. 276:33899-33905(2001). RN [22] RP PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255 AND RP THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242; THR-255; RP THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE PROTEIN. RX PubMed=11152499; DOI=10.1128/jvi.75.3.1265-1273.2001; RA Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C., RA Mathews M.B.; RT "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple RT competition with autophosphorylation sites in the RNA-binding domain."; RL J. Virol. 75:1265-1273(2001). RN [23] RP MUTAGENESIS OF LYS-60; ALA-67; THR-446 AND THR-451, AND PHOSPHORYLATION AT RP THR-446 AND THR-451. RX PubMed=11337501; DOI=10.1074/jbc.m102108200; RA Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E., RA Mathews M.B., Ozato K., Hinnebusch A.G.; RT "Binding of double-stranded RNA to protein kinase PKR is required for RT dimerization and promotes critical autophosphorylation events in the RT activation loop."; RL J. Biol. Chem. 276:24946-24958(2001). RN [24] RP INTERACTION WITH HHV-8 PROTEIN VIRF2 (MICROBIAL INFECTION). RX PubMed=11160738; DOI=10.1128/jvi.75.5.2345-2352.2001; RA Burysek L., Pitha P.M.; RT "Latently expressed human herpesvirus 8-encoded interferon regulatory RT factor 2 inhibits double-stranded RNA-activated protein kinase."; RL J. Virol. 75:2345-2352(2001). RN [25] RP FUNCTION, AND INTERACTION WITH HHV-1 US11 (MICROBIAL INFECTION). RX PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002; RA Cassady K.A., Gross M.; RT "The herpes simplex virus type 1 U(S)11 protein interacts with protein RT kinase R in infected cells and requires a 30-amino-acid sequence adjacent RT to a kinase substrate domain."; RL J. Virol. 76:2029-2035(2002). RN [26] RP INTERACTION WITH NPM1, AND ACTIVITY REGULATION. RX PubMed=12882984; DOI=10.1074/jbc.m301392200; RA Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W., RA Faulkner G.R., Speckhart A., Bagby G.C.; RT "Nucleophosmin interacts with and inhibits the catalytic function of RT eukaryotic initiation factor 2 kinase PKR."; RL J. Biol. Chem. 278:41709-41717(2003). RN [27] RP FUNCTION, AND INTERACTION WITH MAP2K6. RX PubMed=15229216; DOI=10.1074/jbc.m406554200; RA Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.; RT "Protein kinase R (PKR) interacts with and activates mitogen-activated RT protein kinase kinase 6 (MKK6) in response to double-stranded RNA RT stimulation."; RL J. Biol. Chem. 279:37670-37676(2004). RN [28] RP IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70. RX PubMed=15299030; DOI=10.1074/jbc.m403884200; RA Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.; RT "The Fanconi anemia proteins functionally interact with the protein kinase RT regulated by RNA (PKR)."; RL J. Biol. Chem. 279:43910-43919(2004). RN [29] RP FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR RP LOCATION. RX PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004; RA Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H., RA Alcami J., Esteban M.; RT "TRAF family proteins link PKR with NF-kappa B activation."; RL Mol. Cell. Biol. 24:4502-4512(2004). RN [30] RP INHIBITION BY VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=15207627; DOI=10.1016/j.virol.2004.03.012; RA Langland J.O., Jacobs B.L.; RT "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains RT of E3L."; RL Virology 324:419-429(2004). RN [31] RP REVIEW. RX PubMed=17158706; DOI=10.1128/mmbr.00027-06; RA Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., RA Esteban M.; RT "Impact of protein kinase PKR in cell biology: from antiviral to RT antiproliferative action."; RL Microbiol. Mol. Biol. Rev. 70:1032-1060(2006). RN [32] RP INTERACTION WITH HCMV TRS1 (MICROBIAL INFECTION). RX PubMed=16987971; DOI=10.1128/jvi.00957-06; RA Hakki M., Marshall E.E., De Niro K.L., Geballe A.P.; RT "Binding and nuclear relocalization of protein kinase R by human RT cytomegalovirus TRS1."; RL J. Virol. 80:11817-11826(2006). RN [33] RP PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293. RX PubMed=16373505; DOI=10.1073/pnas.0508207103; RA Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.; RT "Tyrosine phosphorylation acts as a molecular switch to full-scale RT activation of the eIF2alpha RNA-dependent protein kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006). RN [34] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=16951545; DOI=10.1016/s1016-8478(23)17385-7; RA Liang Y., Kang C.B., Yoon H.S.; RT "Molecular and structural characterization of the domain 2 of hepatitis C RT virus non-structural protein 5A."; RL Mol. Cells 22:13-20(2006). RN [35] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=17451199; DOI=10.3748/wjg.v13.i8.1195; RA Veillon P., Payan C., Le Guillou-Guillemette H., Gaudy C., Lunel F.; RT "Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b RT during interferon or combined interferon-ribavirin therapy."; RL World J. Gastroenterol. 13:1195-1203(2007). RN [36] RP INTERACTION WITH HCV MATURE CORE PROTEIN (MICROBIAL INFECTION). RX PubMed=17267064; DOI=10.1016/j.virusres.2006.12.010; RA Yan X.B., Battaglia S., Boucreux D., Chen Z., Brechot C., Pavio N.; RT "Mapping of the interacting domains of hepatitis C virus core protein and RT the double-stranded RNA-activated protein kinase PKR."; RL Virus Res. 125:79-87(2007). RN [37] RP INTERACTION WITH ADAR. RX PubMed=17079286; DOI=10.1128/jvi.01527-06; RA Nie Y., Hammond G.L., Yang J.H.; RT "Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus RT infection."; RL J. Virol. 81:917-923(2007). RN [38] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003; RA Cole J.L.; RT "Activation of PKR: an open and shut case?"; RL Trends Biochem. Sci. 32:57-62(2007). RN [39] RP FUNCTION, INTERACTION WITH NCK1, AND ACTIVITY REGULATION. RX PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112; RA Cardin E., Larose L.; RT "Nck-1 interacts with PKR and modulates its activation by dsRNA."; RL Biochem. Biophys. Res. Commun. 377:231-235(2008). RN [40] RP INTERACTION WITH DUS2L, AND ACTIVITY REGULATION. RX PubMed=18096616; DOI=10.1093/nar/gkm1129; RA Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V., RA Patel R.C.; RT "Interaction of human tRNA-dihydrouridine synthase-2 with interferon- RT induced protein kinase PKR."; RL Nucleic Acids Res. 36:998-1008(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP MUTAGENESIS OF ASP-486, AND INTERACTION WITH VACCINIA VIRUS PROTEIN K3 RP (MICROBIAL INFECTION). RX PubMed=18971339; DOI=10.1073/pnas.0805524105; RA Seo E.J., Liu F., Kawagishi-Kobayashi M., Ung T.L., Cao C., Dar A.C., RA Sicheri F., Dever T.E.; RT "Protein kinase PKR mutants resistant to the poxvirus pseudosubstrate K3L RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 105:16894-16899(2008). RN [43] RP FUNCTION. RX PubMed=19507191; DOI=10.1002/jcp.21848; RA Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J., RA Martinelli G., Cocco L., Martelli A.M.; RT "PKR activity is required for acute leukemic cell maintenance and growth: a RT role for PKR-mediated phosphatase activity to regulate GSK-3 RT phosphorylation."; RL J. Cell. Physiol. 221:232-241(2009). RN [44] RP FUNCTION, AND INTERACTION WITH DHX9. RX PubMed=19229320; DOI=10.1371/journal.ppat.1000311; RA Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.; RT "An antiviral response directed by PKR phosphorylation of the RNA helicase RT A."; RL PLoS Pathog. 5:E1000311-E1000311(2009). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [46] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007; RA Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P., Ahn B.Y.; RT "PKR protein kinase is activated by hepatitis C virus and inhibits viral RT replication through translational control."; RL Virus Res. 142:51-56(2009). RN [47] RP FUNCTION. RX PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008; RA Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.; RT "A role for protein kinase PKR in the mediation of Epstein-Barr virus RT latent membrane protein-1-induced IL-6 and IL-10 expression."; RL Cytokine 50:210-219(2010). RN [48] RP FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS TYROSINE-PROTEIN RP KINASE. RX PubMed=20395957; DOI=10.1038/embor.2010.45; RA Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.; RT "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers RT Cdc2 polyubiquitination and G2 arrest under genotoxic stresses."; RL EMBO Rep. 11:393-399(2010). RN [49] RP FUNCTION. RX PubMed=21123651; DOI=10.1101/gad.1965010; RA Harashima A., Guettouche T., Barber G.N.; RT "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase RT PKR constitutes a novel mechanism of translational regulation and cellular RT defense."; RL Genes Dev. 24:2640-2653(2010). RN [50] RP INTERACTION WITH HRSV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=20519500; DOI=10.1074/jbc.m109.077321; RA Groskreutz D.J., Babor E.C., Monick M.M., Varga S.M., Hunninghake G.W.; RT "Respiratory syncytial virus limits alpha subunit of eukaryotic translation RT initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and RT viral replication."; RL J. Biol. Chem. 285:24023-24031(2010). RN [51] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x; RA Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N., RA Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.; RT "Double-stranded RNA-activated protein kinase inhibits hepatitis C virus RT replication but may be not essential in interferon treatment."; RL Liver Int. 30:311-318(2010). RN [52] RP FUNCTION, AND PHOSPHORYLATION AT THR-451. RX PubMed=20685959; DOI=10.1091/mbc.e10-06-0481; RA Yang X., Nath A., Opperman M.J., Chan C.; RT "The double-stranded RNA-dependent protein kinase differentially regulates RT insulin receptor substrates 1 and 2 in HepG2 cells."; RL Mol. Biol. Cell 21:3449-3458(2010). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x; RA Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F., Hugon J.; RT "Modulation of tau phosphorylation by the kinase PKR: implications in RT Alzheimer's disease."; RL Brain Pathol. 21:189-200(2011). RN [56] RP REVIEW. RX PubMed=21924887; DOI=10.1016/j.coi.2011.08.009; RA Pfaller C.K., Li Z., George C.X., Samuel C.E.; RT "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old RT players as modulators of the interferon response."; RL Curr. Opin. Immunol. 23:573-582(2011). RN [57] RP REVIEW. RX PubMed=21166592; DOI=10.1089/jir.2010.0099; RA Pindel A., Sadler A.; RT "The role of protein kinase R in the interferon response."; RL J. Interferon Cytokine Res. 31:59-70(2011). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION. RX PubMed=21072047; DOI=10.1038/leu.2010.264; RA Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I., RA Martelli A.M., Follo M.Y., Cocco L.; RT "Multiple forms of PKR present in the nuclei of acute leukemia cells RT represent an active kinase that is responsive to stress."; RL Leukemia 25:236-245(2011). RN [59] RP FUNCTION IN HBV RESTRICTION. RX PubMed=21710204; DOI=10.1007/s10059-011-1059-6; RA Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.; RT "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B virus RT replication."; RL Mol. Cells 32:167-172(2011). RN [60] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [61] RP REVIEW. RX PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010; RA Lacy-Hulbert A., Stuart L.M.; RT "Penetration resistance: PKR's other talent."; RL Immunity 36:695-696(2012). RN [62] RP FUNCTION. RX PubMed=22948139; DOI=10.1074/jbc.m112.390039; RA McAllister C.S., Taghavi N., Samuel C.E.; RT "Protein kinase PKR amplification of interferon beta induction occurs RT through initiation factor eIF-2alpha-mediated translational control."; RL J. Biol. Chem. 287:36384-36392(2012). RN [63] RP FUNCTION, AND INTERACTION WITH STAT3. RX PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013; RA Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., RA Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O., RA Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.; RT "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity."; RL Mol. Cell 48:667-680(2012). RN [64] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [65] RP FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND RP AUTOPHOSPHORYLATION. RX PubMed=22801494; DOI=10.1038/nature11290; RA Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., RA Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., RA Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., RA Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.; RT "Novel role of PKR in inflammasome activation and HMGB1 release."; RL Nature 488:670-674(2012). RN [66] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [67] RP REVIEW. RX PubMed=23092889; DOI=10.1126/scisignal.2003511; RA Kang R., Tang D.; RT "PKR-dependent inflammatory signals."; RL Sci. Signal. 5:PE47-PE47(2012). RN [68] RP FUNCTION. RX PubMed=22381929; DOI=10.1016/j.virol.2012.01.029; RA Taghavi N., Samuel C.E.; RT "Protein kinase PKR catalytic activity is required for the PKR-dependent RT activation of mitogen-activated protein kinases and amplification of RT interferon beta induction following virus infection."; RL Virology 427:208-216(2012). RN [69] RP REVIEW. RX PubMed=23202496; DOI=10.3390/v4112598; RA Dabo S., Meurs E.F.; RT "dsRNA-dependent protein kinase PKR and its role in stress, signaling and RT HCV infection."; RL Viruses 4:2598-2635(2012). RN [70] RP TISSUE SPECIFICITY. RX PubMed=23403623; DOI=10.1182/blood-2012-09-456400; RA Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.; RT "PKR regulates proliferation, differentiation and survival of murine RT hematopoietic stem/progenitor cells."; RL Blood 121:3364-3374(2013). RN [71] RP REVIEW. RX PubMed=23354059; DOI=10.1007/s00018-012-1252-6; RA Donnelly N., Gorman A.M., Gupta S., Samali A.; RT "The eIF2alpha kinases: their structures and functions."; RL Cell. Mol. Life Sci. 70:3493-3511(2013). RN [72] RP FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ACTIVITY REGULATION. RX PubMed=23229543; DOI=10.1074/jbc.m112.401851; RA Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.; RT "Activation of double-stranded RNA-activated protein kinase (PKR) by RT interferon-stimulated gene 15 (ISG15) modification down-regulates protein RT translation."; RL J. Biol. Chem. 288:2839-2847(2013). RN [73] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [74] RP INTERACTION WITH TOSCANA VIRUS PROTEIN NSS (MICROBIAL INFECTION), AND RP ACTIVITY REGULATION. RX PubMed=23325696; DOI=10.1128/jvi.02506-12; RA Kalveram B., Ikegami T.; RT "Toscana virus NSs protein promotes degradation of double-stranded RNA- RT dependent protein kinase."; RL J. Virol. 87:3710-3718(2013). RN [75] RP FUNCTION IN MV RESTRICTION. RX PubMed=23115276; DOI=10.1128/jvi.02270-12; RA Okonski K.M., Samuel C.E.; RT "Stress granule formation induced by measles virus is protein kinase PKR RT dependent and impaired by RNA adenosine deaminase ADAR1."; RL J. Virol. 87:756-766(2013). RN [76] RP FUNCTION. RX PubMed=23372823; DOI=10.1371/journal.pone.0055108; RA Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.; RT "Protein kinase regulated by dsRNA downregulates the interferon production RT in dengue virus- and dsrna-stimulated human lung epithelial cells."; RL PLoS ONE 8:E55108-E55108(2013). RN [77] RP FUNCTION IN HCV RESTRICTION. RX PubMed=23399035; DOI=10.1016/j.virol.2013.01.015; RA Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M., Shih J.W., RA Wang R.Y.; RT "The modulation of hepatitis C virus 1a replication by PKR is dependent on RT NF-kB mediated interferon beta response in Huh7.5.1 cells."; RL Virology 438:28-36(2013). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [79] RP INTERACTION WITH VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=25740987; DOI=10.1128/jvi.03288-14; RA Dueck K.J., Hu Y.S., Chen P., Deschambault Y., Lee J., Varga J., Cao J.; RT "Mutational analysis of vaccinia virus E3 protein: the biological functions RT do not correlate with its biochemical capacity to bind double-stranded RT RNA."; RL J. Virol. 89:5382-5394(2015). RN [80] RP INTERACTION WITH MBIP AND MOCS2B, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=26705305; DOI=10.1093/jmcb/mjv070; RA Suganuma T., Swanson S.K., Florens L., Washburn M.P., Workman J.L.; RT "Moco biosynthesis and the ATAC acetyltransferase engage translation RT initiation by inhibiting latent PKR activity."; RL J. Mol. Cell Biol. 8:44-50(2016). RN [81] RP MUTAGENESIS OF PHE-489; THR-496; ILE-502; LYS-510 AND GLN-516, RP CHARACTERIZATION OF VARIANT VAL-506, AND INTERACTION WITH HCMV TRS1 RP (MICROBIAL INFECTION). RX PubMed=27780231; DOI=10.1371/journal.ppat.1005966; RA Carpentier K.S., Esparo N.M., Child S.J., Geballe A.P.; RT "A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated RT Viral Antagonists."; RL PLoS Pathog. 12:e1005966-e1005966(2016). RN [82] RP INTERACTION WITH HUMAN HERPES VIRUS 8 PROTEIN KTA/ORF57 (MICROBIAL RP INFECTION). RX PubMed=29084250; DOI=10.1371/journal.ppat.1006677; RA Sharma N.R., Majerciak V., Kruhlak M.J., Zheng Z.M.; RT "KSHV inhibits stress granule formation by viral ORF57 blocking PKR RT activation."; RL PLoS Pathog. 13:e1006677-e1006677(2017). RN [83] {ECO:0007744|PDB:1QU6} RP STRUCTURE BY NMR OF 1-170, AND DOMAIN. RX PubMed=9736623; DOI=10.1093/emboj/17.18.5458; RA Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.; RT "Structure of the double-stranded RNA-binding domain of the protein kinase RT PKR reveals the molecular basis of its dsRNA-mediated activation."; RL EMBO J. 17:5458-5465(1998). RN [84] {ECO:0007744|PDB:2A19, ECO:0007744|PDB:2A1A} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 258-550 IN COMPLEX WITH RP EIF2S1/EIF-2ALPHA, PHOSPHORYLATION AT THR-446, DOMAIN, SUBUNIT, COFACTOR, RP AND INTERACTION WITH EIF2S1/EIF-2ALPHA. RX PubMed=16179258; DOI=10.1016/j.cell.2005.06.044; RA Dar A.C., Dever T.E., Sicheri F.; RT "Higher-order substrate recognition of eIF2alpha by the RNA-dependent RT protein kinase PKR."; RL Cell 122:887-900(2005). RN [85] {ECO:0007744|PDB:6D3K, ECO:0007744|PDB:6D3L} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 229-551, AND SUBUNIT. RX PubMed=31246429; DOI=10.1021/acs.biochem.9b00161; RA Mayo C.B., Erlandsen H., Mouser D.J., Feinstein A.G., Robinson V.L., RA May E.R., Cole J.L.; RT "Structural Basis of Protein Kinase R Autophosphorylation."; RL Biochemistry 58:2967-2977(2019). RN [86] RP INVOLVEMENT IN LEUDEN, FUNCTION, VARIANTS LEUDEN LEU-11; SER-32; PHE-97; RP SER-109; VAL-109; PHE-133; SER-325 AND CYS-461, CHARACTERIZATION OF RP VARIANTS LEUDEN LEU-11; PHE-133 AND CYS-461, AND VARIANT GLN-114. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [87] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [88] RP VARIANTS DYT33 THR-32; ARG-130 AND ALA-138, CHARACTERIZATION OF VARIANTS RP DYT33 THR-32 AND ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33236446; DOI=10.1002/ana.25973; RA Kuipers D.J.S., Mandemakers W., Lu C.S., Olgiati S., Breedveld G.J., RA Fevga C., Tadic V., Carecchio M., Osterman B., Sagi-Dain L., Wu-Chou Y.H., RA Chen C.C., Chang H.C., Wu S.L., Yeh T.H., Weng Y.H., Elia A.E., RA Panteghini C., Marotta N., Pauly M.G., Kuehn A.A., Volkmann J., Lace B., RA Meijer I.A., Kandaswamy K., Quadri M., Garavaglia B., Lohmann K., Bauer P., RA Mencacci N.E., Lubbe S.J., Klein C., Bertoli-Avella A.M., Bonifati V.; RT "EIF2AK2 Missense Variants Associated with Early Onset Generalized RT Dystonia."; RL Ann. Neurol. 89:485-497(2021). RN [89] RP VARIANT DYT33 ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33866603; DOI=10.1002/ana.26081; RA Musacchio T., Zech M., Reich M.M., Winkelmann J., Volkmann J.; RT "A Recurrent EIF2AK2 Missense Variant Causes Autosomal-Dominant Isolated RT Dystonia."; RL Ann. Neurol. 89:1257-1258(2021). RN [90] RP VARIANT DYT33 ARG-130. RX PubMed=35146068; DOI=10.1002/mdc3.13371; RA Magrinelli F., Moualek D., Tazir M., Pacha L.A., Verghese A., Bhatia K.P., RA Maroofian R., Houlden H.; RT "Heterozygous EIF2AK2 Variant Causes Adolescence-Onset Generalized Dystonia RT Partially Responsive to DBS."; RL Mov. Disord. Clin. Pract. 9:268-271(2022). CC -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase CC that phosphorylates the alpha subunit of eukaryotic translation CC initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the CC innate immune response to viral infection (PubMed:18835251, CC PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, CC PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral CC replication via the integrated stress response (ISR): EIF2S1/eIF-2- CC alpha phosphorylation in response to viral infection converts CC EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting CC to a shutdown of cellular and viral protein synthesis, while CC concomitantly initiating the preferential translation of ISR-specific CC mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, CC PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its CC antiviral activity on a wide range of DNA and RNA viruses including CC hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) CC and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, CC PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, CC PubMed:23399035). Also involved in the regulation of signal CC transduction, apoptosis, cell proliferation and differentiation: CC phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, CC ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, CC PubMed:19229320, PubMed:22214662). In addition to serine/threonine- CC protein kinase activity, also has tyrosine-protein kinase activity and CC phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its CC ubiquitination and proteasomal degradation (PubMed:20395957). Either as CC an adapter protein and/or via its kinase activity, can regulate various CC signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling CC pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) CC involved in the expression of genes encoding pro-inflammatory cytokines CC and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates CC the NF-kappa-B pathway via interaction with IKBKB and TRAF family of CC proteins and activates the p38 MAP kinase pathway via interaction with CC MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as CC both a positive and negative regulator of the insulin signaling pathway CC (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the CC inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at CC 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A CC which activates FOXO1, which in turn up-regulates the expression of CC insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate CC NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 CC and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the CC regulation of the cytoskeleton by binding to gelsolin (GSN), CC sequestering the protein in an inactive conformation away from actin CC (By similarity). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, CC ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, CC ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, CC ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, CC ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, CC ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, CC ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, CC ECO:0000269|PubMed:32197074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:16179258, ECO:0000303|PubMed:31246429}; CC -!- ACTIVITY REGULATION: Initially produced in an inactive form and is CC activated by binding to viral dsRNA, which causes dimerization and CC autophosphorylation in the activation loop and stimulation of function. CC ISGylation can activate it in the absence of viral infection. Can also CC be activated by heparin, pro-inflammatory stimuli, growth factors, CC cytokines, oxidative stress and the cellular protein PRKRA. Activity is CC markedly stimulated by manganese ions. Activation is blocked by the CC viral components HIV-1 Tat protein and large amounts of HIV-1 trans- CC activation response (TAR) RNA element as well as by the cellular CC proteins TARBP2, DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana CC virus (TOS) and Rift valley fever virus (RVFV) NSS which promote its CC proteasomal degradation. Inhibited by vaccinia virus protein E3, CC probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251, CC ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: Homodimer (PubMed:16179258, PubMed:31246429). Interacts with CC STRBP (By similarity). Interacts with DNAJC3. Forms a complex with CC FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1. Interacts CC with IRS1 (By similarity). The inactive form interacts with NCK1 and CC GSN. Interacts (via the kinase catalytic domain) with STAT3 (via SH2 CC domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). CC Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 CC and AIM2. Interacts (via DRBM 1 domain) with DUS2L (via DRBM domain). CC Interacts with DHX9 (via N-terminus) and this interaction is dependent CC upon activation of the kinase. Interacts with EIF2S1/EIF-2ALPHA; this CC interaction induces a conformational change in EIF2S1 and its CC phosphorylation by EIF2AK2 (PubMed:16179258). Interacts with MBIP; the CC interaction is direct and leads to inhibition of EIF2AK2 self- CC activating autophosphorylation (PubMed:26705305). Interacts with the CC molybdopterin synthase complex subunit MOCS2B; the interaction is CC direct and enhances the interaction between EIF2AK2 and MBIP CC (PubMed:26705305). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10390359, ECO:0000269|PubMed:10848580, CC ECO:0000269|PubMed:11438532, ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:15299030, ECO:0000269|PubMed:16179258, CC ECO:0000269|PubMed:17079286, ECO:0000269|PubMed:18096616, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19229320, CC ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:25740987, ECO:0000269|PubMed:26705305, CC ECO:0000269|PubMed:31246429, ECO:0000269|PubMed:8576172, CC ECO:0000269|PubMed:9079663, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9781815}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) TRS1; this interaction retains EIF2AK2 to the nucleus and CC prevents its activation. {ECO:0000269|PubMed:16987971, CC ECO:0000269|PubMed:27780231}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia virus protein K3 CC (K3L); this interaction inhibits EIF2AK2. CC {ECO:0000269|PubMed:18971339}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes simplex CC virus 1 (HHV-1) protein US11 in an RNA-dependent manner. CC {ECO:0000269|PubMed:11836380}. CC -!- SUBUNIT: (Microbial infection) The inactive form interacts with Toscana CC virus (TOS) NSS. {ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein v- CC IRF2; this interaction inhibits EIF2AK2 activation. CC {ECO:0000269|PubMed:11160738}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia protein E3. CC {ECO:0000269|PubMed:25740987}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with CC Hepatitis C virus (HCV) mature core protein (via N-terminus); this CC interaction induces the autophosphorylation of EIF2AK2. CC {ECO:0000269|PubMed:17267064}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC non-structural protein 5A (NS5A); this interaction leads to disruption CC of EIF2AK2 dimerization by NS5A. {ECO:0000269|PubMed:16951545, CC ECO:0000269|PubMed:17451199, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9710605}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks CC its inhibitory effect on protein synthesis and cell growth. CC {ECO:0000269|PubMed:9143277}. CC -!- SUBUNIT: (Microbial infection) Interacts with human respiratory CC syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2 CC phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation CC shutoff. {ECO:0000269|PubMed:20519500}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 8 CC protein MTA/ORF57; this interaction inhibits stress granule formation. CC {ECO:0000269|PubMed:29084250}. CC -!- INTERACTION: CC P19525; P78563-4: ADARB1; NbExp=3; IntAct=EBI-640775, EBI-12002366; CC P19525; P06493: CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308; CC P19525; Q7L2E3: DHX30; NbExp=4; IntAct=EBI-640775, EBI-1211456; CC P19525; Q96C10: DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193; CC P19525; Q08211: DHX9; NbExp=4; IntAct=EBI-640775, EBI-352022; CC P19525; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506; CC P19525; Q6P2E9: EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038; CC P19525; P19525: EIF2AK2; NbExp=2; IntAct=EBI-640775, EBI-640775; CC P19525; P05198: EIF2S1; NbExp=5; IntAct=EBI-640775, EBI-1056162; CC P19525; P56537: EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243; CC P19525; Q8IY81: FTSJ3; NbExp=3; IntAct=EBI-640775, EBI-744088; CC P19525; Q9HCE1: MOV10; NbExp=3; IntAct=EBI-640775, EBI-1055820; CC P19525; Q96P20: NLRP3; NbExp=6; IntAct=EBI-640775, EBI-6253230; CC P19525; P06748: NPM1; NbExp=4; IntAct=EBI-640775, EBI-78579; CC P19525; O75569: PRKRA; NbExp=6; IntAct=EBI-640775, EBI-713955; CC P19525; O75569-1: PRKRA; NbExp=3; IntAct=EBI-640775, EBI-15588172; CC P19525; Q9NUL3: STAU2; NbExp=3; IntAct=EBI-640775, EBI-722938; CC P19525; Q15633: TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581; CC P19525; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615; CC P19525; Q9UL40: ZNF346; NbExp=4; IntAct=EBI-640775, EBI-2462313; CC P19525; Q27968: DNAJC3; Xeno; NbExp=5; IntAct=EBI-640775, EBI-640793; CC P19525; P0DTC9: N; Xeno; NbExp=8; IntAct=EBI-640775, EBI-25475856; CC P19525; P20639: OPG041; Xeno; NbExp=3; IntAct=EBI-640775, EBI-8674942; CC P19525; P04487: US11; Xeno; NbExp=3; IntAct=EBI-640775, EBI-6150681; CC P19525; Q2HR71: vIRF-2; Xeno; NbExp=2; IntAct=EBI-640775, EBI-8876177; CC P19525; PRO_0000278746 [O92972]; Xeno; NbExp=2; IntAct=EBI-640775, EBI-6918883; CC P19525; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-640775, EBI-6904269; CC P19525; PRO_0000037576 [P27958]; Xeno; NbExp=5; IntAct=EBI-640775, EBI-8753518; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15121867, CC ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:26705305}. Nucleus {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:15121867}. Note=Nuclear CC localization is elevated in acute leukemia, myelodysplastic syndrome CC (MDS), melanoma, breast, colon, prostate and lung cancer patient CC samples or cell lines as well as neurocytes from advanced Creutzfeldt- CC Jakob disease patients. {ECO:0000269|PubMed:21072047}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P19525-1; Sequence=Displayed; CC Name=2; CC IsoId=P19525-2; Sequence=VSP_046177; CC -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone marrow CC compared to non-hematopoietic tissues such as small intestine, liver, CC or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer CC disease (AD) brain. Elevated levels seen in breast and colon CC carcinomas, and which correlates with tumor progression and CC invasiveness or risk of progression. {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:23403623}. CC -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}. CC -!- DOMAIN: Contains 2 dsRNA-binding domain (DRBM) (PubMed:9736623). The N- CC terminus contains the catalytic domain dimerization. The C-terminus CC binds EIF2S1/EIF2-alpha (PubMed:16179258). CC {ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:9736623}. CC -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues. CC Autophosphorylation of Thr-451 is dependent on Thr-446 and is CC stimulated by dsRNA binding and dimerization. Autophosphorylation CC apparently leads to the activation of the kinase. Tyrosine CC autophosphorylation is essential for efficient dsRNA-binding, CC dimerization, and kinase activation. Autophosphorylation is inhibited CC by the concerted action of ATAC complex subunit MBIP and molybdopterin CC synthase complex subunit MOCS2B (PubMed:26705305). CC {ECO:0000269|PubMed:11152499, ECO:0000269|PubMed:11337501, CC ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:16373505, CC ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. CC -!- DISEASE: Leukoencephalopathy, developmental delay, and episodic CC neurologic regression syndrome (LEUDEN) [MIM:618877]: An autosomal CC dominant disorder characterized by global developmental delay apparent CC in early childhood, cognitive impairment, ataxia, poor or absent speech CC with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, CC and abnormal involuntary movements. Affected individuals also exhibit CC neurological regression in the setting of febrile illness or infection. CC Many patients have seizures. Brain imaging shows diffuse white matter CC abnormalities with poor myelination. {ECO:0000269|PubMed:32197074}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Dystonia 33 (DYT33) [MIM:619687]: A form of dystonia, a CC disorder defined by the presence of sustained involuntary muscle CC contraction, often leading to abnormal postures. DYT33 is a slowly CC progressive form characterized by onset of focal or generalized CC dystonia in the first decades of life. Disease manifestations are CC variable. Some patients show ambulation difficulties, dysarthria, or CC dysphagia. Some affected individuals may manifest motor delay, lower CC limb spasticity, and mild developmental delay with intellectual CC disability. DYT33 penetrance is incomplete. Inheritance can be CC autosomal dominant or recessive. {ECO:0000269|PubMed:33236446, CC ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41866/EIF2AK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M35663; AAA36409.1; -; mRNA. DR EMBL; M85294; AAA18253.1; -; mRNA. DR EMBL; U50648; AAC50768.1; -; Genomic_DNA. DR EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; AF167472; AAF13156.1; -; Genomic_DNA. DR EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AY302136; AAP57628.1; -; mRNA. DR EMBL; AK290655; BAF83344.1; -; mRNA. DR EMBL; AK313818; BAG36554.1; -; mRNA. DR EMBL; AY228338; AAO38055.1; -; Genomic_DNA. DR EMBL; AC007899; AAY24317.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00407.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00408.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00409.1; -; Genomic_DNA. DR EMBL; BC093676; AAH93676.1; -; mRNA. DR EMBL; BC101475; AAI01476.1; -; mRNA. DR CCDS; CCDS1786.1; -. [P19525-1] DR CCDS; CCDS46259.1; -. [P19525-2] DR PIR; JC5225; JC5225. DR RefSeq; NP_001129123.1; NM_001135651.3. [P19525-1] DR RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2] DR RefSeq; NP_002750.1; NM_002759.4. [P19525-1] DR RefSeq; XP_011531289.1; XM_011532987.3. [P19525-1] DR RefSeq; XP_054198993.1; XM_054343018.1. [P19525-1] DR PDB; 1QU6; NMR; -; A=1-170. DR PDB; 2A19; X-ray; 2.50 A; B/C=258-550. DR PDB; 2A1A; X-ray; 2.80 A; B=258-550. DR PDB; 3UIU; X-ray; 2.90 A; A/B=254-551. DR PDB; 6D3K; X-ray; 2.60 A; A/B/C=229-551. DR PDB; 6D3L; X-ray; 3.10 A; A=229-551. DR PDB; 7OBK; X-ray; 1.80 A; B=541-551. DR PDB; 7OBL; X-ray; 1.80 A; B=541-551. DR PDB; 8BI7; X-ray; 1.40 A; B=541-551. DR PDB; 8I9J; EM; 6.39 A; A=1-170. DR PDB; 8IZN; EM; 6.67 A; A=1-170. DR PDBsum; 1QU6; -. DR PDBsum; 2A19; -. DR PDBsum; 2A1A; -. DR PDBsum; 3UIU; -. DR PDBsum; 6D3K; -. DR PDBsum; 6D3L; -. DR PDBsum; 7OBK; -. DR PDBsum; 7OBL; -. DR PDBsum; 8BI7; -. DR PDBsum; 8I9J; -. DR PDBsum; 8IZN; -. DR AlphaFoldDB; P19525; -. DR BMRB; P19525; -. DR EMDB; EMD-35274; -. DR EMDB; EMD-35866; -. DR SMR; P19525; -. DR BioGRID; 111596; 395. DR DIP; DIP-2657N; -. DR FunCoup; P19525; 998. DR IntAct; P19525; 176. DR MINT; P19525; -. DR STRING; 9606.ENSP00000233057; -. DR BindingDB; P19525; -. DR ChEMBL; CHEMBL5785; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07995; H-89. DR DrugBank; DB00328; Indomethacin. DR DrugCentral; P19525; -. DR GuidetoPHARMACOLOGY; 2016; -. DR GlyGen; P19525; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P19525; -. DR PhosphoSitePlus; P19525; -. DR SwissPalm; P19525; -. DR BioMuta; EIF2AK2; -. DR DMDM; 125527; -. DR jPOST; P19525; -. DR MassIVE; P19525; -. DR PaxDb; 9606-ENSP00000233057; -. DR PeptideAtlas; P19525; -. DR ProteomicsDB; 19391; -. DR ProteomicsDB; 53670; -. [P19525-1] DR Pumba; P19525; -. DR TopDownProteomics; P19525-1; -. [P19525-1] DR Antibodypedia; 3548; 1196 antibodies from 44 providers. DR DNASU; 5610; -. DR Ensembl; ENST00000233057.9; ENSP00000233057.4; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000395127.6; ENSP00000378559.2; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000405334.5; ENSP00000385014.1; ENSG00000055332.20. [P19525-2] DR Ensembl; ENST00000647926.1; ENSP00000497534.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000679507.1; ENSP00000506024.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681463.1; ENSP00000505138.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681507.1; ENSP00000505772.1; ENSG00000055332.20. [P19525-1] DR GeneID; 5610; -. DR KEGG; hsa:5610; -. DR MANE-Select; ENST00000233057.9; ENSP00000233057.4; NM_001135651.3; NP_001129123.1. DR UCSC; uc010fab.3; human. [P19525-1] DR AGR; HGNC:9437; -. DR ClinPGx; PA33779; -. DR CTD; 5610; -. DR DisGeNET; 5610; -. DR GeneCards; EIF2AK2; -. DR HGNC; HGNC:9437; EIF2AK2. DR HPA; ENSG00000055332; Low tissue specificity. DR MalaCards; EIF2AK2; -. DR MIM; 176871; gene. DR MIM; 618877; phenotype. DR MIM; 619687; phenotype. DR OpenTargets; ENSG00000055332; -. DR Orphanet; 256; Early-onset generalized limb-onset dystonia. DR VEuPathDB; HostDB:ENSG00000055332; -. DR eggNOG; KOG1033; Eukaryota. DR GeneTree; ENSGT00940000160736; -. DR HOGENOM; CLU_023682_1_0_1; -. DR InParanoid; P19525; -. DR OMA; KIACEMM; -. DR OrthoDB; 341578at2759; -. DR PAN-GO; P19525; 2 GO annotations based on evolutionary models. DR PhylomeDB; P19525; -. DR PathwayCommons; P19525; -. DR Reactome; R-HSA-1169408; ISG15 antiviral mechanism. DR Reactome; R-HSA-169131; Inhibition of PKR. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-9833109; Evasion by RSV of host interferon responses. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SignaLink; P19525; -. DR SIGNOR; P19525; -. DR Agora; ENSG00000055332; -. DR BioGRID-ORCS; 5610; 13 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; EIF2AK2; human. DR EvolutionaryTrace; P19525; -. DR GeneWiki; Protein_kinase_R; -. DR GenomeRNAi; 5610; -. DR Pharos; P19525; Tchem. DR PRO; PR:P19525; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P19525; protein. DR Bgee; ENSG00000055332; Expressed in endometrium epithelium and 211 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005840; C:ribosome; TAS:AgBase. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:UniProt. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019888; F:protein phosphatase regulator activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProt. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IEP:ARUK-UCL. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB. DR GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB. DR GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IMP:UniProtKB. DR GO; GO:0006412; P:translation; IEA:Ensembl. DR CDD; cd19903; DSRM_EIF2AK2_rpt1; 1. DR CDD; cd19904; DSRM_EIF2AK2_rpt2; 1. DR CDD; cd14047; STKc_EIF2AK2_PKR; 1. DR DisProt; DP03944; -. DR FunFam; 3.30.160.20:FF:000045; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.160.20:FF:000062; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.200.20:FF:000536; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 1.10.510.10:FF:000251; eukaryotic translation initiation factor 2-alpha kinase 3; 1. DR Gene3D; 3.30.160.20; -; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00443; -. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR014720; dsRBD_dom. DR InterPro; IPR044452; EIF2AK2_DSRM_1. DR InterPro; IPR044453; EIF2AK2_DSRM_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF163; INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00035; dsrm; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00358; DSRM; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54768; dsRNA-binding domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50137; DS_RBD; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Antiviral defense; KW ATP-binding; Cytoplasm; Direct protein sequencing; Disease variant; KW Dystonia; Host-virus interaction; Immunity; Innate immunity; KW Isopeptide bond; Kinase; Magnesium; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Tyrosine-protein kinase; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..551 FT /note="Interferon-induced, double-stranded RNA-activated FT protein kinase" FT /id="PRO_0000085945" FT DOMAIN 9..77 FT /note="DRBM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 100..167 FT /note="DRBM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 267..538 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 331..343 FT /note="1" FT REPEAT 345..357 FT /note="2" FT REGION 2..180 FT /note="(Microbial infection) Interaction with HCV NS5A" FT /evidence="ECO:0000269|PubMed:17267064" FT REGION 202..222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 266..551 FT /note="Interaction with TRAF5" FT /evidence="ECO:0000269|PubMed:15121867" FT REGION 266..362 FT /note="Dimerization" FT /evidence="ECO:0000269|PubMed:16179258" FT REGION 331..357 FT /note="2 X 13 AA approximate repeats" FT REGION 379..496 FT /note="Interaction with EIF2S1/EIF-2ALPHA" FT /evidence="ECO:0000269|PubMed:16179258" FT COMPBIAS 202..215 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 414 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 273..281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 296 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 432 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000305|PubMed:16179258, FT ECO:0000305|PubMed:31246429" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT MOD_RES 83 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11152499, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 88 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 89 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 90 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 101 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 242 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 255 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 258 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 293 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 446 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:16179258" FT MOD_RES 451 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:20685959" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 542 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 69 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT VAR_SEQ 263..303 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_046177" FT VARIANT 11 FT /note="M -> L (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084260" FT VARIANT 32 FT /note="N -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084261" FT VARIANT 32 FT /note="N -> T (in DYT33; uncertain significance; gain-of- FT function variant resulting in increased levels of FT phosphorylated EIF2AK2 and EIF2A in patient cells compared FT to controls)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086715" FT VARIANT 97 FT /note="S -> F (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084262" FT VARIANT 109 FT /note="A -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084263" FT VARIANT 109 FT /note="A -> V (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084264" FT VARIANT 114 FT /note="L -> Q (found in a patient with dysmorphic facies, FT syndactyly, congenital microcephaly and global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084265" FT VARIANT 130 FT /note="G -> R (in DYT33; gain-of-function variant resulting FT in increased levels of phosphorylated EIF2AK2 and EIF2A in FT patient cells compared to controls)" FT /evidence="ECO:0000269|PubMed:33236446, FT ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068" FT /id="VAR_086716" FT VARIANT 133 FT /note="Y -> F (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084266" FT VARIANT 138 FT /note="G -> A (in DYT33; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086717" FT VARIANT 325 FT /note="G -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084267" FT VARIANT 428 FT /note="V -> E (in dbSNP:rs56219559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040474" FT VARIANT 439 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040475" FT VARIANT 461 FT /note="S -> C (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084268" FT VARIANT 506 FT /note="I -> V (no effect on PKR inhibition by HCMV protein FT TRS1; dbSNP:rs34821155)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:27780231" FT /id="VAR_040476" FT MUTAGEN 59..60 FT /note="SK->AA: In FL-PKR-2AI; moderate loss of activity but FT no effect on dsRNA binding." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 60 FT /note="K->A: Impairs dsRNA binding but not dimerization or FT activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 67 FT /note="A->E: Significant loss of activity; loss of dsRNA FT binding and dimerization." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 83 FT /note="S->A: No effect on enzymatic activity; when FT associated with A-88; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 88 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 89 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 90 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-89." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 149..150 FT /note="TK->AA: In FL-PKR-2AII; no effect on activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 242 FT /note="S->A: Moderate loss of activity; when associated FT with A-255 and A-258." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 244..296 FT /note="Missing: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 255 FT /note="T->A: Moderate loss of activity; when associated FT with A-242 and A-255." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 258 FT /note="T->A: Moderate loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 296 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 446 FT /note="T->A: Significant loss of activity and impairs FT autophosphorylation of T-451." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 451 FT /note="T->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 486 FT /note="D->V: 15-fold decrease in K3L binding affinity and FT thus resistance of mutated PKR to K3L inhibition." FT /evidence="ECO:0000269|PubMed:18971339" FT MUTAGEN 489 FT /note="F->S: Loss of PKR inhibition by HCMV protein TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 496 FT /note="T->K: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 502 FT /note="I->T: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 510 FT /note="K->R: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 516 FT /note="Q->E: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT CONFLICT 102 FT /note="I -> M (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 224 FT /note="S -> R (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 512 FT /note="K -> E (in Ref. 6; AAF13156)" FT /evidence="ECO:0000305" FT STRAND 5..7 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 26..32 FT /evidence="ECO:0007829|PDB:1QU6" FT TURN 35..37 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 41..50 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 61..76 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 102..111 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 115..123 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 125..138 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 144..149 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 150..167 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 261..266 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 267..274 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:2A19" FT TURN 287..289 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 303..305 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 306..314 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 323..332 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 358..366 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 388..407 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:2A1A" FT HELIX 417..419 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 420..424 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 433..435 FT /evidence="ECO:0007829|PDB:6D3L" FT STRAND 437..440 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 468..482 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 488..499 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:3UIU" FT HELIX 509..518 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 523..525 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 529..539 FT /evidence="ECO:0007829|PDB:2A19" SQ SEQUENCE 551 AA; 62094 MW; 815AD83ACAB45DA3 CRC64; MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK KSPEKNERHT C // ID EPHA7_HUMAN Reviewed; 998 AA. AC Q15375; A0AUX7; B2R8W1; B7ZLJ9; B7ZLK0; Q59G40; Q5VTU0; Q8N368; Q9H124; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2007, sequence version 3. DT 28-JAN-2026, entry version 236. DE RecName: Full=Ephrin type-A receptor 7; DE EC=2.7.10.1; DE AltName: Full=EPH homology kinase 3; DE Short=EHK-3; DE AltName: Full=EPH-like kinase 11; DE Short=EK11; DE Short=hEK11; DE Flags: Precursor; GN Name=EPHA7; Synonyms=EHK3, HEK11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7898931; RA Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R., RA Welcher A.A.; RT "cDNA cloning and tissue distribution of five human EPH-like receptor RT protein-tyrosine kinases."; RL Oncogene 10:897-905(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4), AND RP VARIANT VAL-138. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [8] RP FUNCTION IN MAP2K1; MAP2K2; MAPK1 AND MAPK3 PHOSPHORYLATION. RX PubMed=17726105; DOI=10.1073/pnas.0703211104; RA Nakanishi H., Nakamura T., Canaani E., Croce C.M.; RT "ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation RT in human acute leukemias."; RL Proc. Natl. Acad. Sci. U.S.A. 104:14442-14447(2007). RN [9] RP ALTERNATIVE SPLICING (ISOFORM 5). RX PubMed=20126984; RA Tsuboi M., Mori H., Bunai T., Kageyama S., Suzuki M., Okudela K., RA Takamochi K., Ogawa H., Niwa H., Shinmura K., Sugimura H.; RT "Secreted form of EphA7 in lung cancer."; RL Int. J. Oncol. 36:635-640(2010). RN [10] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 32-204. RA Walker J.R., Yermekbayeva L., Seitova A., Kania J., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.; RT "Ephrin A7 ligand binding domain."; RL Submitted (JUN-2010) to the PDB data bank. RN [11] RP VARIANT [LARGE SCALE ANALYSIS] TRP-371. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-138; LYS-170; ARG-232; SER-278 AND RP SER-903. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Among GPI-anchored ephrin-A CC ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their CC interaction regulates brain development modulating cell-cell adhesion CC and repulsion. Has a repellent activity on axons and is for instance CC involved in the guidance of corticothalamic axons and in the proper CC topographic mapping of retinal axons to the colliculus. May also CC regulate brain development through a caspase(CASP3)-dependent CC proapoptotic activity. Forward signaling may result in activation of CC components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 CC and MAPK3 which are phosphorylated upon activation of EPHA7. CC {ECO:0000269|PubMed:17726105}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts (via PDZ-binding motif) with GRIP1 and PICK1 (via PDZ domain) CC (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q15375; P07333: CSF1R; NbExp=2; IntAct=EBI-1383428, EBI-2835440; CC Q15375; P52803: EFNA5; NbExp=4; IntAct=EBI-1383428, EBI-1753674; CC Q15375; P29317: EPHA2; NbExp=7; IntAct=EBI-1383428, EBI-702104; CC Q15375; P29320: EPHA3; NbExp=4; IntAct=EBI-1383428, EBI-1641575; CC Q15375; P29323: EPHB2; NbExp=2; IntAct=EBI-1383428, EBI-1059294; CC Q15375; P54760: EPHB4; NbExp=3; IntAct=EBI-1383428, EBI-702121; CC Q15375; Q9H8Y8: GORASP2; NbExp=2; IntAct=EBI-1383428, EBI-739467; CC Q15375; Q9NUP9: LIN7C; NbExp=2; IntAct=EBI-1383428, EBI-1171517; CC Q15375; Q16288: NTRK3; NbExp=2; IntAct=EBI-1383428, EBI-3936704; CC Q15375; Q8NI35: PATJ; NbExp=2; IntAct=EBI-1383428, EBI-724390; CC Q15375; P52793: Efna1; Xeno; NbExp=2; IntAct=EBI-1383428, EBI-5241529; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I CC membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; Synonyms=EPHA7-FL; CC IsoId=Q15375-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15375-2; Sequence=VSP_014382; CC Name=3; CC IsoId=Q15375-3; Sequence=VSP_014380, VSP_014381; CC Name=4; CC IsoId=Q15375-4; Sequence=VSP_041945; CC Name=5; Synonyms=EPHA7-S; CC IsoId=Q15375-5; Sequence=VSP_041943, VSP_041944; CC -!- TISSUE SPECIFICITY: Widely expressed. CC -!- PTM: Phosphorylated. {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing donor splice CC site. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Expressed in lung cancer cells, lacks the CC kinase domain and is most probably secreted. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92506.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40466/EPHA7"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36642; AAA74243.1; -; mRNA. DR EMBL; AK313529; BAG36308.1; -; mRNA. DR EMBL; AB209269; BAD92506.1; ALT_INIT; mRNA. DR EMBL; AL121966; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL354857; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL591036; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48518.1; -; Genomic_DNA. DR EMBL; BC027940; AAH27940.1; -; mRNA. DR EMBL; BC126125; AAI26126.1; -; mRNA. DR EMBL; BC126151; AAI26152.1; -; mRNA. DR EMBL; BC143857; AAI43858.1; -; mRNA. DR EMBL; BC143858; AAI43859.1; -; mRNA. DR CCDS; CCDS5031.1; -. [Q15375-1] DR CCDS; CCDS75494.1; -. [Q15375-3] DR CCDS; CCDS93973.1; -. [Q15375-4] DR PIR; I58351; I58351. DR RefSeq; NP_001275558.1; NM_001288629.2. [Q15375-2] DR RefSeq; NP_001275559.1; NM_001288630.2. [Q15375-3] DR RefSeq; NP_001363394.1; NM_001376465.1. [Q15375-4] DR RefSeq; NP_004431.1; NM_004440.4. [Q15375-1] DR PDB; 2REI; X-ray; 1.60 A; A=590-899. DR PDB; 3DKO; X-ray; 2.00 A; A=590-899. DR PDB; 3H8M; X-ray; 2.10 A; A/B=919-990. DR PDB; 3NRU; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L=32-204. DR PDB; 7EEC; X-ray; 3.10 A; A=599-899. DR PDB; 7EED; X-ray; 3.05 A; A=599-899. DR PDB; 7EEF; X-ray; 2.60 A; A=599-899. DR PDBsum; 2REI; -. DR PDBsum; 3DKO; -. DR PDBsum; 3H8M; -. DR PDBsum; 3NRU; -. DR PDBsum; 7EEC; -. DR PDBsum; 7EED; -. DR PDBsum; 7EEF; -. DR AlphaFoldDB; Q15375; -. DR SMR; Q15375; -. DR BioGRID; 108359; 316. DR FunCoup; Q15375; 1198. DR IntAct; Q15375; 282. DR MINT; Q15375; -. DR STRING; 9606.ENSP00000358309; -. DR BindingDB; Q15375; -. DR ChEMBL; CHEMBL4602; -. DR DrugBank; DB07970; 5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q15375; -. DR GuidetoPHARMACOLOGY; 1827; -. DR GlyCosmos; Q15375; 4 sites, 1 glycan. DR GlyGen; Q15375; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q15375; -. DR PhosphoSitePlus; Q15375; -. DR SwissPalm; Q15375; -. DR BioMuta; EPHA7; -. DR DMDM; 146345416; -. DR CPTAC; CPTAC-1783; -. DR CPTAC; CPTAC-2787; -. DR CPTAC; CPTAC-2830; -. DR jPOST; Q15375; -. DR MassIVE; Q15375; -. DR PaxDb; 9606-ENSP00000358309; -. DR PeptideAtlas; Q15375; -. DR ProteomicsDB; 60549; -. [Q15375-1] DR ProteomicsDB; 60550; -. [Q15375-2] DR ProteomicsDB; 60551; -. [Q15375-3] DR ProteomicsDB; 60552; -. [Q15375-4] DR ProteomicsDB; 60553; -. [Q15375-5] DR Pumba; Q15375; -. DR Antibodypedia; 642; 553 antibodies from 37 providers. DR DNASU; 2045; -. DR Ensembl; ENST00000369297.1; ENSP00000358303.1; ENSG00000135333.16. [Q15375-3] DR Ensembl; ENST00000369303.9; ENSP00000358309.4; ENSG00000135333.16. [Q15375-1] DR Ensembl; ENST00000680224.1; ENSP00000506130.1; ENSG00000135333.16. [Q15375-4] DR GeneID; 2045; -. DR KEGG; hsa:2045; -. DR MANE-Select; ENST00000369303.9; ENSP00000358309.4; NM_004440.4; NP_004431.1. DR UCSC; uc003poe.5; human. [Q15375-1] DR AGR; HGNC:3390; -. DR ClinPGx; PA27822; -. DR CTD; 2045; -. DR DisGeNET; 2045; -. DR GeneCards; EPHA7; -. DR HGNC; HGNC:3390; EPHA7. DR HPA; ENSG00000135333; Group enriched (intestine, parathyroid gland). DR MalaCards; EPHA7; -. DR MIM; 602190; gene. DR OpenTargets; ENSG00000135333; -. DR VEuPathDB; HostDB:ENSG00000135333; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160189; -. DR HOGENOM; CLU_000288_141_0_1; -. DR InParanoid; Q15375; -. DR OMA; ETDYNTG; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q15375; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q15375; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15375; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; Q15375; -. DR SIGNOR; Q15375; -. DR Agora; ENSG00000135333; -. DR BioGRID-ORCS; 2045; 14 hits in 1184 CRISPR screens. DR ChiTaRS; EPHA7; human. DR EvolutionaryTrace; Q15375; -. DR GeneWiki; EPHA7; -. DR GenomeRNAi; 2045; -. DR Pharos; Q15375; Tchem. DR PRO; PR:Q15375; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15375; protein. DR Bgee; ENSG00000135333; Expressed in cortical plate and 131 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; ISS:UniProtKB. DR GO; GO:0045499; F:chemorepellent activity; ISS:UniProtKB. DR GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0007420; P:brain development; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0050919; P:negative chemotaxis; ISS:UniProtKB. DR GO; GO:0048671; P:negative regulation of collateral sprouting; IEA:Ensembl. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0051964; P:negative regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0072178; P:nephric duct morphogenesis; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0016310; P:phosphorylation; ISS:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0031952; P:regulation of protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR CDD; cd10485; EphR_LBD_A7; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09548; SAM_EPH-A7; 1. DR CDD; cd00185; TNFRSF; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034283; EphA7_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF9; EPHRIN TYPE-A RECEPTOR 7; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Glycoprotein; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..998 FT /note="Ephrin type-A receptor 7" FT /id="PRO_0000016818" FT TOPO_DOM 28..555 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 556..576 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 577..998 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..210 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 331..441 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 442..537 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 633..894 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 923..987 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 996..998 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 758 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 639..647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 665 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 608 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 614 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 791 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 940 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 278..279 FT /note="PC -> RK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014380" FT VAR_SEQ 280..998 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014381" FT VAR_SEQ 442..450 FT /note="APSQVSGVM -> GMFCVYLH (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_041943" FT VAR_SEQ 451..998 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_041944" FT VAR_SEQ 540..544 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.3" FT /id="VSP_014382" FT VAR_SEQ 600..604 FT /note="FKFPG -> C (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041945" FT VARIANT 138 FT /note="I -> V (in dbSNP:rs2278107)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022105" FT VARIANT 170 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042150" FT VARIANT 232 FT /note="G -> R (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs2127994473)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042151" FT VARIANT 278 FT /note="P -> S (in dbSNP:rs2278106)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_022106" FT VARIANT 371 FT /note="R -> W (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs371089003)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036090" FT VARIANT 903 FT /note="P -> S (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs2127846874)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042152" FT STRAND 33..37 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 48..51 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 67..74 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 96..106 FT /evidence="ECO:0007829|PDB:3NRU" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 121..132 FT /evidence="ECO:0007829|PDB:3NRU" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 168..174 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 178..190 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:3NRU" FT HELIX 611..613 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 614..616 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 617..624 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 633..641 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 643..652 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:3DKO" FT STRAND 660..666 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 673..686 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 697..701 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 708..712 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 719..725 FT /evidence="ECO:0007829|PDB:2REI" FT TURN 726..728 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 732..751 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 761..763 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 764..766 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 772..774 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 800..802 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 805..810 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 815..830 FT /evidence="ECO:0007829|PDB:2REI" FT TURN 836..839 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 842..850 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 863..872 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 883..895 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 897..899 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 928..934 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 938..940 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 952..956 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 971..988 FT /evidence="ECO:0007829|PDB:3H8M" FT CONFLICT Q15375-3:278 FT /note="R -> C (in Ref. 6; AAH27940)" FT /evidence="ECO:0000305" SQ SEQUENCE 998 AA; 112097 MW; 479B9CA0D2BB06EB CRC64; MVFQTRYPSW IILCYIWLLR FAHTGEAQAA KEVLLLDSKA QQTELEWISS PPNGWEEISG LDENYTPIRT YQVCQVMEPN QNNWLRTNWI SKGNAQRIFV ELKFTLRDCN SLPGVLGTCK ETFNLYYYET DYDTGRNIRE NLYVKIDTIA ADESFTQGDL GERKMKLNTE VREIGPLSKK GFYLAFQDVG ACIALVSVKV YYKKCWSIIE NLAIFPDTVT GSEFSSLVEV RGTCVSSAEE EAENAPRMHC SAEGEWLVPI GKCICKAGYQ QKGDTCEPCG RGFYKSSSQD LQCSRCPTHS FSDKEGSSRC ECEDGYYRAP SDPPYVACTR PPSAPQNLIF NINQTTVSLE WSPPADNGGR NDVTYRILCK RCSWEQGECV PCGSNIGYMP QQTGLEDNYV TVMDLLAHAN YTFEVEAVNG VSDLSRSQRL FAAVSITTGQ AAPSQVSGVM KERVLQRSVE LSWQEPEHPN GVITEYEIKY YEKDQRERTY STVKTKSTSA SINNLKPGTV YVFQIRAFTA AGYGNYSPRL DVATLEEATG KMFEATAVSS EQNPVIIIAV VAVAGTIILV FMVFGFIIGR RHCGYSKADQ EGDEELYFHF KFPGTKTYID PETYEDPNRA VHQFAKELDA SCIKIERVIG AGEFGEVCSG RLKLPGKRDV AVAIKTLKVG YTEKQRRDFL CEASIMGQFD HPNVVHLEGV VTRGKPVMIV IEFMENGALD AFLRKHDGQF TVIQLVGMLR GIAAGMRYLA DMGYVHRDLA ARNILVNSNL VCKVSDFGLS RVIEDDPEAV YTTTGGKIPV RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM SNQDVIKAIE EGYRLPAPMD CPAGLHQLML DCWQKERAER PKFEQIVGIL DKMIRNPNSL KTPLGTCSRP ISPLLDQNTP DFTTFCSVGE WLQAIKMERY KDNFTAAGYN SLESVARMTI EDVMSLGITL VGHQKKIMSS IQTMRAQMLH LHGTGIQV // ID EPHA8_HUMAN Reviewed; 1005 AA. AC P29322; Q6IN80; Q8IUX6; Q9NUA9; Q9P269; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 235. DE RecName: Full=Ephrin type-A receptor 8; DE EC=2.7.10.1; DE AltName: Full=EPH- and ELK-related kinase; DE AltName: Full=EPH-like kinase 3; DE Short=EK3; DE Short=hEK3; DE AltName: Full=Tyrosine-protein kinase receptor EEK; DE Flags: Precursor; GN Name=EPHA8; Synonyms=EEK, HEK3, KIAA1459; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-1005 (ISOFORM 1), AND VARIANT RP GLN-612. RC TISSUE=Brain; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 706-726. RX PubMed=1648701; RA Chan J., Watt V.M.; RT "eek and erk, new members of the eph subclass of receptor protein-tyrosine RT kinases."; RL Oncogene 6:1057-1061(1991). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP INTERACTION WITH FYN. RX PubMed=10498895; DOI=10.1038/sj.onc.1202917; RA Choi S., Park S.; RT "Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn RT binding to the Tyr-615 site by enhancing tyrosine kinase activity."; RL Oncogene 18:5413-5422(1999). RN [7] RP INTERACTION WITH PIK3CG. RX PubMed=11416136; DOI=10.1128/mcb.21.14.4579-4597.2001; RA Gu C., Park S.; RT "The EphA8 receptor regulates integrin activity through p110gamma RT phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent RT manner."; RL Mol. Cell. Biol. 21:4579-4597(2001). RN [8] RP INTERACTION WITH ANKS1B. RX PubMed=17875921; DOI=10.1128/mcb.00794-07; RA Shin J., Gu C., Park E., Park S.; RT "Identification of phosphotyrosine binding domain-containing proteins as RT novel downstream targets of the EphA8 signaling function."; RL Mol. Cell. Biol. 27:8113-8126(2007). RN [9] RP INTERACTION WITH TIAM1. RX PubMed=20496116; DOI=10.1007/s10059-010-0075-2; RA Yoo S., Shin J., Park S.; RT "EphA8-ephrinA5 signaling and clathrin-mediated endocytosis is regulated by RT Tiam-1, a Rac-specific guanine nucleotide exchange factor."; RL Mol. Cells 29:603-609(2010). RN [10] RP STRUCTURE BY NMR OF 437-534 AND 932-1000. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain and of sterile alpha motif RT (SAM) domain of EPH receptor A8 protein."; RL Submitted (NOV-2005) to the PDB data bank. RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] SER-45; LEU-60; LYS-123; CYS-179; LEU-198 RP AND LEU-860. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, CC EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. CC With EFNA5 may regulate integrin-mediated cell adhesion and migration CC on fibronectin substrate but also neurite outgrowth. During development CC of the nervous system also plays a role in axon guidance. Downstream CC effectors of the EPHA8 signaling pathway include FYN which promotes CC cell adhesion upon activation by EPHA8 and the MAP kinases in the CC stimulation of neurite outgrowth (By similarity). {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses. May also form CC heterodimers with other ephrin receptors (By similarity). Interacts CC with FYN; possible downstream effector of EPHA8 in regulation of cell CC adhesion. Interacts with PIK3CG; regulates integrin-mediated cell CC adhesion to substrate. Interacts with TIAM1; regulates clathrin- CC mediated endocytosis of EPHA8. Interacts with ANKS1A and ANKS1B; EPHA8 CC kinase activity-independent but stimulated by EPHA8 ubiquitination. CC {ECO:0000250, ECO:0000269|PubMed:10498895, ECO:0000269|PubMed:11416136, CC ECO:0000269|PubMed:17875921, ECO:0000269|PubMed:20496116}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:O09127}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection CC {ECO:0000250|UniProtKB:O09127}. Early endosome membrane CC {ECO:0000250|UniProtKB:O09127}. Note=Undergoes clathrin-mediated CC endocytosis upon EFNA5-binding and is targeted to early endosomes. CC {ECO:0000250|UniProtKB:O09127}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29322-1; Sequence=Displayed; CC Name=2; CC IsoId=P29322-2; Sequence=VSP_041946, VSP_041947; CC -!- PTM: Phosphorylated. Phosphorylation is stimulated upon binding of its CC ligands including EFNA2, EFNA3 and EFNA5. Autophosphorylation on Tyr- CC 616 is critical for association with FYN. Autophosphorylation on Tyr- CC 839 modulates tyrosine kinase activity (By similarity). {ECO:0000250}. CC -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor CC stability and activity through proteasomal degradation. ANKS1A prevents CC ubiquitination and degradation (By similarity). {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA41980.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL035703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC038796; AAH38796.1; -; mRNA. DR EMBL; BC072417; AAH72417.2; -; mRNA. DR EMBL; AB040892; BAA95983.1; -; mRNA. DR EMBL; X59291; CAA41980.1; ALT_INIT; Genomic_DNA. DR CCDS; CCDS225.1; -. [P29322-1] DR CCDS; CCDS30626.1; -. [P29322-2] DR PIR; S23361; S23361. DR RefSeq; NP_001006944.1; NM_001006943.3. [P29322-2] DR RefSeq; NP_065387.1; NM_020526.5. [P29322-1] DR PDB; 1UCV; NMR; -; A=933-1000. DR PDB; 1X5L; NMR; -; A=437-534. DR PDB; 3KUL; X-ray; 2.15 A; A/B=602-909. DR PDBsum; 1UCV; -. DR PDBsum; 1X5L; -. DR PDBsum; 3KUL; -. DR AlphaFoldDB; P29322; -. DR BMRB; P29322; -. DR SMR; P29322; -. DR BioGRID; 108360; 162. DR CORUM; P29322; -. DR FunCoup; P29322; 354. DR IntAct; P29322; 151. DR MINT; P29322; -. DR STRING; 9606.ENSP00000166244; -. DR BindingDB; P29322; -. DR ChEMBL; CHEMBL4134; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P29322; -. DR GuidetoPHARMACOLOGY; 1828; -. DR GlyCosmos; P29322; 3 sites, No reported glycans. DR GlyGen; P29322; 4 sites, 1 O-linked glycan (1 site). DR iPTMnet; P29322; -. DR PhosphoSitePlus; P29322; -. DR BioMuta; EPHA8; -. DR DMDM; 19857975; -. DR CPTAC; CPTAC-2820; -. DR CPTAC; CPTAC-3204; -. DR jPOST; P29322; -. DR MassIVE; P29322; -. DR PaxDb; 9606-ENSP00000166244; -. DR PeptideAtlas; P29322; -. DR ProteomicsDB; 54538; -. [P29322-1] DR ProteomicsDB; 54539; -. [P29322-2] DR Antibodypedia; 4046; 174 antibodies from 33 providers. DR DNASU; 2046; -. DR Ensembl; ENST00000166244.8; ENSP00000166244.3; ENSG00000070886.12. [P29322-1] DR Ensembl; ENST00000374644.8; ENSP00000363775.4; ENSG00000070886.12. [P29322-2] DR GeneID; 2046; -. DR KEGG; hsa:2046; -. DR MANE-Select; ENST00000166244.8; ENSP00000166244.3; NM_020526.5; NP_065387.1. DR UCSC; uc001bfw.4; human. [P29322-1] DR AGR; HGNC:3391; -. DR ClinPGx; PA27823; -. DR CTD; 2046; -. DR DisGeNET; 2046; -. DR GeneCards; EPHA8; -. DR HGNC; HGNC:3391; EPHA8. DR HPA; ENSG00000070886; Tissue enriched (choroid). DR MIM; 176945; gene. DR OpenTargets; ENSG00000070886; -. DR VEuPathDB; HostDB:ENSG00000070886; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160469; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P29322; -. DR OMA; MRMNIDD; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29322; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29322; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29322; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29322; -. DR SIGNOR; P29322; -. DR Agora; ENSG00000070886; -. DR BioGRID-ORCS; 2046; 11 hits in 1180 CRISPR screens. DR ChiTaRS; EPHA8; human. DR EvolutionaryTrace; P29322; -. DR GeneWiki; EPHA8; -. DR GenomeRNAi; 2046; -. DR Pharos; P29322; Tchem. DR PRO; PR:P29322; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29322; protein. DR Bgee; ENSG00000070886; Expressed in endothelial cell and 47 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0043005; C:neuron projection; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0031175; P:neuron projection development; ISS:UniProtKB. DR GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0030155; P:regulation of cell adhesion; ISS:UniProtKB. DR GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; ISS:UniProtKB. DR GO; GO:0006929; P:substrate-dependent cell migration; ISS:UniProtKB. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09550; SAM_EPH-A8; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR FunFam; 1.10.150.50:FF:000058; ephrin type-A receptor 8; 1. DR FunFam; 3.30.200.20:FF:000143; Ephrin type-B receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF7; EPHRIN TYPE-A RECEPTOR 8; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Developmental protein; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..1005 FT /note="Ephrin type-A receptor 8" FT /id="PRO_0000016822" FT TOPO_DOM 28..542 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 543..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..1005 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..209 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..438 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 439..534 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 635..896 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 930..994 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 564..570 FT /note="Mediates interaction with ANKS1A and ANKS1B" FT /evidence="ECO:0000250" FT REGION 589..644 FT /note="Mediates interaction with PIK3CG and required for FT endocytosis" FT /evidence="ECO:0000250" FT MOTIF 1003..1005 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 760 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 641..649 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 667 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 616 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT MOD_RES 839 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT CARBOHYD 340 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 432 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 439..495 FT /note="APSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEKDKEMQSYSTL FT KAVTT -> GRRRNSVPQRPGPPASPASDPSRDQSSAGDVLWAFRQVPLWPCAPHQDPE FT LEALHCL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041946" FT VAR_SEQ 496..1005 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041947" FT VARIANT 45 FT /note="G -> S (in dbSNP:rs45498698)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042153" FT VARIANT 60 FT /note="V -> L (in dbSNP:rs56402644)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042154" FT VARIANT 123 FT /note="N -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042155" FT VARIANT 179 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1557556639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042156" FT VARIANT 198 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042157" FT VARIANT 321 FT /note="P -> L (in dbSNP:rs56656925)" FT /id="VAR_061292" FT VARIANT 444 FT /note="V -> M (in dbSNP:rs2295021)" FT /id="VAR_022107" FT VARIANT 612 FT /note="E -> Q (in dbSNP:rs999765)" FT /evidence="ECO:0000269|PubMed:10819331" FT /id="VAR_024514" FT VARIANT 860 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042158" FT CONFLICT 237 FT /note="S -> L (in Ref. 3; BAA95983)" FT /evidence="ECO:0000305" FT STRAND 456..460 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 472..482 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 488..499 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 507..510 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:1X5L" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 635..643 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 644..646 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 647..654 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 662..669 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 675..688 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 699..703 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 705..707 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 710..714 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 721..726 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 727..730 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 734..753 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 766..768 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 774..776 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 802..804 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 807..812 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 817..832 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 833..835 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 838..841 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 844..852 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 865..874 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 879..881 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 885..897 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 935..941 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 945..947 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 948..953 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 959..962 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 967..973 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 978..995 FT /evidence="ECO:0007829|PDB:1UCV" SQ SEQUENCE 1005 AA; 111003 MW; 6FBF85535E4212B3 CRC64; MAPARGRLPP ALWVVTAAAA AATCVSAARG EVNLLDTSTI HGDWGWLTYP AHGWDSINEV DESFQPIHTY QVCNVMSPNQ NNWLRTSWVP RDGARRVYAE IKFTLRDCNS MPGVLGTCKE TFNLYYLESD RDLGASTQES QFLKIDTIAA DESFTGADLG VRRLKLNTEV RSVGPLSKRG FYLAFQDIGA CLAILSLRIY YKKCPAMVRN LAAFSEAVTG ADSSSLVEVR GQCVRHSEER DTPKMYCSAE GEWLVPIGKC VCSAGYEERR DACVACELGF YKSAPGDQLC ARCPPHSHSA APAAQACHCD LSYYRAALDP PSSACTRPPS APVNLISSVN GTSVTLEWAP PLDPGGRSDI TYNAVCRRCP WALSRCEACG SGTRFVPQQT SLVQASLLVA NLLAHMNYSF WIEAVNGVSD LSPEPRRAAV VNITTNQAAP SQVVVIRQER AGQTSVSLLW QEPEQPNGII LEYEIKYYEK DKEMQSYSTL KAVTTRATVS GLKPGTRYVF QVRARTSAGC GRFSQAMEVE TGKPRPRYDT RTIVWICLTL ITGLVVLLLL LICKKRHCGY SKAFQDSDEE KMHYQNGQAP PPVFLPLHHP PGKLPEPQFY AEPHTYEEPG RAGRSFTREI EASRIHIEKI IGSGDSGEVC YGRLRVPGQR DVPVAIKALK AGYTERQRRD FLSEASIMGQ FDHPNIIRLE GVVTRGRLAM IVTEYMENGS LDTFLRTHDG QFTIMQLVGM LRGVGAGMRY LSDLGYVHRD LAARNVLVDS NLVCKVSDFG LSRVLEDDPD AAYTTTGGKI PIRWTAPEAI AFRTFSSASD VWSFGVVMWE VLAYGERPYW NMTNRDVISS VEEGYRLPAP MGCPHALHQL MLDCWHKDRA QRPRFSQIVS VLDALIRSPE SLRATATVSR CPPPAFVRSC FDLRGGSGGG GGLTVGDWLD SIRMGRYRDH FAAGGYSSLG MVLRMNAQDV RALGITLMGH QKKILGSIQT MRAQLTSTQG PRRHL // ID EPHB4_HUMAN Reviewed; 987 AA. AC P54760; B5A970; B5A971; B5A972; Q7Z635; Q9BTA5; Q9BXP0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=Ephrin type-B receptor 4; DE EC=2.7.10.1; DE AltName: Full=Hepatoma transmembrane kinase; DE AltName: Full=Tyrosine-protein kinase TYRO11; DE Flags: Precursor; GN Name=EPHB4; Synonyms=HTK, MYK1, TYRO11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=8188704; DOI=10.1016/s0021-9258(17)36776-5; RA Bennett B.D., Wang Z., Kuang W.J., Wang A., Groopman J.E., Goeddel D.V., RA Scadden D.T.; RT "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase RT of the EPH subfamily."; RL J. Biol. Chem. 269:14211-14218(1994). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11239002; DOI=10.1093/nar/29.6.1352; RA Wilson M.D., Riemer C., Martindale D.W., Schnupf P., Boright A.P., RA Cheung T.L., Hardy D.M., Schwartz S., Scherer S.W., Tsui L.-C., Miller W., RA Koop B.F.; RT "Comparative analysis of the gene-dense ACHE/TFR2 region on human RT chromosome 7q22 with the orthologous region on mouse chromosome 5."; RL Nucleic Acids Res. 29:1352-1365(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-162. RC TISSUE=Ovary, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=12734395; DOI=10.1242/jcs.00426; RA Fueller T., Korff T., Kilian A., Dandekar G., Augustin H.G.; RT "Forward EphB4 signaling in endothelial cells controls cellular repulsion RT and segregation from ephrinB2 positive cells."; RL J. Cell Sci. 116:2461-2470(2003). RN [7] RP FUNCTION IN ANGIOGENESIS. RX PubMed=16424904; DOI=10.1038/sj.emboj.7600949; RA Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J., RA Hammes H.P., Grobholz R., Ullrich A., Vajkoczy P.; RT "EphB4 controls blood vascular morphogenesis during postnatal RT angiogenesis."; RL EMBO J. 25:628-641(2006). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-976, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911; THR-976 AND TYR-987, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769; SER-770 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-943, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 17-196 IN COMPLEX WITH EFNB2, RP MUTAGENESIS OF LEU-95, AND DISULFIDE BOND. RX PubMed=16867992; DOI=10.1074/jbc.m605766200; RA Chrencik J.E., Brooun A., Kraus M.L., Recht M.I., Kolatkar A.R., Han G.W., RA Seifert J.M., Widmer H., Auer M., Kuhn P.; RT "Structural and biophysical characterization of the EphB4*ephrinB2 protein- RT protein interaction and receptor specificity."; RL J. Biol. Chem. 281:28185-28192(2006). RN [16] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 17-196 IN COMPLEX WITH RP ANTAGONISTIC PEPTIDE, AND DISULFIDE BOND. RX PubMed=16472751; DOI=10.1016/j.str.2005.11.011; RA Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R., RA Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P.; RT "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 RT antagonist peptide complex reveals the determinants for receptor RT specificity."; RL Structure 14:321-330(2006). RN [17] RP STRUCTURE BY NMR OF 434-529. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain from human ephrin type-B RT receptor 4."; RL Submitted (JUL-2007) to the PDB data bank. RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-67; ILE-113; LEU-346; VAL-371; GLU-576; RP HIS-678; THR-882; TRP-889 AND ASP-890. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [19] RP INVOLVEMENT IN LMPHM7, VARIANTS LMPHM7 GLN-739 AND SER-782, RP CHARACTERIZATION OF VARIANTS LMPHM7 GLU-739 AND SER-782, AND FUNCTION. RX PubMed=27400125; DOI=10.1172/jci85794; RA Martin-Almedina S., Martinez-Corral I., Holdhus R., Vicente A., Fotiou E., RA Lin S., Petersen K., Simpson M.A., Hoischen A., Gilissen C., Jeffery H., RA Atton G., Karapouliou C., Brice G., Gordon K., Wiseman J.W., Wedin M., RA Rockson S.G., Jeffery S., Mortimer P.S., Snyder M.P., Berland S., RA Mansour S., Makinen T., Ostergaard P.; RT "EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic- RT related hydrops fetalis."; RL J. Clin. Invest. 126:3080-3088(2016). RN [20] RP VARIANTS CMAVM2 LYS-59; PRO-74; TYR-115 DEL; 130-TRP--TYR-987 DEL; RP 161-VAL-LYS-162 DELINS LEU; PRO-187; 244-GLN--TYR-987 DEL; ARG-268; RP 352-ARG--TYR-987 DEL; 375-GLY--TYR-987 DEL; 431-ARG--TYR-987 DEL; GLY-469; RP ARG-516; 520-GLN--TYR-987 DEL; 596-TYR--TYR-987 DEL; TRP-656; LYS-664; RP THR-725; 739-ARG--TYR-987 DEL; ASP-745; ARG-789; SER-789; 806-TYR--TYR-987 RP DEL; ARG-807; LEU-820; THR-820; TRP-838; ARG-845; TYR-856; TRP-864 AND RP PRO-874, CHARACTERIZATION OF VARIANTS CMAVM2 LYS-664; TRP-838; ARG-845 AND RP TRP-864, INVOLVEMENT IN CMAVM2, AND SUBCELLULAR LOCATION. RX PubMed=28687708; DOI=10.1161/circulationaha.116.026886; RA Amyere M., Revencu N., Helaers R., Pairet E., Baselga E., Cordisco M., RA Chung W., Dubois J., Lacour J.P., Martorell L., Mazereeuw-Hautier J., RA Pyeritz R.E., Amor D.J., Bisdorff A., Blei F., Bombei H., Dompmartin A., RA Brooks D., Dupont J., Gonzalez-Ensenat M.A., Frieden I., Gerard M., RA Kvarnung M., Hanson-Kahn A.K., Hudgins L., Leaute-Labreze C., McCuaig C., RA Metry D., Parent P., Paul C., Petit F., Phan A., Quere I., Salhi A., RA Turner A., Vabres P., Vicente A., Wargon O., Watanabe S., Weibel L., RA Wilson A., Willing M., Mulliken J.B., Boon L.M., Vikkula M.; RT "Germline loss-of-function mutations in EPHB4 cause a second form of RT capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RT RAS-MAPK signaling."; RL Circulation 136:1037-1048(2017). RN [21] RP VARIANT CMAVM2 GLY-802, AND INVOLVEMENT IN CMAVM2. RX PubMed=28730721; DOI=10.1111/pde.13208; RA Yu J., Streicher J.L., Medne L., Krantz I.D., Yan A.C.; RT "EPHB4 mutation implicated in capillary malformation-arteriovenous RT malformation syndrome: A case report."; RL Pediatr. Dermatol. 34:E227-E230(2017). RN [22] RP VARIANTS CMAVM2 ARG-107 AND GLU-870, AND INVOLVEMENT IN CMAVM2. RX PubMed=29444212; DOI=10.1093/brain/awy020; RA Vivanti A., Ozanne A., Grondin C., Saliou G., Quevarec L., Maurey H., RA Aubourg P., Benachi A., Gut M., Gut I., Martinovic J., Senat M.V., Tawk M., RA Melki J.; RT "Loss of function mutations in EPHB4 are responsible for vein of Galen RT aneurysmal malformation."; RL Brain 141:979-988(2018). RN [23] RP VARIANT GLY-509, CHARACTERIZATION OF VARIANT GLY-509, VARIANTS CMAVM2 RP ASN-650 AND LEU-867, CHARACTERIZATION OF VARIANTS CMAVM2 ASN-650 AND RP LEU-867, INVOLVEMENT IN CMAVM2, FUNCTION, AND INTERACTION WITH RASA1. RX PubMed=30578106; DOI=10.1016/j.neuron.2018.11.041; RA Duran D., Zeng X., Jin S.C., Choi J., Nelson-Williams C., Yatsula B., RA Gaillard J., Furey C.G., Lu Q., Timberlake A.T., Dong W., Sorscher M.A., RA Loring E., Klein J., Allocco A., Hunt A., Conine S., Karimy J.K., RA Youngblood M.W., Zhang J., DiLuna M.L., Matouk C.C., Mane S., RA Tikhonova I.R., Castaldi C., Lopez-Giraldez F., Knight J., Haider S., RA Soban M., Alper S.L., Komiyama M., Ducruet A.F., Zabramski J.M., Dardik A., RA Walcott B.P., Stapleton C.J., Aagaard-Kienitz B., Rodesch G., Jackson E., RA Smith E.R., Orbach D.B., Berenstein A., Bilguvar K., Vikkula M., Gunel M., RA Lifton R.P., Kahle K.T.; RT "Mutations in chromatin modifier and ephrin signaling genes in vein of RT Galen malformation."; RL Neuron 101:429-443(2019). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Together with its CC cognate ligand/functional ligand EFNB2 it is involved in the regulation CC of cell adhesion and migration, and plays a central role in heart CC morphogenesis, angiogenesis and blood vessel remodeling and CC permeability. EPHB4-mediated forward signaling controls cellular CC repulsion and segregation from EFNB2-expressing cells. CC {ECO:0000269|PubMed:12734395, ECO:0000269|PubMed:16424904, CC ECO:0000269|PubMed:27400125, ECO:0000269|PubMed:30578106}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with RASA1; the interaction depends on EPHB4 tyrosine- CC phosphorylation (PubMed:30578106). {ECO:0000250, CC ECO:0000269|PubMed:30578106}. CC -!- INTERACTION: CC P54760; P52799: EFNB2; NbExp=7; IntAct=EBI-702121, EBI-7532268; CC P54760; P54756: EPHA5; NbExp=2; IntAct=EBI-702121, EBI-1383718; CC P54760; Q9UF33: EPHA6; NbExp=2; IntAct=EBI-702121, EBI-3950019; CC P54760; Q15375: EPHA7; NbExp=3; IntAct=EBI-702121, EBI-1383428; CC P54760; P01588: EPO; NbExp=6; IntAct=EBI-702121, EBI-1027362; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28687708, CC ECO:0000269|PubMed:8188704}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:8188704}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P54760-1; Sequence=Displayed; CC Name=2; CC IsoId=P54760-2; Sequence=VSP_056024, VSP_056025; CC Name=3; CC IsoId=P54760-3; Sequence=VSP_056020, VSP_056021; CC Name=4; CC IsoId=P54760-4; Sequence=VSP_056022, VSP_056023; CC -!- TISSUE SPECIFICITY: Abundantly expressed in placenta but also detected CC in kidney, liver, lung, pancreas, skeletal muscle and heart. Expressed CC in primitive and myeloid, but not lymphoid, hematopoietic cells. Also CC observed in cell lines derived from liver, breast, colon, lung, CC melanocyte and cervix. {ECO:0000269|PubMed:8188704}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal heart, lung, liver and to a CC lower extent in brain. Not expressed in adult brain. CC {ECO:0000269|PubMed:8188704}. CC -!- PTM: Phosphorylated; autophosphorylation is stimulated by EFNB2. CC -!- DISEASE: Lymphatic malformation 7 (LMPHM7) [MIM:617300]: A form of CC primary lymphedema, a disease characterized by swelling of body parts CC due to developmental anomalies and functional defects of the lymphatic CC system. Patients with lymphedema may suffer from recurrent local CC infections. LMPHM7 is an autosomal dominant form with variable CC expressivity. Some individuals present with severe non-immune hydrops CC fetalis, which may cause perinatal demise or fully resolve after the CC neonatal period. Others present with no edema and have milder clinical CC features, such as atrial septal defect or varicose veins as adults. CC {ECO:0000269|PubMed:27400125}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Capillary malformation-arteriovenous malformation 2 (CMAVM2) CC [MIM:618196]: An autosomal dominant disorder characterized by multiple, CC round to oval or more irregularly shaped macules that are pinkish red CC in color and are randomly distributed across the body. These capillary CC malformations are associated with either arteriovenous malformation, CC arteriovenous fistula, or Parkes Weber syndrome. CC {ECO:0000269|PubMed:28687708, ECO:0000269|PubMed:28730721, CC ECO:0000269|PubMed:29444212, ECO:0000269|PubMed:30578106}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07695; AAA20598.1; -; mRNA. DR EMBL; AF312032; AAK21010.1; -; Genomic_DNA. DR EMBL; EU826608; ACF47644.1; -; mRNA. DR EMBL; EU826609; ACF47645.1; -; mRNA. DR EMBL; EU826610; ACF47646.1; -; mRNA. DR EMBL; BC004264; AAH04264.1; -; mRNA. DR EMBL; BC052804; AAH52804.1; -; mRNA. DR CCDS; CCDS5706.1; -. [P54760-1] DR PIR; A54092; A54092. DR RefSeq; NP_004435.3; NM_004444.4. [P54760-1] DR PDB; 2BBA; X-ray; 1.65 A; A=17-196. DR PDB; 2E7H; NMR; -; A=434-529. DR PDB; 2HLE; X-ray; 2.05 A; A=17-196. DR PDB; 2QKQ; X-ray; 2.10 A; A/B=896-977. DR PDB; 2VWU; X-ray; 2.00 A; A=598-899. DR PDB; 2VWV; X-ray; 1.90 A; A=598-899. DR PDB; 2VWW; X-ray; 1.90 A; A=598-899. DR PDB; 2VWX; X-ray; 1.65 A; A=598-899. DR PDB; 2VWY; X-ray; 1.65 A; A=598-899. DR PDB; 2VWZ; X-ray; 1.65 A; A=598-899. DR PDB; 2VX0; X-ray; 2.10 A; A=598-899. DR PDB; 2VX1; X-ray; 1.65 A; A=598-899. DR PDB; 2X9F; X-ray; 1.75 A; A=598-899. DR PDB; 2XVD; X-ray; 1.70 A; A=598-899. DR PDB; 2YN8; X-ray; 2.11 A; A/B=598-892. DR PDB; 3ZEW; X-ray; 2.50 A; A/B=598-892. DR PDB; 4AW5; X-ray; 2.33 A; A=605-890. DR PDB; 4BB4; X-ray; 1.65 A; A=598-899. DR PDB; 6FNI; X-ray; 1.47 A; A=598-892. DR PDB; 6FNJ; X-ray; 1.24 A; A/B=598-892. DR PDB; 6FNK; X-ray; 1.05 A; A=598-892. DR PDB; 6FNL; X-ray; 1.27 A; A=598-892. DR PDB; 6FNM; X-ray; 1.16 A; A=598-892. DR PDBsum; 2BBA; -. DR PDBsum; 2E7H; -. DR PDBsum; 2HLE; -. DR PDBsum; 2QKQ; -. DR PDBsum; 2VWU; -. DR PDBsum; 2VWV; -. DR PDBsum; 2VWW; -. DR PDBsum; 2VWX; -. DR PDBsum; 2VWY; -. DR PDBsum; 2VWZ; -. DR PDBsum; 2VX0; -. DR PDBsum; 2VX1; -. DR PDBsum; 2X9F; -. DR PDBsum; 2XVD; -. DR PDBsum; 2YN8; -. DR PDBsum; 3ZEW; -. DR PDBsum; 4AW5; -. DR PDBsum; 4BB4; -. DR PDBsum; 6FNI; -. DR PDBsum; 6FNJ; -. DR PDBsum; 6FNK; -. DR PDBsum; 6FNL; -. DR PDBsum; 6FNM; -. DR AlphaFoldDB; P54760; -. DR BMRB; P54760; -. DR SASBDB; P54760; -. DR SMR; P54760; -. DR BioGRID; 108364; 154. DR FunCoup; P54760; 1222. DR IntAct; P54760; 108. DR MINT; P54760; -. DR STRING; 9606.ENSP00000350896; -. DR BindingDB; P54760; -. DR ChEMBL; CHEMBL5147; -. DR DrugBank; DB07256; 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE. DR DrugBank; DB07252; 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07251; N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE. DR DrugBank; DB07250; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07253; N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine. DR DrugBank; DB07255; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07249; N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine. DR DrugBank; DB07254; N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE. DR DrugBank; DB11973; Tesevatinib. DR DrugCentral; P54760; -. DR GuidetoPHARMACOLOGY; 1833; -. DR TCDB; 8.A.23.1.15; the basigin (basigin) family. DR GlyConnect; 1214; 3 N-Linked glycans (1 site). DR GlyCosmos; P54760; 3 sites, 3 glycans. DR GlyGen; P54760; 4 sites, 10 N-linked glycans (3 sites). DR iPTMnet; P54760; -. DR PhosphoSitePlus; P54760; -. DR SwissPalm; P54760; -. DR BioMuta; EPHB4; -. DR DMDM; 19860819; -. DR CPTAC; CPTAC-2788; -. DR CPTAC; CPTAC-2841; -. DR CPTAC; CPTAC-2919; -. DR jPOST; P54760; -. DR MassIVE; P54760; -. DR PaxDb; 9606-ENSP00000350896; -. DR PeptideAtlas; P54760; -. DR ProteomicsDB; 56715; -. [P54760-1] DR Pumba; P54760; -. DR Antibodypedia; 4623; 752 antibodies from 43 providers. DR CPTC; P54760; 2 antibodies. DR DNASU; 2050; -. DR Ensembl; ENST00000358173.8; ENSP00000350896.3; ENSG00000196411.11. [P54760-1] DR Ensembl; ENST00000616502.4; ENSP00000482702.1; ENSG00000196411.11. [P54760-3] DR GeneID; 2050; -. DR KEGG; hsa:2050; -. DR MANE-Select; ENST00000358173.8; ENSP00000350896.3; NM_004444.5; NP_004435.3. DR UCSC; uc011kkg.2; human. [P54760-1] DR AGR; HGNC:3395; -. DR CIViC; 2050; 1 evidence item across 1 molecular profile. DR ClinPGx; PA27827; -. DR CTD; 2050; -. DR DisGeNET; 2050; -. DR GeneCards; EPHB4; -. DR GeneReviews; EPHB4; -. DR HGNC; HGNC:3395; EPHB4. DR HPA; ENSG00000196411; Low tissue specificity. DR MalaCards; EPHB4; -. DR MIM; 600011; gene. DR MIM; 617300; phenotype. DR MIM; 618196; phenotype. DR OpenTargets; ENSG00000196411; -. DR Orphanet; 693912; EPHB4-related capillary malformation-arteriovenous malformation. DR Orphanet; 568065; EPHB4-related lymphatic-related hydrops fetalis. DR Orphanet; 90186; Meige disease. DR Orphanet; 1053; Vein of Galen aneurysmal malformation. DR VEuPathDB; HostDB:ENSG00000196411; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160057; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P54760; -. DR OMA; STKCRAC; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54760; 9 GO annotations based on evolutionary models. DR PhylomeDB; P54760; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54760; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54760; -. DR SIGNOR; P54760; -. DR Agora; ENSG00000196411; -. DR BioGRID-ORCS; 2050; 13 hits in 1190 CRISPR screens. DR ChiTaRS; EPHB4; human. DR EvolutionaryTrace; P54760; -. DR GeneWiki; EPH_receptor_B4; -. DR GenomeRNAi; 2050; -. DR Pharos; P54760; Tchem. DR PRO; PR:P54760; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P54760; protein. DR Bgee; ENSG00000196411; Expressed in olfactory bulb and 209 other cell types or tissues. DR ExpressionAtlas; P54760; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IDA:UniProt. DR GO; GO:0007155; P:cell adhesion; IDA:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IDA:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB. DR CDD; cd10474; EphR_LBD_B4; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09554; SAM_EPH-B4; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000071; Ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.10:FF:000787; ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.1770:FF:000003; ephrin type-B receptor 4; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR037636; EPH-B4_SAM. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034290; EphB4_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF19; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; ATP-binding; KW Cell membrane; Developmental protein; Disease variant; Disulfide bond; KW Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Repeat; Signal; KW Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..15 FT /evidence="ECO:0000255" FT CHAIN 16..987 FT /note="Ephrin type-B receptor 4" FT /id="PRO_0000016834" FT TOPO_DOM 16..539 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 540..560 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 561..987 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 17..202 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 323..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 436..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 615..899 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 907..971 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 965..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 985..987 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT COMPBIAS 976..987 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 769 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 911 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 943 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 976 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 335 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..184 FT DISULFID 97..107 FT VAR_SEQ 270..306 FT /note="ACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRV -> GRRGSQQRAVP FT EDVRKPGRAAGAEAGSQLPGAGTGAL (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056020" FT VAR_SEQ 307..987 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056021" FT VAR_SEQ 406..414 FT /note="VTALNGVSS -> YLLQCLTSG (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056022" FT VAR_SEQ 415..987 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056023" FT VAR_SEQ 507..516 FT /note="VRARSEAGYG -> RARAGGSSWP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056024" FT VAR_SEQ 517..987 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056025" FT VARIANT 59 FT /note="E -> K (in CMAVM2; uncertain significance; FT dbSNP:rs1584667224)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081689" FT VARIANT 67 FT /note="P -> L (in dbSNP:rs34653459)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042181" FT VARIANT 74 FT /note="R -> P (in CMAVM2; uncertain significance; FT dbSNP:rs61735971)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081690" FT VARIANT 107 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1562974383)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081691" FT VARIANT 113 FT /note="V -> I (in dbSNP:rs55866373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042182" FT VARIANT 115 FT /note="Missing (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081692" FT VARIANT 130..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081693" FT VARIANT 161..162 FT /note="VK -> L (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081694" FT VARIANT 162 FT /note="K -> R (in dbSNP:rs17854760)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_071163" FT VARIANT 187 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584666053)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081695" FT VARIANT 244..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081696" FT VARIANT 268 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs201816920)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081697" FT VARIANT 346 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267601191)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042183" FT VARIANT 352..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081698" FT VARIANT 371 FT /note="A -> V (in dbSNP:rs55720981)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042184" FT VARIANT 375..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081699" FT VARIANT 431..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081700" FT VARIANT 469 FT /note="V -> G (in CMAVM2; uncertain significance; FT dbSNP:rs1584662591)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081701" FT VARIANT 509 FT /note="A -> G (does not affect tyrosine phosphorylation; FT does not affect interaction with RASA1; dbSNP:rs146937374)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081702" FT VARIANT 516 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs776305185)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081703" FT VARIANT 520..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081704" FT VARIANT 576 FT /note="D -> E (in dbSNP:rs36050247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042185" FT VARIANT 596..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081705" FT VARIANT 650 FT /note="K -> N (in CMAVM2; highly decreased tyrosine FT phosphorylation; highly decreased interaction with RASA1; FT dbSNP:rs1584658113)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081706" FT VARIANT 656 FT /note="R -> W (in CMAVM2; uncertain significance; FT dbSNP:rs745584371)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081707" FT VARIANT 664 FT /note="E -> K (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1562969219)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081708" FT VARIANT 678 FT /note="R -> H (in dbSNP:rs55692440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042186" FT VARIANT 725 FT /note="A -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1159930961)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081709" FT VARIANT 739..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081710" FT VARIANT 739 FT /note="R -> Q (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519263)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078063" FT VARIANT 745 FT /note="N -> D (in CMAVM2; dbSNP:rs1584654433)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081711" FT VARIANT 782 FT /note="I -> S (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519264)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078064" FT VARIANT 789 FT /note="P -> R (in CMAVM2; uncertain significance; FT dbSNP:rs753075600)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081712" FT VARIANT 789 FT /note="P -> S (in CMAVM2; uncertain significance; FT dbSNP:rs1417508111)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081713" FT VARIANT 802 FT /note="D -> G (in CMAVM2; dbSNP:rs776410552)" FT /evidence="ECO:0000269|PubMed:28730721" FT /id="VAR_081714" FT VARIANT 806..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081715" FT VARIANT 807 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1330628156)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081716" FT VARIANT 820 FT /note="P -> L (in CMAVM2; uncertain significance; FT dbSNP:rs1584653650)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081717" FT VARIANT 820 FT /note="P -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1584653653)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081718" FT VARIANT 838 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs764827256)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081719" FT VARIANT 845 FT /note="C -> R (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1584653054)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081720" FT VARIANT 856 FT /note="C -> Y (in CMAVM2; dbSNP:rs1584653005)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081721" FT VARIANT 864 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs769965440)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081722" FT VARIANT 867 FT /note="F -> L (in CMAVM2; loss of tyrosine phosphorylation; FT loss of interaction with RASA1; dbSNP:rs1584652949)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081723" FT VARIANT 870 FT /note="V -> E (in CMAVM2; uncertain significance; FT dbSNP:rs1584652920)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081724" FT VARIANT 874 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584652900)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081725" FT VARIANT 882 FT /note="A -> T (in dbSNP:rs34918225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042187" FT VARIANT 889 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs762016655)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042188" FT VARIANT 890 FT /note="E -> D (in dbSNP:rs35638378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042189" FT MUTAGEN 95 FT /note="L->R: Reduces binding affinity for EFNB2." FT /evidence="ECO:0000269|PubMed:16867992" FT CONFLICT 62 FT /note="D -> E (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="Y -> D (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 464 FT /note="V -> W (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 926..927 FT /note="ES -> AR (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT STRAND 17..22 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 23..25 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 33..36 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 43..48 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 70..74 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 84..95 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 109..121 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 135..142 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2HLE" FT TURN 151..153 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 154..156 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 160..166 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 171..182 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 184..196 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 449..453 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 460..462 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 466..473 FT /evidence="ECO:0007829|PDB:2E7H" FT TURN 479..481 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 482..496 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 503..510 FT /evidence="ECO:0007829|PDB:2E7H" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 615..623 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 625..634 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:6FNJ" FT STRAND 642..649 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 655..668 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 679..683 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 685..694 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 701..707 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 708..710 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 761..763 FT /evidence="ECO:0007829|PDB:6FNI" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:2VWX" FT HELIX 784..786 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 789..794 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 799..814 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 815..817 FT /evidence="ECO:0007829|PDB:6FNI" FT TURN 820..823 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 826..834 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 847..856 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 861..863 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 867..879 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 881..884 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 912..918 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 922..924 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 925..930 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 936..939 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 944..950 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 955..965 FT /evidence="ECO:0007829|PDB:2QKQ" SQ SEQUENCE 987 AA; 108270 MW; 11A004622F194706 CRC64; MELRVLLCWA SLAAALEETL LNTKLETADL KWVTFPQVDG QWEELSGLDE EQHSVRTYEV CDVQRAPGQA HWLRTGWVPR RGAVHVYATL RFTMLECLSL PRAGRSCKET FTVFYYESDA DTATALTPAW MENPYIKVDT VAAEHLTRKR PGAEATGKVN VKTLRLGPLS KAGFYLAFQD QGACMALLSL HLFYKKCAQL TVNLTRFPET VPRELVVPVA GSCVVDAVPA PGPSPSLYCR EDGQWAEQPV TGCSCAPGFE AAEGNTKCRA CAQGTFKPLS GEGSCQPCPA NSHSNTIGSA VCQCRVGYFR ARTDPRGAPC TTPPSAPRSV VSRLNGSSLH LEWSAPLESG GREDLTYALR CRECRPGGSC APCGGDLTFD PGPRDLVEPW VVVRGLRPDF TYTFEVTALN GVSSLATGPV PFEPVNVTTD REVPPAVSDI RVTRSSPSSL SLAWAVPRAP SGAVLDYEVK YHEKGAEGPS SVRFLKTSEN RAELRGLKRG ASYLVQVRAR SEAGYGPFGQ EHHSQTQLDE SEGWREQLAL IAGTAVVGVV LVLVVIVVAV LCLRKQSNGR EAEYSDKHGQ YLIGHGTKVY IDPFTYEDPN EAVREFAKEI DVSYVKIEEV IGAGEFGEVC RGRLKAPGKK ESCVAIKTLK GGYTERQRRE FLSEASIMGQ FEHPNIIRLE GVVTNSMPVM ILTEFMENGA LDSFLRLNDG QFTVIQLVGM LRGIASGMRY LAEMSYVHRD LAARNILVNS NLVCKVSDFG LSRFLEENSS DPTYTSSLGG KIPIRWTAPE AIAFRKFTSA SDAWSYGIVM WEVMSFGERP YWDMSNQDVI NAIEQDYRLP PPPDCPTSLH QLMLDCWQKD RNARPRFPQV VSALDKMIRN PASLKIVARE NGGASHPLLD QRQPHYSAFG SVGEWLRAIK MGRYEESFAA AGFGSFELVS QISAEDLLRI GVTLAGHQKK ILASVQHMKS QAKPGTPGGT GGPAPQY // ID GSDME_HUMAN Reviewed; 496 AA. AC O60443; A4D156; B2RAX9; B3KT05; O14590; Q08AQ8; Q9UBV3; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 2. DT 28-JAN-2026, entry version 177. DE RecName: Full=Gasdermin-E {ECO:0000303|PubMed:28459430}; DE AltName: Full=Inversely correlated with estrogen receptor expression 1 {ECO:0000303|PubMed:9523727}; DE Short=ICERE-1 {ECO:0000303|PubMed:9523727}; DE AltName: Full=Non-syndromic hearing impairment protein 5 {ECO:0000303|PubMed:9771715}; DE Contains: DE RecName: Full=Gasdermin-E, N-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-NT {ECO:0000303|PubMed:28459430}; DE Contains: DE RecName: Full=Gasdermin-E, C-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-CT {ECO:0000303|PubMed:28459430}; GN Name=GSDME {ECO:0000303|PubMed:28459430, ECO:0000312|HGNC:HGNC:2810}; GN Synonyms=DFNA5 {ECO:0000303|PubMed:9771715}, GN ICERE1 {ECO:0000303|PubMed:9523727}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INVOLVEMENT RP IN DFNA5. RC TISSUE=Cochlea; RX PubMed=9771715; DOI=10.1038/2503; RA Van Laer L., Huizing E.H., Verstreken M., van Zuijlen D., Wauters J.G., RA Bossuyt P.J., Van de Heyning P., McGuirt W.T., Smith R.J.H., Willems P.J., RA Legan P.K., Richardson G.P., Van Camp G.; RT "Nonsyndromic hearing impairment is associated with a mutation in DFNA5."; RL Nat. Genet. 20:194-197(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Van Laer L., Van Camp G.; RL Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Mei G., Yu W., Gibbs R.A.; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-142. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 5-496 (ISOFORM 1). RC TISSUE=Mammary gland; RX PubMed=9523727; DOI=10.1046/j.1432-1327.1998.2520169.x; RA Thompson D.A., Weigel R.J.; RT "Characterization of a gene that is inversely correlated with estrogen RT receptor expression (ICERE-1) in breast carcinomas."; RL Eur. J. Biochem. 252:169-177(1998). RN [10] RP SEQUENCE REVISION TO C-TERMINUS. RA Thompson D.A.; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [11] RP FUNCTION IN TP53-MEDIATED CELLULAR RESPONSE. RX PubMed=16897187; DOI=10.1007/s10038-006-0004-6; RA Masuda Y., Futamura M., Kamino H., Nakamura Y., Kitamura N., Ohnishi S., RA Miyamoto Y., Ichikawa H., Ohta T., Ohki M., Kiyono T., Egami H., Baba H., RA Arakawa H.; RT "The potential role of DFNA5, a hearing impairment gene, in p53-mediated RT cellular response to DNA damage."; RL J. Hum. Genet. 51:652-664(2006). RN [12] RP INVOLVEMENT IN CRC. RX PubMed=18223688; DOI=10.1038/sj.onc.1211021; RA Kim M.S., Chang X., Yamashita K., Nagpal J.K., Baek J.H., Wu G., Trink B., RA Ratovitski E.A., Mori M., Sidransky D.; RT "Aberrant promoter methylation and tumor suppressive activity of the DFNA5 RT gene in colorectal carcinoma."; RL Oncogene 27:3624-3634(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP FUNCTION. RX PubMed=21522185; DOI=10.1038/ejhg.2011.63; RA Op de Beeck K., Van Camp G., Thys S., Cools N., Callebaut I., Vrijens K., RA Van Nassauw L., Van Tendeloo V.F., Timmermans J.P., Van Laer L.; RT "The DFNA5 gene, responsible for hearing loss and involved in cancer, RT encodes a novel apoptosis-inducing protein."; RL Eur. J. Hum. Genet. 19:965-973(2011). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP INVOLVEMENT IN DFNA5. RX PubMed=19911014; DOI=10.1038/jhg.2009.114; RA Park H.J., Cho H.J., Baek J.I., Ben-Yosef T., Kwon T.J., Griffith A.J., RA Kim U.K.; RT "Evidence for a founder mutation causing DFNA5 hearing loss in East RT Asians."; RL J. Hum. Genet. 55:59-62(2010). RN [18] RP INVOLVEMENT IN DFNA5. RX PubMed=24506266; DOI=10.1111/ahg.12053; RA Nishio A., Noguchi Y., Sato T., Naruse T.K., Kimura A., Takagi A., RA Kitamura K.; RT "A DFNA5 mutation identified in Japanese families with autosomal dominant RT hereditary hearing loss."; RL Ann. Hum. Genet. 78:83-91(2014). RN [19] RP INVOLVEMENT IN DFNA5. RX PubMed=26236191; DOI=10.3389/fncel.2015.00231; RA Van Rossom S., Op de Beeck K., Hristovska V., Winderickx J., Van Camp G.; RT "The deafness gene DFNA5 induces programmed cell death through mitochondria RT and MAPK-related pathways."; RL Front. Cell. Neurosci. 9:231-231(2015). RN [20] RP FUNCTION, AND MUTAGENESIS OF ILE-313; PHE-388 AND ALA-392. RX PubMed=27281216; DOI=10.1038/nature18590; RA Ding J., Wang K., Liu W., She Y., Sun Q., Shi J., Sun H., Wang D.C., RA Shao F.; RT "Pore-forming activity and structural autoinhibition of the gasdermin RT family."; RL Nature 535:111-116(2016). RN [21] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF ASP-267 AND ASP-270. RX PubMed=28459430; DOI=10.1038/nature22393; RA Wang Y., Gao W., Shi X., Ding J., Liu W., He H., Wang K., Shao F.; RT "Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a RT gasdermin."; RL Nature 547:99-103(2017). RN [22] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF PHE-2; LYS-39; LYS-40; RP LYS-41 AND ASP-270. RX PubMed=28045099; DOI=10.1038/ncomms14128; RA Rogers C., Fernandes-Alnemri T., Mayes L., Alnemri D., Cingolani G., RA Alnemri E.S.; RT "Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to RT secondary necrotic/pyroptotic cell death."; RL Nat. Commun. 8:14128-14128(2017). RN [23] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY GZMB, RP DOMAIN, MUTAGENESIS OF PHE-2 AND ASP-270, VARIANTS TYR-14; VAL-18; ASP-24; RP CYS-44; ILE-48; THR-137; GLU-199; LEU-212 AND ASN-217, AND CHARACTERIZATION RP OF VARIANTS TYR-14; VAL-18; ASP-24; CYS-44; ILE-48; THR-137; GLU-199; RP LEU-212 AND ASN-217. RX PubMed=32188940; DOI=10.1038/s41586-020-2071-9; RA Zhang Z., Zhang Y., Xia S., Kong Q., Li S., Liu X., Junqueira C., RA Meza-Sosa K.F., Mok T.M.Y., Ansara J., Sengupta S., Yao Y., Wu H., RA Lieberman J.; RT "Gasdermin E suppresses tumour growth by activating anti-tumour immunity."; RL Nature 579:415-420(2020). RN [24] RP SUCCINATION AT CYS-45; CYS-156; CYS-168; CYS-180; CYS-235; CYS-371; RP CYS-417; CYS-408 AND CYS-489. RX PubMed=32820063; DOI=10.1126/science.abb9818; RA Humphries F., Shmuel-Galia L., Ketelut-Carneiro N., Li S., Wang B., RA Nemmara V.V., Wilson R., Jiang Z., Khalighinejad F., Muneeruddin K., RA Shaffer S.A., Dutta R., Ionete C., Pesiridis S., Yang S., Thompson P.R., RA Fitzgerald K.A.; RT "Succination inactivates gasdermin D and blocks pyroptosis."; RL Science 369:1633-1637(2020). RN [25] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, AND CLEAVAGE BY RP GZMB. RX PubMed=31953257; DOI=10.1126/sciimmunol.aax7969; RA Liu Y., Fang Y., Chen X., Wang Z., Liang X., Zhang T., Liu M., Zhou N., RA Lv J., Tang K., Xie J., Gao Y., Cheng F., Zhou Y., Zhang Z., Hu Y., RA Zhang X., Gao Q., Zhang Y., Huang B.; RT "Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers RT cytokine release syndrome."; RL Sci. Immunol. 5:0-0(2020). RN [26] RP FUNCTION, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-270. RX PubMed=33852854; DOI=10.1016/j.celrep.2021.108998; RA Zhou B., Abbott D.W.; RT "Gasdermin E permits interleukin-1 beta release in distinct sublytic and RT pyroptotic phases."; RL Cell Rep. 35:108998-108998(2021). RN [27] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=35972780; DOI=10.7554/elife.73792; RA Zhao Z., Li Q., Ashraf U., Yang M., Zhu W., Gu J., Chen Z., Gu C., Si Y., RA Cao S., Ye J.; RT "Zika virus causes placental pyroptosis and associated adverse fetal RT outcomes by activating GSDME."; RL Elife 11:0-0(2022). RN [28] RP FUNCTION, ACTIVITY REGULATION, AND ACTIVITY REGULATION (MICROBIAL RP INFECTION). RX PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033; RG COVID Human Genetic Effort; RA Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K., RA Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R., RA Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y., RA Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O., RA Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S., RA Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.; RT "Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung RT epithelial cells."; RL Mol. Cell 82:2385-2400(2022). RN [29] RP FUNCTION, AND UBIQUITINATION AT LYS-120 AND LYS-189. RX PubMed=36607699; DOI=10.1158/0008-5472.can-22-1812; RA Ren Y., Feng M., Hao X., Liu X., Li J., Li P., Gao J., Qi Q., Du L., RA Wang C., Wang Q., Wang Y.; RT "USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer."; RL Cancer Res. 83:1074-1093(2023). RN [30] RP PALMITOYLATION. RX PubMed=38599239; DOI=10.1038/s41586-024-07373-5; RA Du G., Healy L.B., David L., Walker C., El-Baba T.J., Lutomski C.A., RA Goh B., Gu B., Pi X., Devant P., Fontana P., Dong Y., Ma X., Miao R., RA Balasubramanian A., Puthenveetil R., Banerjee A., Luo H.R., Kagan J.C., RA Oh S.F., Robinson C.V., Lieberman J., Wu H.; RT "ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D."; RL Nature 0:0-0(2024). CC -!- FUNCTION: [Gasdermin-E]: Precursor of a pore-forming protein that CC converts non-inflammatory apoptosis to pyroptosis (PubMed:27281216, CC PubMed:28459430, PubMed:33852854, PubMed:35594856, PubMed:36607699). CC This form constitutes the precursor of the pore-forming protein: upon CC cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) CC binds to membranes and forms pores, triggering pyroptosis CC (PubMed:28459430). {ECO:0000269|PubMed:27281216, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856, ECO:0000269|PubMed:36607699}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: Pore-forming protein produced by CC cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory CC apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, CC respectively (PubMed:27281216, PubMed:28459430, PubMed:32188940, CC PubMed:33852854, PubMed:35594856). After cleavage, moves to the plasma CC membrane, homooligomerizes within the membrane and forms pores of 10-15 CC nanometers (nm) of inner diameter, allowing the release of mature CC interleukins (IL1B and IL16) and triggering pyroptosis CC (PubMed:28459430, PubMed:32188940, PubMed:33852854, PubMed:35594856). CC Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, CC such as phosphatidylinositol (4,5)-bisphosphate (PubMed:28459430). CC Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or CC danger signals, such as chemotherapy drugs, to pyroptosis CC (PubMed:27281216, PubMed:28459430, PubMed:32188940). Mediates secondary CC necrosis downstream of the mitochondrial apoptotic pathway and CASP3 CC activation as well as in response to viral agents (PubMed:28045099). CC Exhibits bactericidal activity (PubMed:27281216). Cleavage by GZMB CC promotes tumor suppressor activity by triggering robust anti-tumor CC immunity (PubMed:21522185, PubMed:32188940). Suppresses tumors by CC mediating granzyme-mediated pyroptosis in target cells of natural CC killer (NK) cells: cleavage by granzyme B (GZMB), delivered to target CC cells from NK-cells, triggers pyroptosis of tumor cells and tumor CC suppression (PubMed:31953257, PubMed:32188940). May play a role in the CC p53/TP53-regulated cellular response to DNA damage (PubMed:16897187). CC {ECO:0000269|PubMed:16897187, ECO:0000269|PubMed:21522185, CC ECO:0000269|PubMed:27281216, ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: (Microbial infection) Pore-forming CC protein, which promotes maternal placental pyroptosis in response to CC Zika virus infection, contributing to adverse fetal outcomes. CC {ECO:0000269|PubMed:35972780}. CC -!- ACTIVITY REGULATION: [Gasdermin-E]: The full-length protein before CC cleavage is inactive: intramolecular interactions between N- and C- CC terminal domains mediate autoinhibition in the absence of activation CC signal (PubMed:28045099, PubMed:28459430). The intrinsic pyroptosis- CC inducing activity is carried by the released N-terminal moiety CC (Gasdermin-E, N-terminal) following cleavage by CASP3 or granzyme B CC (GZMB) (PubMed:28459430, PubMed:31953257, PubMed:32188940, CC PubMed:35594856). Activated by NLRP1 in the absence of GSDMD CC expression: NLRP1 cleaves and activates CASP8, promoting downstream CC activation of CASP3 and subsequent activation of GSDME CC (PubMed:33852854, PubMed:35594856). {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- ACTIVITY REGULATION: (Microbial infection) Activated upon human CC coronavirus SARS-CoV-2 infection, leading to lung epithelial cell death CC (PubMed:35594856). Activation takes place in response to (1) activation CC of NLRP1 and (2) inactivation of GSDMD following NLRP1 and GSDMD CC cleavage by the SARS-CoV-2 3C-like proteinase nsp5 (PubMed:35594856). CC {ECO:0000269|PubMed:35594856}. CC -!- SUBUNIT: [Gasdermin-E, N-terminal]: Homooligomer; homooligomeric ring- CC shaped pore complex containing 27-28 subunits when inserted in the CC membrane. {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- INTERACTION: CC O60443; Q96CG3: TIFA; NbExp=3; IntAct=EBI-719315, EBI-740711; CC -!- SUBCELLULAR LOCATION: [Gasdermin-E, N-terminal]: Cell membrane CC {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430}; Multi-pass CC membrane protein {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- SUBCELLULAR LOCATION: [Gasdermin-E]: Cytoplasm, cytosol CC {ECO:0000269|PubMed:28045099}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O60443-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O60443-2; Sequence=VSP_004190; CC Name=3; CC IsoId=O60443-3; Sequence=VSP_044276; CC -!- TISSUE SPECIFICITY: Expressed in cochlea (PubMed:9771715). Low level of CC expression in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas, with highest expression in placenta CC (PubMed:9771715). {ECO:0000269|PubMed:9771715}. CC -!- DOMAIN: Intramolecular interactions between N- and C-terminal domains CC may be important for autoinhibition in the absence of activation CC signal. The intrinsic pyroptosis-inducing activity is carried by the N- CC terminal domain, that is released upon cleavage by CASP3 or granzyme B CC (GZMB). {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: Cleavage at Asp-270 by CASP3 (mature and uncleaved precursor CC forms) or granzyme B (GZMB) relieves autoinhibition and is sufficient CC to initiate pyroptosis. {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: [Gasdermin-E]: Succination by the Krebs cycle intermediate CC fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits CC processing by caspases, and ability to initiate pyroptosis CC (PubMed:32820063). Succination modification is catalyzed by a non- CC enzymatic reaction caused by an accumulation of fumarate CC (PubMed:32820063). {ECO:0000269|PubMed:32820063}. CC -!- PTM: [Gasdermin-E]: Ubiquitinated at Lys-120 and Lys-189 via 'Lys-48'- CC linked polyubiquitin chains, leading to proteasomal degradation. CC Deubiquitinated by USP48, leading to increased stability. CC {ECO:0000269|PubMed:36607699}. CC -!- PTM: Palmitoylated. {ECO:0000269|PubMed:38599239}. CC -!- DISEASE: Deafness, autosomal dominant, 5 (DFNA5) [MIM:600994]: A form CC of non-syndromic sensorineural hearing loss. Sensorineural deafness CC results from damage to the neural receptors of the inner ear, the nerve CC pathways to the brain, or the area of the brain that receives sound CC information. {ECO:0000269|PubMed:19911014, ECO:0000269|PubMed:24506266, CC ECO:0000269|PubMed:26236191, ECO:0000269|PubMed:9771715}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Is a tumor suppressor gene with an important role in CC colorectal cancer (CRC). {ECO:0000303|PubMed:18223688}. CC -!- SIMILARITY: Belongs to the gasdermin family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB83938.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=AAC39635.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF073308; AAC69324.1; -; mRNA. DR EMBL; AF075171; AAC69326.1; -; mRNA. DR EMBL; AF131765; AAD20039.1; -; mRNA. DR EMBL; AK094714; BAG52917.1; -; mRNA. DR EMBL; AK314402; BAG37026.1; -; mRNA. DR EMBL; AC003093; AAB83938.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH236948; EAL24246.1; -; Genomic_DNA. DR EMBL; CH471073; EAW93813.1; -; Genomic_DNA. DR EMBL; BC125065; AAI25066.1; -; mRNA. DR EMBL; AF007790; AAC39635.2; ALT_INIT; mRNA. DR CCDS; CCDS47563.1; -. [O60443-3] DR CCDS; CCDS5389.1; -. [O60443-1] DR RefSeq; NP_001120925.1; NM_001127453.2. [O60443-1] DR RefSeq; NP_001120926.1; NM_001127454.2. [O60443-3] DR RefSeq; NP_001424988.1; NM_001438059.1. [O60443-3] DR RefSeq; NP_004394.1; NM_004403.3. [O60443-1] DR RefSeq; XP_024302438.1; XM_024446670.2. [O60443-1] DR RefSeq; XP_054213373.1; XM_054357398.1. [O60443-1] DR AlphaFoldDB; O60443; -. DR BioGRID; 108049; 65. DR FunCoup; O60443; 518. DR IntAct; O60443; 158. DR MINT; O60443; -. DR STRING; 9606.ENSP00000339587; -. DR TCDB; 1.C.123.1.5; the pore-forming gasdermin (gasdermin) family. DR GlyGen; O60443; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O60443; -. DR PhosphoSitePlus; O60443; -. DR SwissPalm; O60443; -. DR BioMuta; GSDME; -. DR jPOST; O60443; -. DR MassIVE; O60443; -. DR PaxDb; 9606-ENSP00000339587; -. DR PeptideAtlas; O60443; -. DR ProteomicsDB; 3659; -. DR ProteomicsDB; 49403; -. [O60443-1] DR ProteomicsDB; 49404; -. [O60443-2] DR Antibodypedia; 1157; 225 antibodies from 32 providers. DR DNASU; 1687; -. DR Ensembl; ENST00000342947.9; ENSP00000339587.3; ENSG00000105928.17. [O60443-1] DR Ensembl; ENST00000409970.6; ENSP00000387119.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000419307.6; ENSP00000401332.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000645220.1; ENSP00000494186.1; ENSG00000105928.17. [O60443-1] DR GeneID; 1687; -. DR KEGG; hsa:1687; -. DR MANE-Select; ENST00000645220.1; ENSP00000494186.1; NM_001127453.2; NP_001120925.1. DR UCSC; uc003sxa.2; human. [O60443-1] DR AGR; HGNC:2810; -. DR ClinPGx; PA27281; -. DR CTD; 1687; -. DR DisGeNET; 1687; -. DR GeneCards; GSDME; -. DR GeneReviews; GSDME; -. DR HGNC; HGNC:2810; GSDME. DR HPA; ENSG00000105928; Low tissue specificity. DR MalaCards; GSDME; -. DR MIM; 600994; phenotype. DR MIM; 608798; gene. DR OpenTargets; ENSG00000105928; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000105928; -. DR eggNOG; ENOG502QRAB; Eukaryota. DR GeneTree; ENSGT00940000155880; -. DR HOGENOM; CLU_042999_0_0_1; -. DR InParanoid; O60443; -. DR OMA; EMTNDCL; -. DR OrthoDB; 8815334at2759; -. DR PAN-GO; O60443; 2 GO annotations based on evolutionary models. DR PhylomeDB; O60443; -. DR PathwayCommons; O60443; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand. DR Reactome; R-HSA-9710421; Defective pyroptosis. DR SignaLink; O60443; -. DR Agora; ENSG00000105928; -. DR BioGRID-ORCS; 1687; 9 hits in 1147 CRISPR screens. DR ChiTaRS; DFNA5; human. DR GeneWiki; DFNA5; -. DR GenomeRNAi; 1687; -. DR Pharos; O60443; Tbio. DR PRO; PR:O60443; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; O60443; protein. DR Bgee; ENSG00000105928; Expressed in germinal epithelium of ovary and 190 other cell types or tissues. DR ExpressionAtlas; O60443; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:1901612; F:cardiolipin binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0022829; F:wide pore channel activity; IDA:UniProt. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0042491; P:inner ear auditory receptor cell differentiation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0002839; P:positive regulation of immune response to tumor cell; IDA:UniProt. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0012501; P:programmed cell death; IMP:UniProtKB. DR GO; GO:0141201; P:pyroptotic cell death; IDA:UniProt. DR GO; GO:0070269; P:pyroptotic inflammatory response; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; TAS:ProtInc. DR InterPro; IPR040460; Gasdermin_pore. DR InterPro; IPR041263; Gasdermin_PUB. DR InterPro; IPR042377; GSDME. DR PANTHER; PTHR15207:SF1; GASDERMIN-E; 1. DR PANTHER; PTHR15207; NONSYNDROMIC HEARING IMPAIRMENT PROTEIN; 1. DR Pfam; PF04598; Gasdermin; 1. DR Pfam; PF17708; Gasdermin_C; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cytoplasm; Deafness; Isopeptide bond; KW Lipoprotein; Membrane; Necrosis; Non-syndromic deafness; Palmitate; KW Proteomics identification; Reference proteome; Transmembrane; KW Transmembrane beta strand; Tumor suppressor; Ubl conjugation. FT CHAIN 1..496 FT /note="Gasdermin-E" FT /id="PRO_0000148178" FT CHAIN 1..270 FT /note="Gasdermin-E, N-terminal" FT /evidence="ECO:0000269|PubMed:27281216, FT ECO:0000305|PubMed:28459430, ECO:0000305|PubMed:32188940" FT /id="PRO_0000442786" FT CHAIN 271..496 FT /note="Gasdermin-E, C-terminal" FT /evidence="ECO:0000305|PubMed:28459430" FT /id="PRO_0000442787" FT REGION 1..56 FT /note="Membrane targeting domain" FT /evidence="ECO:0000269|PubMed:28045099" FT SITE 270..271 FT /note="Cleavage; by CASP3 or granzyme B" FT /evidence="ECO:0000269|PubMed:28459430, FT ECO:0000269|PubMed:32188940" FT MOD_RES 45 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 156 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 168 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 180 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 235 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 371 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 408 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 417 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 489 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT CROSSLNK 120 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT CROSSLNK 189 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT VAR_SEQ 1..395 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2, ECO:0000303|Ref.3" FT /id="VSP_004190" FT VAR_SEQ 1..164 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044276" FT VARIANT 14 FT /note="D -> Y (in a breast carcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083903" FT VARIANT 18 FT /note="D -> V (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083904" FT VARIANT 24 FT /note="N -> D (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083905" FT VARIANT 44 FT /note="W -> C (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083906" FT VARIANT 48 FT /note="R -> I (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083907" FT VARIANT 137 FT /note="I -> T (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083908" FT VARIANT 142 FT /note="P -> T (in dbSNP:rs754554)" FT /evidence="ECO:0000269|PubMed:12690205" FT /id="VAR_030824" FT VARIANT 174 FT /note="M -> T (in dbSNP:rs876306)" FT /id="VAR_053102" FT VARIANT 199 FT /note="G -> E (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083909" FT VARIANT 207 FT /note="V -> M (in dbSNP:rs12540919)" FT /id="VAR_030825" FT VARIANT 212 FT /note="P -> L (in a melanoma sample; somatic mutation; FT reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083910" FT VARIANT 217 FT /note="I -> N (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083911" FT MUTAGEN 2 FT /note="F->A: No effect on plasma membrane targeting. FT Decreases induction of necrotic activity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-40." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:32188940" FT MUTAGEN 39 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-40 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 40 FT /note="K->A: No effect on plasma membrane targeting. No FT effect on induction of cytotoxivity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-2 or A-39 and A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 41 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-39 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 267 FT /note="D->A: Abolishes cleavage by CASP3. Abolishes FT pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28459430" FT MUTAGEN 270 FT /note="D->A,E: Abolishes cleavage by CASP3 or granzyme B. FT Abolishes pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:32188940, FT ECO:0000269|PubMed:33852854" FT MUTAGEN 313 FT /note="I->D: No spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 388 FT /note="F->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 392 FT /note="A->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" SQ SEQUENCE 496 AA; 54555 MW; A407C9AC31AA716B CRC64; MFAKATRNFL REVDADGDLI AVSNLNDSDK LQLLSLVTKK KRFWCWQRPK YQFLSLTLGD VLIEDQFPSP VVVESDFVKY EGKFANHVSG TLETALGKVK LNLGGSSRVE SQSSFGTLRK QEVDLQQLIR DSAERTINLR NPVLQQVLEG RNEVLCVLTQ KITTMQKCVI SEHMQVEEKC GGIVGIQTKT VQVSATEDGN VTKDSNVVLE IPAATTIAYG VIELYVKLDG QFEFCLLRGK QGGFENKKRI DSVYLDPLVF REFAFIDMPD AAHGISSQDG PLSVLKQATL LLERNFHPFA ELPEPQQTAL SDIFQAVLFD DELLMVLEPV CDDLVSGLSP TVAVLGELKP RQQQDLVAFL QLVGCSLQGG CPGPEDAGSK QLFMTAYFLV SALAEMPDSA AALLGTCCKL QIIPTLCHLL RALSDDGVSD LEDPTLTPLK DTERFGIVQR LFASADISLE RLKSSVKAVI LKDSKVFPLL LCITLNGLCA LGREHS // ID ITA2B_HUMAN Reviewed; 1039 AA. AC P08514; B2RCY8; O95366; Q14443; Q17R67; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 3. DT 28-JAN-2026, entry version 272. DE RecName: Full=Integrin alpha-IIb {ECO:0000305}; DE AltName: Full=GPalpha IIb; DE Short=GPIIb {ECO:0000303|PubMed:2345548}; DE AltName: Full=Platelet membrane glycoprotein IIb; DE AltName: CD_antigen=CD41; DE Contains: DE RecName: Full=Integrin alpha-IIb heavy chain; DE Contains: DE RecName: Full=Integrin alpha-IIb light chain, form 1; DE Contains: DE RecName: Full=Integrin alpha-IIb light chain, form 2; DE Flags: Precursor; GN Name=ITGA2B {ECO:0000312|HGNC:HGNC:6138}; Synonyms=GP2B, ITGAB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-313. RX PubMed=2439501; DOI=10.1016/s0021-9258(18)47438-8; RA Poncz M., Eisman R., Heidenreich R., Silver S.M., Vilaire G., Surrey S., RA Schwartz E., Bennett J.S.; RT "Structure of the platelet membrane glycoprotein IIb. Homology to the alpha RT subunits of the vitronectin and fibronectin membrane receptors."; RL J. Biol. Chem. 262:8476-8482(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-313. RX PubMed=2345548; DOI=10.1007/bf00422712; RA Frachet P., Uzan G., Thevenon D., Denarier E., Prandini M.H., Marguerie G.; RT "GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte RT cDNAs."; RL Mol. Biol. Rep. 14:27-33(1990). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=2322558; DOI=10.1021/bi00457a020; RA Heidenreich R., Eisman R., Surrey S., Delgrosso K., Bennett J.S., RA Schwartz E., Poncz M.; RT "Organization of the gene for platelet glycoprotein IIb."; RL Biochemistry 29:1232-1244(1990). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-62 AND 1021-1039. RX PubMed=2845986; DOI=10.1016/s0006-291x(88)80884-2; RA Prandini M.H., Denarier E., Frachet P., Uzan G., Marguerie G.; RT "Isolation of the human platelet glycoprotein IIb gene and characterization RT of the 5' flanking region."; RL Biochem. Biophys. Res. Commun. 156:595-601(1988). RN [8] RP PROTEIN SEQUENCE OF 32-56 AND 903-917. RX PubMed=3534886; DOI=10.1073/pnas.83.21.8351; RA Charo I.F., Fitzgerald L.A., Steiner B., Rall S.C., Bekeart L.S., RA Phillips D.R.; RT "Platelet glycoproteins IIb and IIIa: evidence for a family of RT immunologically and structurally related glycoproteins in mammalian RT cells."; RL Proc. Natl. Acad. Sci. U.S.A. 83:8351-8355(1986). RN [9] RP PROTEIN SEQUENCE OF 32-42. RX PubMed=1953640; DOI=10.1042/bj2790419; RA Catimel B., Parmentier S., Leung L.L., McGregor J.L.; RT "Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, RT GPIIa and GMP-140) by F.P.L.C. Characterization by monoclonal antibodies RT and gas-phase sequencing."; RL Biochem. J. 279:419-425(1991). RN [10] RP PROTEIN SEQUENCE OF 32 AND 872. RX PubMed=8620874; DOI=10.1111/j.1432-1033.1996.0205n.x; RA Makogonenko E.M., Yakubenko V.P., Ingham K.C., Medved L.V.; RT "Thermal stability of individual domains in platelet glycoprotein RT IIbIIIa."; RL Eur. J. Biochem. 237:205-211(1996). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 392-1039 (ISOFORM 1). RX PubMed=3422188; DOI=10.1111/j.1432-1033.1988.tb13762.x; RA Uzan G., Frachet P., Lajmanovich A., Prandini M.-H., Denarier E., RA Duperray A., Loftus J., Ginsberg M., Plow E., Marguerie G.; RT "cDNA clones for human platelet GPIIb corresponding to mRNA from RT megakaryocytes and HEL cells. Evidence for an extensive homology to other RT Arg-Gly-Asp adhesion receptors."; RL Eur. J. Biochem. 171:87-93(1988). RN [12] RP PROTEIN SEQUENCE OF 487-501 AND 1026-1038. RX PubMed=3801670; RA Hiraiwa A., Matsukage A., Shiku H., Takahashi T., Naito K., Yamada K.; RT "Purification and partial amino acid sequence of human platelet membrane RT glycoproteins IIb and IIIa."; RL Blood 69:560-564(1987). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 753-1039 (ISOFORM 3), AND TISSUE SPECIFICITY. RX PubMed=9809974; RA Trikha M., Cai Y., Grignon D., Honn K.V.; RT "Identification of a novel truncated alphaIIb integrin."; RL Cancer Res. 58:4771-4775(1998). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 868-1039 (ISOFORM 1). RX PubMed=3479442; DOI=10.1172/jci113277; RA Bray P.F., Rosa J.P., Johnston G.I., Shiu D.T., Cook R.G., Lau C., RA Kan Y.W., McEver R.P., Shuman M.A.; RT "Platelet glycoprotein IIb. Chromosomal localization and tissue RT expression."; RL J. Clin. Invest. 80:1812-1817(1987). RN [15] RP PROTEIN SEQUENCE OF 903-922 AND 934-939. RX PubMed=2476117; DOI=10.1042/bj2610551; RA Calvete J.J., Alvarez M.V., Rivas G., Hew C.L., Henschen A., RA Gonzalez-Rodriguez J.; RT "Interchain and intrachain disulphide bonds in human platelet glycoprotein RT IIb. Localization of the epitopes for several monoclonal antibodies."; RL Biochem. J. 261:551-560(1989). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 938-997 (ISOFORMS 1 AND 2), AND TISSUE RP SPECIFICITY. RC TISSUE=Erythroleukemia; RX PubMed=2351656; DOI=10.1016/s0021-9258(19)38705-8; RA Bray P.F., Leung C.S.-I., Shuman M.A.; RT "Human platelets and megakaryocytes contain alternately spliced RT glycoprotein IIb mRNAs."; RL J. Biol. Chem. 265:9587-9590(1990). RN [17] RP PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-46; RP ASN-280; ASN-601 AND ASN-711. RX PubMed=2775232; DOI=10.1042/bj2610561; RA Calvete J.J., Henschen A., Gonzalez-Rodriguez J.; RT "Complete localization of the intrachain disulphide bonds and the N- RT glycosylation points in the alpha-subunit of human platelet glycoprotein RT IIb."; RL Biochem. J. 261:561-568(1989). RN [18] RP PARTIAL PROTEIN SEQUENCE, AND GLYCOSYLATION AT SER-878. RX PubMed=7688323; DOI=10.1016/0014-5793(93)80959-x; RA Calvete J.J., Muniz-Diaz E.; RT "Localization of an O-glycosylation site in the alpha-subunit of the human RT platelet integrin GPIIb/IIIa involved in Baka (HPA-3a) alloantigen RT expression."; RL FEBS Lett. 328:30-34(1993). RN [19] RP PROTEOLYTIC CLEAVAGE, AND PYROGLUTAMATE FORMATION AT GLN-891. RX PubMed=2226834; DOI=10.1016/0014-5793(90)80443-m; RA Calvete J.J., Schafer W., Henschen A., Gonzalez-Rodriguez J.; RT "Characterization of the beta-chain N-terminus heterogeneity and the alpha- RT chain C-terminus of human platelet GPIIb. Posttranslational cleavage RT sites."; RL FEBS Lett. 272:37-40(1990). RN [20] RP INTERACTION WITH CIB1. RC TISSUE=Fetal liver; RX PubMed=9030514; DOI=10.1074/jbc.272.8.4651; RA Naik U.P., Patel P.M., Parise L.V.; RT "Identification of a novel calcium-binding protein that interacts with the RT integrin alphaIIb cytoplasmic domain."; RL J. Biol. Chem. 272:4651-4654(1997). RN [21] RP FUNCTION, AND PROTEOLYTIC CLEAVAGE BY ELANE. RX PubMed=9111081; DOI=10.1074/jbc.272.17.11636; RA Si-Tahar M., Pidard D., Balloy V., Moniatte M., Kieffer N., RA Van Dorsselaer A., Chignard M.; RT "Human neutrophil elastase proteolytically activates the platelet integrin RT alphaIIbbeta3 through cleavage of the carboxyl terminus of the alphaIIb RT subunit heavy chain. Involvement in the potentiation of platelet RT aggregation."; RL J. Biol. Chem. 272:11636-11647(1997). RN [22] RP INTERACTION WITH CIB1. RX PubMed=10477286; DOI=10.1042/bj3420729; RA Shock D.D., Naik U.P., Brittain J.E., Alahari S.K., Sondek J., Parise L.V.; RT "Calcium-dependent properties of CIB binding to the integrin alphaIIb RT cytoplasmic domain and translocation to the platelet cytoskeleton."; RL Biochem. J. 342:729-735(1999). RN [23] RP MUTAGENESIS OF 1029-PRO-PRO-1030. RX PubMed=10212286; DOI=10.1074/jbc.274.18.12945; RA Leisner T.M., Wencel-Drake J.D., Wang W., Lam S.C.; RT "Bidirectional transmembrane modulation of integrin alphaIIbbeta3 RT conformations."; RL J. Biol. Chem. 274:12945-12949(1999). RN [24] RP FUNCTION. RX PubMed=12477717; DOI=10.1074/jbc.m211282200; RA Hermand P., Gane P., Huet M., Jallu V., Kaplan C., Sonneborn H.H., RA Cartron J.P., Bailly P.; RT "Red cell ICAM-4 is a novel ligand for platelet-activated alpha IIbbeta 3 RT integrin."; RL J. Biol. Chem. 278:4892-4898(2003). RN [25] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-601. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [26] RP INTERACTION WITH RNF181. RX PubMed=18331836; DOI=10.1016/j.bbrc.2008.02.142; RA Brophy T.M., Raab M., Daxecker H., Culligan K.G., Lehmann I., Chubb A.J., RA Treumann A., Moran N.; RT "RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif RT of platelet integrin alpha(IIb)beta3."; RL Biochem. Biophys. Res. Commun. 369:1088-1093(2008). RN [27] RP INTERACTION WITH CIB1. RX PubMed=21388953; DOI=10.1074/jbc.m110.179028; RA Huang H., Ishida H., Yamniuk A.P., Vogel H.J.; RT "Solution structures of Ca2+-CIB1 and Mg2+-CIB1 and their interactions with RT the platelet integrin alphaIIb cytoplasmic domain."; RL J. Biol. Chem. 286:17181-17192(2011). RN [28] RP INTERACTION WITH CIB1; CIB2; CIB3 AND CIB4. RX PubMed=22779914; DOI=10.1139/o2012-021; RA Huang H., Bogstie J.N., Vogel H.J.; RT "Biophysical and structural studies of the human calcium- and integrin- RT binding protein family: understanding their functional similarities and RT differences."; RL Biochem. Cell Biol. 90:646-656(2012). RN [29] RP INTERACTION WITH CIB1. RX PubMed=22283712; DOI=10.1021/ja2111306; RA Huang H., Vogel H.J.; RT "Structural basis for the activation of platelet integrin alphaIIbbeta3 by RT calcium- and integrin-binding protein 1."; RL J. Am. Chem. Soc. 134:3864-3872(2012). RN [30] RP INTERACTION WITH SELP. RX PubMed=37184585; DOI=10.26508/lsa.202201747; RA Takada Y.K., Simon S.I., Takada Y.; RT "The C-type lectin domain of CD62P (P-selectin) functions as an integrin RT ligand."; RL Life. Sci Alliance 6:0-0(2023). RN [31] {ECO:0007744|PDB:1TYE} RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 32-483 IN COMPLEX WITH ITGB3 AND RP CALCIUM, GLYCOSYLATION AT ASN-46, AND DISULFIDE BONDS. RX PubMed=15378069; DOI=10.1038/nature02976; RA Xiao T., Takagi J., Coller B.S., Wang J.H., Springer T.A.; RT "Structural basis for allostery in integrins and binding to fibrinogen- RT mimetic therapeutics."; RL Nature 432:59-67(2004). RN [32] {ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU} RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 32-989 IN COMPLEX WITH ITGB3 AND RP CALCIUM, GLYCOSYLATION AT ASN-46; ASN-280 AND ASN-601, AND DISULFIDE BONDS. RX PubMed=19111664; DOI=10.1016/j.molcel.2008.11.018; RA Zhu J., Luo B.H., Xiao T., Zhang C., Nishida N., Springer T.A.; RT "Structure of a complete integrin ectodomain in a physiologic resting state RT and activation and deactivation by applied forces."; RL Mol. Cell 32:849-861(2008). RN [33] RP REVIEW ON GT1 VARIANTS. RX PubMed=7878622; RA Bray P.F.; RT "Inherited diseases of platelet glycoproteins: considerations for rapid RT molecular characterization."; RL Thromb. Haemost. 72:492-502(1994). RN [34] RP VARIANT SER-874, POLYMORPHISM, AND DESCRIPTION OF ALLOANTIGEN SYSTEM BAK. RX PubMed=2350579; RA Lyman S., Aster R.H., Visentin G.P., Newman P.J.; RT "Polymorphism of human platelet membrane glycoprotein IIb associated with RT the Baka/Bakb alloantigen system."; RL Blood 75:2343-2348(1990). RN [35] RP POLYMORPHISM, DESCRIPTION OF ALLOANTIGEN SYSTEM BAK, AND INVOLVEMENT IN RP FMAIT2. RX PubMed=7197082; DOI=10.1111/j.1423-0410.1980.tb01845.x; RA von dem Borne A.E., von Riesz E., Verheugt F.W., ten Cate J.W., Koppe J.G., RA Engelfriet C.P., Nijenhuis L.E.; RT "Baka, a new platelet-specific antigen involved in neonatal allo-immune RT thrombocytopenia."; RL Vox Sang. 39:113-120(1980). RN [36] RP VARIANT GT1 ASP-273. RX PubMed=8282784; DOI=10.1172/jci116942; RA Poncz M., Rifat S., Coller B.S., Newman P.J., Shattil S.J., Parrella T., RA Fortina P., Bennett J.S.; RT "Glanzmann thrombasthenia secondary to a Gly273-->Asp mutation adjacent to RT the first calcium-binding domain of platelet glycoprotein IIb."; RL J. Clin. Invest. 93:172-179(1994). RN [37] RP VARIANT GT1 ASP-449. RX PubMed=7508443; DOI=10.1016/s0021-9258(17)41800-x; RA Wilcox D.A., Wautier J.-L., Pidard D., Newman P.J.; RT "A single amino acid substitution flanking the fourth calcium binding RT domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin RT complex."; RL J. Biol. Chem. 269:4450-4457(1994). RN [38] RP VARIANT MET-868, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=7620155; RA Noris P., Simsek S., de Bruijne-Admiraal L.G., Porcelijn L., Huiskes E., RA van der Vlist G.J., van Leeuwen E.F., van der Schoot C.E., RA von dem Borne A.E.; RT "Max(a), a new low-frequency platelet-specific antigen localized on RT glycoprotein IIb, is associated with neonatal alloimmune RT thrombocytopenia."; RL Blood 86:1019-1026(1995). RN [39] RP VARIANT GT1 HIS-358. RX PubMed=7706461; DOI=10.1172/jci117828; RA Wilcox D.A., Paddock C.M., Lyman S., Gill J.C., Newman P.J.; RT "Glanzmann thrombasthenia resulting from a single amino acid substitution RT between the second and third calcium-binding domains of GPIIb. Role of the RT GPIIb amino terminus in integrin subunit association."; RL J. Clin. Invest. 95:1553-1560(1995). RN [40] RP VARIANT GT1 456-VAL-ASP-457 DEL, AND CHARACTERIZATION OF VARIANT GT1 RP 456-VAL-ASP-457 DEL. RX PubMed=8704171; RA Basani R.B., Vilaire G., Shattil S.J., Kolodziej M.A., Bennett J.S., RA Poncz M.; RT "Glanzmann thrombasthenia due to a two amino acid deletion in the fourth RT calcium-binding domain of alpha IIb: demonstration of the importance of RT calcium-binding domains in the conformation of alpha IIb beta 3."; RL Blood 88:167-173(1996). RN [41] RP VARIANTS GT1 ILE-207; THR-596 AND GLN-1026. RX PubMed=9215749; DOI=10.1006/bcmd.1997.0117; RA French D.L., Coller B.S.; RT "Hematologically important mutations: Glanzmann thrombasthenia."; RL Blood Cells Mol. Dis. 23:39-51(1997). RN [42] RP VARIANT GT1 PRO-214, AND CHARACTERIZATION OF VARIANT GT1 PRO-214. RX PubMed=9473221; RA Grimaldi C.M., Chen F., Wu C., Weiss H.J., Coller B.S., French D.L.; RT "Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with RT both quantitative and qualitative abnormalities in GPIIb/IIIa."; RL Blood 91:1562-1571(1998). RN [43] RP VARIANT GT1 PRO-778. RX PubMed=9763559; RA Tadokoro S., Tomiyama Y., Honda S., Arai M., Yamamoto N., Shiraga M., RA Kosugi S., Kanakura Y., Kurata Y., Matsuzawa Y.; RT "A Gln747-->Pro substitution in the IIb subunit is responsible for a RT moderate IIbbeta3 deficiency in Glanzmann thrombasthenia."; RL Blood 92:2750-2758(1998). RN [44] RP VARIANT BDPLT16 GLN-1026, AND CHARACTERIZATION OF VARIANT BDPLT16 GLN-1026. RX PubMed=9834222; RA Peyruchaud O., Nurden A.T., Milet S., Macchi L., Pannochia A., Bray P.F., RA Kieffer N., Bourre F.; RT "R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic RT domain of the integrin IIb subunit in a patient with a Glanzmann's RT thrombasthenia-like syndrome."; RL Blood 92:4178-4187(1998). RN [45] RP VARIANTS GT1 SER-320; LYS-355 AND PRO-778. RX PubMed=9722314; DOI=10.1046/j.1365-2141.1998.00824.x; RA Ambo H., Kamata T., Handa M., Kawai Y., Oda A., Murata M., Takada Y., RA Ikeda Y.; RT "Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys RT and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese RT patients."; RL Br. J. Haematol. 102:829-840(1998). RN [46] RP VARIANTS GT1 LYS-355 AND THR-596. RX PubMed=9734640; DOI=10.1046/j.1365-2141.1998.00852.x; RA Ruan J., Peyruchaud O., Alberio L., Valles G., Clemetson K., Bourre F., RA Nurden A.T.; RT "Double heterozygosity of the GPIIb gene in a Swiss patient with RT Glanzmann's thrombasthenia."; RL Br. J. Haematol. 102:918-925(1998). RN [47] RP VARIANTS ILE-40; SER-874 AND ASN-968. RX PubMed=10391209; DOI=10.1038/10290; RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RT "Characterization of single-nucleotide polymorphisms in coding regions of RT human genes."; RL Nat. Genet. 22:231-238(1999). RN [48] RP VARIANT GT1 ARG-705, AND CHARACTERIZATION OF VARIANT GT1 ARG-705. RX PubMed=9920835; RA Gonzalez-Manchon C., Fernandez-Pinel M., Arias-Salgado E.G., Ferrer M., RA Alvarez M.-V., Garcia-Munoz S., Ayuso M.S., Parrilla R.; RT "Molecular genetic analysis of a compound heterozygote for the glycoprotein RT (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the RT 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa RT complexes."; RL Blood 93:866-875(1999). RN [49] RP ERRATUM OF PUBMED:9920835. RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RL Nat. Genet. 23:373-373(1999). RN [50] RP VARIANTS GT1 ALA-176 AND LEU-176. RX PubMed=10607701; RA Basani R.B., French D.L., Vilaire G., Brown D.L., Chen F., Coller B.S., RA Derrick J.M., Gartner T.K., Bennett J.S., Poncz M.; RT "A naturally occurring mutation near the amino terminus of alphaIIb defines RT a new region involved in ligand binding to alphaIIbbeta3."; RL Blood 95:180-188(2000). RN [51] RP VARIANTS GT1 TRP-161; LEU-222; ARG-412 AND PRO-847. RX PubMed=11798398; DOI=10.1080/095371001317126383; RA Vinciguerra C., Bordet J.C., Beaune G., Grenier C., Dechavanne M., RA Negrier C.; RT "Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) RT and glycoprotein IIIa (beta3) genes."; RL Platelets 12:486-495(2001). RN [52] RP VARIANT GT1 PRO-86, AND CHARACTERIZATION OF VARIANT GT1 PRO-86. RX PubMed=12181054; DOI=10.1046/j.1365-2141.2002.03678.x; RA Tanaka S., Hayashi T., Hori Y., Terada C., Han K.S., Ahn H.S., Bourre F., RA Tani Y.; RT "A Leu55 to Pro substitution in the integrin alphaIIb is responsible for a RT case of Glanzmann's thrombasthenia."; RL Br. J. Haematol. 118:833-835(2002). RN [53] RP VARIANTS GT1 VAL-139; ALA-176; GLU-267; ASP-380; THR-405; ASP-581; ARG-705; RP VAL-752 AND PRO-755. RX PubMed=12083483; RA D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G., RA Margaglione M.; RT "Glanzmann's thrombasthenia: identification of 19 new mutations in 30 RT patients."; RL Thromb. Haemost. 87:1034-1042(2002). RN [54] RP VARIANTS GT1 PHE-329 AND THR-405, AND CHARACTERIZATION OF VARIANTS GT1 RP PHE-329 AND THR-405. RX PubMed=12424194; DOI=10.1182/blood-2002-07-2266; RA Mitchell W.B., Li J.H., Singh F., Michelson A.D., Bussel J., Coller B.S., RA French D.L.; RT "Two novel mutations in the alpha IIb calcium-binding domains identify RT hydrophobic regions essential for alpha IIbbeta 3 biogenesis."; RL Blood 101:2268-2276(2003). RN [55] RP VARIANT GT1 HIS-174, AND CHARACTERIZATION OF VARIANT GT1 HIS-174. RX PubMed=12506038; DOI=10.1182/blood-2002-07-2144; RA Kiyoi T., Tomiyama Y., Honda S., Tadokoro S., Arai M., Kashiwagi H., RA Kosugi S., Kato H., Kurata Y., Matsuzawa Y.; RT "A naturally occurring Tyr143His alpha IIb mutation abolishes alpha IIb RT beta 3 function for soluble ligands but retains its ability for mediating RT cell adhesion and clot retraction: comparison with other mutations causing RT ligand-binding defects."; RL Blood 101:3485-3491(2003). RN [56] RP POLYMORPHISM. RX PubMed=14516468; DOI=10.1046/j.1423-0410.2003.00331.x; RA Metcalfe P., Watkins N.A., Ouwehand W.H., Kaplan C., Newman P., RA Kekomaki R., De Haas M., Aster R., Shibata Y., Smith J., Kiefel V., RA Santoso S.; RT "Nomenclature of human platelet antigens."; RL Vox Sang. 85:240-245(2003). RN [57] RP VARIANT GT1 MET-982, CHARACTERIZATION OF VARIANT GT1 MET-982, AND VARIANT RP THR-989. RX PubMed=15099289; DOI=10.1046/j.1538-7836.2004.00711.x; RA Nurden A.T., Breillat C., Jacquelin B., Combrie R., Freedman J., RA Blanchette V.S., Schmugge M., Rand M.L.; RT "Triple heterozygosity in the integrin alphaIIb subunit in a patient with RT Glanzmann's thrombasthenia."; RL J. Thromb. Haemost. 2:813-819(2004). RN [58] RP VARIANT GT1 CYS-202, AND CHARACTERIZATION OF VARIANT GT1 CYS-202. RX PubMed=15219201; DOI=10.1111/j.1538-7836.2004.00758.x; RA Rosenberg N., Landau M., Luboshitz J., Rechavi G., Seligsohn U.; RT "A novel Phe171Cys mutation in integrin alpha causes Glanzmann RT thrombasthenia by abrogating alphaIIbbeta3 complex formation."; RL J. Thromb. Haemost. 2:1167-1175(2004). RN [59] RP POLYMORPHISM, DESCRIPTION OF ALLOANTIGEN SYSTEM BAK, AND INVOLVEMENT IN RP FMAIT2. RX PubMed=15569236; DOI=10.1111/j.1365-3148.2004.00537.x; RA Kataoka S., Kobayashi H., Chiba K., Nakamura M., Shinada S., Morita S., RA Lin M., Shibata Y.; RT "Neonatal alloimmune thrombocytopenia due to an antibody against a labile RT component of human platelet antigen-3b (Bak b)."; RL Transfus. Med. 14:419-423(2004). RN [60] RP VARIANT GT1 LEU-943, AND CHARACTERIZATION OF VARIANT GT1 LEU-943. RX PubMed=17018384; RA Jayo A., Pabon D., Lastres P., Jimenez-Yuste V., Gonzalez-Manchon C.; RT "Type II Glanzmann thrombasthenia in a compound heterozygote for the alpha RT IIb gene. A novel missense mutation in exon 27."; RL Haematologica 91:1352-1359(2006). RN [61] RP VARIANTS GT1 THR-405; THR-596; ARG-705; PRO-778; PHE-934; LEU-957; MET-982 RP AND THR-989, CHARACTERIZATION OF VARIANTS GT1 PHE-934 AND LEU-957, AND RP SUBCELLULAR LOCATION. RX PubMed=20020534; DOI=10.1002/humu.21179; RA Jallu V., Dusseaux M., Panzer S., Torchet M.F., Hezard N., Goudemand J., RA de Brevern A.G., Kaplan C.; RT "AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, RT effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure- RT function."; RL Hum. Mutat. 31:237-246(2010). RN [62] RP VARIANT MET-650, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=19821948; DOI=10.1111/j.1537-2995.2009.02438.x; RA Peterson J.A., Gitter M.L., Kanack A., Curtis B., McFarland J., Bougie D., RA Aster R.; RT "New low-frequency platelet glycoprotein polymorphisms associated with RT neonatal alloimmune thrombocytopenia."; RL Transfusion 50:324-333(2010). RN [63] RP VARIANT LEU-771, POLYMORPHISM, AND INVOLVEMENT IN FMAIT2. RX PubMed=23305224; DOI=10.1111/trf.12067; RA Poles A., Wozniak M.J., Walser P., Ridgwell K., Fitzgerald J., Green A., RA Gilmore R., Lucas G.; RT "A V740L mutation in glycoprotein IIb defines a novel epitope (War) RT associated with fetomaternal alloimmune thrombocytopenia."; RL Transfusion 53:1965-1973(2013). RN [64] RP VARIANT BDPLT16 TRP-1026, AND CHARACTERIZATION OF VARIANT BDPLT16 TRP-1026. RX PubMed=21454453; DOI=10.1182/blood-2010-12-323691; RA Kunishima S., Kashiwagi H., Otsu M., Takayama N., Eto K., Onodera M., RA Miyajima Y., Takamatsu Y., Suzumiya J., Matsubara K., Tomiyama Y., RA Saito H.; RT "Heterozygous ITGA2B R995W mutation inducing constitutive activation of the RT alphaIIbbeta3 receptor affects proplatelet formation and causes congenital RT macrothrombocytopenia."; RL Blood 117:5479-5484(2011). CC -!- FUNCTION: Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for CC fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and CC vitronectin. It recognizes the sequence R-G-D in a wide array of CC ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in CC fibrinogen gamma chain (By similarity). Following activation integrin CC alpha-IIb/beta-3 brings about platelet/platelet interaction through CC binding of soluble fibrinogen (PubMed:9111081). This step leads to CC rapid platelet aggregation which physically plugs ruptured endothelial CC cell surface (By similarity). Integrin ITGA2B:ITGB3 is also the CC receptor of erythrocyte-specific ICAM4 ligand involved in heterotypic CC cell-cell adhesion between erythrocytes and activated platelets CC (PubMed:12477717). {ECO:0000250|UniProtKB:O54890, CC ECO:0000269|PubMed:12477717, ECO:0000269|PubMed:9111081}. CC -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha subunit CC is composed of a heavy and a light chain linked by a disulfide bond. CC Alpha-IIb associates with beta-3. Directly interacts with RNF181. CC Interacts (via C-terminus cytoplasmic tail region) with CIB1; the CC interaction is direct and calcium-dependent. Interacts (via C-terminus CC cytoplasmic tail region) with CIB2, CIB3 and CIB4; the interactions are CC stabilized/increased in a calcium and magnesium-dependent manner. CC ITGA2B:ITGB3 interacts with PPIA/CYPA; the interaction is ROS and CC PPIase activity-dependent and is increased in the presence of thrombin CC (By similarity). ITGA2B:ITGB3 interacts with SELP (via C-type lectin CC domain); the interaction mediates cell-cell interaction and adhesion CC (PubMed:37184585). {ECO:0000250|UniProtKB:Q9QUM0, CC ECO:0000269|PubMed:10477286, ECO:0000269|PubMed:18331836, CC ECO:0000269|PubMed:21388953, ECO:0000269|PubMed:22283712, CC ECO:0000269|PubMed:22779914, ECO:0000269|PubMed:37184585, CC ECO:0000269|PubMed:9030514}. CC -!- INTERACTION: CC P08514; P08514: ITGA2B; NbExp=7; IntAct=EBI-702693, EBI-702693; CC P08514; P05106: ITGB3; NbExp=12; IntAct=EBI-702693, EBI-702847; CC P08514-1; P21333: FLNA; NbExp=3; IntAct=EBI-15805658, EBI-350432; CC P08514-1; P05106: ITGB3; NbExp=4; IntAct=EBI-15805658, EBI-702847; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20020534}; CC Single-pass type I membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P08514-1; Sequence=Displayed; CC Name=2; CC IsoId=P08514-2; Sequence=VSP_002737; CC Name=3; Synonyms=tr-alpha-IIb {ECO:0000303|PubMed:9809974}; CC IsoId=P08514-3; Sequence=VSP_002736; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in platelets CC and megakaryocytes, but not in reticulocytes. Not detected in Jurkat, CC nor in U937 cell lines (PubMed:2351656). Isoform 3 is expressed in CC prostate adenocarcinoma, as well as in several erythroleukemia, CC prostate adenocarcinoma and melanoma cell lines, including PC-3, DU- CC 145, HEL, WM983A, WM983B and WM35. Not detected in platelets, nor in CC normal prostate (at protein level) (PubMed:9809974). CC {ECO:0000269|PubMed:2351656, ECO:0000269|PubMed:9809974}. CC -!- PTM: [Integrin alpha-IIb heavy chain]: Cleaved by ELANE; the cleavage CC promotes activation of platelet fibrinogen receptor integrin alpha- CC IIb/beta-3. {ECO:0000269|PubMed:9111081}. CC -!- POLYMORPHISM: Genetic variants in ITGA2B define different platelet- CC specific alloantigen systems that are involved in fetomaternal CC alloimmune thromobocytopenia. Alloantigen system Bak, also known as CC HPA-3 or Lek, is characterized by variant p.Ser874Ile (alloantigen CC Bak(a) or Lek(a) or HPA-3a) and variant p.Ile874Ser (alloantigen Bak(b) CC or Lek(b) or HPA-3b) (PubMed:2350579, PubMed:7197082, PubMed:14516468, CC PubMed:15569236). Additional platelet-specific alloantigens involved in CC fetomaternal alloimmune thromobocytopenia are known (PubMed:7620155, CC PubMed:19821948, PubMed:23305224). {ECO:0000269|PubMed:14516468, CC ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:19821948, CC ECO:0000269|PubMed:23305224, ECO:0000269|PubMed:2350579, CC ECO:0000269|PubMed:7197082, ECO:0000269|PubMed:7620155}. CC -!- DISEASE: Fetomaternal alloimmune thrombocytopenia 2 (FMAIT2) CC [MIM:621266]: A form of fetomaternal alloimmune thrombocytopenia, a CC bleeding disorder caused by maternal/fetal incompatibility for platelet CC alloantigens and arising when a fetus inherits a paternal platelet CC alloantigen that the mother does not possess. During pregnancy, as well CC as parturition, maternal alloantibodies against paternally-inherited CC platelet antigens cause destruction of fetal platelets and CC fetal/neonatal thrombocytopenia. Disease severity and clinical features CC in the fetus or neonate are heterogeneous. While most fetuses remain CC asymptomatic, others develop skin bleedings (petechiae) or internal CC organ bleedings. The most severe symptom is intracranial hemorrhage CC that is mostly discovered postnatally and can result in neurological CC complications or even death. Mothers with circulating platelet CC alloantibodies may experience miscarriage. FMAIT2 transmission pattern CC is consistent with autosomal dominant paternal inheritance. CC {ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:19821948, CC ECO:0000269|PubMed:23305224, ECO:0000269|PubMed:7197082, CC ECO:0000269|PubMed:7620155}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Glanzmann thrombasthenia 1 (GT1) [MIM:273800]: A form of CC Glanzmann thrombasthenia, a disorder characterized by failure of CC platelet aggregation, absent or diminished clot retraction, and CC mucocutaneous bleeding of mild-to-moderate severity. Glanzmann CC thrombasthenia has been classified into clinical types I and II. In CC type I, platelets show absence of glycoprotein IIb-IIIa complexes at CC their surface and lack fibrinogen and clot retraction capability. In CC type II, the platelets express glycoprotein IIb-IIIa complexes at CC reduced levels, have detectable amounts of fibrinogen, and have low or CC moderate clot retraction capability. GT1 inheritance is autosomal CC recessive. {ECO:0000269|PubMed:10607701, ECO:0000269|PubMed:11798398, CC ECO:0000269|PubMed:12083483, ECO:0000269|PubMed:12181054, CC ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:12506038, CC ECO:0000269|PubMed:15099289, ECO:0000269|PubMed:15219201, CC ECO:0000269|PubMed:17018384, ECO:0000269|PubMed:20020534, CC ECO:0000269|PubMed:7508443, ECO:0000269|PubMed:7706461, CC ECO:0000269|PubMed:8282784, ECO:0000269|PubMed:8704171, CC ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9473221, CC ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9734640, CC ECO:0000269|PubMed:9763559, ECO:0000269|PubMed:9920835}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bleeding disorder, platelet-type, 16 (BDPLT16) [MIM:187800]: CC An autosomal dominant form of congenital macrothrombocytopenia CC associated with platelet anisocytosis. It is a disorder of platelet CC production. Affected individuals may have no or only mildly increased CC bleeding tendency. In vitro studies show mild platelet functional CC abnormalities. {ECO:0000269|PubMed:21454453, CC ECO:0000269|PubMed:9834222}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the integrin alpha chain family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J02764; AAA60114.1; -; mRNA. DR EMBL; M34480; AAA35926.1; -; mRNA. DR EMBL; M34344; AAA53150.1; -; Genomic_DNA. DR EMBL; M33319; AAA53150.1; JOINED; Genomic_DNA. DR EMBL; M33320; AAA53150.1; JOINED; Genomic_DNA. DR EMBL; AK315335; BAG37735.1; -; mRNA. DR EMBL; AC003043; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117443; AAI17444.1; -; mRNA. DR EMBL; BC126442; AAI26443.1; -; mRNA. DR EMBL; M22568; AAA52587.1; -; Genomic_DNA. DR EMBL; M22569; AAA52588.1; -; Genomic_DNA. DR EMBL; X06831; CAA29987.1; -; mRNA. DR EMBL; AF098114; AAC98507.1; -; mRNA. DR EMBL; M18085; AAA52597.1; -; mRNA. DR EMBL; M54799; AAA52599.1; -; Genomic_DNA. DR CCDS; CCDS32665.1; -. [P08514-1] DR PIR; A34269; A34269. DR RefSeq; NP_000410.2; NM_000419.5. [P08514-1] DR PDB; 1DPK; NMR; -; A=1020-1039. DR PDB; 1DPQ; NMR; -; A=1020-1039. DR PDB; 1KUP; NMR; -; A=1018-1028. DR PDB; 1KUZ; NMR; -; A=1018-1028. DR PDB; 1M8O; NMR; -; A=1020-1039. DR PDB; 1S4W; NMR; -; A=1020-1039. DR PDB; 1TYE; X-ray; 2.90 A; A/C/E=32-483. DR PDB; 2K1A; NMR; -; A=989-1029. DR PDB; 2K9J; NMR; -; A=989-1029. DR PDB; 2KNC; NMR; -; A=991-1039. DR PDB; 2MTP; NMR; -; B=1019-1039. DR PDB; 2N9Y; NMR; -; A=989-1029. DR PDB; 2VC2; X-ray; 3.10 A; A=32-483. DR PDB; 2VDK; X-ray; 2.80 A; A=32-483. DR PDB; 2VDL; X-ray; 2.75 A; A=32-483. DR PDB; 2VDM; X-ray; 2.90 A; A=32-483. DR PDB; 2VDN; X-ray; 2.90 A; A=32-483. DR PDB; 2VDO; X-ray; 2.51 A; A=32-483. DR PDB; 2VDP; X-ray; 2.80 A; A=32-483. DR PDB; 2VDQ; X-ray; 2.59 A; A=32-483. DR PDB; 2VDR; X-ray; 2.40 A; A=32-483. DR PDB; 3FCS; X-ray; 2.55 A; A/C=32-989. DR PDB; 3FCU; X-ray; 2.90 A; A/C/E=32-488. DR PDB; 3NID; X-ray; 2.30 A; A/C=32-488. DR PDB; 3NIF; X-ray; 2.40 A; A/C=32-488. DR PDB; 3NIG; X-ray; 2.25 A; A/C=32-488. DR PDB; 3T3M; X-ray; 2.60 A; A/C=32-488. DR PDB; 3T3P; X-ray; 2.20 A; A/C=32-488. DR PDB; 3ZDX; X-ray; 2.45 A; A/C=32-488. DR PDB; 3ZDY; X-ray; 2.45 A; A/C=32-488. DR PDB; 3ZDZ; X-ray; 2.75 A; A/C=32-488. DR PDB; 3ZE0; X-ray; 2.95 A; A/C=32-488. DR PDB; 3ZE1; X-ray; 3.00 A; A/C=32-488. DR PDB; 3ZE2; X-ray; 2.35 A; A/C=32-488. DR PDB; 4CAK; EM; 20.50 A; A=32-989. DR PDB; 4Z7N; X-ray; 2.60 A; A/C=32-486. DR PDB; 4Z7O; X-ray; 2.85 A; A/C=32-486. DR PDB; 4Z7Q; X-ray; 2.70 A; A/C=32-485. DR PDB; 5HDB; X-ray; 2.70 A; A/C=32-485. DR PDB; 6V4P; EM; 2.80 A; A=1-963. DR PDB; 7KN0; NMR; -; A=989-1029. DR PDB; 7L8P; X-ray; 2.35 A; A/C=32-488. DR PDB; 7LA4; EM; 3.30 A; A=1-1039. DR PDB; 7SC4; X-ray; 1.85 A; A/B=1019-1039. DR PDB; 7SFT; NMR; -; B=1019-1039. DR PDB; 7TCT; X-ray; 2.50 A; A/C=32-488. DR PDB; 7TD8; X-ray; 2.60 A; A/C=32-484. DR PDB; 7THO; X-ray; 2.75 A; A/C=32-485. DR PDB; 7TMZ; X-ray; 2.20 A; A/C=32-485. DR PDB; 7TPD; X-ray; 2.60 A; A/C=32-488. DR PDB; 7U60; X-ray; 2.55 A; A/C=32-486. DR PDB; 7U9F; X-ray; 2.70 A; A/C=32-485. DR PDB; 7U9V; X-ray; 2.25 A; A/C=32-485. DR PDB; 7UBR; X-ray; 2.05 A; A/C=32-485. DR PDB; 7UCY; X-ray; 2.35 A; A/C=32-488. DR PDB; 7UDG; X-ray; 2.80 A; A/C=32-488. DR PDB; 7UDH; X-ray; 2.00 A; A/C=32-488. DR PDB; 7UE0; X-ray; 2.74 A; A/C=32-488. DR PDB; 7UFH; X-ray; 3.00 A; A/C=32-488. DR PDB; 7UH8; X-ray; 2.75 A; A/C=32-488. DR PDB; 7UJE; X-ray; 2.50 A; A/C=32-485. DR PDB; 7UJK; X-ray; 2.43 A; A/C=32-488. DR PDB; 7UK9; X-ray; 2.60 A; A/C=32-488. DR PDB; 7UKO; X-ray; 2.60 A; A/C=32-488. DR PDB; 7UKP; X-ray; 2.80 A; A/C=32-488. DR PDB; 7UKT; X-ray; 2.37 A; A/C=32-488. DR PDB; 8GCD; EM; 2.97 A; A=1-1039. DR PDB; 8GCE; EM; 3.12 A; A=1-1039. DR PDB; 8T2U; EM; 3.10 A; A=32-1039. DR PDB; 8T2V; EM; 3.40 A; A=32-1039. DR PDB; 9AXL; EM; 3.30 A; A=1-1039. DR PDB; 9DAO; EM; 2.80 A; A=32-1039. DR PDB; 9DAX; EM; 3.30 A; A=32-1039. DR PDB; 9DEQ; EM; 4.10 A; A=32-1039. DR PDB; 9DER; EM; 3.90 A; A=32-1039. DR PDBsum; 1DPK; -. DR PDBsum; 1DPQ; -. DR PDBsum; 1KUP; -. DR PDBsum; 1KUZ; -. DR PDBsum; 1M8O; -. DR PDBsum; 1S4W; -. DR PDBsum; 1TYE; -. DR PDBsum; 2K1A; -. DR PDBsum; 2K9J; -. DR PDBsum; 2KNC; -. DR PDBsum; 2MTP; -. DR PDBsum; 2N9Y; -. DR PDBsum; 2VC2; -. DR PDBsum; 2VDK; -. DR PDBsum; 2VDL; -. DR PDBsum; 2VDM; -. DR PDBsum; 2VDN; -. DR PDBsum; 2VDO; -. DR PDBsum; 2VDP; -. DR PDBsum; 2VDQ; -. DR PDBsum; 2VDR; -. DR PDBsum; 3FCS; -. DR PDBsum; 3FCU; -. DR PDBsum; 3NID; -. DR PDBsum; 3NIF; -. DR PDBsum; 3NIG; -. DR PDBsum; 3T3M; -. DR PDBsum; 3T3P; -. DR PDBsum; 3ZDX; -. DR PDBsum; 3ZDY; -. DR PDBsum; 3ZDZ; -. DR PDBsum; 3ZE0; -. DR PDBsum; 3ZE1; -. DR PDBsum; 3ZE2; -. DR PDBsum; 4CAK; -. DR PDBsum; 4Z7N; -. DR PDBsum; 4Z7O; -. DR PDBsum; 4Z7Q; -. DR PDBsum; 5HDB; -. DR PDBsum; 6V4P; -. DR PDBsum; 7KN0; -. DR PDBsum; 7L8P; -. DR PDBsum; 7LA4; -. DR PDBsum; 7SC4; -. DR PDBsum; 7SFT; -. DR PDBsum; 7TCT; -. DR PDBsum; 7TD8; -. DR PDBsum; 7THO; -. DR PDBsum; 7TMZ; -. DR PDBsum; 7TPD; -. DR PDBsum; 7U60; -. DR PDBsum; 7U9F; -. DR PDBsum; 7U9V; -. DR PDBsum; 7UBR; -. DR PDBsum; 7UCY; -. DR PDBsum; 7UDG; -. DR PDBsum; 7UDH; -. DR PDBsum; 7UE0; -. DR PDBsum; 7UFH; -. DR PDBsum; 7UH8; -. DR PDBsum; 7UJE; -. DR PDBsum; 7UJK; -. DR PDBsum; 7UK9; -. DR PDBsum; 7UKO; -. DR PDBsum; 7UKP; -. DR PDBsum; 7UKT; -. DR PDBsum; 8GCD; -. DR PDBsum; 8GCE; -. DR PDBsum; 8T2U; -. DR PDBsum; 8T2V; -. DR PDBsum; 9AXL; -. DR PDBsum; 9DAO; -. DR PDBsum; 9DAX; -. DR PDBsum; 9DEQ; -. DR PDBsum; 9DER; -. DR AlphaFoldDB; P08514; -. DR BMRB; P08514; -. DR EMDB; EMD-21044; -. DR EMDB; EMD-2281; -. DR EMDB; EMD-23245; -. DR EMDB; EMD-29931; -. DR EMDB; EMD-29932; -. DR EMDB; EMD-40988; -. DR EMDB; EMD-40989; -. DR EMDB; EMD-43046; -. DR EMDB; EMD-43969; -. DR EMDB; EMD-43983; -. DR EMDB; EMD-46695; -. DR EMDB; EMD-46701; -. DR EMDB; EMD-46793; -. DR EMDB; EMD-46794; -. DR SMR; P08514; -. DR BioGRID; 109881; 22. DR ComplexPortal; CPX-1799; Integrin alphaIIb-beta3 complex. DR CORUM; P08514; -. DR DIP; DIP-68N; -. DR FunCoup; P08514; 856. DR IntAct; P08514; 6. DR MINT; P08514; -. DR STRING; 9606.ENSP00000262407; -. DR BindingDB; P08514; -. DR ChEMBL; CHEMBL212; -. DR DrugBank; DB00054; Abciximab. DR DrugBank; DB00063; Eptifibatide. DR DrugBank; DB06472; Fradafiban. DR DrugBank; DB09526; Hydroquinone. DR DrugBank; DB04863; Lefradafiban. DR DrugBank; DB00775; Tirofiban. DR DrugCentral; P08514; -. DR GuidetoPHARMACOLOGY; 2441; -. DR GlyCosmos; P08514; 8 sites, 4 glycans. DR GlyGen; P08514; 8 sites, 4 O-linked glycans (2 sites). DR iPTMnet; P08514; -. DR PhosphoSitePlus; P08514; -. DR BioMuta; ITGA2B; -. DR DMDM; 226694183; -. DR OGP; P08514; -. DR jPOST; P08514; -. DR MassIVE; P08514; -. DR PaxDb; 9606-ENSP00000262407; -. DR PeptideAtlas; P08514; -. DR ProteomicsDB; 52113; -. [P08514-1] DR ProteomicsDB; 52114; -. [P08514-2] DR ProteomicsDB; 52115; -. [P08514-3] DR TopDownProteomics; P08514-1; -. [P08514-1] DR ABCD; P08514; 23 sequenced antibodies. DR Antibodypedia; 4350; 2013 antibodies from 53 providers. DR DNASU; 3674; -. DR Ensembl; ENST00000262407.6; ENSP00000262407.5; ENSG00000005961.20. [P08514-1] DR GeneID; 3674; -. DR KEGG; hsa:3674; -. DR MANE-Select; ENST00000262407.6; ENSP00000262407.5; NM_000419.5; NP_000410.2. DR UCSC; uc002igt.2; human. [P08514-1] DR AGR; HGNC:6138; -. DR ClinPGx; PA29938; -. DR CTD; 3674; -. DR DisGeNET; 3674; -. DR GeneCards; ITGA2B; -. DR HGNC; HGNC:6138; ITGA2B. DR HPA; ENSG00000005961; Tissue enhanced (bone marrow, epididymis, lymphoid tissue). DR MalaCards; ITGA2B; -. DR MIM; 187800; phenotype. DR MIM; 273800; phenotype. DR MIM; 607759; gene. DR MIM; 621266; phenotype. DR OpenTargets; ENSG00000005961; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 853; Fetal and neonatal alloimmune thrombocytopenia. DR Orphanet; 849; Glanzmann thrombasthenia. DR VEuPathDB; HostDB:ENSG00000005961; -. DR eggNOG; KOG3637; Eukaryota. DR GeneTree; ENSGT00940000160724; -. DR HOGENOM; CLU_004111_4_1_1; -. DR InParanoid; P08514; -. DR OMA; LQMDTAN; -. DR OrthoDB; 5317514at2759; -. DR PAN-GO; P08514; 8 GO annotations based on evolutionary models. DR PhylomeDB; P08514; -. DR PathwayCommons; P08514; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-3000178; ECM proteoglycans. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins. DR Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins. DR Reactome; R-HSA-445144; Signal transduction by L1. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR SignaLink; P08514; -. DR SIGNOR; P08514; -. DR Agora; ENSG00000005961; -. DR BioGRID-ORCS; 3674; 20 hits in 1173 CRISPR screens. DR ChiTaRS; ITGA2B; human. DR EvolutionaryTrace; P08514; -. DR GeneWiki; ITGA2B; -. DR GenomeRNAi; 3674; -. DR Pharos; P08514; Tclin. DR PRO; PR:P08514; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P08514; protein. DR Bgee; ENSG00000005961; Expressed in monocyte and 130 other cell types or tissues. DR ExpressionAtlas; P08514; baseline and differential. DR GO; GO:0072562; C:blood microparticle; HDA:UniProtKB. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IEA:Ensembl. DR GO; GO:0070442; C:integrin alphaIIb-beta3 complex; IDA:UniProt. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031092; C:platelet alpha granule membrane; TAS:Reactome. DR GO; GO:0050840; F:extracellular matrix binding; IEA:Ensembl. DR GO; GO:0070051; F:fibrinogen binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0007160; P:cell-matrix adhesion; NAS:ComplexPortal. DR GO; GO:0007229; P:integrin-mediated signaling pathway; HDA:UniProtKB. DR GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl. DR DisProt; DP01841; -. DR FunFam; 2.60.40.1510:FF:000001; Integrin alpha V; 1. DR FunFam; 2.130.10.130:FF:000012; Integrin alpha-IIb; 1. DR FunFam; 1.20.5.930:FF:000001; Integrin subunit alpha V; 1. DR FunFam; 2.60.40.1460:FF:000001; Integrin, alpha V; 1. DR Gene3D; 1.20.5.930; Bicelle-embedded integrin alpha(iib) transmembrane segment; 1. DR Gene3D; 2.130.10.130; Integrin alpha, N-terminal; 1. DR Gene3D; 2.60.40.1460; Integrin domains. Chain A, domain 2; 1. DR Gene3D; 2.60.40.1510; ntegrin, alpha v. Chain A, domain 3; 1. DR Gene3D; 2.60.40.1530; ntegrin, alpha v. Chain A, domain 4; 1. DR InterPro; IPR013517; FG-GAP. DR InterPro; IPR013519; Int_alpha_beta-p. DR InterPro; IPR000413; Integrin_alpha. DR InterPro; IPR018184; Integrin_alpha_C_CS. DR InterPro; IPR013649; Integrin_alpha_Ig-like_1. DR InterPro; IPR048285; Integrin_alpha_Ig-like_2. DR InterPro; IPR048286; Integrin_alpha_Ig-like_3. DR InterPro; IPR028994; Integrin_alpha_N. DR InterPro; IPR032695; Integrin_dom_sf. DR PANTHER; PTHR23220; INTEGRIN ALPHA; 1. DR PANTHER; PTHR23220:SF73; INTEGRIN ALPHA-IIB; 1. DR Pfam; PF01839; FG-GAP; 2. DR Pfam; PF08441; Integrin_A_Ig_1; 1. DR Pfam; PF20805; Integrin_A_Ig_2; 1. DR Pfam; PF20806; Integrin_A_Ig_3; 1. DR Pfam; PF00357; Integrin_alpha; 1. DR PRINTS; PR01185; INTEGRINA. DR SMART; SM00191; Int_alpha; 5. DR SUPFAM; SSF69318; Integrin alpha N-terminal domain; 1. DR SUPFAM; SSF69179; Integrin domains; 3. DR PROSITE; PS51470; FG_GAP; 7. DR PROSITE; PS00242; INTEGRIN_ALPHA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell membrane; KW Cleavage on pair of basic residues; Direct protein sequencing; KW Disease variant; Disulfide bond; Glycoprotein; Integrin; Membrane; KW Metal-binding; Proteomics identification; Pyrrolidone carboxylic acid; KW Receptor; Reference proteome; Repeat; Signal; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..31 FT /evidence="ECO:0000269|PubMed:1953640, FT ECO:0000269|PubMed:3534886, ECO:0000269|PubMed:8620874" FT CHAIN 32..1039 FT /note="Integrin alpha-IIb" FT /id="PRO_0000016275" FT CHAIN 32..887 FT /note="Integrin alpha-IIb heavy chain" FT /id="PRO_0000016276" FT CHAIN 891..1039 FT /note="Integrin alpha-IIb light chain, form 1" FT /id="PRO_0000292348" FT CHAIN 903..1039 FT /note="Integrin alpha-IIb light chain, form 2" FT /id="PRO_0000016277" FT TOPO_DOM 32..993 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 994..1019 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1020..1039 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 35..96 FT /note="FG-GAP 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 110..173 FT /note="FG-GAP 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 187..238 FT /note="FG-GAP 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 251..305 FT /note="FG-GAP 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 306..371 FT /note="FG-GAP 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 373..432 FT /note="FG-GAP 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 435..496 FT /note="FG-GAP 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT MOTIF 1022..1026 FT /note="GFFKR motif" FT BINDING 274 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 276 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 278 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 281 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 283 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 328 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 330 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 332 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 334 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 336 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 396 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 398 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 400 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 402 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 404 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 457 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 459 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 461 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 463 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT BINDING 465 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0007744|PDB:1TYE, FT ECO:0007744|PDB:3FCS, ECO:0007744|PDB:3FCU" FT MOD_RES 891 FT /note="Pyrrolidone carboxylic acid; in light chain form 1" FT /evidence="ECO:0000269|PubMed:2226834" FT CARBOHYD 46 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT CARBOHYD 601 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:3FCS" FT CARBOHYD 711 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2775232" FT CARBOHYD 874 FT /note="O-linked (GalNAc...) serine; in variant S-874" FT CARBOHYD 878 FT /note="O-linked (GalNAc...) serine" FT /evidence="ECO:0000269|PubMed:7688323" FT CARBOHYD 962 FT /note="N-linked (GlcNAc...) asparagine" FT DISULFID 87..96 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 138..161 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 177..198 FT /evidence="ECO:0000269|PubMed:15378069, FT ECO:0000269|PubMed:19111664, ECO:0000269|PubMed:2775232, FT ECO:0007744|PDB:1TYE, ECO:0007744|PDB:3FCS, FT ECO:0007744|PDB:3FCU" FT DISULFID 504..515 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 521..576 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 633..639 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 705..718 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0000269|PubMed:2775232, ECO:0007744|PDB:3FCS" FT DISULFID 857..921 FT /note="Interchain (between heavy and light chains)" FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0007744|PDB:3FCS" FT DISULFID 911..916 FT /evidence="ECO:0000269|PubMed:19111664, FT ECO:0007744|PDB:3FCS" FT VAR_SEQ 910..1039 FT /note="SCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWF FT NVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWK FT VGFFKRNRPPLEEDDEEGE -> VSRLSGLWPGLPGTHGAEGMGGGRGVRVCCGPLWAT FT LGPWEHFK (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_002736" FT VAR_SEQ 948..981 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_002737" FT VARIANT 40 FT /note="T -> I (in dbSNP:rs5915)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_014176" FT VARIANT 86 FT /note="L -> P (in GT1; cells co-transfected with mutated FT alpha-IIb and wild-type beta-3 scarcely expressed the FT alpha-IIb/beta-3 complex; dbSNP:rs1052533574)" FT /evidence="ECO:0000269|PubMed:12181054" FT /id="VAR_030445" FT VARIANT 139 FT /note="A -> V (in GT1; dbSNP:rs2143489510)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030446" FT VARIANT 161 FT /note="C -> W (in GT1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030447" FT VARIANT 174 FT /note="Y -> H (in GT1; abolishes the binding function of FT alpha-IIb/beta-3 for soluble ligands without disturbing FT alpha-IIb/beta-3 expression; functional defect is likely FT caused by its allosteric effect rather than by a defect in FT the ligand-binding site itself; dbSNP:rs2048640612)" FT /evidence="ECO:0000269|PubMed:12506038" FT /id="VAR_030448" FT VARIANT 176 FT /note="P -> A (in GT1; impairs surface expression of alpha- FT IIb/beta-3 and abrogates ligand binding to the activated FT integrin; dbSNP:rs2048640485)" FT /evidence="ECO:0000269|PubMed:10607701, FT ECO:0000269|PubMed:12083483" FT /id="VAR_009885" FT VARIANT 176 FT /note="P -> L (in GT1; impairs surface expression of alpha- FT IIb/beta-3; dbSNP:rs148327798)" FT /evidence="ECO:0000269|PubMed:10607701" FT /id="VAR_009886" FT VARIANT 202 FT /note="F -> C (in GT1; results in abrogation of alpha-IIb/ FT beta-3 complex formation)" FT /evidence="ECO:0000269|PubMed:15219201" FT /id="VAR_030449" FT VARIANT 207 FT /note="T -> I (in GT1; dbSNP:rs2143485911)" FT /evidence="ECO:0000269|PubMed:9215749" FT /id="VAR_030450" FT VARIANT 214 FT /note="L -> P (in GT1; disrupts the structural conformation FT and the ligand binding properties of the heterodimeric FT complex; in addition the mutation appears to confer FT susceptibility to proteolysis; dbSNP:rs137852911)" FT /evidence="ECO:0000269|PubMed:9473221" FT /id="VAR_030451" FT VARIANT 222 FT /note="F -> L (in GT1; uncertain significance; FT dbSNP:rs2048633474)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030452" FT VARIANT 267 FT /note="G -> E (in GT1; dbSNP:rs2048627164)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030453" FT VARIANT 273 FT /note="G -> D (in GT1; alters the heterodimer conformation FT thus impairing their intracellular transport; FT dbSNP:rs137852907)" FT /evidence="ECO:0000269|PubMed:8282784" FT /id="VAR_003979" FT VARIANT 313 FT /note="G -> A (in dbSNP:rs1126554)" FT /evidence="ECO:0000269|PubMed:2345548, FT ECO:0000269|PubMed:2439501" FT /id="VAR_054820" FT VARIANT 320 FT /note="F -> S (in GT1; type I; impairs surface expression FT of alpha-IIb/beta-3)" FT /evidence="ECO:0000269|PubMed:9722314" FT /id="VAR_009887" FT VARIANT 329 FT /note="V -> F (in GT1; expression of mutant subunit alpha- FT IIb/bet-3 is 28% of control; mutant pro-alpha-IIb subunit FT is retained in the endoplasmic reticulum; FT dbSNP:rs2048619428)" FT /evidence="ECO:0000269|PubMed:12424194" FT /id="VAR_030454" FT VARIANT 355 FT /note="E -> K (in GT1; type I; impairs surface expression FT of alpha-IIb/beta-3; dbSNP:rs137852910)" FT /evidence="ECO:0000269|PubMed:9722314, FT ECO:0000269|PubMed:9734640" FT /id="VAR_009888" FT VARIANT 358 FT /note="R -> H (in GT1; type II; dbSNP:rs137852908)" FT /evidence="ECO:0000269|PubMed:7706461" FT /id="VAR_003980" FT VARIANT 380 FT /note="G -> D (in GT1; uncertain significance; FT dbSNP:rs766006685)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030455" FT VARIANT 405 FT /note="I -> T (in GT1; expression of mutant subunit alpha- FT IIb/bet-3 is 11% of control; mutant pro-alpha-IIb subunit FT is retained in the endoplasmic reticulum; FT dbSNP:rs75622274)" FT /evidence="ECO:0000269|PubMed:12083483, FT ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:20020534" FT /id="VAR_030456" FT VARIANT 412 FT /note="G -> R (in GT1; dbSNP:rs780786843)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030457" FT VARIANT 449 FT /note="G -> D (in GT1; type I; dbSNP:rs1598380253)" FT /evidence="ECO:0000269|PubMed:7508443" FT /id="VAR_003981" FT VARIANT 456..457 FT /note="Missing (in GT1; alteres the conformation of FT heterodimers such that they were neither recognized by the FT heterodimer-specific antibody A2A9 nor able to undergo FT further intracellular processing or transport to the cell FT surface)" FT /id="VAR_030458" FT VARIANT 581 FT /note="A -> D (in GT1; uncertain significance; FT dbSNP:rs2143458780)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030459" FT VARIANT 596 FT /note="I -> T (in GT1; type I; dbSNP:rs76811038)" FT /evidence="ECO:0000269|PubMed:20020534, FT ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9734640" FT /id="VAR_030460" FT VARIANT 649 FT /note="V -> L (in dbSNP:rs7207402)" FT /id="VAR_054821" FT VARIANT 650 FT /note="T -> M (risk factor for FMAIT2; alloantigen Kno)" FT /evidence="ECO:0000269|PubMed:19821948" FT /id="VAR_091064" FT VARIANT 705 FT /note="C -> R (in GT1; type II; the rate of subunit FT maturation and the surface exposure of glycoprotein IIb/ FT beta-3 are strongly reduced; dbSNP:rs77961246)" FT /evidence="ECO:0000269|PubMed:12083483, FT ECO:0000269|PubMed:20020534, ECO:0000269|PubMed:9920835" FT /id="VAR_030461" FT VARIANT 752 FT /note="L -> V (in GT1; uncertain significance; FT dbSNP:rs761174160)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030462" FT VARIANT 755 FT /note="R -> P (in GT1; uncertain significance; FT dbSNP:rs763762304)" FT /evidence="ECO:0000269|PubMed:12083483" FT /id="VAR_030463" FT VARIANT 771 FT /note="V -> L (risk factor for FMAIT2; alloantigen War)" FT /evidence="ECO:0000269|PubMed:23305224" FT /id="VAR_091065" FT VARIANT 778 FT /note="Q -> P (in GT1; type II; dbSNP:rs74475415)" FT /evidence="ECO:0000269|PubMed:20020534, FT ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9763559" FT /id="VAR_003982" FT VARIANT 847 FT /note="L -> P (in GT1; uncertain significance; FT dbSNP:rs1344532070)" FT /evidence="ECO:0000269|PubMed:11798398" FT /id="VAR_030464" FT VARIANT 868 FT /note="V -> M (risk factor for FMAIT2; alloantigen Max(a); FT Max(a)-positive individuals also carry alloantigen Bak(b))" FT /evidence="ECO:0000269|PubMed:7620155" FT /id="VAR_091066" FT VARIANT 874 FT /note="I -> S (risk factor for FMAIT2; alloantigen Bak(b); FT dbSNP:rs5911)" FT /evidence="ECO:0000269|PubMed:10391209, FT ECO:0000269|PubMed:15569236, ECO:0000269|PubMed:2350579" FT /id="VAR_003983" FT VARIANT 934 FT /note="V -> F (in GT1; severe type 1 phenotype; the FT mutation prevented normal ITGA2B/ITGB3 complex expression FT on the cell surface; dbSNP:rs77458039)" FT /evidence="ECO:0000269|PubMed:20020534" FT /id="VAR_069917" FT VARIANT 943 FT /note="P -> L (in GT1; marked reduction in the rate of FT surface expression)" FT /evidence="ECO:0000269|PubMed:17018384" FT /id="VAR_030465" FT VARIANT 957 FT /note="S -> L (in GT1; uncertain significance; severe type FT 1 phenotype; the mutation prevented normal ITGA2B/ITGB3 FT complex expression on the cell surface; the mutation may FT interfere with correct folding of the protein; FT dbSNP:rs80002943)" FT /evidence="ECO:0000269|PubMed:20020534" FT /id="VAR_069918" FT VARIANT 968 FT /note="Y -> N (in dbSNP:rs5914)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_014177" FT VARIANT 982 FT /note="V -> M (in GT1; much reduced surface expression of FT alpha-IIb/beta-3 and a block in the maturation of pro- FT alpha-IIb; dbSNP:rs78657866)" FT /evidence="ECO:0000269|PubMed:15099289, FT ECO:0000269|PubMed:20020534" FT /id="VAR_030466" FT VARIANT 989 FT /note="A -> T (in dbSNP:rs78165611)" FT /evidence="ECO:0000269|PubMed:15099289, FT ECO:0000269|PubMed:20020534" FT /id="VAR_030467" FT VARIANT 1026 FT /note="R -> Q (in GT1 and BDPLT16; uncertain significance; FT results in low surface expression of the mutant protein; FT dbSNP:rs879255514)" FT /evidence="ECO:0000269|PubMed:9215749, FT ECO:0000269|PubMed:9834222" FT /id="VAR_030468" FT VARIANT 1026 FT /note="R -> W (in BDPLT16; uncertain significance; results FT in abnormal membrane ruffling and cytoplasmic protrusions FT as well as defective proplatelet formation; FT dbSNP:rs766503255)" FT /evidence="ECO:0000269|PubMed:21454453" FT /id="VAR_069919" FT MUTAGEN 1029..1030 FT /note="PP->AA: Imparts constitutive activity (ligand- FT binding) to alpha-IIb/beta-3." FT /evidence="ECO:0000269|PubMed:10212286" FT CONFLICT 23 FT /note="P -> A (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 120 FT /note="A -> S (in Ref. 4; BAG37735)" FT /evidence="ECO:0000305" FT CONFLICT 287..288 FT /note="GA -> VP (in Ref. 3; AAA53150)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="E -> D (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 565 FT /note="N -> D (in Ref. 2; AAA35926)" FT /evidence="ECO:0000305" FT CONFLICT 566 FT /note="L -> V (in Ref. 11; CAA29987)" FT /evidence="ECO:0000305" FT CONFLICT 633 FT /note="C -> S (in Ref. 1; AAA60114)" FT /evidence="ECO:0000305" FT CONFLICT 729 FT /note="Q -> E (in Ref. 11; CAA29987)" FT /evidence="ECO:0000305" FT CONFLICT 971 FT /note="P -> A (in Ref. 3; AAA53150)" FT /evidence="ECO:0000305" FT CONFLICT 1029 FT /note="P -> H (in Ref. 2; AAA35926 and 7; AAA52588)" FT /evidence="ECO:0000305" FT CONFLICT 1030 FT /note="P -> T (in Ref. 7; AAA52588)" FT /evidence="ECO:0000305" FT STRAND 36..38 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 52..58 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 60..62 FT /evidence="ECO:0007829|PDB:1TYE" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:7UCY" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 126..131 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 143..148 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 151..153 FT /evidence="ECO:0007829|PDB:2VDL" FT STRAND 159..165 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 166..169 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 170..174 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 189..193 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:7LA4" FT STRAND 211..216 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 219..222 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 225..230 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 231..237 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 268..273 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:7UJE" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 291..294 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 297..301 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 307..312 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 314..318 FT /evidence="ECO:0007829|PDB:7LA4" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 336..341 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 352..355 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 358..362 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 375..379 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 391..398 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 400..402 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 404..409 FT /evidence="ECO:0007829|PDB:7UDH" FT TURN 413..416 FT /evidence="ECO:0007829|PDB:6V4P" FT STRAND 419..423 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:1TYE" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 450..456 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 461..463 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 465..470 FT /evidence="ECO:0007829|PDB:7UDH" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 475..479 FT /evidence="ECO:0007829|PDB:7UDH" FT STRAND 484..493 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8T2V" FT STRAND 507..509 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 512..525 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 534..541 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 542..544 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 547..549 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 555..557 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 559..567 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 575..583 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 592..594 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 596..603 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 616..619 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 622..627 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 634..637 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 643..651 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 653..655 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 662..670 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 678..683 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 688..695 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 698..700 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 705..708 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 710..713 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 715..721 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 728..738 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 746..755 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 759..761 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 767..774 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 779..792 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 810..819 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 821..823 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 825..836 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 842..854 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 856..861 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 906..909 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 911..913 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 916..926 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 931..940 FT /evidence="ECO:0007829|PDB:3FCS" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 952..965 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 967..969 FT /evidence="ECO:0007829|PDB:3FCS" FT STRAND 977..988 FT /evidence="ECO:0007829|PDB:3FCS" FT TURN 991..994 FT /evidence="ECO:0007829|PDB:2KNC" FT TURN 996..1001 FT /evidence="ECO:0007829|PDB:8GCD" FT HELIX 1002..1015 FT /evidence="ECO:0007829|PDB:8GCD" FT STRAND 1019..1027 FT /evidence="ECO:0007829|PDB:7SC4" FT HELIX 1028..1031 FT /evidence="ECO:0007829|PDB:1DPK" FT TURN 1035..1038 FT /evidence="ECO:0007829|PDB:1DPQ" SQ SEQUENCE 1039 AA; 113377 MW; 063EE298E026F116 CRC64; MARALCPLQA LWLLEWVLLL LGPCAAPPAW ALNLDPVQLT FYAGPNGSQF GFSLDFHKDS HGRVAIVVGA PRTLGPSQEE TGGVFLCPWR AEGGQCPSLL FDLRDETRNV GSQTLQTFKA RQGLGASVVS WSDVIVACAP WQHWNVLEKT EEAEKTPVGS CFLAQPESGR RAEYSPCRGN TLSRIYVEND FSWDKRYCEA GFSSVVTQAG ELVLGAPGGY YFLGLLAQAP VADIFSSYRP GILLWHVSSQ SLSFDSSNPE YFDGYWGYSV AVGEFDGDLN TTEYVVGAPT WSWTLGAVEI LDSYYQRLHR LRGEQMASYF GHSVAVTDVN GDGRHDLLVG APLYMESRAD RKLAEVGRVY LFLQPRGPHA LGAPSLLLTG TQLYGRFGSA IAPLGDLDRD GYNDIAVAAP YGGPSGRGQV LVFLGQSEGL RSRPSQVLDS PFPTGSAFGF SLRGAVDIDD NGYPDLIVGA YGANQVAVYR AQPVVKASVQ LLVQDSLNPA VKSCVLPQTK TPVSCFNIQM CVGATGHNIP QKLSLNAELQ LDRQKPRQGR RVLLLGSQQA GTTLNLDLGG KHSPICHTTM AFLRDEADFR DKLSPIVLSL NVSLPPTEAG MAPAVVLHGD THVQEQTRIV LDCGEDDVCV PQLQLTASVT GSPLLVGADN VLELQMDAAN EGEGAYEAEL AVHLPQGAHY MRALSNVEGF ERLICNQKKE NETRVVLCEL GNPMKKNAQI GIAMLVSVGN LEEAGESVSF QLQIRSKNSQ NPNSKIVLLD VPVRAEAQVE LRGNSFPASL VVAAEEGERE QNSLDSWGPK VEHTYELHNN GPGTVNGLHL SIHLPGQSQP SDLLYILDIQ PQGGLQCFPQ PPVNPLKVDW GLPIPSPSPI HPAHHKRDRR QIFLPEPEQP SRLQDPVLVS CDSAPCTVVQ CDLQEMARGQ RAMVTVLAFL WLPSLYQRPL DQFVLQSHAW FNVSSLPYAV PPLSLPRGEA QVWTQLLRAL EERAIPIWWV LVGVLGGLLL LTILVLAMWK VGFFKRNRPP LEEDDEEGE // ID ITK_HUMAN Reviewed; 620 AA. AC Q08881; B2R752; Q32ML7; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1994, sequence version 1. DT 28-JAN-2026, entry version 239. DE RecName: Full=Tyrosine-protein kinase ITK/TSK; DE EC=2.7.10.2; DE AltName: Full=Interleukin-2-inducible T-cell kinase; DE Short=IL-2-inducible T-cell kinase; DE AltName: Full=Kinase EMT; DE AltName: Full=T-cell-specific kinase; DE AltName: Full=Tyrosine-protein kinase Lyk; GN Name=ITK; Synonyms=EMT, LYK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION. RX PubMed=8504851; DOI=10.1016/0014-5793(93)81520-a; RA Tanaka N., Asao H., Ohtani K., Nakamura M., Sugamura K.; RT "A novel human tyrosine kinase gene inducible in T cells by interleukin RT 2."; RL FEBS Lett. 324:1-5(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Thymus; RX PubMed=8364206; RA Gibson S., Leung B., Squire J.A., Hill M., Arima N., Goss P., Hogg D., RA Mills G.B.; RT "Identification, cloning, and characterization of a novel human T-cell- RT specific tyrosine kinase located at the hematopoietin complex on chromosome RT 5q."; RL Blood 82:1561-1572(1993). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 171-192, AND PHOSPHORYLATION AT TYR-180. RX PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1; RA Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A., RA Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.; RT "Identification of phosphorylation sites within the SH3 domains of Tec RT family tyrosine kinases."; RL Biochim. Biophys. Acta 1645:123-132(2003). RN [7] RP PHOSPHORYLATION BY LCK. RX PubMed=9312162; DOI=10.1074/jbc.272.40.25401; RA Heyeck S.D., Wilcox H.M., Bunnell S.C., Berg L.J.; RT "Lck phosphorylates the activation loop tyrosine of the Itk kinase domain RT and activates Itk kinase activity."; RL J. Biol. Chem. 272:25401-25408(1997). RN [8] RP INDUCTION. RX PubMed=9701039; DOI=10.1093/intimm/10.7.1009; RA King P.D., Sadra A., Teng J.M., Bell G.M., Dupont B.; RT "CD2-mediated activation of the Tec-family tyrosine kinase ITK is RT controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail."; RL Int. Immunol. 10:1009-1016(1998). RN [9] RP DOMAIN. RX PubMed=10795735; DOI=10.1016/s1074-7613(00)80189-2; RA Yang W.C., Collette Y., Nunes J.A., Olive D.; RT "Tec kinases: a family with multiple roles in immunity."; RL Immunity 12:373-382(2000). RN [10] RP FUNCTION IN PHOSPHORYLATION OF LAT. RX PubMed=12186560; DOI=10.1021/bi025554o; RA Perez-Villar J.J., Whitney G.S., Sitnick M.T., Dunn R.J., Venkatesan S., RA O'Day K., Schieven G.L., Lin T.A., Kanner S.B.; RT "Phosphorylation of the linker for activation of T-cells by Itk promotes RT recruitment of Vav."; RL Biochemistry 41:10732-10740(2002). RN [11] RP FUNCTION. RX PubMed=12682224; DOI=10.4049/jimmunol.170.8.3971; RA Grasis J.A., Browne C.D., Tsoukas C.D.; RT "Inducible T cell tyrosine kinase regulates actin-dependent cytoskeletal RT events induced by the T cell antigen receptor."; RL J. Immunol. 170:3971-3976(2003). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [13] RP INTERACTION WITH PPIA/CYPA, AND MUTAGENESIS OF PRO-288. RX PubMed=15308100; DOI=10.1016/j.immuni.2004.07.005; RA Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y., RA Sokolskaja E., Andreotti A., Luban J.; RT "Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline- RT directed conformational switch in Itk."; RL Immunity 21:189-201(2004). RN [14] RP INTERACTION WITH VAV1. RX PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385; RA Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A., RA Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K., Schwartzberg P.L.; RT "Kinase-independent functions for Itk in TCR-induced regulation of Vav and RT the actin cytoskeleton."; RL J. Immunol. 174:1385-1392(2005). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=17060314; DOI=10.1074/jbc.m609180200; RA Qi Q., Sahu N., August A.; RT "Tec kinase Itk forms membrane clusters specifically in the vicinity of RT recruiting receptors."; RL J. Biol. Chem. 281:38529-38534(2006). RN [16] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [17] RP AUTOPHOSPHORYLATION. RX PubMed=19523959; DOI=10.1016/j.jmb.2009.06.023; RA Joseph R.E., Severin A., Min L., Fulton D.B., Andreotti A.H.; RT "SH2-dependent autophosphorylation within the Tec family kinase Itk."; RL J. Mol. Biol. 391:164-177(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-512 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP UBIQUITINATION. RX PubMed=20596523; DOI=10.1371/journal.pone.0011332; RA Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B., RA Spruck C.; RT "Development and validation of a method for profiling post-translational RT modification activities using protein microarrays."; RL PLoS ONE 5:E11332-E11332(2010). RN [20] RP FUNCTION IN PHOSPHORYLATION OF LCP2. RX PubMed=21725281; DOI=10.1038/emboj.2011.213; RA Sela M., Bogin Y., Beach D., Oellerich T., Lehne J., Smith-Garvin J.E., RA Okumura M., Starosvetsky E., Kosoff R., Libman E., Koretzky G., RA Kambayashi T., Urlaub H., Wienands J., Chernoff J., Yablonski D.; RT "Sequential phosphorylation of SLP-76 at tyrosine 173 is required for RT activation of T and mast cells."; RL EMBO J. 30:3160-3172(2011). RN [21] RP STRUCTURE BY NMR OF 113-239. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the BTK motif and the SH3 domain of tyrosine-protein RT kinase ITK from human."; RL Submitted (OCT-2007) to the PDB data bank. RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-19; LEU-23; GLN-451; TRP-581 AND RP ILE-587. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANT LPFS1 TRP-335, AND CHARACTERIZATION OF VARIANT LPSA1 TRP-335. RX PubMed=19425169; DOI=10.1172/jci37901; RA Huck K., Feyen O., Niehues T., Rueschendorf F., Huebner N., Laws H.-J., RA Telieps T., Knapp S., Wacker H.-H., Meindl A., Jumaa H., Borkhardt A.; RT "Girls homozygous for an IL-2-inducible T cell kinase mutation that leads RT to protein deficiency develop fatal EBV-associated lymphoproliferation."; RL J. Clin. Invest. 119:1350-1358(2009). CC -!- FUNCTION: Tyrosine kinase that plays an essential role in regulation of CC the adaptive immune response. Regulates the development, function and CC differentiation of conventional T-cells and nonconventional NKT-cells. CC When antigen presenting cells (APC) activate T-cell receptor (TCR), a CC series of phosphorylation lead to the recruitment of ITK to the cell CC membrane, in the vicinity of the stimulated TCR receptor, where it is CC phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation CC and full activation. Once activated, phosphorylates PLCG1, leading to CC the activation of this lipase and subsequent cleavage of its CC substrates. In turn, the endoplasmic reticulum releases calcium in the CC cytoplasm and the nuclear activator of activated T-cells (NFAT) CC translocates into the nucleus to perform its transcriptional duty. CC Phosphorylates 2 essential adapter proteins: the linker for activation CC of T-cells/LAT protein and LCP2. Then, a large number of signaling CC molecules such as VAV1 are recruited and ultimately lead to lymphokine CC production, T-cell proliferation and differentiation (PubMed:12186560, CC PubMed:12682224, PubMed:21725281). Required for TCR-mediated calcium CC response in gamma-delta T-cells, may also be involved in the modulation CC of the transcriptomic signature in the Vgamma2-positive subset of CC immature gamma-delta T-cells (By similarity). Phosphorylates TBX21 at CC 'Tyr-530' and mediates its interaction with GATA3 (By similarity). CC {ECO:0000250|UniProtKB:Q03526, ECO:0000269|PubMed:12186560, CC ECO:0000269|PubMed:12682224, ECO:0000269|PubMed:21725281}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- SUBUNIT: Homooligomerizes; this association negatively regulates kinase CC activity (By similarity). Interacts with PPIA/CYPA; this interaction CC regulates TCR signal strength via a proline-directed conformational CC switch in ITK. Interacts with THEMIS (By similarity). Interacts with CC FASLG. Interacts with VAV1; this interaction is important for VAV1 CC localization and TCR-induced actin polarization. Interacts with TBX21 CC (By similarity). {ECO:0000250|UniProtKB:Q03526, CC ECO:0000269|PubMed:15308100, ECO:0000269|PubMed:15661896, CC ECO:0000269|PubMed:19807924}. CC -!- INTERACTION: CC Q08881; P04626: ERBB2; NbExp=2; IntAct=EBI-968552, EBI-641062; CC Q08881; P48023: FASLG; NbExp=3; IntAct=EBI-968552, EBI-495538; CC Q08881; P08238: HSP90AB1; NbExp=3; IntAct=EBI-968552, EBI-352572; CC Q08881; Q13094: LCP2; NbExp=4; IntAct=EBI-968552, EBI-346946; CC Q08881; P31947: SFN; NbExp=2; IntAct=EBI-968552, EBI-476295; CC Q08881; P62258: YWHAE; NbExp=2; IntAct=EBI-968552, EBI-356498; CC Q08881; P10686: Plcg1; Xeno; NbExp=2; IntAct=EBI-968552, EBI-520788; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17060314}. Nucleus CC {ECO:0000250|UniProtKB:Q03526}. Note=Localizes in the vicinity of cell CC surface receptors in the plasma membrane after receptor stimulation. CC -!- TISSUE SPECIFICITY: T-cell lines and natural killer cell lines. CC -!- INDUCTION: Through a myriad of surface receptors including the TCR/CD3 CC signaling complex, coreceptors, or chemokine receptors. CC {ECO:0000269|PubMed:8504851, ECO:0000269|PubMed:9701039}. CC -!- DOMAIN: The N-terminal PH domain allows ITK to be recruited to the CC plasma membrane by an activated PI3 kinase. This domain also contains a CC proline-rich region (PRR). The adjoining domain is a SH3 domain, which CC binds to PRR (from itself or from other proteins). Next, a SH2 domain CC is required for binding tyrosine-phosphorylated substrates. In the C- CC terminal region, the kinase domain is required for tyrosine CC phosphorylation. {ECO:0000269|PubMed:10795735}. CC -!- PTM: Phosphorylated at Tyr-512 in the activation loop of the kinase CC domain by LCK. Subsequent autophosphorylation at Tyr-180 leads to the CC kinase activation. The autophosphorylated Tyr-180 lies within the CC substrate binding sequence of the SH3 domain. CC {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:9312162}. CC -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}. CC -!- DISEASE: Lymphoproliferative syndrome 1 (LPFS1) [MIM:613011]: A rare CC immunodeficiency characterized by extreme susceptibility to infection CC with Epstein-Barr virus (EBV). Inadequate immune response to EBV can CC have a fatal outcome. Clinical features include splenomegaly, CC lymphadenopathy, anemia, thrombocytopenia, pancytopenia, recurrent CC infections. There is an increased risk for lymphoma. CC {ECO:0000269|PubMed:19425169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/43329/ITK"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D13720; BAA02873.1; -; mRNA. DR EMBL; L10717; AAA36748.1; -; mRNA. DR EMBL; S65186; AAB28072.2; -; mRNA. DR EMBL; AK312846; BAG35699.1; -; mRNA. DR EMBL; CH471062; EAW61608.1; -; Genomic_DNA. DR EMBL; BC109077; AAI09078.1; -; mRNA. DR EMBL; BC109078; AAI09079.1; -; mRNA. DR CCDS; CCDS4336.1; -. DR PIR; S33253; S33253. DR RefSeq; NP_005537.3; NM_005546.3. DR PDB; 1SM2; X-ray; 2.30 A; A/B=357-620. DR PDB; 1SNU; X-ray; 2.50 A; A/B=357-620. DR PDB; 1SNX; X-ray; 3.20 A; A/B=357-620. DR PDB; 2E6I; NMR; -; A=113-169. DR PDB; 2LMJ; NMR; -; A=171-231. DR PDB; 2YUQ; NMR; -; A=162-239. DR PDB; 3MIY; X-ray; 1.67 A; A/B=357-620. DR PDB; 3MJ1; X-ray; 1.72 A; A=357-620. DR PDB; 3MJ2; X-ray; 1.90 A; A=357-620. DR PDB; 3QGW; X-ray; 2.10 A; A/B=357-620. DR PDB; 3QGY; X-ray; 2.10 A; A/B=357-620. DR PDB; 3T9T; X-ray; 1.65 A; A=354-620. DR PDB; 3V5J; X-ray; 2.59 A; A/B=357-620. DR PDB; 3V5L; X-ray; 1.86 A; A/B/C/D=357-620. DR PDB; 3V8T; X-ray; 2.00 A; A/B=357-620. DR PDB; 3V8W; X-ray; 2.27 A; A/B=357-620. DR PDB; 4HCT; X-ray; 1.48 A; A=354-620. DR PDB; 4HCU; X-ray; 1.43 A; A=354-620. DR PDB; 4HCV; X-ray; 1.48 A; A=354-620. DR PDB; 4KIO; X-ray; 2.18 A; A/B/C/D=357-620. DR PDB; 4L7S; X-ray; 2.03 A; A/B=357-620. DR PDB; 4M0Y; X-ray; 1.70 A; A=354-620. DR PDB; 4M0Z; X-ray; 2.00 A; A=354-620. DR PDB; 4M12; X-ray; 2.15 A; A=354-620. DR PDB; 4M13; X-ray; 1.85 A; A=354-620. DR PDB; 4M14; X-ray; 1.55 A; A=354-620. DR PDB; 4M15; X-ray; 1.52 A; A=354-620. DR PDB; 4MF0; X-ray; 2.67 A; A/B=357-620. DR PDB; 4MF1; X-ray; 2.11 A; A/B=357-620. DR PDB; 4PP9; X-ray; 2.58 A; A/B=357-620. DR PDB; 4PPA; X-ray; 2.67 A; A/B=357-620. DR PDB; 4PPB; X-ray; 2.82 A; A/B=357-620. DR PDB; 4PPC; X-ray; 2.95 A; A/B=357-620. DR PDB; 4PQN; X-ray; 1.71 A; A=357-620. DR PDB; 4QD6; X-ray; 2.45 A; A/B=357-620. DR PDB; 4RFM; X-ray; 2.10 A; A=357-620. DR PDBsum; 1SM2; -. DR PDBsum; 1SNU; -. DR PDBsum; 1SNX; -. DR PDBsum; 2E6I; -. DR PDBsum; 2LMJ; -. DR PDBsum; 2YUQ; -. DR PDBsum; 3MIY; -. DR PDBsum; 3MJ1; -. DR PDBsum; 3MJ2; -. DR PDBsum; 3QGW; -. DR PDBsum; 3QGY; -. DR PDBsum; 3T9T; -. DR PDBsum; 3V5J; -. DR PDBsum; 3V5L; -. DR PDBsum; 3V8T; -. DR PDBsum; 3V8W; -. DR PDBsum; 4HCT; -. DR PDBsum; 4HCU; -. DR PDBsum; 4HCV; -. DR PDBsum; 4KIO; -. DR PDBsum; 4L7S; -. DR PDBsum; 4M0Y; -. DR PDBsum; 4M0Z; -. DR PDBsum; 4M12; -. DR PDBsum; 4M13; -. DR PDBsum; 4M14; -. DR PDBsum; 4M15; -. DR PDBsum; 4MF0; -. DR PDBsum; 4MF1; -. DR PDBsum; 4PP9; -. DR PDBsum; 4PPA; -. DR PDBsum; 4PPB; -. DR PDBsum; 4PPC; -. DR PDBsum; 4PQN; -. DR PDBsum; 4QD6; -. DR PDBsum; 4RFM; -. DR AlphaFoldDB; Q08881; -. DR BMRB; Q08881; -. DR SMR; Q08881; -. DR BioGRID; 109907; 55. DR CORUM; Q08881; -. DR DIP; DIP-29974N; -. DR FunCoup; Q08881; 1866. DR IntAct; Q08881; 45. DR MINT; Q08881; -. DR STRING; 9606.ENSP00000398655; -. DR BindingDB; Q08881; -. DR ChEMBL; CHEMBL2959; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q08881; -. DR GuidetoPHARMACOLOGY; 2046; -. DR GlyGen; Q08881; 1 site. DR iPTMnet; Q08881; -. DR PhosphoSitePlus; Q08881; -. DR BioMuta; ITK; -. DR DMDM; 585361; -. DR CPTAC; CPTAC-2862; -. DR CPTAC; CPTAC-2863; -. DR jPOST; Q08881; -. DR MassIVE; Q08881; -. DR PaxDb; 9606-ENSP00000398655; -. DR PeptideAtlas; Q08881; -. DR ProteomicsDB; 58650; -. DR Pumba; Q08881; -. DR ABCD; Q08881; 4 sequenced antibodies. DR Antibodypedia; 16533; 527 antibodies from 42 providers. DR DNASU; 3702; -. DR Ensembl; ENST00000422843.8; ENSP00000398655.4; ENSG00000113263.15. DR GeneID; 3702; -. DR KEGG; hsa:3702; -. DR MANE-Select; ENST00000422843.8; ENSP00000398655.4; NM_005546.4; NP_005537.3. DR UCSC; uc003lwo.2; human. DR AGR; HGNC:6171; -. DR ClinPGx; PA29968; -. DR CTD; 3702; -. DR DisGeNET; 3702; -. DR GeneCards; ITK; -. DR HGNC; HGNC:6171; ITK. DR HPA; ENSG00000113263; Tissue enriched (lymphoid). DR MalaCards; ITK; -. DR MIM; 186973; gene. DR MIM; 613011; phenotype. DR OpenTargets; ENSG00000113263; -. DR Orphanet; 538963; Combined immunodeficiency due to ITK deficiency. DR VEuPathDB; HostDB:ENSG00000113263; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000158850; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q08881; -. DR OMA; GYWLEKT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q08881; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q08881; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q08881; -. DR Reactome; R-HSA-202433; Generation of second messenger molecules. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR SignaLink; Q08881; -. DR SIGNOR; Q08881; -. DR Agora; ENSG00000113263; -. DR BioGRID-ORCS; 3702; 17 hits in 1184 CRISPR screens. DR CD-CODE; F345034F; Signaling cluster. DR ChiTaRS; ITK; human. DR EvolutionaryTrace; Q08881; -. DR GeneWiki; ITK_(gene); -. DR GenomeRNAi; 3702; -. DR Pharos; Q08881; Tclin. DR PRO; PR:Q08881; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q08881; protein. DR Bgee; ENSG00000113263; Expressed in granulocyte and 129 other cell types or tissues. DR ExpressionAtlas; Q08881; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central. DR GO; GO:0006968; P:cellular defense response; TAS:ProtInc. DR GO; GO:0046629; P:gamma-delta T cell activation; ISS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042110; P:T cell activation; TAS:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB. DR CDD; cd01238; PH_Btk; 1. DR CDD; cd05112; PTKc_Itk; 1. DR CDD; cd10396; SH2_Tec_Itk; 1. DR CDD; cd11908; SH3_ITK; 1. DR FunFam; 1.10.510.10:FF:000052; Tyrosine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000244; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000176; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000061; Tyrosine-protein kinase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042785; ITK_PTKc. DR InterPro; IPR035583; ITK_SH3. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001562; Znf_Btk_motif. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF00779; BTK; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00107; BTK; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR PROSITE; PS51113; ZF_BTK; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Cytoplasm; KW Direct protein sequencing; Disease variant; Immunity; Kinase; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..620 FT /note="Tyrosine-protein kinase ITK/TSK" FT /id="PRO_0000088106" FT DOMAIN 4..111 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 171..231 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 239..338 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 363..615 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 113..149 FT /note="Btk-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT ACT_SITE 482 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 133 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 143 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 369..377 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 391 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 180 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12573241" FT MOD_RES 512 FT /note="Phosphotyrosine; by LCK" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT VARIANT 19 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1753502279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041710" FT VARIANT 23 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041711" FT VARIANT 193 FT /note="R -> Q (in dbSNP:rs17054374)" FT /id="VAR_051696" FT VARIANT 335 FT /note="R -> W (in LPFS1; shows nearly undetectable mutant FT ITK protein consistent with severe protein instability; FT dbSNP:rs121908191)" FT /evidence="ECO:0000269|PubMed:19425169" FT /id="VAR_063424" FT VARIANT 451 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs779372373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041712" FT VARIANT 581 FT /note="R -> W (in dbSNP:rs34482255)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041713" FT VARIANT 587 FT /note="V -> I (in dbSNP:rs56005928)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041714" FT MUTAGEN 288 FT /note="P->G: Complete loss of interaction with PPIA/CYPA." FT /evidence="ECO:0000269|PubMed:15308100" FT CONFLICT 171..172 FT /note="PE -> GS (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="V -> W (in Ref. 2; AAB28072)" FT /evidence="ECO:0000305" FT STRAND 127..133 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 148..152 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 175..180 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 197..205 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 208..212 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 218..221 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 360..362 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 363..371 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:4KIO" FT STRAND 376..382 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 383..385 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 386..393 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 395..397 FT /evidence="ECO:0007829|PDB:3T9T" FT HELIX 400..411 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 421..425 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 427..436 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 443..448 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 449..452 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 456..475 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 485..487 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 503..506 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 510..513 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 522..524 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 527..532 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 537..552 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:4PQN" FT TURN 558..561 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 564..572 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 581..583 FT /evidence="ECO:0007829|PDB:3V8W" FT HELIX 585..594 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 605..617 FT /evidence="ECO:0007829|PDB:4HCU" SQ SEQUENCE 620 AA; 71831 MW; DAE396BD2309319D CRC64; MNNFILLEEQ LIKKSQQKRR TSPSNFKVRF FVLTKASLAY FEDRHGKKRT LKGSIELSRI KCVEIVKSDI SIPCHYKYPF QVVHDNYLLY VFAPDRESRQ RWVLALKEET RNNNSLVPKY HPNFWMDGKW RCCSQLEKLA TGCAQYDPTK NASKKPLPPT PEDNRRPLWE PEETVVIALY DYQTNDPQEL ALRRNEEYCL LDSSEIHWWR VQDRNGHEGY VPSSYLVEKS PNNLETYEWY NKSISRDKAE KLLLDTGKEG AFMVRDSRTA GTYTVSVFTK AVVSENNPCI KHYHIKETND NPKRYYVAEK YVFDSIPLLI NYHQHNGGGL VTRLRYPVCF GRQKAPVTAG LRYGKWVIDP SELTFVQEIG SGQFGLVHLG YWLNKDKVAI KTIREGAMSE EDFIEEAEVM MKLSHPKLVQ LYGVCLEQAP ICLVFEFMEH GCLSDYLRTQ RGLFAAETLL GMCLDVCEGM AYLEEACVIH RDLAARNCLV GENQVIKVSD FGMTRFVLDD QYTSSTGTKF PVKWASPEVF SFSRYSSKSD VWSFGVLMWE VFSEGKIPYE NRSNSEVVED ISTGFRLYKP RLASTHVYQI MNHCWKERPE DRPAFSRLLR QLAEIAESGL // ID KS6A2_HUMAN Reviewed; 733 AA. AC Q15349; B3KTK9; Q15419; Q59GJ3; Q5TI68; Q96J38; Q9UJN5; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Ribosomal protein S6 kinase alpha-2; DE Short=S6K-alpha-2; DE EC=2.7.11.1; DE AltName: Full=90 kDa ribosomal protein S6 kinase 2; DE Short=p90-RSK 2; DE Short=p90RSK2; DE AltName: Full=MAP kinase-activated protein kinase 1c; DE Short=MAPK-activated protein kinase 1c; DE Short=MAPKAP kinase 1c; DE Short=MAPKAPK-1c; DE AltName: Full=Ribosomal S6 kinase 3; DE Short=RSK-3; DE AltName: Full=pp90RSK3; GN Name=RPS6KA2; Synonyms=MAPKAPK1C, RSK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP SUBCELLULAR LOCATION. RX PubMed=7623830; DOI=10.1128/mcb.15.8.4353; RA Zhao Y., Bjoerbaek C., Weremowicz S., Morton C.C., Moller D.E.; RT "RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: RT growth factor-stimulated kinase function and nuclear translocation."; RL Mol. Cell. Biol. 15:4353-4363(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-540 (ISOFORM 1). RX PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351; RA Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.; RT "Human rsk isoforms: cloning and characterization of tissue-specific RT expression."; RL Am. J. Physiol. 266:C351-C359(1994). RN [7] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-218. RX PubMed=10480933; DOI=10.1074/jbc.274.38.27168; RA Jensen C.J., Buch M.-B., Krag T.O., Hemmings B.A., Gammeltoft S., RA Froedin M.; RT "90-kDa ribosomal S6 kinase is phosphorylated and activated by 3- RT phosphoinositide-dependent protein kinase-1."; RL J. Biol. Chem. 274:27168-27176(1999). RN [8] RP FUNCTION IN TUMORIGENESIS, AND TISSUE SPECIFICITY. RX PubMed=16878154; DOI=10.1038/sj.onc.1209827; RA Bignone P.A., Lee K.Y., Liu Y., Emilion G., Finch J., Soosay A.E., RA Charnock F.M., Beck S., Dunham I., Mungall A.J., Ganesan T.S.; RT "RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial RT ovarian cancer."; RL Oncogene 26:683-700(2007). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP REVIEW ON FUNCTION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-311 AND GLN-732. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK CC (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and CC stress-induced activation of transcription factors, regulates CC translation, and mediates cellular proliferation, survival, and CC differentiation. May function as tumor suppressor in epithelial ovarian CC cancer cells. {ECO:0000269|PubMed:16878154, CC ECO:0000269|PubMed:7623830}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation, CC phosphorylated at Thr-570 in the C-terminal kinase domain (CTKD) by CC MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates CC Ser-377, allowing binding of PDPK1, which in turn phosphorylates Ser- CC 218 in the N-terminal kinase domain (NTDK) leading to the full CC activation of the protein and subsequent phosphorylation of the CC substrates by the NTKD. {ECO:0000269|PubMed:10480933}. CC -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in CC quiescent cells. Transiently dissociates following mitogenic CC stimulation (By similarity). Interacts with FBXO5; cooperate to induce CC the metaphase arrest of early blastomeres; increases and stabilizes CC interaction of FBXO5 with CDC20 (By similarity). {ECO:0000250, CC ECO:0000250|UniProtKB:Q9WUT3}. CC -!- INTERACTION: CC Q15349; P05067: APP; NbExp=3; IntAct=EBI-1384149, EBI-77613; CC Q15349; P15056: BRAF; NbExp=2; IntAct=EBI-1384149, EBI-365980; CC Q15349; P67870: CSNK2B; NbExp=4; IntAct=EBI-1384149, EBI-348169; CC Q15349; O14901: KLF11; NbExp=3; IntAct=EBI-1384149, EBI-948266; CC Q15349; P28482: MAPK1; NbExp=12; IntAct=EBI-1384149, EBI-959949; CC Q15349; Q02156: PRKCE; NbExp=2; IntAct=EBI-1384149, EBI-706254; CC Q15349; Q14160: SCRIB; NbExp=9; IntAct=EBI-1384149, EBI-357345; CC Q15349; Q9Y566: SHANK1; NbExp=2; IntAct=EBI-1384149, EBI-3442234; CC Q15349; P62258: YWHAE; NbExp=2; IntAct=EBI-1384149, EBI-356498; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:7623830}. Cytoplasm CC {ECO:0000269|PubMed:7623830}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q15349-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15349-2; Sequence=VSP_017732; CC Name=3; CC IsoId=Q15349-3; Sequence=VSP_041836; CC -!- TISSUE SPECIFICITY: Widely expressed with higher expression in lung, CC skeletal muscle, brain, uterus, ovary, thyroid and prostate. CC {ECO:0000269|PubMed:16878154, ECO:0000269|PubMed:7623830}. CC -!- PTM: Activated by phosphorylation at Ser-218 by PDPK1. CC Autophosphorylated on Ser-377, as part of the activation process. May CC be phosphorylated at Thr-356 and Ser-360 by MAPK1/ERK2 and MAPK3/ERK1 CC (By similarity). {ECO:0000250}. CC -!- PTM: N-terminal myristoylation results in an activated kinase in the CC absence of added growth factors. {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC82496.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAD92353.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAG53121.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X85106; CAA59427.1; -; mRNA. DR EMBL; AB209116; BAD92353.1; ALT_INIT; mRNA. DR EMBL; AK095751; BAG53121.1; ALT_FRAME; mRNA. DR EMBL; AL022069; CAI19651.1; -; Genomic_DNA. DR EMBL; Z98049; CAI19651.1; JOINED; Genomic_DNA. DR EMBL; AL023775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL159163; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z98049; CAI20579.1; -; Genomic_DNA. DR EMBL; AL022069; CAI20579.1; JOINED; Genomic_DNA. DR EMBL; BC002363; AAH02363.1; -; mRNA. DR EMBL; L07598; AAC82496.1; ALT_INIT; mRNA. DR CCDS; CCDS34570.1; -. [Q15349-3] DR CCDS; CCDS5294.1; -. [Q15349-1] DR CCDS; CCDS83148.1; -. [Q15349-2] DR PIR; A57459; A57459. DR RefSeq; NP_001006933.3; NM_001006932.3. [Q15349-3] DR RefSeq; NP_001305865.2; NM_001318936.2. DR RefSeq; NP_001305866.1; NM_001318937.1. DR RefSeq; NP_001305867.1; NM_001318938.1. DR RefSeq; NP_066958.2; NM_021135.5. [Q15349-1] DR AlphaFoldDB; Q15349; -. DR SMR; Q15349; -. DR BioGRID; 112110; 201. DR DIP; DIP-295N; -. DR FunCoup; Q15349; 3133. DR IntAct; Q15349; 62. DR MINT; Q15349; -. DR STRING; 9606.ENSP00000422435; -. DR BindingDB; Q15349; -. DR ChEMBL; CHEMBL3906; -. DR DrugCentral; Q15349; -. DR GuidetoPHARMACOLOGY; 1529; -. DR iPTMnet; Q15349; -. DR PhosphoSitePlus; Q15349; -. DR BioMuta; RPS6KA2; -. DR DMDM; 90110031; -. DR REPRODUCTION-2DPAGE; Q15349; -. DR CPTAC; CPTAC-2945; -. DR jPOST; Q15349; -. DR MassIVE; Q15349; -. DR PaxDb; 9606-ENSP00000427015; -. DR PeptideAtlas; Q15349; -. DR ProteomicsDB; 60536; -. [Q15349-1] DR ProteomicsDB; 60537; -. [Q15349-2] DR ProteomicsDB; 60538; -. [Q15349-3] DR Antibodypedia; 33522; 564 antibodies from 43 providers. DR DNASU; 6196; -. DR Ensembl; ENST00000265678.9; ENSP00000265678.4; ENSG00000071242.14. [Q15349-1] DR Ensembl; ENST00000503859.5; ENSP00000427015.1; ENSG00000071242.14. [Q15349-3] DR GeneID; 6196; -. DR KEGG; hsa:6196; -. DR MANE-Select; ENST00000265678.9; ENSP00000265678.4; NM_021135.6; NP_066958.2. DR UCSC; uc003qvb.2; human. [Q15349-1] DR AGR; HGNC:10431; -. DR ClinPGx; PA34846; -. DR CTD; 6196; -. DR DisGeNET; 6196; -. DR GeneCards; RPS6KA2; -. DR HGNC; HGNC:10431; RPS6KA2. DR HPA; ENSG00000071242; Low tissue specificity. DR MIM; 601685; gene. DR OpenTargets; ENSG00000071242; -. DR VEuPathDB; HostDB:ENSG00000071242; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159956; -. DR InParanoid; Q15349; -. DR OMA; GAMKATY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q15349; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q15349; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15349; -. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-199920; CREB phosphorylation. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR SignaLink; Q15349; -. DR SIGNOR; Q15349; -. DR Agora; ENSG00000071242; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 6196; 19 hits in 1179 CRISPR screens. DR ChiTaRS; RPS6KA2; human. DR GeneWiki; RPS6KA2; -. DR GenomeRNAi; 6196; -. DR Pharos; Q15349; Tchem. DR PRO; PR:Q15349; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15349; protein. DR Bgee; ENSG00000071242; Expressed in inferior olivary complex and 215 other cell types or tissues. DR ExpressionAtlas; Q15349; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0002035; P:brain renin-angiotensin system; IEA:Ensembl. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome. DR GO; GO:0060047; P:heart contraction; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc. DR GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0001556; P:oocyte maturation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0070613; P:regulation of protein processing; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14178; STKc_RSK3_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR042766; RSK3_STKc. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Magnesium; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..733 FT /note="Ribosomal protein S6 kinase alpha-2" FT /id="PRO_0000086201" FT DOMAIN 59..318 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 319..388 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 415..672 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 184 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 532 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 91 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 421..429 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 444 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 218 FT /note="Phosphoserine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10480933" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVGPATEDTAEEGKSDSAACKTKVAGSV (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017732" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVEPTTEDTAE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041836" FT VARIANT 311 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267600891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040627" FT VARIANT 732 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376029388)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040628" FT CONFLICT 256 FT /note="S -> A (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 269 FT /note="A -> S (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 339 FT /note="V -> L (in Ref. 1; CAA59427 and 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 447 FT /note="D -> G (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:32 FT /note="E -> G (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:34 FT /note="T -> A (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" SQ SEQUENCE 733 AA; 83239 MW; 087CFB819A313760 CRC64; MDLSMKKFAV RRFFSVYLRR KSRSKSSSLS RLEEEGVVKE IDISHHVKEG FEKADPSQFE LLKVLGQGSY GKVFLVRKVK GSDAGQLYAM KVLKKATLKV RDRVRSKMER DILAEVNHPF IVKLHYAFQT EGKLYLILDF LRGGDLFTRL SKEVMFTEED VKFYLAELAL ALDHLHSLGI IYRDLKPENI LLDEEGHIKI TDFGLSKEAI DHDKRAYSFC GTIEYMAPEV VNRRGHTQSA DWWSFGVLMF EMLTGSLPFQ GKDRKETMAL ILKAKLGMPQ FLSGEAQSLL RALFKRNPCN RLGAGIDGVE EIKRHPFFVT IDWNTLYRKE IKPPFKPAVG RPEDTFHFDP EFTARTPTDS PGVPPSANAH HLFRGFSFVA SSLIQEPSQQ DLHKVPVHPI VQQLHGNNIH FTDGYEIKED IGVGSYSVCK RCVHKATDTE YAVKIIDKSK RDPSEEIEIL LRYGQHPNII TLKDVYDDGK FVYLVMELMR GGELLDRILR QRYFSEREAS DVLCTITKTM DYLHSQGVVH RDLKPSNILY RDESGSPESI RVCDFGFAKQ LRAGNGLLMT PCYTANFVAP EVLKRQGYDA ACDIWSLGIL LYTMLAGFTP FANGPDDTPE EILARIGSGK YALSGGNWDS ISDAAKDVVS KMLHVDPHQR LTAMQVLKHP WVVNREYLSP NQLSRQDVHL VKGAMAATYF ALNRTPQAPR LEPVLSSNLA QRRGMKRLTS TRL // ID M3K15_HUMAN Reviewed; 1313 AA. AC Q6ZN16; A2AI49; A2AI50; A6NJ61; Q5JPR4; Q6ZMV3; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 15; DE EC=2.7.11.25 {ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}; DE AltName: Full=Apoptosis signal-regulating kinase 3; DE AltName: Full=MAPK/ERK kinase kinase 15; DE Short=MEK kinase 15; DE Short=MEKK 15; GN Name=MAP3K15; Synonyms=ASK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [4] RP FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY. RX PubMed=20362554; DOI=10.1016/j.bbrc.2010.03.164; RA Kaji T., Yoshida S., Kawai K., Fuchigami Y., Watanabe W., Kubodera H., RA Kishimoto T.; RT "ASK3, a novel member of the apoptosis signal-regulating kinase family, is RT essential for stress-induced cell death in HeLa cells."; RL Biochem. Biophys. Res. Commun. 395:213-218(2010). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-994, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-681. RX PubMed=26732173; DOI=10.1038/srep18710; RA Maruyama J., Kobayashi Y., Umeda T., Vandewalle A., Takeda K., Ichijo H., RA Naguro I.; RT "Osmotic stress induces the phosphorylation of WNK4 Ser575 via the p38MAPK- RT MK pathway."; RL Sci. Rep. 6:18710-18710(2016). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] THR-192; ASN-199; HIS-226; SER-255; RP GLY-456; CYS-494; LEU-562; GLN-677; SER-838; LEU-993; HIS-1029; ARG-1247 RP AND GLU-1251. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as a component of the MAP CC kinase signal transduction pathway (PubMed:20362554, PubMed:26732173). CC Once activated, acts as an upstream activator of the p38 MAPK signal CC transduction cascade through the phosphorylation and activation of CC several MAP kinase kinases (PubMed:20362554, PubMed:26732173). May CC function in a signal transduction pathway that is activated by various CC cell stresses and leads to apoptosis (PubMed:20362554). Involved in CC phosphorylation of WNK4 in response to osmotic stress or hypotonic low- CC chloride stimulation via the p38 MAPK signal transduction cascade CC (PubMed:26732173). {ECO:0000269|PubMed:20362554, CC ECO:0000269|PubMed:26732173}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC Evidence={ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC Evidence={ECO:0000269|PubMed:20362554}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q99683}; CC -!- ACTIVITY REGULATION: Contains an N-terminal autoinhibitory domain. CC Activated by phosphorylation at Thr-812, inhibited by phosphorylation CC at Ser-924 and Ser-994 (By similarity). {ECO:0000250|UniProtKB:Q99683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6ZN16-1; Sequence=Displayed; CC Name=2; CC IsoId=Q6ZN16-2; Sequence=VSP_021038; CC Name=3; CC IsoId=Q6ZN16-3; Sequence=VSP_021039, VSP_021040; CC -!- TISSUE SPECIFICITY: Isoform 2 and isoform 3 are widely expressed. CC Isoform 2 highest levels are observed in fetal brain, and isoform 3 CC highest levels in pancreas, peripheral blood leukocytes, fetal brain CC and spleen. {ECO:0000269|PubMed:20362554}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131412; BAD18559.1; -; mRNA. DR EMBL; AK131477; BAD18622.1; -; mRNA. DR EMBL; AL732326; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL732423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS35212.2; -. [Q6ZN16-1] DR RefSeq; NP_001001671.3; NM_001001671.4. [Q6ZN16-1] DR RefSeq; XP_011543813.1; XM_011545511.2. [Q6ZN16-2] DR RefSeq; XP_054183016.1; XM_054327041.1. [Q6ZN16-2] DR PDB; 6V0M; X-ray; 1.80 A; A/B/C=1241-1308. DR PDBsum; 6V0M; -. DR AlphaFoldDB; Q6ZN16; -. DR SMR; Q6ZN16; -. DR BioGRID; 133293; 23. DR FunCoup; Q6ZN16; 177. DR IntAct; Q6ZN16; 9. DR STRING; 9606.ENSP00000345629; -. DR BindingDB; Q6ZN16; -. DR ChEMBL; CHEMBL1163127; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q6ZN16; -. DR GlyGen; Q6ZN16; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN16; -. DR PhosphoSitePlus; Q6ZN16; -. DR BioMuta; MAP3K15; -. DR DMDM; 116248533; -. DR CPTAC; CPTAC-841; -. DR CPTAC; CPTAC-842; -. DR jPOST; Q6ZN16; -. DR MassIVE; Q6ZN16; -. DR PaxDb; 9606-ENSP00000345629; -. DR PeptideAtlas; Q6ZN16; -. DR ProteomicsDB; 67956; -. [Q6ZN16-1] DR ProteomicsDB; 67957; -. [Q6ZN16-2] DR ProteomicsDB; 67958; -. [Q6ZN16-3] DR Antibodypedia; 571; 146 antibodies from 26 providers. DR DNASU; 389840; -. DR Ensembl; ENST00000338883.9; ENSP00000345629.4; ENSG00000180815.16. [Q6ZN16-1] DR GeneID; 389840; -. DR KEGG; hsa:389840; -. DR MANE-Select; ENST00000338883.9; ENSP00000345629.4; NM_001001671.4; NP_001001671.3. DR UCSC; uc004czj.3; human. [Q6ZN16-1] DR AGR; HGNC:31689; -. DR ClinPGx; PA134935369; -. DR CTD; 389840; -. DR DisGeNET; 389840; -. DR GeneCards; MAP3K15; -. DR HGNC; HGNC:31689; MAP3K15. DR HPA; ENSG00000180815; Group enriched (adrenal gland, choroid plexus). DR MalaCards; MAP3K15; -. DR MIM; 300820; gene. DR OpenTargets; ENSG00000180815; -. DR VEuPathDB; HostDB:ENSG00000180815; -. DR eggNOG; KOG4279; Eukaryota. DR GeneTree; ENSGT00940000159562; -. DR HOGENOM; CLU_048342_0_0_1; -. DR InParanoid; Q6ZN16; -. DR OMA; CLCGRIC; -. DR OrthoDB; 275301at2759; -. DR PAN-GO; Q6ZN16; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN16; -. DR PathwayCommons; Q6ZN16; -. DR SignaLink; Q6ZN16; -. DR Agora; ENSG00000180815; -. DR BioGRID-ORCS; 389840; 3 hits in 297 CRISPR screens. DR CD-CODE; FBBE2A73; Synthetic Condensate 000275. DR ChiTaRS; MAP3K15; human. DR GenomeRNAi; 389840; -. DR Pharos; Q6ZN16; Tchem. DR PRO; PR:Q6ZN16; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q6ZN16; protein. DR Bgee; ENSG00000180815; Expressed in adrenal tissue and 80 other cell types or tissues. DR ExpressionAtlas; Q6ZN16; baseline and differential. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0007254; P:JNK cascade; IBA:GO_Central. DR GO; GO:0038066; P:p38MAPK cascade; IBA:GO_Central. DR CDD; cd06624; STKc_ASK; 1. DR FunFam; 1.10.510.10:FF:000054; Mitogen-activated protein kinase kinase kinase 5; 1. DR FunFam; 3.30.200.20:FF:000067; Mitogen-activated protein kinase kinase kinase 5; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046872; DRHyd-ASK. DR InterPro; IPR046873; HisK-N-like. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR043969; MAP3K_PH. DR InterPro; IPR025136; MAP3K_TRAF-bd. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11584:SF363; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 15; 1. DR PANTHER; PTHR11584; SERINE/THREONINE PROTEIN KINASE; 1. DR Pfam; PF19039; ASK_PH; 1. DR Pfam; PF20309; DRHyd-ASK; 1. DR Pfam; PF20302; HisK-N-like; 1. DR Pfam; PF13281; MAP3K_TRAF_bd; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Coiled coil; Kinase; KW Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1313 FT /note="Mitogen-activated protein kinase kinase kinase 15" FT /id="PRO_0000253481" FT DOMAIN 652..908 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..58 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 939..958 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1179..1225 FT /evidence="ECO:0000255" FT COMPBIAS 28..43 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 44..57 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 942..955 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 773 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 658..666 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 681 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 994 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..565 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021038" FT VAR_SEQ 1..525 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021039" FT VAR_SEQ 526..582 FT /note="GLRFPVLVIEPTKVYQPSYVSINNEAEERTVSLWHVSPTEMKQMHEWNFTAS FT SIKGI -> MACLTHRNETDARMEFYSLFHKGNKAGVQWHDLGSLQPLPPRFKRFSCLS FT LQSSWDY (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021040" FT VARIANT 192 FT /note="A -> T (in dbSNP:rs5909299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040716" FT VARIANT 199 FT /note="S -> N (in dbSNP:rs55916006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040717" FT VARIANT 226 FT /note="D -> H (in dbSNP:rs56338727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040718" FT VARIANT 255 FT /note="R -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040719" FT VARIANT 456 FT /note="S -> G (in dbSNP:rs56212339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040720" FT VARIANT 494 FT /note="R -> C (in dbSNP:rs41305349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040721" FT VARIANT 562 FT /note="S -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs2063704764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040722" FT VARIANT 677 FT /note="R -> Q (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040723" FT VARIANT 838 FT /note="G -> S (in dbSNP:rs56381411)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040724" FT VARIANT 993 FT /note="S -> L (in dbSNP:rs56233219)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040725" FT VARIANT 1029 FT /note="N -> H (in dbSNP:rs55787622)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040726" FT VARIANT 1247 FT /note="W -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs2063287881)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040727" FT VARIANT 1251 FT /note="Q -> E (in dbSNP:rs15943)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040728" FT MUTAGEN 681 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:26732173" FT CONFLICT 793 FT /note="F -> L (in Ref. 1; BAD18622)" FT /evidence="ECO:0000305" FT HELIX 1241..1250 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1255..1263 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1268..1273 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1277..1282 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1287..1307 FT /evidence="ECO:0007829|PDB:6V0M" SQ SEQUENCE 1313 AA; 147437 MW; 60751706D6AEE3E9 CRC64; MESGGGNAPA GALGAASESP QCPPPPGVEG AAGPAEPDGA AEGAAGGSGE GESGGGPRRA LRAVYVRSES SQGGAAGGPE AGARQCLLRA CEAEGAHLTS VPFGELDFGE TAVLDAFYDA DVAVVDMSDV SRQPSLFYHL GVRESFDMAN NVILYHDTDA DTALSLKDMV TQKNTASSGN YYFIPYIVTP CADYFCCESD AQRRASEYMQ PNWDNILGPL CMPLVDRFIS LLKDIHVTSC VYYKETLLND IRKAREKYQG EELAKELARI KLRMDNTEVL TSDIIINLLL SYRDIQDYDA MVKLVETLEM LPTCDLADQH NIKFHYAFAL NRRNSTGDRE KALQIMLQVL QSCDHPGPDM FCLCGRIYKD IFLDSDCKDD TSRDSAIEWY RKGFELQSSL YSGINLAVLL IVAGQQFETS LELRKIGVRL NSLLGRKGSL EKMNNYWDVG QFFSVSMLAH DVGKAVQAAE RLFKLKPPVW YLRSLVQNLL LIRRFKKTII EHSPRQERLN FWLDIIFEAT NEVTNGLRFP VLVIEPTKVY QPSYVSINNE AEERTVSLWH VSPTEMKQMH EWNFTASSIK GISLSKFDER CCFLYVHDNS DDFQIYFSTE EQCSRFFSLV KEMITNTAGS TVELEGETDG DTLEYEYDHD ANGERVVLGK GTYGIVYAGR DLSNQVRIAI KEIPERDSRY SQPLHEEIAL HKYLKHRNIV QYLGSVSENG YIKIFMEQVP GGSLSALLRS KWGPMKEPTI KFYTKQILEG LKYLHENQIV HRDIKGDNVL VNTYSGVVKI SDFGTSKRLA GVNPCTETFT GTLQYMAPEI IDQGPRGYGA PADIWSLGCT IIEMATSKPP FHELGEPQAA MFKVGMFKIH PEIPEALSAE ARAFILSCFE PDPHKRATTA ELLREGFLRQ VNKGKKNRIA FKPSEGPRGV VLALPTQGEP MATSSSEHGS VSPDSDAQPD ALFERTRAPR HHLGHLLSVP DESSALEDRG LASSPEDRDQ GLFLLRKDSE RRAILYKILW EEQNQVASNL QECVAQSSEE LHLSVGHIKQ IIGILRDFIR SPEHRVMATT ISKLKVDLDF DSSSISQIHL VLFGFQDAVN KILRNHLIRP HWMFAMDNII RRAVQAAVTI LIPELRAHFE PTCETEGVDK DMDEAEEGYP PATGPGQEAQ PHQQHLSLQL GELRQETNRL LEHLVEKERE YQNLLRQTLE QKTQELYHLQ LKLKSNCITE NPAGPYGQRT DKELIDWLRL QGADAKTIEK IVEEGYTLSD ILNEITKEDL RYLRLRGGLL CRLWSAVSQY RRAQEASETK DKA // ID M3K9_HUMAN Reviewed; 1104 AA. AC P80192; A3KN85; Q0D2G7; Q6EH31; Q9H2N5; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 214. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 9; DE EC=2.7.11.25; DE AltName: Full=Mixed lineage kinase 1; GN Name=MAP3K9; Synonyms=MLK1, PRKE1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-304; THR-305; SER-308 AND THR-312, AND MUTAGENESIS RP OF LYS-171; THR-304; THR-305; SER-308 AND THR-312. RX PubMed=15610029; DOI=10.1021/bi049866y; RA Durkin J.T., Holskin B.P., Kopec K.K., Reed M.S., Spais C.M., Steffy B.M., RA Gessner G., Angeles T.S., Pohl J., Ator M.A., Meyer S.L.; RT "Phosphoregulation of mixed-lineage kinase 1 activity by multiple RT phosphorylation in the activation loop."; RL Biochemistry 43:16348-16355(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 53-1104 (ISOFORM 2). RA McNee J.J., Dower S.K., Guesdon F.; RT "cDNA sequence and gene organisation of mixed lineage kinase 1."; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 142-535, AND TISSUE SPECIFICITY. RC TISSUE=Colon epithelium; RX PubMed=8477742; DOI=10.1111/j.1432-1033.1993.tb17810.x; RA Dorow D.S., Devereux L., Dietzsch E., de Kretser T.; RT "Identification of a new family of human epithelial protein kinases RT containing two leucine/isoleucine-zipper domains."; RL Eur. J. Biochem. 213:701-710(1993). RN [5] RP ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND PHOSPHORYLATION OF RP MAP2K4/MKK4. RX PubMed=11325962; DOI=10.1074/jbc.m011601200; RA Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., RA Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W., Vaught J.L.; RT "Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase RT family."; RL J. Biol. Chem. 276:25302-25308(2001). RN [6] RP FUNCTION IN THE APOPTOSIS PATHWAY. RX PubMed=11416147; DOI=10.1128/mcb.21.14.4713-4724.2001; RA Xu Z., Maroney A.C., Dobrzanski P., Kukekov N.V., Greene L.A.; RT "The MLK family mediates c-Jun N-terminal kinase activation in neuronal RT apoptosis."; RL Mol. Cell. Biol. 21:4713-4724(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11755341; DOI=10.1016/s0960-894x(01)00690-4; RA Murakata C., Kaneko M., Gessner G., Angeles T.S., Ator M.A., O'Kane T.M., RA McKenna B.A., Thomas B.A., Mathiasen J.R., Saporito M.S., RA Bozyczko-Coyne D., Hudkins R.L.; RT "Mixed lineage kinase activity of indolocarbazole analogues."; RL Bioorg. Med. Chem. Lett. 12:147-150(2002). RN [8] RP POSSIBLE ROLE IN ESOPHAGEAL CANCER. RX PubMed=18241037; DOI=10.1002/ijc.23397; RA Chen J., Guo L., Peiffer D.A., Zhou L., Chan O.T., Bibikova M., RA Wickham-Garcia E., Lu S.H., Zhan Q., Wang-Rodriguez J., Jiang W., Fan J.B.; RT "Genomic profiling of 766 cancer-related genes in archived esophageal RT normal and carcinoma tissues."; RL Int. J. Cancer 122:2249-2254(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 136-406. RX PubMed=18714982; DOI=10.1021/jm8005838; RA Hudkins R.L., Diebold J.L., Tao M., Josef K.A., Park C.H., Angeles T.S., RA Aimone L.D., Husten J., Ator M.A., Meyer S.L., Holskin B.P., Durkin J.T., RA Fedorov A.A., Fedorov E.V., Almo S.C., Mathiasen J.R., Bozyczko-Coyne D., RA Saporito M.S., Scott R.W., Mallamo J.P.; RT "Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective RT dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed- RT lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4- RT phenyltetrahydropyridine models."; RL J. Med. Chem. 51:5680-5689(2008). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-246; CYS-467; GLN-497 AND CYS-646. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. Plays an important role CC in the cascades of cellular responses evoked by changes in the CC environment. Once activated, acts as an upstream activator of the CC MKK/JNK signal transduction cascade through the phosphorylation of CC MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The CC MKK/JNK signaling pathway regulates stress response via activator CC protein-1 (JUN) and GATA4 transcription factors. Also plays a role in CC mitochondrial death signaling pathway, including the release cytochrome CC c, leading to apoptosis. {ECO:0000269|PubMed:11416147, CC ECO:0000269|PubMed:15610029}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Homodimerization via the leucine zipper domains is CC required for autophosphorylation of multiple sites in the activation CC loop and subsequent activation. Autophosphorylation at Thr-312 is the CC key step in activation of MAP3K9/MLK1 and is required for full CC phosphorylation. Autophosphorylation at Thr-304 and Ser-308 have been CC shown to be of secondary importance in the activation of MAP3K9/MLK1. CC CEP-1347 and many indolocarbazole analogs have been shown to act as CC inhibitors of MAP3K9/MLK1 activity. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:11755341, ECO:0000269|PubMed:15610029}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=62 uM for ATP {ECO:0000269|PubMed:11325962}; CC KM=7 uM for myelin basic protein (MBP) as substrate CC {ECO:0000269|PubMed:11325962}; CC -!- SUBUNIT: Homodimer. {ECO:0000250}. CC -!- INTERACTION: CC P80192; P08238: HSP90AB1; NbExp=2; IntAct=EBI-3951604, EBI-352572; CC P80192; Q92993: KAT5; NbExp=3; IntAct=EBI-3951604, EBI-399080; CC P80192; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-3951604, EBI-11742507; CC P80192; P17252: PRKCA; NbExp=3; IntAct=EBI-3951604, EBI-1383528; CC P80192; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-3951604, EBI-9090795; CC P80192; P62258: YWHAE; NbExp=3; IntAct=EBI-3951604, EBI-356498; CC P80192; P61981: YWHAG; NbExp=4; IntAct=EBI-3951604, EBI-359832; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P80192-1; Sequence=Displayed; CC Name=2; CC IsoId=P80192-4; Sequence=VSP_013765; CC -!- TISSUE SPECIFICITY: Expressed in epithelial tumor cell lines of CC colonic, breast and esophageal origin. {ECO:0000269|PubMed:8477742}. CC -!- PTM: Autophosphorylation on serine and threonine residues within the CC activation loop plays a role in enzyme activation. Thr-312 is likely to CC be the main autophosphorylation site. Autophosphorylation also occurs CC on Thr-304 and Ser-308. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:15610029}. CC -!- DISEASE: Note=May play a role in esophageal cancer susceptibility CC and/or development. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAI11408.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY327900; AAQ23054.1; -; mRNA. DR EMBL; BC111407; AAI11408.1; ALT_INIT; mRNA. DR EMBL; BC133706; AAI33707.1; -; mRNA. DR EMBL; AF251442; AAG44591.1; -; mRNA. DR CCDS; CCDS32112.1; -. [P80192-4] DR CCDS; CCDS61488.1; -. [P80192-1] DR PIR; S32467; JU0229. DR RefSeq; NP_001271159.1; NM_001284230.2. [P80192-1] DR RefSeq; NP_149132.2; NM_033141.3. [P80192-4] DR PDB; 3DTC; X-ray; 2.60 A; A=136-406. DR PDB; 4UY9; X-ray; 2.81 A; A/B=135-456. DR PDBsum; 3DTC; -. DR PDBsum; 4UY9; -. DR AlphaFoldDB; P80192; -. DR SMR; P80192; -. DR BioGRID; 110439; 29. DR FunCoup; P80192; 485. DR IntAct; P80192; 32. DR STRING; 9606.ENSP00000451263; -. DR BindingDB; P80192; -. DR ChEMBL; CHEMBL2872; -. DR DrugBank; DB08703; 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P80192; -. DR GuidetoPHARMACOLOGY; 2084; -. DR GlyGen; P80192; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P80192; -. DR PhosphoSitePlus; P80192; -. DR BioMuta; MAP3K9; -. DR DMDM; 116242625; -. DR CPTAC; CPTAC-860; -. DR CPTAC; CPTAC-861; -. DR jPOST; P80192; -. DR MassIVE; P80192; -. DR PaxDb; 9606-ENSP00000451263; -. DR PeptideAtlas; P80192; -. DR ProteomicsDB; 57671; -. [P80192-1] DR ProteomicsDB; 57672; -. [P80192-4] DR Antibodypedia; 75; 343 antibodies from 33 providers. DR DNASU; 4293; -. DR Ensembl; ENST00000554752.7; ENSP00000451612.2; ENSG00000006432.17. [P80192-1] DR Ensembl; ENST00000555993.6; ENSP00000451263.2; ENSG00000006432.17. [P80192-4] DR GeneID; 4293; -. DR KEGG; hsa:4293; -. DR MANE-Select; ENST00000554752.7; ENSP00000451612.2; NM_001284230.2; NP_001271159.1. DR UCSC; uc001xml.5; human. [P80192-1] DR AGR; HGNC:6861; -. DR ClinPGx; PA30607; -. DR CTD; 4293; -. DR DisGeNET; 4293; -. DR GeneCards; MAP3K9; -. DR HGNC; HGNC:6861; MAP3K9. DR HPA; ENSG00000006432; Tissue enhanced (retina). DR MIM; 600136; gene. DR OpenTargets; ENSG00000006432; -. DR VEuPathDB; HostDB:ENSG00000006432; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000158243; -. DR InParanoid; P80192; -. DR OMA; GCGPYRE; -. DR OrthoDB; 339325at2759; -. DR PAN-GO; P80192; 1 GO annotation based on evolutionary models. DR PhylomeDB; P80192; -. DR PathwayCommons; P80192; -. DR SABIO-RK; P80192; -. DR SignaLink; P80192; -. DR SIGNOR; P80192; -. DR Agora; ENSG00000006432; -. DR BioGRID-ORCS; 4293; 8 hits in 1178 CRISPR screens. DR ChiTaRS; MAP3K9; human. DR EvolutionaryTrace; P80192; -. DR GeneWiki; MAP3K9; -. DR GenomeRNAi; 4293; -. DR Pharos; P80192; Tchem. DR PRO; PR:P80192; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P80192; protein. DR Bgee; ENSG00000006432; Expressed in buccal mucosa cell and 161 other cell types or tissues. DR ExpressionAtlas; P80192; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; NAS:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd12059; SH3_MLK1-3; 1. DR CDD; cd14145; STKc_MLK1; 1. DR DisProt; DP02571; -. DR FunFam; 1.10.510.10:FF:000076; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 2.30.30.40:FF:000079; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 3.30.200.20:FF:000085; Mitogen-activated protein kinase kinase kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR035779; MLK1-3_SH3. DR InterPro; IPR016231; MLK1-4. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR PANTHER; PTHR44329:SF35; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF14604; SH3_9; 1. DR PIRSF; PIRSF000556; MAPKKK9_11; 1. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00326; SH3; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Kinase; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; SH3 domain; KW Stress response; Transcription; Transcription regulation; Transferase. FT CHAIN 1..1104 FT /note="Mitogen-activated protein kinase kinase kinase 9" FT /id="PRO_0000086258" FT DOMAIN 52..116 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 144..412 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 12..47 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 430..451 FT /note="Leucine-zipper 1" FT REGION 465..486 FT /note="Leucine-zipper 2" FT REGION 532..636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 675..742 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 781..819 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 890..1038 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 12..22 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 29..39 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..575 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 723..739 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 785..797 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 893..910 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 929..944 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1014..1038 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 268 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 150..158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 171 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 304 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 305 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 308 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 312 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 675 FT /note="M -> MALLAASWVVPIDIE (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_013765" FT VARIANT 246 FT /note="A -> V (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040698" FT VARIANT 467 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs773256562)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040699" FT VARIANT 497 FT /note="R -> Q (in dbSNP:rs56196343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040700" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34322726)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040701" FT MUTAGEN 171 FT /note="K->A: Loss of kinase activity and threonine FT phosphorylation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 304 FT /note="T->A: Reduces threonine phosphorylation. Impairs JNK FT activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 305 FT /note="T->A: Little effect on threonine phosphorylation. FT Mildly impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 308 FT /note="S->A: Impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 312 FT /note="T->A: Loss of threonine phosphorylation. Strongly FT impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT CONFLICT 356 FT /note="A -> R (in Ref. 4)" FT /evidence="ECO:0000305" FT CONFLICT 433 FT /note="M -> T (in Ref. 1; AAQ23054)" FT /evidence="ECO:0000305" FT CONFLICT 511..535 FT /note="KLKDGNRISLPSDFQHKFTVQASPT -> AQPVLPFPHGHSRCPGGTGSSWG FT GQ (in Ref. 4)" FT /evidence="ECO:0000305" FT STRAND 143..153 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 156..163 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 166..172 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 185..197 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 206..210 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 228..232 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 239..258 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 271..273 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 274..278 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 290..292 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 299..301 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 318..323 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 328..344 FT /evidence="ECO:0007829|PDB:3DTC" FT TURN 348..351 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 354..362 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 376..385 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 390..392 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 396..404 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 410..412 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 418..439 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:4UY9" SQ SEQUENCE 1104 AA; 121895 MW; 0F059C867FCE7276 CRC64; MEPSRALLGC LASAAAAAPP GEDGAGAGAE EEEEEEEEAA AAVGPGELGC DAPLPYWTAV FEYEAAGEDE LTLRLGDVVE VLSKDSQVSG DEGWWTGQLN QRVGIFPSNY VTPRSAFSSR CQPGGEDPSC YPPIQLLEID FAELTLEEII GIGGFGKVYR AFWIGDEVAV KAARHDPDED ISQTIENVRQ EAKLFAMLKH PNIIALRGVC LKEPNLCLVM EFARGGPLNR VLSGKRIPPD ILVNWAVQIA RGMNYLHDEA IVPIIHRDLK SSNILILQKV ENGDLSNKIL KITDFGLARE WHRTTKMSAA GTYAWMAPEV IRASMFSKGS DVWSYGVLLW ELLTGEVPFR GIDGLAVAYG VAMNKLALPI PSTCPEPFAK LMEDCWNPDP HSRPSFTNIL DQLTTIEESG FFEMPKDSFH CLQDNWKHEI QEMFDQLRAK EKELRTWEEE LTRAALQQKN QEELLRRREQ ELAEREIDIL ERELNIIIHQ LCQEKPRVKK RKGKFRKSRL KLKDGNRISL PSDFQHKFTV QASPTMDKRK SLINSRSSPP ASPTIIPRLR AIQLTPGESS KTWGRSSVVP KEEGEEEEKR APKKKGRTWG PGTLGQKELA SGDEGSPQRR EKANGLSTPS ESPHFHLGLK SLVDGYKQWS SSAPNLVKGP RSSPALPGFT SLMEMEDEDS EGPGSGESRL QHSPSQSYLC IPFPRGEDGD GPSSDGIHEE PTPVNSATST PQLTPTNSLK RGGAHHRRCE VALLGCGAVL AATGLGFDLL EAGKCQLLPL EEPEPPAREE KKRREGLFQR SSRPRRSTSP PSRKLFKKEE PMLLLGDPSA SLTLLSLSSI SECNSTRSLL RSDSDEIVVY EMPVSPVEAP PLSPCTHNPL VNVRVERFKR DPNQSLTPTH VTLTTPSQPS SHRRTPSDGA LKPETLLASR SPSSNGLSPS PGAGMLKTPS PSRDPGEFPR LPDPNVVFPP TPRRWNTQQD STLERPKTLE FLPRPRPSAN RQRLDPWWFV SPSHARSTSP ANSSSTETPS NLDSCFASSS STVEERPGLP ALLPFQAGPL PPTERTLLDL DAEGQSQDST VPLCRAELNT HRPAPYEIQQ EFWS // ID MP2K4_HUMAN Reviewed; 399 AA. AC P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 229. DE RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4; DE Short=MAP kinase kinase 4; DE Short=MAPKK 4; DE EC=2.7.12.2; DE AltName: Full=JNK-activating kinase 1; DE AltName: Full=MAPK/ERK kinase 4; DE Short=MEK 4; DE AltName: Full=SAPK/ERK kinase 1; DE Short=SEK1; DE AltName: Full=Stress-activated protein kinase kinase 1; DE Short=SAPK kinase 1; DE Short=SAPKK-1; DE Short=SAPKK1; DE AltName: Full=c-Jun N-terminal kinase kinase 1; DE Short=JNKK; GN Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=7839144; DOI=10.1126/science.7839144; RA Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J., RA Davis R.J.; RT "Independent human MAP-kinase signal transduction pathways defined by MEK RT and MKK isoforms."; RL Science 267:682-685(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION. RX PubMed=7716521; DOI=10.1126/science.7716521; RA Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C., RA Mercurio F., Johnson G.L., Karin M.; RT "Identification of a dual specificity kinase that activates the Jun kinases RT and p38-Mpk2."; RL Science 268:286-290(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9622070; RA Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H., RA Kern S.E.; RT "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as RT a genetically targeted tumor suppressor gene."; RL Cancer Res. 58:2339-2342(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-16. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PHOSPHORYLATION AT THR-261, ACTIVITY REGULATION, AND INTERACTION WITH RP MAP3K11/MLK3. RX PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x; RA Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R., RA Lassam N.J.; RT "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6."; RL EMBO J. 15:7026-7035(1996). RN [12] RP CLEAVAGE BY ANTHRAX LETHAL FACTOR. RX PubMed=11104681; DOI=10.1042/bj3520739; RA Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.; RT "Susceptibility of mitogen-activated protein kinase kinase family members RT to proteolysis by anthrax lethal factor."; RL Biochem. J. 352:739-745(2000). RN [13] RP INTERACTION WITH ARRB2. RX PubMed=11090355; DOI=10.1126/science.290.5496.1574; RA McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T., RA Davis R.J., Lefkowitz R.J.; RT "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of RT JNK3."; RL Science 290:1574-1577(2000). RN [14] RP INTERACTION WITH MAPK8IP3/JIP3. RX PubMed=12189133; DOI=10.1074/jbc.m202004200; RA Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M., RA Yoshioka K., Ichijo H.; RT "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK RT signaling pathway. A new mode of regulation of the MAP kinase cascade."; RL J. Biol. Chem. 277:40703-40709(2002). RN [15] RP DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3; MAPK11 RP AND MAPK14. RX PubMed=12788955; DOI=10.1074/jbc.m304229200; RA Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.; RT "A docking site in MKK4 mediates high affinity binding to JNK MAPKs and RT competes with similar docking sites in JNK substrates."; RL J. Biol. Chem. 278:32662-32672(2003). RN [16] RP DOMAIN. RX PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001; RA Takekawa M., Tatebayashi K., Saito H.; RT "Conserved docking site is essential for activation of mammalian MAP kinase RT kinases by specific MAP kinase kinase kinases."; RL Mol. Cell 18:295-306(2005). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP INTERACTION WITH ARRB1 AND ARRB2. RX PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035; RA Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C., RA Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.; RT "A scanning peptide array approach uncovers association sites within the RT JNK/beta arrestin signalling complex."; RL FEBS Lett. 583:3310-3316(2009). RN [20] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17496909; DOI=10.1038/sj.onc.1210392; RA Raman M., Chen W., Cobb M.H.; RT "Differential regulation and properties of MAPKs."; RL Oncogene 26:3100-3112(2007). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20801953; DOI=10.1093/jb/mvq098; RA Asaoka Y., Nishina H.; RT "Diverse physiological functions of MKK4 and MKK7 during early RT embryogenesis."; RL J. Biochem. 148:393-401(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP REVIEW ON REGULATION, AND REVIEW ON FUNCTION. RX PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008; RA Haeusgen W., Herdegen T., Waetzig V.; RT "The bottleneck of JNK signaling: molecular and functional characteristics RT of MKK4 and MKK7."; RL Eur. J. Cell Biol. 90:536-544(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399. RX PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071; RA Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.; RT "Crystal structures of MKK4 kinase domain reveal that substrate peptide RT binds to an allosteric site and induces an auto-inhibition state."; RL Biochem. Biophys. Res. Commun. 400:369-373(2010). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND RP THR-279. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Dual specificity protein kinase which acts as an essential CC component of the MAP kinase signal transduction pathway. Essential CC component of the stress-activated protein kinase/c-Jun N-terminal CC kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the CC only known kinase to directly activate the stress-activated protein CC kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. CC MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, CC but they differ in their preference for the phosphorylation site in the CC Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the CC Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of CC the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK CC activation at least in response to pro-inflammatory cytokines, while CC other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which CC synergistically phosphorylate JNKs. MAP2K4 is required for maintaining CC peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also CC involved in mitochondrial death signaling pathway, including the CC release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 CC exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 CC MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- ACTIVITY REGULATION: Activated in response to a variety of cellular CC stresses, including UV and gamma-irradiation, heat shock, CC hyperosmolarity, T-cell receptor stimulation, peroxide and inflammatory CC cytokines. Also activated by developmental cues. MAP2K4/MKK4 is CC activated by the majority of MKKKs, such as MAP3K5/ASK1, MAP3K1/MEKK1, CC MAP3K7/TAK1, MAP3K10/MLK2, MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK. CC {ECO:0000269|PubMed:9003778}. CC -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its D CC domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3, MAPK11 CC and MAPK14. Interacts (via its DVD domain) with MAP3Ks activators like CC MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with ARRB1, ARRB2 and CC MAPK8IP3/JIP3. {ECO:0000250, ECO:0000269|PubMed:11090355, CC ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:12788955, CC ECO:0000269|PubMed:19782076, ECO:0000269|PubMed:9003778}. CC -!- INTERACTION: CC P45985; Q13233: MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776; CC P45985; P45983: MAPK8; NbExp=4; IntAct=EBI-447868, EBI-286483; CC P45985; P45984: MAPK9; NbExp=3; IntAct=EBI-447868, EBI-713568; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P45985-1; Sequence=Displayed; CC Name=2; CC IsoId=P45985-2; Sequence=VSP_038838; CC -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal muscle. CC It is also widely expressed in other tissues. CC -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved docking CC site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD CC sites bind to their specific upstream MAP kinase kinase kinases CC (MAP3Ks) and are essential for activation. CC -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking site CC and is required for the binding to MAPK substrates. CC -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase CC kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/244/MAP2K4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36870; AAC41719.1; -; mRNA. DR EMBL; U17743; AAC50127.1; -; mRNA. DR EMBL; AF070090; AAC24130.1; -; Genomic_DNA. DR EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; CR536564; CAG38801.1; -; mRNA. DR EMBL; BT019676; AAV38482.1; -; mRNA. DR EMBL; AK131544; BAG54774.1; -; mRNA. DR EMBL; AK313053; BAG35884.1; -; mRNA. DR EMBL; DQ015703; AAY22176.1; -; Genomic_DNA. DR EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW89975.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89974.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89976.1; -; Genomic_DNA. DR EMBL; BC036032; AAH36032.1; -; mRNA. DR EMBL; BC060764; AAH60764.1; -; mRNA. DR CCDS; CCDS11162.1; -. [P45985-1] DR CCDS; CCDS62095.1; -. [P45985-2] DR PIR; I38901; I38901. DR RefSeq; NP_001268364.1; NM_001281435.2. [P45985-2] DR RefSeq; NP_003001.1; NM_003010.4. [P45985-1] DR PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399. DR PDB; 3ALO; X-ray; 2.60 A; A=80-399. DR PDB; 3VUT; X-ray; 3.50 A; A/B=80-399. DR PDB; 8YP5; X-ray; 2.50 A; A=80-399. DR PDBsum; 3ALN; -. DR PDBsum; 3ALO; -. DR PDBsum; 3VUT; -. DR PDBsum; 8YP5; -. DR AlphaFoldDB; P45985; -. DR SMR; P45985; -. DR BioGRID; 112315; 69. DR CORUM; P45985; -. DR FunCoup; P45985; 2185. DR IntAct; P45985; 26. DR MINT; P45985; -. DR STRING; 9606.ENSP00000410402; -. DR BindingDB; P45985; -. DR ChEMBL; CHEMBL2897; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB14904; Pimasertib. DR DrugCentral; P45985; -. DR GuidetoPHARMACOLOGY; 2065; -. DR GlyCosmos; P45985; 2 sites, 1 glycan. DR GlyGen; P45985; 4 sites, 1 O-linked glycan (2 sites). DR iPTMnet; P45985; -. DR PhosphoSitePlus; P45985; -. DR BioMuta; MAP2K4; -. DR DMDM; 1170596; -. DR CPTAC; CPTAC-816; -. DR CPTAC; CPTAC-817; -. DR jPOST; P45985; -. DR MassIVE; P45985; -. DR PaxDb; 9606-ENSP00000410402; -. DR PeptideAtlas; P45985; -. DR ProteomicsDB; 55703; -. [P45985-1] DR ProteomicsDB; 55704; -. [P45985-2] DR Pumba; P45985; -. DR Antibodypedia; 3571; 1422 antibodies from 43 providers. DR CPTC; P45985; 1 antibody. DR DNASU; 6416; -. DR Ensembl; ENST00000353533.10; ENSP00000262445.5; ENSG00000065559.16. [P45985-1] DR Ensembl; ENST00000415385.7; ENSP00000410402.3; ENSG00000065559.16. [P45985-2] DR GeneID; 6416; -. DR KEGG; hsa:6416; -. DR MANE-Select; ENST00000353533.10; ENSP00000262445.5; NM_003010.4; NP_003001.1. DR UCSC; uc002gnj.5; human. [P45985-1] DR AGR; HGNC:6844; -. DR CIViC; 6416; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA30589; -. DR CTD; 6416; -. DR DisGeNET; 6416; -. DR GeneCards; MAP2K4; -. DR HGNC; HGNC:6844; MAP2K4. DR HPA; ENSG00000065559; Low tissue specificity. DR MalaCards; MAP2K4; -. DR MIM; 601335; gene. DR OpenTargets; ENSG00000065559; -. DR VEuPathDB; HostDB:ENSG00000065559; -. DR eggNOG; KOG1006; Eukaryota. DR GeneTree; ENSGT00940000154744; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; P45985; -. DR OMA; HILLEFC; -. DR OrthoDB; 10252354at2759; -. DR PAN-GO; P45985; 2 GO annotations based on evolutionary models. DR PhylomeDB; P45985; -. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; P45985; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5210891; Uptake and function of anthrax toxins. DR Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation. DR SABIO-RK; P45985; -. DR SignaLink; P45985; -. DR SIGNOR; P45985; -. DR Agora; ENSG00000065559; -. DR BioGRID-ORCS; 6416; 53 hits in 1202 CRISPR screens. DR ChiTaRS; MAP2K4; human. DR EvolutionaryTrace; P45985; -. DR GeneWiki; MAP2K4; -. DR GenomeRNAi; 6416; -. DR Pharos; P45985; Tchem. DR PRO; PR:P45985; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P45985; protein. DR Bgee; ENSG00000065559; Expressed in lateral nuclear group of thalamus and 204 other cell types or tissues. DR ExpressionAtlas; P45985; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008545; F:JUN kinase kinase activity; TAS:Reactome. DR GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0036481; P:intrinsic apoptotic signaling pathway in response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0007254; P:JNK cascade; TAS:Reactome. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0009611; P:response to wounding; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0034390; P:smooth muscle cell apoptotic process; IEA:Ensembl. DR CDD; cd06616; PKc_MKK4; 1. DR DisProt; DP01400; -. DR FunFam; 1.10.510.10:FF:000090; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR FunFam; 3.30.200.20:FF:000126; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR48013:SF15; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4; 1. DR PANTHER; PTHR48013; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transferase; KW Tyrosine-protein kinase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..399 FT /note="Dual specificity mitogen-activated protein kinase FT kinase 4" FT /id="PRO_0000086381" FT DOMAIN 102..367 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 37..52 FT /note="D domain" FT REGION 364..387 FT /note="DVD domain" FT COMPBIAS 7..22 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 229 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 108..116 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 131 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 45..46 FT /note="Cleavage; by anthrax lethal factor" FT SITE 58..59 FT /note="Cleavage; by anthrax lethal factor" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 58 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 58 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 90 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 257 FT /note="Phosphoserine; by MAP3K" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" FT MOD_RES 261 FT /note="Phosphothreonine; by MAP3K" FT /evidence="ECO:0000269|PubMed:9003778" FT VAR_SEQ 39 FT /note="G -> GFQINFCEKAQS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038838" FT VARIANT 16 FT /note="S -> R (in dbSNP:rs17855590)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_062963" FT VARIANT 142 FT /note="Q -> L (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040818" FT VARIANT 154 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1567657403)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040819" FT VARIANT 234 FT /note="N -> I (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040820" FT VARIANT 251 FT /note="S -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040821" FT VARIANT 279 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs753665559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040822" FT CONFLICT 118 FT /note="K -> R (in Ref. 4; CAG38801)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="E -> G (in Ref. 6; BAG35884)" FT /evidence="ECO:0000305" FT CONFLICT 356 FT /note="P -> L (in Ref. 10; AAH60764)" FT /evidence="ECO:0000305" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 112..121 FT /evidence="ECO:0007829|PDB:3ALN" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 127..134 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 139..153 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 164..169 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 171..178 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 202..223 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 243..245 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 255..259 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 267..270 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 287..302 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:3ALO" FT STRAND 316..321 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 338..347 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 358..361 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 365..372 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 377..387 FT /evidence="ECO:0007829|PDB:3ALN" SQ SEQUENCE 399 AA; 44288 MW; A472537F2F26770B CRC64; MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD // ID MTOR_HUMAN Reviewed; 2549 AA. AC P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 243. DE RecName: Full=Serine/threonine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423}; DE AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1; DE AltName: Full=FKBP12-rapamycin complex-associated protein; DE AltName: Full=Mammalian target of rapamycin; DE Short=mTOR; DE AltName: Full=Mechanistic target of rapamycin; DE AltName: Full=Rapamycin and FKBP12 target 1; DE AltName: Full=Rapamycin target protein 1; DE AltName: Full=Tyrosine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.10.2 {ECO:0000305|PubMed:26584640}; GN Name=MTOR {ECO:0000312|HGNC:HGNC:3942}; GN Synonyms=FRAP, FRAP1, FRAP2, RAFT1, RAPT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=8008069; DOI=10.1038/369756a0; RA Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., RA Schreiber S.L.; RT "A mammalian protein targeted by G1-arresting rapamycin-receptor complex."; RL Nature 369:756-758(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9653645; DOI=10.1006/geno.1997.5186; RA Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.; RT "Molecular cloning and expression analysis of five novel genes in RT chromosome 1p36."; RL Genomics 50:187-198(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R., RA Okazaki N., Koga H., Nagase T., Ohara O.; RT "Preparation of a set of expression-ready clones of mammalian long cDNAs RT encoding large proteins by the ORF trap cloning method."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cerebellum; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549. RX PubMed=11426320; DOI=10.1038/sj.gene.6363745; RA Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C., RA Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S., RA Fujita T., Schwaeble W.; RT "The human gene for mannan-binding lectin-associated serine protease-2 RT (MASP-2), the effector component of the lectin route of complement RT activation, is part of a tightly linked gene cluster on chromosome 1p36.2- RT 3."; RL Genes Immun. 2:119-127(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY. RC TISSUE=B-cell; RX PubMed=7809080; DOI=10.1073/pnas.91.26.12574; RA Chiu M.I., Katz H., Berlin V.; RT "RAPT1, a mammalian homolog of yeast Tor, interacts with the RT FKBP12/rapamycin complex."; RL Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994). RN [8] RP SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION. RX PubMed=9434772; DOI=10.1006/bbrc.1997.7878; RA Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M., Alarcon C.M., RA Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.; RT "Expression, enzyme activity, and subcellular localization of mammalian RT target of rapamycin in insulin-responsive cells."; RL Biochem. Biophys. Res. Commun. 241:704-709(1997). RN [9] RP INTERACTION WITH UBQLN1. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [10] RP FUNCTION IN NUTRIENT-DEPENDENT CELL GROWTH, CATALYTIC ACTIVITY, FUNCTION IN RP PHOSPHORYLATION OF RPS6KB1, AND INTERACTION WITH RPTOR. RX PubMed=12150925; DOI=10.1016/s0092-8674(02)00808-5; RA Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "mTOR interacts with raptor to form a nutrient-sensitive complex that RT signals to the growth machinery."; RL Cell 110:163-175(2002). RN [11] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=12150926; DOI=10.1016/s0092-8674(02)00833-4; RA Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., RA Tokunaga C., Avruch J., Yonezawa K.; RT "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR RT action."; RL Cell 110:177-189(2002). RN [12] RP INTERACTION WITH CLIP1, FUNCTION IN PHOSPHORYLATION OF CLIP1, AND CATALYTIC RP ACTIVITY. RX PubMed=12231510; DOI=10.1093/embo-reports/kvf197; RA Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., Zheng X.F.; RT "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase."; RL EMBO Rep. 3:988-994(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF RPS6KB2, AND CATALYTIC ACTIVITY. RX PubMed=12087098; DOI=10.1074/jbc.m204080200; RA Park I.H., Bachmann R., Shirazi H., Chen J.; RT "Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin."; RL J. Biol. Chem. 277:31423-31429(2002). RN [14] RP INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP TISSUE SPECIFICITY. RX PubMed=12408816; DOI=10.1016/s1097-2765(02)00636-6; RA Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., RA Bonenfant D., Oppliger W., Jenoe P., Hall M.N.; RT "Two TOR complexes, only one of which is rapamycin sensitive, have distinct RT roles in cell growth control."; RL Mol. Cell 10:457-468(2002). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=11930000; DOI=10.1073/pnas.261702698; RA Desai B.N., Myers B.R., Schreiber S.L.; RT "FKBP12-rapamycin-associated protein associates with mitochondria and RT senses osmotic stress via mitochondrial dysfunction."; RL Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002). RN [16] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO LOW CELLULAR ENERGY. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH MLST8. RX PubMed=12718876; DOI=10.1016/s1097-2765(03)00114-x; RA Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "GbetaL, a positive regulator of the rapamycin-sensitive pathway required RT for the nutrient-sensitive interaction between raptor and mTOR."; RL Mol. Cell 11:895-904(2003). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PRKCA, CATALYTIC ACTIVITY, FUNCTION IN RP REGULATION OF THE ACTIN CYTOSKELETON, IDENTIFICATION IN THE MTORC2 COMPLEX, RP AND INTERACTION WITH RICTOR. RX PubMed=15268862; DOI=10.1016/j.cub.2004.06.054; RA Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive RT and raptor-independent pathway that regulates the cytoskeleton."; RL Curr. Biol. 14:1296-1302(2004). RN [19] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO HYPOXIA. RX PubMed=15545625; DOI=10.1101/gad.1256804; RA Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., RA Witters L.A., Ellisen L.W., Kaelin W.G. Jr.; RT "Regulation of mTOR function in response to hypoxia by REDD1 and the RT TSC1/TSC2 tumor suppressor complex."; RL Genes Dev. 18:2893-2904(2004). RN [20] RP SUBCELLULAR LOCATION. RX PubMed=14578359; DOI=10.1074/jbc.m305912200; RA Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.; RT "FKBP12-rapamycin-associated protein or mammalian target of rapamycin RT (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi RT apparatus."; RL J. Biol. Chem. 279:772-778(2004). RN [21] RP FUNCTION IN REGULATION OF THE ACTIN CYTOSKELETON, CATALYTIC ACTIVITY, RP FUNCTION IN PHOSPHORYLATION OF PXN, IDENTIFICATION IN THE MTORC2 COMPLEX, RP INTERACTION WITH RICTOR, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15467718; DOI=10.1038/ncb1183; RA Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N.; RT "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin RT insensitive."; RL Nat. Cell Biol. 6:1122-1128(2004). RN [22] RP PHOSPHORYLATION AT SER-2448. RX PubMed=15899889; DOI=10.1074/jbc.m501707200; RA Chiang G.G., Abraham R.T.; RT "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is RT mediated by p70S6 kinase."; RL J. Biol. Chem. 280:25485-25490(2005). RN [23] RP PHOSPHORYLATION AT THR-2446 AND SER-2448. RX PubMed=15905173; DOI=10.1074/jbc.m504045200; RA Holz M.K., Blenis J.; RT "Identification of S6 kinase 1 as a novel mammalian target of rapamycin RT (mTOR)-phosphorylating kinase."; RL J. Biol. Chem. 280:26089-26093(2005). RN [24] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=17517883; DOI=10.1074/jbc.m702636200; RA Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., RA Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K.; RT "The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological RT substrate of mammalian target of rapamycin complex 1."; RL J. Biol. Chem. 282:20329-20339(2007). RN [26] RP IDENTIFICATION IN THE MTORC2 COMPLEX, AND INTERACTION WITH PRR5. RX PubMed=17599906; DOI=10.1074/jbc.m704343200; RA Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I., RA Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.; RT "PRR5, a novel component of mTOR complex 2, regulates platelet-derived RT growth factor receptor beta expression and signaling."; RL J. Biol. Chem. 282:25604-25612(2007). RN [27] RP INTERACTION WITH AKT1S1, AND ACTIVITY REGULATION. RX PubMed=17386266; DOI=10.1016/j.molcel.2007.03.003; RA Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., RA Spooner E., Carr S.A., Sabatini D.M.; RT "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase."; RL Mol. Cell 25:903-915(2007). RN [28] RP IDENTIFICATION IN THE MTORC1 AND MTORC2 COMPLEXES, CATALYTIC ACTIVITY, AND RP FUNCTION IN PHOSPHORYLATION OF RPS6KB1 AND SGK1. RX PubMed=18925875; DOI=10.1042/bj20081668; RA Garcia-Martinez J.M., Alessi D.R.; RT "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and RT activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)."; RL Biochem. J. 416:375-385(2008). RN [29] RP FUNCTION IN LIPID SYNTHESIS AND CELL GROWTH. RX PubMed=18762023; DOI=10.1016/j.cmet.2008.07.007; RA Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., RA Griffiths J.R., Chung Y.L., Schulze A.; RT "SREBP activity is regulated by mTORC1 and contributes to Akt-dependent RT cell growth."; RL Cell Metab. 8:224-236(2008). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18372248; DOI=10.1074/jbc.m800723200; RA Wang L., Harris T.E., Lawrence J.C. Jr.; RT "Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by RT mammalian target of rapamycin complex 1 (mTORC1)-mediated RT phosphorylation."; RL J. Biol. Chem. 283:15619-15627(2008). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=18497260; DOI=10.1126/science.1157535; RA Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., RA Bar-Peled L., Sabatini D.M.; RT "The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1."; RL Science 320:1496-1501(2008). RN [34] RP INTERACTION WITH DEPTOR, AND ACTIVITY REGULATION. RX PubMed=19446321; DOI=10.1016/j.cell.2009.03.046; RA Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., RA Gray N.S., Sabatini D.M.; RT "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma RT cells and required for their survival."; RL Cell 137:873-886(2009). RN [35] RP PHOSPHORYLATION AT SER-1261, AND ACTIVITY REGULATION. RX PubMed=19487463; DOI=10.1128/mcb.01665-08; RA Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A., RA Feener E.P., Ballif B.A., Fingar D.C.; RT "Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and RT cell growth."; RL Mol. Cell. Biol. 29:4308-4324(2009). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [37] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [38] RP PHOSPHORYLATION AT SER-2448. RX PubMed=19145465; DOI=10.1007/s00726-008-0230-7; RA Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M.; RT "mTOR phosphorylated at S2448 binds to raptor and rictor."; RL Amino Acids 38:223-228(2010). RN [39] RP SUBCELLULAR LOCATION, AND ACTIVITY REGULATION. RX PubMed=20381137; DOI=10.1016/j.cell.2010.02.024; RA Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M.; RT "Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is RT necessary for its activation by amino acids."; RL Cell 141:290-303(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF DAP, FUNCTION IN AUTOPHAGY, AND CATALYTIC RP ACTIVITY. RX PubMed=20537536; DOI=10.1016/j.cub.2010.04.041; RA Koren I., Reem E., Kimchi A.; RT "DAP1, a novel substrate of mTOR, negatively regulates autophagy."; RL Curr. Biol. 20:1093-1098(2010). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT SER-2481. RX PubMed=20022946; DOI=10.1074/jbc.m109.096222; RA Soliman G.A., Acosta-Jaquez H.A., Dunlop E.A., Ekim B., Maj N.E., Tee A.R., RA Fingar D.C.; RT "mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic RT activity and clarifies rapamycin mechanism of action."; RL J. Biol. Chem. 285:7866-7879(2010). RN [42] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=21376236; DOI=10.1016/j.cell.2011.02.014; RA Zinzalla V., Stracka D., Oppliger W., Hall M.N.; RT "Activation of mTORC2 by association with the ribosome."; RL Cell 144:757-768(2011). RN [43] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [44] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [45] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [46] RP FUNCTION IN REGULATION OF RNA POLYMERASE III TRANSCRIPTION, FUNCTION IN RP PHOSPHORYLATION OF MAF1, AND CATALYTIC ACTIVITY. RX PubMed=20516213; DOI=10.1128/mcb.00319-10; RA Michels A.A., Robitaille A.M., Buczynski-Ruchonnet D., Hodroj W., RA Reina J.H., Hall M.N., Hernandez N.; RT "mTORC1 directly phosphorylates and regulates human MAF1."; RL Mol. Cell. Biol. 30:3749-3757(2010). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND THR-1162, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [48] RP SUBCELLULAR LOCATION. RX PubMed=21867682; DOI=10.1016/j.bbrc.2011.08.034; RA Boulbes D.R., Shaiken T., Sarbassov D.D.; RT "Endoplasmic reticulum is a main localization site of mTORC2."; RL Biochem. Biophys. Res. Commun. 413:46-52(2011). RN [49] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [50] RP PHOSPHORYLATION AT SER-2159; THR-2164 AND SER-2481, AND MUTAGENESIS OF RP SER-2159 AND THR-2164. RX PubMed=21576368; DOI=10.1128/mcb.05437-11; RA Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P., RA Fingar D.C.; RT "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, RT and cell cycle progression."; RL Mol. Cell. Biol. 31:2787-2801(2011). RN [51] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [52] RP FUNCTION IN PHOSPHORYLATION OF GRB10, CATALYTIC ACTIVITY, AND FUNCTION IN RP INSR-DEPENDENT SIGNALING. RX PubMed=21659604; DOI=10.1126/science.1199498; RA Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., RA Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M.; RT "The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated RT inhibition of growth factor signaling."; RL Science 332:1317-1322(2011). RN [53] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22576015; DOI=10.4161/auto.19653; RA Martina J.A., Chen Y., Gucek M., Puertollano R.; RT "MTORC1 functions as a transcriptional regulator of autophagy by preventing RT nuclear transport of TFEB."; RL Autophagy 8:903-914(2012). RN [54] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22343943; DOI=10.1038/emboj.2012.32; RA Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Erdin S., RA Huynh T., Ferron M., Karsenty G., Vellard M.C., Facchinetti V., RA Sabatini D.M., Ballabio A.; RT "A lysosome-to-nucleus signalling mechanism senses and regulates the RT lysosome via mTOR and TFEB."; RL EMBO J. 31:1095-1108(2012). RN [55] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22692423; DOI=10.1126/scisignal.2002790; RA Roczniak-Ferguson A., Petit C.S., Froehlich F., Qian S., Ky J., RA Angarola B., Walther T.C., Ferguson S.M.; RT "The transcription factor TFEB links mTORC1 signaling to transcriptional RT control of lysosome homeostasis."; RL Sci. Signal. 5:RA42-RA42(2012). RN [56] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP FUNCTION, AND INTERACTION WITH TPCN1 AND TPCN2. RX PubMed=23394946; DOI=10.1016/j.cell.2013.01.023; RA Cang C., Zhou Y., Navarro B., Seo Y.J., Aranda K., Shi L., RA Battaglia-Hsu S., Nissim I., Clapham D.E., Ren D.; RT "mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to RT metabolic state."; RL Cell 152:778-790(2013). RN [59] RP FUNCTION. RX PubMed=23426360; DOI=10.1074/jbc.m112.441493; RA Eaton J.M., Mullins G.R., Brindley D.N., Harris T.E.; RT "Phosphorylation of lipin 1 and charge on the phosphatidic acid head group RT control its phosphatidic acid phosphatase activity and membrane RT association."; RL J. Biol. Chem. 288:9933-9945(2013). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=25657994; RA So E.Y., Ouchi T.; RT "The potential role of BRCA1-associated ATM activator-1 (BRAT1) in RT regulation of mTOR."; RL J. Cancer Biol. Res. 1:0-0(2013). RN [61] RP PHOSPHORYLATION AT THR-2173, AND MUTAGENESIS OF THR-2173. RX PubMed=24247430; DOI=10.1083/jcb.201305103; RA Halova L., Du W., Kirkham S., Smith D.L., Petersen J.; RT "Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a RT novel mode of TOR inhibition."; RL J. Cell Biol. 203:595-604(2013). RN [62] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [63] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [64] RP INTERACTION WITH NBN. RX PubMed=23762398; DOI=10.1371/journal.pone.0065586; RA Wang J.Q., Chen J.H., Chen Y.C., Chen M.Y., Hsieh C.Y., Teng S.C., Wu K.J.; RT "Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific RT domains."; RL PLoS ONE 8:E65586-E65586(2013). RN [65] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429704; DOI=10.1126/science.1228771; RA Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., RA Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.; RT "Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine RT synthesis."; RL Science 339:1320-1323(2013). RN [66] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429703; DOI=10.1126/science.1228792; RA Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.; RT "Stimulation of de novo pyrimidine synthesis by growth signaling through RT mTOR and S6K1."; RL Science 339:1323-1328(2013). RN [67] RP FUNCTION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=24403073; DOI=10.1074/jbc.m113.482067; RA Coffman K., Yang B., Lu J., Tetlow A.L., Pelliccio E., Lu S., Guo D.C., RA Tang C., Dong M.Q., Tamanoi F.; RT "Characterization of the Raptor/4E-BP1 interaction by chemical cross- RT linking coupled with mass spectrometry analysis."; RL J. Biol. Chem. 289:4723-4734(2014). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2448, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [69] RP FUNCTION. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [70] RP FUNCTION. RX PubMed=24448649; DOI=10.1126/scisignal.2004754; RA Martina J.A., Diab H.I., Lishu L., Jeong-A L., Patange S., Raben N., RA Puertollano R.; RT "The nutrient-responsive transcription factor TFE3 promotes autophagy, RT lysosomal biogenesis, and clearance of cellular debris."; RL Sci. Signal. 7:ra9-ra9(2014). RN [71] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=25851998; DOI=10.1002/ajmg.a.37070; RA Baynam G., Overkov A., Davis M., Mina K., Schofield L., Allcock R., RA Laing N., Cook M., Dawkins H., Goldblatt J.; RT "A germline MTOR mutation in Aboriginal Australian siblings with RT intellectual disability, dysmorphism, macrocephaly, and small thoraces."; RL Am. J. Med. Genet. A 167:1659-1667(2015). RN [72] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 ASP-1459; PRO-1460; RP PHE-2215 AND TYR-2215, AND CHARACTERIZATION OF VARIANTS FCORD2 ASP-1459; RP PRO-1460; PHE-2215 AND TYR-2215. RX PubMed=26018084; DOI=10.1002/ana.24444; RA Nakashima M., Saitsu H., Takei N., Tohyama J., Kato M., Kitaura H., RA Shiina M., Shirozu H., Masuda H., Watanabe K., Ohba C., Tsurusaki Y., RA Miyake N., Zheng Y., Sato T., Takebayashi H., Ogata K., Kameyama S., RA Kakita A., Matsumoto N.; RT "Somatic mutations in the MTOR gene cause focal cortical dysplasia type RT IIb."; RL Ann. Neurol. 78:375-386(2015). RN [73] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=26542245; DOI=10.1186/s12881-015-0240-8; RA Mroske C., Rasmussen K., Shinde D.N., Huether R., Powis Z., Lu H.M., RA Baxter R.M., McPherson E., Tang S.; RT "Germline activating MTOR mutation arising through gonadal mosaicism in two RT brothers with megalencephaly and neurodevelopmental abnormalities."; RL BMC Med. Genet. 16:102-102(2015). RN [74] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [75] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [76] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 HIS-624; ASP-1450; RP ARG-1483; HIS-1709; LYS-1977; CYS-2193; PHE-2215; GLN-2427 AND PRO-2427, RP AND CHARACTERIZATION OF VARIANTS FCORD2 ARG-1483; GLN-2427 AND PRO-2427. RX PubMed=25799227; DOI=10.1038/nm.3824; RA Lim J.S., Kim W.I., Kang H.C., Kim S.H., Park A.H., Park E.K., Cho Y.W., RA Kim S., Kim H.M., Kim J.A., Kim J., Rhee H., Kang S.G., Kim H.D., Kim D., RA Kim D.S., Lee J.H.; RT "Brain somatic mutations in MTOR cause focal cortical dysplasia type II RT leading to intractable epilepsy."; RL Nat. Med. 21:395-400(2015). RN [77] RP ACTIVITY REGULATION. RX PubMed=25561175; DOI=10.1038/nature14107; RA Rebsamen M., Pochini L., Stasyk T., de Araujo M.E., Galluccio M., RA Kandasamy R.K., Snijder B., Fauster A., Rudashevskaya E.L., Bruckner M., RA Scorzoni S., Filipek P.A., Huber K.V., Bigenzahn J.W., Heinz L.X., RA Kraft C., Bennett K.L., Indiveri C., Huber L.A., Superti-Furga G.; RT "SLC38A9 is a component of the lysosomal amino acid sensing machinery that RT controls mTORC1."; RL Nature 519:477-481(2015). RN [78] RP INVOLVEMENT IN FCORD2, AND VARIANT FCORD2 GLY-1456. RX PubMed=25878179; DOI=10.1212/wnl.0000000000001594; RA Leventer R.J., Scerri T., Marsh A.P., Pope K., Gillies G., Maixner W., RA MacGregor D., Harvey A.S., Delatycki M.B., Amor D.J., Crino P., Bahlo M., RA Lockhart P.J.; RT "Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in RT MTOR."; RL Neurology 84:2029-2032(2015). RN [79] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [80] RP ACTIVITY REGULATION. RX PubMed=25567906; DOI=10.1126/science.1257132; RA Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E., RA Yuan E.D., Jones T.D., Chantranupong L., Comb W., Wang T., Bar-Peled L., RA Zoncu R., Straub C., Kim C., Park J., Sabatini B.L., Sabatini D.M.; RT "Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine RT sufficiency to mTORC1."; RL Science 347:188-194(2015). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [82] RP INTERACTION WITH WAC. RX PubMed=26812014; DOI=10.1016/j.devcel.2015.12.019; RA David-Morrison G., Xu Z., Rui Y.N., Charng W.L., Jaiswal M., Yamamoto S., RA Xiong B., Zhang K., Sandoval H., Duraine L., Zuo Z., Zhang S., Bellen H.J.; RT "WAC regulates mTOR activity by acting as an adaptor for the TTT and RT Pontin/Reptin complexes."; RL Dev. Cell 36:139-151(2016). RN [83] RP SUBCELLULAR LOCATION. RX PubMed=27623384; DOI=10.1016/j.devcel.2016.08.001; RA Krishna S., Palm W., Lee Y., Yang W., Bandyopadhyay U., Xu H., Florey O., RA Thompson C.B., Overholtzer M.; RT "PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following RT Engulfment."; RL Dev. Cell 38:536-547(2016). RN [84] RP INVOLVEMENT IN FCORD2, VARIANTS GLU-1376 AND VAL-2501, VARIANTS FCORD2 RP SER-1459; PRO-1460; PHE-2215 AND TYR-2215, AND VARIANTS SKS ARG-1490; RP ILE-1595; THR-1832; CYS-1888 AND ILE-2327. RX PubMed=27830187; DOI=10.1212/nxg.0000000000000118; RA Moeller R.S., Weckhuysen S., Chipaux M., Marsan E., Taly V., Bebin E.M., RA Hiatt S.M., Prokop J.W., Bowling K.M., Mei D., Conti V., de la Grange P., RA Ferrand-Sorbets S., Dorfmueller G., Lambrecq V., Larsen L.H., Leguern E., RA Guerrini R., Rubboli G., Cooper G.M., Baulac S.; RT "Germline and somatic mutations in the MTOR gene in focal cortical RT dysplasia and epilepsy."; RL Neurol. Genet. 2:E118-E118(2016). RN [85] RP FUNCTION. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [86] RP SUBCELLULAR LOCATION, AND INTERACTION WITH MEAK7. RX PubMed=29750193; DOI=10.1126/sciadv.aao5838; RA Nguyen J.T., Ray C., Fox A.L., Mendonca D.B., Kim J.K., Krebsbach P.H.; RT "Mammalian EAK-7 activates alternative mTOR signaling to regulate cell RT proliferation and migration."; RL Sci. Adv. 4:EAAO5838-EAAO5838(2018). RN [87] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-2159, AND MUTAGENESIS RP OF SER-2159. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [88] RP INTERACTION WITH TM4SF5, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2357 RP AND VAL-2364. RX PubMed=30956113; DOI=10.1016/j.cmet.2019.03.005; RA Jung J.W., Macalino S.J.Y., Cui M., Kim J.E., Kim H.J., Song D.G., RA Nam S.H., Kim S., Choi S., Lee J.W.; RT "Transmembrane 4 L six family member 5 senses arginine for mTORC1 RT signaling."; RL Cell Metab. 29:1306-1319(2019). RN [89] RP FUNCTION. RX PubMed=30704899; DOI=10.1016/j.molcel.2018.12.017; RA Cheng X., Ma X., Zhu Q., Song D., Ding X., Li L., Jiang X., Wang X., RA Tian R., Su H., Shen Z., Chen S., Liu T., Gong W., Liu W., Sun Q.; RT "Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of RT autophagosome maturation and lipid metabolism."; RL Mol. Cell 73:1-15(2019). RN [90] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=31112131; DOI=10.7554/elife.43038; RA Jewell J.L., Fu V., Hong A.W., Yu F.X., Meng D., Melick C.H., Wang H., RA Lam W.M., Yuan H.X., Taylor S.S., Guan K.L.; RT "GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor."; RL Elife 8:0-0(2019). RN [91] RP FUNCTION. RX PubMed=31695197; DOI=10.1038/s41586-019-1738-6; RA MacVicar T., Ohba Y., Nolte H., Mayer F.C., Tatsuta T., Sprenger H.G., RA Lindner B., Zhao Y., Li J., Bruns C., Krueger M., Habich M., Riemer J., RA Schwarzer R., Pasparakis M., Henschke S., Bruening J.C., Zamboni N., RA Langer T.; RT "Lipid signalling drives proteolytic rewiring of mitochondria by YME1L."; RL Nature 575:361-365(2019). RN [92] RP INTERACTION WITH GPR137B. RX PubMed=31036939; DOI=10.1038/s41556-019-0321-6; RA Gan L., Seki A., Shen K., Iyer H., Han K., Hayer A., Wollman R., Ge X., RA Lin J.R., Dey G., Talbot W.S., Meyer T.; RT "The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 RT localization and activity."; RL Nat. Cell Biol. 21:614-626(2019). RN [93] RP FUNCTION. RX PubMed=31601708; DOI=10.1126/science.aay0166; RA Rogala K.B., Gu X., Kedir J.F., Abu-Remaileh M., Bianchi L.F., RA Bottino A.M.S., Dueholm R., Niehaus A., Overwijn D., Fils A.P., Zhou S.X., RA Leary D., Laqtom N.N., Brignole E.J., Sabatini D.M.; RT "Structural basis for the docking of mTORC1 on the lysosomal surface."; RL Science 366:468-475(2019). RN [94] RP INTERACTION WITH RICTOR. RX PubMed=33378666; DOI=10.1016/j.celrep.2020.108564; RA Wrobel L., Siddiqi F.H., Hill S.M., Son S.M., Karabiyik C., Kim H., RA Rubinsztein D.C.; RT "mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RT RICTOR."; RL Cell Rep. 33:108564-108564(2020). RN [95] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=32612235; DOI=10.1038/s41586-020-2444-0; RA Napolitano G., Di Malta C., Esposito A., de Araujo M.E.G., Pece S., RA Bertalot G., Matarese M., Benedetti V., Zampelli A., Stasyk T., RA Siciliano D., Venuta A., Cesana M., Vilardo C., Nusco E., Monfregola J., RA Calcagni A., Di Fiore P.P., Huber L.A., Ballabio A.; RT "A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome."; RL Nature 585:597-602(2020). RN [96] RP FUNCTION. RX PubMed=32561715; DOI=10.1038/s41467-020-16886-2; RA Son S.M., Park S.J., Stamatakou E., Vicinanza M., Menzies F.M., RA Rubinsztein D.C.; RT "Leucine regulates autophagy via acetylation of the mTORC1 component RT raptor."; RL Nat. Commun. 11:3148-3148(2020). RN [97] RP INTERACTION WITH NCKAP1L. RX PubMed=32647003; DOI=10.1126/science.aay5663; RA Cook S.A., Comrie W.A., Poli M.C., Similuk M., Oler A.J., Faruqi A.J., RA Kuhns D.B., Yang S., Vargas-Hernandez A., Carisey A.F., Fournier B., RA Anderson D.E., Price S., Smelkinson M., Abou Chahla W., Forbes L.R., RA Mace E.M., Cao T.N., Coban-Akdemir Z.H., Jhangiani S.N., Muzny D.M., RA Gibbs R.A., Lupski J.R., Orange J.S., Cuvelier G.D.E., Al Hassani M., RA Al Kaabi N., Al Yafei Z., Jyonouchi S., Raje N., Caldwell J.W., Huang Y., RA Burkhardt J.K., Latour S., Chen B., ElGhazali G., Rao V.K., Chinn I.K., RA Lenardo M.J.; RT "HEM1 deficiency disrupts mTORC2 and F-actin control in inherited RT immunodysregulatory disease."; RL Science 369:202-207(2020). RN [98] RP FUNCTION. RX PubMed=34289345; DOI=10.1016/j.cell.2021.06.028; RA Evavold C.L., Hafner-Bratkovic I., Devant P., D'Andrea J.M., Ngwa E.M., RA Borsic E., Doench J.G., LaFleur M.W., Sharpe A.H., Thiagarajah J.R., RA Kagan J.C.; RT "Control of gasdermin D oligomerization and pyroptosis by the Ragulator- RT Rag-mTORC1 pathway."; RL Cell 184:4495-4511(2021). RN [99] RP INTERACTION WITH SLC38A7. RX PubMed=35561222; DOI=10.1073/pnas.2123261119; RA Meng D., Yang Q., Jeong M.H., Curukovic A., Tiwary S., Melick C.H., RA Lama-Sherpa T.D., Wang H., Huerta-Rosario M., Urquhart G., Zacharias L.G., RA Lewis C., DeBerardinis R.J., Jewell J.L.; RT "SNAT7 regulates mTORC1 via macropinocytosis."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2123261119-e2123261119(2022). RN [100] RP INTERACTION WITH TSPAN8. RX PubMed=35904232; DOI=10.1002/cbin.11870; RA Zhuang L., Jin G., Hu X., Yang Q., Pei X., Zhao W.; RT "TSPAN8 alleviates high glucose-induced apoptosis and autophagy via RT targeting mTORC2."; RL Cell Biol. Int. 46:1693-1703(2022). RN [101] RP FUNCTION. RX PubMed=36691768; DOI=10.15252/embj.2022112344; RA Shetty S., Hofstetter J., Battaglioni S., Ritz D., Hall M.N.; RT "TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to RT activate dormant ribosomes."; RL EMBO J. 42:e112344-e112344(2023). RN [102] RP SUBCELLULAR LOCATION. RX PubMed=37057673; DOI=10.1016/j.gim.2023.100838; RA Reijnders M.R.F., Seibt A., Brugger M., Lamers I.J.C., Ott T., Klaas O., RA Horvath J., Rose A.M.S., Craghill I.M., Brunet T., Graf E., Mayerhanser K., RA Hellebrekers D., Pauck D., Neuen-Jacob E., Rodenburg R.J.T., Wieczorek D., RA Klee D., Mayatepek E., Driessen G., Bindermann R., Averdunk L., RA Lohmeier K., Sinnema M., Stegmann A.P.A., Roepman R., Poulter J.A., RA Distelmaier F.; RT "De novo missense variants in RRAGC lead to a fatal mTORopathy of early RT childhood."; RL Genet. Med. 25:100838-100838(2023). RN [103] RP FUNCTION. RX PubMed=36608670; DOI=10.1016/j.molcel.2022.12.013; RA Nardone C., Palanski B.A., Scott D.C., Timms R.T., Barber K.W., Gu X., RA Mao A., Leng Y., Watson E.V., Schulman B.A., Cole P.A., Elledge S.J.; RT "A central role for regulated protein stability in the control of TFE3 and RT MITF by nutrients."; RL Mol. Cell 83:57-73(2023). RN [104] RP FUNCTION, UBIQUITINATION AT LYS-2066, AND MUTAGENESIS OF LYS-2066. RX PubMed=37979583; DOI=10.1016/j.cmet.2023.10.016; RA Ge M.K., Zhang C., Zhang N., He P., Cai H.Y., Li S., Wu S., Chu X.L., RA Zhang Y.X., Ma H.M., Xia L., Yang S., Yu J.X., Yao S.Y., Zhou X.L., Su B., RA Chen G.Q., Shen S.M.; RT "The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid RT insufficiency."; RL Cell Metab. 35:2216-2230.e8(2023). RN [105] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37751742; DOI=10.1016/j.molcel.2023.08.032; RA He L., Chen J., Deng P., Huang S., Liu P., Wang C., Huang X., Li Y., RA Chen B., Shi D., Xiao Y., Chen X., Ouyang Y., Song L., Lin C.; RT "Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in RT cancer cells."; RL Mol. Cell 83:3502-3519(2023). RN [106] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=8662507; DOI=10.1126/science.273.5272.239; RA Choi J., Chen J., Schreiber S.L., Clardy J.; RT "Structure of the FKBP12-rapamycin complex interacting with the binding RT domain of human FRAP."; RL Science 273:239-242(1996). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=10089303; DOI=10.1107/s0907444998014747; RA Liang J., Choi J., Clardy J.; RT "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A RT resolution."; RL Acta Crystallogr. D 55:736-744(1999). RN [108] RP 3D-STRUCTURE MODELING, HEAT-REPEATS, AND TPR-REPEATS. RX PubMed=20060908; DOI=10.1016/j.jsb.2010.01.002; RA Knutson B.A.; RT "Insights into the domain and repeat architecture of target of rapamycin."; RL J. Struct. Biol. 170:354-363(2010). RN [109] RP STRUCTURE BY ELECTRON MICROSCOPY (26 ANGSTROMS) OF MTORC1 COMPLEX, AND RP SUBUNIT. RX PubMed=20542007; DOI=10.1016/j.molcel.2010.05.017; RA Yip C.K., Murata K., Walz T., Sabatini D.M., Kang S.A.; RT "Structure of the human mTOR complex I and its implications for rapamycin RT inhibition."; RL Mol. Cell 38:768-774(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1376-2549 IN COMPLEX WITH MLST8, RP SUBUNIT, TPR-REPEATS, DOMAINS, AND MUTAGENESIS OF HIS-2340. RX PubMed=23636326; DOI=10.1038/nature12122; RA Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P.; RT "mTOR kinase structure, mechanism and regulation."; RL Nature 497:217-223(2013). RN [111] {ECO:0007744|PDB:5H64} RP STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) IN COMPLEX WITH RPTOR AND RP MLST8, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=27909983; DOI=10.1007/s13238-016-0346-6; RA Yang H., Wang J., Liu M., Chen X., Huang M., Tan D., Dong M.Q., Wong C.C., RA Wang J., Xu Y., Wang H.W.; RT "4.4 Aa Resolution Cryo-EM structure of human mTOR Complex 1."; RL Protein Cell 7:878-887(2016). RN [112] {ECO:0007744|PDB:5FLC} RP STRUCTURE BY ELECTRON MICROSCOPY (5.90 ANGSTROMS) IN COMPLEX WITH MLST8. RX PubMed=26678875; DOI=10.1126/science.aaa3870; RA Aylett C.H., Sauer E., Imseng S., Boehringer D., Hall M.N., Ban N., RA Maier T.; RT "Architecture of human mTOR complex 1."; RL Science 351:48-52(2016). RN [113] {ECO:0007744|PDB:5WBH, ECO:0007744|PDB:5WBU, ECO:0007744|PDB:5WBY, ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX} RP STRUCTURE BY ELECTRON MICROSCOPY (3.43 ANGSTROMS) IN COMPLEX WITH ATP; RP MAGNESIUM; MLST8; RPTOR; RHEB; AKT1S1; RPS6KB1 AND EIF4EBP1, FUNCTION, RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 RP COMPLEX. RX PubMed=29236692; DOI=10.1038/nature25023; RA Yang H., Jiang X., Li B., Yang H.J., Miller M., Yang A., Dhar A., RA Pavletich N.P.; RT "Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40."; RL Nature 552:368-373(2017). RN [114] {ECO:0007744|PDB:5ZCS} RP STRUCTURE BY ELECTRON MICROSCOPY (4.90 ANGSTROMS) OF THE MTORC2 COMPLEX, RP AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=29567957; DOI=10.1038/s41422-018-0029-3; RA Chen X., Liu M., Tian Y., Li J., Qi Y., Zhao D., Wu Z., Huang M., RA Wong C.C.L., Wang H.W., Wang J., Yang H., Xu Y.; RT "Cryo-EM structure of human mTOR complex 2."; RL Cell Res. 28:518-528(2018). RN [115] RP STRUCTURE BY ELECTRON MICROSCOPY OF THE MTORC2 COMPLEX, AND IDENTIFICATION RP IN THE MTORC2 COMPLEX. RX PubMed=29424687; DOI=10.7554/elife.33101; RA Stuttfeld E., Aylett C.H., Imseng S., Boehringer D., Scaiola A., Sauer E., RA Hall M.N., Maier T., Ban N.; RT "Architecture of the human mTORC2 core complex."; RL Elife 7:0-0(2018). RN [116] {ECO:0007744|PDB:6SB0, ECO:0007744|PDB:6SB2} RP STRUCTURE BY ELECTRON MICROSCOPY (5.50 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; RPTOR; MLST8 AND AKT1S1, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP SUBCELLULAR LOCATION. RX PubMed=31601764; DOI=10.1126/science.aax3939; RA Anandapadamanaban M., Masson G.R., Perisic O., Berndt A., Kaufman J., RA Johnson C.M., Santhanam B., Rogala K.B., Sabatini D.M., Williams R.L.; RT "Architecture of human Rag GTPase heterodimers and their complex with RT mTORC1."; RL Science 366:203-210(2019). RN [117] {ECO:0007744|PDB:6ZWM, ECO:0007744|PDB:6ZWO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF THE MTORC2 COMPLEX IN RP COMPLEX WITH 1D-MYO-INOSITOL HEXAKISPHOSPHATE, AND IDENTIFICATION IN THE RP MTORC2 COMPLEX. RX PubMed=33158864; DOI=10.1126/sciadv.abc1251; RA Scaiola A., Mangia F., Imseng S., Boehringer D., Berneiser K., RA Shimobayashi M., Stuttfeld E., Hall M.N., Ban N., Maier T.; RT "The 3.2-Aa resolution structure of human mTORC2."; RL Sci. Adv. 6:0-0(2020). RN [118] {ECO:0007744|PDB:7PE7, ECO:0007744|PDB:7PE8, ECO:0007744|PDB:7PE9, ECO:0007744|PDB:7PEA, ECO:0007744|PDB:7PEB, ECO:0007744|PDB:7PEC} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-230 IN COMPLEX WITH DEPTOR; RP MLST8; MAPKAP1; RICTOR AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN RP THE MTORC1 COMPLEX, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=34519268; DOI=10.7554/elife.70871; RA Waelchli M., Berneiser K., Mangia F., Imseng S., Craigie L.M., RA Stuttfeld E., Hall M.N., Maier T.; RT "Regulation of human mTOR complexes by DEPTOR."; RL Elife 10:0-0(2021). RN [119] {ECO:0007744|PDB:7OWG} RP STRUCTURE BY ELECTRON MICROSCOPY (4.70 ANGSTROMS) IN COMPLEX WITH DEPTOR; RP MLST8 AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN THE MTORC1 COMPLEX, RP AND FUNCTION. RX PubMed=34519269; DOI=10.7554/elife.68799; RA Heimhalt M., Berndt A., Wagstaff J., Anandapadamanaban M., Perisic O., RA Maslen S., McLaughlin S., Yu C.W., Masson G.R., Boland A., Ni X., RA Yamashita K., Murshudov G.N., Skehel M., Freund S.M., Williams R.L.; RT "Bipartite binding and partial inhibition links DEPTOR and mTOR in a RT mutually antagonistic embrace."; RL Elife 10:0-0(2021). RN [120] {ECO:0007744|PDB:7TZO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.28 ANGSTROMS) OF THE MTORC2 COMPLEX, RP FUNCTION, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=35926713; DOI=10.1016/j.jbc.2022.102288; RA Yu Z., Chen J., Takagi E., Wang F., Saha B., Liu X., Joubert L.M., RA Gleason C.E., Jin M., Li C., Nowotny C., Agard D., Cheng Y., Pearce D.; RT "Interactions between mTORC2 core subunits Rictor and mSin1 dictate RT selective and context-dependent phosphorylation of substrate kinases SGK1 RT and Akt."; RL J. Biol. Chem. 298:102288-102288(2022). RN [121] {ECO:0007744|PDB:7UXC, ECO:0007744|PDB:7UXH} RP STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; LAMTOR1; LAMTOR2; LAMTOR3; LAMTOR4; LAMTOR5; RPTOR; MLST8 AND TFEB, RP FUNCTION, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=36697823; DOI=10.1038/s41586-022-05652-7; RA Cui Z., Napolitano G., de Araujo M.E.G., Esposito A., Monfregola J., RA Huber L.A., Ballabio A., Hurley J.H.; RT "Structure of the lysosomal mTORC1-TFEB-Rag-Ragulator megacomplex."; RL Nature 614:572-579(2023). RN [122] RP VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134; RP PHE-1178; VAL-2011; TYR-2215 AND LEU-2476. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [123] RP VARIANTS PHE-2220 AND ALA-2406. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). CC -!- FUNCTION: Serine/threonine protein kinase which is a central regulator CC of cellular metabolism, growth and survival in response to hormones, CC growth factors, nutrients, energy and stress signals (PubMed:12087098, CC PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, CC PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, CC PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, CC PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, CC PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, CC PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, CC PubMed:34519269, PubMed:37751742). MTOR directly or indirectly CC regulates the phosphorylation of at least 800 proteins CC (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, CC PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, CC PubMed:21659604, PubMed:23429704, PubMed:30171069, PubMed:29236692, CC PubMed:37751742). Functions as part of 2 structurally and functionally CC distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) CC (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, CC PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, CC PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to CC nutrients, growth factors or amino acids, mTORC1 is recruited to the CC lysosome membrane and promotes protein, lipid and nucleotide synthesis CC by phosphorylating key regulators of mRNA translation and ribosome CC synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, CC PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, CC PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, CC PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, CC PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, CC PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, CC PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release CC of its inhibition toward the elongation initiation factor 4E (eiF4E) CC (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and CC activates RPS6KB1 and RPS6KB2 that promote protein synthesis by CC modulating the activity of their downstream targets including ribosomal CC protein S6, eukaryotic translation initiation factor EIF4B, and the CC inhibitor of translation initiation PDCD4 (PubMed:12087098, CC PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). CC Stimulates the pyrimidine biosynthesis pathway, both by acute CC regulation through RPS6KB1-mediated phosphorylation of the biosynthetic CC enzyme CAD, and delayed regulation, through transcriptional enhancement CC of the pentose phosphate pathway which produces 5-phosphoribosyl-1- CC pyrophosphate (PRPP), an allosteric activator of CAD at a later step in CC synthesis, this function is dependent on the mTORC1 complex CC (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by CC activating RNA polymerase III-dependent transcription through CC phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor CC (PubMed:20516213). Activates dormant ribosomes by mediating CC phosphorylation of SERBP1, leading to SERBP1 inactivation and CC reactivation of translation (PubMed:36691768). In parallel to protein CC synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and CC LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also CC regulate mitochondrial biogenesis through regulation of PPARGC1A (By CC similarity). In the same time, mTORC1 inhibits catabolic pathways: CC negatively regulates autophagy through phosphorylation of ULK1 CC (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at CC 'Ser-758', disrupting the interaction with AMPK and preventing CC activation of ULK1 (PubMed:32561715). Also prevents autophagy through CC phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also CC prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich CC conditions (PubMed:30704899). Prevents autophagy by mediating CC phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate CC ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA CC (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on CC upstream growth factor signaling that includes phosphorylation and CC activation of GRB10 a INSR-dependent signaling suppressor CC (PubMed:21659604). Among other potential targets mTORC1 may CC phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The CC mTORC1 complex is inhibited in response to starvation and amino acid CC depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, CC PubMed:31695197). The non-canonical mTORC1 complex, which acts CC independently of RHEB, specifically mediates phosphorylation of MiT/TFE CC factors MITF, TFEB and TFE3 in the presence of nutrients, promoting CC their cytosolic retention and inactivation (PubMed:22343943, CC PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, CC PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, CC inhibition of mTORC1 induces dephosphorylation and nuclear CC translocation of TFEB and TFE3, promoting their transcription factor CC activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, CC PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex CC regulates pyroptosis in macrophages by promoting GSDMD oligomerization CC (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits CC mTORC1 (By similarity). As part of the mTORC2 complex, MTOR transduces CC signals from growth factors to pathways involved in proliferation, CC cytoskeletal organization, lipogenesis and anabolic output CC (PubMed:15268862, PubMed:15467718, PubMed:24670654, PubMed:29424687, CC PubMed:29567957, PubMed:35926713). In response to growth factors, CC mTORC2 phosphorylates and activates AGC protein kinase family members, CC including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and CC SGK1 (PubMed:15268862, PubMed:15467718, PubMed:21376236, CC PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In CC contrast to mTORC1, mTORC2 is nutrient-insensitive (PubMed:15467718). CC mTORC2 plays a critical role in AKT1 activation by mediating CC phosphorylation of different sites depending on the context, such as CC 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the CC phosphorylation of the activation loop of AKT1 on 'Thr-308' by CC PDPK1/PDK1 which is a prerequisite for full activation CC (PubMed:15718470, PubMed:21376236, PubMed:24670654, PubMed:29424687, CC PubMed:29567957). mTORC2 also regulates the phosphorylation of SGK1 at CC 'Ser-422' (PubMed:18925875). mTORC2 may regulate the actin CC cytoskeleton, through phosphorylation of PRKCA, PXN and activation of CC the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or CC RAC1B (PubMed:15268862). The mTORC2 complex also phosphorylates various CC proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By CC similarity). May also regulate insulin signaling by acting as a CC tyrosine protein kinase that catalyzes phosphorylation of IGF1R and CC INSR; additional evidence are however required to confirm this result CC in vivo (PubMed:26584640). Regulates osteoclastogenesis by adjusting CC the expression of CEBPB isoforms (By similarity). Plays an important CC regulatory role in the circadian clock function; regulates period CC length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and CC liver clocks (By similarity). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, CC ECO:0000269|PubMed:22692423, ECO:0000269|PubMed:23426360, CC ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:24670654, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25799227, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:29424687, ECO:0000269|PubMed:29567957, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30704899, CC ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:31601708, CC ECO:0000269|PubMed:31695197, ECO:0000269|PubMed:32561715, CC ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34289345, CC ECO:0000269|PubMed:34519269, ECO:0000269|PubMed:35926713, CC ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:36691768, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:37751742}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:20516213, ECO:0000269|PubMed:20537536, CC ECO:0000269|PubMed:21659604, ECO:0000269|PubMed:22343943, CC ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423, CC ECO:0000269|PubMed:29150432}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:37751742}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000305|PubMed:26584640}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10597; CC Evidence={ECO:0000305|PubMed:26584640}; CC -!- ACTIVITY REGULATION: The mTORC1 complex is activated in response to CC nutrients, growth factors or amino acids: activation requires CC relocalization of the mTORC1 complex to lysosomes that is mediated by CC the Ragulator complex, SLC38A9, and the Rag GTPases RagA/RRAGA, CC RagB/RRAGB, RagC/RRAGC and RagD/RRAGD (PubMed:18497260, CC PubMed:20381137, PubMed:25561175, PubMed:25567906). Activation of CC mTORC1 by growth factors such as insulin involves AKT1-mediated CC phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB CC GTPase a potent activator of the protein kinase activity of mTORC1 CC (PubMed:14651849, PubMed:15545625, PubMed:29236692). Insulin-stimulated CC and amino acid-dependent phosphorylation at Ser-1261 promotes CC autophosphorylation and the activation of mTORC1 (PubMed:19487463). On CC the other hand, low cellular energy levels can inhibit mTORC1 through CC activation of PRKAA1 while hypoxia inhibits mTORC1 through a REDD1- CC dependent mechanism which may also require PRKAA1 (PubMed:14651849, CC PubMed:15545625). The kinase activity of MTOR within the mTORC1 complex CC is positively regulated by MLST8 (PubMed:12718876). The kinase activity CC of MTOR is inhibited by DEPTOR and AKT1S1 (PubMed:17386266, CC PubMed:19446321, PubMed:29236692, PubMed:34519268, PubMed:34519269). CC The non-canonical mTORC1 complex is independent of the RHEB GTPase and CC specifically mediates phosphorylation of MiT/TFE factors TFEB and TFE3 CC but not other mTORC1 substrates: it is activated by FLCN, which CC activates Rag GTPases RagC/RRAGC and RagD/RRAGD (PubMed:32612235, CC PubMed:36697823). MTOR is the target of the immunosuppressive and anti- CC cancer drug rapamycin which acts in complex with FKBP1A/FKBP12, and CC specifically inhibits its kinase activity (PubMed:10089303, CC PubMed:8662507). mTORC2 is also activated by growth factors, but seems CC to be nutrient-insensitive (PubMed:15467718). mTORC2 associates and is CC directly activated by ribosomes (PubMed:21376236). mTORC2 may also be CC regulated by RHEB but in an indirect manner through the PI3K signaling CC pathway (PubMed:15467718). {ECO:0000269|PubMed:10089303, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15545625, CC ECO:0000269|PubMed:17386266, ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:19487463, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:25561175, ECO:0000269|PubMed:25567906, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:32612235, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:8662507}. CC -!- SUBUNIT: Part of the mechanistic target of rapamycin complex 1 (mTORC1) CC which contains MTOR, MLST8 and RPTOR (PubMed:12150925, PubMed:12150926, CC PubMed:12408816, PubMed:12718876, PubMed:18925875, PubMed:20542007, CC PubMed:23636326, PubMed:24403073, PubMed:26678875, PubMed:27909983, CC PubMed:29236692, PubMed:31601764, PubMed:34519268, PubMed:34519269, CC PubMed:36697823). The mTORC1 complex is a 1 Md obligate dimer of two CC stoichiometric heterotetramers with overall dimensions of 290 A x 210 A CC x 135 A (PubMed:20542007, PubMed:23636326). It has a rhomboid shape and CC a central cavity, the dimeric interfaces are formed by interlocking CC interactions between the two MTOR and the two RPTOR subunits CC (PubMed:20542007, PubMed:23636326, PubMed:27909983). The MLST8 subunit CC forms distal foot-like protuberances, and contacts only one MTOR within CC the complex, while the small AKT1S1/PRAS40 localizes to the midsection CC of the central core, in close proximity to RPTOR (PubMed:20542007, CC PubMed:23636326, PubMed:27909983, PubMed:29236692). mTORC1 associates CC with AKT1S1/PRAS40, which inhibits its activity by blocking MTOR CC substrate-recruitment site (PubMed:17386266, PubMed:29236692). CC Component of the mechanistic target of rapamycin complex 2 (mTORC2), CC consisting in two heterotretramers composed of MTOR, MLST8, RICTOR and CC MAPKAP1/SIN1 (PubMed:15268862, PubMed:15467718, PubMed:17599906, CC PubMed:18925875, PubMed:29424687, PubMed:29567957, PubMed:33158864, CC PubMed:35926713). Interacts with PLPP7 and PML (By similarity). CC Interacts with PRR5 and RICTOR; the interaction is direct within the CC mTORC2 complex and interaction with RICTOR is enhanced by CC deubiquitination of RICTOR by USP9X (PubMed:17599906, PubMed:33378666, CC PubMed:29424687, PubMed:34519268). mTORC1 and mTORC2 associate with CC DEPTOR, which regulates their activity (PubMed:19446321, CC PubMed:34519268, PubMed:34519269). Interacts with WAC; WAC positively CC regulates MTOR activity by promoting the assembly of the TTT complex CC composed of TELO2, TTI1 and TTI2 and the RUVBL complex composed of CC RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the CC dimerization of the mTORC1 complex and its subsequent activation CC (PubMed:26812014). Interacts with UBQLN1 (PubMed:11853878). Interacts CC with TTI1 and TELO2 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with CLIP1; phosphorylates and regulates CC CLIP1 (PubMed:12231510). Interacts with NBN (PubMed:23762398). CC Interacts with HTR6 (PubMed:23027611). Interacts with BRAT1 CC (PubMed:25657994). Interacts with MEAK7 (via C-terminal domain); the CC interaction increases upon nutrient stimulation (PubMed:29750193). CC Interacts with TM4SF5; the interaction is positively regulated by CC arginine and is negatively regulated by leucine (PubMed:30956113). CC Interacts with GPR137B (PubMed:31036939). Interacts with NCKAP1L CC (PubMed:32647003). Interacts with TPCN1 and TPCN2; the interaction is CC required for TPCN1 and TPCN2 sensitivity to ATP (PubMed:23394946). CC Interacts with ATP6V1A and with CRYAB, forming a ternary complex (By CC similarity). Interacts with SLC38A7; this interaction mediates the CC recruitment of mTORC1 to the lysosome and its subsequent activation CC (PubMed:35561222). Interacts with TSPAN8 (PubMed:35904232). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:11853878, CC ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:12408816, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:17386266, CC ECO:0000269|PubMed:17599906, ECO:0000269|PubMed:18925875, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20542007, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:23394946, ECO:0000269|PubMed:23636326, CC ECO:0000269|PubMed:23762398, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:25657994, ECO:0000269|PubMed:26678875, CC ECO:0000269|PubMed:26812014, ECO:0000269|PubMed:27909983, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:29424687, CC ECO:0000269|PubMed:29567957, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31036939, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:32647003, CC ECO:0000269|PubMed:33158864, ECO:0000269|PubMed:33378666, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:35561222, ECO:0000269|PubMed:35904232, CC ECO:0000269|PubMed:35926713, ECO:0000269|PubMed:36697823}. CC -!- INTERACTION: CC P42345; P31749: AKT1; NbExp=6; IntAct=EBI-359260, EBI-296087; CC P42345; Q07817-1: BCL2L1; NbExp=4; IntAct=EBI-359260, EBI-287195; CC P42345; Q6UXB4: CLEC4G; NbExp=4; IntAct=EBI-359260, EBI-2114729; CC P42345; Q8TB45: DEPTOR; NbExp=5; IntAct=EBI-359260, EBI-2359040; CC P42345; Q13541: EIF4EBP1; NbExp=2; IntAct=EBI-359260, EBI-74090; CC P42345; Q969H0: FBXW7; NbExp=5; IntAct=EBI-359260, EBI-359574; CC P42345; P62942: FKBP1A; NbExp=5; IntAct=EBI-359260, EBI-1027571; CC P42345; P24522: GADD45A; NbExp=4; IntAct=EBI-359260, EBI-448167; CC P42345; Q8WUA4: GTF3C2; NbExp=3; IntAct=EBI-359260, EBI-1237062; CC P42345; Q9BVC4: MLST8; NbExp=7; IntAct=EBI-359260, EBI-1387471; CC P42345; Q9BVC4-1: MLST8; NbExp=7; IntAct=EBI-359260, EBI-16056342; CC P42345; Q13615: MTMR3; NbExp=3; IntAct=EBI-359260, EBI-371938; CC P42345; P42345: MTOR; NbExp=2; IntAct=EBI-359260, EBI-359260; CC P42345; Q9Y4G2: PLEKHM1; NbExp=6; IntAct=EBI-359260, EBI-473814; CC P42345; Q8TCU6: PREX1; NbExp=11; IntAct=EBI-359260, EBI-1046542; CC P42345; P62820: RAB1A; NbExp=4; IntAct=EBI-359260, EBI-716845; CC P42345; Q15382: RHEB; NbExp=4; IntAct=EBI-359260, EBI-1055287; CC P42345; Q6R327: RICTOR; NbExp=37; IntAct=EBI-359260, EBI-1387196; CC P42345; Q8N122: RPTOR; NbExp=48; IntAct=EBI-359260, EBI-1567928; CC P42345; Q96EB6: SIRT1; NbExp=2; IntAct=EBI-359260, EBI-1802965; CC P42345; O14894: TM4SF5; NbExp=7; IntAct=EBI-359260, EBI-19125949; CC P42345; Q92544: TM9SF4; NbExp=4; IntAct=EBI-359260, EBI-6138615; CC P42345; Q8NHX9: TPCN2; NbExp=2; IntAct=EBI-359260, EBI-5239949; CC P42345; O75385: ULK1; NbExp=7; IntAct=EBI-359260, EBI-908831; CC P42345; P63104: YWHAZ; NbExp=3; IntAct=EBI-359260, EBI-347088; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:37057673}; Peripheral CC membrane protein {ECO:0000269|PubMed:30956113, CC ECO:0000269|PubMed:31112131}; Cytoplasmic side CC {ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:14578359}; Peripheral membrane CC protein {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Golgi apparatus membrane CC {ECO:0000269|PubMed:14578359}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Cell membrane CC {ECO:0000269|PubMed:21867682}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}. Mitochondrion outer membrane CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}; Peripheral CC membrane protein {ECO:0000269|PubMed:11930000, CC ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}. Cytoplasm CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:18497260}. Nucleus CC {ECO:0000250|UniProtKB:Q9JLN9}. Nucleus, PML body CC {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane CC {ECO:0000269|PubMed:9434772}. Cytoplasmic vesicle, phagosome CC {ECO:0000269|PubMed:27623384}. Note=Shuttles between cytoplasm and CC nucleus. Accumulates in the nucleus in response to hypoxia (By CC similarity). Targeting to lysosomes depends on amino acid availability CC and RRAGA and RRAGB (PubMed:18497260, PubMed:20381137). Lysosome CC targeting also depends on interaction with MEAK7. Translocates to the CC lysosome membrane in the presence of TM4SF5 (PubMed:30956113). The CC mTORC2 complex localizes to membranes: mTORC2 is active at the plasma CC membrane, endoplasmic reticulum membrane and lysosomes CC (PubMed:21867682). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:20381137, CC ECO:0000269|PubMed:21867682, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113}. CC -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest levels CC in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}. CC -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but has a CC highly restricted catalytic center. {ECO:0000269|PubMed:23636326}. CC -!- DOMAIN: The FAT domain forms three discontinuous subdomains of alpha- CC helical TPR repeats plus a single subdomain of HEAT repeats. The four CC domains pack sequentially to form a C-shaped a-solenoid that clamps CC onto the kinase domain (PubMed:23636326). CC {ECO:0000269|PubMed:23636326}. CC -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2 (PubMed:15467718, CC PubMed:20022946, PubMed:9434772). Phosphorylation at Ser-1261, Ser-2159 CC and Thr-2164 promotes autophosphorylation (PubMed:19487463). CC Phosphorylated at Ser-2448 by RPS6KB1 (PubMed:15899889, CC PubMed:15905173, PubMed:19145465). Phosphorylation in the kinase domain CC modulates the interactions of MTOR with RPTOR and AKT1S1/PRAS40 and CC leads to increased intrinsic mTORC1 kinase activity (PubMed:15905173, CC PubMed:19145465, PubMed:21576368). Phosphorylation at Ser-2159 by TBK1 CC in response to growth factors and pathogen recognition receptors CC promotes mTORC1 activity (PubMed:29150432). Phosphorylation at Ser-2159 CC by TBK1 in response to EGF growth factor promotes mTORC2 activity, CC leading to AKT1 phosphorylation and activation (By similarity). CC Phosphorylation at Thr-2173 in the ATP-binding region by AKT1 strongly CC reduces kinase activity (PubMed:24247430). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, CC ECO:0000269|PubMed:19487463, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:24247430, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:9434772}. CC -!- PTM: Ubiquitinated at Lys-2066 by the SCF(FBXO22) complex via 'Lys-27'- CC linked ubiquitination prevents mTORC1 substrate recruitment. CC {ECO:0000269|PubMed:37979583}. CC -!- DISEASE: Smith-Kingsmore syndrome (SKS) [MIM:616638]: An autosomal CC dominant syndrome characterized by intellectual disability, CC macrocephaly, seizures, umbilical hernia, and facial dysmorphic CC features. {ECO:0000269|PubMed:25851998, ECO:0000269|PubMed:26542245, CC ECO:0000269|PubMed:27830187}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Focal cortical dysplasia 2 (FCORD2) [MIM:607341]: A form of CC focal cortical dysplasia, a malformation of cortical development that CC results in medically refractory epilepsy in the pediatric population CC and in adults. FCORD2 is a severe form, with onset usually in CC childhood, characterized by disrupted cortical lamination and specific CC cytological abnormalities. It is classified in 2 subtypes: type IIA CC characterized by dysmorphic neurons and lack of balloon cells; type IIB CC with dysmorphic neurons and balloon cells. CC {ECO:0000269|PubMed:25799227, ECO:0000269|PubMed:25878179, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC39933.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAE06077.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40639/FRAP1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin entry; CC URL="https://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L34075; AAA58486.1; -; mRNA. DR EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA. DR EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA. DR EMBL; AL109811; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391561; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL049653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117166; AAI17167.1; -; mRNA. DR EMBL; AJ300188; CAC15570.1; -; Genomic_DNA. DR EMBL; L35478; AAC41713.1; -; mRNA. DR CCDS; CCDS127.1; -. DR PIR; S45340; S45340. DR RefSeq; NP_001373429.1; NM_001386500.1. DR RefSeq; NP_004949.1; NM_004958.4. DR PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114. DR PDB; 1FAP; X-ray; 2.70 A; B=2018-2112. DR PDB; 1NSG; X-ray; 2.20 A; B=2019-2112. DR PDB; 2FAP; X-ray; 2.20 A; B=2019-2112. DR PDB; 2GAQ; NMR; -; A=2015-2114. DR PDB; 2NPU; NMR; -; A=2015-2114. DR PDB; 2RSE; NMR; -; B=2019-2112. DR PDB; 3FAP; X-ray; 1.85 A; B=2019-2112. DR PDB; 3JBZ; EM; 28.00 A; A=1385-2549. DR PDB; 4DRH; X-ray; 2.30 A; B/E=2025-2114. DR PDB; 4DRI; X-ray; 1.45 A; B=2025-2114. DR PDB; 4DRJ; X-ray; 1.80 A; B=2025-2114. DR PDB; 4FAP; X-ray; 2.80 A; B=2019-2112. DR PDB; 4JSN; X-ray; 3.20 A; A/B=1376-2549. DR PDB; 4JSP; X-ray; 3.30 A; A/B=1376-2549. DR PDB; 4JSV; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JSX; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JT5; X-ray; 3.45 A; A/B=1376-2549. DR PDB; 4JT6; X-ray; 3.60 A; A/B=1376-2549. DR PDB; 5FLC; EM; 5.90 A; B/F=1382-2549. DR PDB; 5GPG; X-ray; 1.67 A; B=2021-2112. DR PDB; 5H64; EM; 4.40 A; A/a=1-2549. DR PDB; 5WBH; X-ray; 1.75 A; A/B/C/D/E=2018-2114. DR PDB; 5WBU; X-ray; 3.42 A; A/B=1376-2549. DR PDB; 5WBY; X-ray; 3.10 A; A/B=1376-2549. DR PDB; 5ZCS; EM; 4.90 A; A/B=1-2549. DR PDB; 6BCU; EM; 3.43 A; A/B=1-2549. DR PDB; 6BCX; EM; 3.00 A; A/B=1-2549. DR PDB; 6M4U; X-ray; 2.20 A; B/F=2021-2113. DR PDB; 6M4W; X-ray; 3.11 A; G/H/I=2021-2113. DR PDB; 6SB0; EM; 5.50 A; A/B=60-2549. DR PDB; 6SB2; EM; 6.20 A; A/B=54-2549. DR PDB; 6ZWM; EM; 3.20 A; A/B=1-2549. DR PDB; 6ZWO; EM; 3.00 A; B=1-2549. DR PDB; 7EPD; EM; 3.90 A; B=2019-2114. DR PDB; 7OWG; EM; 4.70 A; B=1-2549. DR PDB; 7PE7; EM; 3.41 A; A/B=1-2549. DR PDB; 7PE8; EM; 3.20 A; A=1-2549. DR PDB; 7PE9; EM; 3.70 A; A=1-2549. DR PDB; 7PEA; EM; 4.07 A; A/B=1-2549. DR PDB; 7PEB; EM; 3.67 A; A=1-2549. DR PDB; 7PEC; EM; 4.24 A; A=1-2549. DR PDB; 7TZO; EM; 3.28 A; A/B=1-2549. DR PDB; 7UXC; EM; 3.20 A; A=1-2549. DR PDB; 7UXH; EM; 3.20 A; A/C=1-2549. DR PDB; 8ER6; X-ray; 2.81 A; B/D/F=2019-2112. DR PDB; 8ER7; X-ray; 3.07 A; B/D/F=2019-2112. DR PDB; 8ERA; EM; 2.86 A; A=1-2549. DR PDB; 8PPZ; X-ray; 1.85 A; B=2025-2114. DR PDB; 8RCH; EM; 4.00 A; A/B=1-2549. DR PDB; 8RCK; EM; 3.40 A; B=1-2549. DR PDB; 8RCN; EM; 3.10 A; B=1-2549. DR PDB; 9F44; EM; 3.68 A; A/B=1-2549. DR PDB; 9F45; EM; 3.74 A; A/B=1-2549. DR PDBsum; 1AUE; -. DR PDBsum; 1FAP; -. DR PDBsum; 1NSG; -. DR PDBsum; 2FAP; -. DR PDBsum; 2GAQ; -. DR PDBsum; 2NPU; -. DR PDBsum; 2RSE; -. DR PDBsum; 3FAP; -. DR PDBsum; 3JBZ; -. DR PDBsum; 4DRH; -. DR PDBsum; 4DRI; -. DR PDBsum; 4DRJ; -. DR PDBsum; 4FAP; -. DR PDBsum; 4JSN; -. DR PDBsum; 4JSP; -. DR PDBsum; 4JSV; -. DR PDBsum; 4JSX; -. DR PDBsum; 4JT5; -. DR PDBsum; 4JT6; -. DR PDBsum; 5FLC; -. DR PDBsum; 5GPG; -. DR PDBsum; 5H64; -. DR PDBsum; 5WBH; -. DR PDBsum; 5WBU; -. DR PDBsum; 5WBY; -. DR PDBsum; 5ZCS; -. DR PDBsum; 6BCU; -. DR PDBsum; 6BCX; -. DR PDBsum; 6M4U; -. DR PDBsum; 6M4W; -. DR PDBsum; 6SB0; -. DR PDBsum; 6SB2; -. DR PDBsum; 6ZWM; -. DR PDBsum; 6ZWO; -. DR PDBsum; 7EPD; -. DR PDBsum; 7OWG; -. DR PDBsum; 7PE7; -. DR PDBsum; 7PE8; -. DR PDBsum; 7PE9; -. DR PDBsum; 7PEA; -. DR PDBsum; 7PEB; -. DR PDBsum; 7PEC; -. DR PDBsum; 7TZO; -. DR PDBsum; 7UXC; -. DR PDBsum; 7UXH; -. DR PDBsum; 8ER6; -. DR PDBsum; 8ER7; -. DR PDBsum; 8ERA; -. DR PDBsum; 8PPZ; -. DR PDBsum; 8RCH; -. DR PDBsum; 8RCK; -. DR PDBsum; 8RCN; -. DR PDBsum; 9F44; -. DR PDBsum; 9F45; -. DR AlphaFoldDB; P42345; -. DR BMRB; P42345; -. DR EMDB; EMD-10132; -. DR EMDB; EMD-10133; -. DR EMDB; EMD-11488; -. DR EMDB; EMD-11489; -. DR EMDB; EMD-11490; -. DR EMDB; EMD-11491; -. DR EMDB; EMD-11492; -. DR EMDB; EMD-13097; -. DR EMDB; EMD-13347; -. DR EMDB; EMD-13348; -. DR EMDB; EMD-13349; -. DR EMDB; EMD-13350; -. DR EMDB; EMD-13351; -. DR EMDB; EMD-13352; -. DR EMDB; EMD-19052; -. DR EMDB; EMD-19053; -. DR EMDB; EMD-19056; -. DR EMDB; EMD-26213; -. DR EMDB; EMD-26857; -. DR EMDB; EMD-26861; -. DR EMDB; EMD-28551; -. DR EMDB; EMD-3212; -. DR EMDB; EMD-3213; -. DR EMDB; EMD-50183; -. DR EMDB; EMD-50184; -. DR EMDB; EMD-6668; -. DR EMDB; EMD-6913; -. DR EMDB; EMD-7086; -. DR EMDB; EMD-7087; -. DR SMR; P42345; -. DR BioGRID; 108757; 392. DR ComplexPortal; CPX-4402; mTORC2 complex. DR ComplexPortal; CPX-503; mTORC1 complex. DR CORUM; P42345; -. DR DIP; DIP-790N; -. DR FunCoup; P42345; 4303. DR IntAct; P42345; 203. DR MINT; P42345; -. DR STRING; 9606.ENSP00000354558; -. DR BindingDB; P42345; -. DR ChEMBL; CHEMBL2842; -. DR DrugBank; DB12180; Apitolisib. DR DrugBank; DB12774; AZD-8055. DR DrugBank; DB14846; Bimiralisib. DR DrugBank; DB11651; Dactolisib. DR DrugBank; DB01590; Everolimus. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB13072; GDC-0349. DR DrugBank; DB11896; Gedatolisib. DR DrugBank; DB11978; Glasdegib. DR DrugBank; DB11962; GSK-1059615. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB13062; ME-344. DR DrugBank; DB19085; Novolimus. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB12570; Onatasertib. DR DrugBank; DB12387; OSI-027. DR DrugBank; DB11974; PF-04691502. DR DrugBank; DB00337; Pimecrolimus. DR DrugBank; DB08052; PP-121. DR DrugBank; DB06233; Ridaforolimus. DR DrugBank; DB04974; Rimiducid. DR DrugBank; DB12681; Salirasib. DR DrugBank; DB11836; Sapanisertib. DR DrugBank; DB05210; SF1126. DR DrugBank; DB00877; Sirolimus. DR DrugBank; DB06287; Temsirolimus. DR DrugBank; DB11925; Vistusertib. DR DrugBank; DB12400; Voxtalisib. DR DrugBank; DB12986; VS-5584. DR DrugBank; DB05241; XL765. DR DrugBank; DB18761; Zotarolimus. DR DrugCentral; P42345; -. DR GuidetoPHARMACOLOGY; 2109; -. DR GlyGen; P42345; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P42345; -. DR MetOSite; P42345; -. DR PhosphoSitePlus; P42345; -. DR SwissPalm; P42345; -. DR BioMuta; MTOR; -. DR DMDM; 1169735; -. DR CPTAC; CPTAC-1360; -. DR CPTAC; CPTAC-1361; -. DR CPTAC; CPTAC-3133; -. DR CPTAC; CPTAC-3134; -. DR CPTAC; CPTAC-5752; -. DR CPTAC; CPTAC-5753; -. DR CPTAC; CPTAC-5754; -. DR CPTAC; CPTAC-5755; -. DR CPTAC; CPTAC-5756; -. DR CPTAC; CPTAC-5793; -. DR CPTAC; CPTAC-5794; -. DR CPTAC; CPTAC-5795; -. DR CPTAC; CPTAC-5796; -. DR CPTAC; CPTAC-5797; -. DR CPTAC; CPTAC-5798; -. DR CPTAC; CPTAC-5799; -. DR CPTAC; CPTAC-5800; -. DR CPTAC; non-CPTAC-5421; -. DR CPTAC; non-CPTAC-5422; -. DR CPTAC; non-CPTAC-5423; -. DR CPTAC; non-CPTAC-5424; -. DR CPTAC; non-CPTAC-5425; -. DR CPTAC; non-CPTAC-5560; -. DR CPTAC; non-CPTAC-5561; -. DR CPTAC; non-CPTAC-5562; -. DR CPTAC; non-CPTAC-5563; -. DR CPTAC; non-CPTAC-5709; -. DR CPTAC; non-CPTAC-5710; -. DR CPTAC; non-CPTAC-5711; -. DR CPTAC; non-CPTAC-5712; -. DR jPOST; P42345; -. DR MassIVE; P42345; -. DR PaxDb; 9606-ENSP00000354558; -. DR PeptideAtlas; P42345; -. DR ProteomicsDB; 55511; -. DR Pumba; P42345; -. DR Antibodypedia; 3566; 1829 antibodies from 54 providers. DR CPTC; P42345; 10 antibodies. DR DNASU; 2475; -. DR Ensembl; ENST00000361445.9; ENSP00000354558.4; ENSG00000198793.15. DR Ensembl; ENST00000703143.2; ENSP00000515200.2; ENSG00000198793.15. DR GeneID; 2475; -. DR KEGG; hsa:2475; -. DR MANE-Select; ENST00000361445.9; ENSP00000354558.4; NM_004958.4; NP_004949.1. DR UCSC; uc001asd.4; human. DR AGR; HGNC:3942; -. DR CIViC; 2475; 31 evidence items across 26 molecular profiles. DR ClinPGx; PA28360; -. DR CTD; 2475; -. DR DisGeNET; 2475; -. DR GeneCards; MTOR; -. DR HGNC; HGNC:3942; MTOR. DR HPA; ENSG00000198793; Low tissue specificity. DR MalaCards; MTOR; -. DR MIM; 601231; gene. DR MIM; 607341; phenotype. DR MIM; 616638; phenotype. DR OpenTargets; ENSG00000198793; -. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 269001; Isolated focal cortical dysplasia type IIa. DR Orphanet; 269008; Isolated focal cortical dysplasia type IIb. DR Orphanet; 457485; Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome. DR VEuPathDB; HostDB:ENSG00000198793; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00930000151037; -. DR HOGENOM; CLU_000178_7_1_1; -. DR InParanoid; P42345; -. DR OMA; MRQHSAK; -. DR OrthoDB; 2250022at2759; -. DR PAN-GO; P42345; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42345; -. DR PathwayCommons; P42345; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-166208; mTORC1-mediated signalling. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9639288; Amino acids regulate mTORC1. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR SABIO-RK; P42345; -. DR SignaLink; P42345; -. DR SIGNOR; P42345; -. DR Agora; ENSG00000198793; -. DR BioGRID-ORCS; 2475; 805 hits in 1184 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MTOR; human. DR EvolutionaryTrace; P42345; -. DR GeneWiki; Mammalian_target_of_rapamycin; -. DR GenomeRNAi; 2475; -. DR Pharos; P42345; Tclin. DR PRO; PR:P42345; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P42345; protein. DR Bgee; ENSG00000198793; Expressed in primordial germ cell in gonad and 132 other cell types or tissues. DR ExpressionAtlas; P42345; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0012505; C:endomembrane system; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005635; C:nuclear envelope; IDA:CACAO. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB. DR GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:UniProtKB. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0043022; F:ribosome binding; IDA:UniProtKB. DR GO; GO:0001002; F:RNA polymerase III type 1 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001003; F:RNA polymerase III type 2 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001156; F:TFIIIC-class transcription factor complex binding; IDA:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IEA:Ensembl. DR GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl. DR GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl. DR GO; GO:0030030; P:cell projection organization; IEA:Ensembl. DR GO; GO:0034198; P:cellular response to amino acid starvation; IDA:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:CAFA. DR GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0071233; P:cellular response to L-leucine; IDA:CAFA. DR GO; GO:1990253; P:cellular response to leucine starvation; IDA:CAFA. DR GO; GO:0061431; P:cellular response to methionine; IDA:UniProt. DR GO; GO:0031670; P:cellular response to nutrient; IDA:UniProt. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:UniProt. DR GO; GO:0071470; P:cellular response to osmotic stress; NAS:ComplexPortal. DR GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; NAS:ComplexPortal. DR GO; GO:0006974; P:DNA damage response; NAS:ComplexPortal. DR GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl. DR GO; GO:0003179; P:heart valve morphogenesis; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0016236; P:macroautophagy; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0010507; P:negative regulation of autophagy; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProt. DR GO; GO:1905672; P:negative regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016242; P:negative regulation of macroautophagy; IDA:MGI. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IDA:UniProtKB. DR GO; GO:0019228; P:neuronal action potential; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl. DR GO; GO:0030307; P:positive regulation of cell growth; NAS:ComplexPortal. DR GO; GO:1904690; P:positive regulation of cytoplasmic translational initiation; TAS:ARUK-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; NAS:ComplexPortal. DR GO; GO:0051549; P:positive regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; IEA:Ensembl. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; IEA:Ensembl. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:1905857; P:positive regulation of pentose-phosphate shunt; NAS:ComplexPortal. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:Reactome. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IEA:Ensembl. DR GO; GO:0062027; P:positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process; IDA:UniProt. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IMP:UniProtKB. DR GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB. DR GO; GO:0045948; P:positive regulation of translational initiation; IDA:UniProt. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IDA:UniProt. DR GO; GO:0050821; P:protein stabilization; ISS:UniProt. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0008361; P:regulation of cell size; IMP:CAFA. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:1904059; P:regulation of locomotor rhythm; ISS:UniProtKB. DR GO; GO:1905671; P:regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:Reactome. DR GO; GO:0090559; P:regulation of membrane permeability; IEA:Ensembl. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0043200; P:response to amino acid; IDA:UniProtKB. DR GO; GO:0009408; P:response to heat; IEA:Ensembl. DR GO; GO:0031667; P:response to nutrient levels; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0002296; P:T-helper 1 cell lineage commitment; IEA:Ensembl. DR GO; GO:0031929; P:TOR signaling; IMP:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IDA:UniProtKB. DR GO; GO:0038203; P:TORC2 signaling; IDA:UniProtKB. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl. DR CDD; cd05169; PIKKc_TOR; 1. DR DisProt; DP03874; -. DR FunFam; 1.10.1070.11:FF:000074; DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1); 1. DR FunFam; 1.10.1070.11:FF:000058; MTOR isoform 6; 1. DR FunFam; 1.25.10.10:FF:000060; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000094; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000532; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.20.120.150:FF:000001; Serine/threonine-protein kinase TOR; 1. DR FunFam; 1.25.10.10:FF:000083; Serine/threonine-protein kinase TOR; 1. DR FunFam; 3.30.1010.10:FF:000004; Serine/threonine-protein kinase TOR; 1. DR Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR IDEAL; IID00598; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR009076; FRB_dom. DR InterPro; IPR036738; FRB_sf. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024585; mTOR_dom. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR026683; TOR_cat. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF08771; FRB_dom; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF11865; mTOR_dom; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01346; DUF3385; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01345; Rapamycin_bind; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell membrane; Cytoplasm; KW Cytoplasmic vesicle; Disease variant; Endoplasmic reticulum; Epilepsy; KW Golgi apparatus; Intellectual disability; Isopeptide bond; Kinase; KW Lysosome; Membrane; Microsome; Mitochondrion; Mitochondrion outer membrane; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; TPR repeat; KW Transferase; Ubl conjugation. FT CHAIN 1..2549 FT /note="Serine/threonine-protein kinase mTOR" FT /id="PRO_0000088808" FT REPEAT 16..53 FT /note="HEAT 1" FT REPEAT 55..99 FT /note="HEAT 2" FT REPEAT 100..137 FT /note="HEAT 3" FT REPEAT 138..179 FT /note="HEAT 4" FT REPEAT 180..220 FT /note="HEAT 5" FT REPEAT 222..276 FT /note="HEAT 6" FT REPEAT 277..313 FT /note="HEAT 7" FT REPEAT 314..364 FT /note="HEAT 8" FT REPEAT 365..409 FT /note="HEAT 9" FT REPEAT 410..445 FT /note="HEAT 10" FT REPEAT 446..494 FT /note="HEAT 11" FT REPEAT 495..529 FT /note="HEAT 12" FT REPEAT 530..563 FT /note="HEAT 13" FT REPEAT 564..596 FT /note="HEAT 14" FT REPEAT 597..636 FT /note="HEAT 15" FT REPEAT 637..683 FT /note="HEAT 16" FT REPEAT 686..724 FT /note="HEAT 17" FT REPEAT 727..766 FT /note="HEAT 18" FT REPEAT 769..811 FT /note="HEAT 19" FT REPEAT 814..853 FT /note="HEAT 20" FT REPEAT 857..893 FT /note="HEAT 21" FT REPEAT 894..942 FT /note="HEAT 22" FT REPEAT 943..988 FT /note="HEAT 23" FT REPEAT 989..1027 FT /note="HEAT 24" FT REPEAT 1029..1068 FT /note="HEAT 25" FT REPEAT 1069..1105 FT /note="HEAT 26" FT REPEAT 1106..1144 FT /note="HEAT 27" FT REPEAT 1145..1188 FT /note="HEAT 28" FT REPEAT 1189..1225 FT /note="HEAT 29" FT REPEAT 1226..1273 FT /note="HEAT 30" FT REPEAT 1274..1311 FT /note="HEAT 31" FT REPEAT 1312..1345 FT /note="HEAT 32" FT REPEAT 1346..1382 FT /note="TPR 1" FT DOMAIN 1382..1982 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 1383..1408 FT /note="TPR 2" FT REPEAT 1409..1442 FT /note="TPR 3" FT REPEAT 1443..1473 FT /note="TPR 4" FT REPEAT 1474..1507 FT /note="TPR 5" FT REPEAT 1508..1541 FT /note="TPR 6" FT REPEAT 1542..1574 FT /note="TPR 7" FT REPEAT 1575..1614 FT /note="TPR 8" FT REPEAT 1615..1649 FT /note="TPR 9" FT REPEAT 1650..1693 FT /note="TPR 10" FT REPEAT 1694..1731 FT /note="TPR 11" FT REPEAT 1732..1786 FT /note="TPR 12" FT REPEAT 1787..1846 FT /note="TPR 13" FT REPEAT 1898..1930 FT /note="TPR 14" FT REPEAT 1931..1970 FT /note="TPR 15" FT REPEAT 1971..2005 FT /note="TPR 16" FT DOMAIN 2156..2469 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2517..2549 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1..651 FT /note="Interaction with NBN" FT /evidence="ECO:0000269|PubMed:23762398" FT REGION 1812..1867 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2012..2144 FT /note="Sufficient for interaction with the FKBP1A/rapamycin FT complex" FT /evidence="ECO:0000250|UniProtKB:Q9JLN9" FT REGION 2162..2168 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2258..2296 FT /note="Interaction with MLST8" FT REGION 2335..2343 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2355..2380 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT COMPBIAS 1820..1860 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1662 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1702 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1749 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 2165 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2167 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2185 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2187 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2190 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2225 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2238 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2240 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2245 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2343 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2357 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231" FT MOD_RES 1162 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1218 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19487463, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2159 FT /note="Phosphoserine; by TBK1" FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MOD_RES 2164 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21576368" FT MOD_RES 2173 FT /note="Phosphothreonine; by PKB/AKT1" FT /evidence="ECO:0000269|PubMed:24247430" FT MOD_RES 2446 FT /note="Phosphothreonine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15905173" FT MOD_RES 2448 FT /note="Phosphoserine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15899889, FT ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2481 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:20022946, FT ECO:0000269|PubMed:21576368, ECO:0007744|PubMed:18669648" FT CROSSLNK 2066 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:37979583" FT VARIANT 8 FT /note="A -> S (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs748801456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041537" FT VARIANT 135 FT /note="M -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041538" FT VARIANT 624 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs913197212)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078824" FT VARIANT 1083 FT /note="M -> V (in dbSNP:rs56164650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041539" FT VARIANT 1134 FT /note="A -> V (in dbSNP:rs28730685)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041540" FT VARIANT 1178 FT /note="S -> F (in dbSNP:rs55975118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041541" FT VARIANT 1376 FT /note="D -> E (found in a patient with focal epilepsy; FT uncertain significance; dbSNP:rs975577894)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078825" FT VARIANT 1450 FT /note="Y -> D (in FCORD2; somatic mutation)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078826" FT VARIANT 1456 FT /note="W -> G (in FCORD2; somatic mutation; FT dbSNP:rs1085307114)" FT /evidence="ECO:0000269|PubMed:25878179" FT /id="VAR_078827" FT VARIANT 1459 FT /note="A -> D (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1644347782)" FT /evidence="ECO:0000269|PubMed:26018084" FT /id="VAR_078828" FT VARIANT 1459 FT /note="A -> S (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs1644347846)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078829" FT VARIANT 1460 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1057519779)" FT /evidence="ECO:0000269|PubMed:26018084, FT ECO:0000269|PubMed:27830187" FT /id="VAR_078830" FT VARIANT 1483 FT /note="C -> R (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1057519914)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078831" FT VARIANT 1490 FT /note="W -> R (in SKS; dbSNP:rs2100566800)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078832" FT VARIANT 1595 FT /note="M -> I (in SKS; dbSNP:rs869312671)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078833" FT VARIANT 1709 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs587777895)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078834" FT VARIANT 1799 FT /note="E -> K (in SKS; results in increased mTOR signaling; FT dbSNP:rs863225264)" FT /evidence="ECO:0000269|PubMed:25851998, FT ECO:0000269|PubMed:26542245" FT /id="VAR_075072" FT VARIANT 1832 FT /note="A -> T (in SKS; dbSNP:rs369088781)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078835" FT VARIANT 1888 FT /note="F -> C (in SKS; dbSNP:rs869312666)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078836" FT VARIANT 1977 FT /note="T -> K (in FCORD2; somatic mutation; FT dbSNP:rs587777893)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078837" FT VARIANT 2011 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2100412651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041542" FT VARIANT 2193 FT /note="R -> C (in FCORD2; somatic mutation; FT dbSNP:rs1642723200)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078838" FT VARIANT 2215 FT /note="S -> F (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:25799227, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_078839" FT VARIANT 2215 FT /note="S -> Y (in FCORD2; also found in a colorectal FT adenocarcinoma sample; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_041543" FT VARIANT 2220 FT /note="L -> F (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100381099)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064733" FT VARIANT 2327 FT /note="M -> I (in SKS; dbSNP:rs878855328)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078840" FT VARIANT 2406 FT /note="V -> A (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100316251)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064734" FT VARIANT 2427 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078841" FT VARIANT 2427 FT /note="L -> Q (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078842" FT VARIANT 2476 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041544" FT VARIANT 2501 FT /note="I -> V (found in a patient with non-lesional FT nocturnal frontal epilepsy; uncertain significance; FT dbSNP:rs968817513)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078843" FT MUTAGEN 2066 FT /note="K->R: Complete loss ubiquitination by the FT SCF(FBXO22) complex." FT /evidence="ECO:0000269|PubMed:37979583" FT MUTAGEN 2159 FT /note="S->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2164. Reduced FT activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2159 FT /note="S->D: Mimics phosphorylation; leading to stronger FT phosphorylation of RPS6KB1; when associated with E-2164. FT Increased activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2164 FT /note="T->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2164 FT /note="T->E: Stronger phosphorylation of RPS6KB1; when FT associated with D-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2173 FT /note="T->A: Increased mTOR kinase activity." FT /evidence="ECO:0000269|PubMed:24247430" FT MUTAGEN 2340 FT /note="H->A: Barely detectable kinase activity." FT /evidence="ECO:0000269|PubMed:23636326" FT MUTAGEN 2357 FT /note="D->E: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with I-2364." FT /evidence="ECO:0000269|PubMed:30956113" FT MUTAGEN 2364 FT /note="V->I: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with E-2357." FT /evidence="ECO:0000269|PubMed:30956113" FT CONFLICT 353 FT /note="K -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 359 FT /note="S -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 364 FT /note="D -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 390 FT /note="M -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="R -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 455..457 FT /note="VLD -> GVE (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 461 FT /note="A -> G (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 482..484 FT /note="VFT -> FFN (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 489 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 513 FT /note="L -> I (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 539 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 553 FT /note="R -> C (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 857 FT /note="P -> L (in Ref. 3; BAE06077)" FT /evidence="ECO:0000305" FT CONFLICT 1075 FT /note="I -> S (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 38..52 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 61..73 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 83..93 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 94..96 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 102..114 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 123..134 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 141..155 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 165..178 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 180..183 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 184..186 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 188..197 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 204..222 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 234..245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 277..288 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 357..360 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 362..375 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 380..382 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 387..402 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 404..409 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 413..424 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 427..443 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 449..451 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 452..462 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 479..490 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 495..497 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 499..510 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 517..527 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:6ZWM" FT HELIX 533..548 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 601..611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 616..629 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 649..665 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 681..683 FT /evidence="ECO:0007829|PDB:6ZWM" FT TURN 685..688 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 690..699 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 706..717 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 723..742 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 749..762 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 772..783 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 792..808 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 811..813 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 814..816 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 817..828 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 838..851 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 856..860 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 864..870 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 871..873 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 878..891 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 896..902 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 934..937 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 943..958 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 964..982 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 986..989 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 990..1002 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1006..1008 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1009..1023 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1024..1030 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1031..1040 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1046..1062 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1065..1069 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1071..1083 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1088..1090 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 1091..1103 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1104..1107 FT /evidence="ECO:0007829|PDB:7UXC" FT TURN 1108..1110 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1111..1123 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1125..1127 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1129..1142 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1143..1145 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1150..1152 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1153..1163 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1167..1169 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1170..1182 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1185..1191 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1192..1202 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1207..1218 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1222..1226 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1229..1237 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1263..1269 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1277..1293 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1304..1309 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1311..1315 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1318..1328 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1331..1347 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1351..1366 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1367..1369 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1375..1379 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1380..1390 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1393..1406 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1410..1422 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1426..1439 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1441..1444 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1447..1452 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1456..1469 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1474..1487 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1490..1499 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1501..1504 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1506..1523 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1526..1533 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1538..1540 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1541..1553 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1557..1579 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1584..1586 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1587..1602 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1603..1605 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:4JSP" FT HELIX 1609..1611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1612..1623 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1630..1640 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1641..1643 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1646..1648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1650..1662 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1666..1677 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1681..1683 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1685..1687 FT /evidence="ECO:0007829|PDB:6ZWO" FT STRAND 1691..1693 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 1694..1706 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1710..1730 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1737..1758 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1759..1762 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1766..1768 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1769..1782 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1783..1785 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1787..1809 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1810..1813 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1868..1877 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1878..1880 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1881..1893 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1896..1898 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1900..1913 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1917..1929 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1933..1935 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:7PE7" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1944..1947 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1951..1966 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1970..1972 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1973..1980 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1985..1999 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2005..2019 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2020..2022 FT /evidence="ECO:0007829|PDB:2NPU" FT HELIX 2025..2039 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2044..2058 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2065..2091 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2094..2111 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2115..2117 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2120..2122 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2123..2126 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2128..2132 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:6ZWO" FT TURN 2141..2143 FT /evidence="ECO:0007829|PDB:5WBY" FT STRAND 2146..2148 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2152..2156 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2158..2162 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2164..2167 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2170..2179 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2181..2187 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2194..2210 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2213..2216 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2217..2219 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2227..2229 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2231..2233 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2235..2238 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2241..2245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2246..2256 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2263..2271 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2273..2277 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2280..2292 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2298..2305 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2308..2310 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2311..2334 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2341..2343 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2344..2350 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2353..2355 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2362..2364 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2365..2367 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2369..2371 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2381..2385 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2392..2394 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2395..2409 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2411..2422 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2425..2428 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2429..2432 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2433..2435 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 2493..2509 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2512..2516 FT /evidence="ECO:0007829|PDB:4JT5" FT HELIX 2521..2532 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2535..2539 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2543..2545 FT /evidence="ECO:0007829|PDB:8ERA" SQ SEQUENCE 2549 AA; 288892 MW; 7D9AD6E784882AB4 CRC64; MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD VPTQVELLIK QATSHENLCQ CYIGWCPFW // ID NDOR1_HUMAN Reviewed; 597 AA. AC Q9UHB4; D3YTG6; D3YTH9; Q5VSG4; Q86US9; Q96BC6; DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 183. DE RecName: Full=NADPH-dependent diflavin oxidoreductase 1 {ECO:0000255|HAMAP-Rule:MF_03178}; DE EC=1.18.1.- {ECO:0000255|HAMAP-Rule:MF_03178, ECO:0000269|PubMed:23596212, ECO:0000269|PubMed:28648056}; DE AltName: Full=NADPH-dependent FMN and FAD-containing oxidoreductase {ECO:0000255|HAMAP-Rule:MF_03178}; DE AltName: Full=Novel reductase 1 {ECO:0000303|PubMed:10625700}; GN Name=NDOR1 {ECO:0000255|HAMAP-Rule:MF_03178}; GN Synonyms=NR1 {ECO:0000303|PubMed:10625700}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION. RX PubMed=10625700; DOI=10.1074/jbc.275.2.1471; RA Paine M.J., Garner A.P., Powell D., Sibbald J., Sales M., Pratt N., RA Smith T., Tew D.G., Wolf C.R.; RT "Cloning and characterization of a novel human dual flavin reductase."; RL J. Biol. Chem. 275:1471-1478(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=12871939; DOI=10.1074/jbc.m306355200; RA Kwasnicka D.A., Krakowiak A., Thacker C., Brenner C., Vincent S.R.; RT "Coordinate expression of NADPH-dependent flavin reductase, Fre-1, and RT Hint-related 7meGMP-directed hydrolase, DCS-1."; RL J. Biol. Chem. 278:39051-39058(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Hippocampus, and Umbilical vein endothelial cell; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ILE-522. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 1-8, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=12871938; DOI=10.1074/jbc.m306282200; RA Olteanu H., Banerjee R.; RT "Redundancy in the pathway for redox regulation of mammalian methionine RT synthase: reductive activation by the dual flavoprotein, novel reductase RT 1."; RL J. Biol. Chem. 278:38310-38314(2003). RN [7] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=12631275; DOI=10.1046/j.1432-1033.2003.03474.x; RA Finn R.D., Basran J., Roitel O., Wolf C.R., Munro A.W., Paine M.J., RA Scrutton N.S.; RT "Determination of the redox potentials and electron transfer properties of RT the FAD- and FMN-binding domains of the human oxidoreductase NR1."; RL Eur. J. Biochem. 270:1164-1175(2003). RN [8] RP INTERACTION WITH DCPS, AND CYTOTOXICITY. RX PubMed=16140270; DOI=10.1016/j.bbrc.2005.08.129; RA Kwasnicka-Crawford D.A., Vincent S.R.; RT "Role of a novel dual flavin reductase (NR1) and an associated histidine RT triad protein (DCS-1) in menadione-induced cytotoxicity."; RL Biochem. Biophys. Res. Commun. 336:565-571(2005). RN [9] RP FUNCTION, AND INTERACTION WITH CIAPIN1. RX PubMed=20802492; DOI=10.1038/nchembio.432; RA Netz D.J., Stumpfig M., Dore C., Muhlenhoff U., Pierik A.J., Lill R.; RT "Tah18 transfers electrons to Dre2 in cytosolic iron-sulfur protein RT biogenesis."; RL Nat. Chem. Biol. 6:758-765(2010). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [11] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=28648056; DOI=10.1021/jacs.7b05003; RA Camponeschi F., Ciofi-Baffoni S., Banci L.; RT "Anamorsin/Ndor1 Complex Reduces [2Fe-2S]-MitoNEET via a Transient Protein- RT Protein Interaction."; RL J. Am. Chem. Soc. 139:9479-9482(2017). RN [12] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-161 IN COMPLEX WITH FMN, RP FUNCTION, COFACTOR, INTERACTION WITH CIAPIN1, AND CATALYTIC ACTIVITY. RX PubMed=23596212; DOI=10.1073/pnas.1302378110; RA Banci L., Bertini I., Calderone V., Ciofi-Baffoni S., Giachetti A., RA Jaiswal D., Mikolajczyk M., Piccioli M., Winkelmann J.; RT "Molecular view of an electron transfer process essential for iron-sulfur RT protein biogenesis."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7136-7141(2013). RN [13] RP VARIANT ILE-522, CHARACTERIZATION OF VARIANT ILE-522, FUNCTION, AND RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=15900210; DOI=10.1097/01213011-200506000-00002; RA Finn R.D., Wilkie M., Smith G., Paine M.J.; RT "Identification of a functionally impaired allele of human novel RT oxidoreductase 1 (NDOR1), NDOR1*1."; RL Pharmacogenet. Genomics 15:381-386(2005). CC -!- FUNCTION: NADPH-dependent reductase which is a central component of the CC cytosolic iron-sulfur (Fe-S) protein assembly (CIA) machinery CC (PubMed:10625700, PubMed:15900210, PubMed:20802492, PubMed:23596212, CC PubMed:28648056). Transfers electrons from NADPH via its FAD and FMN CC prosthetic groups to the [2Fe-2S] cluster of CIAPIN1, another key CC component of the CIA machinery (PubMed:20802492, PubMed:23596212, CC PubMed:28648056). In turn, this reduced cluster provides electrons for CC assembly of cytosolic iron-sulfur cluster proteins (PubMed:20802492, CC PubMed:23596212). It can also reduce the [2Fe-2S] cluster of CISD1 and CC activate this protein implicated in Fe/S cluster repair CC (PubMed:28648056). In vitro can fully activate methionine synthase/MTR CC in the presence of soluble cytochrome b5/CYB5A (PubMed:12871938). CC {ECO:0000255|HAMAP-Rule:MF_03178, ECO:0000269|PubMed:10625700, CC ECO:0000269|PubMed:12871938, ECO:0000269|PubMed:15900210, CC ECO:0000269|PubMed:20802492, ECO:0000269|PubMed:23596212, CC ECO:0000269|PubMed:28648056}. CC -!- CATALYTIC ACTIVITY: CC Reaction=2 oxidized [2Fe-2S]-[protein] + NADPH = 2 reduced [2Fe-2S]- CC [protein] + NADP(+) + H(+); Xref=Rhea:RHEA:67716, Rhea:RHEA- CC COMP:17327, Rhea:RHEA-COMP:17328, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:33737, ChEBI:CHEBI:33738, ChEBI:CHEBI:57783, CC ChEBI:CHEBI:58349; Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:23596212, ECO:0000269|PubMed:28648056}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67717; CC Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000305|PubMed:23596212}; CC -!- COFACTOR: CC Name=FAD; Xref=ChEBI:CHEBI:57692; CC Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:10625700}; CC -!- COFACTOR: CC Name=FMN; Xref=ChEBI:CHEBI:58210; CC Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:10625700, ECO:0000269|PubMed:23596212}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=21 uM for cytochrome c {ECO:0000269|PubMed:10625700}; CC KM=1.08 uM for NADPH {ECO:0000269|PubMed:12631275, CC ECO:0000269|PubMed:15900210, ECO:0000269|PubMed:23596212}; CC Vmax=1.2 umol/min/ug enzyme for cytochrome c reduction CC {ECO:0000269|PubMed:10625700}; CC Vmax=1.98 umol/min/ug enzyme for cytochrome c reduction CC {ECO:0000269|PubMed:12871938}; CC Vmax=2.8 umol/min/ug enzyme for methionine synthase reductive CC activation {ECO:0000269|PubMed:12871938}; CC pH dependence: CC Optimum pH is about 8.0. {ECO:0000305|PubMed:10625700}; CC Redox potential: CC E(0) is -315 +/- 5 mV for the FAD oxidized/semiquinone couple, E(0) CC is -365 +/- 15 mV for the FAD semiquinone/dihydroquinone couple, E(0) CC is -146 +/- 5 mV for the FMN oxidized/semiquinone couple, and E(0) is CC -305 +/- 5 mV for the FMN semiquinone/dihydroquinone couple. CC {ECO:0000269|PubMed:12631275}; CC -!- SUBUNIT: Interacts with CIAPIN1; as part of the cytosolic iron-sulfur CC (Fe-S) protein assembly (CIA) machinery (By similarity) CC (PubMed:20802492, PubMed:23596212). Interacts with DCPS CC (PubMed:16140270). {ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:16140270, ECO:0000269|PubMed:20802492, CC ECO:0000269|PubMed:23596212}. CC -!- INTERACTION: CC Q9UHB4; Q86UT8: CENATAC; NbExp=3; IntAct=EBI-10249760, EBI-11028020; CC Q9UHB4; Q6FI81: CIAPIN1; NbExp=16; IntAct=EBI-10249760, EBI-750511; CC Q9UHB4; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-10249760, EBI-2349927; CC Q9UHB4; O95995: GAS8; NbExp=3; IntAct=EBI-10249760, EBI-1052570; CC Q9UHB4; O76003: GLRX3; NbExp=2; IntAct=EBI-10249760, EBI-374781; CC Q9UHB4; Q13227: GPS2; NbExp=5; IntAct=EBI-10249760, EBI-713355; CC Q9UHB4; P14652: HOXB2; NbExp=3; IntAct=EBI-10249760, EBI-5329558; CC Q9UHB4; Q6ZU52: KIAA0408; NbExp=3; IntAct=EBI-10249760, EBI-739493; CC Q9UHB4; P25791-3: LMO2; NbExp=3; IntAct=EBI-10249760, EBI-11959475; CC Q9UHB4; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-10249760, EBI-11742507; CC Q9UHB4; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-10249760, EBI-739832; CC Q9UHB4; P50221: MEOX1; NbExp=3; IntAct=EBI-10249760, EBI-2864512; CC Q9UHB4; Q5JR59: MTUS2; NbExp=4; IntAct=EBI-10249760, EBI-742948; CC Q9UHB4; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-10249760, EBI-11522433; CC Q9UHB4; Q15742: NAB2; NbExp=3; IntAct=EBI-10249760, EBI-8641936; CC Q9UHB4; Q9UBE8: NLK; NbExp=3; IntAct=EBI-10249760, EBI-366978; CC Q9UHB4; P28072: PSMB6; NbExp=3; IntAct=EBI-10249760, EBI-359288; CC Q9UHB4; P15884: TCF4; NbExp=4; IntAct=EBI-10249760, EBI-533224; CC Q9UHB4; P15884-3: TCF4; NbExp=3; IntAct=EBI-10249760, EBI-13636688; CC Q9UHB4; Q9BT92: TCHP; NbExp=7; IntAct=EBI-10249760, EBI-740781; CC Q9UHB4; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-10249760, EBI-11139477; CC Q9UHB4; Q08117-2: TLE5; NbExp=3; IntAct=EBI-10249760, EBI-11741437; CC Q9UHB4; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-10249760, EBI-741480; CC Q9UHB4; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-10249760, EBI-947187; CC Q9UHB4; B2RXF5: ZBTB42; NbExp=5; IntAct=EBI-10249760, EBI-12287587; CC Q9UHB4; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-10249760, EBI-14104088; CC Q9UHB4; Q6ZNG0: ZNF620; NbExp=3; IntAct=EBI-10249760, EBI-4395669; CC Q9UHB4; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-10249760, EBI-10251462; CC -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region {ECO:0000255|HAMAP- CC Rule:MF_03178, ECO:0000269|PubMed:10625700, CC ECO:0000269|PubMed:12871939}. Note=Concentrated in perinuclear CC structure. {ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:12871939}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9UHB4-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UHB4-2; Sequence=VSP_031487; CC Name=3; CC IsoId=Q9UHB4-3; Sequence=VSP_046313, VSP_046314; CC Name=4; CC IsoId=Q9UHB4-4; Sequence=VSP_053807; CC -!- TISSUE SPECIFICITY: Low expression in brain, heart, kidney, pancreas, CC prostate and skeletal muscle. Highest levels in the placenta. Expressed CC in cancer cell lines including promyelocytic leukemia, HeLaS3, chronic CC myelagenous leukemia, lymphoblastic leukemia, Burkitt's lymphoma, CC colorectal adenocarcinoma, lung carcinoma, and melanoma G-361. CC {ECO:0000269|PubMed:12871939}. CC -!- SIMILARITY: Belongs to the NADPH-dependent diflavin oxidoreductase CC NDOR1 family. {ECO:0000255|HAMAP-Rule:MF_03178}. CC -!- SIMILARITY: In the N-terminal section; belongs to the flavodoxin CC family. {ECO:0000255|HAMAP-Rule:MF_03178}. CC -!- SIMILARITY: In the C-terminal section; belongs to the flavoprotein CC pyridine nucleotide cytochrome reductase family. {ECO:0000255|HAMAP- CC Rule:MF_03178}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF199509; AAF25205.1; -; mRNA. DR EMBL; AY077845; AAL77754.1; -; mRNA. DR EMBL; AK074403; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK290026; BAF82715.1; -; mRNA. DR EMBL; AL929554; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX255925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC015735; AAH15735.1; -; mRNA. DR EMBL; BC093782; AAH93782.1; -; mRNA. DR EMBL; BC111943; AAI11944.1; -; mRNA. DR CCDS; CCDS48061.1; -. [Q9UHB4-2] DR CCDS; CCDS48062.1; -. [Q9UHB4-4] DR CCDS; CCDS48063.1; -. [Q9UHB4-3] DR CCDS; CCDS7036.1; -. [Q9UHB4-1] DR RefSeq; NP_001137498.1; NM_001144026.3. [Q9UHB4-2] DR RefSeq; NP_001137499.1; NM_001144027.3. [Q9UHB4-3] DR RefSeq; NP_001137500.1; NM_001144028.3. [Q9UHB4-4] DR RefSeq; NP_055249.1; NM_014434.4. [Q9UHB4-1] DR PDB; 4H2D; X-ray; 1.80 A; A/B=1-161. DR PDBsum; 4H2D; -. DR AlphaFoldDB; Q9UHB4; -. DR SMR; Q9UHB4; -. DR BioGRID; 118038; 54. DR ComplexPortal; CPX-26562; Anamorsin-NDOR1 complex. DR FunCoup; Q9UHB4; 2917. DR IntAct; Q9UHB4; 41. DR STRING; 9606.ENSP00000360576; -. DR GlyCosmos; Q9UHB4; 2 sites, 1 glycan. DR GlyGen; Q9UHB4; 2 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q9UHB4; -. DR PhosphoSitePlus; Q9UHB4; -. DR BioMuta; NDOR1; -. DR DMDM; 74735011; -. DR jPOST; Q9UHB4; -. DR MassIVE; Q9UHB4; -. DR PaxDb; 9606-ENSP00000360576; -. DR PeptideAtlas; Q9UHB4; -. DR ProteomicsDB; 12813; -. DR ProteomicsDB; 12819; -. DR ProteomicsDB; 84294; -. [Q9UHB4-1] DR ProteomicsDB; 84295; -. [Q9UHB4-2] DR Pumba; Q9UHB4; -. DR Antibodypedia; 18959; 224 antibodies from 25 providers. DR DNASU; 27158; -. DR Ensembl; ENST00000371521.8; ENSP00000360576.4; ENSG00000188566.16. [Q9UHB4-2] DR Ensembl; ENST00000427047.6; ENSP00000394309.1; ENSG00000188566.16. [Q9UHB4-3] DR Ensembl; ENST00000458322.2; ENSP00000389905.1; ENSG00000188566.16. [Q9UHB4-4] DR Ensembl; ENST00000684003.1; ENSP00000507194.1; ENSG00000188566.16. [Q9UHB4-1] DR GeneID; 27158; -. DR KEGG; hsa:27158; -. DR MANE-Select; ENST00000684003.1; ENSP00000507194.1; NM_014434.4; NP_055249.1. DR UCSC; uc004clw.4; human. [Q9UHB4-1] DR AGR; HGNC:29838; -. DR ClinPGx; PA134885020; -. DR CTD; 27158; -. DR DisGeNET; 27158; -. DR GeneCards; NDOR1; -. DR HGNC; HGNC:29838; NDOR1. DR HPA; ENSG00000188566; Low tissue specificity. DR MIM; 606073; gene. DR OpenTargets; ENSG00000188566; -. DR VEuPathDB; HostDB:ENSG00000188566; -. DR eggNOG; KOG1159; Eukaryota. DR GeneTree; ENSGT00930000151050; -. DR HOGENOM; CLU_001570_17_6_1; -. DR InParanoid; Q9UHB4; -. DR OMA; DIMSIPR; -. DR OrthoDB; 1856718at2759; -. DR PAN-GO; Q9UHB4; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHB4; -. DR BRENDA; 1.5.1.30; 2681. DR PathwayCommons; Q9UHB4; -. DR Reactome; R-HSA-2564830; Cytosolic iron-sulfur cluster assembly. DR SignaLink; Q9UHB4; -. DR Agora; ENSG00000188566; -. DR BioGRID-ORCS; 27158; 656 hits in 1148 CRISPR screens. DR ChiTaRS; NDOR1; human. DR EvolutionaryTrace; Q9UHB4; -. DR GeneWiki; NDOR1; -. DR GenomeRNAi; 27158; -. DR Pharos; Q9UHB4; Tbio. DR PRO; PR:Q9UHB4; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9UHB4; protein. DR Bgee; ENSG00000188566; Expressed in granulocyte and 94 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0009055; F:electron transfer activity; IDA:UniProtKB. DR GO; GO:0071949; F:FAD binding; IDA:UniProtKB. DR GO; GO:0050660; F:flavin adenine dinucleotide binding; IBA:GO_Central. DR GO; GO:0010181; F:FMN binding; IDA:UniProtKB. DR GO; GO:0050661; F:NADP binding; IDA:UniProtKB. DR GO; GO:0070402; F:NADPH binding; IDA:UniProtKB. DR GO; GO:0003958; F:NADPH-hemoprotein reductase activity; IDA:UniProtKB. DR GO; GO:0160246; F:NADPH-iron-sulfur [2Fe-2S] protein oxidoreductase activity; IDA:UniProtKB. DR GO; GO:0016491; F:oxidoreductase activity; IBA:GO_Central. DR GO; GO:0016653; F:oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor; IDA:UniProtKB. DR GO; GO:0022900; P:electron transport chain; IDA:UniProtKB. DR GO; GO:0016226; P:iron-sulfur cluster assembly; TAS:ARUK-UCL. DR FunFam; 1.20.990.10:FF:000008; NADPH-dependent diflavin oxidoreductase 1; 1. DR FunFam; 3.40.50.360:FF:000015; NADPH-dependent diflavin oxidoreductase 1; 1. DR FunFam; 3.40.50.80:FF:000055; NADPH-dependent diflavin oxidoreductase 1; 1. DR Gene3D; 3.40.50.360; -; 1. DR Gene3D; 1.20.990.10; NADPH-cytochrome p450 Reductase, Chain A, domain 3; 1. DR Gene3D; 3.40.50.80; Nucleotide-binding domain of ferredoxin-NADP reductase (FNR) module; 1. DR Gene3D; 2.40.30.10; Translation factors; 1. DR HAMAP; MF_03178; NDOR1; 1. DR InterPro; IPR003097; CysJ-like_FAD-binding. DR InterPro; IPR017927; FAD-bd_FR_type. DR InterPro; IPR001094; Flavdoxin-like. DR InterPro; IPR008254; Flavodoxin/NO_synth. DR InterPro; IPR001709; Flavoprot_Pyr_Nucl_cyt_Rdtase. DR InterPro; IPR029039; Flavoprotein-like_sf. DR InterPro; IPR039261; FNR_nucleotide-bd. DR InterPro; IPR023173; NADPH_Cyt_P450_Rdtase_alpha. DR InterPro; IPR028879; NDOR1. DR InterPro; IPR001433; OxRdtase_FAD/NAD-bd. DR InterPro; IPR017938; Riboflavin_synthase-like_b-brl. DR PANTHER; PTHR19384:SF10; NADPH-DEPENDENT DIFLAVIN OXIDOREDUCTASE 1; 1. DR PANTHER; PTHR19384; NITRIC OXIDE SYNTHASE-RELATED; 1. DR Pfam; PF00667; FAD_binding_1; 1. DR Pfam; PF00258; Flavodoxin_1; 1. DR Pfam; PF00175; NAD_binding_1; 1. DR PRINTS; PR00369; FLAVODOXIN. DR PRINTS; PR00371; FPNCR. DR SUPFAM; SSF52343; Ferredoxin reductase-like, C-terminal NADP-linked domain; 1. DR SUPFAM; SSF52218; Flavoproteins; 1. DR SUPFAM; SSF63380; Riboflavin synthase domain-like; 1. DR PROSITE; PS51384; FAD_FR; 1. DR PROSITE; PS50902; FLAVODOXIN_LIKE; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Direct protein sequencing; KW FAD; Flavoprotein; FMN; NADP; Oxidoreductase; Proteomics identification; KW Reference proteome. FT CHAIN 1..597 FT /note="NADPH-dependent diflavin oxidoreductase 1" FT /id="PRO_0000319539" FT DOMAIN 6..150 FT /note="Flavodoxin-like" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT DOMAIN 206..447 FT /note="FAD-binding FR-type" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT REGION 188..207 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 12..17 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 59..62 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 97..106 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 132 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 350 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 382..385 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 416..419 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 460 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 515..516 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 521..525 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 558 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 596 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT VAR_SEQ 138..171 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046313" FT VAR_SEQ 392..398 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_053807" FT VAR_SEQ 518 FT /note="Q -> QPPALFSALQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12871939" FT /id="VSP_031487" FT VAR_SEQ 543..597 FT /note="GAYFYLAGNAKSMPADVSEALMSIFQEEGGLCSPDAAAYLARLQQTRRFQTE FT TWA -> ATPSPCQRTSRKP (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046314" FT VARIANT 522 FT /note="V -> I (in allele NDOR1*1; shows a decrease in FT affinity for NADPH and a reduction in ferricyanide FT reductase activity; dbSNP:rs62587579)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15900210" FT /id="VAR_039010" FT STRAND 5..11 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 16..30 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 34..39 FT /evidence="ECO:0007829|PDB:4H2D" FT TURN 40..42 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 52..59 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 62..64 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 68..70 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 71..77 FT /evidence="ECO:0007829|PDB:4H2D" FT TURN 84..89 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 91..98 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 102..104 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 122..125 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 128..131 FT /evidence="ECO:0007829|PDB:4H2D" FT TURN 135..138 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 139..156 FT /evidence="ECO:0007829|PDB:4H2D" SQ SEQUENCE 597 AA; 66763 MW; 0D1340D7280A4D8F CRC64; MPSPQLLVLF GSQTGTAQDV SERLGREARR RRLGCRVQAL DSYPVVNLIN EPLVIFVCAT TGQGDPPDNM KNFWRFIFRK NLPSTALCQM DFAVLGLGDS SYAKFNFVAK KLHRRLLQLG GSALLPVCLG DDQHELGPDA AVDPWLRDLW DRVLGLYPPP PGLTEIPPGV PLPSKFTLLF LQEAPSTGSE GQRVAHPGSQ EPPSESKPFL APMISNQRVT GPSHFQDVRL IEFDILGSGI SFAAGDVVLI QPSNSAAHVQ RFCQVLGLDP DQLFMLQPRE PDVSSPTRLP QPCSMRHLVS HYLDIASVPR RSFFELLACL SLHELEREKL LEFSSAQGQE ELFEYCNRPR RTILEVLCDF PHTAAAIPPD YLLDLIPVIR PRAFSIASSL LTHPSRLQIL VAVVQFQTRL KEPRRGLCSS WLASLDPGQG PVRVPLWVRP GSLAFPETPD TPVIMVGPGT GVAPFRAAIQ ERVAQGQTGN FLFFGCRWRD QDFYWEAEWQ ELEKRDCLTL IPAFSREQEQ KVYVQHRLRE LGSLVWELLD RQGAYFYLAG NAKSMPADVS EALMSIFQEE GGLCSPDAAA YLARLQQTRR FQTETWA // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PAK5_HUMAN Reviewed; 719 AA. AC Q9P286; A8K5T6; D3DW14; Q5W115; Q8TB93; Q9BX09; Q9ULF6; DT 24-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 227. DE RecName: Full=Serine/threonine-protein kinase PAK 5 {ECO:0000305}; DE EC=2.7.11.1; DE AltName: Full=p21-activated kinase 5; DE Short=PAK-5; DE AltName: Full=p21-activated kinase 7; DE Short=PAK-7; GN Name=PAK5 {ECO:0000312|HGNC:HGNC:15916}; Synonyms=KIAA1264, PAK7; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=12032833; DOI=10.1038/sj.onc.1205478; RA Pandey A., Dan I., Kristiansen T.Z., Watanabe N.M., Voldby J., Kajikawa E., RA Khosravi-Far R., Blagoev B., Mann M.; RT "Cloning and characterization of PAK5, a novel member of mammalian p21- RT activated kinase-II subfamily that is predominantly expressed in brain."; RL Oncogene 21:3939-3948(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-511. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP DOMAIN, AND MUTAGENESIS OF 19-HIS--HIS-22. RX PubMed=12860998; DOI=10.1074/jbc.c300234200; RA Ching Y.P., Leong V.Y., Wong C.M., Kung H.F.; RT "Identification of an autoinhibitory domain of p21-activated protein kinase RT 5."; RL J. Biol. Chem. 278:33621-33624(2003). RN [8] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=12897128; DOI=10.1128/mcb.23.16.5526-5539.2003; RA Cotteret S., Jaffer Z.M., Beeser A., Chernoff J.; RT "p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits RT apoptosis by phosphorylating BAD."; RL Mol. Cell. Biol. 23:5526-5539(2003). RN [9] RP FUNCTION, AND INTERACTION WITH MARK2. RX PubMed=16014608; DOI=10.1091/mbc.e05-01-0081; RA Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J., RA Mandelkow E., Mandelkow E.M.; RT "PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable RT microtubules and dynamic actin."; RL Mol. Biol. Cell 16:4410-4422(2005). RN [10] RP INTERACTION WITH RHOD AND RHOH. RX PubMed=17064668; DOI=10.1016/j.bbrc.2006.09.172; RA Wu X., Frost J.A.; RT "Multiple Rho proteins regulate the subcellular targeting of PAK5."; RL Biochem. Biophys. Res. Commun. 351:328-335(2006). RN [11] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16581795; DOI=10.1128/mcb.26.8.3215-3230.2006; RA Cotteret S., Chernoff J.; RT "Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic RT properties."; RL Mol. Cell. Biol. 26:3215-3230(2006). RN [12] RP FUNCTION IN PHOSPHORYLATION OF RAF1. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [13] RP FUNCTION IN PHOSPHORYLATION OF CTNND1. RX PubMed=20564219; DOI=10.1002/jcb.22639; RA Wong L.E., Reynolds A.B., Dissanayaka N.T., Minden A.; RT "p120-catenin is a binding partner and substrate for Group B Pak kinases."; RL J. Cell. Biochem. 110:1244-1254(2010). RN [14] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 425-719. RX PubMed=17292838; DOI=10.1016/j.str.2007.01.001; RA Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A., RA Fedorov O., Deacon S.W., Peterson J.R., Knapp S.; RT "Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 RT reveal catalytic domain plasticity of active group II PAKs."; RL Structure 15:201-213(2007). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-118; ALA-187; PRO-312; PRO-335; RP ASN-511; ASN-538; SER-555; ILE-604 AND SER-704. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine protein kinase that plays a role in a CC variety of different signaling pathways including cytoskeleton CC regulation, cell migration, proliferation or cell survival. Activation CC by various effectors including growth factor receptors or active CDC42 CC and RAC1 results in a conformational change and a subsequent CC autophosphorylation on several serine and/or threonine residues. CC Phosphorylates the proto-oncogene RAF1 and stimulates its kinase CC activity. Promotes cell survival by phosphorylating the BCL2 antagonist CC of cell death BAD. Phosphorylates CTNND1, probably to regulate CC cytoskeletal organization and cell morphology. Keeps microtubules CC stable through MARK2 inhibition and destabilizes the F-actin network CC leading to the disappearance of stress fibers and focal adhesions. CC {ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16014608, CC ECO:0000269|PubMed:16581795, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:20564219}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21 CC and RAC1. Interacts with MARK2, leading to inhibit MARK2 independently CC of kinase activity. Interacts with RHOD and RHOH. CC {ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:17064668}. CC -!- INTERACTION: CC Q9P286; Q8IW93: ARHGEF19; NbExp=3; IntAct=EBI-741896, EBI-7799822; CC Q9P286; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-741896, EBI-742909; CC Q9P286; Q8N5M1: ATPAF2; NbExp=7; IntAct=EBI-741896, EBI-1166928; CC Q9P286; Q9H257: CARD9; NbExp=5; IntAct=EBI-741896, EBI-751319; CC Q9P286; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-741896, EBI-11530605; CC Q9P286; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-741896, EBI-744545; CC Q9P286; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-741896, EBI-10961624; CC Q9P286; P51959: CCNG1; NbExp=4; IntAct=EBI-741896, EBI-3905829; CC Q9P286; P60953: CDC42; NbExp=5; IntAct=EBI-741896, EBI-81752; CC Q9P286; Q96SW2: CRBN; NbExp=4; IntAct=EBI-741896, EBI-2510250; CC Q9P286; P48730: CSNK1D; NbExp=3; IntAct=EBI-741896, EBI-751621; CC Q9P286; P26196: DDX6; NbExp=3; IntAct=EBI-741896, EBI-351257; CC Q9P286; P50402: EMD; NbExp=3; IntAct=EBI-741896, EBI-489887; CC Q9P286; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-741896, EBI-744099; CC Q9P286; Q9Y3B2: EXOSC1; NbExp=3; IntAct=EBI-741896, EBI-371892; CC Q9P286; Q96CN9: GCC1; NbExp=3; IntAct=EBI-741896, EBI-746252; CC Q9P286; P42858: HTT; NbExp=3; IntAct=EBI-741896, EBI-466029; CC Q9P286; Q96EL1: INKA1; NbExp=5; IntAct=EBI-741896, EBI-10285157; CC Q9P286; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-741896, EBI-726510; CC Q9P286; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-741896, EBI-739832; CC Q9P286; Q96JP2: MYO15B; NbExp=3; IntAct=EBI-741896, EBI-7950783; CC Q9P286; P07196: NEFL; NbExp=3; IntAct=EBI-741896, EBI-475646; CC Q9P286; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-741896, EBI-741158; CC Q9P286; P16284: PECAM1; NbExp=3; IntAct=EBI-741896, EBI-716404; CC Q9P286; Q8WWY3: PRPF31; NbExp=6; IntAct=EBI-741896, EBI-1567797; CC Q9P286; Q92530: PSMF1; NbExp=3; IntAct=EBI-741896, EBI-945916; CC Q9P286; Q16825: PTPN21; NbExp=3; IntAct=EBI-741896, EBI-2860264; CC Q9P286; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-741896, EBI-6285694; CC Q9P286; O60504: SORBS3; NbExp=3; IntAct=EBI-741896, EBI-741237; CC Q9P286; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-741896, EBI-744794; CC Q9P286; Q9UBK9: UXT; NbExp=4; IntAct=EBI-741896, EBI-357355; CC Q9P286; O76024: WFS1; NbExp=3; IntAct=EBI-741896, EBI-720609; CC Q9P286; P62258: YWHAE; NbExp=3; IntAct=EBI-741896, EBI-356498; CC Q9P286; P47041: BIT61; Xeno; NbExp=3; IntAct=EBI-741896, EBI-25889; CC Q9P286; P32474: EUG1; Xeno; NbExp=3; IntAct=EBI-741896, EBI-2343998; CC Q9P286; P32502: GCD7; Xeno; NbExp=3; IntAct=EBI-741896, EBI-6260; CC -!- SUBCELLULAR LOCATION: Mitochondrion. Cytoplasm. Nucleus. Note=Shuttles CC between the nucleus and the mitochondria, and mitochondrial CC localization is essential for the role in cell survival. CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. CC -!- DOMAIN: An autoinhibitory domain is present in the N-terminal region of CC the protein. {ECO:0000269|PubMed:12860998}. CC -!- PTM: Autophosphorylated when activated by CDC42/p21. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA86578.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB040812; BAA94194.1; -; mRNA. DR EMBL; AB033090; BAA86578.1; ALT_INIT; mRNA. DR EMBL; AK291401; BAF84090.1; -; mRNA. DR EMBL; AL031652; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL135935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353612; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471133; EAX10358.1; -; Genomic_DNA. DR EMBL; CH471133; EAX10359.1; -; Genomic_DNA. DR EMBL; CH471133; EAX10360.1; -; Genomic_DNA. DR EMBL; BC024179; AAH24179.1; -; mRNA. DR CCDS; CCDS13107.1; -. DR RefSeq; NP_065074.1; NM_020341.5. DR RefSeq; NP_817127.1; NM_177990.4. DR RefSeq; XP_016883449.1; XM_017027960.2. DR RefSeq; XP_016883450.1; XM_017027961.2. DR RefSeq; XP_016883451.1; XM_017027962.2. DR RefSeq; XP_016883453.1; XM_017027964.2. DR RefSeq; XP_016883454.1; XM_017027965.2. DR RefSeq; XP_054179701.1; XM_054323726.1. DR RefSeq; XP_054179702.1; XM_054323727.1. DR RefSeq; XP_054179703.1; XM_054323728.1. DR RefSeq; XP_054179704.1; XM_054323729.1. DR RefSeq; XP_054179705.1; XM_054323730.1. DR PDB; 2F57; X-ray; 1.80 A; A/B=425-719. DR PDB; 8C12; X-ray; 1.55 A; AAA=426-719. DR PDBsum; 2F57; -. DR PDBsum; 8C12; -. DR AlphaFoldDB; Q9P286; -. DR SMR; Q9P286; -. DR BioGRID; 121402; 117. DR FunCoup; Q9P286; 2316. DR IntAct; Q9P286; 116. DR MINT; Q9P286; -. DR STRING; 9606.ENSP00000367686; -. DR BindingDB; Q9P286; -. DR ChEMBL; CHEMBL4524; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P286; -. DR GuidetoPHARMACOLOGY; 2138; -. DR GlyGen; Q9P286; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9P286; -. DR PhosphoSitePlus; Q9P286; -. DR BioMuta; PAK5; -. DR DMDM; 12585290; -. DR CPTAC; non-CPTAC-2960; -. DR CPTAC; non-CPTAC-2961; -. DR jPOST; Q9P286; -. DR MassIVE; Q9P286; -. DR PaxDb; 9606-ENSP00000367686; -. DR PeptideAtlas; Q9P286; -. DR ProteomicsDB; 83751; -. DR Antibodypedia; 8792; 369 antibodies from 39 providers. DR DNASU; 57144; -. DR Ensembl; ENST00000353224.10; ENSP00000322957.5; ENSG00000101349.18. DR Ensembl; ENST00000378423.5; ENSP00000367679.1; ENSG00000101349.18. DR Ensembl; ENST00000378429.3; ENSP00000367686.3; ENSG00000101349.18. DR GeneID; 57144; -. DR KEGG; hsa:57144; -. DR MANE-Select; ENST00000353224.10; ENSP00000322957.5; NM_177990.4; NP_817127.1. DR UCSC; uc002wnj.3; human. DR AGR; HGNC:15916; -. DR ClinPGx; PA32922; -. DR CTD; 57144; -. DR DisGeNET; 57144; -. DR GeneCards; PAK5; -. DR HGNC; HGNC:15916; PAK5. DR HPA; ENSG00000101349; Group enriched (brain, retina). DR MalaCards; PAK5; -. DR MIM; 608038; gene. DR OpenTargets; ENSG00000101349; -. DR VEuPathDB; HostDB:ENSG00000101349; -. DR eggNOG; KOG0578; Eukaryota. DR GeneTree; ENSGT00940000158656; -. DR HOGENOM; CLU_000288_26_6_1; -. DR InParanoid; Q9P286; -. DR OMA; KSHPQGH; -. DR OrthoDB; 1022360at2759; -. DR PAN-GO; Q9P286; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P286; -. DR BRENDA; 2.7.11.1; 2681. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; Q9P286; -. DR Reactome; R-HSA-428540; Activation of RAC1. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013405; RHOD GTPase cycle. DR Reactome; R-HSA-9013407; RHOH GTPase cycle. DR SignaLink; Q9P286; -. DR SIGNOR; Q9P286; -. DR Agora; ENSG00000101349; -. DR BioGRID-ORCS; 57144; 9 hits in 1193 CRISPR screens. DR ChiTaRS; PAK5; human. DR EvolutionaryTrace; Q9P286; -. DR GeneWiki; PAK7; -. DR GenomeRNAi; 57144; -. DR Pharos; Q9P286; Tchem. DR PRO; PR:Q9P286; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q9P286; protein. DR Bgee; ENSG00000101349; Expressed in cortical plate and 93 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0045202; C:synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006915; P:apoptotic process; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; TAS:UniProtKB. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IBA:GO_Central. DR GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007612; P:learning; IEA:Ensembl. DR GO; GO:0007626; P:locomotory behavior; IEA:Ensembl. DR GO; GO:0007613; P:memory; IEA:Ensembl. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR CDD; cd01093; CRIB_PAK_like; 1. DR CDD; cd06658; STKc_PAK5; 1. DR FunFam; 1.10.510.10:FF:000073; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000141; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.90.810.10:FF:000002; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.90.810.10; CRIB domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR036936; CRIB_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051931; PAK3-like. DR InterPro; IPR033923; PAK_BD. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR028754; STKc_PAK5. DR PANTHER; PTHR45832:SF4; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR PANTHER; PTHR45832; SERINE/THREONINE-PROTEIN KINASE SAMKA-RELATED-RELATED; 1. DR Pfam; PF00786; PBD; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00285; PBD; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Apoptosis; ATP-binding; Cytoplasm; Kinase; Mitochondrion; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..719 FT /note="Serine/threonine-protein kinase PAK 5" FT /id="PRO_0000086477" FT DOMAIN 11..24 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT DOMAIN 449..700 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 25..448 FT /note="Linker" FT REGION 97..123 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 256..299 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 340..373 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..291 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 358..373 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 568 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 455..463 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 478 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 104 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C015" FT MOD_RES 107 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q8C015" FT VARIANT 118 FT /note="G -> D (in dbSNP:rs55923311)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040978" FT VARIANT 187 FT /note="P -> A (in dbSNP:rs34280805)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040979" FT VARIANT 312 FT /note="S -> P (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs952665081)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040980" FT VARIANT 335 FT /note="R -> P (in dbSNP:rs11700112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040981" FT VARIANT 511 FT /note="S -> N (in dbSNP:rs2297345)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_021865" FT VARIANT 538 FT /note="T -> N (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040982" FT VARIANT 555 FT /note="A -> S (in dbSNP:rs34102290)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040983" FT VARIANT 604 FT /note="V -> I (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040984" FT VARIANT 704 FT /note="G -> S (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1484691555)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040985" FT MUTAGEN 19..22 FT /note="HRVH->LRVL: Complete loss of CDC42 binding and FT CDC42-mediated autophosphorylation." FT /evidence="ECO:0000269|PubMed:12860998" FT CONFLICT 27 FT /note="P -> A (in Ref. 6; AAH24179)" FT /evidence="ECO:0000305" FT CONFLICT 403 FT /note="S -> Y (in Ref. 6; AAH24179)" FT /evidence="ECO:0000305" FT HELIX 429..437 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 445..447 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 449..457 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 459..468 FT /evidence="ECO:0007829|PDB:2F57" FT TURN 469..471 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 474..481 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 488..500 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 509..515 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 518..524 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 531..535 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 542..561 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 571..573 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 574..576 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 582..584 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 595..597 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 607..609 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 612..615 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 623..638 FT /evidence="ECO:0007829|PDB:2F57" FT TURN 642..645 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 671..680 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 685..687 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 691..695 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 698..702 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 710..712 FT /evidence="ECO:0007829|PDB:2F57" SQ SEQUENCE 719 AA; 80745 MW; 07A12B1EEC4E2A02 CRC64; MFGKKKKKIE ISGPSNFEHR VHTGFDPQEQ KFTGLPQQWH SLLADTANRP KPMVDPSCIT PIQLAPMKTI VRGNKPCKET SINGLLEDFD NISVTRSNSL RKESPPTPDQ GASSHGPGHA EENGFITFSQ YSSESDTTAD YTTEKYREKS LYGDDLDPYY RGSHAAKQNG HVMKMKHGEA YYSEVKPLKS DFARFSADYH SHLDSLSKPS EYSDLKWEYQ RASSSSPLDY SFQFTPSRTA GTSGCSKESL AYSESEWGPS LDDYDRRPKS SYLNQTSPQP TMRQRSRSGS GLQEPMMPFG ASAFKTHPQG HSYNSYTYPR LSEPTMCIPK VDYDRAQMVL SPPLSGSDTY PRGPAKLPQS QSKSGYSSSS HQYPSGYHKA TLYHHPSLQS SSQYISTASY LSSLSLSSST YPPPSWGSSS DQQPSRVSHE QFRAALQLVV SPGDPREYLA NFIKIGEGST GIVCIATEKH TGKQVAVKKM DLRKQQRREL LFNEVVIMRD YHHDNVVDMY SSYLVGDELW VVMEFLEGGA LTDIVTHTRM NEEQIATVCL SVLRALSYLH NQGVIHRDIK SDSILLTSDG RIKLSDFGFC AQVSKEVPKR KSLVGTPYWM APEVISRLPY GTEVDIWSLG IMVIEMIDGE PPYFNEPPLQ AMRRIRDSLP PRVKDLHKVS SVLRGFLDLM LVREPSQRAT AQELLGHPFL KLAGPPSCIV PLMRQYRHH // ID PKN1_HUMAN Reviewed; 942 AA. AC Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Serine/threonine-protein kinase N1; DE EC=2.7.11.13 {ECO:0000269|PubMed:18066052}; DE AltName: Full=Protease-activated kinase 1; DE Short=PAK-1; DE AltName: Full=Protein kinase C-like 1; DE AltName: Full=Protein kinase C-like PKN; DE AltName: Full=Protein kinase PKN-alpha; DE AltName: Full=Protein-kinase C-related kinase 1; DE AltName: Full=Serine-threonine protein kinase N; GN Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644. RC TISSUE=Hippocampus; RX PubMed=8135837; DOI=10.1006/bbrc.1994.1313; RA Mukai H., Ono Y.; RT "A novel protein kinase with leucine zipper-like sequences: its catalytic RT domain is highly homologous to that of protein kinase C."; RL Biochem. Biophys. Res. Commun. 199:897-904(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x; RA Palmer R.H., Ridden J., Parker P.J.; RT "Cloning and expression patterns of two members of a novel protein-kinase- RT C-related kinase family."; RL Eur. J. Biochem. 227:344-351(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS RP ILE-555 AND ILE-901. RC TISSUE=Kidney, Synovium, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP ILE-901. RC TISSUE=Brain, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718. RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [7] RP FUNCTION. RX PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3; RA Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T., RA Parker P.J.; RT "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and RT serine 163."; RL FEBS Lett. 378:281-285(1996). RN [8] RP FUNCTION. RX PubMed=8621664; DOI=10.1074/jbc.271.16.9816; RA Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., RA Sunakawa H., Ono Y.; RT "PKN associates and phosphorylates the head-rod domain of neurofilament RT protein."; RL J. Biol. Chem. 271:9816-9822(1996). RN [9] RP ACTIVITY REGULATION, AND INTERACTION WITH RHOA. RX PubMed=8571126; DOI=10.1126/science.271.5249.645; RA Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N., RA Mukai H., Ono Y., Kakizuka A., Narumiya S.; RT "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of RT small GTPase Rho."; RL Science 271:645-648(1996). RN [10] RP FUNCTION. RX PubMed=9175763; DOI=10.1006/bbrc.1997.6669; RA Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y., RA Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.; RT "Domain-specific phosphorylation of vimentin and glial fibrillary acidic RT protein by PKN."; RL Biochem. Biophys. Res. Commun. 234:621-625(1997). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB. RX PubMed=9478917; DOI=10.1074/jbc.273.9.4811; RA Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.; RT "PRK1 is targeted to endosomes by the small GTPase, RhoB."; RL J. Biol. Chem. 273:4811-4814(1998). RN [12] RP ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108; RP ASP-451; ASP-454; ASP-558 AND ASP-560. RX PubMed=9751706; DOI=10.1073/pnas.95.20.11566; RA Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.; RT "Proteolytic activation of PKN by caspase-3 or related protease during RT apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998). RN [13] RP PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=10792047; DOI=10.1073/pnas.090491897; RA Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.; RT "Phosphorylation of protein kinase N by phosphoinositide-dependent protein RT kinase-1 mediates insulin signals to the actin cytoskeleton."; RL Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000). RN [14] RP FUNCTION. RX PubMed=11104762; DOI=10.1074/jbc.m007427200; RA Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., RA Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.; RT "Phosphorylation of tau is regulated by PKN."; RL J. Biol. Chem. 276:10025-10031(2001). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR. RX PubMed=12514133; DOI=10.1093/emboj/cdg023; RA Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.; RT "A novel inducible transactivation domain in the androgen receptor: RT implications for PRK in prostate cancer."; RL EMBO J. 22:270-280(2003). RN [16] RP INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION). RX PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x; RA Haraga A., Miller S.I.; RT "A Salmonella type III secretion effector interacts with the mammalian RT serine/threonine protein kinase PKN1."; RL Cell. Microbiol. 8:837-846(2006). RN [17] RP INTERACTION WITH CCNT2. RX PubMed=16331689; DOI=10.1002/jcp.20566; RA Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G., RA De Luca A.; RT "Pkn is a novel partner of cyclin T2a in muscle differentiation."; RL J. Cell. Physiol. 207:232-237(2006). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [19] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=17332740; DOI=10.1038/sj.emboj.7601637; RA Schmidt A., Durgan J., Magalhaes A., Hall A.; RT "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from RT cytokinesis."; RL EMBO J. 26:1624-1636(2007). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644. RX PubMed=18066052; DOI=10.1038/ncb1668; RA Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N., RA Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R., RA Schule R.; RT "Phosphorylation of histone H3 at threonine 11 establishes a novel RT chromatin mark for transcriptional regulation."; RL Nat. Cell Biol. 10:53-60(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559; RP SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [24] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537; RP SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [27] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057; RA Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B., RA McKinsey T.A.; RT "Protein kinase C-related kinase targets nuclear localization signals in a RT subset of class IIa histone deacetylases."; RL FEBS Lett. 584:1103-1110(2010). RN [28] RP INTERACTION WITH PRKCB. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND RP MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [32] RP FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY. RX PubMed=21754995; DOI=10.1371/journal.pone.0021732; RA Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., RA Collazos A., Parker P.J.; RT "Regulatory domain selectivity in the cell-type specific PKN-dependence of RT cell migration."; RL PLoS ONE 6:E21732-E21732(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537; RP SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA. RX PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5; RA Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.; RT "The structural basis of Rho effector recognition revealed by the crystal RT structure of human RhoA complexed with the effector domain of PKN/PRK1."; RL Mol. Cell 4:793-803(1999). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98. RX PubMed=10388627; DOI=10.1006/jsbi.1999.4114; RA Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.; RT "Biochemical and crystallographic characterization of a Rho effector domain RT of the protein serine/threonine kinase N in a complex with RhoA."; RL J. Struct. Biol. 126:166-170(1999). RN [39] RP STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1. RX PubMed=14514689; DOI=10.1074/jbc.m304313200; RA Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y., RA Parker P.J., Blundell T.L., Mott H.R.; RT "Molecular dissection of the interaction between the small G proteins Rac1 RT and RhoA and protein kinase C-related kinase 1 (PRK1)."; RL J. Biol. Chem. 278:50578-50587(2003). RN [40] RP STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1. RX PubMed=18006505; DOI=10.1074/jbc.m706760200; RA Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.; RT "The Rac1 polybasic region is required for interaction with its effector RT PRK1."; RL J. Biol. Chem. 283:1492-1500(2008). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH RP SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF RP ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND RP INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION). RX PubMed=24248594; DOI=10.1128/mcb.01360-13; RA Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., RA Sicheri F.; RT "Structure of an SspH1-PKN1 complex reveals the basis for host substrate RT recognition and mechanism of activation for a bacterial E3 ubiquitin RT ligase."; RL Mol. Cell. Biol. 34:362-373(2014). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520; RP ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in CC various processes such as regulation of the intermediate filaments of CC the actin cytoskeleton, cell migration, tumor cell invasion and CC transcription regulation. Part of a signaling cascade that begins with CC the activation of the adrenergic receptor ADRA1B and leads to the CC activation of MAPK14. Regulates the cytoskeletal network by CC phosphorylating proteins such as VIM and neurofilament proteins NEFH, CC NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates CC 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to CC bind to microtubules, resulting in disruption of tubulin assembly. Acts CC as a key coactivator of androgen receptor (AR)-dependent transcription, CC by being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for CC epigenetic transcriptional activation that promotes demethylation of CC histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, CC HDAC7 and HDAC9, leading to impair their import in the nucleus. CC Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' CC of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. CC {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, CC ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, CC ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, CC ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, CC ECO:0000269|PubMed:9175763}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho CC proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly CC cardiolipin and to a lesser extent by other acidic phospholipids. CC Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific CC sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn CC motif), need to be phosphorylated for its full activation. CC {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095}; CC -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR CC (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts CC (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689, CC PubMed:18006505). Interacts (via REM 1 repeat) with RHOA CC (PubMed:10619026, PubMed:8571126). Interacts with RHOB CC (PubMed:9478917). Interacts (via C-terminus) with PDPK1 CC (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent CC transcription (PubMed:16331689). Component of a signaling complex CC containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this CC complex, AKAP13 interacts directly with PKN1, which in turn recruits CC MAPK14, MAP2K3 and ZAK (PubMed:21224381). CC {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026, CC ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689, CC ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126, CC ECO:0000269|PubMed:9478917}. CC -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat) CC with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine- CC rich repeat region) (PubMed:16611232, PubMed:24248594). CC {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}. CC -!- INTERACTION: CC Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507; CC Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530; CC Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576; CC Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613; CC Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357; CC Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378; CC Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012; CC Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676; CC Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887; CC Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674; CC Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062; CC Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367; CC Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486; CC Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988; CC Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624; CC Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333; CC Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027; CC Q16512; Q8IW40: DNAAF19; NbExp=3; IntAct=EBI-602382, EBI-10261970; CC Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680; CC Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467; CC Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990; CC Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189; CC Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309; CC Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454; CC Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814; CC Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791; CC Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420; CC Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203; CC Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204; CC Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258; CC Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960; CC Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878; CC Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566; CC Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410; CC Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756; CC Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001; CC Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093; CC Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674; CC Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506; CC Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716; CC Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424; CC Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346; CC Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406; CC Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316; CC Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526; CC Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642; CC Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751; CC Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269; CC Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433; CC Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646; CC Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165; CC Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345; CC Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004; CC Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350; CC Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839; CC Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621; CC Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919; CC Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317; CC Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028; CC Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557; CC Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135; CC Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466; CC Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286; CC Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224; CC Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744; CC Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493; CC Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794; CC Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957; CC Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895; CC Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844; CC Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867; CC Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023; CC Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733; CC Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520; CC Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853; CC Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740, CC ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}. CC Endosome {ECO:0000269|PubMed:9478917}. Cell membrane CC {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow CC {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}. CC Note=Associates with chromatin in a ligand-dependent manner. CC Localization to endosomes is mediated via its interaction with RHOB. CC Association to the cell membrane is dependent on Ser-377 CC phosphorylation. Accumulates during telophase at the cleavage furrow CC and finally concentrates around the midbody in cytokinesis. CC {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q16512-1; Sequence=Displayed; CC Name=2; CC IsoId=Q16512-2; Sequence=VSP_038143; CC Name=3; CC IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214; CC -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain, CC placenta, lung, skeletal muscle, kidney and pancreas. Expressed in CC numerous tumor cell lines, especially in breast tumor cells. CC {ECO:0000269|PubMed:21754995}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during CC mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}. CC -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}. CC -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by CC the bacterial E3 ubiquitin-protein ligase SspH1, leading to its CC proteasomal degradation. {ECO:0000269|PubMed:24248594}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26181; BAA05169.1; -; mRNA. DR EMBL; S75546; AAB33345.1; -; mRNA. DR EMBL; U33053; AAC50209.1; -; mRNA. DR EMBL; AK123007; BAG53845.1; -; mRNA. DR EMBL; AK292130; BAF84819.1; -; mRNA. DR EMBL; AK313886; BAG36611.1; -; mRNA. DR EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040061; AAH40061.1; -; mRNA. DR EMBL; BC094766; AAH94766.1; -; mRNA. DR CCDS; CCDS42513.1; -. [Q16512-1] DR CCDS; CCDS42514.1; -. [Q16512-2] DR PIR; JC2129; JC2129. DR PIR; S51162; S51162. DR RefSeq; NP_002732.3; NM_002741.3. [Q16512-1] DR RefSeq; NP_998725.1; NM_213560.3. [Q16512-2] DR PDB; 1CXZ; X-ray; 2.20 A; B=13-98. DR PDB; 1URF; NMR; -; A=122-199. DR PDB; 2RMK; NMR; -; B=122-199. DR PDB; 4NKG; X-ray; 2.90 A; B/D=122-199. DR PDB; 4OTD; X-ray; 2.00 A; A=605-942. DR PDB; 4OTG; X-ray; 2.60 A; A=605-942. DR PDB; 4OTH; X-ray; 1.80 A; A=605-942. DR PDB; 4OTI; X-ray; 1.93 A; A=605-942. DR PDBsum; 1CXZ; -. DR PDBsum; 1URF; -. DR PDBsum; 2RMK; -. DR PDBsum; 4NKG; -. DR PDBsum; 4OTD; -. DR PDBsum; 4OTG; -. DR PDBsum; 4OTH; -. DR PDBsum; 4OTI; -. DR AlphaFoldDB; Q16512; -. DR SMR; Q16512; -. DR BioGRID; 111571; 147. DR CORUM; Q16512; -. DR DIP; DIP-34240N; -. DR ELM; Q16512; -. DR FunCoup; Q16512; 2793. DR IntAct; Q16512; 116. DR MINT; Q16512; -. DR STRING; 9606.ENSP00000343325; -. DR BindingDB; Q16512; -. DR ChEMBL; CHEMBL3384; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q16512; -. DR GuidetoPHARMACOLOGY; 1520; -. DR GlyConnect; 1737; 1 N-Linked glycan (1 site). DR GlyCosmos; Q16512; 3 sites, 2 glycans. DR GlyGen; Q16512; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q16512; -. DR MetOSite; Q16512; -. DR PhosphoSitePlus; Q16512; -. DR BioMuta; PKN1; -. DR DMDM; 259016304; -. DR CPTAC; CPTAC-3003; -. DR jPOST; Q16512; -. DR MassIVE; Q16512; -. DR PaxDb; 9606-ENSP00000343325; -. DR PeptideAtlas; Q16512; -. DR ProteomicsDB; 60877; -. [Q16512-1] DR ProteomicsDB; 60878; -. [Q16512-2] DR ProteomicsDB; 60879; -. [Q16512-3] DR Pumba; Q16512; -. DR Antibodypedia; 1296; 250 antibodies from 36 providers. DR DNASU; 5585; -. DR Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.14. [Q16512-1] DR Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.14. [Q16512-2] DR GeneID; 5585; -. DR KEGG; hsa:5585; -. DR MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3. DR UCSC; uc002myp.4; human. [Q16512-1] DR AGR; HGNC:9405; -. DR ClinPGx; PA33769; -. DR CTD; 5585; -. DR DisGeNET; 5585; -. DR GeneCards; PKN1; -. DR HGNC; HGNC:9405; PKN1. DR HPA; ENSG00000123143; Low tissue specificity. DR MalaCards; PKN1; -. DR MIM; 601032; gene. DR OpenTargets; ENSG00000123143; -. DR VEuPathDB; HostDB:ENSG00000123143; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000154990; -. DR HOGENOM; CLU_000288_132_1_1; -. DR InParanoid; Q16512; -. DR OMA; CTELRIE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q16512; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q16512; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q16512; -. DR Reactome; R-HSA-5625740; RHO GTPases activate PKNs. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SABIO-RK; Q16512; -. DR SignaLink; Q16512; -. DR SIGNOR; Q16512; -. DR Agora; ENSG00000123143; -. DR BioGRID-ORCS; 5585; 15 hits in 1195 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PKN1; human. DR EvolutionaryTrace; Q16512; -. DR GeneWiki; Protein_kinase_N1; -. DR GenomeRNAi; 5585; -. DR Pharos; Q16512; Tchem. DR PRO; PR:Q16512; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q16512; protein. DR Bgee; ENSG00000123143; Expressed in apex of heart and 142 other cell types or tissues. DR ExpressionAtlas; Q16512; baseline and differential. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB. DR GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB. DR GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl. DR GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome. DR GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB. DR GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl. DR GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR CDD; cd08687; C2_PKN-like; 1. DR CDD; cd11630; HR1_PKN1_2; 1. DR CDD; cd11636; HR1_PKN1_3; 1. DR CDD; cd11622; HR1_PKN_1; 1. DR CDD; cd05589; STKc_PKN; 1. DR FunFam; 1.10.287.160:FF:000001; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000002; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000003; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 3.30.200.20:FF:000058; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.510.10:FF:000038; serine/threonine-protein kinase N2 isoform X1; 1. DR Gene3D; 1.10.287.160; HR1 repeat; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00416; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037784; C2_PKN. DR InterPro; IPR011072; HR1_rho-bd. DR InterPro; IPR036274; HR1_rpt_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR037317; PKN1_HR1_2. DR InterPro; IPR037313; PKN_HR1_1. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF02185; HR1; 3. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00742; Hr1; 3. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF46585; HR1 repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS51860; REM_1; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome; KW Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..942 FT /note="Serine/threonine-protein kinase N1" FT /id="PRO_0000055719" FT DOMAIN 25..100 FT /note="REM-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 112..193 FT /note="REM-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 201..280 FT /note="REM-1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 307..470 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 615..874 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..942 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 102..121 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 181..185 FT /note="Important for interaction with bacterial SspH1 and FT SspH1-mediated polyubiquitination" FT /evidence="ECO:0000269|PubMed:24248594" FT REGION 341..363 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 581..596 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 644 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 108..109 FT /note="Cleavage; by caspase-3" FT SITE 454..455 FT /note="Cleavage; by caspase-3" FT SITE 558..559 FT /note="Cleavage; by caspase-3" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332" FT MOD_RES 374 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63433" FT MOD_RES 448 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 540 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 559 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 562 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 774 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10792047" FT MOD_RES 778 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 914 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 916 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..7 FT /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038143" FT VAR_SEQ 603 FT /note="S -> R (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039213" FT VAR_SEQ 604..942 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039214" FT VARIANT 185 FT /note="R -> C (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267605306)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042337" FT VARIANT 197 FT /note="A -> E (in dbSNP:rs1287763348)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042338" FT VARIANT 436 FT /note="R -> W (in dbSNP:rs35132656)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042339" FT VARIANT 520 FT /note="R -> Q (in dbSNP:rs56273055)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042340" FT VARIANT 555 FT /note="L -> I (in dbSNP:rs34309238)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042341" FT VARIANT 635 FT /note="R -> Q (in dbSNP:rs35416389)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042342" FT VARIANT 718 FT /note="I -> V (in dbSNP:rs2230539)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7988719" FT /id="VAR_042343" FT VARIANT 873 FT /note="F -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042344" FT VARIANT 901 FT /note="V -> I (in dbSNP:rs10846)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_014937" FT VARIANT 921 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042345" FT MUTAGEN 108 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF1 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 181 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 181 FT /note="R->K: Decreases interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 185 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 451 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 454 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 558 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 560 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 644 FT /note="K->E: Abolishes Serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT MUTAGEN 644 FT /note="K->R: Substantial reduction of autophosphorylation." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT CONFLICT 191 FT /note="G -> D (in Ref. 2; AAB33345/AAC50209)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="S -> P (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 736 FT /note="I -> T (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="T -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 800 FT /note="G -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="E -> G (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="L -> P (in Ref. 3; BAG53845)" FT /evidence="ECO:0000305" FT HELIX 15..18 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 29..66 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 71..95 FT /evidence="ECO:0007829|PDB:1CXZ" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:1URF" FT HELIX 126..151 FT /evidence="ECO:0007829|PDB:4NKG" FT TURN 157..159 FT /evidence="ECO:0007829|PDB:4NKG" FT HELIX 160..187 FT /evidence="ECO:0007829|PDB:4NKG" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:2RMK" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 615..624 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 627..634 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 640..647 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 657..671 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 672..674 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 688..696 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 700..702 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 703..706 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 763..765 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 779..781 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 784..788 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 794..810 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 820..829 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 840..849 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 854..856 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 862..864 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 865..869 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 879..883 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 906..909 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 926..930 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 931..934 FT /evidence="ECO:0007829|PDB:4OTH" SQ SEQUENCE 942 AA; 103932 MW; 61360295EC70BB8E CRC64; MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC // ID PRKDC_HUMAN Reviewed; 4128 AA. AC P78527; P78528; Q13327; Q13337; Q14175; Q59H99; Q7Z611; Q96SE6; Q9UME3; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 31-OCT-2003, sequence version 3. DT 28-JAN-2026, entry version 246. DE RecName: Full=DNA-dependent protein kinase catalytic subunit; DE Short=DNA-PK catalytic subunit; DE Short=DNA-PKcs; DE EC=2.7.11.1 {ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:32103174, ECO:0000269|PubMed:35460603}; DE AltName: Full=DNPK1; DE AltName: Full=Ser-473 kinase {ECO:0000303|PubMed:15262962}; DE Short=S473K {ECO:0000303|PubMed:15262962}; DE AltName: Full=p460; GN Name=PRKDC; Synonyms=HYRC, HYRC1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Cervix carcinoma; RX PubMed=7671312; DOI=10.1016/0092-8674(95)90482-4; RA Hartley K.O., Gell D., Smith G.C.M., Zhang H., Divecha N., Connelly M.A., RA Admon A., Lees-Miller S.P., Anderson C.W., Jackson S.P.; RT "DNA-dependent protein kinase catalytic subunit: a relative of RT phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product."; RL Cell 82:849-856(1995). RN [2] RP SEQUENCE REVISION, AND ALTERNATIVE SPLICING. RA Gell D., Anderson C.W.; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-6; ILE-333; SER-605; RP MET-680; SER-695; SER-1071; VAL-1314; VAL-1588; HIS-1603; VAL-2095; RP GLU-2702; CYS-2899; ASP-3149; SER-3201; GLU-3404; THR-3434; SER-3459; RP MET-3562; LEU-3836 AND VAL-3932. RG NIEHS SNPs program; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-1689. RX PubMed=11418067; DOI=10.1667/0033-7587(2001)156[0002:fmiptg]2.0.co;2; RA Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M., RA Allalunis-Turner M.J.; RT "Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair- RT defective, human, glioma-derived cell line M059J."; RL Radiat. Res. 156:2-9(2001). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49. RX PubMed=9284934; DOI=10.1159/000134594; RA Ladenburger E.M., Fackelmayer F.O., Hameister H., Knippers R.; RT "MCM4 and PRKDC, human genes encoding proteins MCM4 and DNA-PKcs, are close RT neighbours located on chromosome 8q12-->q13."; RL Cytogenet. Cell Genet. 77:268-270(1997). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1789-2203. RC TISSUE=Placenta; RX PubMed=7638222; DOI=10.1073/pnas.92.16.7515; RA Sipley J.D., Menninger J.C., Hartley K.O., Ward D.C., Jackson S.P., RA Anderson C.W.; RT "Gene for the catalytic subunit of the human DNA-activated protein kinase RT maps to the site of the XRCC7 gene on chromosome 8."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7515-7519(1995). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2255-2335. RC TISSUE=Placenta; RA Abe M.; RL Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 3199-4128 (ISOFORM 1). RC TISSUE=Fetal lung; RX PubMed=7594449; RA Poltoratsky V.P., Shi X., York J.D., Lieber M.R., Carter T.H.; RT "Human DNA-activated protein kinase (DNA-PK) is homologous to RT phosphatidylinositol kinases."; RL J. Immunol. 155:4529-4533(1995). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3250-4128 (ISOFORM 1). RA Anderson C.W., Dunn J.J., Freimuth P.I.; RT "Sequence of the 3' segment (exons 70-86) of PRKDC, the gene for human DNA- RT PKcs."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3372-4128 (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno F.R.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP FUNCTION, AND PHOSPHORYLATION OF HSPCA. RX PubMed=2507541; DOI=10.1016/s0021-9258(18)71488-9; RA Lees-Miller S.P., Anderson C.W.; RT "The human double-stranded DNA-activated protein kinase phosphorylates the RT 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine RT residues."; RL J. Biol. Chem. 264:17275-17280(1989). RN [12] RP FUNCTION, AND PHOSPHORYLATION OF H1. RX PubMed=2247066; DOI=10.1128/mcb.10.12.6460-6471.1990; RA Carter T., Vancurova I., Sun I., Lou W., DeLeon S.; RT "A DNA-activated protein kinase from HeLa cell nuclei."; RL Mol. Cell. Biol. 10:6460-6471(1990). RN [13] RP FUNCTION, AND PHOSPHORYLATION OF MYC. RX PubMed=1597196; DOI=10.1111/j.1432-1033.1992.tb16964.x; RA Iijima S., Teraoka H., Date T., Tsukada K.; RT "DNA-activated protein kinase in Raji Burkitt's lymphoma cells. RT Phosphorylation of c-Myc oncoprotein."; RL Eur. J. Biochem. 206:595-603(1992). RN [14] RP FUNCTION, AND PHOSPHORYLATION OF SRF. RX PubMed=8407951; DOI=10.1016/s0021-9258(19)36904-2; RA Liu S.-H., Ma J.-T., Yueh A.Y., Lees-Miller S.P., Anderson C.W., Ng S.-Y.; RT "The carboxyl-terminal transactivation domain of human serum response RT factor contains DNA-activated protein kinase phosphorylation sites."; RL J. Biol. Chem. 268:21147-21154(1993). RN [15] RP FUNCTION, AND PHOSPHORYLATION OF JUN. RX PubMed=8464713; DOI=10.1093/nar/21.5.1289; RA Bannister A.J., Gottlieb T.M., Kouzarides T., Jackson S.P.; RT "c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro; RT definition of the minimal kinase recognition motif."; RL Nucleic Acids Res. 21:1289-1295(1993). RN [16] RP CLEAVAGE BY CASPASE-3. RX PubMed=8804412; DOI=10.1016/0014-5793(96)00842-3; RA Teraoka H., Yumoto Y., Watanabe F., Tsukada K., Suwa A., Enari M., RA Nagata S.; RT "CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent RT protein kinase in the holoenzyme."; RL FEBS Lett. 393:1-6(1996). RN [17] RP ALTERNATIVE SPLICING. RX PubMed=8917110; DOI=10.1016/0378-1119(96)00135-7; RA Connelly M.A., Zhang H., Kieleczawa J., Anderson C.W.; RT "Alternate splice-site utilization in the gene for the catalytic subunit of RT the DNA-activated protein kinase, DNA-PKcs."; RL Gene 175:271-273(1996). RN [18] RP FUNCTION, AND PHOSPHORYLATION OF TP53. RX PubMed=9363941; DOI=10.1016/s0092-8674(00)80416-x; RA Shieh S.-Y., Ikeda M., Taya Y., Prives C.; RT "DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2."; RL Cell 91:325-334(1997). RN [19] RP CHARACTERIZATION, AND INTERACTION WITH CIB1. RX PubMed=9372844; DOI=10.1016/s0921-8777(97)00035-9; RA Wu X., Lieber M.R.; RT "Interaction between DNA-dependent protein kinase and a novel protein, RT KIP."; RL Mutat. Res. 385:13-20(1997). RN [20] RP FUNCTION, AND PHOSPHORYLATION OF XRCC6. RX PubMed=9362500; DOI=10.1093/emboj/16.22.6874; RA Jin S., Weaver D.T.; RT "Double-strand break repair by Ku70 requires heterodimerization with Ku80 RT and DNA binding functions."; RL EMBO J. 16:6874-6885(1997). RN [21] RP FUNCTION, AND PHOSPHORYLATION OF RFA2. RX PubMed=9139719; DOI=10.1074/jbc.272.19.12634; RA Niu H., Erdjument-Bromage H., Pan Z.-Q., Lee S.-H., Tempst P., Hurwitz J.; RT "Mapping of amino acid residues in the p34 subunit of human single-stranded RT DNA-binding protein phosphorylated by DNA-dependent protein kinase and Cdc2 RT kinase in vitro."; RL J. Biol. Chem. 272:12634-12641(1997). RN [22] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [23] RP FUNCTION, INTERACTION WITH C1D, AND MUTAGENESIS OF LEU-1510 AND RP 1516-GLU-LEU-1517. RX PubMed=9679063; DOI=10.1101/gad.12.14.2188; RA Yavuzer U., Smith G.C.M., Bliss T., Werner D., Jackson S.P.; RT "DNA end-independent activation of DNA-PK mediated via association with the RT DNA-binding protein C1D."; RL Genes Dev. 12:2188-2199(1998). RN [24] RP INTERACTION WITH ILF3. RX PubMed=9442054; DOI=10.1074/jbc.273.4.2136; RA Ting N.S.Y., Kao P.N., Chan D.W., Lintott L.G., Lees-Miller S.P.; RT "DNA-dependent protein kinase interacts with antigen receptor response RT element binding proteins NF90 and NF45."; RL J. Biol. Chem. 273:2136-2145(1998). RN [25] RP DNA-BINDING. RX PubMed=9435225; DOI=10.1073/pnas.95.2.525; RA Hammarsten O., Chu G.; RT "DNA-dependent protein kinase: DNA binding and activation in the absence of RT Ku."; RL Proc. Natl. Acad. Sci. U.S.A. 95:525-530(1998). RN [26] RP FUNCTION, AND PHOSPHORYLATION OF XRCC5 AND XRCC6. RX PubMed=10026262; DOI=10.1021/bi982584b; RA Chan D.W., Ye R., Veillette C.J., Lees-Miller S.P.; RT "DNA-dependent protein kinase phosphorylation sites in Ku 70/80 RT heterodimer."; RL Biochemistry 38:1819-1828(1999). RN [27] RP FUNCTION, AND PHOSPHORYLATION OF PARP1. RX PubMed=10467406; DOI=10.1038/sj.onc.1202823; RA Ariumi Y., Masutani M., Copeland T.D., Mimori T., Sugimura T., RA Shimotohno K., Ueda K., Hatanaka M., Noda M.; RT "Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent RT protein kinase in vitro."; RL Oncogene 18:4616-4625(1999). RN [28] RP PHOSPHORYLATION AT THR-2609; SER-2612; THR-2638 AND THR-2647. RX PubMed=12186630; DOI=10.1042/bj20020973; RA Douglas P., Sapkota G.P., Morrice N., Yu Y., Goodarzi A.A., Merkle D., RA Meek K., Alessi D.R., Lees-Miller S.P.; RT "Identification of in vitro and in vivo phosphorylation sites in the RT catalytic subunit of the DNA-dependent protein kinase."; RL Biochem. J. 368:243-251(2002). RN [29] RP FUNCTION, AND INTERACTION WITH DCLRE1C. RX PubMed=11955432; DOI=10.1016/s0092-8674(02)00671-2; RA Ma Y., Pannicke U., Schwarz K., Lieber M.R.; RT "Hairpin opening and overhang processing by an Artemis/DNA-dependent RT protein kinase complex in nonhomologous end joining and V(D)J RT recombination."; RL Cell 108:781-794(2002). RN [30] RP FUNCTION, AND PHOSPHORYLATION OF XRCC4. RX PubMed=12509254; DOI=10.1016/s1568-7864(01)00018-0; RA Hsu H.-L., Yannone S.M., Chen D.J.; RT "Defining interactions between DNA-PK and ligase IV/XRCC4."; RL DNA Repair 1:225-235(2002). RN [31] RP PHOSPHORYLATION AT THR-2609, MUTAGENESIS OF THR-2609, SUBCELLULAR LOCATION, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12231622; DOI=10.1101/gad.1015202; RA Chan D.W., Chen B.P., Prithivirajsingh S., Kurimasa A., Story M.D., Qin J., RA Chen D.J.; RT "Autophosphorylation of the DNA-dependent protein kinase catalytic subunit RT is required for rejoining of DNA double-strand breaks."; RL Genes Dev. 16:2333-2338(2002). RN [32] RP FUNCTION, AND PHOSPHORYLATION OF WRN. RX PubMed=11889123; DOI=10.1074/jbc.m111523200; RA Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P., RA Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.; RT "Werner protein is a target of DNA-dependent protein kinase in vivo and in RT vitro, and its catalytic activities are regulated by phosphorylation."; RL J. Biol. Chem. 277:18291-18302(2002). RN [33] RP FUNCTION, AND MUTAGENESIS OF THR-2638 AND THR-2647. RX PubMed=12649176; RA Soubeyrand S., Pope L., Pakuts B., Hache R.J.; RT "Threonines 2638/2647 in DNA-PK are essential for cellular resistance to RT ionizing radiation."; RL Cancer Res. 63:1198-1201(2003). RN [34] RP FUNCTION, AND PHOSPHORYLATION OF POU2F1. RX PubMed=14612514; RA Schild-Poulter C., Shih A., Yarymowich N.C., Hache R.J.G.; RT "Down-regulation of histone H2B by DNA-dependent protein kinase in response RT to DNA damage through modulation of octamer transcription factor 1."; RL Cancer Res. 63:7197-7205(2003). RN [35] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=14599745; DOI=10.1016/s1568-7864(03)00143-5; RA Yu Y., Wang W., Ding Q., Ye R., Chen D., Merkle D., Schriemer D., Meek K., RA Lees-Miller S.P.; RT "DNA-PK phosphorylation sites in XRCC4 are not required for survival after RT radiation or for V(D)J recombination."; RL DNA Repair 2:1239-1252(2003). RN [36] RP FUNCTION, AND PHOSPHORYLATION OF H2AX. RX PubMed=14627815; DOI=10.1093/nar/gkg921; RA Park E.-J., Chan D.W., Park J.-H., Oettinger M.A., Kwon J.; RT "DNA-PK is activated by nucleosomes and phosphorylates H2AX within the RT nucleosomes in an acetylation-dependent manner."; RL Nucleic Acids Res. 31:6819-6827(2003). RN [37] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=15177042; DOI=10.1016/j.dnarep.2003.11.005; RA Lee K.J., Jovanovic M., Udayakumar D., Bladen C.L., Dynan W.S.; RT "Identification of DNA-PKcs phosphorylation sites in XRCC4 and effects of RT mutations at these sites on DNA end joining in a cell-free system."; RL DNA Repair 3:267-276(2004). RN [38] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [39] RP FUNCTION IN PHOSPHORYLATION OF NHEJ1. RX PubMed=18644470; DOI=10.1016/j.dnarep.2008.06.015; RA Yu Y., Mahaney B.L., Yano K., Ye R., Fang S., Douglas P., Chen D.J., RA Lees-Miller S.P.; RT "DNA-PK and ATM phosphorylation sites in XLF/Cernunnos are not required for RT repair of DNA double strand breaks."; RL DNA Repair 7:1680-1692(2008). RN [40] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=26666690; DOI=10.1093/jrr/rrv086; RA Sharma M.K., Imamichi S., Fukuchi M., Samarth R.M., Tomita M., RA Matsumoto Y.; RT "In cellulo phosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA RT damage."; RL J. Radiat. Res. 57:115-120(2016). RN [41] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=30247612; DOI=10.1093/jrr/rry072; RA Amiri Moghani A.R., Sharma M.K., Matsumoto Y.; RT "In cellulo phosphorylation of DNA double-strand break repair protein XRCC4 RT on Ser260 by DNA-PK."; RL J. Radiat. Res. 59:700-708(2018). RN [42] RP INTERACTION WITH DCLRE1C. RX PubMed=15071507; DOI=10.1038/sj.emboj.7600206; RA Pannicke U., Ma Y., Hopfner K.-P., Niewolik D., Lieber M.R., Schwarz K.; RT "Functional and biochemical dissection of the structure-specific nuclease RT ARTEMIS."; RL EMBO J. 23:1987-1997(2004). RN [43] RP INTERACTION WITH DCLRE1C. RX PubMed=14744996; DOI=10.1084/jem.20031142; RA Poinsignon C., Moshous D., Callebaut I., de Chasseval R., Villey I., RA de Villartay J.-P.; RT "The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes the RT catalytic core for V(D)J recombination."; RL J. Exp. Med. 199:315-321(2004). RN [44] RP FUNCTION, AND INTERACTION WITH DCLRE1C. RX PubMed=15574326; DOI=10.1016/j.molcel.2004.11.017; RA Ma Y., Lu H., Tippin B., Goodman M.F., Shimazaki N., Koiwai O., RA Hsieh C.-L., Schwarz K., Lieber M.R.; RT "A biochemically defined system for mammalian nonhomologous DNA end RT joining."; RL Mol. Cell 16:701-713(2004). RN [45] RP INTERACTION WITH DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [46] RP FUNCTION, AND PHOSPHORYLATION OF DHX9. RX PubMed=14704337; DOI=10.1093/nar/gkg933; RA Zhang S., Schlott B., Goerlach M., Grosse F.; RT "DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase RT II/RNA helicase A and hnRNP proteins in an RNA-dependent manner."; RL Nucleic Acids Res. 32:1-10(2004). RN [47] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-2056 AND THR-2609, RP AND DEPHOSPHORYLATION AT SER-2056 AND THR-2609. RX PubMed=14734805; DOI=10.1073/pnas.0307765100; RA Wechsler T., Chen B.P., Harper R., Morotomi-Yano K., Huang B.C., Meek K., RA Cleaver J.E., Chen D.J., Wabl M.; RT "DNA-PKcs function regulated specifically by protein phosphatase 5."; RL Proc. Natl. Acad. Sci. U.S.A. 101:1247-1252(2004). RN [48] RP FUNCTION, AND PHOSPHORYLATION OF H2AX. RX PubMed=16046194; DOI=10.1016/j.dnarep.2005.06.005; RA Reitsema T., Klokov D., Banath J.P., Olive P.L.; RT "DNA-PK is responsible for enhanced phosphorylation of histone H2AX under RT hypertonic conditions."; RL DNA Repair 4:1172-1181(2005). RN [49] RP INTERACTION WITH DCLRE1C. RX PubMed=15811628; DOI=10.1016/j.dnarep.2005.02.001; RA Wang J., Pluth J.M., Cooper P.K., Cowan M.J., Chen D.J., Yannone S.M.; RT "Artemis deficiency confers a DNA double-strand break repair defect and RT Artemis phosphorylation status is altered by DNA damage and cell cycle RT progression."; RL DNA Repair 4:556-570(2005). RN [50] RP INTERACTION WITH DCLRE1C. RX PubMed=15936993; DOI=10.1016/j.dnarep.2005.04.013; RA Ma Y., Schwarz K., Lieber M.R.; RT "The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and gaps."; RL DNA Repair 4:845-851(2005). RN [51] RP INTERACTION WITH XRCC5. RX PubMed=15758953; DOI=10.1038/nature03442; RA Falck J., Coates J., Jackson S.P.; RT "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA RT damage."; RL Nature 434:605-611(2005). RN [52] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [53] RP FUNCTION, AND PHOSPHORYLATION OF XRCC1. RX PubMed=16397295; DOI=10.1093/nar/gkj409; RA Levy N., Martz A., Bresson A., Spenlehauer C., de Murcia G., RA Menissier-de Murcia J.; RT "XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA RT damage."; RL Nucleic Acids Res. 34:32-41(2006). RN [54] RP REVIEW. RX PubMed=15592499; DOI=10.1038/sj.onc.1208332; RA Collis S.J., DeWeese T.L., Jeggo P.A., Parker A.R.; RT "The life and death of DNA-PK."; RL Oncogene 24:949-961(2005). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [56] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205 AND SER-4026, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [57] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [58] RP INVOLVEMENT IN IMD26, AND VARIANT IMD26 ARG-3062. RX PubMed=19075392; DOI=10.1172/jci37141; RA van der Burg M., Ijspeert H., Verkaik N.S., Turul T., Wiegant W.W., RA Morotomi-Yano K., Mari P.O., Tezcan I., Chen D.J., Zdzienicka M.Z., RA van Dongen J.J., van Gent D.C.; RT "A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis RT activation and nonhomologous end-joining."; RL J. Clin. Invest. 119:91-98(2009). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-893; SER-2612; SER-3205 AND RP SER-4026, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [61] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-117; LYS-828; LYS-1209; LYS-1970; RP LYS-2259; LYS-3241; LYS-3260; LYS-3621; LYS-3638 AND LYS-3642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [62] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [63] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [64] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205 AND SER-4026, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [66] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [67] RP INTERACTION WITH BRAT1, AND PHOSPHORYLATION AT SER-2056. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612 AND SER-3205, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [69] RP SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS]. RX PubMed=22002106; DOI=10.1074/mcp.m111.013680; RA Ahmad Y., Boisvert F.M., Lundberg E., Uhlen M., Lamond A.I.; RT "Systematic analysis of protein pools, isoforms, and modifications RT affecting turnover and subcellular localization."; RL Mol. Cell. Proteomics 11:M111.013680.01-M111.013680.15(2012). RN [70] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511; SER-687; SER-841; RP SER-1065; THR-2535; SER-2612; THR-2638; THR-2647; SER-2789; SER-3205; RP SER-3731; SER-3821 AND SER-4026, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [71] RP INTERACTION WITH SETX. RX PubMed=23149945; DOI=10.1128/mcb.01195-12; RA Yuce O., West S.C.; RT "Senataxin, defective in the neurodegenerative disorder ataxia with RT oculomotor apraxia 2, lies at the interface of transcription and the DNA RT damage response."; RL Mol. Cell. Biol. 33:406-417(2013). RN [72] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [73] RP UBIQUITINATION BY RNF144A. RX PubMed=24979766; DOI=10.1073/pnas.1323107111; RA Ho S.R., Mahanic C.S., Lee Y.J., Lin W.C.; RT "RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during RT DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E2646-E2655(2014). RN [74] RP INTERACTION WITH NR4A3. RX PubMed=25852083; DOI=10.1093/cvr/cvv126; RA Medunjanin S., Daniel J.M., Weinert S., Dutzmann J., Burgbacher F., RA Brecht S., Bruemmer D., Kaehne T., Naumann M., Sedding D.G., RA Zuschratter W., Braun-Dullaeus R.C.; RT "DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell RT proliferation through phosphorylation of the orphan nuclear receptor RT NOR1."; RL Cardiovasc. Res. 106:488-497(2015). RN [75] RP SUBUNIT. RX PubMed=25941166; DOI=10.1038/cdd.2015.22; RA Craxton A., Somers J., Munnur D., Jukes-Jones R., Cain K., Malewicz M.; RT "XLS (c9orf142) is a new component of mammalian DNA double-stranded break RT repair."; RL Cell Death Differ. 22:890-897(2015). RN [76] RP FUNCTION IN PHOSPHORYLATION OF FH, AND CATALYTIC ACTIVITY. RX PubMed=26237645; DOI=10.1038/ncb3209; RA Jiang Y., Qian X., Shen J., Wang Y., Li X., Liu R., Xia Y., Chen Q., RA Peng G., Lin S.Y., Lu Z.; RT "Local generation of fumarate promotes DNA repair through inhibition of RT histone H3 demethylation."; RL Nat. Cell Biol. 17:1158-1168(2015). RN [77] RP SUBUNIT. RX PubMed=25670504; DOI=10.1038/ncomms7233; RA Xing M., Yang M., Huo W., Feng F., Wei L., Jiang W., Ning S., Yan Z., RA Li W., Wang Q., Hou M., Dong C., Guo R., Gao G., Ji J., Zha S., Lan L., RA Liang H., Xu D.; RT "Interactome analysis identifies a new paralogue of XRCC4 in non-homologous RT end joining DNA repair pathway."; RL Nat. Commun. 6:6233-6233(2015). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [79] RP INTERACTION WITH PAXX. RX PubMed=25574025; DOI=10.1126/science.1261971; RA Ochi T., Blackford A.N., Coates J., Jhujh S., Mehmood S., Tamura N., RA Travers J., Wu Q., Draviam V.M., Robinson C.V., Blundell T.L., RA Jackson S.P.; RT "DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote RT DNA double-strand break repair."; RL Science 347:185-188(2015). RN [80] RP FUNCTION, AND INTERACTION WITH HEXIM1; XRCC5; XRCC6; SFPQ; NONO; PSPC1; RP RBM14 AND MATR3. RX PubMed=28712728; DOI=10.1016/j.molcel.2017.06.020; RA Morchikh M., Cribier A., Raffel R., Amraoui S., Cau J., Severac D., RA Dubois E., Schwartz O., Bennasser Y., Benkirane M.; RT "HEXIM1 and NEAT1 Long non-coding RNA form a multi-subunit complex that RT regulates DNA-mediated innate immune response."; RL Mol. Cell 67:387-399(2017). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29478807; DOI=10.1016/j.molcel.2018.01.031; RA Huang T.H., Fowler F., Chen C.C., Shen Z.J., Sleckman B., Tyler J.K.; RT "The histone chaperones ASF1 and CAF-1 promote MMS22L-TONSL-mediated Rad51 RT loading onto ssDNA during homologous recombination in human cells."; RL Mol. Cell 69:879-892(2018). RN [82] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP THR-2609. RX PubMed=32103174; DOI=10.1038/s41586-020-2041-2; RA Shao Z., Flynn R.A., Crowe J.L., Zhu Y., Liang J., Jiang W., Aryan F., RA Aoude P., Bertozzi C.R., Estes V.M., Lee B.J., Bhagat G., Zha S., Calo E.; RT "DNA-PKcs has KU-dependent function in rRNA processing and RT haematopoiesis."; RL Nature 579:291-296(2020). RN [83] RP FUNCTION. RX PubMed=33273464; DOI=10.1038/s41467-020-19941-0; RA Sun X., Liu T., Zhao J., Xia H., Xie J., Guo Y., Zhong L., Li M., Yang Q., RA Peng C., Rouvet I., Belot A., Shu H.B., Feng P., Zhang J.; RT "DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity."; RL Nat. Commun. 11:6182-6182(2020). RN [84] RP INTERACTION WITH KAT5. RX PubMed=32832608; DOI=10.1126/sciadv.aba7822; RA Gao S.S., Guan H., Yan S., Hu S., Song M., Guo Z.P., Xie D.F., Liu Y., RA Liu X., Zhang S., Zhou P.K.; RT "TIP60 K430 SUMOylation attenuates its interaction with DNA-PKcs in S-phase RT cells: Facilitating homologous recombination and emerging target for cancer RT therapy."; RL Sci. Adv. 6:eaba7822-eaba7822(2020). RN [85] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35460603; DOI=10.1016/j.molcel.2022.03.034; RA Wang F., Zhao M., Chang B., Zhou Y., Wu X., Ma M., Liu S., Cao Y., RA Zheng M., Dang Y., Xu J., Chen L., Liu T., Tang F., Ren Y., Xu Z., Mao Z., RA Huang K., Luo M., Li J., Liu H., Ge B.; RT "Cytoplasmic PARP1 links the genome instability to the inhibition of RT antiviral immunity through PARylating cGAS."; RL Mol. Cell 0:0-0(2022). RN [86] {ECO:0007744|PDB:7NFC, ECO:0007744|PDB:7NFE} RP STRUCTURE BY ELECTRON MICROSCOPY (4.14 ANGSTROMS) IN COMPLEX WITH THE NHEJ RP COMPLEX AND DNA, FUNCTION, IDENTIFICATION IN THE NHEJ COMPLEX, AND RP PHOSPHORYLATION AT SER-2056 AND THR-2609. RX PubMed=34352203; DOI=10.1016/j.molcel.2021.07.005; RA Chaplin A.K., Hardwick S.W., Stavridi A.K., Buehl C.J., Goff N.J., RA Ropars V., Liang S., De Oliveira T.M., Chirgadze D.Y., Meek K., RA Charbonnier J.B., Blundell T.L.; RT "Cryo-EM of NHEJ supercomplexes provides insights into DNA repair."; RL Mol. Cell 81:3400-3409(2021). RN [87] {ECO:0007744|PDB:7LT3} RP STRUCTURE BY ELECTRON MICROSCOPY (4.6 ANGSTROMS) IN COMPLEX WITH THE NHEJ RP COMPLEX, FUNCTION, IDENTIFICATION IN THE NHEJ COMPLEX, AND RP AUTOPHOSPHORYLATION. RX PubMed=33854234; DOI=10.1038/s41586-021-03458-7; RA Chen S., Lee L., Naila T., Fishbain S., Wang A., Tomkinson A.E., RA Lees-Miller S.P., He Y.; RT "Structural basis of long-range to short-range synaptic transition in RT NHEJ."; RL Nature 593:294-298(2021). RN [88] RP VARIANTS [LARGE SCALE ANALYSIS] SER-6; ASN-263; ILE-333; ILE-420; SER-500; RP SER-605; LEU-649; SER-695; HIS-1136; VAL-1190; THR-1237; PHE-1279; RP MET-1447; GLY-1619; VAL-1680; VAL-1680; PRO-2023; GLN-2598; ASN-2810; RP CYS-2899; ALA-2941; ASP-3085; ASP-3149; SER-3198; SER-3201; GLU-3404; RP THR-3434; MET-3562; PHE-3584; ILE-3800; LEU-3836; SER-3936 AND MET-3937. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [89] RP VARIANT IMD26 VAL-3574, AND CHARACTERIZATION OF VARIANT IMD26 VAL-3574. RX PubMed=23722905; DOI=10.1172/jci67349; RA Woodbine L., Neal J.A., Sasi N.K., Shimada M., Deem K., Coleman H., RA Dobyns W.B., Ogi T., Meek K., Davies E.G., Jeggo P.A.; RT "PRKDC mutations in a SCID patient with profound neurological RT abnormalities."; RL J. Clin. Invest. 123:2969-2980(2013). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a molecular CC sensor for DNA damage (PubMed:11955432, PubMed:12649176, CC PubMed:14734805, PubMed:33854234). Involved in DNA non-homologous end CC joining (NHEJ) required for double-strand break (DSB) repair and V(D)J CC recombination (PubMed:11955432, PubMed:12649176, PubMed:14734805, CC PubMed:33854234, PubMed:34352203). Must be bound to DNA to express its CC catalytic properties (PubMed:11955432). Promotes processing of hairpin CC DNA structures in V(D)J recombination by activation of the hairpin CC endonuclease artemis (DCLRE1C) (PubMed:11955432). Recruited by XRCC5 CC and XRCC6 to DNA ends and is required to (1) protect and align broken CC ends of DNA, thereby preventing their degradation, (2) and sequester CC the DSB for repair by NHEJ (PubMed:11955432, PubMed:12649176, CC PubMed:14734805, PubMed:15574326, PubMed:33854234). Acts as a scaffold CC protein to aid the localization of DNA repair proteins to the site of CC damage (PubMed:11955432, PubMed:12649176, PubMed:14734805, CC PubMed:15574326). The assembly of the DNA-PK complex at DNA ends is CC also required for the NHEJ ligation step (PubMed:11955432, CC PubMed:12649176, PubMed:14734805, PubMed:15574326). Found at the ends CC of chromosomes, suggesting a further role in the maintenance of CC telomeric stability and the prevention of chromosomal end fusion (By CC similarity). Also involved in modulation of transcription CC (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326). CC As part of the DNA-PK complex, involved in the early steps of ribosome CC assembly by promoting the processing of precursor rRNA into mature 18S CC rRNA in the small-subunit processome (PubMed:32103174). Binding to U3 CC small nucleolar RNA, recruits PRKDC and XRCC5/Ku86 to the small-subunit CC processome (PubMed:32103174). Recognizes the substrate consensus CC sequence [ST]-Q (PubMed:11955432, PubMed:12649176, PubMed:14734805, CC PubMed:15574326). Phosphorylates 'Ser-139' of histone variant H2AX, CC thereby regulating DNA damage response mechanism (PubMed:14627815, CC PubMed:16046194). Phosphorylates ASF1A, DCLRE1C, c-Abl/ABL1, histone CC H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, FH, SRF, CC NHEJ1/XLF, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2 CC (PubMed:10026262, PubMed:10467406, PubMed:11889123, PubMed:12509254, CC PubMed:14599745, PubMed:14612514, PubMed:14704337, PubMed:15177042, CC PubMed:1597196, PubMed:16397295, PubMed:18644470, PubMed:2247066, CC PubMed:2507541, PubMed:26237645, PubMed:26666690, PubMed:28712728, CC PubMed:29478807, PubMed:30247612, PubMed:8407951, PubMed:8464713, CC PubMed:9139719, PubMed:9362500). Can phosphorylate C1D not only in the CC presence of linear DNA but also in the presence of supercoiled DNA CC (PubMed:9679063). Ability to phosphorylate p53/TP53 in the presence of CC supercoiled DNA is dependent on C1D (PubMed:9363941). Acts as a CC regulator of the phosphatidylinositol 3-kinase/protein kinase B signal CC transduction by mediating phosphorylation of 'Ser-473' of protein CC kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), promoting their activation CC (PubMed:15262962). Contributes to the determination of the circadian CC period length by antagonizing phosphorylation of CRY1 'Ser-588' and CC increasing CRY1 protein stability, most likely through an indirect CC mechanism (By similarity). Plays a role in the regulation of DNA virus- CC mediated innate immune response by assembling into the HDP-RNP complex, CC a complex that serves as a platform for IRF3 phosphorylation and CC subsequent innate immune response activation through the cGAS-STING CC pathway (PubMed:28712728). Also regulates the cGAS-STING pathway by CC catalyzing phosphorylation of CGAS, thereby impairing CGAS CC oligomerization and activation (PubMed:33273464). Also regulates the CC cGAS-STING pathway by mediating phosphorylation of PARP1 CC (PubMed:35460603). {ECO:0000250|UniProtKB:P97313, CC ECO:0000269|PubMed:10026262, ECO:0000269|PubMed:10467406, CC ECO:0000269|PubMed:11889123, ECO:0000269|PubMed:11955432, CC ECO:0000269|PubMed:12509254, ECO:0000269|PubMed:12649176, CC ECO:0000269|PubMed:14599745, ECO:0000269|PubMed:14612514, CC ECO:0000269|PubMed:14627815, ECO:0000269|PubMed:14704337, CC ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15177042, CC ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:15574326, CC ECO:0000269|PubMed:1597196, ECO:0000269|PubMed:16046194, CC ECO:0000269|PubMed:16397295, ECO:0000269|PubMed:18644470, CC ECO:0000269|PubMed:2247066, ECO:0000269|PubMed:2507541, CC ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:26666690, CC ECO:0000269|PubMed:28712728, ECO:0000269|PubMed:29478807, CC ECO:0000269|PubMed:30247612, ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:33273464, ECO:0000269|PubMed:33854234, CC ECO:0000269|PubMed:34352203, ECO:0000269|PubMed:35460603, CC ECO:0000269|PubMed:8407951, ECO:0000269|PubMed:8464713, CC ECO:0000269|PubMed:9139719, ECO:0000269|PubMed:9362500, CC ECO:0000269|PubMed:9363941, ECO:0000269|PubMed:9679063}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:29478807, CC ECO:0000269|PubMed:32103174}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:29478807, CC ECO:0000269|PubMed:32103174}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:35460603}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:35460603}; CC -!- ACTIVITY REGULATION: Activity seems to be attenuated by CC autophosphorylation. Binding to the SL1 region of U3 small nucleolar CC RNA promotes auto-phosphorylation activity (PubMed:32103174). Inhibited CC by wortmannin (PubMed:9766667). {ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: DNA-PK is a heterotrimer of PRKDC and the Ku dimer (composed CC of XRCC6/Ku70 and XRCC5/Ku86) (PubMed:15758953, PubMed:25670504). CC Formation of this complex may be promoted by interaction with ILF3 CC (PubMed:9442054). Component of the core long-range non-homologous end CC joining (NHEJ) complex (also named DNA-PK complex) composed of PRKDC, CC LIG4, XRCC4, XRCC6/Ku70, XRCC5/Ku86 and NHEJ1/XLF (PubMed:15758953, CC PubMed:25670504, PubMed:33854234, PubMed:34352203). Additional CC component of the NHEJ complex includes PAXX (PubMed:25574025, CC PubMed:25941166). Following autophosphorylation, PRKDC dissociates from CC DNA (PubMed:33854234). Interacts with DNA-PKcs-interacting protein CC (KIP) with the region upstream the kinase domain (PubMed:9372844). CC PRKDC alone also interacts with and phosphorylates DCLRE1C, thereby CC activating the latent endonuclease activity of this protein CC (PubMed:11955432, PubMed:14744996, PubMed:15071507, PubMed:15456891, CC PubMed:15574326, PubMed:15811628, PubMed:15936993). Interacts with C1D CC (PubMed:9679063). Interacts with TTI1 and TELO2 (PubMed:20427287, CC PubMed:20801936, PubMed:20810650). Interacts with CIB1 CC (PubMed:9372844). Interacts with SETX (PubMed:23149945). Interacts with CC NR4A3; the DNA-dependent protein kinase complex DNA-PK phosphorylates CC and activates NR4A3 and prevents NR4A3 ubiquitination and degradation CC (PubMed:25852083). Interacts with BRAT1 (PubMed:22977523). Part of the CC HDP-RNP complex composed of at least HEXIM1, PRKDC, XRCC5, XRCC6, CC paraspeckle proteins (SFPQ, NONO, PSPC1, RBM14, and MATR3) and NEAT1 CC RNA (PubMed:28712728). Interacts with KAT5 (PubMed:32832608). CC {ECO:0000269|PubMed:11955432, ECO:0000269|PubMed:14744996, CC ECO:0000269|PubMed:15071507, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15574326, ECO:0000269|PubMed:15758953, CC ECO:0000269|PubMed:15811628, ECO:0000269|PubMed:15936993, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:23149945, ECO:0000269|PubMed:25574025, CC ECO:0000269|PubMed:25670504, ECO:0000269|PubMed:25852083, CC ECO:0000269|PubMed:25941166, ECO:0000269|PubMed:28712728, CC ECO:0000269|PubMed:32832608, ECO:0000269|PubMed:33854234, CC ECO:0000269|PubMed:34352203, ECO:0000269|PubMed:9372844, CC ECO:0000269|PubMed:9442054, ECO:0000269|PubMed:9679063}. CC -!- INTERACTION: CC P78527; O43918: AIRE; NbExp=2; IntAct=EBI-352053, EBI-1753081; CC P78527; P10275: AR; NbExp=3; IntAct=EBI-352053, EBI-608057; CC P78527; Q96SD1: DCLRE1C; NbExp=5; IntAct=EBI-352053, EBI-11694104; CC P78527; P14921: ETS1; NbExp=2; IntAct=EBI-352053, EBI-913209; CC P78527; P50549: ETV1; NbExp=2; IntAct=EBI-352053, EBI-3905068; CC P78527; P09629: HOXB7; NbExp=2; IntAct=EBI-352053, EBI-1248457; CC P78527; Q9BPZ7: MAPKAP1; NbExp=2; IntAct=EBI-352053, EBI-749938; CC P78527; Q96RI1-2: NR1H4; NbExp=4; IntAct=EBI-352053, EBI-9640524; CC P78527; P10276: RARA; NbExp=3; IntAct=EBI-352053, EBI-413374; CC P78527; P17947: SPI1; NbExp=2; IntAct=EBI-352053, EBI-2293548; CC P78527; P13010: XRCC5; NbExp=9; IntAct=EBI-352053, EBI-357997; CC P78527; P12956: XRCC6; NbExp=8; IntAct=EBI-352053, EBI-353208; CC P78527; P61981: YWHAG; NbExp=2; IntAct=EBI-352053, EBI-359832; CC P78527; P25490: YY1; NbExp=2; IntAct=EBI-352053, EBI-765538; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12231622, CC ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:22002106}. Nucleus, nucleolus CC {ECO:0000269|PubMed:22002106, ECO:0000269|PubMed:32103174}. Cytoplasm, CC cytosol {ECO:0000269|PubMed:15262962}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P78527-1; Sequence=Displayed; CC Name=2; CC IsoId=P78527-2; Sequence=VSP_004708; CC -!- PTM: Autophosphorylated at two clusters, the T2609 cluster and the CC S2056 cluster (PubMed:33854234). Autophosphorylated on Ser-2056, Thr- CC 2609, Thr-2638 and Thr-2647 (PubMed:12186630, PubMed:12231622, CC PubMed:14734805, PubMed:33854234). Ser-2056 and Thr-2609 are DNA CC damage-inducible phosphorylation sites (inducible with ionizing CC radiation, IR) dephosphorylated by PPP5C (PubMed:12186630, CC PubMed:12231622, PubMed:14734805). Autophosphorylation induces a CC conformational change that leads to remodeling of the DNA-PK complex, CC requisite for efficient end processing and DNA repair (PubMed:12186630, CC PubMed:12231622, PubMed:14734805). Autophosphorylation in trans within CC DNA-PK complexes loaded on DNA ends leads to the dissociation of PRKDC CC from DNA and the transition into the short-range NHEJ complex CC (PubMed:33854234). Autophosphorylation of the T2609 cluster is required CC for hematopoietic development and protein synthesis in erythrocytes CC precursors (By similarity). {ECO:0000250|UniProtKB:P97313, CC ECO:0000269|PubMed:12186630, ECO:0000269|PubMed:12231622, CC ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:33854234}. CC -!- PTM: S-nitrosylated by GAPDH. {ECO:0000250|UniProtKB:P97313}. CC -!- PTM: Polyubiquitinated by RNF144A, leading to proteasomal degradation. CC {ECO:0000269|PubMed:24979766}. CC -!- DISEASE: Immunodeficiency 26 with or without neurologic abnormalities CC (IMD26) [MIM:615966]: A form of severe combined immunodeficiency CC characterized by reduced or absent T and B cells, recurrent CC candidiasis, and lower respiratory tract infections. Some patients show CC dysmorphic features, severe growth failure, microcephaly, seizures, and CC impaired neurological functions. {ECO:0000269|PubMed:19075392, CC ECO:0000269|PubMed:23722905}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U47077; AAB39925.5; -; mRNA. DR EMBL; U34994; AAC50210.3; -; mRNA. DR EMBL; AY316117; AAP69525.1; -; Genomic_DNA. DR EMBL; U63630; AAC52019.2; -; Genomic_DNA. DR EMBL; U90415; AAB51722.1; -; Genomic_DNA. DR EMBL; L27425; AAA79244.1; -; Genomic_DNA. DR EMBL; AB052953; BAB79635.1; -; Genomic_DNA. DR EMBL; U35835; AAA79184.1; -; mRNA. DR EMBL; AY030284; AAK40350.1; -; Genomic_DNA. DR EMBL; AB208860; BAD92097.1; -; mRNA. DR CCDS; CCDS75734.1; -. [P78527-2] DR CCDS; CCDS75735.1; -. [P78527-1] DR PIR; A57099; A57099. DR PIR; G02083; G02083. DR RefSeq; NP_001075109.1; NM_001081640.2. [P78527-2] DR RefSeq; NP_008835.5; NM_006904.6. [P78527-1] DR PDB; 5LUQ; X-ray; 4.30 A; A/B=2-2575, A/B=2774-4127. DR PDB; 5W1R; EM; 4.40 A; A=1-4128. DR PDB; 5Y3R; EM; 6.60 A; C=10-4128. DR PDB; 6ZFP; EM; 3.24 A; A=1-4128. DR PDB; 6ZH2; EM; 3.92 A; A=1-4128. DR PDB; 6ZH4; EM; 3.62 A; A=1-4128. DR PDB; 6ZH6; EM; 3.93 A; A=1-4128. DR PDB; 6ZH8; EM; 4.14 A; A=1-4128. DR PDB; 6ZHA; EM; 3.91 A; A=1-4128. DR PDB; 6ZHE; EM; 7.24 A; A/F=1-4128. DR PDB; 7K0Y; EM; 3.70 A; A=1-4128. DR PDB; 7K10; EM; 3.30 A; A=1-4128. DR PDB; 7K11; EM; 3.21 A; A=1-4128. DR PDB; 7K19; EM; 4.30 A; A=1-4128. DR PDB; 7K1B; EM; 4.30 A; A=1-4128. DR PDB; 7K1J; EM; 3.90 A; A=1-4128. DR PDB; 7K1K; EM; 4.10 A; A=1-4128. DR PDB; 7K1N; EM; 3.90 A; A=1-4128. DR PDB; 7LT3; EM; 4.60 A; C/L=1-4128. DR PDB; 7NFC; EM; 4.14 A; A/F=1-4128. DR PDB; 7NFE; EM; 4.29 A; A=1-4128. DR PDB; 7OTM; EM; 3.33 A; A=1-4128. DR PDB; 7OTP; EM; 3.40 A; A=1-4128. DR PDB; 7OTV; EM; 3.24 A; A=1-4128. DR PDB; 7OTW; EM; 2.99 A; A=1-4128. DR PDB; 7OTY; EM; 2.96 A; A=1-4128. DR PDB; 7SGL; EM; 3.00 A; A=1-4128. DR PDB; 7SU3; EM; 3.30 A; A=1-4128. DR PDB; 7SUD; EM; 3.60 A; A=1-4128. DR PDB; 7TYR; EM; 3.33 A; A=1-4128. DR PDB; 7Z87; EM; 2.91 A; A=1-4128. DR PDB; 7Z88; EM; 3.33 A; A=1-4128. DR PDB; 8BH3; EM; 4.55 A; A/S=1-4128. DR PDB; 8BHV; EM; 4.51 A; A/F=1-4128. DR PDB; 8BHY; EM; 5.33 A; A/S=1-4128. DR PDB; 8BOT; EM; 7.76 A; A/F/S=1-4128. DR PDB; 8EZ9; EM; 5.67 A; C/L=1-4128. DR PDB; 8EZA; EM; 4.39 A; C/L=1-4128. DR PDB; 8EZB; EM; 8.90 A; C/L=1-4128. DR PDB; 8RD4; EM; 3.58 A; A=1-4128. DR PDB; 9G9L; EM; 4.63 A; A=1-4128. DR PDB; 9GD7; EM; 4.25 A; S=1-4128. DR PDBsum; 5LUQ; -. DR PDBsum; 5W1R; -. DR PDBsum; 5Y3R; -. DR PDBsum; 6ZFP; -. DR PDBsum; 6ZH2; -. DR PDBsum; 6ZH4; -. DR PDBsum; 6ZH6; -. DR PDBsum; 6ZH8; -. DR PDBsum; 6ZHA; -. DR PDBsum; 6ZHE; -. DR PDBsum; 7K0Y; -. DR PDBsum; 7K10; -. DR PDBsum; 7K11; -. DR PDBsum; 7K19; -. DR PDBsum; 7K1B; -. DR PDBsum; 7K1J; -. DR PDBsum; 7K1K; -. DR PDBsum; 7K1N; -. DR PDBsum; 7LT3; -. DR PDBsum; 7NFC; -. DR PDBsum; 7NFE; -. DR PDBsum; 7OTM; -. DR PDBsum; 7OTP; -. DR PDBsum; 7OTV; -. DR PDBsum; 7OTW; -. DR PDBsum; 7OTY; -. DR PDBsum; 7SGL; -. DR PDBsum; 7SU3; -. DR PDBsum; 7SUD; -. DR PDBsum; 7TYR; -. DR PDBsum; 7Z87; -. DR PDBsum; 7Z88; -. DR PDBsum; 8BH3; -. DR PDBsum; 8BHV; -. DR PDBsum; 8BHY; -. DR PDBsum; 8BOT; -. DR PDBsum; 8EZ9; -. DR PDBsum; 8EZA; -. DR PDBsum; 8EZB; -. DR PDBsum; 8RD4; -. DR PDBsum; 9G9L; -. DR PDBsum; 9GD7; -. DR EMDB; EMD-11185; -. DR EMDB; EMD-11211; -. DR EMDB; EMD-11213; -. DR EMDB; EMD-11215; -. DR EMDB; EMD-11216; -. DR EMDB; EMD-11217; -. DR EMDB; EMD-11219; -. DR EMDB; EMD-12299; -. DR EMDB; EMD-12301; -. DR EMDB; EMD-13062; -. DR EMDB; EMD-13064; -. DR EMDB; EMD-13067; -. DR EMDB; EMD-13068; -. DR EMDB; EMD-13069; -. DR EMDB; EMD-14545; -. DR EMDB; EMD-14546; -. DR EMDB; EMD-16044; -. DR EMDB; EMD-16070; -. DR EMDB; EMD-16074; -. DR EMDB; EMD-16145; -. DR EMDB; EMD-19065; -. DR EMDB; EMD-22618; -. DR EMDB; EMD-22619; -. DR EMDB; EMD-22620; -. DR EMDB; EMD-22622; -. DR EMDB; EMD-22623; -. DR EMDB; EMD-22624; -. DR EMDB; EMD-22625; -. DR EMDB; EMD-22626; -. DR EMDB; EMD-23510; -. DR EMDB; EMD-23511; -. DR EMDB; EMD-25113; -. DR EMDB; EMD-25114; -. DR EMDB; EMD-25115; -. DR EMDB; EMD-25439; -. DR EMDB; EMD-25440; -. DR EMDB; EMD-26192; -. DR EMDB; EMD-26198; -. DR EMDB; EMD-28731; -. DR EMDB; EMD-28732; -. DR EMDB; EMD-28733; -. DR EMDB; EMD-28734; -. DR EMDB; EMD-28735; -. DR EMDB; EMD-28737; -. DR EMDB; EMD-28738; -. DR EMDB; EMD-51156; -. DR EMDB; EMD-51249; -. DR EMDB; EMD-5831; -. DR EMDB; EMD-5832; -. DR EMDB; EMD-5833; -. DR EMDB; EMD-6803; -. DR EMDB; EMD-8751; -. DR EMDB; EMD-8752; -. DR SASBDB; P78527; -. DR SMR; P78527; -. DR BioGRID; 111577; 791. DR ComplexPortal; CPX-3403; DNA-dependent protein kinase complex. DR CORUM; P78527; -. DR DIP; DIP-24186N; -. DR ELM; P78527; -. DR FunCoup; P78527; 3427. DR IntAct; P78527; 304. DR MINT; P78527; -. DR STRING; 9606.ENSP00000313420; -. DR BindingDB; P78527; -. DR ChEMBL; CHEMBL3142; -. DR DrugBank; DB07453; alpha-Naphthoflavone. DR DrugBank; DB16834; AZD-7648. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB16252; Nedisertib. DR DrugBank; DB17047; PIK-75. DR DrugBank; DB08052; PP-121. DR DrugBank; DB05210; SF1126. DR DrugCentral; P78527; -. DR GuidetoPHARMACOLOGY; 2800; -. DR CarbonylDB; P78527; -. DR GlyConnect; 1183; 1 N-Linked glycan (1 site). DR GlyCosmos; P78527; 9 sites, 3 glycans. DR GlyGen; P78527; 17 sites, 5 N-linked glycans (8 sites), 2 O-linked glycans (9 sites). DR iPTMnet; P78527; -. DR MetOSite; P78527; -. DR PhosphoSitePlus; P78527; -. DR SwissPalm; P78527; -. DR BioMuta; PRKDC; -. DR DMDM; 38258929; -. DR CPTAC; CPTAC-2931; -. DR jPOST; P78527; -. DR MassIVE; P78527; -. DR PaxDb; 9606-ENSP00000313420; -. DR PeptideAtlas; P78527; -. DR ProteomicsDB; 57634; -. [P78527-1] DR ProteomicsDB; 57635; -. [P78527-2] DR Pumba; P78527; -. DR Antibodypedia; 52433; 1580 antibodies from 45 providers. DR DNASU; 5591; -. DR Ensembl; ENST00000314191.7; ENSP00000313420.3; ENSG00000253729.10. [P78527-1] DR Ensembl; ENST00000338368.7; ENSP00000345182.4; ENSG00000253729.10. [P78527-2] DR GeneID; 5591; -. DR KEGG; hsa:5591; -. DR MANE-Select; ENST00000314191.7; ENSP00000313420.3; NM_006904.7; NP_008835.5. DR UCSC; uc033bkh.1; human. [P78527-1] DR AGR; HGNC:9413; -. DR CIViC; 5591; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33776; -. DR CTD; 5591; -. DR DisGeNET; 5591; -. DR GeneCards; PRKDC; -. DR HGNC; HGNC:9413; PRKDC. DR HPA; ENSG00000253729; Low tissue specificity. DR MalaCards; PRKDC; -. DR MIM; 600899; gene. DR MIM; 615966; phenotype. DR OpenTargets; ENSG00000253729; -. DR Orphanet; 317425; Severe combined immunodeficiency due to DNA-PKcs deficiency. DR VEuPathDB; HostDB:ENSG00000253729; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00940000155633; -. DR HOGENOM; CLU_224534_0_0_1; -. DR InParanoid; P78527; -. DR OMA; PSPMCRE; -. DR OrthoDB; 431717at2759; -. DR PAN-GO; P78527; 7 GO annotations based on evolutionary models. DR PhylomeDB; P78527; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P78527; -. DR Reactome; R-HSA-1834949; Cytosolic sensors of pathogen-associated DNA. DR Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-8866654; E3 ubiquitin ligases ubiquitinate target proteins. DR SignaLink; P78527; -. DR SIGNOR; P78527; -. DR Agora; ENSG00000253729; -. DR BioGRID-ORCS; 5591; 69 hits in 380 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PRKDC; human. DR GeneWiki; DNA-PKcs; -. DR GenomeRNAi; 5591; -. DR Pharos; P78527; Tchem. DR PRO; PR:P78527; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P78527; protein. DR Bgee; ENSG00000253729; Expressed in ventricular zone and 206 other cell types or tissues. DR ExpressionAtlas; P78527; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProt. DR GO; GO:0000781; C:chromosome, telomeric region; HDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070418; C:DNA-dependent protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005958; C:DNA-dependent protein kinase-DNA ligase 4 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0070419; C:nonhomologous end joining complex; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IMP:CAFA. DR GO; GO:0032993; C:protein-DNA complex; IDA:CAFA. DR GO; GO:0032040; C:small-subunit processome; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:MGI. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:CAFA. DR GO; GO:0019899; F:enzyme binding; IEA:Ensembl. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; IDA:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:CACAO. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0034511; F:U3 snoRNA binding; IDA:UniProtKB. DR GO; GO:0002218; P:activation of innate immune response; IDA:UniProtKB. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006302; P:double-strand break repair; IMP:BHF-UCL. DR GO; GO:0097681; P:double-strand break repair via alternative nonhomologous end joining; TAS:BHF-UCL. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0002327; P:immature B cell differentiation; IEA:Ensembl. DR GO; GO:0033152; P:immunoglobulin V(D)J recombination; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0000460; P:maturation of 5.8S rRNA; IDA:UniProtKB. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:CACAO. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:2001034; P:positive regulation of double-strand break repair via nonhomologous end joining; IDA:UniProtKB. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; ISS:UniProtKB. DR GO; GO:0045621; P:positive regulation of lymphocyte differentiation; ISS:UniProtKB. DR GO; GO:1905221; P:positive regulation of platelet formation; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0045727; P:positive regulation of translation; ISS:UniProtKB. DR GO; GO:0002328; P:pro-B cell differentiation; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IEA:Ensembl. DR GO; GO:0036211; P:protein modification process; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR GO; GO:0034462; P:small-subunit processome assembly; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl. DR GO; GO:0016233; P:telomere capping; IMP:BHF-UCL. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR CDD; cd05172; PIKKc_DNA-PK; 1. DR FunFam; 1.10.1070.11:FF:000018; DNA-dependent protein kinase catalytic subunit; 1. DR FunFam; 1.25.10.10:FF:000380; DNA-dependent protein kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000013; Protein kinase, DNA-activated, catalytic subunit; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR037706; DNA-PK_dom. DR InterPro; IPR046804; DNA-PKcs_N. DR InterPro; IPR046803; DNAPKcs_CC1-2. DR InterPro; IPR012582; DNAPKcs_CC3. DR InterPro; IPR045581; DNAPKcs_CC5. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF68; DNA-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; 1. DR Pfam; PF20500; DNA-PKcs_N; 1. DR Pfam; PF20502; DNAPKcs_CC1-2; 1. DR Pfam; PF08163; DNAPKcs_CC3; 1. DR Pfam; PF19704; DNAPKcs_CC5; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM01344; NUC194; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Biological rhythms; Cytoplasm; Disease variant; DNA damage; KW DNA recombination; DNA repair; DNA-binding; Immunity; Innate immunity; KW Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Ribosome biogenesis; KW SCID; Serine/threonine-protein kinase; TPR repeat; Transferase; KW Ubl conjugation. FT CHAIN 1..4128 FT /note="DNA-dependent protein kinase catalytic subunit" FT /id="PRO_0000225598" FT REPEAT 288..323 FT /note="HEAT 1" FT REPEAT 1004..1040 FT /note="HEAT 2" FT REPEAT 1723..1756 FT /note="TPR 1" FT DOMAIN 2906..3539 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 2920..2948 FT /note="TPR 2" FT REPEAT 2949..2982 FT /note="TPR 3" FT DOMAIN 3722..4053 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 4096..4128 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1503..1538 FT /note="Interaction with C1D" FT /evidence="ECO:0000269|PubMed:9679063" FT REGION 1503..1538 FT /note="Leucine-zipper" FT REGION 2050..2073 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2436..3212 FT /note="KIP-binding" FT /evidence="ECO:0000269|PubMed:9372844" FT REGION 2737..2765 FT /note="May split the end of the DNA molecule, with the two FT strands separating around the region" FT /evidence="ECO:0000269|PubMed:34352203" FT REGION 3200..3222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3728..3734 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3919..3927 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3939..3964 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 2020..2021 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:8804412" FT MOD_RES 117 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 511 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 687 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 828 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 841 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 893 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 1065 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1209 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1970 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 2056 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14734805, FT ECO:0000269|PubMed:22977523, ECO:0000269|PubMed:34352203" FT MOD_RES 2259 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 2535 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2609 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0000269|PubMed:12231622, ECO:0000269|PubMed:14734805, FT ECO:0000269|PubMed:32103174, ECO:0000269|PubMed:34352203" FT MOD_RES 2612 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 2638 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2647 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 3205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3241 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3260 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3621 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3638 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3642 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3731 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 3821 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 4026 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 3799..3829 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.10" FT /id="VSP_004708" FT VARIANT 6 FT /note="A -> S (in dbSNP:rs8177999)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019179" FT VARIANT 263 FT /note="K -> N (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs758032015)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041602" FT VARIANT 333 FT /note="M -> I (in dbSNP:rs8178017)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019180" FT VARIANT 420 FT /note="V -> I (in dbSNP:rs55925466)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041603" FT VARIANT 500 FT /note="G -> S (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041604" FT VARIANT 605 FT /note="T -> S (in dbSNP:rs8178033)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019181" FT VARIANT 649 FT /note="F -> L (in dbSNP:rs55811715)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041605" FT VARIANT 680 FT /note="I -> M (in dbSNP:rs8178040)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019182" FT VARIANT 695 FT /note="P -> S (in dbSNP:rs8178046)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019183" FT VARIANT 1071 FT /note="N -> S (in dbSNP:rs8178070)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019184" FT VARIANT 1136 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs781401034)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041606" FT VARIANT 1190 FT /note="L -> V (in dbSNP:rs34598508)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041607" FT VARIANT 1237 FT /note="A -> T (in dbSNP:rs191531119)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041608" FT VARIANT 1279 FT /note="L -> F" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041609" FT VARIANT 1314 FT /note="G -> V (in dbSNP:rs8178090)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019185" FT VARIANT 1447 FT /note="R -> M (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041610" FT VARIANT 1588 FT /note="D -> V (in dbSNP:rs8178104)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019186" FT VARIANT 1603 FT /note="Q -> H (in dbSNP:rs8178106)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019187" FT VARIANT 1619 FT /note="A -> G (in dbSNP:rs56182356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041611" FT VARIANT 1680 FT /note="A -> V (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs55735910)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041612" FT VARIANT 2023 FT /note="S -> P (in dbSNP:rs56042895)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041613" FT VARIANT 2095 FT /note="A -> V (in dbSNP:rs8178147)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019188" FT VARIANT 2598 FT /note="R -> Q (in dbSNP:rs55923149)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041614" FT VARIANT 2702 FT /note="K -> E (in dbSNP:rs8178178)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019189" FT VARIANT 2810 FT /note="S -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041615" FT VARIANT 2899 FT /note="R -> C (in dbSNP:rs4278157)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019190" FT VARIANT 2941 FT /note="G -> A (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041616" FT VARIANT 3062 FT /note="L -> R (in IMD26; shows increased long palindromic FT (P)-nucleotide stretches in the immunoglobulin coding FT joints indicating a defect in hairpin opening and FT insufficient DCLRE1C activation; dbSNP:rs587777685)" FT /evidence="ECO:0000269|PubMed:19075392" FT /id="VAR_072569" FT VARIANT 3085 FT /note="E -> D (in dbSNP:rs56135402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041617" FT VARIANT 3149 FT /note="G -> D (in dbSNP:rs8178208)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019191" FT VARIANT 3198 FT /note="T -> S (in dbSNP:rs55793951)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041618" FT VARIANT 3201 FT /note="P -> S (in dbSNP:rs8178216)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019192" FT VARIANT 3404 FT /note="G -> E (in dbSNP:rs8178225)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019193" FT VARIANT 3434 FT /note="I -> T (in dbSNP:rs7830743)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019194" FT VARIANT 3459 FT /note="N -> S (in dbSNP:rs8178228)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019195" FT VARIANT 3562 FT /note="L -> M (in dbSNP:rs8178232)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019196" FT VARIANT 3574 FT /note="A -> V (in IMD26; shows impaired function in FT response to irradiation and a less severe defect in V(D)J FT end-joining suggesting that the missense mutation retained FT some functional capacity; consistent with a loss of FT function mutation; dbSNP:rs587777686)" FT /evidence="ECO:0000269|PubMed:23722905" FT /id="VAR_072570" FT VARIANT 3584 FT /note="L -> F (in dbSNP:rs55866966)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041619" FT VARIANT 3702 FT /note="P -> L (in dbSNP:rs8178236)" FT /id="VAR_050534" FT VARIANT 3800 FT /note="L -> I (in dbSNP:rs56216442)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041620" FT VARIANT 3836 FT /note="P -> L (in dbSNP:rs8178245)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019197" FT VARIANT 3932 FT /note="M -> V (in dbSNP:rs8178248)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019198" FT VARIANT 3936 FT /note="G -> S (in dbSNP:rs55670423)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041621" FT VARIANT 3937 FT /note="V -> M (in dbSNP:rs56090750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041622" FT MUTAGEN 1510 FT /note="L->P: Loss of interaction with C1D." FT /evidence="ECO:0000269|PubMed:9679063" FT MUTAGEN 1516..1517 FT /note="EL->PD: Loss of interaction with C1D." FT /evidence="ECO:0000269|PubMed:9679063" FT MUTAGEN 2609 FT /note="T->A: Leads to radiation sensitivity and impaired FT DSB joining. Gives rise to reduced phosphorylation; when FT associated with A-2612." FT /evidence="ECO:0000269|PubMed:12231622" FT MUTAGEN 2612 FT /note="S->A: Reduced phosphorylation; when associated with FT A-2609." FT MUTAGEN 2638 FT /note="T->A: Alleviates phosphorylation, leaves a fully FT active enzyme with compromised cellular resistance to FT ionizing radiation without affecting DNA end joining; when FT associated with A-2647." FT /evidence="ECO:0000269|PubMed:12649176" FT MUTAGEN 2647 FT /note="T->A: Alleviates phosphorylation, leaves a fully FT active enzyme with compromised cellular resistance to FT ionizing radiation without affecting DNA end joining; when FT associated with A-2638." FT /evidence="ECO:0000269|PubMed:12649176" FT CONFLICT 405 FT /note="D -> Y (in Ref. 2; AAC50210)" FT /evidence="ECO:0000305" FT CONFLICT 1008 FT /note="A -> S (in Ref. 2; AAC50210)" FT /evidence="ECO:0000305" FT CONFLICT 3660 FT /note="N -> T (in Ref. 8; AAA79184)" FT /evidence="ECO:0000305" FT CONFLICT 3817 FT /note="L -> W (in Ref. 8; AAA79184)" FT /evidence="ECO:0000305" FT CONFLICT 3862 FT /note="A -> P (in Ref. 8; AAA79184)" FT /evidence="ECO:0000305" FT CONFLICT 4031 FT /note="I -> V (in Ref. 9; AAK40350)" FT /evidence="ECO:0000305" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 11..20 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 27..44 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 48..58 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 65..71 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 76..78 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 79..95 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 98..103 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 104..117 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 121..137 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 143..146 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 149..159 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 171..183 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 189..192 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 193..209 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 211..213 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 232..234 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 238..240 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 244..256 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 258..260 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 267..278 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 279..281 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 284..287 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 290..301 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 302..304 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 308..329 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 330..332 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 335..350 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 356..376 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 377..379 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 380..383 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 384..386 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 387..396 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 397..399 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 401..403 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 406..409 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 410..421 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 432..444 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 446..448 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 451..453 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 454..468 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 469..471 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 473..491 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 513..518 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 528..534 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 539..541 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 542..544 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 545..547 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 560..577 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 583..585 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7TYR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 617..633 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 639..642 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 646..658 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 666..679 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 680..685 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 700..717 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 718..720 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 723..735 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 738..743 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 745..747 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 749..758 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 759..761 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 763..779 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 782..784 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 786..788 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 789..792 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 793..795 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 797..799 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 800..804 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 817..822 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 828..838 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 848..861 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 866..869 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 874..876 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 877..881 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 886..889 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 893..895 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 904..906 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 907..909 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 911..919 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 924..945 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 946..948 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 951..954 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 959..973 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 978..995 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 998..1002 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1004..1017 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1019..1021 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 1023..1042 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1046..1050 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 1056..1067 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1068..1070 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1072..1085 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1086..1090 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1096..1115 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1119..1121 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 1123..1138 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1139..1141 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1142..1144 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1166..1175 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1181..1194 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1195..1198 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1204..1215 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1219..1222 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1223..1227 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1228..1232 FT /evidence="ECO:0007829|PDB:7OTW" FT TURN 1235..1237 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 1239..1242 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 1243..1245 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1248..1250 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1251..1266 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1268..1272 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1274..1276 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1278..1282 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1283..1286 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 1290..1300 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1301..1303 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 1309..1311 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 1317..1319 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1324..1349 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1351..1353 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1357..1359 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1360..1363 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1366..1376 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1380..1383 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1391..1406 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1409..1411 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1413..1422 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1425..1431 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1432..1435 FT /evidence="ECO:0007829|PDB:7TYR" FT STRAND 1437..1439 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1441..1446 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1447..1461 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1464..1467 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1472..1476 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1478..1489 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1494..1496 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1505..1521 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1525..1532 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1543..1551 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 1557..1562 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1575..1583 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1584..1588 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1590..1606 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1607..1610 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1613..1624 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1625..1628 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1631..1633 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1634..1637 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1639..1655 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1658..1660 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 1665..1667 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1668..1680 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1682..1684 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1686..1693 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1694..1698 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1699..1701 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1704..1706 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1707..1718 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1724..1726 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1734..1752 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1756..1766 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1769..1771 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1775..1786 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1787..1789 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 1791..1806 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1813..1830 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1832..1834 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1837..1851 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1857..1859 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 1860..1882 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1887..1890 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1891..1893 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1896..1899 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1900..1902 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 1906..1908 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 1909..1923 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1931..1933 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1934..1952 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1959..1961 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1962..1965 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1967..1969 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1971..1973 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1974..1976 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1978..1981 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1984..1986 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 1992..1996 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 1999..2013 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2026..2028 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 2031..2033 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 2035..2047 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2065..2067 FT /evidence="ECO:0007829|PDB:7TYR" FT STRAND 2086..2089 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2091..2093 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2094..2105 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2106..2110 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 2125..2133 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2136..2138 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 2140..2152 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2154..2157 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2158..2163 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2166..2173 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2179..2181 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2185..2195 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2196..2199 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2206..2221 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2228..2244 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2245..2248 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2256..2260 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2264..2266 FT /evidence="ECO:0007829|PDB:7TYR" FT TURN 2268..2270 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2271..2282 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2292..2294 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2296..2305 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2306..2308 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2313..2332 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2335..2337 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 2338..2353 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2354..2356 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2357..2370 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2372..2374 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2375..2385 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2386..2388 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2392..2403 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2404..2407 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2412..2417 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2420..2425 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2429..2442 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2443..2445 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2448..2459 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2460..2463 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2467..2481 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2487..2490 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 2492..2494 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2495..2508 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2509..2511 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2517..2526 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2528..2530 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2535..2543 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2548..2550 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2551..2563 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2566..2570 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2572..2576 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2581..2583 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2594..2602 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 2634..2636 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 2658..2660 FT /evidence="ECO:0007829|PDB:7SU3" FT STRAND 2721..2723 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 2736..2766 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2772..2774 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 2777..2779 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2788..2798 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2802..2819 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2822..2824 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2826..2846 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2852..2863 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2866..2868 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2873..2882 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2886..2897 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2920..2933 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2936..2940 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2941..2943 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2951..2961 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2965..2976 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2982..2984 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2988..3004 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3008..3016 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3017..3019 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3022..3024 FT /evidence="ECO:0007829|PDB:7OTW" FT TURN 3026..3031 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3034..3036 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3037..3040 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3041..3053 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3061..3068 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3069..3072 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3073..3081 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3085..3092 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3096..3115 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3122..3124 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3125..3129 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3132..3146 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3148..3152 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3155..3165 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3171..3173 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3176..3195 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3200..3203 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3206..3210 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3213..3220 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3227..3248 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3252..3260 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3261..3265 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3270..3288 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3289..3291 FT /evidence="ECO:0007829|PDB:7Z88" FT STRAND 3293..3295 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3296..3307 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3308..3310 FT /evidence="ECO:0007829|PDB:7SU3" FT TURN 3312..3318 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3320..3343 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3347..3350 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3353..3355 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3356..3360 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3364..3366 FT /evidence="ECO:0007829|PDB:7OTY" FT TURN 3369..3371 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3372..3393 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3403..3405 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 3410..3428 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3434..3439 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3442..3455 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3459..3462 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3463..3466 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3467..3473 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3477..3479 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3481..3488 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3492..3498 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3499..3502 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3503..3507 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3509..3511 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 3512..3514 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3515..3524 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3526..3528 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 3530..3538 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3545..3547 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3548..3561 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3563..3566 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3567..3576 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3581..3593 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3594..3598 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3602..3604 FT /evidence="ECO:0007829|PDB:7K10" FT HELIX 3605..3615 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3616..3618 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3621..3626 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3633..3639 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3642..3649 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3651..3653 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3657..3660 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3661..3672 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3681..3683 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3685..3689 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3694..3696 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 3707..3709 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3713..3715 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3719..3722 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3730..3733 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3736..3738 FT /evidence="ECO:0007829|PDB:7Z88" FT STRAND 3739..3742 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3743..3745 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 3747..3753 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3759..3774 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3775..3777 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3779..3783 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3793..3797 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3800..3804 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3809..3811 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3812..3819 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3822..3829 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3835..3847 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3848..3851 FT /evidence="ECO:0007829|PDB:7Z88" FT HELIX 3854..3860 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3864..3875 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3876..3878 FT /evidence="ECO:0007829|PDB:7K11" FT HELIX 3882..3889 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3890..3893 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 3894..3917 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3927..3931 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3932..3934 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3937..3939 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3945..3947 FT /evidence="ECO:0007829|PDB:7SU3" FT TURN 3949..3951 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3952..3955 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3959..3961 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 3965..3970 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3971..3973 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3976..3978 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 3979..3992 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3996..4001 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4004..4007 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4009..4011 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 4013..4021 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 4027..4029 FT /evidence="ECO:0007829|PDB:7SU3" FT STRAND 4030..4032 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 4034..4036 FT /evidence="ECO:0007829|PDB:7K11" FT HELIX 4039..4049 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4052..4054 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4056..4068 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4069..4071 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 4074..4082 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4085..4087 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4089..4092 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4095..4097 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4100..4111 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4114..4117 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4122..4124 FT /evidence="ECO:0007829|PDB:7Z87" SQ SEQUENCE 4128 AA; 469089 MW; AC6E747FEB09F3E5 CRC64; MAGSGAGVRC SLLRLQETLS AADRCGAALA GHQLIRGLGQ ECVLSSSPAV LALQTSLVFS RDFGLLVFVR KSLNSIEFRE CREEILKFLC IFLEKMGQKI APYSVEIKNT CTSVYTKDRA AKCKIPALDL LIKLLQTFRS SRLMDEFKIG ELFSKFYGEL ALKKKIPDTV LEKVYELLGL LGEVHPSEMI NNAENLFRAF LGELKTQMTS AVREPKLPVL AGCLKGLSSL LCNFTKSMEE DPQTSREIFN FVLKAIRPQI DLKRYAVPSA GLRLFALHAS QFSTCLLDNY VSLFEVLLKW CAHTNVELKK AALSALESFL KQVSNMVAKN AEMHKNKLQY FMEQFYGIIR NVDSNNKELS IAIRGYGLFA GPCKVINAKD VDFMYVELIQ RCKQMFLTQT DTGDDRVYQM PSFLQSVASV LLYLDTVPEV YTPVLEHLVV MQIDSFPQYS PKMQLVCCRA IVKVFLALAA KGPVLRNCIS TVVHQGLIRI CSKPVVLPKG PESESEDHRA SGEVRTGKWK VPTYKDYVDL FRHLLSSDQM MDSILADEAF FSVNSSSESL NHLLYDEFVK SVLKIVEKLD LTLEIQTVGE QENGDEAPGV WMIPTSDPAA NLHPAKPKDF SAFINLVEFC REILPEKQAE FFEPWVYSFS YELILQSTRL PLISGFYKLL SITVRNAKKI KYFEGVSPKS LKHSPEDPEK YSCFALFVKF GKEVAVKMKQ YKDELLASCL TFLLSLPHNI IELDVRAYVP ALQMAFKLGL SYTPLAEVGL NALEEWSIYI DRHVMQPYYK DILPCLDGYL KTSALSDETK NNWEVSALSR AAQKGFNKVV LKHLKKTKNL SSNEAISLEE IRIRVVQMLG SLGGQINKNL LTVTSSDEMM KSYVAWDREK RLSFAVPFRE MKPVIFLDVF LPRVTELALT ASDRQTKVAA CELLHSMVMF MLGKATQMPE GGQGAPPMYQ LYKRTFPVLL RLACDVDQVT RQLYEPLVMQ LIHWFTNNKK FESQDTVALL EAILDGIVDP VDSTLRDFCG RCIREFLKWS IKQITPQQQE KSPVNTKSLF KRLYSLALHP NAFKRLGASL AFNNIYREFR EEESLVEQFV FEALVIYMES LALAHADEKS LGTIQQCCDA IDHLCRIIEK KHVSLNKAKK RRLPRGFPPS ASLCLLDLVK WLLAHCGRPQ TECRHKSIEL FYKFVPLLPG NRSPNLWLKD VLKEEGVSFL INTFEGGGCG QPSGILAQPT LLYLRGPFSL QATLCWLDLL LAALECYNTF IGERTVGALQ VLGTEAQSSL LKAVAFFLES IAMHDIIAAE KCFGTGAAGN RTSPQEGERY NYSKCTVVVR IMEFTTTLLN TSPEGWKLLK KDLCNTHLMR VLVQTLCEPA SIGFNIGDVQ VMAHLPDVCV NLMKALKMSP YKDILETHLR EKITAQSIEE LCAVNLYGPD AQVDRSRLAA VVSACKQLHR AGLLHNILPS QSTDLHHSVG TELLSLVYKG IAPGDERQCL PSLDLSCKQL ASGLLELAFA FGGLCERLVS LLLNPAVLST ASLGSSQGSV IHFSHGEYFY SLFSETINTE LLKNLDLAVL ELMQSSVDNT KMVSAVLNGM LDQSFRERAN QKHQGLKLAT TILQHWKKCD SWWAKDSPLE TKMAVLALLA KILQIDSSVS FNTSHGSFPE VFTTYISLLA DTKLDLHLKG QAVTLLPFFT SLTGGSLEEL RRVLEQLIVA HFPMQSREFP PGTPRFNNYV DCMKKFLDAL ELSQSPMLLE LMTEVLCREQ QHVMEELFQS SFRRIARRGS CVTQVGLLES VYEMFRKDDP RLSFTRQSFV DRSLLTLLWH CSLDALREFF STIVVDAIDV LKSRFTKLNE STFDTQITKK MGYYKILDVM YSRLPKDDVH AKESKINQVF HGSCITEGNE LTKTLIKLCY DAFTENMAGE NQLLERRRLY HCAAYNCAIS VICCVFNELK FYQGFLFSEK PEKNLLIFEN LIDLKRRYNF PVEVEVPMER KKKYIEIRKE AREAANGDSD GPSYMSSLSY LADSTLSEEM SQFDFSTGVQ SYSYSSQDPR PATGRFRRRE QRDPTVHDDV LELEMDELNR HECMAPLTAL VKHMHRSLGP PQGEEDSVPR DLPSWMKFLH GKLGNPIVPL NIRLFLAKLV INTEEVFRPY AKHWLSPLLQ LAASENNGGE GIHYMVVEIV ATILSWTGLA TPTGVPKDEV LANRLLNFLM KHVFHPKRAV FRHNLEIIKT LVECWKDCLS IPYRLIFEKF SGKDPNSKDN SVGIQLLGIV MANDLPPYDP QCGIQSSEYF QALVNNMSFV RYKEVYAAAA EVLGLILRYV MERKNILEES LCELVAKQLK QHQNTMEDKF IVCLNKVTKS FPPLADRFMN AVFFLLPKFH GVLKTLCLEV VLCRVEGMTE LYFQLKSKDF VQVMRHRDDE RQKVCLDIIY KMMPKLKPVE LRELLNPVVE FVSHPSTTCR EQMYNILMWI HDNYRDPESE TDNDSQEIFK LAKDVLIQGL IDENPGLQLI IRNFWSHETR LPSNTLDRLL ALNSLYSPKI EVHFLSLATN FLLEMTSMSP DYPNPMFEHP LSECEFQEYT IDSDWRFRST VLTPMFVETQ ASQGTLQTRT QEGSLSARWP VAGQIRATQQ QHDFTLTQTA DGRSSFDWLT GSSTDPLVDH TSPSSDSLLF AHKRSERLQR APLKSVGPDF GKKRLGLPGD EVDNKVKGAA GRTDLLRLRR RFMRDQEKLS LMYARKGVAE QKREKEIKSE LKMKQDAQVV LYRSYRHGDL PDIQIKHSSL ITPLQAVAQR DPIIAKQLFS SLFSGILKEM DKFKTLSEKN NITQKLLQDF NRFLNTTFSF FPPFVSCIQD ISCQHAALLS LDPAAVSAGC LASLQQPVGI RLLEEALLRL LPAELPAKRV RGKARLPPDV LRWVELAKLY RSIGEYDVLR GIFTSEIGTK QITQSALLAE ARSDYSEAAK QYDEALNKQD WVDGEPTEAE KDFWELASLD CYNHLAEWKS LEYCSTASID SENPPDLNKI WSEPFYQETY LPYMIRSKLK LLLQGEADQS LLTFIDKAMH GELQKAILEL HYSQELSLLY LLQDDVDRAK YYIQNGIQSF MQNYSSIDVL LHQSRLTKLQ SVQALTEIQE FISFISKQGN LSSQVPLKRL LNTWTNRYPD AKMDPMNIWD DIITNRCFFL SKIEEKLTPL PEDNSMNVDQ DGDPSDRMEV QEQEEDISSL IRSCKFSMKM KMIDSARKQN NFSLAMKLLK ELHKESKTRD DWLVSWVQSY CRLSHCRSRS QGCSEQVLTV LKTVSLLDEN NVSSYLSKNI LAFRDQNILL GTTYRIIANA LSSEPACLAE IEEDKARRIL ELSGSSSEDS EKVIAGLYQR AFQHLSEAVQ AAEEEAQPPS WSCGPAAGVI DAYMTLADFC DQQLRKEEEN ASVIDSAELQ AYPALVVEKM LKALKLNSNE ARLKFPRLLQ IIERYPEETL SLMTKEISSV PCWQFISWIS HMVALLDKDQ AVAVQHSVEE ITDNYPQAIV YPFIISSESY SFKDTSTGHK NKEFVARIKS KLDQGGVIQD FINALDQLSN PELLFKDWSN DVRAELAKTP VNKKNIEKMY ERMYAALGDP KAPGLGAFRR KFIQTFGKEF DKHFGKGGSK LLRMKLSDFN DITNMLLLKM NKDSKPPGNL KECSPWMSDF KVEFLRNELE IPGQYDGRGK PLPEYHVRIA GFDERVTVMA SLRRPKRIII RGHDEREHPF LVKGGEDLRQ DQRVEQLFQV MNGILAQDSA CSQRALQLRT YSVVPMTSRL GLIEWLENTV TLKDLLLNTM SQEEKAAYLS DPRAPPCEYK DWLTKMSGKH DVGAYMLMYK GANRTETVTS FRKRESKVPA DLLKRAFVRM STSPEAFLAL RSHFASSHAL ICISHWILGI GDRHLNNFMV AMETGGVIGI DFGHAFGSAT QFLPVPELMP FRLTRQFINL MLPMKETGLM YSIMVHALRA FRSDPGLLTN TMDVFVKEPS FDWKNFEQKM LKKGGSWIQE INVAEKNWYP RQKICYAKRK LAGANPAVIT CDELLLGHEK APAFRDYVAV ARGSKDHNIR AQEPESGLSE ETQVKCLMDQ ATDPNILGRT WEGWEPWM // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID PTK6_HUMAN Reviewed; 451 AA. AC Q13882; B2RCR3; B4DW46; Q58F01; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Protein-tyrosine kinase 6; DE EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}; DE AltName: Full=Breast tumor kinase; DE AltName: Full=Tyrosine-protein kinase BRK; GN Name=PTK6; Synonyms=BRK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary tumor; RX PubMed=8036022; RA Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., RA Page M.J., Gusterson B.A., Crompton M.R.; RT "Cloning and characterisation of cDNAs encoding a novel non-receptor RT tyrosine kinase, brk, expressed in human breast tumours."; RL Oncogene 9:2383-2390(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=9333026; DOI=10.1038/sj.onc.1201292; RA Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.; RT "Characterisation and chromosome mapping of the human non receptor tyrosine RT kinase gene, brk."; RL Oncogene 15:1497-1502(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Melanocyte; RX PubMed=9749526; RA Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.; RT "Exon-intron structure of the human PTK6 gene demonstrates that PTK6 RT constitutes a distinct family of non-receptor tyrosine kinase."; RL Mol. Cells 8:401-407(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND RP TYR-447. RX PubMed=8940083; DOI=10.1074/jbc.271.48.30956; RA Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., RA Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.; RT "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, RT sensitizes mammary epithelial cells to epidermal growth factor."; RL J. Biol. Chem. 271:30956-30963(1996). RN [8] RP TISSUE SPECIFICITY. RX PubMed=9185712; RX DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f; RA Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A., RA Bennett D.C.; RT "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK RT in metastatic melanoma."; RL Int. J. Cancer 71:1061-1065(1997). RN [9] RP FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66; RP ARG-105 AND LYS-219. RX PubMed=10980601; DOI=10.1038/sj.onc.1203775; RA Mitchell P.J., Sara E.A., Crompton M.R.; RT "A novel adaptor-like protein which is a substrate for the non-receptor RT tyrosine kinase, BRK."; RL Oncogene 19:4273-4282(2000). RN [10] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH RP KHDRBS1. RX PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000; RA Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., RA Cochrane A.W., Chen T., Tyner A.L.; RT "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RT RNA binding ability."; RL Mol. Cell. Biol. 20:6114-6126(2000). RN [11] RP PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351, RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342 RP AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12121988; DOI=10.1074/jbc.m203877200; RA Qiu H., Miller W.T.; RT "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation RT and by autoinhibition."; RL J. Biol. Chem. 277:34634-34641(2002). RN [12] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12833144; DOI=10.1038/sj.onc.1206465; RA Derry J.J., Prins G.S., Ray V., Tyner A.L.; RT "Altered localization and activity of the intracellular tyrosine kinase RT BRK/Sik in prostate tumor cells."; RL Oncogene 22:4212-4220(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND RP PHOSPHORYLATION. RX PubMed=15471878; DOI=10.1074/jbc.m409579200; RA Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.; RT "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA- RT binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2."; RL J. Biol. Chem. 279:54398-54404(2004). RN [14] RP FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR RP LOCATION, AND INTERACTION WITH PXN. RX PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004; RA Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.; RT "Brk activates rac1 and promotes cell migration and invasion by RT phosphorylating paxillin."; RL Mol. Cell. Biol. 24:10558-10572(2004). RN [15] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010; RA Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.; RT "Differential expression of the non-receptor tyrosine kinase BRK in oral RT squamous cell carcinoma and normal oral epithelium."; RL Oral Oncol. 40:1040-1047(2004). RN [16] RP FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK. RX PubMed=15539407; DOI=10.1074/jbc.m412038200; RA Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., RA Lange C.A.; RT "Regulated association of protein kinase B/Akt with breast tumor kinase."; RL J. Biol. Chem. 280:1982-1991(2005). RN [17] RP MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION. RX PubMed=15961400; DOI=10.1074/jbc.m504568200; RA Kim H.I.E., Lee S.T.; RT "An intramolecular interaction between SH2-kinase linker and kinase domain RT is essential for the catalytic activity of protein-tyrosine kinase-6."; RL J. Biol. Chem. 280:28973-28980(2005). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KHDRBS1. RX PubMed=16179349; DOI=10.1074/jbc.m505802200; RA Lukong K.E., Larocque D., Tyner A.L., Richard S.; RT "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates RT intranuclear localization and cell cycle progression."; RL J. Biol. Chem. 280:38639-38647(2005). RN [19] RP INTERACTION WITH IRS4, AND ACTIVITY REGULATION. RX PubMed=15870689; DOI=10.1038/sj.onc.1208721; RA Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.; RT "Interaction between Brk kinase and insulin receptor substrate-4."; RL Oncogene 24:5656-5664(2005). RN [20] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16651629; DOI=10.2353/ajpath.2006.050521; RA Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., RA Marzec M., Gimotty P., Crompton M.R., Wasik M.A.; RT "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in RT lymphocytes."; RL Am. J. Pathol. 168:1631-1641(2006). RN [21] RP FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION. RX PubMed=16568091; DOI=10.1038/sj.onc.1209501; RA Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.; RT "Identification of STAT3 as a specific substrate of breast tumor kinase."; RL Oncogene 25:4904-4912(2006). RN [22] RP ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44. RX PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055; RA Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.; RT "Molecular dissection of the interaction between the SH3 domain and the RT SH2-Kinase Linker region in PTK6."; RL Biochem. Biophys. Res. Commun. 362:829-834(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF STAT5B. RX PubMed=17997837; DOI=10.1186/bcr1794; RA Weaver A.M., Silva C.M.; RT "Signal transducer and activator of transcription 5b: a new target of RT breast tumor kinase/protein tyrosine kinase 6."; RL Breast Cancer Res. 9:R79-R79(2007). RN [24] RP FUNCTION IN PHOSPHORYLATION OF ARHGAP35. RX PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997; RA Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., RA Settleman J., Chen R.H.; RT "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and RT promote breast carcinoma growth, migration, and invasion."; RL Cancer Res. 68:7779-7787(2008). RN [25] RP INTERACTION WITH ADAM15. RX PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028; RA Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., RA Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., RA Edwards D.R.; RT "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human RT mammary carcinoma."; RL Mol. Cancer Res. 6:383-394(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [27] RP INTERACTION WITH ERBB2. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [28] RP INTERACTION WITH SFPQ. RX PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008; RA Lukong K.E., Huot M.E., Richard S.; RT "BRK phosphorylates PSF promoting its cytoplasmic localization and cell RT cycle arrest."; RL Cell. Signal. 21:1415-1422(2009). RN [29] RP REVIEW ON FUNCTION. RX PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003; RA Brauer P.M., Tyner A.L.; RT "Building a better understanding of the intracellular tyrosine kinase PTK6 RT - BRK by BRK."; RL Biochim. Biophys. Acta 1806:66-73(2010). RN [30] RP FUNCTION, AND MUTAGENESIS OF ARG-105 AND LYS-219. RX PubMed=20554524; DOI=10.1074/jbc.m109.088971; RA Kang S.A., Lee E.S., Yoon H.Y., Randazzo P.A., Lee S.T.; RT "PTK6 inhibits down-regulation of EGF receptor through phosphorylation of RT ARAP1."; RL J. Biol. Chem. 285:26013-26021(2010). RN [31] RP PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [32] RP FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1. RX PubMed=21479203; DOI=10.1371/journal.pone.0014789; RA Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M., RA Tyner A.L.; RT "The alternative splice variant of protein tyrosine kinase 6 negatively RT regulates growth and enhances PTK6-mediated inhibition of beta-catenin."; RL PLoS ONE 6:E14789-E14789(2011). RN [33] RP STRUCTURE BY NMR OF 75-174. RX PubMed=15056653; DOI=10.1074/jbc.m313185200; RA Hong E., Shin J., Kim H.I., Lee S.T., Lee W.; RT "Solution structure and backbone dynamics of the non-receptor protein- RT tyrosine kinase-6 Src homology 2 domain."; RL J. Biol. Chem. 279:29700-29708(2004). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF LYS-219. RX PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121; RA Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.; RT "Crystal structure of the kinase domain of human protein tyrosine kinase 6 RT (PTK6) at 2.33 A resolution."; RL Biochem. Biophys. Res. Commun. 478:637-642(2016). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH RP INHIBITORS, AND CATALYTIC ACTIVITY. RX PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030; RA Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S., RA Tyagi R., Gosu R.; RT "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel RT imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution."; RL Biochem. Biophys. Res. Commun. 482:1289-1295(2017). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the CC regulation of a variety of signaling pathways that control the CC differentiation and maintenance of normal epithelia, as well as tumor CC growth. Function seems to be context dependent and differ depending on CC cell type, as well as its intracellular localization. A number of CC potential nuclear and cytoplasmic substrates have been identified. CC These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, CC KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B CC and a variety of signaling molecules: ARHGAP35/p190RhoGAP, CC PXN/paxillin, BTK/ATK, STAP2/BKS. Phosphorylates the GTPase-activating CC protein ARAP1 following EGF stimulation which enhances EGFR signaling CC by delaying EGFR down-regulation (PubMed:20554524). Also associates CC with a variety of proteins that are likely upstream of PTK6 in various CC signaling pathways, or for which PTK6 may play an adapter-like role. CC These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal CC or non-tumorigenic tissues, PTK6 promotes cellular differentiation and CC apoptosis. In tumors PTK6 contributes to cancer progression by CC sensitizing cells to mitogenic signals and enhancing proliferation, CC anchorage-independent survival and migration/invasion. Association with CC EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and CC growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 CC kinase. Contributes to migration and proliferation by contributing to CC EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes CC association with RASA1/p120RasGAP, inactivating RhoA while activating CC RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by CC PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration CC and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. CC Nuclear PTK6 may be important for regulating growth in normal CC epithelia, while cytoplasmic PTK6 might activate oncogenic signaling CC pathways. {ECO:0000269|PubMed:20554524}. CC -!- FUNCTION: [Isoform 2]: Inhibits PTK6 phosphorylation and PTK6 CC association with other tyrosine-phosphorylated proteins. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, CC ECO:0000269|PubMed:27993680}; CC -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by CC SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an CC association between the SH3 domain and the SH2-TK linker region. CC Interaction between Trp-184 within SH2-TK linker region and the CC catalytic domain appears essential for positive regulation of kinase CC activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091, CC ECO:0000269|PubMed:17822667}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=83 uM for ATP {ECO:0000269|PubMed:12121988}; CC Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988}; CC -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3 CC and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with CC phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) CC with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2. CC Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK. CC Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193, CC ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407, CC ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:8940083}. CC -!- INTERACTION: CC Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652; CC Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093; CC Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027; CC Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634; CC Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012; CC Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258; CC Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927; CC Q13882; P00533: EGFR; NbExp=2; IntAct=EBI-1383632, EBI-297353; CC Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062; CC Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824; CC Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823; CC Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684; CC Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572; CC Q13882; P42858: HTT; NbExp=4; IntAct=EBI-1383632, EBI-466029; CC Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204; CC Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808; CC Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326; CC Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503; CC Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850; CC Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269; CC Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487; CC Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265; CC Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284; CC Q13882; Q13882: PTK6; NbExp=3; IntAct=EBI-1383632, EBI-1383632; CC Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352; CC Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453; CC Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587; CC Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615; CC Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle. CC Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or CC KHDRBS3, within the nucleus. Nuclear localization in epithelial cells CC of normal prostate but cytoplasmic localization in cancer prostate. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13882-1; Sequence=Displayed; CC Name=2; Synonyms=ALT-PTK6, LambdaM5; CC IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067; CC -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and CC high levels in small intestine and prostate, and low levels in some CC fetal tissues. Not expressed in breast or ovarian tissue but expressed CC in high percentage of breast and ovarian cancers. Also overexpressed in CC some metastatic melanomas, lymphomas, colon cancers, squamous cell CC carcinomas and prostate cancers. Also found in melanocytes. Not CC expressed in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas. Isoform 2 is present in prostate epithelial cell CC lines derived from normal prostate and prostate adenocarcinomas, as CC well as in a variety of cell lines. {ECO:0000269|PubMed:12833144, CC ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629, CC ECO:0000269|PubMed:9185712}. CC -!- DOMAIN: The SH3 domain plays a major role in substrate interactions. CC The SH2 domain of PTK6 plays a role in protein-protein interactions, CC but is likely more important for the regulation of catalytic activity. CC -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an CC increase of kinase activity. Tyr-447 binds to the SH2 domain when CC phosphorylated and negatively regulates kinase activity. CC {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988, CC ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}. CC -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket. CC {ECO:0000269|PubMed:27993680}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X78549; CAA55295.1; -; mRNA. DR EMBL; U61412; AAC34935.1; -; Genomic_DNA. DR EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; AK315232; BAG37660.1; -; mRNA. DR EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA. DR EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC035843; AAH35843.1; -; mRNA. DR CCDS; CCDS13524.1; -. [Q13882-1] DR CCDS; CCDS74750.1; -. [Q13882-2] DR PIR; S49016; S49016. DR RefSeq; NP_001243287.1; NM_001256358.2. [Q13882-2] DR RefSeq; NP_005966.1; NM_005975.4. [Q13882-1] DR PDB; 1RJA; NMR; -; A=75-174. DR PDB; 2KGT; NMR; -; A=1-72. DR PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446. DR PDB; 5DA3; X-ray; 1.70 A; A=185-446. DR PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446. DR PDB; 6CZ2; X-ray; 2.50 A; A=182-443. DR PDB; 6CZ3; X-ray; 1.80 A; A=182-443. DR PDB; 6CZ4; X-ray; 1.50 A; A=182-443. DR PDB; 8S1C; X-ray; 1.75 A; A/B=11-72. DR PDBsum; 1RJA; -. DR PDBsum; 2KGT; -. DR PDBsum; 5D7V; -. DR PDBsum; 5DA3; -. DR PDBsum; 5H2U; -. DR PDBsum; 6CZ2; -. DR PDBsum; 6CZ3; -. DR PDBsum; 6CZ4; -. DR PDBsum; 8S1C; -. DR AlphaFoldDB; Q13882; -. DR BMRB; Q13882; -. DR SMR; Q13882; -. DR BioGRID; 111720; 103. DR DIP; DIP-39785N; -. DR FunCoup; Q13882; 312. DR IntAct; Q13882; 83. DR MINT; Q13882; -. DR STRING; 9606.ENSP00000442460; -. DR BindingDB; Q13882; -. DR ChEMBL; CHEMBL4601; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q13882; -. DR GuidetoPHARMACOLOGY; 2182; -. DR GlyGen; Q13882; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13882; -. DR PhosphoSitePlus; Q13882; -. DR BioMuta; PTK6; -. DR DMDM; 8928302; -. DR CPTAC; CPTAC-2842; -. DR CPTAC; CPTAC-2880; -. DR jPOST; Q13882; -. DR MassIVE; Q13882; -. DR PaxDb; 9606-ENSP00000442460; -. DR PeptideAtlas; Q13882; -. DR ProteomicsDB; 59709; -. [Q13882-1] DR ProteomicsDB; 59710; -. [Q13882-2] DR Antibodypedia; 29774; 545 antibodies from 39 providers. DR DNASU; 5753; -. DR Ensembl; ENST00000217185.3; ENSP00000217185.3; ENSG00000101213.8. [Q13882-2] DR Ensembl; ENST00000542869.3; ENSP00000442460.2; ENSG00000101213.8. [Q13882-1] DR GeneID; 5753; -. DR KEGG; hsa:5753; -. DR MANE-Select; ENST00000542869.3; ENSP00000442460.2; NM_005975.4; NP_005966.1. DR UCSC; uc002yfg.5; human. [Q13882-1] DR AGR; HGNC:9617; -. DR ClinPGx; PA33960; -. DR CTD; 5753; -. DR DisGeNET; 5753; -. DR GeneCards; PTK6; -. DR HGNC; HGNC:9617; PTK6. DR HPA; ENSG00000101213; Tissue enhanced (esophagus, skin, vagina). DR MIM; 602004; gene. DR OpenTargets; ENSG00000101213; -. DR VEuPathDB; HostDB:ENSG00000101213; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161218; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q13882; -. DR OMA; LWKGQVR; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q13882; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q13882; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13882; -. DR Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8849472; PTK6 Down-Regulation. DR Reactome; R-HSA-8849473; PTK6 Expression. DR Reactome; R-HSA-8849474; PTK6 Activates STAT3. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-9707564; Cytoprotection by HMOX1. DR SABIO-RK; Q13882; -. DR SignaLink; Q13882; -. DR SIGNOR; Q13882; -. DR Agora; ENSG00000101213; -. DR BioGRID-ORCS; 5753; 17 hits in 1179 CRISPR screens. DR EvolutionaryTrace; Q13882; -. DR GeneWiki; PTK6; -. DR GenomeRNAi; 5753; -. DR Pharos; Q13882; Tchem. DR PRO; PR:Q13882; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13882; protein. DR Bgee; ENSG00000101213; Expressed in esophagus squamous epithelium and 125 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0001726; C:ruffle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome. DR GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl. DR GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome. DR GO; GO:0045740; P:positive regulation of DNA replication; TAS:Reactome. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; TAS:Reactome. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB. DR CDD; cd05148; PTKc_Srm_Brk; 1. DR CDD; cd10358; SH2_PTK6_Brk; 1. DR CDD; cd11847; SH3_Brk; 1. DR FunFam; 1.10.510.10:FF:000399; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000229; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000074; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR035846; PTK6_SH2. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase. FT CHAIN 1..451 FT /note="Protein-tyrosine kinase 6" FT /id="PRO_0000088133" FT DOMAIN 8..72 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 78..170 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 191..445 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 171..190 FT /note="Linker" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 197..205 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 219 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680" FT MOD_RES 13 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 61 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 66 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 114 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0007744|PubMed:18691976" FT MOD_RES 342 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 351 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 447 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:10913193" FT VAR_SEQ 78..134 FT /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI FT WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR FT ALPEARA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042066" FT VAR_SEQ 135..451 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042067" FT VARIANT 16 FT /note="L -> F (in a renal papillary sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041760" FT VARIANT 436 FT /note="A -> T (in dbSNP:rs56145017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041761" FT MUTAGEN 44 FT /note="W->A: Strong decrease in STAP2 phosphorylation. FT Markedly decreased interaction between SH3 domain the FT linker region." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:17822667" FT MUTAGEN 66 FT /note="Y->A: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 105 FT /note="R->A: Abolishes interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:20554524" FT MUTAGEN 105 FT /note="R->L: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 184 FT /note="W->A: Abrogates interaction between PTK6-domain FT kinase and PTK6-linker. Abrogates autophosphorylation and FT phosphorylation of KHDRBS1." FT /evidence="ECO:0000269|PubMed:15961400" FT MUTAGEN 219 FT /note="K->M: Abolishes kinase activity and cell FT transformation, and phosphorylation of STAP2. Reduces FT interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20554524, FT ECO:0000269|PubMed:8940083" FT MUTAGEN 219 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:27480927" FT MUTAGEN 342 FT /note="Y->A: 3-fold lower specific kinase activity. FT Decreased, but still significant, autophosphorylation. FT Decreased, but still significant, autophosphorylation; when FT associated with A-447." FT /evidence="ECO:0000269|PubMed:12121988" FT MUTAGEN 447 FT /note="Y->F: Decrease in transforming potential and FT increase in the kinase activity level. Decreased, but still FT significant, autophosphorylation; when associated with A- FT 342." FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 45..50 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2KGT" FT TURN 64..66 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 67..70 FT /evidence="ECO:0007829|PDB:2KGT" FT HELIX 85..92 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 102..106 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 114..118 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 125..131 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 137..140 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 143..147 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 148..157 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 162..164 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 188..190 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 191..200 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 214..221 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 229..240 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 256..264 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:6CZ2" FT HELIX 272..278 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:5DA3" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 339..342 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 356..361 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 366..380 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 381..384 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 434..441 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 442..444 FT /evidence="ECO:0007829|PDB:5D7V" SQ SEQUENCE 451 AA; 51834 MW; CDCAC0EE242E1BD7 CRC64; MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM LTCWCRDPEQ RPCFKALRER LSSFTSYENP T // ID RABL3_HUMAN Reviewed; 236 AA. AC Q5HYI8; Q8WUD3; DT 04-DEC-2007, integrated into UniProtKB/Swiss-Prot. DT 15-FEB-2005, sequence version 1. DT 28-JAN-2026, entry version 169. DE RecName: Full=Rab-like protein 3; DE EC=3.6.5.2 {ECO:0000250|UniProtKB:Q9D4V7}; GN Name=RABL3 {ECO:0000312|HGNC:HGNC:18072}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Bone marrow, Fetal skin, and Heart; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [8] RP FUNCTION, INTERACTION WITH RAB11, MUTAGENESIS OF SER-20, AND SUBCELLULAR RP LOCATION. RX PubMed=36052645; DOI=10.1242/jcs.260021; RA Kobayashi T., Ikeda T., Ota R., Yasukawa T., Itoh H.; RT "The atypical small GTPase RABL3 interacts with RAB11 to regulate early RT ciliogenesis in human cells."; RL J. Cell Sci. 135:0-0(2022). RN [9] RP FUNCTION, INTERACTION WITH RAP1GDS1, INVOLVEMENT IN PNCA5, VARIANTS PNCA5 RP 36-SER--ASP-236 DEL AND GLN-184, AND CHARACTERIZATION OF VARIANT PNCA5 RP 36-SER--ASP-236 DEL. RX PubMed=31406347; DOI=10.1038/s41588-019-0475-y; RA Nissim S., Leshchiner I., Mancias J.D., Greenblatt M.B., Maertens O., RA Cassa C.A., Rosenfeld J.A., Cox A.G., Hedgepeth J., Wucherpfennig J.I., RA Kim A.J., Henderson J.E., Gonyo P., Brandt A., Lorimer E., Unger B., RA Prokop J.W., Heidel J.R., Wang X.X., Ukaegbu C.I., Jennings B.C., RA Paulo J.A., Gableske S., Fierke C.A., Getz G., Sunyaev S.R., RA Wade Harper J., Cichowski K., Kimmelman A.C., Houvras Y., Syngal S., RA Williams C., Goessling W.; RT "Mutations in RABL3 alter KRAS prenylation and are associated with RT hereditary pancreatic cancer."; RL Nat. Genet. 51:1308-1314(2019). CC -!- FUNCTION: Small GTPase required for KRAS signaling regulation and CC modulation of cell proliferation (PubMed:31406347). Regulator of KRAS CC prenylation, and probably prenylation of other small GTPases CC (PubMed:31406347). Required for lymphocyte development and function (By CC similarity). Not required for myeloid cell development (By similarity). CC Interacts with Rab11 to promote ciliary vesicle formation at the mother CC centriole, thereby regulating early ciliogenesis. The GTP-binding CC capacity of RABL3 is essential for ciliogenesis (PubMed:36052645). CC {ECO:0000250|UniProtKB:Q9D4V7, ECO:0000269|PubMed:31406347, CC ECO:0000269|PubMed:36052645}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000250|UniProtKB:P62493}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670; CC Evidence={ECO:0000250|UniProtKB:P62493}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9D4V7}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with GPR89; the CC interaction stabilizes GPR89 (By similarity). Interacts with RAP1GDS1 CC (PubMed:31406347). Interacts (GDP-bound) with RAB11A (GTP-bound); the CC interaction stabilizes RABL3 and regulates ciliary vesicle formation CC during early ciliogenesis (PubMed:36052645). CC {ECO:0000250|UniProtKB:Q9D4V7, ECO:0000269|PubMed:31406347, CC ECO:0000269|PubMed:36052645}. CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:36052645}. Golgi apparatus CC {ECO:0000269|PubMed:36052645}. Note=Accumulates around the centrosome CC during early ciliogenesis. {ECO:0000269|PubMed:36052645}. CC -!- DOMAIN: Switch I, switch II and the interswitch regions are CC characteristic of Rab GTPases and mediate the interactions with Rab CC downstream effectors. The switch regions undergo conformational changes CC upon nucleotide binding which drive interaction with specific sets of CC effector proteins, with most effectors only binding to GTP-bound Rab. CC {ECO:0000250|UniProtKB:P62820}. CC -!- DISEASE: Pancreatic cancer 5 (PNCA5) [MIM:618680]: A malignant neoplasm CC of the pancreas. Tumors can arise from both the exocrine and endocrine CC portions of the pancreas, but 95% of them develop from the exocrine CC portion, including the ductal epithelium, acinar cells, connective CC tissue, and lymphatic tissue. {ECO:0000269|PubMed:31406347}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. RABL3 variants have been found in CC families with a history of pancreatic ductal adenocarcinoma and CC multiple other occurrences of cancer, including melanoma, breast CC cancer, prostate cancer, and colon cancer. CC {ECO:0000269|PubMed:31406347}. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Rab family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK293085; BAF85774.1; -; mRNA. DR EMBL; BX647664; CAI46059.1; -; mRNA. DR EMBL; BX647593; CAI46064.1; -; mRNA. DR EMBL; BX647559; CAI46095.1; -; mRNA. DR EMBL; CH471052; EAW79521.1; -; Genomic_DNA. DR EMBL; BC020832; AAH20832.1; -; mRNA. DR CCDS; CCDS3001.1; -. DR RefSeq; NP_776186.2; NM_173825.5. DR AlphaFoldDB; Q5HYI8; -. DR SMR; Q5HYI8; -. DR BioGRID; 130066; 248. DR FunCoup; Q5HYI8; 2126. DR IntAct; Q5HYI8; 118. DR MINT; Q5HYI8; -. DR STRING; 9606.ENSP00000273375; -. DR ChEMBL; CHEMBL4105853; -. DR DrugCentral; Q5HYI8; -. DR iPTMnet; Q5HYI8; -. DR PhosphoSitePlus; Q5HYI8; -. DR SwissPalm; Q5HYI8; -. DR BioMuta; RABL3; -. DR DMDM; 74762186; -. DR jPOST; Q5HYI8; -. DR MassIVE; Q5HYI8; -. DR PaxDb; 9606-ENSP00000273375; -. DR PeptideAtlas; Q5HYI8; -. DR ProteomicsDB; 62938; -. DR Pumba; Q5HYI8; -. DR TopDownProteomics; Q5HYI8; -. DR Antibodypedia; 32810; 46 antibodies from 20 providers. DR DNASU; 285282; -. DR Ensembl; ENST00000273375.8; ENSP00000273375.4; ENSG00000144840.11. DR GeneID; 285282; -. DR KEGG; hsa:285282; -. DR MANE-Select; ENST00000273375.8; ENSP00000273375.4; NM_173825.5; NP_776186.2. DR UCSC; uc003edx.3; human. DR AGR; HGNC:18072; -. DR ClinPGx; PA34161; -. DR CTD; 285282; -. DR DisGeNET; 285282; -. DR GeneCards; RABL3; -. DR HGNC; HGNC:18072; RABL3. DR HPA; ENSG00000144840; Low tissue specificity. DR MalaCards; RABL3; -. DR MIM; 618542; gene. DR MIM; 618680; phenotype. DR OpenTargets; ENSG00000144840; -. DR Orphanet; 1333; Familial pancreatic carcinoma. DR VEuPathDB; HostDB:ENSG00000144840; -. DR eggNOG; ENOG502QT3S; Eukaryota. DR GeneTree; ENSGT00390000007467; -. DR HOGENOM; CLU_084875_1_0_1; -. DR InParanoid; Q5HYI8; -. DR OMA; HIRFDME; -. DR OrthoDB; 5914890at2759; -. DR PAN-GO; Q5HYI8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q5HYI8; -. DR PathwayCommons; Q5HYI8; -. DR SignaLink; Q5HYI8; -. DR Agora; ENSG00000144840; -. DR BioGRID-ORCS; 285282; 34 hits in 1157 CRISPR screens. DR GenomeRNAi; 285282; -. DR Pharos; Q5HYI8; Tbio. DR PRO; PR:Q5HYI8; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q5HYI8; protein. DR Bgee; ENSG00000144840; Expressed in adrenal tissue and 198 other cell types or tissues. DR ExpressionAtlas; Q5HYI8; baseline and differential. DR GO; GO:0012505; C:endomembrane system; IBA:GO_Central. DR GO; GO:0003925; F:G protein activity; IMP:UniProtKB. DR GO; GO:0005525; F:GTP binding; ISS:UniProtKB. DR GO; GO:0003924; F:GTPase activity; IBA:GO_Central. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB. DR GO; GO:0006886; P:intracellular protein transport; IBA:GO_Central. DR GO; GO:0001779; P:natural killer cell differentiation; ISS:UniProtKB. DR GO; GO:0045724; P:positive regulation of cilium assembly; IMP:UniProtKB. DR GO; GO:0050821; P:protein stabilization; ISS:UniProtKB. DR GO; GO:1903059; P:regulation of protein lipidation; IMP:UniProtKB. DR GO; GO:0046578; P:regulation of Ras protein signal transduction; IMP:UniProtKB. DR GO; GO:0033077; P:T cell differentiation in thymus; ISS:UniProtKB. DR CDD; cd04102; RabL3; 1. DR FunFam; 3.40.50.300:FF:000525; rab-like protein 3 isoform X1; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR24073; DRAB5-RELATED; 1. DR Pfam; PF08477; Roc; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51419; RAB; 1. PE 1: Evidence at protein level; KW Cytoplasm; Cytoskeleton; Disease variant; Golgi apparatus; GTP-binding; KW Hydrolase; Magnesium; Metal-binding; Nucleotide-binding; KW Proteomics identification; Reference proteome. FT CHAIN 1..236 FT /note="Rab-like protein 3" FT /id="PRO_0000312166" FT REGION 1..236 FT /note="Small GTPase-like" FT REGION 33..41 FT /note="Switch-I" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00753" FT REGION 69..89 FT /note="Switch-II" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00753" FT BINDING 15 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 16 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 19 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 20 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 20 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 21 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 38 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 38 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 66 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 148 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 150 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 179 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 180 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT VARIANT 36..236 FT /note="Missing (in PNCA5; associated with disease FT susceptibility; increased KRAS signaling and cell FT proliferation; increased interaction with RAP1GDS1; FT increased KRAS prenylation)" FT /evidence="ECO:0000269|PubMed:31406347" FT /id="VAR_083453" FT VARIANT 184 FT /note="R -> Q (in PNCA5; associated with disease FT susceptibility; dbSNP:rs61756477)" FT /evidence="ECO:0000269|PubMed:31406347" FT /id="VAR_083454" FT MUTAGEN 20 FT /note="S->N: Dominant-negative mutant (GDP-bound form). FT Increased interaction with GTP-bound RAB11A. Increased FT recruitment to the centrosome. Impaired positive regulation FT of ciliary vesicle formation." FT /evidence="ECO:0000269|PubMed:36052645" FT CONFLICT 60 FT /note="Y -> C (in Ref. 4; AAH20832)" FT /evidence="ECO:0000305" FT CONFLICT 163 FT /note="R -> T (in Ref. 4; AAH20832)" FT /evidence="ECO:0000305" SQ SEQUENCE 236 AA; 26423 MW; B80898B1293C88C6 CRC64; MASLDRVKVL VLGDSGVGKS SLVHLLCQNQ VLGNPSWTVG CSVDVRVHDY KEGTPEEKTY YIELWDVGGS VGSASSVKST RAVFYNSVNG IIFVHDLTNK KSSQNLRRWS LEALNRDLVP TGVLVTNGDY DQEQFADNQI PLLVIGTKLD QIHETKRHEV LTRTAFLAED FNPEEINLDC TNPRYLAAGS SNAVKLSRFF DKVIEKRYFL REGNQIPGFP DRKRFGAGTL KSLHYD // ID RASH_HUMAN Reviewed; 189 AA. AC P01112; B5BUA0; Q14080; Q6FHV9; Q9BR65; Q9UCE2; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 279. DE RecName: Full=GTPase HRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:9020151}; DE AltName: Full=H-Ras-1; DE AltName: Full=Ha-Ras; DE AltName: Full=Transforming protein p21; DE AltName: Full=c-H-ras; DE AltName: Full=p21ras; DE Contains: DE RecName: Full=GTPase HRas, N-terminally processed; DE Flags: Precursor; GN Name=HRAS; Synonyms=HRAS1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN BLADDER CANCER. RX PubMed=6298635; DOI=10.1038/302033a0; RA Capon D.J., Chen E.Y., Levinson A.D., Seeburg P.H., Goeddel D.V.; RT "Complete nucleotide sequences of the T24 human bladder carcinoma oncogene RT and its normal homologue."; RL Nature 302:33-37(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN BLADDER CANCER. RX PubMed=6844927; DOI=10.1126/science.6844927; RA Reddy E.P.; RT "Nucleotide sequence analysis of the T24 human bladder carcinoma RT oncogene."; RL Science 220:1061-1063(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=6087347; DOI=10.1073/pnas.81.15.4771; RA Sekiya T., Fushimi M., Hori H., Hirohashi S., Nishimura S., Sugimura T.; RT "Molecular cloning and the total nucleotide sequence of the human c-Ha-ras- RT 1 gene activated in a melanoma from a Japanese patient."; RL Proc. Natl. Acad. Sci. U.S.A. 81:4771-4775(1984). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INTERACTION WITH RACK1, RP SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND RP MUTAGENESIS OF SER-17. RX PubMed=14500341; RA Guil S., de La Iglesia N., Fernandez-Larrea J., Cifuentes D., Ferrer J.C., RA Guinovart J.J., Bach-Elias M.; RT "Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras RT family protein that trafficks to cytoplasm and nucleus."; RL Cancer Res. 63:5178-5187(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP PROTEIN SEQUENCE OF 1-41; 43-117; 129-161 AND 170-185, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY RP MASS SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=6290897; DOI=10.1038/300143a0; RA Tabin C.J., Bradley S.M., Bargmann C.I., Weinberg R.A., Papageorge A.G., RA Scolnick E.M., Dhar R., Lowy D.R., Chang E.H.; RT "Mechanism of activation of a human oncogene."; RL Nature 300:143-149(1982). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=3670300; DOI=10.1128/mcb.7.8.2933-2940.1987; RA Honkawa H., Masahashi W., Hashimoto S., Hashimoto-Gotoh T.; RT "Identification of the principal promoter sequence of the c-H-ras RT transforming oncogene: deletion analysis of the 5'-flanking region by focus RT formation assay."; RL Mol. Cell. Biol. 7:2933-2940(1987). RN [15] RP PROTEIN SEQUENCE OF 108-117 AND 132-153. RX PubMed=8393791; DOI=10.1111/j.1432-1033.1993.tb18056.x; RA Loew A., Sprinzl M., Faulhammer H.G.; RT "Affinity labeling of c-H-ras p21 consensus elements with periodate- RT oxidized GDP and GTP."; RL Eur. J. Biochem. 215:473-479(1993). RN [16] RP MUTAGENESIS OF ALA-83; ASP-119 AND THR-144. RX PubMed=3088563; DOI=10.1073/pnas.83.13.4607; RA Feig L.A., Pan B.-T., Roberts T.M., Cooper G.M.; RT "Isolation of ras GTP-binding mutants using an in situ colony-binding RT assay."; RL Proc. Natl. Acad. Sci. U.S.A. 83:4607-4611(1986). RN [17] RP MUTAGENESIS OF 164-ARG-GLN-165. RX PubMed=3011420; DOI=10.1002/j.1460-2075.1986.tb04267.x; RA Lacal J.C., Anderson P.S., Aaronson S.A.; RT "Deletion mutants of Harvey ras p21 protein reveal the absolute requirement RT of at least two distant regions for GTP-binding and transforming RT activities."; RL EMBO J. 5:679-687(1986). RN [18] RP PALMITOYLATION AT CYS-181 AND CYS-184. RX PubMed=2661017; DOI=10.1016/0092-8674(89)90054-8; RA Hancock J.F., Magee A.I., Childs J.E., Marshall C.J.; RT "All ras proteins are polyisoprenylated but only some are palmitoylated."; RL Cell 57:1167-1177(1989). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=8626586; DOI=10.1074/jbc.271.17.10217; RA Popoff M.R., Chaves-Olarte E., Lemichez E., von Eichel-Streiber C., RA Thelestam M., Chardin P., Cussac D., Antonny B., Chavrier P., Flatau G., RA Giry M., de Gunzburg J., Boquet P.; RT "Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium RT sordellii lethal toxin glucosylation."; RL J. Biol. Chem. 271:10217-10224(1996). RN [20] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=8626575; DOI=10.1074/jbc.271.17.10149; RA Just I., Selzer J., Hofmann F., Green G.A., Aktories K.; RT "Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed RT glucosylation."; RL J. Biol. Chem. 271:10149-10153(1996). RN [21] RP PALMITOYLATION AT CYS-181 AND CYS-184, ISOPRENYLATION AT CYS-186, RP METHYLATION AT CYS-186, AND MUTAGENESIS OF CYS-181 AND CYS-184. RX PubMed=8626715; DOI=10.1074/jbc.271.19.11541; RA Dudler T., Gelb M.H.; RT "Palmitoylation of Ha-Ras facilitates membrane binding, activation of RT downstream effectors, and meiotic maturation in Xenopus oocytes."; RL J. Biol. Chem. 271:11541-11547(1996). RN [22] RP S-NITROSYLATION AT CYS-118, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS RP OF CYS-118. RX PubMed=9020151; DOI=10.1074/jbc.272.7.4323; RA Lander H.M., Hajjar D.P., Hempstead B.L., Mirza U.A., Chait B.T., RA Campbell S., Quilliam L.A.; RT "A molecular redox switch on p21(ras). Structural basis for the nitric RT oxide-p21(ras) interaction."; RL J. Biol. Chem. 272:4323-4326(1997). RN [23] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=9632667; DOI=10.1074/jbc.273.26.16134; RA Herrmann C., Ahmadian M.R., Hofmann F., Just I.; RT "Functional consequences of monoglucosylation of Ha-Ras at effector domain RT amino acid threonine 35."; RL J. Biol. Chem. 273:16134-16139(1998). RN [24] RP INTERACTION WITH IKZF3. RX PubMed=10369681; DOI=10.1093/emboj/18.12.3419; RA Romero F., Martinez-A C., Camonis J., Rebollo A.; RT "Aiolos transcription factor controls cell death in T cells by regulating RT Bcl-2 expression and its cellular localization."; RL EMBO J. 18:3419-3430(1999). RN [25] RP INTERACTION WITH RAPGEF2. RX PubMed=10608844; DOI=10.1074/jbc.274.53.37815; RA Liao Y., Kariya K., Hu C.-D., Shibatohge M., Goshima M., Okada T., RA Watari Y., Gao X., Jin T.-G., Yamawaki-Kataoka Y., Kataoka T.; RT "RA-GEF, a novel Rap1A guanine nucleotide exchange factor containing a RT Ras/Rap1A-associating domain, is conserved between nematode and humans."; RL J. Biol. Chem. 274:37815-37820(1999). RN [26] RP INTERACTION WITH PLCE1, CHARACTERIZATION OF VARIANT VAL-12, AND MUTAGENESIS RP OF SER-17; ASN-26; VAL-29; TYR-32; PRO-34; THR-35; GLU-37; ASP-38 AND RP SER-39. RX PubMed=11022048; DOI=10.1074/jbc.m008324200; RA Song C., Hu C.-D., Masago M., Kariya K., Yamawaki-Kataoka Y., RA Shibatohge M., Wu D., Satoh T., Kataoka T.; RT "Regulation of a novel human phospholipase C, PLCepsilon, through membrane RT targeting by Ras."; RL J. Biol. Chem. 276:2752-2757(2001). RN [27] RP INTERACTION WITH RAPGEF2. RX PubMed=11598133; DOI=10.1074/jbc.m108373200; RA Pham N., Rotin D.; RT "Nedd4 regulates ubiquitination and stability of the guanine-nucleotide RT exchange factor CNrasGEF."; RL J. Biol. Chem. 276:46995-47003(2001). RN [28] RP IDENTIFICATION IN A COMPLEX WITH RASGRP1 AND DGKZ. RX PubMed=11257115; DOI=10.1083/jcb.152.6.1135; RA Topham M.K., Prescott S.M.; RT "Diacylglycerol kinase zeta regulates Ras activation by a novel RT mechanism."; RL J. Cell Biol. 152:1135-1143(2001). RN [29] RP INTERACTION WITH PDE6D. RX PubMed=11980706; DOI=10.1093/emboj/21.9.2095; RA Hanzal-Bayer M., Renault L., Roversi P., Wittinghofer A., Hillig R.C.; RT "The complex of Arl2-GTP and PDE delta: from structure to function."; RL EMBO J. 21:2095-2106(2002). RN [30] RP LIPIDATION AT CYS-184, AND MUTAGENESIS OF CYS-184. RX PubMed=12684535; DOI=10.1073/pnas.0735842100; RA Oliva J.L., Perez-Sala D., Castrillo A., Martinez N., Canada F.J., RA Bosca L., Rojas J.M.; RT "The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and RT activates H-Ras."; RL Proc. Natl. Acad. Sci. U.S.A. 100:4772-4777(2003). RN [31] RP FUNCTION, VARIANT CYS-89, AND CHARACTERIZATION OF VARIANT CYS-89. RX PubMed=22821884; DOI=10.1002/ajmg.a.35449; RA Gripp K.W., Bifeld E., Stabley D.L., Hopkins E., Meien S., Vinette K., RA Sol-Church K., Rosenberger G.; RT "A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased RT downstream signaling suggests a new dimension of RAS pathway dysregulation RT in human development."; RL Am. J. Med. Genet. A 158A:2106-2118(2012). RN [32] RP CHARACTERIZATION OF CSTLO VARIANT VAL-12. RX PubMed=15546861; DOI=10.1074/jbc.m410775200; RA Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.; RT "Dephosphorylation of tau by protein phosphatase 5: impairment in RT Alzheimer's disease."; RL J. Biol. Chem. 280:1790-1796(2005). RN [33] RP PALMITOYLATION AT CYS-181 AND CYS-184. RX PubMed=16000296; DOI=10.1074/jbc.m504113200; RA Swarthout J.T., Lobo S., Farh L., Croke M.R., Greentree W.K., RA Deschenes R.J., Linder M.E.; RT "DHHC9 and GCP16 constitute a human protein fatty acyltransferase with RT specificity for H- and N-Ras."; RL J. Biol. Chem. 280:31141-31148(2005). RN [34] RP PALMITOYLATION AT CYS-181 AND CYS-184, MUTAGENESIS OF CYS-181 AND CYS-184, RP AND SUBCELLULAR LOCATION. RX PubMed=15705808; DOI=10.1126/science.1105654; RA Rocks O., Peyker A., Kahms M., Verveer P.J., Koerner C., Lumbierres M., RA Kuhlmann J., Waldmann H., Wittinghofer A., Bastiaens P.I.H.; RT "An acylation cycle regulates localization and activity of palmitoylated RT Ras isoforms."; RL Science 307:1746-1752(2005). RN [35] RP INTERACTION WITH TBC1D10C. RX PubMed=17230191; DOI=10.1038/nature05476; RA Pan F., Sun L., Kardian D.B., Whartenby K.A., Pardoll D.M., Liu J.O.; RT "Feedback inhibition of calcineurin and Ras by a dual inhibitory protein RT Carabin."; RL Nature 445:433-436(2007). RN [36] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [37] RP ACYLATION, AND MUTAGENESIS OF 167-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [38] RP UBIQUITINATION AT LYS-170, AND MUTAGENESIS OF LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [39] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [40] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [41] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND MUTAGENESIS OF RP GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS). RX PubMed=2448879; DOI=10.1126/science.2448879; RA de Vos A.M., Tong L., Milburn M.V., Matias P.M., Jancarik J., Noguchi S., RA Nishimura S., Miura K., Ohtsuka E., Kim S.-H.; RT "Three-dimensional structure of an oncogene protein: catalytic domain of RT human c-H-ras p21."; RL Science 239:888-893(1988). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS). RX PubMed=2476675; DOI=10.1038/341209a0; RA Pai E.F., Kabsch W., Krengel U., Holmes K.C., John J., Wittinghofer A.; RT "Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene RT product p21 in the triphosphate conformation."; RL Nature 341:209-214(1989). RN [44] {ECO:0007744|PDB:5P21} RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS). RX PubMed=2196171; DOI=10.1002/j.1460-2075.1990.tb07409.x; RA Pai E.F., Krengel U., Petsko G.A., Goody R.S., Kabsch W., Wittinghofer A.; RT "Refined crystal structure of the triphosphate conformation of H-ras p21 at RT 1.35-A resolution: implications for the mechanism of GTP hydrolysis."; RL EMBO J. 9:2351-2359(1990). RN [45] {ECO:0007744|PDB:1Q21, ECO:0007744|PDB:2Q21} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS). RX PubMed=1899707; DOI=10.1016/0022-2836(91)90753-s; RA Tong L.A., de Vos A.M., Milburn M.V., Kim S.H.; RT "Crystal structures at 2.2-A resolution of the catalytic domains of normal RT ras protein and an oncogenic mutant complexed with GDP."; RL J. Mol. Biol. 217:503-516(1991). RN [46] {ECO:0007744|PDB:121P} RP STRUCTURE BY NMR OF 1-166. RX PubMed=8142349; DOI=10.1021/bi00178a008; RA Kraulis P.J., Domaille P.J., Campbell-Burk S.L., van Aken T., Laue E.D.; RT "Solution structure and dynamics of ras p21.GDP determined by heteronuclear RT three- and four-dimensional NMR spectroscopy."; RL Biochemistry 33:3515-3531(1994). RN [47] {ECO:0007744|PDB:1WQ1} RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-166 IN COMPLEX WITH RP RASA1/RASGAP. RX PubMed=9219684; DOI=10.1126/science.277.5324.333; RA Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmuller L., Lautwein A., RA Schmitz F., Wittinghofer A.; RT "The Ras-RasGAP complex: structural basis for GTPase activation and its RT loss in oncogenic Ras mutants."; RL Science 277:333-338(1997). RN [48] {ECO:0007744|PDB:1CTQ, ECO:0007744|PDB:1QRA} RP X-RAY CRYSTALLOGRAPHY (1.26 ANGSTROMS). RX PubMed=10574788; DOI=10.1016/s0969-2126(00)80021-0; RA Scheidig A.J., Burmester C., Goody R.S.; RT "The pre-hydrolysis state of p21(ras) in complex with GTP: new insights RT into the role of water molecules in the GTP hydrolysis reaction of ras-like RT proteins."; RL Structure 7:1311-1324(1999). RN [49] {ECO:0007744|PDB:1LF0, ECO:0007744|PDB:1LF5} RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP RP ANALOGS. RX PubMed=12213964; DOI=10.1073/pnas.192453199; RA Hall B.E., Bar-Sagi D., Nassar N.; RT "The structural basis for the transition from Ras-GTP to Ras-GDP."; RL Proc. Natl. Acad. Sci. U.S.A. 99:12138-12142(2002). RN [50] RP STRUCTURE BY NMR OF 1-166, S-NITROSYLATION, FUNCTION, MUTAGENESIS OF RP CYS-118, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12740440; DOI=10.1073/pnas.1037299100; RA Williams J.G., Pappu K., Campbell S.L.; RT "Structural and biochemical studies of p21Ras S-nitrosylation and nitric RT oxide-mediated guanine nucleotide exchange."; RL Proc. Natl. Acad. Sci. U.S.A. 100:6376-6381(2003). RN [51] {ECO:0007744|PDB:2CE2, ECO:0007744|PDB:2CL0, ECO:0007744|PDB:2CL6, ECO:0007744|PDB:2CL7, ECO:0007744|PDB:2CLC, ECO:0007744|PDB:2CLD, ECO:0007744|PDB:2EVW} RP X-RAY CRYSTALLOGRAPHY (1.00 ANGSTROMS) OF 1-166 IN COMPLEX WITH GTP AND RP MAGNESIUM. RX PubMed=16698776; DOI=10.1529/biophysj.105.078931; RA Klink B.U., Goody R.S., Scheidig A.J.; RT "A newly designed microspectrofluorometer for kinetic studies on protein RT crystals in combination with x-ray diffraction."; RL Biophys. J. 91:981-992(2006). RN [52] {ECO:0007744|PDB:2RGA, ECO:0007744|PDB:2RGB, ECO:0007744|PDB:2RGC, ECO:0007744|PDB:2RGD, ECO:0007744|PDB:2RGE, ECO:0007744|PDB:2RGG} RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP RP ANALOG, CHARACTERIZATION OF VARIANTS LEU-61 AND LYS-61, AND MUTAGENESIS OF RP GLN-61. RX PubMed=18073111; DOI=10.1016/j.str.2007.10.011; RA Buhrman G., Wink G., Mattos C.; RT "Transformation efficiency of RasQ61 mutants linked to structural features RT of the switch regions in the presence of Raf."; RL Structure 15:1618-1629(2007). RN [53] {ECO:0007744|PDB:3DDC} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-166 IN COMPLEX WITH RASSF5. RX PubMed=18596699; DOI=10.1038/emboj.2008.125; RA Stieglitz B., Bee C., Schwarz D., Yildiz O., Moshnikova A., RA Khokhlatchev A., Herrmann C.; RT "Novel type of Ras effector interaction established between tumour RT suppressor NORE1A and Ras switch II."; RL EMBO J. 27:1995-2005(2008). RN [54] {ECO:0007744|PDB:7VV8, ECO:0007744|PDB:7VV9, ECO:0007744|PDB:7VVG} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1-166 IN COMPLEX WITH MAPKAP1, RP AND INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [55] RP VARIANT SER-12. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [56] RP INVOLVEMENT IN NMTC2, AND VARIANT NMTC2 LYS-61. RX PubMed=12727991; DOI=10.1210/jc.2002-021907; RA Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W. II, RA Tallini G., Kroll T.G., Nikiforov Y.E.; RT "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: RT evidence for distinct molecular pathways in thyroid follicular carcinoma."; RL J. Clin. Endocrinol. Metab. 88:2318-2326(2003). RN [57] RP VARIANTS CSTLO ALA-12; SER-12; VAL-12 AND ASP-13. RX PubMed=16170316; DOI=10.1038/ng1641; RA Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., RA Filocamo M., Kato K., Suzuki Y., Kure S., Matsubara Y.; RT "Germline mutations in HRAS proto-oncogene cause Costello syndrome."; RL Nat. Genet. 37:1038-1040(2005). RN [58] RP VARIANTS CSTLO ALA-12; SER-12 AND CYS-13. RX PubMed=16329078; DOI=10.1002/ajmg.a.31047; RA Gripp K.W., Lin A.E., Stabley D.L., Nicholson L., Scott C.I. Jr., Doyle D., RA Aoki Y., Matsubara Y., Zackai E.H., Lapunzina P., Gonzalez-Meneses A., RA Holbrook J., Agresta C.A., Gonzalez I.L., Sol-Church K.; RT "HRAS mutation analysis in Costello syndrome: genotype and phenotype RT correlation."; RL Am. J. Med. Genet. A 140:1-7(2006). RN [59] RP VARIANTS CSTLO SER-12; CYS-12; GLU-12; ALA-12 AND ARG-117. RX PubMed=16443854; DOI=10.1136/jmg.2005.040352; RA Kerr B., Delrue M.-A., Sigaudy S., Perveen R., Marche M., Burgelin I., RA Stef M., Tang B., Eden O.B., O'Sullivan J., De Sandre-Giovannoli A., RA Reardon W., Brewer C., Bennett C., Quarell O., M'Cann E., Donnai D., RA Stewart F., Hennekam R., Cave H., Verloes A., Philip N., Lacombe D., RA Levy N., Arveiler B., Black G.; RT "Genotype-phenotype correlation in Costello syndrome: HRAS mutation RT analysis in 43 cases."; RL J. Med. Genet. 43:401-405(2006). RN [60] RP VARIANTS CSTLO SER-12 AND THR-146. RX PubMed=17054105; DOI=10.1002/humu.20431; RA Zampino G., Pantaleoni F., Carta C., Cobellis G., Vasta I., Neri C., RA Pogna E.A., De Feo E., Delogu A., Sarkozy A., Atzeri F., Selicorni A., RA Rauen K.A., Cytrynbaum C.S., Weksberg R., Dallapiccola B., Ballabio A., RA Gelb B.D., Neri G., Tartaglia M.; RT "Diversity, parental germline origin, and phenotypic spectrum of de novo RT HRAS missense changes in Costello syndrome."; RL Hum. Mutat. 28:265-272(2007). RN [61] RP VARIANTS CMEMS VAL-12; SER-12; LYS-22 AND LYS-63. RX PubMed=17412879; DOI=10.1136/jmg.2007.049270; RA van der Burgt I., Kupsky W., Stassou S., Nadroo A., Barroso C., Diem A., RA Kratz C.P., Dvorsky R., Ahmadian M.R., Zenker M.; RT "Myopathy caused by HRAS germline mutations: implications for disturbed RT myogenic differentiation in the presence of constitutive HRas activation."; RL J. Med. Genet. 44:459-462(2007). RN [62] RP VARIANTS CSTLO ILE-58 AND VAL-146. RX PubMed=18247425; DOI=10.1002/ajmg.a.32227; RA Gripp K.W., Innes A.M., Axelrad M.E., Gillan T.L., Parboosingh J.S., RA Davies C., Leonard N.J., Lapointe M., Doyle D., Catalano S., Nicholson L., RA Stabley D.L., Sol-Church K.; RT "Costello syndrome associated with novel germline HRAS mutations: an RT attenuated phenotype?"; RL Am. J. Med. Genet. A 146:683-690(2008). RN [63] RP VARIANTS CSTLO ASP-12 AND CYS-12. RX PubMed=18039947; DOI=10.1136/jmg.2007.054411; RA Lo I.F., Brewer C., Shannon N., Shorto J., Tang B., Black G., Soo M.T., RA Ng D.K., Lam S.T., Kerr B.; RT "Severe neonatal manifestations of Costello syndrome."; RL J. Med. Genet. 45:167-171(2008). RN [64] RP VARIANT CSTLO GLU-37 INS. RX PubMed=19995790; DOI=10.1093/hmg/ddp548; RA Gremer L., De Luca A., Merbitz-Zahradnik T., Dallapiccola B., Morlot S., RA Tartaglia M., Kutsche K., Ahmadian M.R., Rosenberger G.; RT "Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP RT binding and underlies Costello syndrome by promoting enhanced growth RT factor-dependent MAPK and AKT activation."; RL Hum. Mol. Genet. 19:790-802(2010). RN [65] RP VARIANT SFM ARG-13, AND CHARACTERIZATION OF VARIANT SFM ARG-13. RX PubMed=22683711; DOI=10.1038/ng.2316; RA Groesser L., Herschberger E., Ruetten A., Ruivenkamp C., Lopriore E., RA Zutt M., Langmann T., Singer S., Klingseisen L., Schneider-Brachert W., RA Toll A., Real F.X., Landthaler M., Hafner C.; RT "Postzygotic HRAS and KRAS mutations cause nevus sebaceous and RT Schimmelpenning syndrome."; RL Nat. Genet. 44:783-787(2012). CC -!- FUNCTION: Involved in the activation of Ras protein signal transduction CC (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic CC GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151). CC {ECO:0000269|PubMed:12740440, ECO:0000269|PubMed:14500341, CC ECO:0000269|PubMed:22821884, ECO:0000269|PubMed:9020151}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:9020151}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP. Activated by a guanine nucleotide- CC exchange factor (GEF) and inactivated by a GTPase-activating protein CC (GAP). CC -!- SUBUNIT: In its GTP-bound form interacts with PLCE1 (PubMed:11022048). CC Interacts with TBC1D10C (PubMed:17230191). Interacts with RGL3 (By CC similarity). Interacts with HSPD1 (By similarity). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14 (By similarity). CC Interacts (active GTP-bound form) with RGS14 (via RBD 1 domain) (By CC similarity). Forms a signaling complex with RASGRP1 and DGKZ CC (PubMed:11257115). Interacts with RASSF5 (PubMed:18596699). Interacts CC with PDE6D (PubMed:11980706). Interacts with IKZF3 (PubMed:10369681). CC Interacts with RACK1 (PubMed:14500341). Interacts with PIK3CG; the CC interaction is required for membrane recruitment and beta-gamma G CC protein dimer-dependent activation of the PI3K gamma complex CC PIK3CG:PIK3R6 (By similarity). Interacts with RAPGEF2 (PubMed:10608844, CC PubMed:11598133). Interacts (active GTP-bound form) with both SHOC2 and CC PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c CC preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS CC and H-Ras/HRAS (PubMed:35768504, PubMed:35831509, PubMed:36175670). CC Interacts (GTP-bound form) with MAPKAP1/SIN1; inhibiting H-Ras/HRAS CC activity (PubMed:35522713). {ECO:0000250|UniProtKB:P20171, CC ECO:0000250|UniProtKB:Q61411, ECO:0000269|PubMed:10369681, CC ECO:0000269|PubMed:10608844, ECO:0000269|PubMed:11022048, CC ECO:0000269|PubMed:11257115, ECO:0000269|PubMed:11598133, CC ECO:0000269|PubMed:11980706, ECO:0000269|PubMed:14500341, CC ECO:0000269|PubMed:17230191, ECO:0000269|PubMed:18596699, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35831509, ECO:0000269|PubMed:36175670}. CC -!- INTERACTION: CC P01112; Q99996-3: AKAP9; NbExp=3; IntAct=EBI-350145, EBI-11022349; CC P01112; P53677-2: AP3M2; NbExp=3; IntAct=EBI-350145, EBI-12177015; CC P01112; P10398: ARAF; NbExp=7; IntAct=EBI-350145, EBI-365961; CC P01112; Q9NXL2-1: ARHGEF38; NbExp=3; IntAct=EBI-350145, EBI-18172597; CC P01112; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-350145, EBI-718459; CC P01112; Q9H7T9: AUNIP; NbExp=3; IntAct=EBI-350145, EBI-10693257; CC P01112; Q00994: BEX3; NbExp=3; IntAct=EBI-350145, EBI-741753; CC P01112; Q9H2G9: BLZF1; NbExp=4; IntAct=EBI-350145, EBI-2548012; CC P01112; P15056: BRAF; NbExp=9; IntAct=EBI-350145, EBI-365980; CC P01112; Q7Z569: BRAP; NbExp=3; IntAct=EBI-350145, EBI-349900; CC P01112; Q5PSV4: BRMS1L; NbExp=3; IntAct=EBI-350145, EBI-5666615; CC P01112; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-350145, EBI-23662416; CC P01112; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-350145, EBI-751596; CC P01112; Q03135: CAV1; NbExp=2; IntAct=EBI-350145, EBI-603614; CC P01112; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-350145, EBI-744556; CC P01112; Q49A88-3: CCDC14; NbExp=3; IntAct=EBI-350145, EBI-12105646; CC P01112; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-350145, EBI-9091443; CC P01112; P24941: CDK2; NbExp=3; IntAct=EBI-350145, EBI-375096; CC P01112; O95674: CDS2; NbExp=3; IntAct=EBI-350145, EBI-3913685; CC P01112; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-350145, EBI-1003700; CC P01112; Q9Y4F5-3: CEP170B; NbExp=3; IntAct=EBI-350145, EBI-12950757; CC P01112; Q86XR8: CEP57; NbExp=3; IntAct=EBI-350145, EBI-308614; CC P01112; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-350145, EBI-11953200; CC P01112; Q8WUX9: CHMP7; NbExp=4; IntAct=EBI-350145, EBI-749253; CC P01112; Q14117: DPYS; NbExp=3; IntAct=EBI-350145, EBI-12275416; CC P01112; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-350145, EBI-3443946; CC P01112; O14641: DVL2; NbExp=3; IntAct=EBI-350145, EBI-740850; CC P01112; A0AVK6: E2F8; NbExp=3; IntAct=EBI-350145, EBI-7779316; CC P01112; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-350145, EBI-9917523; CC P01112; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-350145, EBI-8468186; CC P01112; Q969H0: FBXW7; NbExp=5; IntAct=EBI-350145, EBI-359574; CC P01112; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-350145, EBI-11958845; CC P01112; P15407: FOSL1; NbExp=3; IntAct=EBI-350145, EBI-744510; CC P01112; P15408: FOSL2; NbExp=3; IntAct=EBI-350145, EBI-3893419; CC P01112; P52655: GTF2A1; NbExp=3; IntAct=EBI-350145, EBI-389518; CC P01112; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-350145, EBI-2514791; CC P01112; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-350145, EBI-2558143; CC P01112; Q8IV36: HID1; NbExp=3; IntAct=EBI-350145, EBI-743438; CC P01112; O43248: HOXC11; NbExp=3; IntAct=EBI-350145, EBI-2652631; CC P01112; Q53GQ0: HSD17B12; NbExp=3; IntAct=EBI-350145, EBI-2963255; CC P01112; P10809: HSPD1; NbExp=3; IntAct=EBI-350145, EBI-352528; CC P01112; Q8NDH6-2: ICA1L; NbExp=3; IntAct=EBI-350145, EBI-12141931; CC P01112; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-350145, EBI-11742277; CC P01112; Q8NA54: IQUB; NbExp=3; IntAct=EBI-350145, EBI-10220600; CC P01112; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-350145, EBI-712105; CC P01112; P28290-2: ITPRID2; NbExp=3; IntAct=EBI-350145, EBI-25863618; CC P01112; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-350145, EBI-14069005; CC P01112; Q2M2Z5: KIZ; NbExp=3; IntAct=EBI-350145, EBI-2554344; CC P01112; Q6P597: KLC3; NbExp=3; IntAct=EBI-350145, EBI-1643885; CC P01112; P57682: KLF3; NbExp=3; IntAct=EBI-350145, EBI-8472267; CC P01112; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-350145, EBI-8524663; CC P01112; P08727: KRT19; NbExp=3; IntAct=EBI-350145, EBI-742756; CC P01112; Q14525: KRT33B; NbExp=3; IntAct=EBI-350145, EBI-1049638; CC P01112; Q14847-2: LASP1; NbExp=3; IntAct=EBI-350145, EBI-9088686; CC P01112; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-350145, EBI-741355; CC P01112; P27338: MAOB; NbExp=3; IntAct=EBI-350145, EBI-3911344; CC P01112; Q99558: MAP3K14; NbExp=3; IntAct=EBI-350145, EBI-358011; CC P01112; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-350145, EBI-348259; CC P01112; Q8TAC0: MGC27345; NbExp=3; IntAct=EBI-350145, EBI-25851300; CC P01112; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-350145, EBI-2801965; CC P01112; Q8NEH6: MNS1; NbExp=3; IntAct=EBI-350145, EBI-743811; CC P01112; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-350145, EBI-995714; CC P01112; Q96HT8: MRFAP1L1; NbExp=3; IntAct=EBI-350145, EBI-748896; CC P01112; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-350145, EBI-928842; CC P01112; P21359: NF1; NbExp=3; IntAct=EBI-350145, EBI-1172917; CC P01112; Q8N5V2: NGEF; NbExp=3; IntAct=EBI-350145, EBI-718372; CC P01112; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-350145, EBI-2802743; CC P01112; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-350145, EBI-22002759; CC P01112; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-350145, EBI-8466445; CC P01112; O43482: OIP5; NbExp=3; IntAct=EBI-350145, EBI-536879; CC P01112; Q9BR81: PCDHGC3; NbExp=3; IntAct=EBI-350145, EBI-22012354; CC P01112; O15534: PER1; NbExp=3; IntAct=EBI-350145, EBI-2557276; CC P01112; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-350145, EBI-722852; CC P01112; O00329: PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-718309; CC P01112; O00329-2: PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-6470902; CC P01112; Q9UPR0: PLCL2; NbExp=3; IntAct=EBI-350145, EBI-311059; CC P01112; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-350145, EBI-710402; CC P01112; Q15435-3: PPP1R7; NbExp=3; IntAct=EBI-350145, EBI-10695066; CC P01112; P04049: RAF1; NbExp=30; IntAct=EBI-350145, EBI-365996; CC P01112; P11233: RALA; NbExp=2; IntAct=EBI-350145, EBI-1036803; CC P01112; Q15311: RALBP1; NbExp=3; IntAct=EBI-350145, EBI-749285; CC P01112; Q12967: RALGDS; NbExp=3; IntAct=EBI-350145, EBI-365861; CC P01112; P52306: RAP1GDS1; NbExp=2; IntAct=EBI-350145, EBI-746389; CC P01112; Q9NS23-2: RASSF1; NbExp=2; IntAct=EBI-350145, EBI-438698; CC P01112; Q9NS23-4: RASSF1; NbExp=4; IntAct=EBI-350145, EBI-438710; CC P01112; Q8WWW0: RASSF5; NbExp=2; IntAct=EBI-350145, EBI-367390; CC P01112; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-350145, EBI-12068216; CC P01112; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-350145, EBI-1504830; CC P01112; Q9NZL6: RGL1; NbExp=4; IntAct=EBI-350145, EBI-365926; CC P01112; O15211: RGL2; NbExp=3; IntAct=EBI-350145, EBI-712355; CC P01112; Q8IXN7: RIMKLA; NbExp=3; IntAct=EBI-350145, EBI-21890191; CC P01112; Q13671: RIN1; NbExp=15; IntAct=EBI-350145, EBI-366017; CC P01112; Q13671-1: RIN1; NbExp=2; IntAct=EBI-350145, EBI-366030; CC P01112; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-350145, EBI-749039; CC P01112; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-350145, EBI-25837959; CC P01112; Q13435: SF3B2; NbExp=3; IntAct=EBI-350145, EBI-749111; CC P01112; Q13485: SMAD4; NbExp=5; IntAct=EBI-350145, EBI-347263; CC P01112; Q12824: SMARCB1; NbExp=3; IntAct=EBI-350145, EBI-358419; CC P01112; Q13573: SNW1; NbExp=3; IntAct=EBI-350145, EBI-632715; CC P01112; Q07889: SOS1; NbExp=11; IntAct=EBI-350145, EBI-297487; CC P01112; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-350145, EBI-12041693; CC P01112; P12931: SRC; NbExp=2; IntAct=EBI-350145, EBI-621482; CC P01112; Q92783-2: STAM; NbExp=3; IntAct=EBI-350145, EBI-12025738; CC P01112; O75886: STAM2; NbExp=3; IntAct=EBI-350145, EBI-373258; CC P01112; Q13586: STIM1; NbExp=4; IntAct=EBI-350145, EBI-448878; CC P01112; Q8N4C7: STX19; NbExp=3; IntAct=EBI-350145, EBI-8484990; CC P01112; O75528: TADA3; NbExp=3; IntAct=EBI-350145, EBI-473249; CC P01112; P54274-2: TERF1; NbExp=3; IntAct=EBI-350145, EBI-711018; CC P01112; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-350145, EBI-12090309; CC P01112; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-350145, EBI-12833746; CC P01112; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-350145, EBI-7684443; CC P01112; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-350145, EBI-9089156; CC P01112; P36406: TRIM23; NbExp=3; IntAct=EBI-350145, EBI-740098; CC P01112; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-350145, EBI-11525489; CC P01112; Q99598: TSNAX; NbExp=3; IntAct=EBI-350145, EBI-21353855; CC P01112; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-350145, EBI-8656864; CC P01112; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-350145, EBI-10964469; CC P01112; Q9Y5Z9: UBIAD1; NbExp=9; IntAct=EBI-350145, EBI-2819725; CC P01112; P22415: USF1; NbExp=3; IntAct=EBI-350145, EBI-1054489; CC P01112; Q495M9: USH1G; NbExp=3; IntAct=EBI-350145, EBI-8601749; CC P01112; Q9H270: VPS11; NbExp=3; IntAct=EBI-350145, EBI-373380; CC P01112; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-350145, EBI-2850578; CC P01112; P19544-6: WT1; NbExp=3; IntAct=EBI-350145, EBI-11745701; CC P01112; O43829: ZBTB14; NbExp=3; IntAct=EBI-350145, EBI-10176632; CC P01112; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-350145, EBI-8489702; CC P01112; Q7Z637; NbExp=3; IntAct=EBI-350145, EBI-25831475; CC P01112; Q86V28; NbExp=3; IntAct=EBI-350145, EBI-10259496; CC P01112; P42337: Pik3ca; Xeno; NbExp=3; IntAct=EBI-350145, EBI-641748; CC P01112; Q9Z0S9: Rabac1; Xeno; NbExp=4; IntAct=EBI-350145, EBI-476965; CC P01112; Q9EQZ6: Rapgef4; Xeno; NbExp=3; IntAct=EBI-350145, EBI-772212; CC P01112; P27671: Rasgrf1; Xeno; NbExp=2; IntAct=EBI-350145, EBI-645522; CC P01112; Q5EBH1: Rassf5; Xeno; NbExp=13; IntAct=EBI-350145, EBI-960530; CC P01112; Q5EBH1-1: Rassf5; Xeno; NbExp=3; IntAct=EBI-350145, EBI-960543; CC P01112-2; P52306-5: RAP1GDS1; NbExp=5; IntAct=EBI-13290525, EBI-12832744; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P20171}; CC Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus CC membrane; Lipid-anchor. Note=The active GTP-bound form is localized CC most strongly to membranes than the inactive GDP-bound form (By CC similarity). Shuttles between the plasma membrane and the Golgi CC apparatus. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Cytoplasm, CC perinuclear region. Note=Colocalizes with RACK1 to the perinuclear CC region. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=H-Ras4A, p21; CC IsoId=P01112-1; Sequence=Displayed; CC Name=2; Synonyms=H-RasIDX, p19; CC IsoId=P01112-2; Sequence=VSP_041597; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:14500341}. CC -!- PTM: Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of CC de- and re-palmitoylation regulates rapid exchange between plasma CC membrane and Golgi. CC -!- PTM: S-nitrosylated; critical for redox regulation. Important for CC stimulating guanine nucleotide exchange. No structural perturbation on CC nitrosylation. CC -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14- CC prostaglandin-J2 is autocatalytic and reversible. It may occur as an CC alternative to other cysteine modifications, such as S-nitrosylation CC and S-palmitoylation. CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000250}. CC -!- PTM: Fatty-acylated at Lys-170. {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000269|PubMed:30442762}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL (PubMed:19744486, PubMed:8626575, PubMed:8626586, PubMed:9632667). CC Monoglucosylation completely prevents the recognition of the downstream CC effector, blocking the GTPases in their inactive form, leading to CC inhibit Ras signaling (PubMed:8626575, PubMed:8626586, PubMed:9632667). CC {ECO:0000269|PubMed:19744486, ECO:0000269|PubMed:8626575, CC ECO:0000269|PubMed:8626586, ECO:0000269|PubMed:9632667}. CC -!- DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition CC characterized by prenatally increased growth, postnatal growth CC deficiency, intellectual disability, distinctive facial appearance, CC cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic CC cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin CC and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, CC ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, CC ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, CC ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) CC [MIM:218040]: Variant of Costello syndrome. CC {ECO:0000269|PubMed:17412879}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Thyroid cancer, non-medullary, 2 (NMTC2) [MIM:188470]: A form CC of non-medullary thyroid cancer (NMTC), a cancer characterized by CC tumors originating from the thyroid follicular cells. NMTCs represent CC approximately 95% of all cases of thyroid cancer and are classified CC into papillary, follicular, Hurthle cell, and anaplastic neoplasms. CC {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Mutations which change positions 12, 13 or 61 activate CC the potential of HRAS to transform cultured cells and are implicated in CC a variety of human tumors. {ECO:0000269|PubMed:3670300}. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:22683711}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/108/HRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J00277; AAB02605.1; -; Genomic_DNA. DR EMBL; AJ437024; CAD24594.1; -; mRNA. DR EMBL; AF493916; AAM12630.1; -; mRNA. DR EMBL; CR536579; CAG38816.1; -; mRNA. DR EMBL; CR542271; CAG47067.1; -; mRNA. DR EMBL; BT019421; AAV38228.1; -; mRNA. DR EMBL; EF015887; ABI97389.1; -; Genomic_DNA. DR EMBL; AB451336; BAG70150.1; -; mRNA. DR EMBL; AB451485; BAG70299.1; -; mRNA. DR EMBL; CH471158; EAX02337.1; -; Genomic_DNA. DR EMBL; CH471158; EAX02338.1; -; Genomic_DNA. DR EMBL; BC006499; AAH06499.1; -; mRNA. DR EMBL; BC095471; AAH95471.1; -; mRNA. DR EMBL; M17232; AAA35685.1; -; Genomic_DNA. DR CCDS; CCDS7698.1; -. [P01112-1] DR CCDS; CCDS7699.1; -. [P01112-2] DR PIR; A93299; TVHUH. DR RefSeq; NP_001123914.1; NM_001130442.3. [P01112-1] DR RefSeq; NP_001304983.1; NM_001318054.1. DR RefSeq; NP_005334.1; NM_005343.4. [P01112-1] DR RefSeq; NP_789765.1; NM_176795.5. [P01112-2] DR RefSeq; XP_054224585.1; XM_054368610.1. [P01112-1] DR PDB; 121P; X-ray; 1.54 A; A=1-166. DR PDB; 1AA9; NMR; -; A=1-171. DR PDB; 1AGP; X-ray; 2.30 A; A=1-166. DR PDB; 1BKD; X-ray; 2.80 A; R=1-166. DR PDB; 1CLU; X-ray; 1.70 A; A=1-166. DR PDB; 1CRP; NMR; -; A=1-166. DR PDB; 1CRQ; NMR; -; A=1-166. DR PDB; 1CRR; NMR; -; A=1-166. DR PDB; 1CTQ; X-ray; 1.26 A; A=1-166. DR PDB; 1GNP; X-ray; 2.70 A; A=1-166. DR PDB; 1GNQ; X-ray; 2.50 A; A=1-166. DR PDB; 1GNR; X-ray; 1.85 A; A=1-166. DR PDB; 1HE8; X-ray; 3.00 A; B=1-166. DR PDB; 1IAQ; X-ray; 2.90 A; A/B/C=1-166. DR PDB; 1IOZ; X-ray; 2.00 A; A=1-171. DR PDB; 1JAH; X-ray; 1.80 A; A=1-166. DR PDB; 1JAI; X-ray; 1.80 A; A=1-166. DR PDB; 1K8R; X-ray; 3.00 A; A=1-166. DR PDB; 1LF0; X-ray; 1.70 A; A=1-166. DR PDB; 1LF5; X-ray; 1.70 A; A=1-166. DR PDB; 1LFD; X-ray; 2.10 A; B/D=1-167. DR PDB; 1NVU; X-ray; 2.20 A; Q/R=1-166. DR PDB; 1NVV; X-ray; 2.18 A; Q/R=1-166. DR PDB; 1NVW; X-ray; 2.70 A; Q/R=1-166. DR PDB; 1NVX; X-ray; 3.20 A; Q/R=1-166. DR PDB; 1P2S; X-ray; 2.45 A; A=1-166. DR PDB; 1P2T; X-ray; 2.00 A; A=1-166. DR PDB; 1P2U; X-ray; 2.00 A; A=1-166. DR PDB; 1P2V; X-ray; 2.30 A; A=1-166. DR PDB; 1PLJ; X-ray; 2.80 A; A=1-166. DR PDB; 1PLK; X-ray; 2.80 A; A=1-166. DR PDB; 1PLL; X-ray; 2.80 A; A=1-166. DR PDB; 1Q21; X-ray; 2.20 A; A=1-171. DR PDB; 1QRA; X-ray; 1.60 A; A=1-166. DR PDB; 1RVD; X-ray; 1.90 A; A=1-166. DR PDB; 1WQ1; X-ray; 2.50 A; R=1-166. DR PDB; 1XCM; X-ray; 1.84 A; A=1-167. DR PDB; 1XD2; X-ray; 2.70 A; A/B=1-166. DR PDB; 1XJ0; X-ray; 1.70 A; A=1-166. DR PDB; 1ZVQ; X-ray; 2.00 A; A=1-166. DR PDB; 1ZW6; X-ray; 1.50 A; A=1-166. DR PDB; 221P; X-ray; 2.30 A; A=1-166. DR PDB; 2C5L; X-ray; 1.90 A; A/B=1-166. DR PDB; 2CE2; X-ray; 1.00 A; X=1-166. DR PDB; 2CL0; X-ray; 1.80 A; X=1-166. DR PDB; 2CL6; X-ray; 1.24 A; X=1-166. DR PDB; 2CL7; X-ray; 1.25 A; X=1-166. DR PDB; 2CLC; X-ray; 1.30 A; X=1-166. DR PDB; 2CLD; X-ray; 1.22 A; X=1-166. DR PDB; 2EVW; X-ray; 1.05 A; X=1-166. DR PDB; 2LCF; NMR; -; A=1-166. DR PDB; 2LWI; NMR; -; A=1-166. DR PDB; 2N42; NMR; -; A=1-166. DR PDB; 2N46; NMR; -; A=1-166. DR PDB; 2Q21; X-ray; 2.20 A; A=1-171. DR PDB; 2QUZ; X-ray; 1.49 A; A=1-166. DR PDB; 2RGA; X-ray; 1.90 A; A=1-166. DR PDB; 2RGB; X-ray; 1.35 A; A=1-166. DR PDB; 2RGC; X-ray; 1.60 A; A=1-166. DR PDB; 2RGD; X-ray; 2.00 A; A=1-166. DR PDB; 2RGE; X-ray; 1.40 A; A=1-166. DR PDB; 2RGG; X-ray; 1.45 A; A=1-166. DR PDB; 2UZI; X-ray; 2.00 A; R=1-166. DR PDB; 2VH5; X-ray; 2.70 A; R=1-166. DR PDB; 2X1V; X-ray; 1.70 A; A=1-166. DR PDB; 3DDC; X-ray; 1.80 A; A=1-166. DR PDB; 3I3S; X-ray; 1.36 A; R=1-166. DR PDB; 3K8Y; X-ray; 1.30 A; A=1-166. DR PDB; 3K9L; X-ray; 1.80 A; A/B/C=1-166. DR PDB; 3K9N; X-ray; 2.00 A; A=1-166. DR PDB; 3KKM; X-ray; 1.70 A; A=1-166. DR PDB; 3KKN; X-ray; 2.09 A; A=1-166. DR PDB; 3KUD; X-ray; 2.15 A; A=1-166. DR PDB; 3L8Y; X-ray; 2.02 A; A=1-166. DR PDB; 3L8Z; X-ray; 1.44 A; A=1-166. DR PDB; 3LBH; X-ray; 1.85 A; A=1-166. DR PDB; 3LBI; X-ray; 2.09 A; A=1-166. DR PDB; 3LBN; X-ray; 1.86 A; A=1-166. DR PDB; 3LO5; X-ray; 2.57 A; A/C/E=1-166. DR PDB; 3OIU; X-ray; 1.32 A; A=1-166. DR PDB; 3OIV; X-ray; 1.84 A; A=1-166. DR PDB; 3OIW; X-ray; 1.30 A; A=1-166. DR PDB; 3RRY; X-ray; 1.60 A; A=1-166. DR PDB; 3RRZ; X-ray; 1.60 A; A=1-166. DR PDB; 3RS0; X-ray; 1.40 A; A=1-166. DR PDB; 3RS2; X-ray; 1.84 A; A=1-166. DR PDB; 3RS3; X-ray; 1.52 A; A=1-166. DR PDB; 3RS4; X-ray; 1.70 A; A=1-166. DR PDB; 3RS5; X-ray; 1.68 A; A=1-166. DR PDB; 3RS7; X-ray; 1.70 A; A=1-166. DR PDB; 3RSL; X-ray; 1.70 A; A=1-166. DR PDB; 3RSO; X-ray; 1.60 A; A=1-166. DR PDB; 3TGP; X-ray; 1.31 A; A=1-166. DR PDB; 421P; X-ray; 2.20 A; A=1-166. DR PDB; 4DLR; X-ray; 1.32 A; A=1-166. DR PDB; 4DLS; X-ray; 1.82 A; A=1-166. DR PDB; 4DLT; X-ray; 1.70 A; A=1-166. DR PDB; 4DLU; X-ray; 1.60 A; A=1-166. DR PDB; 4DLV; X-ray; 1.57 A; A=1-166. DR PDB; 4DLW; X-ray; 1.72 A; A=1-166. DR PDB; 4DLX; X-ray; 1.73 A; A=1-166. DR PDB; 4DLY; X-ray; 1.57 A; A=1-166. DR PDB; 4DLZ; X-ray; 1.66 A; A=1-166. DR PDB; 4DST; X-ray; 2.30 A; A=2-167. DR PDB; 4DSU; X-ray; 1.70 A; A=2-167. DR PDB; 4EFL; X-ray; 1.90 A; A=1-166. DR PDB; 4EFM; X-ray; 1.90 A; A=1-166. DR PDB; 4EFN; X-ray; 2.30 A; A=1-166. DR PDB; 4G0N; X-ray; 2.45 A; A=1-166. DR PDB; 4G3X; X-ray; 3.25 A; A=1-166. DR PDB; 4K81; X-ray; 2.40 A; B/D/F/H=1-166. DR PDB; 4L9S; X-ray; 1.61 A; A=1-166. DR PDB; 4L9W; X-ray; 1.95 A; A=1-166. DR PDB; 4NYI; X-ray; 2.96 A; Q/R=1-166. DR PDB; 4NYJ; X-ray; 2.85 A; Q/R=1-166. DR PDB; 4NYM; X-ray; 3.55 A; Q/R=1-166. DR PDB; 4Q21; X-ray; 2.00 A; A=1-189. DR PDB; 4RSG; Neutron; 1.91 A; A=1-166. DR PDB; 4URU; X-ray; 2.83 A; R=1-166. DR PDB; 4URV; X-ray; 2.58 A; R=1-166. DR PDB; 4URW; X-ray; 2.76 A; R=1-166. DR PDB; 4URX; X-ray; 2.49 A; R=1-166. DR PDB; 4URY; X-ray; 2.47 A; R=1-166. DR PDB; 4URZ; X-ray; 2.24 A; R=1-166. DR PDB; 4US0; X-ray; 2.17 A; R=1-166. DR PDB; 4US1; X-ray; 2.65 A; R=1-166. DR PDB; 4US2; X-ray; 2.48 A; R=1-166. DR PDB; 4XVQ; X-ray; 1.89 A; A=1-166. DR PDB; 4XVR; X-ray; 2.03 A; A=1-166. DR PDB; 521P; X-ray; 2.60 A; A=1-166. DR PDB; 5B2Z; X-ray; 1.56 A; A=1-166. DR PDB; 5B30; X-ray; 1.60 A; A=1-166. DR PDB; 5E95; X-ray; 1.40 A; A=1-166. DR PDB; 5P21; X-ray; 1.35 A; A=1-166. DR PDB; 5VBE; X-ray; 1.57 A; A=1-166. DR PDB; 5VBZ; X-ray; 2.20 A; A/B/C=1-166. DR PDB; 5WDO; X-ray; 1.65 A; A=1-166. DR PDB; 5WDP; X-ray; 1.35 A; A=1-166. DR PDB; 5WDQ; X-ray; 1.25 A; A=1-166. DR PDB; 5WFO; X-ray; 1.99 A; Q/R=1-166. DR PDB; 5WFP; X-ray; 2.08 A; Q/R=1-166. DR PDB; 5WFQ; X-ray; 2.26 A; Q/R=1-166. DR PDB; 5WFR; X-ray; 2.46 A; Q/R=1-166. DR PDB; 5WPL; X-ray; 2.15 A; A/D/G/J=1-166. DR PDB; 5X9S; X-ray; 2.50 A; A=1-166. DR PDB; 5ZC6; NMR; -; A=1-166. DR PDB; 621P; X-ray; 2.40 A; A=1-166. DR PDB; 6AMB; X-ray; 2.50 A; A=1-168. DR PDB; 6AXG; X-ray; 3.30 A; B/D/F/H/J/L=1-166. DR PDB; 6BVI; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVJ; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVK; X-ray; 1.80 A; A/C=1-166. DR PDB; 6BVL; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVM; X-ray; 1.80 A; A/C=1-166. DR PDB; 6CUO; X-ray; 1.73 A; A/C=1-166. DR PDB; 6CUP; X-ray; 1.83 A; A/C=1-166. DR PDB; 6CUR; X-ray; 1.73 A; A/C=1-166. DR PDB; 6D55; X-ray; 1.68 A; A/C=1-166. DR PDB; 6D56; X-ray; 1.68 A; A/C=1-166. DR PDB; 6D59; X-ray; 1.70 A; A/C=1-166. DR PDB; 6D5E; X-ray; 1.75 A; A/C=1-166. DR PDB; 6D5G; X-ray; 1.92 A; A/C=1-166. DR PDB; 6D5H; X-ray; 1.80 A; A/C=1-166. DR PDB; 6D5J; X-ray; 1.75 A; A/C=1-166. DR PDB; 6D5L; X-ray; 1.70 A; A/C=1-166. DR PDB; 6D5M; X-ray; 2.08 A; Q/R=1-166. DR PDB; 6D5V; X-ray; 2.04 A; Q/R=1-166. DR PDB; 6D5W; X-ray; 2.48 A; Q/R=1-166. DR PDB; 6DZH; X-ray; 1.95 A; A/B/C=1-166. DR PDB; 6E6C; X-ray; 1.90 A; A=1-166. DR PDB; 6E6P; X-ray; 1.93 A; A/B/C=1-166. DR PDB; 6MQT; X-ray; 1.50 A; A/B/C/D/E/F/G/H=1-166. DR PDB; 6NTC; X-ray; 2.90 A; A=1-166. DR PDB; 6NTD; X-ray; 3.15 A; A=1-166. DR PDB; 6Q21; X-ray; 1.95 A; A/B/C/D=1-171. DR PDB; 6V94; X-ray; 1.80 A; A/C=1-166. DR PDB; 6V9F; X-ray; 1.85 A; A/C=1-166. DR PDB; 6V9J; X-ray; 1.76 A; A/C=1-166. DR PDB; 6V9L; X-ray; 1.70 A; A/C=1-166. DR PDB; 6V9M; X-ray; 1.65 A; A/C=1-166. DR PDB; 6V9N; X-ray; 1.65 A; A/C=1-166. DR PDB; 6V9O; X-ray; 1.80 A; A/C=1-166. DR PDB; 6ZJ0; X-ray; 1.76 A; A=1-166. DR PDB; 6ZL3; X-ray; 2.03 A; A=1-166. DR PDB; 721P; X-ray; 2.00 A; A=1-166. DR PDB; 7DPH; X-ray; 1.54 A; A=1-166. DR PDB; 7DPJ; X-ray; 1.98 A; A=1-166. DR PDB; 7JHP; X-ray; 2.77 A; A=1-166. DR PDB; 7JIF; X-ray; 1.76 A; A=1-166. DR PDB; 7JIG; X-ray; 2.32 A; A=1-166. DR PDB; 7JIH; X-ray; 1.99 A; A/B=1-166. DR PDB; 7JII; X-ray; 1.53 A; A/B=1-166. DR PDB; 7L0F; X-ray; 1.98 A; A/E/G/L=1-166. DR PDB; 7L0G; X-ray; 2.54 A; A/B/E/G=1-166. DR PDB; 7OG9; X-ray; 1.75 A; A=1-166. DR PDB; 7OGA; X-ray; 1.90 A; A=1-166. DR PDB; 7OGB; X-ray; 1.85 A; A=1-166. DR PDB; 7OGC; X-ray; 1.70 A; A=1-166. DR PDB; 7OGD; X-ray; 1.95 A; A=1-166. DR PDB; 7OGE; X-ray; 2.10 A; A=1-166. DR PDB; 7OGF; X-ray; 1.80 A; A=1-166. DR PDB; 7TAM; X-ray; 1.87 A; A=1-166. DR PDB; 7VV8; X-ray; 1.70 A; A=1-166. DR PDB; 7VV9; X-ray; 1.60 A; A=1-170. DR PDB; 7VVG; X-ray; 1.70 A; A=1-166. DR PDB; 821P; X-ray; 1.50 A; A=1-166. DR PDB; 8BE6; X-ray; 2.90 A; R=1-166. DR PDB; 8BE7; X-ray; 3.00 A; R=1-166. DR PDB; 8BE8; X-ray; 2.40 A; R=1-166. DR PDB; 8BE9; X-ray; 2.51 A; R=1-166. DR PDB; 8BEA; X-ray; 2.47 A; R=1-166. DR PDB; 8BOS; X-ray; 2.10 A; R=1-166. DR PDB; 8BWG; X-ray; 1.32 A; R=1-166. DR PDB; 8CNJ; X-ray; 1.35 A; A/B=1-166. DR PDB; 8CNN; X-ray; 1.48 A; A=1-166. DR PDB; 8ELK; X-ray; 1.80 A; A=1-189. DR PDB; 8ELR; X-ray; 2.05 A; A=1-189. DR PDB; 8ELS; X-ray; 2.27 A; A=1-189. DR PDB; 8ELT; X-ray; 1.66 A; A=1-189. DR PDB; 8ELU; X-ray; 1.93 A; A=1-189. DR PDB; 8ELV; X-ray; 2.15 A; A=1-189. DR PDB; 8ELW; X-ray; 1.70 A; A=1-189. DR PDB; 8ELX; X-ray; 1.98 A; A=1-189. DR PDB; 8ELY; X-ray; 1.75 A; A=1-189. DR PDB; 8ELZ; X-ray; 1.96 A; A=1-189. DR PDB; 8EM0; X-ray; 2.11 A; A=1-189. DR PDB; 8FG3; X-ray; 1.49 A; A=1-166. DR PDB; 8FG4; X-ray; 1.85 A; A=1-166. DR PDB; 8OSM; X-ray; 2.05 A; A=1-166. DR PDB; 8OSN; X-ray; 1.80 A; A=1-166. DR PDB; 8OSO; X-ray; 2.50 A; A=1-166. DR PDB; 8TBG; X-ray; 1.20 A; A/B=1-166. DR PDB; 8TLR; X-ray; 1.70 A; A=1-166. DR PDB; 8WWC; X-ray; 2.80 A; A/B=1-166. DR PDBsum; 121P; -. DR PDBsum; 1AA9; -. DR PDBsum; 1AGP; -. DR PDBsum; 1BKD; -. DR PDBsum; 1CLU; -. DR PDBsum; 1CRP; -. DR PDBsum; 1CRQ; -. DR PDBsum; 1CRR; -. DR PDBsum; 1CTQ; -. DR PDBsum; 1GNP; -. DR PDBsum; 1GNQ; -. DR PDBsum; 1GNR; -. DR PDBsum; 1HE8; -. DR PDBsum; 1IAQ; -. DR PDBsum; 1IOZ; -. DR PDBsum; 1JAH; -. DR PDBsum; 1JAI; -. DR PDBsum; 1K8R; -. DR PDBsum; 1LF0; -. DR PDBsum; 1LF5; -. DR PDBsum; 1LFD; -. DR PDBsum; 1NVU; -. DR PDBsum; 1NVV; -. DR PDBsum; 1NVW; -. DR PDBsum; 1NVX; -. DR PDBsum; 1P2S; -. DR PDBsum; 1P2T; -. DR PDBsum; 1P2U; -. DR PDBsum; 1P2V; -. DR PDBsum; 1PLJ; -. DR PDBsum; 1PLK; -. DR PDBsum; 1PLL; -. DR PDBsum; 1Q21; -. DR PDBsum; 1QRA; -. DR PDBsum; 1RVD; -. DR PDBsum; 1WQ1; -. DR PDBsum; 1XCM; -. DR PDBsum; 1XD2; -. DR PDBsum; 1XJ0; -. DR PDBsum; 1ZVQ; -. DR PDBsum; 1ZW6; -. DR PDBsum; 221P; -. DR PDBsum; 2C5L; -. DR PDBsum; 2CE2; -. DR PDBsum; 2CL0; -. DR PDBsum; 2CL6; -. DR PDBsum; 2CL7; -. DR PDBsum; 2CLC; -. DR PDBsum; 2CLD; -. DR PDBsum; 2EVW; -. DR PDBsum; 2LCF; -. DR PDBsum; 2LWI; -. DR PDBsum; 2N42; -. DR PDBsum; 2N46; -. DR PDBsum; 2Q21; -. DR PDBsum; 2QUZ; -. DR PDBsum; 2RGA; -. DR PDBsum; 2RGB; -. DR PDBsum; 2RGC; -. DR PDBsum; 2RGD; -. DR PDBsum; 2RGE; -. DR PDBsum; 2RGG; -. DR PDBsum; 2UZI; -. DR PDBsum; 2VH5; -. DR PDBsum; 2X1V; -. DR PDBsum; 3DDC; -. DR PDBsum; 3I3S; -. DR PDBsum; 3K8Y; -. DR PDBsum; 3K9L; -. DR PDBsum; 3K9N; -. DR PDBsum; 3KKM; -. DR PDBsum; 3KKN; -. DR PDBsum; 3KUD; -. DR PDBsum; 3L8Y; -. DR PDBsum; 3L8Z; -. DR PDBsum; 3LBH; -. DR PDBsum; 3LBI; -. DR PDBsum; 3LBN; -. DR PDBsum; 3LO5; -. DR PDBsum; 3OIU; -. DR PDBsum; 3OIV; -. DR PDBsum; 3OIW; -. DR PDBsum; 3RRY; -. DR PDBsum; 3RRZ; -. DR PDBsum; 3RS0; -. DR PDBsum; 3RS2; -. DR PDBsum; 3RS3; -. DR PDBsum; 3RS4; -. DR PDBsum; 3RS5; -. DR PDBsum; 3RS7; -. DR PDBsum; 3RSL; -. DR PDBsum; 3RSO; -. DR PDBsum; 3TGP; -. DR PDBsum; 421P; -. DR PDBsum; 4DLR; -. DR PDBsum; 4DLS; -. DR PDBsum; 4DLT; -. DR PDBsum; 4DLU; -. DR PDBsum; 4DLV; -. DR PDBsum; 4DLW; -. DR PDBsum; 4DLX; -. DR PDBsum; 4DLY; -. DR PDBsum; 4DLZ; -. DR PDBsum; 4DST; -. DR PDBsum; 4DSU; -. DR PDBsum; 4EFL; -. DR PDBsum; 4EFM; -. DR PDBsum; 4EFN; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4K81; -. DR PDBsum; 4L9S; -. DR PDBsum; 4L9W; -. DR PDBsum; 4NYI; -. DR PDBsum; 4NYJ; -. DR PDBsum; 4NYM; -. DR PDBsum; 4Q21; -. DR PDBsum; 4RSG; -. DR PDBsum; 4URU; -. DR PDBsum; 4URV; -. DR PDBsum; 4URW; -. DR PDBsum; 4URX; -. DR PDBsum; 4URY; -. DR PDBsum; 4URZ; -. DR PDBsum; 4US0; -. DR PDBsum; 4US1; -. DR PDBsum; 4US2; -. DR PDBsum; 4XVQ; -. DR PDBsum; 4XVR; -. DR PDBsum; 521P; -. DR PDBsum; 5B2Z; -. DR PDBsum; 5B30; -. DR PDBsum; 5E95; -. DR PDBsum; 5P21; -. DR PDBsum; 5VBE; -. DR PDBsum; 5VBZ; -. DR PDBsum; 5WDO; -. DR PDBsum; 5WDP; -. DR PDBsum; 5WDQ; -. DR PDBsum; 5WFO; -. DR PDBsum; 5WFP; -. DR PDBsum; 5WFQ; -. DR PDBsum; 5WFR; -. DR PDBsum; 5WPL; -. DR PDBsum; 5X9S; -. DR PDBsum; 5ZC6; -. DR PDBsum; 621P; -. DR PDBsum; 6AMB; -. DR PDBsum; 6AXG; -. DR PDBsum; 6BVI; -. DR PDBsum; 6BVJ; -. DR PDBsum; 6BVK; -. DR PDBsum; 6BVL; -. DR PDBsum; 6BVM; -. DR PDBsum; 6CUO; -. DR PDBsum; 6CUP; -. DR PDBsum; 6CUR; -. DR PDBsum; 6D55; -. DR PDBsum; 6D56; -. DR PDBsum; 6D59; -. DR PDBsum; 6D5E; -. DR PDBsum; 6D5G; -. DR PDBsum; 6D5H; -. DR PDBsum; 6D5J; -. DR PDBsum; 6D5L; -. DR PDBsum; 6D5M; -. DR PDBsum; 6D5V; -. DR PDBsum; 6D5W; -. DR PDBsum; 6DZH; -. DR PDBsum; 6E6C; -. DR PDBsum; 6E6P; -. DR PDBsum; 6MQT; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6Q21; -. DR PDBsum; 6V94; -. DR PDBsum; 6V9F; -. DR PDBsum; 6V9J; -. DR PDBsum; 6V9L; -. DR PDBsum; 6V9M; -. DR PDBsum; 6V9N; -. DR PDBsum; 6V9O; -. DR PDBsum; 6ZJ0; -. DR PDBsum; 6ZL3; -. DR PDBsum; 721P; -. DR PDBsum; 7DPH; -. DR PDBsum; 7DPJ; -. DR PDBsum; 7JHP; -. DR PDBsum; 7JIF; -. DR PDBsum; 7JIG; -. DR PDBsum; 7JIH; -. DR PDBsum; 7JII; -. DR PDBsum; 7L0F; -. DR PDBsum; 7L0G; -. DR PDBsum; 7OG9; -. DR PDBsum; 7OGA; -. DR PDBsum; 7OGB; -. DR PDBsum; 7OGC; -. DR PDBsum; 7OGD; -. DR PDBsum; 7OGE; -. DR PDBsum; 7OGF; -. DR PDBsum; 7TAM; -. DR PDBsum; 7VV8; -. DR PDBsum; 7VV9; -. DR PDBsum; 7VVG; -. DR PDBsum; 821P; -. DR PDBsum; 8BE6; -. DR PDBsum; 8BE7; -. DR PDBsum; 8BE8; -. DR PDBsum; 8BE9; -. DR PDBsum; 8BEA; -. DR PDBsum; 8BOS; -. DR PDBsum; 8BWG; -. DR PDBsum; 8CNJ; -. DR PDBsum; 8CNN; -. DR PDBsum; 8ELK; -. DR PDBsum; 8ELR; -. DR PDBsum; 8ELS; -. DR PDBsum; 8ELT; -. DR PDBsum; 8ELU; -. DR PDBsum; 8ELV; -. DR PDBsum; 8ELW; -. DR PDBsum; 8ELX; -. DR PDBsum; 8ELY; -. DR PDBsum; 8ELZ; -. DR PDBsum; 8EM0; -. DR PDBsum; 8FG3; -. DR PDBsum; 8FG4; -. DR PDBsum; 8OSM; -. DR PDBsum; 8OSN; -. DR PDBsum; 8OSO; -. DR PDBsum; 8TBG; -. DR PDBsum; 8TLR; -. DR PDBsum; 8WWC; -. DR AlphaFoldDB; P01112; -. DR BMRB; P01112; -. DR SMR; P01112; -. DR BioGRID; 109501; 710. DR ComplexPortal; CPX-26353; SHOC2-HRAS-PPP1CA complex. DR ComplexPortal; CPX-395; GTPase HRAS - Son of sevenless homolog 1 complex. DR CORUM; P01112; -. DR DIP; DIP-1050N; -. DR ELM; P01112; -. DR FunCoup; P01112; 3079. DR IntAct; P01112; 623. DR MINT; P01112; -. DR STRING; 9606.ENSP00000407586; -. DR BindingDB; P01112; -. DR ChEMBL; CHEMBL2167; -. DR DrugBank; DB04315; Guanosine-5'-Diphosphate. DR DrugBank; DB04137; Guanosine-5'-Triphosphate. DR DrugBank; DB02210; Hexane-1,6-Diol. DR DrugBank; DB08751; N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE. DR DrugBank; DB03226; Trifluoroethanol. DR DrugBank; DB15588; Ursolic acid. DR DrugCentral; P01112; -. DR GuidetoPHARMACOLOGY; 2822; -. DR GlyCosmos; P01112; 1 site, No reported glycans. DR GlyGen; P01112; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P01112; -. DR PhosphoSitePlus; P01112; -. DR SwissPalm; P01112; -. DR BioMuta; HRAS; -. DR DMDM; 131869; -. DR CPTAC; CPTAC-1551; -. DR CPTAC; CPTAC-1552; -. DR jPOST; P01112; -. DR MassIVE; P01112; -. DR PaxDb; 9606-ENSP00000407586; -. DR PeptideAtlas; P01112; -. DR ProteomicsDB; 51321; -. [P01112-1] DR ProteomicsDB; 51322; -. [P01112-2] DR Pumba; P01112; -. DR ABCD; P01112; 6 sequenced antibodies. DR Antibodypedia; 22506; 827 antibodies from 38 providers. DR CPTC; P01112; 4 antibodies. DR DNASU; 3265; -. DR Ensembl; ENST00000311189.8; ENSP00000309845.7; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000397594.7; ENSP00000380722.3; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000397596.6; ENSP00000380723.2; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000417302.7; ENSP00000388246.1; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000451590.5; ENSP00000407586.1; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000493230.5; ENSP00000434023.1; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000610977.3; ENSP00000480686.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000615062.2; ENSP00000482366.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000616241.4; ENSP00000480317.1; ENSG00000276536.4. [P01112-2] DR Ensembl; ENST00000631404.1; ENSP00000488757.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000631967.1; ENSP00000488225.1; ENSG00000276536.4. [P01112-2] DR Ensembl; ENST00000634098.1; ENSP00000488296.1; ENSG00000276536.4. [P01112-2] DR GeneID; 3265; -. DR KEGG; hsa:3265; -. DR MANE-Select; ENST00000311189.8; ENSP00000309845.7; NM_005343.4; NP_005334.1. DR UCSC; uc010qvw.3; human. [P01112-1] DR AGR; HGNC:5173; -. DR CIViC; 3265; 22 evidence items across 22 molecular profiles. DR ClinPGx; PA29444; -. DR CTD; 3265; -. DR DisGeNET; 3265; -. DR GeneCards; HRAS; -. DR GeneReviews; HRAS; -. DR HGNC; HGNC:5173; HRAS. DR HPA; ENSG00000174775; Low tissue specificity. DR MalaCards; HRAS; -. DR MIM; 109800; phenotype. DR MIM; 163200; phenotype. DR MIM; 188470; phenotype. DR MIM; 190020; gene. DR MIM; 218040; phenotype. DR OpenTargets; ENSG00000174775; -. DR Orphanet; 3071; Costello syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 2874; Phakomatosis pigmentokeratotica. DR Orphanet; 79414; Woolly hair nevus. DR VEuPathDB; HostDB:ENSG00000174775; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155653; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01112; -. DR OMA; HYREQIR; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01112; 6 GO annotations based on evolutionary models. DR PhylomeDB; P01112; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01112; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SABIO-RK; P01112; -. DR SignaLink; P01112; -. DR SIGNOR; P01112; -. DR Agora; ENSG00000174775; -. DR BioGRID-ORCS; 3265; 28 hits in 1176 CRISPR screens. DR EvolutionaryTrace; P01112; -. DR GeneWiki; HRAS; -. DR GenomeRNAi; 3265; -. DR Pharos; P01112; Tchem. DR PRO; PR:P01112; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P01112; protein. DR Bgee; ENSG00000174775; Expressed in skin of abdomen and 97 other cell types or tissues. DR ExpressionAtlas; P01112; baseline and differential. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:1905360; C:GTPase complex; IPI:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IMP:CAFA. DR GO; GO:0005525; F:GTP binding; IDA:UniProtKB. DR GO; GO:0003924; F:GTPase activity; IDA:WormBase. DR GO; GO:0160185; F:phospholipase C activator activity; IDA:UniProtKB. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0090398; P:cellular senescence; IDA:BHF-UCL. DR GO; GO:0006935; P:chemotaxis; TAS:ProtInc. DR GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl. DR GO; GO:0006897; P:endocytosis; IEA:Ensembl. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0090402; P:oncogene-induced cell senescence; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:2000630; P:positive regulation of miRNA metabolic process; IDA:BHF-UCL. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:UniProtKB. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0032729; P:positive regulation of type II interferon production; IEA:Ensembl. DR GO; GO:0090303; P:positive regulation of wound healing; IDA:BHF-UCL. DR GO; GO:0007265; P:Ras protein signal transduction; IDA:BHF-UCL. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:BHF-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; IDA:ComplexPortal. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0098696; P:regulation of neurotransmitter receptor localization to postsynaptic specialization membrane; IDA:SynGO. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0042088; P:T-helper 1 type immune response; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP00153; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; Cytoplasm; KW Direct protein sequencing; Disease variant; Glycoprotein; Golgi apparatus; KW GTP-binding; Hydrolase; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Nucleus; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW S-nitrosylation; Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase HRas" FT /id="PRO_0000042996" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.12" FT CHAIN 2..186 FT /note="GTPase HRas, N-terminally processed" FT /id="PRO_0000326476" FT PROPEP 187..189 FT /note="Removed in mature form" FT /id="PRO_0000042997" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 13..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 145..147 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase HRas; alternate" FT /evidence="ECO:0000269|Ref.12" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase HRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.12" FT MOD_RES 118 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:9020151" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:8626715" FT LIPID 181 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017, FT ECO:0000269|PubMed:8626715" FT LIPID 184 FT /note="S-(15-deoxy-Delta12,14-prostaglandin J2-9- FT yl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:12684535" FT LIPID 184 FT /note="S-palmitoyl cysteine; alternate" FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017, FT ECO:0000269|PubMed:8626715" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:8626715" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486, FT ECO:0000269|PubMed:8626575, ECO:0000269|PubMed:8626586, FT ECO:0000269|PubMed:9632667" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:30442762" FT VAR_SEQ 152..189 FT /note="VEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS -> SRSGSSSSSG FT TLWDPPGPM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14500341, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041597" FT VARIANT 12 FT /note="G -> A (in CSTLO; dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:16170316, FT ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854" FT /id="VAR_026106" FT VARIANT 12 FT /note="G -> C (in CSTLO; dbSNP:rs104894229)" FT /evidence="ECO:0000269|PubMed:16443854, FT ECO:0000269|PubMed:18039947" FT /id="VAR_045975" FT VARIANT 12 FT /note="G -> D (in CSTLO; severe mutation; FT dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:18039947" FT /id="VAR_068816" FT VARIANT 12 FT /note="G -> E (in CSTLO)" FT /evidence="ECO:0000269|PubMed:16443854" FT /id="VAR_045976" FT VARIANT 12 FT /note="G -> S (in CSTLO and CMEMS; also found in patients FT with oral squamous cell carcinoma; dbSNP:rs104894229)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, FT ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, FT ECO:0000269|PubMed:17412879" FT /id="VAR_006837" FT VARIANT 12 FT /note="G -> V (in CSTLO, bladder carcinoma and CMEMS; FT constitutively activated; interacts and recruits PLCE1 to FT plasma membrane; dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:11022048, FT ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16170316, FT ECO:0000269|PubMed:17412879" FT /id="VAR_006836" FT VARIANT 13 FT /note="G -> C (in CSTLO; dbSNP:rs104894228)" FT /evidence="ECO:0000269|PubMed:16329078" FT /id="VAR_026107" FT VARIANT 13 FT /note="G -> D (in CSTLO; dbSNP:rs104894226)" FT /evidence="ECO:0000269|PubMed:16170316" FT /id="VAR_026108" FT VARIANT 13 FT /note="G -> R (in SFM; somatic mutation; shows constitutive FT activation of the MAPK and PI3K-AKT signaling pathways; FT dbSNP:rs104894228)" FT /evidence="ECO:0000269|PubMed:22683711" FT /id="VAR_068817" FT VARIANT 22 FT /note="Q -> K (in CMEMS; dbSNP:rs121917757)" FT /evidence="ECO:0000269|PubMed:17412879" FT /id="VAR_045977" FT VARIANT 37 FT /note="E -> EE (in CSTLO)" FT /evidence="ECO:0000269|PubMed:19995790" FT /id="VAR_068818" FT VARIANT 58 FT /note="T -> I (in CSTLO; dbSNP:rs121917758)" FT /evidence="ECO:0000269|PubMed:18247425" FT /id="VAR_045978" FT VARIANT 61 FT /note="Q -> K (in NMTC2; somatic mutation; increases FT transformation of cultured cell lines; dbSNP:rs28933406)" FT /evidence="ECO:0000269|PubMed:12727991, FT ECO:0000269|PubMed:18073111" FT /id="VAR_045979" FT VARIANT 61 FT /note="Q -> L (in melanoma; strongly reduced GTP hydrolysis FT in the presence of RAF1; increases transformation of FT cultured cell lines; dbSNP:rs121913233)" FT /evidence="ECO:0000269|PubMed:18073111" FT /id="VAR_006838" FT VARIANT 63 FT /note="E -> K (in CMEMS; dbSNP:rs121917756)" FT /evidence="ECO:0000269|PubMed:17412879" FT /id="VAR_045980" FT VARIANT 89 FT /note="S -> C (found in a patient with severe fetal hydrops FT and pleural effusion; uncertain significance; decreased FT activation of Ras protein signal transduction; FT dbSNP:rs755322824)" FT /evidence="ECO:0000269|PubMed:22821884" FT /id="VAR_078259" FT VARIANT 117 FT /note="K -> R (in CSTLO; dbSNP:rs104894227)" FT /evidence="ECO:0000269|PubMed:16443854" FT /id="VAR_045981" FT VARIANT 146 FT /note="A -> T (in CSTLO; dbSNP:rs104894231)" FT /evidence="ECO:0000269|PubMed:17054105" FT /id="VAR_045982" FT VARIANT 146 FT /note="A -> V (in CSTLO; dbSNP:rs121917759)" FT /evidence="ECO:0000269|PubMed:18247425" FT /id="VAR_045983" FT MUTAGEN 17 FT /note="S->N: Dominant negative. Prevents PLCE1 EGF-induced FT recruitment to plasma membrane. No effect on subcellular FT location of isoform 2." FT /evidence="ECO:0000269|PubMed:11022048, FT ECO:0000269|PubMed:14500341" FT MUTAGEN 26 FT /note="N->G: Loss of interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 29 FT /note="V->A: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 32 FT /note="Y->F: Loss of interaction and recruitment to plasma FT membrane of PLCE1; when associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 34 FT /note="P->G: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 35 FT /note="T->S: Loss of interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 37 FT /note="E->G: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 38 FT /note="D->N: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 39 FT /note="S->C: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 59 FT /note="A->T: Loss of GTPase activity and creation of an FT autophosphorylation site." FT MUTAGEN 61 FT /note="Q->I: Moderately increased transformation of FT cultured cell lines." FT /evidence="ECO:0000269|PubMed:18073111" FT MUTAGEN 61 FT /note="Q->R: Promotes interaction with SHOC2 and PP1C." FT /evidence="ECO:0000269|PubMed:35831509" FT MUTAGEN 61 FT /note="Q->V: Strongly increased transformation of cultured FT cell lines." FT /evidence="ECO:0000269|PubMed:18073111" FT MUTAGEN 83 FT /note="A->T: GTP-binding activity reduced by factor of 30." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 118 FT /note="C->S: Abolishes S-nitrosylation. No stimulation of FT guanine nucleotide exchange." FT /evidence="ECO:0000269|PubMed:12740440, FT ECO:0000269|PubMed:9020151" FT MUTAGEN 119 FT /note="D->N: Loss of GTP-binding activity." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 144 FT /note="T->I: GTP-binding activity reduced by factor of 25." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 164..165 FT /note="RQ->AV: Loss of GTP-binding activity." FT /evidence="ECO:0000269|PubMed:3011420" FT MUTAGEN 167..185 FT /note="KLRKLNPPDESGPGCMSCK->RLRRLNPPDESGPGCMSCR: In H-Ras- FT 3KR mutant; decreased fatty-acylation." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 170 FT /note="K->R: Increased Ras signaling due to impaired FT ubiquitination." FT /evidence="ECO:0000269|PubMed:30442762" FT MUTAGEN 181 FT /note="C->S: Exclusively localized in Golgi. Non- FT specifically localized on all endomembranes; when FT associated with S-184." FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:8626715" FT MUTAGEN 184 FT /note="C->S: Loss of S-(15-deoxy-Delta12,14-prostaglandin FT J2-9-yl)cysteine stimulation of Ras-GTPase activity. Mainly FT localized in Golgi. Non-specifically localized on all FT endomembranes; when associated with S-181." FT /evidence="ECO:0000269|PubMed:12684535, FT ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:8626715" FT STRAND 3..11 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 12..15 FT /evidence="ECO:0007829|PDB:6V9M" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 27..31 FT /evidence="ECO:0007829|PDB:1XCM" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:1XD2" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 60..63 FT /evidence="ECO:0007829|PDB:2CLD" FT HELIX 66..74 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:2CE2" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:1CRP" FT HELIX 87..104 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:7VV9" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:2CLD" FT HELIX 127..136 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 141..144 FT /evidence="ECO:0007829|PDB:2CE2" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:2CE2" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:2CE2" SQ SEQUENCE 189 AA; 21298 MW; EE6DC2D933E2856A CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHQYREQI KRVKDSDDVP MVLVGNKCDL AARTVESRQA QDLARSYGIP YIETSAKTRQ GVEDAFYTLV REIRQHKLRK LNPPDESGPG CMSCKCVLS // ID RHXF1_HUMAN Reviewed; 184 AA. AC Q8NHV9; O95030; Q3SYE0; DT 03-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 170. DE RecName: Full=Rhox homeobox family member 1 {ECO:0000305}; DE AltName: Full=Ovary-, testis- and epididymis-expressed gene protein; DE AltName: Full=Paired-like homeobox protein PEPP-1; GN Name=RHOXF1 {ECO:0000312|HGNC:HGNC:29993}; Synonyms=OTEX, PEPP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND MUTAGENESIS OF THE RP NUCLEAR LOCALIZATION SIGNAL. RC TISSUE=Ovary, and Testis; RX PubMed=11980563; DOI=10.1042/bj20020399; RA Geserick C., Weiss B., Schleuning W.-D., Haendler B.; RT "OTEX, an androgen-regulated human member of the paired-like class of RT homeobox genes."; RL Biochem. J. 366:367-375(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP TISSUE SPECIFICITY. RX PubMed=12490318; DOI=10.1016/s0378-1119(02)01087-9; RA Wayne C.M., MacLean J.A. II, Cornwall G., Wilkinson M.F.; RT "Two novel human X-linked homeobox genes, hPEPP1 and hPEPP2, selectively RT expressed in the testis."; RL Gene 301:1-11(2002). RN [5] RP VARIANT HIS-177. RX PubMed=26506222; DOI=10.1002/ana.24550; RA Park H.J., Hong Y.B., Choi Y.C., Lee J., Kim E.J., Lee J.S., Mo W.M., RA Ki S.M., Kim H.I., Kim H.J., Hyun Y.S., Hong H.D., Nam K., Jung S.C., RA Kim S.B., Kim S.H., Kim D.H., Oh K.W., Kim S.H., Yoo J.H., Lee J.E., RA Chung K.W., Choi B.O.; RT "ADSSL1 mutation relevant to autosomal recessive adolescent onset distal RT myopathy."; RL Ann. Neurol. 79:231-243(2016). RN [6] RP FUNCTION, TISSUE SPECIFICITY, VARIANT HIS-172, AND CHARACTERIZATION OF RP VARIANT HIS-172. RX PubMed=28171660; DOI=10.1093/hmg/ddw313; RA Borgmann J., Tuettelmann F., Dworniczak B., Roepke A., Song H.W., RA Kliesch S., Wilkinson M.F., Laurentino S., Gromoll J.; RT "The human RHOX gene cluster: target genes and functional analysis of gene RT variants in infertile men."; RL Hum. Mol. Genet. 25:4898-4910(2016). RN [7] RP VARIANTS VAL-91; MET-130; VAL-156 AND 160-ARG--ASP-184 DEL. RX PubMed=38258527; DOI=10.1093/molehr/gaae002; RA Yi S., Wang W., Su L., Meng L., Li Y., Tan C., Liu Q., Zhang H., Fan L., RA Lu G., Hu L., Du J., Lin G., Tan Y.Q., Tu C., Zhang Q.; RT "Deleterious variants in X-linked RHOXF1 cause male infertility with RT oligo- and azoospermia."; RL Mol. Hum. Reprod. 30:0-0(2024). CC -!- FUNCTION: Transcription factor maybe involved in reproductive CC processes. Modulates expression of target genes encoding proteins CC involved in processes relevant to spermatogenesis. CC {ECO:0000269|PubMed:28171660}. CC -!- SUBUNIT: Does not interact with itself. CC -!- INTERACTION: CC Q8NHV9; Q9BXW4: MAP1LC3C; NbExp=3; IntAct=EBI-3923409, EBI-2603996; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00108, CC ECO:0000269|PubMed:11980563}. CC -!- TISSUE SPECIFICITY: Ovary, testis and epididymis. Also detected in the CC prostate and the mammary gland. Expressed in many tumor cell lines CC derived from acute lymphocytic leukemia, prostate, endometrial CC adenocarcinoma, melanoma, bladder carcinoma, colon carcinoma, CC erythroleukemia and breast carcinoma. Not expressed in placenta. In CC testis, mainly expressed in germ cells, but also detected in somatic CC cells such as Sertoli cells, Leydig cells and peritubular cells CC (PubMed:28171660). {ECO:0000269|PubMed:12490318, CC ECO:0000269|PubMed:28171660}. CC -!- DEVELOPMENTAL STAGE: Predominantly expressed in late stage germ cells, CC pachytene spermatocytes and round spermatides. CC {ECO:0000269|PubMed:28171660}. CC -!- INDUCTION: By androgen. CC -!- DOMAIN: Mutagenesis of amino acids 147 to 164 and 155 to 164 lead to a CC major cytoplasmic localization, with only minor localization in the CC nucleus. CC -!- SIMILARITY: Belongs to the paired-like homeobox family. PEPP subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC78617.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY099086; AAM22794.1; -; mRNA. DR EMBL; AC005023; AAC78617.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC069324; AAH69324.1; -; mRNA. DR EMBL; BC069529; AAH69529.1; -; mRNA. DR EMBL; BC103857; AAI03858.1; -; mRNA. DR EMBL; BC103858; AAI03859.1; -; mRNA. DR CCDS; CCDS14593.1; -. DR RefSeq; NP_644811.1; NM_139282.3. DR AlphaFoldDB; Q8NHV9; -. DR SMR; Q8NHV9; -. DR BioGRID; 127708; 4. DR FunCoup; Q8NHV9; 31. DR IntAct; Q8NHV9; 3. DR STRING; 9606.ENSP00000217999; -. DR GlyGen; Q8NHV9; 1 site. DR BioMuta; RHOXF1; -. DR DMDM; 37537960; -. DR MassIVE; Q8NHV9; -. DR PaxDb; 9606-ENSP00000217999; -. DR PeptideAtlas; Q8NHV9; -. DR ProteomicsDB; 73767; -. DR Antibodypedia; 29868; 138 antibodies from 25 providers. DR DNASU; 158800; -. DR Ensembl; ENST00000217999.3; ENSP00000217999.1; ENSG00000101883.7. DR Ensembl; ENST00000703667.1; ENSP00000515423.1; ENSG00000101883.7. DR GeneID; 158800; -. DR KEGG; hsa:158800; -. DR MANE-Select; ENST00000217999.3; ENSP00000217999.1; NM_139282.3; NP_644811.1. DR UCSC; uc004esk.2; human. DR AGR; HGNC:29993; -. DR ClinPGx; PA162401287; -. DR CTD; 158800; -. DR DisGeNET; 158800; -. DR GeneCards; RHOXF1; -. DR HGNC; HGNC:29993; RHOXF1. DR HPA; ENSG00000101883; Tissue enhanced (brain, testis). DR MIM; 300446; gene. DR OpenTargets; ENSG00000101883; -. DR VEuPathDB; HostDB:ENSG00000101883; -. DR eggNOG; KOG0490; Eukaryota. DR GeneTree; ENSGT00940000163385; -. DR HOGENOM; CLU_118646_0_0_1; -. DR InParanoid; Q8NHV9; -. DR OMA; DDCVYIV; -. DR OrthoDB; 9634605at2759; -. DR PAN-GO; Q8NHV9; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q8NHV9; -. DR PathwayCommons; Q8NHV9; -. DR SignaLink; Q8NHV9; -. DR SIGNOR; Q8NHV9; -. DR Agora; ENSG00000101883; -. DR BioGRID-ORCS; 158800; 14 hits in 796 CRISPR screens. DR GeneWiki; RHOXF1; -. DR GenomeRNAi; 158800; -. DR Pharos; Q8NHV9; Tbio. DR PRO; PR:Q8NHV9; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q8NHV9; protein. DR Bgee; ENSG00000101883; Expressed in primordial germ cell in gonad and 94 other cell types or tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; NAS:UniProtKB. DR GO; GO:0003700; F:DNA-binding transcription factor activity; NAS:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0030521; P:androgen receptor signaling pathway; IEP:UniProtKB. DR GO; GO:0048666; P:neuron development; IBA:GO_Central. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd00086; homeodomain; 1. DR FunFam; 1.10.10.60:FF:000485; Rhox homeobox family member 1; 1. DR Gene3D; 1.10.10.60; Homeodomain-like; 1. DR InterPro; IPR001356; HD. DR InterPro; IPR017970; Homeobox_CS. DR InterPro; IPR009057; Homeodomain-like_sf. DR InterPro; IPR000047; HTH_motif. DR InterPro; IPR050649; Paired_Homeobox_TFs. DR PANTHER; PTHR24329; HOMEOBOX PROTEIN ARISTALESS; 1. DR PANTHER; PTHR24329:SF549; RHOX HOMEOBOX FAMILY MEMBER 1; 1. DR Pfam; PF00046; Homeodomain; 1. DR PRINTS; PR00031; HTHREPRESSR. DR SMART; SM00389; HOX; 1. DR SUPFAM; SSF46689; Homeodomain-like; 1. DR PROSITE; PS00027; HOMEOBOX_1; 1. DR PROSITE; PS50071; HOMEOBOX_2; 1. PE 1: Evidence at protein level; KW DNA-binding; Homeobox; Nucleus; Proteomics identification; KW Reference proteome; Transcription; Transcription regulation. FT CHAIN 1..184 FT /note="Rhox homeobox family member 1" FT /id="PRO_0000049245" FT DNA_BIND 103..162 FT /note="Homeobox" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108" FT REGION 26..104 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 155..164 FT /note="Nuclear localization signal" FT COMPBIAS 88..99 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VARIANT 91 FT /note="A -> V (found in a man with non-obstructive FT azoospermia; uncertain significance; dbSNP:rs1246288348)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089313" FT VARIANT 130 FT /note="V -> M (found in a man with non-obstructive FT azoospermia; uncertain significance)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089314" FT VARIANT 156 FT /note="A -> V (found in a man with severe oligozoospermia; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089315" FT VARIANT 160..184 FT /note="Missing (found in a man with severe oligozoospermia; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:38258527" FT /id="VAR_089316" FT VARIANT 172 FT /note="R -> H (in dbSNP:rs2301977)" FT /evidence="ECO:0000269|PubMed:28171660" FT /id="VAR_049587" FT VARIANT 177 FT /note="D -> H (in dbSNP:rs138060880)" FT /evidence="ECO:0000269|PubMed:26506222" FT /id="VAR_077002" SQ SEQUENCE 184 AA; 20542 MW; 90C67C7ACA2B292B CRC64; MARSLVHDTV FYCLSVYQVK ISPTPQLGAA SSAEGHVGQG APGLMGNMNP EGGVNHENGM NRDGGMIPEG GGGNQEPRQQ PQPPPEEPAQ AAMEGPQPEN MQPRTRRTKF TLLQVEELES VFRHTQYPDV PTRRELAENL GVTEDKVRVW FKNKRARCRR HQRELMLANE LRADPDDCVY IVVD // ID ROR1_HUMAN Reviewed; 937 AA. AC Q01973; Q5VVX6; Q66K77; Q92776; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 28-NOV-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Inactive tyrosine-protein kinase transmembrane receptor ROR1 {ECO:0000305}; DE AltName: Full=Neurotrophic tyrosine kinase, receptor-related 1; DE Flags: Precursor; GN Name=ROR1; Synonyms=NTRKR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT MET-518. RX PubMed=1334494; DOI=10.1016/s0021-9258(18)35733-8; RA Masiakowski P., Carroll R.D.; RT "A novel family of cell surface receptors with tyrosine kinase-like RT domain."; RL J. Biol. Chem. 267:26181-26190(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT). RX PubMed=8875995; RA Reddy U.R., Phatak S., Pleasure D.; RT "Human neural tissues express a truncated Ror1 receptor tyrosine kinase, RT lacking both extracellular and transmembrane domains."; RL Oncogene 13:1555-1559(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP LACK OF CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-482. RX PubMed=25029443; DOI=10.1371/journal.pone.0102695; RA Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C., Pan B., RA Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R., Sandoval W., RA Costa M., Polakis P., Arnott D., Rubinfeld B., Ernst J.A.; RT "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and RT ROR2 kinase domains."; RL PLoS ONE 9:E102695-E102695(2014). RN [7] RP FUNCTION, AND INTERACTION WITH IGFBP5 AND ERBB2. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [8] RP VARIANT [LARGE SCALE ANALYSIS] ASP-562. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-144; LEU-150; VAL-301; MET-518; RP ILE-567; ARG-624; CYS-646 AND ASN-776. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP INVOLVEMENT IN DFNB108, VARIANT DFNB108 THR-736, CHARACTERIZATION OF RP VARIANT DFNB108 THR-736, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=27162350; DOI=10.1073/pnas.1522512113; RA Diaz-Horta O., Abad C., Sennaroglu L., Foster J. II, DeSmidt A., RA Bademci G., Tokgoz-Yilmaz S., Duman D., Cengiz F.B., Grati M., Fitoz S., RA Liu X.Z., Farooq A., Imtiaz F., Currall B.B., Morton C.C., Nishita M., RA Minami Y., Lu Z., Walz K., Tekin M.; RT "ROR1 is essential for proper innervation of auditory hair cells and RT hearing in humans and mice."; RL Proc. Natl. Acad. Sci. U.S.A. 113:5993-5998(2016). CC -!- FUNCTION: Has very low kinase activity in vitro and is unlikely to CC function as a tyrosine kinase in vivo (PubMed:25029443). Receptor for CC ligand WNT5A which activate downstream NFkB signaling pathway and may CC result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, CC PubMed:27162350). In inner ear, crucial for spiral ganglion neurons to CC innervate auditory hair cells (PubMed:27162350). Via IGFBP5 ligand, CC forms a complex with ERBB2 to enhance CREB oncogenic signaling CC (PubMed:36949068). {ECO:0000269|PubMed:25029443, CC ECO:0000269|PubMed:27162350, ECO:0000269|PubMed:36949068}. CC -!- SUBUNIT: Interacts with ERBB2 and IGFBP5. CC {ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC Q01973; P00533: EGFR; NbExp=8; IntAct=EBI-6082337, EBI-297353; CC Q01973; P12931: SRC; NbExp=9; IntAct=EBI-6082337, EBI-621482; CC Q01973; P05480: Src; Xeno; NbExp=2; IntAct=EBI-6082337, EBI-298680; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:27162350}; Single- CC pass type I membrane protein. Cell projection, axon CC {ECO:0000250|UniProtKB:Q9Z139}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=Long; CC IsoId=Q01973-1; Sequence=Displayed; CC Name=Short; Synonyms=T-ROR1; CC IsoId=Q01973-2; Sequence=VSP_005008; CC Name=3; CC IsoId=Q01973-3; Sequence=VSP_043663, VSP_043664; CC -!- TISSUE SPECIFICITY: Expressed strongly in human heart, lung and kidney, CC but weakly in the CNS. Isoform Short is strongly expressed in fetal and CC adult CNS and in a variety of human cancers, including those CC originating from CNS or PNS neuroectoderm. CC -!- DEVELOPMENTAL STAGE: Expressed at high levels during early embryonic CC development. The expression levels drop strongly around day 16 and CC there are only very low levels in adult tissues. CC -!- DISEASE: Deafness, autosomal recessive, 108 (DFNB108) [MIM:617654]: A CC form of non-syndromic sensorineural hearing loss. Sensorineural CC deafness results from damage to the neural receptors of the inner ear, CC the nerve pathways to the brain, or the area of the brain that receives CC sound information. {ECO:0000269|PubMed:27162350}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. ROR subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: The kinase domain has very low catalytic activity in vitro. CC {ECO:0000269|PubMed:25029443}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M97675; AAA60275.1; -; mRNA. DR EMBL; U38894; AAC50714.1; -; mRNA. DR EMBL; AL137859; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL161742; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445205; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138793; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353713; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808029; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808030; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06556.1; -; Genomic_DNA. DR EMBL; BC080541; AAH80541.1; -; mRNA. DR CCDS; CCDS41344.1; -. [Q01973-3] DR CCDS; CCDS626.1; -. [Q01973-1] DR PIR; A45082; A45082. DR RefSeq; NP_001077061.1; NM_001083592.2. [Q01973-3] DR RefSeq; NP_005003.2; NM_005012.4. [Q01973-1] DR PDB; 5Z55; NMR; -; A=312-394. DR PDB; 6BA5; X-ray; 1.62 A; M/N/O/P=311-391. DR PDB; 6BAN; X-ray; 1.95 A; M/N/O/P=311-391. DR PDB; 6TU9; X-ray; 1.94 A; A/B=453-752. DR PDB; 7TNG; X-ray; 1.40 A; A=312-393. DR PDBsum; 5Z55; -. DR PDBsum; 6BA5; -. DR PDBsum; 6BAN; -. DR PDBsum; 6TU9; -. DR PDBsum; 7TNG; -. DR AlphaFoldDB; Q01973; -. DR SMR; Q01973; -. DR BioGRID; 110973; 124. DR DIP; DIP-29734N; -. DR FunCoup; Q01973; 357. DR IntAct; Q01973; 107. DR MINT; Q01973; -. DR STRING; 9606.ENSP00000360120; -. DR BindingDB; Q01973; -. DR ChEMBL; CHEMBL4665585; -. DR TCDB; 8.A.23.1.60; the basigin (basigin) family. DR GlyCosmos; Q01973; 4 sites, No reported glycans. DR GlyGen; Q01973; 5 sites, 5 N-linked glycans (2 sites). DR iPTMnet; Q01973; -. DR PhosphoSitePlus; Q01973; -. DR SwissPalm; Q01973; -. DR BioMuta; ROR1; -. DR DMDM; 118572711; -. DR jPOST; Q01973; -. DR MassIVE; Q01973; -. DR PaxDb; 9606-ENSP00000360120; -. DR PeptideAtlas; Q01973; -. DR ProteomicsDB; 58025; -. [Q01973-1] DR ProteomicsDB; 58026; -. [Q01973-2] DR ProteomicsDB; 58027; -. [Q01973-3] DR Pumba; Q01973; -. DR ABCD; Q01973; 29 sequenced antibodies. DR Antibodypedia; 33360; 927 antibodies from 43 providers. DR DNASU; 4919; -. DR Ensembl; ENST00000371079.6; ENSP00000360120.1; ENSG00000185483.13. [Q01973-1] DR Ensembl; ENST00000371080.5; ENSP00000360121.1; ENSG00000185483.13. [Q01973-3] DR GeneID; 4919; -. DR KEGG; hsa:4919; -. DR MANE-Select; ENST00000371079.6; ENSP00000360120.1; NM_005012.4; NP_005003.2. DR UCSC; uc001dbi.5; human. [Q01973-1] DR AGR; HGNC:10256; -. DR ClinPGx; PA34628; -. DR CTD; 4919; -. DR DisGeNET; 4919; -. DR GeneCards; ROR1; -. DR HGNC; HGNC:10256; ROR1. DR HPA; ENSG00000185483; Tissue enhanced (parathyroid). DR MalaCards; ROR1; -. DR MIM; 602336; gene. DR MIM; 617654; phenotype. DR OpenTargets; ENSG00000185483; -. DR Orphanet; 90636; Rare autosomal recessive non-syndromic sensorineural deafness type DFNB. DR VEuPathDB; HostDB:ENSG00000185483; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000153947; -. DR HOGENOM; CLU_701993_0_0_1; -. DR InParanoid; Q01973; -. DR OMA; IQNDECP; -. DR OrthoDB; 2431000at2759; -. DR PAN-GO; Q01973; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q01973; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q01973; -. DR Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2. DR SignaLink; Q01973; -. DR SIGNOR; Q01973; -. DR Agora; ENSG00000185483; -. DR BioGRID-ORCS; 4919; 17 hits in 1190 CRISPR screens. DR ChiTaRS; ROR1; human. DR GeneWiki; ROR1; -. DR GenomeRNAi; 4919; -. DR Pharos; Q01973; Tbio. DR PRO; PR:Q01973; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q01973; protein. DR Bgee; ENSG00000185483; Expressed in germinal epithelium of ovary and 154 other cell types or tissues. DR ExpressionAtlas; Q01973; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001725; C:stress fiber; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; TAS:ParkinsonsUK-UCL. DR GO; GO:0038023; F:signaling receptor activity; IDA:UniProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0042813; F:Wnt receptor activity; IMP:UniProtKB. DR GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB. DR GO; GO:0014002; P:astrocyte development; IEA:Ensembl. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; TAS:ProtInc. DR GO; GO:0048839; P:inner ear development; ISS:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd07467; CRD_TK_ROR1; 1. DR CDD; cd00108; KR; 1. DR CDD; cd05090; PTKc_Ror1; 1. DR FunFam; 1.10.2000.10:FF:000002; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.40.20.10:FF:000003; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.60.40.10:FF:000242; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 1.10.510.10:FF:000116; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 3.30.200.20:FF:000139; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR Gene3D; 1.10.2000.10; Frizzled cysteine-rich domain; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.40.20.10; Plasminogen Kringle 4; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR020067; Frizzled_dom. DR InterPro; IPR036790; Frizzled_dom_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000001; Kringle. DR InterPro; IPR013806; Kringle-like. DR InterPro; IPR018056; Kringle_CS. DR InterPro; IPR038178; Kringle_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR016247; Tyr_kinase_rcpt_ROR. DR PANTHER; PTHR24416:SF134; INACTIVE TYROSINE-PROTEIN KINASE TRANSMEMBRANE RECEPTOR ROR1; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF01392; Fz; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00051; Kringle; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000624; TyrPK_TMrec_ROR; 1. DR PRINTS; PR00018; KRINGLE. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00130; KR; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF57440; Kringle-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50038; FZ; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00021; KRINGLE_1; 1. DR PROSITE; PS50070; KRINGLE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; Deafness; KW Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain; KW Kinase; Kringle; Membrane; Non-syndromic deafness; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Signal; Transferase; Transmembrane; Transmembrane helix; KW Wnt signaling pathway. FT SIGNAL 1..29 FT /evidence="ECO:0000255" FT CHAIN 30..937 FT /note="Inactive tyrosine-protein kinase transmembrane FT receptor ROR1" FT /id="PRO_0000024458" FT TOPO_DOM 30..406 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 407..427 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 428..937 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 42..147 FT /note="Ig-like C2-type" FT DOMAIN 165..299 FT /note="FZ" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00090" FT DOMAIN 312..391 FT /note="Kringle" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00121" FT DOMAIN 473..746 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 753..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 833..890 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 753..762 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 763..779 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..864 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..880 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 479..487 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 506 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 645 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 47 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 315 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 79..131 FT /evidence="ECO:0000250" FT DISULFID 170..235 FT /evidence="ECO:0000250" FT DISULFID 178..228 FT /evidence="ECO:0000250" FT DISULFID 219..260 FT /evidence="ECO:0000250" FT DISULFID 248..296 FT /evidence="ECO:0000250" FT DISULFID 252..282 FT /evidence="ECO:0000250" FT DISULFID 313..391 FT /evidence="ECO:0000250" FT DISULFID 334..374 FT /evidence="ECO:0000250" FT DISULFID 362..386 FT /evidence="ECO:0000250" FT VAR_SEQ 1..549 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:8875995" FT /id="VSP_005008" FT VAR_SEQ 392..393 FT /note="DS -> GK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043663" FT VAR_SEQ 394..937 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043664" FT VARIANT 144 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041779" FT VARIANT 150 FT /note="F -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041780" FT VARIANT 301 FT /note="I -> V (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041781" FT VARIANT 518 FT /note="T -> M (in dbSNP:rs7527017)" FT /evidence="ECO:0000269|PubMed:1334494, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041782" FT VARIANT 562 FT /note="E -> D (in a breast cancer sample; somatic mutation; FT dbSNP:rs760789417)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035713" FT VARIANT 567 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041783" FT VARIANT 624 FT /note="G -> R (in dbSNP:rs55832740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041784" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34109134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041785" FT VARIANT 736 FT /note="R -> T (in DFNB108; impairs plasma membrane FT location; abolishes downstream NFkB activation; FT dbSNP:rs1553163562)" FT /evidence="ECO:0000269|PubMed:27162350" FT /id="VAR_079530" FT VARIANT 776 FT /note="S -> N (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041786" FT MUTAGEN 482 FT /note="C->G: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:25029443" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:7TNG" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 365..367 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 373..377 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 383..387 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 470..472 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 473..481 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 486..492 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 501..507 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 514..527 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 538..542 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 544..547 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 549..553 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 560..566 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 589..608 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 621..623 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 625..627 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 636..640 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 642..644 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 656..658 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 661..666 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 671..686 FT /evidence="ECO:0007829|PDB:6TU9" FT TURN 692..695 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 698..706 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 719..728 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 739..748 FT /evidence="ECO:0007829|PDB:6TU9" SQ SEQUENCE 937 AA; 104283 MW; 0EC0E4762A90C6C7 CRC64; MHRPRRRGTR PPLLALLAAL LLAARGAAAQ ETELSVSAEL VPTSSWNISS ELNKDSYLTL DEPMNNITTS LGQTAELHCK VSGNPPPTIR WFKNDAPVVQ EPRRLSFRST IYGSRLRIRN LDTTDTGYFQ CVATNGKEVV SSTGVLFVKF GPPPTASPGY SDEYEEDGFC QPYRGIACAR FIGNRTVYME SLHMQGEIEN QITAAFTMIG TSSHLSDKCS QFAIPSLCHY AFPYCDETSS VPKPRDLCRD ECEILENVLC QTEYIFARSN PMILMRLKLP NCEDLPQPES PEAANCIRIG IPMADPINKN HKCYNSTGVD YRGTVSVTKS GRQCQPWNSQ YPHTHTFTAL RFPELNGGHS YCRNPGNQKE APWCFTLDEN FKSDLCDIPA CDSKDSKEKN KMEILYILVP SVAIPLAIAL LFFFICVCRN NQKSSSAPVQ RQPKHVRGQN VEMSMLNAYK PKSKAKELPL SAVRFMEELG ECAFGKIYKG HLYLPGMDHA QLVAIKTLKD YNNPQQWTEF QQEASLMAEL HHPNIVCLLG AVTQEQPVCM LFEYINQGDL HEFLIMRSPH SDVGCSSDED GTVKSSLDHG DFLHIAIQIA AGMEYLSSHF FVHKDLAARN ILIGEQLHVK ISDLGLSREI YSADYYRVQS KSLLPIRWMP PEAIMYGKFS SDSDIWSFGV VLWEIFSFGL QPYYGFSNQE VIEMVRKRQL LPCSEDCPPR MYSLMTECWN EIPSRRPRFK DIHVRLRSWE GLSSHTSSTT PSGGNATTQT TSLSASPVSN LSNPRYPNYM FPSQGITPQG QIAGFIGPPI PQNQRFIPIN GYPIPPGYAA FPAAHYQPTG PPRVIQHCPP PKSRSPSSAS GSTSTGHVTS LPSSGSNQEA NIPLLPHMSI PNHPGGMGIT VFGNKSQKPY KIDSKQASLL GDANIHGHTE SMISAEL // ID SDCB1_HUMAN Reviewed; 298 AA. AC O00560; B2R5Q7; B4DUH3; B7ZLN2; O00173; O43391; Q14CP2; DT 02-MAY-2002, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1997, sequence version 1. DT 28-JAN-2026, entry version 232. DE RecName: Full=Syntenin-1; DE AltName: Full=Melanoma differentiation-associated protein 9; DE Short=MDA-9; DE AltName: Full=Pro-TGF-alpha cytoplasmic domain-interacting protein 18; DE Short=TACIP18; DE AltName: Full=Scaffold protein Pbp1; DE AltName: Full=Syndecan-binding protein 1; GN Name=SDCBP; Synonyms=MDA9, SYCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Lin J.J., Jiang H., Fisher P.B.; RT "Characterization of a novel melanoma differentiation associated gene, mda- RT 9, that is down-regulated during terminal cell differentiation."; RL Mol. Cell. Differ. 4:317-333(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH SDC2, AND VARIANT RP SER-69. RX PubMed=9391086; DOI=10.1073/pnas.94.25.13683; RA Grootjans J.J., Zimmermann P., Reekmans G., Smets A., Degeest G., Duerr J., RA David G.; RT "Syntenin, a PDZ protein that binds syndecan cytoplasmic domains."; RL Proc. Natl. Acad. Sci. U.S.A. 94:13683-13688(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Burbelo P.D.; RT "A new family of scaffold proteins."; RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=9511750; DOI=10.1016/s0378-1119(97)00562-3; RA Lin J.J., Jiang H., Fisher P.B.; RT "Melanoma differentiation associated gene-9, mda-9, is a human gamma RT interferon responsive gene."; RL Gene 207:105-110(1998). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Rectum, and Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP PROTEIN SEQUENCE OF 2-14; 218-229 AND 289-298, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Pre-B cell; RA Bienvenut W.V., Sumpton D.P., Lilla S., Ozanne B.W.; RL Submitted (FEB-2009) to UniProtKB. RN [10] RP INTERACTION WITH EPHB1 AND EPHA7. RX PubMed=9883737; DOI=10.1016/s0896-6273(00)80663-7; RA Torres R., Firestein B.L., Dong H., Staudinger J., Olson E.N., RA Huganir R.L., Bredt D.S., Gale N.W., Yancopoulos G.D.; RT "PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors RT and their ephrin ligands."; RL Neuron 21:1453-1463(1998). RN [11] RP FUNCTION, AND INTERACTION WITH TGFA. RX PubMed=10230395; DOI=10.1016/s1097-2765(00)80470-0; RA Fernandez-Larrea J., Merlos-Suarez A., Urena J.M., Baselga J., Arribas J.; RT "A role for a PDZ protein in the early secretory pathway for the targeting RT of proTGF-alpha to the cell surface."; RL Mol. Cell 3:423-433(1999). RN [12] RP INTERACTION WITH SYNDECANS; NRXN2 AND EPHB1. RX PubMed=10770943; DOI=10.1074/jbc.m002459200; RA Grootjans J.J., Reekmans G., Ceulemans H., David G.; RT "Syntenin-syndecan binding requires syndecan-synteny and the co-operation RT of both PDZ domains of syntenin."; RL J. Biol. Chem. 275:19933-19941(2000). RN [13] RP INTERACTION WITH SDCBP2. RC TISSUE=Fetal brain; RX PubMed=11152476; DOI=10.1074/jbc.m010647200; RA Koroll M., Rathjen F.G., Volkmer H.; RT "The neural cell recognition molecule neurofascin interacts with syntenin-1 RT but not with syntenin-2, both of which reveal self-associating activity."; RL J. Biol. Chem. 276:10646-10654(2001). RN [14] RP INTERACTION WITH NF2. RX PubMed=11432873; DOI=10.1074/jbc.m105792200; RA Jannatipour M., Dion P., Khan S., Jindal H., Fan X., Laganiere J., RA Chishti A.H., Rouleau G.A.; RT "Schwannomin isoform-1 interacts with syntenin via PDZ domains."; RL J. Biol. Chem. 276:33093-33100(2001). RN [15] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11179419; DOI=10.1091/mbc.12.2.339; RA Zimmermann P., Tomatis D., Rosas M., Grootjans J.J., Leenaerts I., RA Degeest G., Reekmans G., Coomans C., David G.; RT "Characterization of syntenin, a syndecan-binding PDZ protein, as a RT component of cell adhesion sites and microfilaments."; RL Mol. Biol. Cell 12:339-350(2001). RN [16] RP FUNCTION, AND INTERACTION WITH IL5RA. RX PubMed=11498591; DOI=10.1126/science.1059157; RA Geijsen N., Uings I.J., Pals C., Armstrong J., McKinnon M., RA Raaijmakers J.A.M., Lammers J.-W., Koenderman L., Coffer P.J.; RT "Cytokine-specific transcriptional regulation through an IL-5Ralpha RT interacting protein."; RL Science 293:1136-1138(2001). RN [17] RP SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS]. RC TISSUE=Melanoma; RX PubMed=12643545; DOI=10.1021/pr025562r; RA Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K., Valencia J., RA Muller J., Vieira W.D., Watabe H., Shabanowitz J., Hearing V.J., Hunt D.F., RA Appella E.; RT "Proteomic analysis of early melanosomes: identification of novel RT melanosomal proteins."; RL J. Proteome Res. 2:69-79(2003). RN [18] RP SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS]. RC TISSUE=Melanoma; RX PubMed=17081065; DOI=10.1021/pr060363j; RA Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J., RA Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S., RA Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.; RT "Proteomic and bioinformatic characterization of the biogenesis and RT function of melanosomes."; RL J. Proteome Res. 5:3135-3144(2006). RN [19] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDCD6IP. RX PubMed=22660413; DOI=10.1038/ncb2502; RA Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G., Geeraerts A., RA Ivarsson Y., Depoortere F., Coomans C., Vermeiren E., Zimmermann P., RA David G.; RT "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes."; RL Nat. Cell Biol. 14:677-685(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-46, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP REVIEW. RX PubMed=26032692; DOI=10.1111/boc.201500010; RA Friand V., David G., Zimmermann P.; RT "Syntenin and syndecan in the biogenesis of exosomes."; RL Biol. Cell 107:331-341(2015). RN [25] RP REVIEW. RX PubMed=25219541; DOI=10.1517/14728222.2014.959495; RA Kegelman T.P., Das S.K., Emdad L., Hu B., Menezes M.E., Bhoopathi P., RA Wang X.Y., Pellecchia M., Sarkar D., Fisher P.B.; RT "Targeting tumor invasion: the roles of MDA-9/Syntenin."; RL Expert Opin. Ther. Targets 19:97-112(2015). RN [26] RP FUNCTION. RX PubMed=26539120; DOI=10.3389/fphar.2015.00241; RA Kashyap R., Roucourt B., Lembo F., Fares J., Carcavilla A.M., Restouin A., RA Zimmermann P., Ghossoub R.; RT "Syntenin controls migration, growth, proliferation, and cell cycle RT progression in cancer cells."; RL Front. Pharmacol. 6:241-241(2015). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH TGFBR1, AND TISSUE RP SPECIFICITY. RX PubMed=25893292; DOI=10.1038/onc.2015.100; RA Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.; RT "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial- RT to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I RT receptor internalization."; RL Oncogene 35:389-401(2016). RN [28] RP REVIEW, AND FUNCTION. RX PubMed=26291527; DOI=10.1002/jcp.25136; RA Philley J.V., Kannan A., Dasgupta S.; RT "MDA-9/syntenin control."; RL J. Cell. Physiol. 231:545-550(2016). RN [29] RP X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 113-273. RX PubMed=12679023; DOI=10.1016/s0969-2126(03)00052-2; RA Kang B.S., Cooper D.R., Jelen F., Devedjiev Y., Derewenda U., Dauter Z., RA Otlewski J., Derewenda Z.S.; RT "PDZ tandem of human syntenin: crystal structure and functional RT properties."; RL Structure 11:459-468(2003). RN [30] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 197-270 IN COMPLEXES WITH IL5RA RP AND SDC4. RX PubMed=12842047; DOI=10.1016/s0969-2126(03)00125-4; RA Kang B.S., Cooper D.R., Devedjiev Y., Derewenda U., Derewenda Z.S.; RT "Molecular roots of degenerate specificity in syntenin's PDZ2 domain: RT reassessment of the PDZ recognition paradigm."; RL Structure 11:845-853(2003). RN [31] RP X-RAY CRYSTALLOGRAPHY (0.73 ANGSTROMS) OF 197-273. RX PubMed=15081807; DOI=10.1016/j.jmb.2004.02.057; RA Kang B.S., Devedjiev Y., Derewenda U., Derewenda Z.S.; RT "The PDZ2 domain of syntenin at ultra-high resolution: bridging the gap RT between macromolecular and small molecule crystallography."; RL J. Mol. Biol. 338:483-493(2004). RN [32] RP X-RAY CRYSTALLOGRAPHY (1.56 ANGSTROMS) OF 113-273 IN COMPLEXES WITH RP C-TERMINAL PEPTIDES FROM NEUREXIN; EPHB1 AND SDC4. RX PubMed=16533050; DOI=10.1021/bi052225y; RA Grembecka J., Cierpicki T., Devedjiev Y., Derewenda U., Kang B.S., RA Bushweller J.H., Derewenda Z.S.; RT "The binding of the PDZ tandem of syntenin to target proteins."; RL Biochemistry 45:3674-3683(2006). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 111-275 IN COMPLEXES WITH RP C-TERMINAL PEPTIDES FROM FZD7 AND INOSITOL BISPHOSPHATE, INTERACTION WITH RP FZD7, MUTAGENESIS OF LYS-214; ASN-215 AND LYS-250, AND SUBCELLULAR RP LOCATION. RX PubMed=27386966; DOI=10.1038/ncomms12101; RA Egea-Jimenez A.L., Gallardo R., Garcia-Pino A., Ivarsson Y., RA Wawrzyniak A.M., Kashyap R., Loris R., Schymkowitz J., Rousseau F., RA Zimmermann P.; RT "Frizzled 7 and PIP2 binding by syntenin PDZ2 domain supports Frizzled 7 RT trafficking and signalling."; RL Nat. Commun. 7:12101-12101(2016). CC -!- FUNCTION: Multifunctional adapter protein involved in diverse array of CC functions including trafficking of transmembrane proteins, neuro and CC immunomodulation, exosome biogenesis, and tumorigenesis CC (PubMed:26291527). Positively regulates TGFB1-mediated SMAD2/3 CC activation and TGFB1-induced epithelial-to-mesenchymal transition (EMT) CC and cell migration in various cell types. May increase TGFB1 signaling CC by enhancing cell-surface expression of TGFR1 by preventing the CC interaction between TGFR1 and CAV1 and subsequent CAV1-dependent CC internalization and degradation of TGFR1 (PubMed:25893292). In concert CC with SDC1/4 and PDCD6IP, regulates exosome biogenesis CC (PubMed:22660413). Regulates migration, growth, proliferation, and cell CC cycle progression in a variety of cancer types (PubMed:26539120). In CC adherens junctions may function to couple syndecans to cytoskeletal CC proteins or signaling components. Seems to couple transcription factor CC SOX4 to the IL-5 receptor (IL5RA) (PubMed:11498591). May also play a CC role in vesicular trafficking (PubMed:11179419). Seems to be required CC for the targeting of TGFA to the cell surface in the early secretory CC pathway (PubMed:10230395). {ECO:0000269|PubMed:10230395, CC ECO:0000269|PubMed:11179419, ECO:0000269|PubMed:11498591, CC ECO:0000269|PubMed:22660413, ECO:0000269|PubMed:25893292, CC ECO:0000269|PubMed:26539120, ECO:0000303|PubMed:26291527}. CC -!- SUBUNIT: Monomer and homodimer (By similarity). Interacts with SDC1, CC SDC2, SDC3, SDC4, NRXN2, EPHA7, EPHB1, NF2 isoform 1, TGFA and IL5RA. CC Interacts with NFASC and PTPRJ (By similarity). Interacts with SDCBP2 CC (PubMed:11152476). Interacts with PDCD6IP (PubMed:22660413). Forms a CC complex with PDCD6IP and SDC2 (PubMed:22660413). Interacts (via C- CC terminus) with TGFBR1 (PubMed:25893292). Binds to FZD7; this CC interaction is increased by inositol trisphosphate (IP3) CC (PubMed:27386966). Interacts with SMO (By similarity). CC {ECO:0000250|UniProtKB:O08992, ECO:0000250|UniProtKB:Q9JI92, CC ECO:0000269|PubMed:11152476, ECO:0000269|PubMed:22660413, CC ECO:0000269|PubMed:25893292, ECO:0000269|PubMed:27386966}. CC -!- INTERACTION: CC O00560; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-727004, EBI-743598; CC O00560; Q9NX04: AIRIM; NbExp=3; IntAct=EBI-727004, EBI-8643161; CC O00560; Q7Z3H0-1: ANKRD33; NbExp=3; IntAct=EBI-727004, EBI-16746154; CC O00560; Q8N2N9-4: ANKRD36B; NbExp=3; IntAct=EBI-727004, EBI-12170453; CC O00560; Q6AI12: ANKRD40; NbExp=3; IntAct=EBI-727004, EBI-2838246; CC O00560; Q92688: ANP32B; NbExp=6; IntAct=EBI-727004, EBI-762428; CC O00560; Q96GX9: APIP; NbExp=5; IntAct=EBI-727004, EBI-359248; CC O00560; P53365: ARFIP2; NbExp=3; IntAct=EBI-727004, EBI-638194; CC O00560; Q15041: ARL6IP1; NbExp=3; IntAct=EBI-727004, EBI-714543; CC O00560; P54253: ATXN1; NbExp=6; IntAct=EBI-727004, EBI-930964; CC O00560; Q5TBC7: BCL2L15; NbExp=3; IntAct=EBI-727004, EBI-10247136; CC O00560; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-727004, EBI-10181188; CC O00560; Q9H3H3: C11orf68; NbExp=3; IntAct=EBI-727004, EBI-721765; CC O00560; Q9H3H3-3: C11orf68; NbExp=3; IntAct=EBI-727004, EBI-12002214; CC O00560; O14523: C2CD2L; NbExp=3; IntAct=EBI-727004, EBI-12822627; CC O00560; Q9NP86: CABP5; NbExp=3; IntAct=EBI-727004, EBI-10311131; CC O00560; A2RRN7: CADPS; NbExp=3; IntAct=EBI-727004, EBI-10179719; CC O00560; Q9ULU8-4: CADPS; NbExp=3; IntAct=EBI-727004, EBI-10180690; CC O00560; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-727004, EBI-739580; CC O00560; P51636: CAV2; NbExp=3; IntAct=EBI-727004, EBI-603607; CC O00560; O75828: CBR3; NbExp=8; IntAct=EBI-727004, EBI-714504; CC O00560; Q68D86: CCDC102B; NbExp=3; IntAct=EBI-727004, EBI-10171570; CC O00560; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-727004, EBI-711501; CC O00560; P32320: CDA; NbExp=6; IntAct=EBI-727004, EBI-9250559; CC O00560; P49427: CDC34; NbExp=6; IntAct=EBI-727004, EBI-975634; CC O00560; Q9H5V8: CDCP1; NbExp=6; IntAct=EBI-727004, EBI-1019736; CC O00560; O14735: CDIPT; NbExp=3; IntAct=EBI-727004, EBI-358858; CC O00560; P55273: CDKN2D; NbExp=3; IntAct=EBI-727004, EBI-745859; CC O00560; Q53EZ4: CEP55; NbExp=6; IntAct=EBI-727004, EBI-747776; CC O00560; Q6P2H3-3: CEP85; NbExp=3; IntAct=EBI-727004, EBI-12368239; CC O00560; Q9UFW8: CGGBP1; NbExp=3; IntAct=EBI-727004, EBI-723153; CC O00560; Q9UKJ5: CHIC2; NbExp=3; IntAct=EBI-727004, EBI-741528; CC O00560; Q9HD42: CHMP1A; NbExp=3; IntAct=EBI-727004, EBI-1057156; CC O00560; P49760: CLK2; NbExp=3; IntAct=EBI-727004, EBI-750020; CC O00560; P49761: CLK3; NbExp=6; IntAct=EBI-727004, EBI-745579; CC O00560; Q96DZ9: CMTM5; NbExp=3; IntAct=EBI-727004, EBI-2548702; CC O00560; Q96DZ9-2: CMTM5; NbExp=3; IntAct=EBI-727004, EBI-11522780; CC O00560; P13073: COX4I1; NbExp=4; IntAct=EBI-727004, EBI-1056574; CC O00560; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-727004, EBI-10260134; CC O00560; O43186: CRX; NbExp=3; IntAct=EBI-727004, EBI-748171; CC O00560; P02489: CRYAA; NbExp=7; IntAct=EBI-727004, EBI-6875961; CC O00560; Q5HYN5: CT45A1; NbExp=3; IntAct=EBI-727004, EBI-12051833; CC O00560; P0DMU9: CT45A10; NbExp=6; IntAct=EBI-727004, EBI-12153495; CC O00560; Q8NHU0: CT45A3; NbExp=9; IntAct=EBI-727004, EBI-8643558; CC O00560; Q6NSH3: CT45A5; NbExp=3; IntAct=EBI-727004, EBI-8635816; CC O00560; P56545-3: CTBP2; NbExp=3; IntAct=EBI-727004, EBI-10171902; CC O00560; Q9GZU7: CTDSP1; NbExp=3; IntAct=EBI-727004, EBI-751587; CC O00560; Q9NTM9: CUTC; NbExp=6; IntAct=EBI-727004, EBI-714918; CC O00560; P32321: DCTD; NbExp=6; IntAct=EBI-727004, EBI-739870; CC O00560; Q9H773: DCTPP1; NbExp=3; IntAct=EBI-727004, EBI-723569; CC O00560; Q13838: DDX39B; NbExp=3; IntAct=EBI-727004, EBI-348622; CC O00560; Q96Q80: DERL3; NbExp=3; IntAct=EBI-727004, EBI-12831318; CC O00560; Q14565: DMC1; NbExp=7; IntAct=EBI-727004, EBI-930865; CC O00560; G5E9A7: DMWD; NbExp=3; IntAct=EBI-727004, EBI-10976677; CC O00560; P50570: DNM2; NbExp=3; IntAct=EBI-727004, EBI-346547; CC O00560; Q14919: DRAP1; NbExp=5; IntAct=EBI-727004, EBI-712941; CC O00560; Q96EV8: DTNBP1; NbExp=3; IntAct=EBI-727004, EBI-465804; CC O00560; P63172: DYNLT1; NbExp=3; IntAct=EBI-727004, EBI-1176455; CC O00560; Q96JC9: EAF1; NbExp=3; IntAct=EBI-727004, EBI-769261; CC O00560; Q8WWZ3: EDARADD; NbExp=3; IntAct=EBI-727004, EBI-2949647; CC O00560; Q8N9N8: EIF1AD; NbExp=6; IntAct=EBI-727004, EBI-750700; CC O00560; P63241: EIF5A; NbExp=3; IntAct=EBI-727004, EBI-373150; CC O00560; Q9GZV4: EIF5A2; NbExp=6; IntAct=EBI-727004, EBI-748028; CC O00560; Q15717: ELAVL1; NbExp=3; IntAct=EBI-727004, EBI-374260; CC O00560; Q9NT22: EMILIN3; NbExp=3; IntAct=EBI-727004, EBI-3197883; CC O00560; Q8TC92: ENOX1; NbExp=3; IntAct=EBI-727004, EBI-713221; CC O00560; Q96C92-2: ENTR1; NbExp=3; IntAct=EBI-727004, EBI-10178036; CC O00560; A1L162: ERICH2; NbExp=3; IntAct=EBI-727004, EBI-2682520; CC O00560; Q9NPD3: EXOSC4; NbExp=3; IntAct=EBI-727004, EBI-371823; CC O00560; Q13158: FADD; NbExp=6; IntAct=EBI-727004, EBI-494804; CC O00560; Q9NWS6: FAM118A; NbExp=3; IntAct=EBI-727004, EBI-8638992; CC O00560; Q9BPY3: FAM118B; NbExp=3; IntAct=EBI-727004, EBI-726822; CC O00560; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-727004, EBI-8468186; CC O00560; Q8IZU0: FAM9B; NbExp=6; IntAct=EBI-727004, EBI-10175124; CC O00560; Q13643: FHL3; NbExp=3; IntAct=EBI-727004, EBI-741101; CC O00560; Q5TD97: FHL5; NbExp=3; IntAct=EBI-727004, EBI-750641; CC O00560; Q8NFF5: FLAD1; NbExp=4; IntAct=EBI-727004, EBI-742815; CC O00560; O15409: FOXP2; NbExp=3; IntAct=EBI-727004, EBI-983612; CC O00560; Q6NZ44: FTH1; NbExp=3; IntAct=EBI-727004, EBI-10180219; CC O00560; P02792: FTL; NbExp=7; IntAct=EBI-727004, EBI-713279; CC O00560; O75084: FZD7; NbExp=4; IntAct=EBI-727004, EBI-746917; CC O00560; Q7L5D6: GET4; NbExp=3; IntAct=EBI-727004, EBI-711823; CC O00560; O95749: GGPS1; NbExp=3; IntAct=EBI-727004, EBI-10179283; CC O00560; Q5VSY0: GKAP1; NbExp=3; IntAct=EBI-727004, EBI-743722; CC O00560; Q9Y3E0: GOLT1B; NbExp=3; IntAct=EBI-727004, EBI-4402607; CC O00560; Q8N954: GPATCH11; NbExp=3; IntAct=EBI-727004, EBI-2555378; CC O00560; Q8N954-2: GPATCH11; NbExp=3; IntAct=EBI-727004, EBI-12178961; CC O00560; A8MXD5: GRXCR1; NbExp=3; IntAct=EBI-727004, EBI-5235612; CC O00560; O15499: GSC2; NbExp=3; IntAct=EBI-727004, EBI-19954058; CC O00560; Q2KHT4-3: GSG1; NbExp=3; IntAct=EBI-727004, EBI-12951679; CC O00560; V9HW60: HEL-S-182mP; NbExp=3; IntAct=EBI-727004, EBI-10180762; CC O00560; V9HW40: HEL-S-25; NbExp=3; IntAct=EBI-727004, EBI-10330099; CC O00560; Q96MH2: HEXIM2; NbExp=3; IntAct=EBI-727004, EBI-5460660; CC O00560; Q5VTY9: HHAT; NbExp=3; IntAct=EBI-727004, EBI-12951255; CC O00560; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-727004, EBI-2549423; CC O00560; O15347: HMGB3; NbExp=7; IntAct=EBI-727004, EBI-2214136; CC O00560; P07910: HNRNPC; NbExp=6; IntAct=EBI-727004, EBI-357966; CC O00560; Q9NSC5: HOMER3; NbExp=5; IntAct=EBI-727004, EBI-748420; CC O00560; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-727004, EBI-10172004; CC O00560; P49639: HOXA1; NbExp=6; IntAct=EBI-727004, EBI-740785; CC O00560; P31268: HOXA7; NbExp=3; IntAct=EBI-727004, EBI-3910421; CC O00560; P00492: HPRT1; NbExp=7; IntAct=EBI-727004, EBI-748210; CC O00560; O75506: HSBP1; NbExp=8; IntAct=EBI-727004, EBI-748664; CC O00560; O75031: HSF2BP; NbExp=3; IntAct=EBI-727004, EBI-7116203; CC O00560; P42858: HTT; NbExp=12; IntAct=EBI-727004, EBI-466029; CC O00560; O60921: HUS1; NbExp=3; IntAct=EBI-727004, EBI-1056174; CC O00560; Q02535: ID3; NbExp=3; IntAct=EBI-727004, EBI-1387094; CC O00560; P24592: IGFBP6; NbExp=3; IntAct=EBI-727004, EBI-947015; CC O00560; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-727004, EBI-8638439; CC O00560; Q13422: IKZF1; NbExp=3; IntAct=EBI-727004, EBI-745305; CC O00560; Q01344: IL5RA; NbExp=2; IntAct=EBI-727004, EBI-1759442; CC O00560; Q8NBZ0: INO80E; NbExp=6; IntAct=EBI-727004, EBI-769401; CC O00560; Q9H079: KATNBL1; NbExp=3; IntAct=EBI-727004, EBI-715394; CC O00560; O95259: KCNH1; NbExp=3; IntAct=EBI-727004, EBI-2909270; CC O00560; P63252: KCNJ2; NbExp=3; IntAct=EBI-727004, EBI-703457; CC O00560; Q719H9: KCTD1; NbExp=6; IntAct=EBI-727004, EBI-9027502; CC O00560; Q8NC69: KCTD6; NbExp=6; IntAct=EBI-727004, EBI-2511344; CC O00560; Q7L273: KCTD9; NbExp=6; IntAct=EBI-727004, EBI-4397613; CC O00560; Q5VWX1: KHDRBS2; NbExp=6; IntAct=EBI-727004, EBI-742808; CC O00560; O60333-2: KIF1B; NbExp=3; IntAct=EBI-727004, EBI-10975473; CC O00560; Q53G59: KLHL12; NbExp=8; IntAct=EBI-727004, EBI-740929; CC O00560; O95198: KLHL2; NbExp=3; IntAct=EBI-727004, EBI-746999; CC O00560; P02533: KRT14; NbExp=3; IntAct=EBI-727004, EBI-702178; CC O00560; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-727004, EBI-11749135; CC O00560; Q9BYS1: KRTAP1-5; NbExp=3; IntAct=EBI-727004, EBI-11741292; CC O00560; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-727004, EBI-10172290; CC O00560; P26371: KRTAP5-9; NbExp=6; IntAct=EBI-727004, EBI-3958099; CC O00560; O43679: LDB2; NbExp=3; IntAct=EBI-727004, EBI-2865580; CC O00560; P07195: LDHB; NbExp=3; IntAct=EBI-727004, EBI-358748; CC O00560; O95751: LDOC1; NbExp=6; IntAct=EBI-727004, EBI-740738; CC O00560; O95214: LEPROTL1; NbExp=3; IntAct=EBI-727004, EBI-750776; CC O00560; P05162: LGALS2; NbExp=9; IntAct=EBI-727004, EBI-7181544; CC O00560; P62312: LSM6; NbExp=6; IntAct=EBI-727004, EBI-373310; CC O00560; Q8IV03: LURAP1L; NbExp=3; IntAct=EBI-727004, EBI-12898559; CC O00560; Q9NQ48: LZTFL1; NbExp=6; IntAct=EBI-727004, EBI-2824799; CC O00560; Q13257: MAD2L1; NbExp=3; IntAct=EBI-727004, EBI-78203; CC O00560; P45984: MAPK9; NbExp=3; IntAct=EBI-727004, EBI-713568; CC O00560; Q9UPY8: MAPRE3; NbExp=6; IntAct=EBI-727004, EBI-726739; CC O00560; O95460-2: MATN4; NbExp=3; IntAct=EBI-727004, EBI-12072296; CC O00560; O95983: MBD3; NbExp=3; IntAct=EBI-727004, EBI-1783068; CC O00560; Q9NPJ6: MED4; NbExp=3; IntAct=EBI-727004, EBI-394607; CC O00560; P50221: MEOX1; NbExp=3; IntAct=EBI-727004, EBI-2864512; CC O00560; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-727004, EBI-16439278; CC O00560; A0A0C4DFN3: MGLL; NbExp=3; IntAct=EBI-727004, EBI-12866138; CC O00560; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-727004, EBI-10172526; CC O00560; Q9H8M7: MINDY3; NbExp=3; IntAct=EBI-727004, EBI-724928; CC O00560; Q9UHC7: MKRN1; NbExp=3; IntAct=EBI-727004, EBI-373524; CC O00560; Q9BU76: MMTAG2; NbExp=3; IntAct=EBI-727004, EBI-742459; CC O00560; Q13875-3: MOBP; NbExp=3; IntAct=EBI-727004, EBI-12013470; CC O00560; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-727004, EBI-995714; CC O00560; Q96HT8: MRFAP1L1; NbExp=8; IntAct=EBI-727004, EBI-748896; CC O00560; Q5JR59: MTUS2; NbExp=3; IntAct=EBI-727004, EBI-742948; CC O00560; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-727004, EBI-11522433; CC O00560; Q8WY64: MYLIP; NbExp=3; IntAct=EBI-727004, EBI-6952711; CC O00560; O15049: N4BP3; NbExp=3; IntAct=EBI-727004, EBI-2512055; CC O00560; O95544: NADK; NbExp=7; IntAct=EBI-727004, EBI-743949; CC O00560; Q9UJ70: NAGK; NbExp=5; IntAct=EBI-727004, EBI-372578; CC O00560; Q9UJ70-2: NAGK; NbExp=3; IntAct=EBI-727004, EBI-11526455; CC O00560; Q9H115: NAPB; NbExp=3; IntAct=EBI-727004, EBI-3921185; CC O00560; Q7Z6G3-2: NECAB2; NbExp=5; IntAct=EBI-727004, EBI-10172876; CC O00560; Q15223: NECTIN1; NbExp=8; IntAct=EBI-727004, EBI-1771314; CC O00560; Q6ZUT1: NKAPD1; NbExp=8; IntAct=EBI-727004, EBI-3920396; CC O00560; Q6ZUT1-2: NKAPD1; NbExp=3; IntAct=EBI-727004, EBI-10180231; CC O00560; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-727004, EBI-945833; CC O00560; P49902: NT5C2; NbExp=3; IntAct=EBI-727004, EBI-742084; CC O00560; P0CE72: OCM; NbExp=3; IntAct=EBI-727004, EBI-11955379; CC O00560; A1E959: ODAM; NbExp=3; IntAct=EBI-727004, EBI-5774125; CC O00560; Q96CV9: OPTN; NbExp=3; IntAct=EBI-727004, EBI-748974; CC O00560; Q92882: OSTF1; NbExp=3; IntAct=EBI-727004, EBI-1051152; CC O00560; P61457: PCBD1; NbExp=3; IntAct=EBI-727004, EBI-740475; CC O00560; P49585: PCYT1A; NbExp=3; IntAct=EBI-727004, EBI-2563309; CC O00560; Q5VU43: PDE4DIP; NbExp=4; IntAct=EBI-727004, EBI-1105124; CC O00560; Q5VU43-2: PDE4DIP; NbExp=4; IntAct=EBI-727004, EBI-9640281; CC O00560; O76083-2: PDE9A; NbExp=3; IntAct=EBI-727004, EBI-11524542; CC O00560; P50479: PDLIM4; NbExp=3; IntAct=EBI-727004, EBI-372861; CC O00560; Q13113: PDZK1IP1; NbExp=3; IntAct=EBI-727004, EBI-716063; CC O00560; Q99471: PFDN5; NbExp=3; IntAct=EBI-727004, EBI-357275; CC O00560; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-727004, EBI-713786; CC O00560; Q9UIL8: PHF11; NbExp=3; IntAct=EBI-727004, EBI-2861403; CC O00560; Q8WWB5: PIH1D2; NbExp=3; IntAct=EBI-727004, EBI-10232538; CC O00560; Q8ND90: PNMA1; NbExp=8; IntAct=EBI-727004, EBI-302345; CC O00560; Q9UL42: PNMA2; NbExp=7; IntAct=EBI-727004, EBI-302355; CC O00560; P52435: POLR2J; NbExp=3; IntAct=EBI-727004, EBI-394753; CC O00560; Q9Y2Y1: POLR3K; NbExp=3; IntAct=EBI-727004, EBI-11023785; CC O00560; O75170: PPP6R2; NbExp=2; IntAct=EBI-727004, EBI-359739; CC O00560; Q8NAV1: PRPF38A; NbExp=3; IntAct=EBI-727004, EBI-715374; CC O00560; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-727004, EBI-5280197; CC O00560; Q9NZ81: PRR13; NbExp=3; IntAct=EBI-727004, EBI-740924; CC O00560; P49720: PSMB3; NbExp=3; IntAct=EBI-727004, EBI-603340; CC O00560; P62333: PSMC6; NbExp=6; IntAct=EBI-727004, EBI-357669; CC O00560; Q9UL46: PSME2; NbExp=6; IntAct=EBI-727004, EBI-741630; CC O00560; O43586: PSTPIP1; NbExp=3; IntAct=EBI-727004, EBI-1050964; CC O00560; Q03393: PTS; NbExp=4; IntAct=EBI-727004, EBI-712344; CC O00560; Q9UHX1: PUF60; NbExp=3; IntAct=EBI-727004, EBI-1053259; CC O00560; Q53H96: PYCR3; NbExp=8; IntAct=EBI-727004, EBI-2959680; CC O00560; Q53GL6: RALY; NbExp=3; IntAct=EBI-727004, EBI-9512693; CC O00560; Q14498: RBM39; NbExp=3; IntAct=EBI-727004, EBI-395290; CC O00560; Q96HR9: REEP6; NbExp=3; IntAct=EBI-727004, EBI-750345; CC O00560; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-727004, EBI-14065960; CC O00560; Q04864: REL; NbExp=3; IntAct=EBI-727004, EBI-307352; CC O00560; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-727004, EBI-9091816; CC O00560; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-727004, EBI-396669; CC O00560; P13489: RNH1; NbExp=8; IntAct=EBI-727004, EBI-1237106; CC O00560; Q9HAT0: ROPN1; NbExp=6; IntAct=EBI-727004, EBI-1378139; CC O00560; Q8TA86: RP9; NbExp=5; IntAct=EBI-727004, EBI-630339; CC O00560; P49247: RPIA; NbExp=3; IntAct=EBI-727004, EBI-744831; CC O00560; P35268: RPL22; NbExp=5; IntAct=EBI-727004, EBI-354533; CC O00560; Q96P16-3: RPRD1A; NbExp=3; IntAct=EBI-727004, EBI-12840198; CC O00560; Q9NS64: RPRM; NbExp=3; IntAct=EBI-727004, EBI-1052363; CC O00560; P62854: RPS26; NbExp=3; IntAct=EBI-727004, EBI-353438; CC O00560; P31350: RRM2; NbExp=3; IntAct=EBI-727004, EBI-2339245; CC O00560; Q15050: RRS1; NbExp=3; IntAct=EBI-727004, EBI-749186; CC O00560; Q17RB0: RTL8B; NbExp=3; IntAct=EBI-727004, EBI-10238588; CC O00560; Q16799-3: RTN1; NbExp=3; IntAct=EBI-727004, EBI-10180131; CC O00560; Q59EK9: RUNDC3A; NbExp=3; IntAct=EBI-727004, EBI-747225; CC O00560; Q59EK9-3: RUNDC3A; NbExp=3; IntAct=EBI-727004, EBI-11957366; CC O00560; P04271: S100B; NbExp=3; IntAct=EBI-727004, EBI-458391; CC O00560; Q8WXD2: SCG3; NbExp=3; IntAct=EBI-727004, EBI-12162999; CC O00560; Q9UN30-2: SCML1; NbExp=3; IntAct=EBI-727004, EBI-12137487; CC O00560; O00560: SDCBP; NbExp=7; IntAct=EBI-727004, EBI-727004; CC O00560; Q8WYJ6: SEPTIN1; NbExp=3; IntAct=EBI-727004, EBI-693002; CC O00560; Q9UH03: SEPTIN3; NbExp=6; IntAct=EBI-727004, EBI-727037; CC O00560; Q01105: SET; NbExp=3; IntAct=EBI-727004, EBI-1053182; CC O00560; Q01105-2: SET; NbExp=3; IntAct=EBI-727004, EBI-7481343; CC O00560; Q8WV19: SFT2D1; NbExp=3; IntAct=EBI-727004, EBI-2854842; CC O00560; Q8IUQ4: SIAH1; NbExp=3; IntAct=EBI-727004, EBI-747107; CC O00560; Q9BRV3: SLC50A1; NbExp=3; IntAct=EBI-727004, EBI-8634123; CC O00560; P51531: SMARCA2; NbExp=2; IntAct=EBI-727004, EBI-679562; CC O00560; P51531-2: SMARCA2; NbExp=3; IntAct=EBI-727004, EBI-10212306; CC O00560; P37840: SNCA; NbExp=3; IntAct=EBI-727004, EBI-985879; CC O00560; P09012: SNRPA; NbExp=3; IntAct=EBI-727004, EBI-607085; CC O00560; Q13596: SNX1; NbExp=3; IntAct=EBI-727004, EBI-2822329; CC O00560; Q5MJ09: SPANXN3; NbExp=3; IntAct=EBI-727004, EBI-12037215; CC O00560; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-727004, EBI-5235340; CC O00560; P12931: SRC; NbExp=2; IntAct=EBI-727004, EBI-621482; CC O00560; Q8N9Q2: SREK1IP1; NbExp=6; IntAct=EBI-727004, EBI-10268630; CC O00560; Q05519: SRSF11; NbExp=3; IntAct=EBI-727004, EBI-1051785; CC O00560; Q05519-2: SRSF11; NbExp=3; IntAct=EBI-727004, EBI-11975029; CC O00560; P84103: SRSF3; NbExp=3; IntAct=EBI-727004, EBI-372557; CC O00560; Q16629: SRSF7; NbExp=6; IntAct=EBI-727004, EBI-398885; CC O00560; A1L4H1: SSC5D; NbExp=3; IntAct=EBI-727004, EBI-10172867; CC O00560; O43805: SSNA1; NbExp=6; IntAct=EBI-727004, EBI-2515299; CC O00560; P53999: SUB1; NbExp=3; IntAct=EBI-727004, EBI-998260; CC O00560; O43704: SULT1B1; NbExp=3; IntAct=EBI-727004, EBI-10179062; CC O00560; O43759-2: SYNGR1; NbExp=3; IntAct=EBI-727004, EBI-12187159; CC O00560; Q16563: SYPL1; NbExp=3; IntAct=EBI-727004, EBI-2800683; CC O00560; Q8N2H4: SYS1; NbExp=3; IntAct=EBI-727004, EBI-13075176; CC O00560; O43680: TCF21; NbExp=3; IntAct=EBI-727004, EBI-723267; CC O00560; P15884-3: TCF4; NbExp=3; IntAct=EBI-727004, EBI-13636688; CC O00560; P48775: TDO2; NbExp=7; IntAct=EBI-727004, EBI-743494; CC O00560; Q969V4: TEKT1; NbExp=3; IntAct=EBI-727004, EBI-10180409; CC O00560; Q12800: TFCP2; NbExp=3; IntAct=EBI-727004, EBI-717422; CC O00560; Q9NWX6: THG1L; NbExp=3; IntAct=EBI-727004, EBI-746510; CC O00560; Q96CG3: TIFA; NbExp=8; IntAct=EBI-727004, EBI-740711; CC O00560; Q3LXA3: TKFC; NbExp=3; IntAct=EBI-727004, EBI-4291069; CC O00560; Q08117: TLE5; NbExp=3; IntAct=EBI-727004, EBI-717810; CC O00560; Q7Z6W1: TMCO2; NbExp=3; IntAct=EBI-727004, EBI-12807858; CC O00560; Q86X19: TMEM17; NbExp=3; IntAct=EBI-727004, EBI-11343485; CC O00560; Q8WW34: TMEM239; NbExp=3; IntAct=EBI-727004, EBI-9675724; CC O00560; Q8WW34-2: TMEM239; NbExp=3; IntAct=EBI-727004, EBI-11528917; CC O00560; P0DTL5: TMEM276; NbExp=3; IntAct=EBI-727004, EBI-11997340; CC O00560; O95379: TNFAIP8; NbExp=6; IntAct=EBI-727004, EBI-1049336; CC O00560; Q5GJ75: TNFAIP8L3; NbExp=3; IntAct=EBI-727004, EBI-14222571; CC O00560; O95271: TNKS; NbExp=5; IntAct=EBI-727004, EBI-1105254; CC O00560; O00463: TRAF5; NbExp=8; IntAct=EBI-727004, EBI-523498; CC O00560; P14373: TRIM27; NbExp=3; IntAct=EBI-727004, EBI-719493; CC O00560; Q13049: TRIM32; NbExp=7; IntAct=EBI-727004, EBI-742790; CC O00560; O00635: TRIM38; NbExp=3; IntAct=EBI-727004, EBI-2130415; CC O00560; Q9BYV2: TRIM54; NbExp=6; IntAct=EBI-727004, EBI-2130429; CC O00560; Q15645: TRIP13; NbExp=3; IntAct=EBI-727004, EBI-358993; CC O00560; Q86WV8: TSC1; NbExp=3; IntAct=EBI-727004, EBI-12806590; CC O00560; Q15631: TSN; NbExp=3; IntAct=EBI-727004, EBI-1044160; CC O00560; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-727004, EBI-11988865; CC O00560; P0CG47: UBB; NbExp=3; IntAct=EBI-727004, EBI-413034; CC O00560; P49459: UBE2A; NbExp=9; IntAct=EBI-727004, EBI-2339348; CC O00560; P61086: UBE2K; NbExp=3; IntAct=EBI-727004, EBI-473850; CC O00560; Q712K3: UBE2R2; NbExp=3; IntAct=EBI-727004, EBI-2340879; CC O00560; O95292: VAPB; NbExp=3; IntAct=EBI-727004, EBI-1188298; CC O00560; Q9Y3C0: WASHC3; NbExp=6; IntAct=EBI-727004, EBI-712969; CC O00560; O00401: WASL; NbExp=6; IntAct=EBI-727004, EBI-957615; CC O00560; O76024: WFS1; NbExp=3; IntAct=EBI-727004, EBI-720609; CC O00560; O95070: YIF1A; NbExp=3; IntAct=EBI-727004, EBI-2799703; CC O00560; O43829: ZBTB14; NbExp=3; IntAct=EBI-727004, EBI-10176632; CC O00560; Q96BR9: ZBTB8A; NbExp=6; IntAct=EBI-727004, EBI-742740; CC O00560; Q8TBK6: ZCCHC10; NbExp=3; IntAct=EBI-727004, EBI-597063; CC O00560; Q9NP64: ZCCHC17; NbExp=8; IntAct=EBI-727004, EBI-746345; CC O00560; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-727004, EBI-12030590; CC O00560; Q6P1L6: ZNF343; NbExp=3; IntAct=EBI-727004, EBI-10252492; CC O00560; Q8NCK3: ZNF485; NbExp=3; IntAct=EBI-727004, EBI-12901093; CC O00560; Q6AZW8: ZNF660; NbExp=3; IntAct=EBI-727004, EBI-12376497; CC O00560; Q9H5H4: ZNF768; NbExp=3; IntAct=EBI-727004, EBI-1210580; CC O00560; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-727004, EBI-527853; CC O00560; Q3MJ62: ZSCAN23; NbExp=3; IntAct=EBI-727004, EBI-5667532; CC O00560; K9N5R3: E; Xeno; NbExp=2; IntAct=EBI-727004, EBI-26374535; CC O00560-1; P59637: E; Xeno; NbExp=4; IntAct=EBI-9640690, EBI-25487741; CC -!- SUBCELLULAR LOCATION: Cell junction, focal adhesion CC {ECO:0000269|PubMed:11179419}. Cell junction, adherens junction CC {ECO:0000269|PubMed:11179419}. Cell membrane CC {ECO:0000269|PubMed:11179419, ECO:0000269|PubMed:25893292, CC ECO:0000269|PubMed:27386966}; Peripheral membrane protein CC {ECO:0000269|PubMed:11179419, ECO:0000269|PubMed:27386966}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:17081065}; Peripheral membrane CC protein {ECO:0000269|PubMed:17081065}. Nucleus CC {ECO:0000269|PubMed:11179419}. Melanosome {ECO:0000269|PubMed:12643545, CC ECO:0000269|PubMed:17081065}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:11179419}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:11179419}. Secreted, extracellular exosome CC {ECO:0000269|PubMed:22660413}. Membrane raft CC {ECO:0000269|PubMed:25893292}. Note=Mainly membrane-associated. CC Localized to adherens junctions, focal adhesions and endoplasmic CC reticulum. Colocalized with actin stress fibers. Also found in the CC nucleus. Identified by mass spectrometry in melanosome fractions from CC stage I to stage IV. Associated to the plasma membrane in the presence CC of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2) CC (PubMed:27386966). {ECO:0000269|PubMed:11179419, CC ECO:0000269|PubMed:12643545, ECO:0000269|PubMed:17081065, CC ECO:0000269|PubMed:27386966}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=O00560-1; Sequence=Displayed; CC Name=2; CC IsoId=O00560-2; Sequence=VSP_038375; CC Name=3; CC IsoId=O00560-3; Sequence=VSP_038374; CC -!- TISSUE SPECIFICITY: Expressed in lung cancers, including CC adenocarcinoma, squamous cell carcinoma and small-cell carcinoma (at CC protein level) (PubMed:25893292). Widely expressed. Expressed in fetal CC kidney, liver, lung and brain. In adult highest expression in heart and CC placenta. {ECO:0000269|PubMed:25893292}. CC -!- INDUCTION: By IFNG/IFN-gamma in melanoma cells. CC -!- PTM: Phosphorylated on tyrosine residues. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44377/SDCBP"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF006636; AAC52050.1; -; mRNA. DR EMBL; AF000652; AAB97144.1; -; mRNA. DR EMBL; U83463; AAB51246.1; -; mRNA. DR EMBL; AK300647; BAG62335.1; -; mRNA. DR EMBL; AK312274; BAG35204.1; -; mRNA. DR EMBL; AC068522; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471068; EAW86814.1; -; Genomic_DNA. DR EMBL; BC113674; AAI13675.1; -; mRNA. DR EMBL; BC113676; AAI13677.1; -; mRNA. DR EMBL; BC143915; AAI43916.1; -; mRNA. DR EMBL; BC143916; AAI43917.1; -; mRNA. DR CCDS; CCDS47862.1; -. [O00560-2] DR CCDS; CCDS47863.1; -. [O00560-3] DR CCDS; CCDS6172.1; -. [O00560-1] DR PIR; JC6537; JC6537. DR RefSeq; NP_001007068.1; NM_001007067.2. [O00560-1] DR RefSeq; NP_001007069.1; NM_001007068.2. [O00560-3] DR RefSeq; NP_001007070.1; NM_001007069.2. [O00560-2] DR RefSeq; NP_001007071.1; NM_001007070.2. [O00560-2] DR RefSeq; NP_005616.2; NM_005625.4. [O00560-1] DR PDB; 1N99; X-ray; 1.94 A; A/B=113-273. DR PDB; 1NTE; X-ray; 1.24 A; A=197-273. DR PDB; 1OBX; X-ray; 1.35 A; A=197-270. DR PDB; 1OBY; X-ray; 1.85 A; A/B=197-270. DR PDB; 1OBZ; X-ray; 1.69 A; A/B=113-273. DR PDB; 1R6J; X-ray; 0.73 A; A=197-273. DR PDB; 1V1T; X-ray; 1.80 A; A/B=113-273. DR PDB; 1W9E; X-ray; 1.56 A; A/B=113-273. DR PDB; 1W9O; X-ray; 2.25 A; A/B=113-273. DR PDB; 1W9Q; X-ray; 1.70 A; A/B=113-273. DR PDB; 1YBO; X-ray; 2.30 A; A/B=113-273. DR PDB; 4Z33; X-ray; 2.45 A; A/B=111-275. DR PDB; 6R9H; X-ray; 2.00 A; A/B/C/D=113-273. DR PDB; 6RLC; X-ray; 2.20 A; A/B/C/D=113-273. DR PDB; 7FSG; X-ray; 2.02 A; A/B/C/D=106-298. DR PDB; 7FSH; X-ray; 2.11 A; A/B/C/D=106-298. DR PDB; 7FSI; X-ray; 2.31 A; A/B/C/D=106-298. DR PDB; 7FSJ; X-ray; 1.97 A; A/B/C/D=106-298. DR PDB; 7FSK; X-ray; 2.40 A; A/B/C/D=106-298. DR PDB; 7FSL; X-ray; 2.38 A; A/B/C/D=106-298. DR PDB; 7FSM; X-ray; 2.10 A; A/B/C/D=106-298. DR PDB; 7FSN; X-ray; 2.40 A; A/B/C/D=106-298. DR PDB; 7FSO; X-ray; 1.90 A; A/B/C/D=106-298. DR PDB; 7FSP; X-ray; 1.86 A; A/B/C/D=106-298. DR PDB; 7FSQ; X-ray; 2.07 A; A/B/C/D=106-298. DR PDB; 7FSR; X-ray; 2.29 A; A/B/C/D=106-298. DR PDB; 7FSS; X-ray; 2.11 A; A/B/C/D=106-298. DR PDB; 7FST; X-ray; 1.98 A; A/B/C/D=106-298. DR PDB; 7FSU; X-ray; 1.97 A; A/B/C/D=106-298. DR PDB; 7FSV; X-ray; 2.25 A; A/B/C/D=106-298. DR PDB; 7FSW; X-ray; 2.14 A; A/B/C/D=106-298. DR PDB; 7FSX; X-ray; 1.91 A; A/B/C/D=106-298. DR PDB; 7FSY; X-ray; 2.80 A; A/B/C/D=106-298. DR PDB; 7FSZ; X-ray; 2.05 A; A/B/C/D=106-298. DR PDB; 7FT0; X-ray; 2.45 A; A/B/C/D=106-298. DR PDB; 7FT1; X-ray; 2.11 A; A/B/C/D=106-298. DR PDB; 7FT2; X-ray; 2.04 A; A/B/C/D=106-298. DR PDB; 7FT3; X-ray; 2.05 A; A/B/C/D=106-298. DR PDB; 7FT4; X-ray; 2.17 A; A/B/C/D=106-298. DR PDB; 7FT5; X-ray; 1.77 A; A/B/C/D=106-298. DR PDB; 7FT6; X-ray; 1.85 A; A/B/C/D=106-298. DR PDB; 7FT7; X-ray; 1.78 A; A/B/C/D=106-298. DR PDB; 7FT8; X-ray; 2.40 A; A/B/C/D=106-298. DR PDB; 7FT9; X-ray; 1.77 A; A/B/C/D=106-298. DR PDB; 7FTA; X-ray; 2.03 A; A/B/C/D=106-298. DR PDB; 7FTB; X-ray; 2.22 A; A/B/C/D=106-298. DR PDB; 7FTC; X-ray; 1.87 A; A/B/C/D=106-298. DR PDB; 7FTD; X-ray; 1.80 A; A/B/C/D=106-298. DR PDB; 8AAI; X-ray; 2.76 A; A/B/C/D=113-273. DR PDB; 8AAK; X-ray; 2.55 A; A/B=113-273. DR PDB; 8AAO; X-ray; 2.47 A; A/B=113-273. DR PDB; 8AAP; X-ray; 2.17 A; A/B=113-273. DR PDB; 8BLU; X-ray; 1.50 A; A/B/C/D=106-298. DR PDB; 8BLV; X-ray; 1.50 A; A/B=106-298. DR PDB; 8HCK; X-ray; 2.00 A; A=113-191. DR PDBsum; 1N99; -. DR PDBsum; 1NTE; -. DR PDBsum; 1OBX; -. DR PDBsum; 1OBY; -. DR PDBsum; 1OBZ; -. DR PDBsum; 1R6J; -. DR PDBsum; 1V1T; -. DR PDBsum; 1W9E; -. DR PDBsum; 1W9O; -. DR PDBsum; 1W9Q; -. DR PDBsum; 1YBO; -. DR PDBsum; 4Z33; -. DR PDBsum; 6R9H; -. DR PDBsum; 6RLC; -. DR PDBsum; 7FSG; -. DR PDBsum; 7FSH; -. DR PDBsum; 7FSI; -. DR PDBsum; 7FSJ; -. DR PDBsum; 7FSK; -. DR PDBsum; 7FSL; -. DR PDBsum; 7FSM; -. DR PDBsum; 7FSN; -. DR PDBsum; 7FSO; -. DR PDBsum; 7FSP; -. DR PDBsum; 7FSQ; -. DR PDBsum; 7FSR; -. DR PDBsum; 7FSS; -. DR PDBsum; 7FST; -. DR PDBsum; 7FSU; -. DR PDBsum; 7FSV; -. DR PDBsum; 7FSW; -. DR PDBsum; 7FSX; -. DR PDBsum; 7FSY; -. DR PDBsum; 7FSZ; -. DR PDBsum; 7FT0; -. DR PDBsum; 7FT1; -. DR PDBsum; 7FT2; -. DR PDBsum; 7FT3; -. DR PDBsum; 7FT4; -. DR PDBsum; 7FT5; -. DR PDBsum; 7FT6; -. DR PDBsum; 7FT7; -. DR PDBsum; 7FT8; -. DR PDBsum; 7FT9; -. DR PDBsum; 7FTA; -. DR PDBsum; 7FTB; -. DR PDBsum; 7FTC; -. DR PDBsum; 7FTD; -. DR PDBsum; 8AAI; -. DR PDBsum; 8AAK; -. DR PDBsum; 8AAO; -. DR PDBsum; 8AAP; -. DR PDBsum; 8BLU; -. DR PDBsum; 8BLV; -. DR PDBsum; 8HCK; -. DR AlphaFoldDB; O00560; -. DR SMR; O00560; -. DR BioGRID; 112287; 452. DR ComplexPortal; CPX-3282; Syndecan-1-syntenin-1-ALIX complex. DR CORUM; O00560; -. DR DIP; DIP-42705N; -. DR FunCoup; O00560; 1523. DR IntAct; O00560; 454. DR MINT; O00560; -. DR STRING; 9606.ENSP00000428184; -. DR BindingDB; O00560; -. DR ChEMBL; CHEMBL4739667; -. DR MoonDB; O00560; Predicted. DR TCDB; 8.A.24.2.1; the ezrin/radixin/moesin-binding phosphoprotein 50 (ebp50) family. DR GlyGen; O00560; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O00560; -. DR PhosphoSitePlus; O00560; -. DR SwissPalm; O00560; -. DR BioMuta; SDCBP; -. DR jPOST; O00560; -. DR MassIVE; O00560; -. DR PaxDb; 9606-ENSP00000260130; -. DR PeptideAtlas; O00560; -. DR ProteomicsDB; 47974; -. [O00560-1] DR ProteomicsDB; 47975; -. [O00560-2] DR ProteomicsDB; 47976; -. [O00560-3] DR Pumba; O00560; -. DR TopDownProteomics; O00560-1; -. [O00560-1] DR Antibodypedia; 3216; 547 antibodies from 38 providers. DR DNASU; 6386; -. DR Ensembl; ENST00000260130.9; ENSP00000260130.4; ENSG00000137575.13. [O00560-1] DR Ensembl; ENST00000413219.6; ENSP00000411771.2; ENSG00000137575.13. [O00560-1] DR Ensembl; ENST00000424270.6; ENSP00000395351.2; ENSG00000137575.13. [O00560-3] DR Ensembl; ENST00000447182.6; ENSP00000409288.2; ENSG00000137575.13. [O00560-2] DR GeneID; 6386; -. DR KEGG; hsa:6386; -. DR MANE-Select; ENST00000260130.9; ENSP00000260130.4; NM_005625.4; NP_005616.2. DR UCSC; uc003xtn.3; human. [O00560-1] DR AGR; HGNC:10662; -. DR ClinPGx; PA35592; -. DR CTD; 6386; -. DR DisGeNET; 6386; -. DR GeneCards; SDCBP; -. DR HGNC; HGNC:10662; SDCBP. DR HPA; ENSG00000137575; Low tissue specificity. DR MIM; 602217; gene. DR OpenTargets; ENSG00000137575; -. DR VEuPathDB; HostDB:ENSG00000137575; -. DR eggNOG; KOG0849; Eukaryota. DR GeneTree; ENSGT00940000154502; -. DR InParanoid; O00560; -. DR OMA; HKMIKKA; -. DR OrthoDB; 10059177at2759; -. DR PAN-GO; O00560; 5 GO annotations based on evolutionary models. DR PhylomeDB; O00560; -. DR PathwayCommons; O00560; -. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-447043; Neurofascin interactions. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; O00560; -. DR SIGNOR; O00560; -. DR Agora; ENSG00000137575; -. DR BioGRID-ORCS; 6386; 21 hits in 1157 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; SDCBP; human. DR EvolutionaryTrace; O00560; -. DR GeneWiki; SDCBP; -. DR GenomeRNAi; 6386; -. DR Pharos; O00560; Tchem. DR PRO; PR:O00560; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O00560; protein. DR Bgee; ENSG00000137575; Expressed in pigmented layer of retina and 210 other cell types or tissues. DR ExpressionAtlas; O00560; baseline and differential. DR GO; GO:0005912; C:adherens junction; NAS:UniProtKB. DR GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome. DR GO; GO:0072562; C:blood microparticle; HDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005856; C:cytoskeleton; NAS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell. DR GO; GO:0005895; C:interleukin-5 receptor complex; ISS:UniProtKB. DR GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; NAS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0008093; F:cytoskeletal anchor activity; NAS:UniProtKB. DR GO; GO:0005109; F:frizzled binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0005137; F:interleukin-5 receptor binding; ISS:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0140311; F:protein sequestering activity; IDA:UniProtKB. DR GO; GO:0045545; F:syndecan binding; IPI:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; NAS:UniProtKB. DR GO; GO:0007268; P:chemical synaptic transmission; NAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB. DR GO; GO:0002091; P:negative regulation of receptor internalization; IMP:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:UniProtKB. DR GO; GO:1903543; P:positive regulation of exosomal secretion; IMP:UniProtKB. DR GO; GO:1903553; P:positive regulation of extracellular exosome assembly; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IC:BHF-UCL. DR GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0006612; P:protein targeting to membrane; NAS:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0006930; P:substrate-dependent cell migration, cell extension; NAS:UniProtKB. DR CDD; cd06721; PDZ1_syntenin-like; 1. DR CDD; cd06794; PDZ2_syntenin-like; 1. DR FunFam; 2.30.42.10:FF:000043; Syntenin-1 isoform X1; 1. DR FunFam; 2.30.42.10:FF:000065; syntenin-1 isoform X1; 1. DR Gene3D; 2.30.42.10; -; 2. DR InterPro; IPR051230; APP-Binding. DR InterPro; IPR001478; PDZ. DR InterPro; IPR036034; PDZ_sf. DR PANTHER; PTHR12345; SYNTENIN RELATED; 1. DR PANTHER; PTHR12345:SF10; SYNTENIN-1; 1. DR Pfam; PF00595; PDZ; 2. DR SMART; SM00228; PDZ; 2. DR SUPFAM; SSF50156; PDZ domain-like; 2. DR PROSITE; PS50106; PDZ; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell junction; KW Cell membrane; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Endoplasmic reticulum; Lipid-binding; Membrane; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Secreted. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:19413330" FT CHAIN 2..298 FT /note="Syntenin-1" FT /id="PRO_0000184001" FT DOMAIN 114..193 FT /note="PDZ 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00143" FT DOMAIN 198..273 FT /note="PDZ 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00143" FT REGION 2..60 FT /note="Interaction with PDCD6IP" FT /evidence="ECO:0000269|PubMed:22660413" FT MOTIF 3..7 FT /note="LYPX(n)L motif 1" FT /evidence="ECO:0000250|UniProtKB:O08992" FT MOTIF 45..49 FT /note="LYPX(n)L motif 2" FT /evidence="ECO:0000250|UniProtKB:O08992" FT MOTIF 49..53 FT /note="LYPX(n)L motif 3" FT /evidence="ECO:0000250|UniProtKB:O08992" FT BINDING 215 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000269|PubMed:27386966, FT ECO:0007744|PDB:4Z33" FT BINDING 250..251 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000269|PubMed:27386966, FT ECO:0007744|PDB:4Z33" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:19413330" FT MOD_RES 6 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 46 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 12..17 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038374" FT VAR_SEQ 81 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_038375" FT VARIANT 69 FT /note="N -> S (in dbSNP:rs1127509)" FT /evidence="ECO:0000269|PubMed:9391086" FT /id="VAR_013160" FT MUTAGEN 214 FT /note="K->A: Disruption of the cooperative binding of C- FT terminal peptides from FZD7 and phosphatidylinositol-4,5- FT bisphosphate. Impaired interaction with FZD7 and disruption FT of the cooperative binding of C-terminal peptides from FZD7 FT and phosphatidylinositol-4,5-bisphosphate; when associated FT with A-250." FT /evidence="ECO:0000269|PubMed:27386966" FT MUTAGEN 215 FT /note="N->D: Disruption of the cooperative binding of C- FT terminal peptides from FZD7 and phosphatidylinositol-4,5- FT bisphosphate." FT /evidence="ECO:0000269|PubMed:27386966" FT MUTAGEN 250 FT /note="K->A: Disruption of the cooperative binding of C- FT terminal peptides from FZD7 and phosphatidylinositol-4,5- FT bisphosphate. Impaired interaction with FZD7 and disruption FT of the cooperative binding of C-terminal peptides from FZD7 FT and phosphatidylinositol-4,5-bisphosphate; when associated FT with A-214." FT /evidence="ECO:0000269|PubMed:27386966" FT CONFLICT 62 FT /note="N -> S (in Ref. 2; AAB51246)" FT /evidence="ECO:0000305" FT STRAND 111..117 FT /evidence="ECO:0007829|PDB:8BLU" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:8AAP" FT STRAND 127..132 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 135..142 FT /evidence="ECO:0007829|PDB:8BLU" FT HELIX 146..149 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 157..161 FT /evidence="ECO:0007829|PDB:8BLU" FT HELIX 171..180 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 186..191 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 197..202 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 205..208 FT /evidence="ECO:0007829|PDB:1N99" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7FSR" FT HELIX 226..230 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 234..241 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 247..249 FT /evidence="ECO:0007829|PDB:7FTA" FT HELIX 251..260 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 263..271 FT /evidence="ECO:0007829|PDB:1R6J" FT HELIX 272..279 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:7FSR" FT HELIX 284..290 FT /evidence="ECO:0007829|PDB:8BLU" SQ SEQUENCE 298 AA; 32444 MW; 574E1349F86F949F CRC64; MSLYPSLEDL KVDKVIQAQT AFSANPANPA ILSEASAPIP HDGNLYPRLY PELSQYMGLS LNEEEIRANV AVVSGAPLQG QLVARPSSIN YMVAPVTGND VGIRRAEIKQ GIREVILCKD QDGKIGLRLK SIDNGIFVQL VQANSPASLV GLRFGDQVLQ INGENCAGWS SDKAHKVLKQ AFGEKITMTI RDRPFERTIT MHKDSTGHVG FIFKNGKITS IVKDSSAARN GLLTEHNICE INGQNVIGLK DSQIADILST SGTVVTITIM PAFIFEHIIK RMAPSIMKSL MDHTIPEV // ID STK11_HUMAN Reviewed; 433 AA. AC Q15831; B2RBX7; E7EW76; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 245. DE RecName: Full=Serine/threonine-protein kinase STK11 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14976552}; DE AltName: Full=Liver kinase B1; DE Short=LKB1; DE Short=hLKB1; DE AltName: Full=Renal carcinoma antigen NY-REN-19; DE Flags: Precursor; GN Name=STK11 {ECO:0000312|HGNC:HGNC:11389}; Synonyms=LKB1, PJS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS. RC TISSUE=Liver; RX PubMed=9425897; DOI=10.1038/ng0198-38; RA Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R., RA Mueller O., Back W., Zimmer M.; RT "Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine RT kinase."; RL Nat. Genet. 18:38-43(1998). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9537235; RA Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R.; RT "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene RT in sporadic breast cancer."; RL Cancer Res. 58:1384-1386(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=11212897; DOI=10.1023/a:1006442024874; RA Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G.; RT "Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 RT mutations in human carcinoma metastases to the brain."; RL J. Neurooncol. 49:187-195(2000). RN [9] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND RP INTERACTION WITH SMAD4 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [10] RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF LYS-78 RP AND THR-189, AND PHOSPHORYLATION AT THR-189. RX PubMed=11430832; DOI=10.1016/s1097-2765(01)00258-1; RA Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R., Brien T.P., RA Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.; RT "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell RT death."; RL Mol. Cell 7:1307-1319(2001). RN [11] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=12097271; RA Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., RA Engles J.M., Westra W.H., Herman J.G., Sidransky D.; RT "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the RT lung."; RL Cancer Res. 62:3659-3662(2002). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA, PHOSPHORYLATION AT RP THR-336 AND THR-363, AND CHARACTERIZATION OF VARIANT SPORADIC CANCER RP TYR-176. RX PubMed=12805220; DOI=10.1093/emboj/cdg292; RA Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., RA Alessi D.R., Clevers H.C.; RT "Activation of the tumour suppressor kinase LKB1 by the STE20-like RT pseudokinase STRAD."; RL EMBO J. 22:3062-3072(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION IN A RP COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA; STRADB; CAB39 RP AND CAB39L. RX PubMed=14517248; DOI=10.1093/emboj/cdg490; RA Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., RA Prescott A.R., Clevers H.C., Alessi D.R.; RT "MO25alpha/beta interact with STRADalpha/beta enhancing their ability to RT bind, activate and localize LKB1 in the cytoplasm."; RL EMBO J. 22:5102-5114(2003). RN [14] RP FUNCTION IN CELL POLARITY. RX PubMed=15016379; DOI=10.1016/s0092-8674(04)00114-x; RA Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., RA Peters P.J., Clevers H.C.; RT "Complete polarization of single intestinal epithelial cells upon RT activation of LKB1 by STRAD."; RL Cell 116:457-466(2004). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [16] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=15021901; DOI=10.1038/sj.onc.1207502; RA Carretero J., Medina P.P., Pio R., Montuenga L.M., Sanchez-Cespedes M.; RT "Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor RT suppressor gene."; RL Oncogene 23:4037-4040(2004). RN [17] RP FUNCTION. RX PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042; RA Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., RA Alessi D.R.; RT "Identification of the sucrose non-fermenting related kinase SNRK, as a RT novel LKB1 substrate."; RL FEBS Lett. 579:1417-1423(2005). RN [18] RP FUNCTION, INTERACTION WITH PTEN, SUBCELLULAR LOCATION, AND CHARACTERIZATION RP OF VARIANT PJS ASN-176. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [20] RP INTERACTION WITH WDR6. RX PubMed=17216128; DOI=10.1007/s11010-006-9402-5; RA Xie X., Wang Z., Chen Y.; RT "Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell RT growth arrest and p27(Kip1) induction."; RL Mol. Cell. Biochem. 301:115-122(2007). RN [21] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x; RA Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y., RA Mitsudomi T.; RT "LKB1 gene mutations in Japanese lung cancer patients."; RL Cancer Sci. 98:1747-1751(2007). RN [22] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17676035; DOI=10.1038/nature06030; RA Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., RA Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D., RA Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J., RA Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I., RA Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E., RA Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N., RA Sharpless N.E., Wong K.K.; RT "LKB1 modulates lung cancer differentiation and metastasis."; RL Nature 448:807-810(2007). RN [23] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17384680; DOI=10.1038/sj.onc.1210418; RA Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., RA Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.; RT "Prevalence and specificity of LKB1 genetic alterations in lung cancers."; RL Oncogene 26:5911-5918(2007). RN [24] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=18594528; DOI=10.1038/sj.bjc.6604469; RA Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., Naoki K., RA Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K., Richards W.G., RA Sugarbaker D.J., Johnson B.E., Janne P.A.; RT "Mutations in the LKB1 tumour suppressor are frequently detected in tumours RT from Caucasian but not Asian lung cancer patients."; RL Br. J. Cancer 99:245-252(2008). RN [25] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [26] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [27] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-44; LYS-48; LYS-96; LYS-97; RP LYS-296; LYS-311; LYS-416; LYS-423 AND LYS-431, AND MUTAGENESIS OF LYS-44; RP LYS-48; LYS-96 AND LYS-97. RX PubMed=18687677; DOI=10.1074/jbc.m805711200; RA Lan F., Cacicedo J.M., Ruderman N., Ido Y.; RT "SIRT1 modulation of the acetylation status, cytosolic localization, and RT activity of LKB1. Possible role in AMP-activated protein kinase RT activation."; RL J. Biol. Chem. 283:27628-27635(2008). RN [28] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, RP PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428. RX PubMed=18854309; DOI=10.1074/jbc.m806153200; RA Denison F.C., Hiscock N.J., Carling D., Woods A.; RT "Characterization of an alternative splice variant of LKB1."; RL J. Biol. Chem. 284:67-76(2009). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [30] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=20559149; DOI=10.1097/jto.0b013e3181e05016; RA Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y., RA Pao W., Chen H., Ji H.; RT "Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung RT adenocarcinomas."; RL J. Thorac. Oncol. 5:1130-1135(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP FUNCTION. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [33] RP REVIEW ON FUNCTION. RX PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010; RA Alexander A., Walker C.L.; RT "The role of LKB1 and AMPK in cellular responses to stress and damage."; RL FEBS Lett. 585:952-957(2011). RN [34] RP REVIEW ON INVOLVEMENT IN LUNG CANCER. RX PubMed=21380642; DOI=10.1007/s13238-011-1021-6; RA Gao Y., Ge G., Ji H.; RT "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor RT suppressor."; RL Protein Cell 2:99-107(2011). RN [35] RP ACTIVITY REGULATION, INTERACTION WITH NR4A1, AND SUBCELLULAR LOCATION. RX PubMed=22983157; DOI=10.1038/nchembio.1069; RA Zhan Y.Y., Chen Y., Zhang Q., Zhuang J.J., Tian M., Chen H.Z., Zhang L.R., RA Zhang H.K., He J.P., Wang W.J., Wu R., Wang Y., Shi C., Yang K., Li A.Z., RA Xin Y.Z., Li T.Y., Yang J.Y., Zheng Z.H., Yu C.D., Lin S.C., Chang C., RA Huang P.Q., Lin T., Wu Q.; RT "The orphan nuclear receptor Nur77 regulates LKB1 localization and RT activates AMPK."; RL Nat. Chem. Biol. 8:897-904(2012). RN [36] RP INTERACTION WITH NISCH, AND SUBCELLULAR LOCATION. RX PubMed=23572524; DOI=10.1074/jbc.m112.418103; RA Jain P., Baranwal S., Dong S., Struckhoff A.P., Worthylake R.A., RA Alahari S.K.; RT "Integrin-binding protein nischarin interacts with tumor suppressor liver RT kinase B1 (LKB1) to regulate cell migration of breast epithelial cells."; RL J. Biol. Chem. 288:15495-15509(2013). RN [37] RP SUBCELLULAR LOCATION (ISOFORM 2), AND PHOSPHORYLATION AT SER-399 (ISOFORM RP 2). RX PubMed=23612973; DOI=10.1074/jbc.m112.443580; RA Zhu H., Moriasi C.M., Zhang M., Zhao Y., Zou M.H.; RT "Phosphorylation of serine 399 in LKB1 protein short form by protein kinase RT Czeta is required for its nucleocytoplasmic transport and consequent AMP- RT activated protein kinase (AMPK) activation."; RL J. Biol. Chem. 288:16495-16505(2013). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND SER-401, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [40] RP FUNCTION, AND INTERACTION WITH CDKN1A. RX PubMed=25329316; DOI=10.1371/journal.pgen.1004721; RA Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J., Grueso J., RA Hernandez-Losa J., Moline T., Canals F., Ferrer B., Cortes J., Bastian B., RA Cajal S.R.Y., Martin-Caballero J., Flores J.M., Vivancos A., RA Garcia-Patos V., Recio J.A.; RT "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating RT CDKN1A (p21WAF1/CIP1) degradation."; RL PLoS Genet. 10:E1004721-E1004721(2014). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH STRADA AND RP CAB39, ACTIVITY REGULATION, CHARACTERIZATION OF VARIANTS SPORADIC CANCER RP MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170; SER-171; ARG-174; RP TYR-176; ASN-177; GLU-181; GLN-199; THR-205; PHE-216; VAL-223; PRO-230; RP PRO-232; ARG-245; PRO-250; HIS-272; TYR-277; GLN-285 AND SER-315, AND RP MUTAGENESIS OF ARG-74; ASP-194 AND PHE-204. RX PubMed=19892943; DOI=10.1126/science.1178377; RA Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.; RT "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism RT of kinase activation."; RL Science 326:1707-1711(2009). RN [42] RP VARIANTS PJS 50-LEU--ASP-53 DEL; ASN-176 AND CYS-308, CHARACTERIZATION OF RP VARIANTS PJS PRO-67; ASN-176 AND CYS-308, AND MUTAGENESIS OF LYS-78. RX PubMed=9837816; DOI=10.1086/302159; RA Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C., Guex N., RA Blouin J.L., Scott H.S., Antonarakis S.E.; RT "Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for RT allelic and locus heterogeneity."; RL Am. J. Hum. Genet. 63:1641-1650(1998). RN [43] RP VARIANT TGCT ASP-163. RX PubMed=9605748; RA Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A., Stenwig A.E., RA Fossaa S.D., Salovaara R., Aaltonen L.A.; RT "Somatic mutations in LKB1 are rare in sporadic colorectal and testicular RT tumors."; RL Cancer Res. 58:2087-2090(1998). RN [44] RP VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354 AND RP MET-367. RX PubMed=9731485; RA Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H., Park W.S., RA Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y., Yang Y.M., Kim S.H., RA Kim C.S., Lee J.Y.; RT "Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers RT syndrome gene in left-sided colon cancer."; RL Cancer Res. 58:3787-3790(1998). RN [45] RP VARIANT COLORECTAL CANCER HIS-314. RX PubMed=9809980; RA Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., RA Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., RA Rossini F.P., Tenconi R., Guanti G.; RT "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer."; RL Cancer Res. 58:4799-4801(1998). RN [46] RP VARIANT PJS ASN-247 DEL. RX PubMed=9760200; DOI=10.1007/s004390050801; RA Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M., RA Yasutomi M., Matsuura N., Monden M., Nakamura Y.; RT "Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers RT syndrome."; RL Hum. Genet. 103:168-172(1998). RN [47] RP VARIANT GASTRIC CARCINOMA LEU-324. RX PubMed=9683800; RA Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G., RA Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.; RT "Mutations of the STK11 gene in sporadic gastric carcinoma."; RL Int. J. Oncol. 13:601-604(1998). RN [48] RP VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN. RX PubMed=9428765; DOI=10.1038/34432; RA Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., RA Bignell G., Warren W., Aminoff M., Hoeglund P., Jaervinen H., Kristo P., RA Pelin K., Ridanpaeae M., Salovaara R., Toro T., Bodmer W., Olschwang S., RA Olsen A.S., Stratton M.R., de la Chapelle A., Aaltonen L.A.; RT "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome."; RL Nature 391:184-187(1998). RN [49] RP VARIANT LUNG CANCER VAL-194. RX PubMed=10079245; DOI=10.1016/s0002-9440(10)65314-x; RA Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., RA Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., RA Jarvinen H., Aaltonen L.A.; RT "LKB1 somatic mutations in sporadic cancers."; RL Am. J. Pathol. 154:677-681(1999). RN [50] RP VARIANTS PJS 162-ASP--LEU-164 DELINS ASN-ASP-MET; ASN-194 AND LYS-297. RX PubMed=10408777; RX DOI=10.1002/(sici)1098-1004(1999)13:6<476::aid-humu7>3.0.co;2-2; RA Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E., RA Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J., de Rooij F.W.M., RA Wilson J.H.P.; RT "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families."; RL Hum. Mutat. 13:476-481(1999). RN [51] RP CHARACTERIZATION OF VARIANT TGCT ASP-163. RX PubMed=9887330; DOI=10.1093/hmg/8.1.45; RA Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S., RA Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D., Neale K., RA Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H., Maekelae T.P., RA Aaltonen L.A.; RT "Mutations and impaired function of LKB1 in familial and non-familial RT Peutz-Jeghers syndrome and a sporadic testicular cancer."; RL Hum. Mol. Genet. 8:45-51(1999). RN [52] RP VARIANT OVARIAN CARCINOMA LEU-281. RX PubMed=10429654; DOI=10.1111/j.1349-7006.1999.tb00793.x; RA Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of STK11 gene in ovarian carcinomas."; RL Jpn. J. Cancer Res. 90:629-632(1999). RN [53] RP VARIANTS MELANOMA ASP-49 AND ARG-135. RX PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x; RA Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W., RA Tomlinson I.; RT "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic RT malignant melanomas."; RL J. Invest. Dermatol. 112:509-511(1999). RN [54] RP VARIANT MELANOMA TYR-194. RX PubMed=10208439; DOI=10.1038/sj.onc.1202486; RA Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F., RA Zeuthen J.; RT "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in RT malignant melanoma."; RL Oncogene 18:1777-1780(1999). RN [55] RP VARIANTS PJS CYS-239 AND SER-315. RX PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x; RA Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A., Mowat D., RA McPhillips M., Spigelman A.D.; RT "Mutation analysis of the STK11/LKB1 gene and clinical characteristics of RT an Australian series of Peutz-Jeghers syndrome patients."; RL Clin. Genet. 62:282-287(2002). RN [56] RP VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT CERVICAL RP CARCINOMA MET-66. RX PubMed=12533684; DOI=10.1097/01.lab.0000049821.16698.d0; RA Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R., Ueda Y., RA Wada H., Murata Y., Toki T., Konishi I., Fujii S.; RT "Mutations in the STK11 gene characterize minimal deviation adenocarcinoma RT of the uterine cervix."; RL Lab. Invest. 83:35-45(2003). RN [57] RP VARIANT [LARGE SCALE ANALYSIS] LYS-87. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP VARIANT PJS GLY-16. RX PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008; RA Liu L., Du X., Nie J.; RT "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome RT patient significantly diminished p53 activity."; RL Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that CC controls the activity of AMP-activated protein kinase (AMPK) family CC members, thereby playing a role in various processes such as cell CC metabolism, cell polarity, apoptosis and DNA damage response. Acts by CC phosphorylating the T-loop of AMPK family proteins, thus promoting CC their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, CC MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not CC MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN CC and possibly p53/TP53. Acts as a key upstream regulator of AMPK by CC mediating phosphorylation and activation of AMPK catalytic subunits CC PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition CC of signaling pathways that promote cell growth and proliferation when CC energy levels are low, glucose homeostasis in liver, activation of CC autophagy when cells undergo nutrient deprivation, and B-cell CC differentiation in the germinal center in response to DNA damage. Also CC acts as a regulator of cellular polarity by remodeling the actin CC cytoskeleton. Required for cortical neuron polarization by mediating CC phosphorylation and activation of BRSK1 and BRSK2, leading to axon CC initiation and specification. Involved in DNA damage response: CC interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to CC participate in transcription activation. Able to phosphorylate CC p53/TP53; the relevance of such result in vivo is however unclear and CC phosphorylation may be indirect and mediated by downstream STK11/LKB1 CC kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis CC via interaction with p53/TP53: translocates to the mitochondrion during CC apoptosis and regulates p53/TP53-dependent apoptosis pathways. CC Regulates UV radiation-induced DNA damage response mediated by CDKN1A. CC In association with NUAK1, phosphorylates CDKN1A in response to UV CC radiation and contributes to its degradation which is necessary for CC optimal DNA repair (PubMed:25329316). {ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379, CC ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:25329316}. CC -!- FUNCTION: [Isoform 2]: Has a role in spermiogenesis. {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC -!- ACTIVITY REGULATION: Activated by forming a complex with STRAD (STRADA CC or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): STRADA CC (or STRADB)-binding promotes a conformational change of STK11/LKB1 in CC an active conformation, which is stabilized by CAB39/MO25alpha (or CC CAB39L/MO25beta) interacting with the STK11/LKB1 activation loop. CC Sequestration in the nucleus by NR4A1 prevents it from phosphorylating CC and activating cytoplasmic AMPK. {ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157}. CC -!- SUBUNIT: Catalytic component of a trimeric complex composed of CC STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CC CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and CC stimulates its catalytic activity. Found in a ternary complex composed CC of SMAD4, STK11/LKB1 and STK11IP. Interacts with p53/TP53, SMAD4, CC STK11IP and WDR6. Interacts with NR4A1. Interacts with NISCH; this CC interaction may increase STK11 activity. Interacts with PTEN; leading CC to PTEN phosphorylation. Interacts with SIRT1; the interaction CC deacetylates STK11. Interacts with CDKN1A. CC {ECO:0000269|PubMed:11741830, ECO:0000269|PubMed:12805220, CC ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17216128, CC ECO:0000269|PubMed:18687677, ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157, ECO:0000269|PubMed:23572524, CC ECO:0000269|PubMed:25329316}. CC -!- INTERACTION: CC Q15831; Q9Y376: CAB39; NbExp=23; IntAct=EBI-306838, EBI-306905; CC Q15831; Q16543: CDC37; NbExp=6; IntAct=EBI-306838, EBI-295634; CC Q15831; Q9BT78: COPS4; NbExp=5; IntAct=EBI-306838, EBI-742413; CC Q15831; Q13451: FKBP5; NbExp=11; IntAct=EBI-306838, EBI-306914; CC Q15831; P07900: HSP90AA1; NbExp=6; IntAct=EBI-306838, EBI-296047; CC Q15831; P08238: HSP90AB1; NbExp=8; IntAct=EBI-306838, EBI-352572; CC Q15831; O95835: LATS1; NbExp=2; IntAct=EBI-306838, EBI-444209; CC Q15831; Q96L34: MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319; CC Q15831; P26927: MST1; NbExp=2; IntAct=EBI-306838, EBI-6929133; CC Q15831; P54646: PRKAA2; NbExp=3; IntAct=EBI-306838, EBI-1383852; CC Q15831; Q7RTN6: STRADA; NbExp=23; IntAct=EBI-306838, EBI-1109114; CC Q15831; Q7RTN6-1: STRADA; NbExp=3; IntAct=EBI-306838, EBI-15787241; CC Q15831; Q9C0K7: STRADB; NbExp=14; IntAct=EBI-306838, EBI-306893; CC Q15831; Q8NFZ5: TNIP2; NbExp=5; IntAct=EBI-306838, EBI-359372; CC Q15831; Q9NNW5: WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315; CC Q15831; P63104: YWHAZ; NbExp=6; IntAct=EBI-306838, EBI-347088; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane {ECO:0000250}. CC Mitochondrion. Note=A small fraction localizes at membranes (By CC similarity). Relocates to the cytoplasm when bound to STRAD (STRADA or CC STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta). CC Translocates to the mitochondrion during apoptosis. PTEN promotes CC cytoplasmic localization. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:23612973}. Cytoplasm {ECO:0000269|PubMed:23612973}. CC Note=Predominantly nuclear, but translocates to the cytoplasm in CC response to metformin or peroxynitrite treatment. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LKB1(L); CC IsoId=Q15831-1; Sequence=Displayed; CC Name=2; Synonyms=LKB1(S); CC IsoId=Q15831-2; Sequence=VSP_041746; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression in CC testis and fetal liver. CC -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing radiation CC (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some PKA is required CC to inhibit cell growth. Phosphorylation at Ser-428 is also required CC during neuronal polarization to mediate phosphorylation of BRSK1 and CC BRSK2 (By similarity). Phosphorylation by PKC/PRKCZ at Ser-399 in CC isoform 2 promotes metformin (or peroxynitrite)-induced nuclear export CC of STK11 and activation of AMPK. UV radiation-induced phosphorylation CC at Thr-363 mediates CDKN1A degradation (By similarity). CC {ECO:0000250|UniProtKB:Q9WTK7, ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:18854309}. CC -!- PTM: Acetylated. Deacetylation at Lys-48 enhances cytoplasmic CC localization and kinase activity in vitro. CC {ECO:0000269|PubMed:18687677}. CC -!- DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal CC dominant disorder characterized by melanocytic macules of the lips, CC multiple gastrointestinal hamartomatous polyps and an increased risk CC for various neoplasms, including gastrointestinal cancer. CC {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054, CC ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391, CC ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765, CC ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Defects in STK11 are associated with some sporadic CC cancers, especially lung cancers. Frequently mutated and inactivated in CC non-small cell lung cancer (NSCLC). Defects promote lung cancerigenesis CC process, especially lung cancer progression and metastasis. Confers CC lung adenocarcinoma the ability to trans-differentiate into squamous CC cell carcinoma. Also able to promote lung cancer metastasis, via both CC cancer-cell autonomous and non-cancer-cell autonomous mechanisms. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. LKB1 subfamily. {ECO:0000305}. CC -!- CAUTION: Its phosphorylation by PKC/PRKCZ at Ser-428 is reported to CC promote peroxynitrite-induced nuclear export of STK11, leading to PTEN CC activation and subsequent inhibition of PI3K/AKT signaling and CC induction of apoptosis in vein endothelial cells (PubMed:18321849). CC However this paper was withdrawn by the authors due to concerns of CC image duplication in the figures. Its phosphorylation by PKC/PRKCZ has CC been confirmed in other studies (PubMed:18854309, PubMed:23612973). CC {ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:18854309, CC ECO:0000269|PubMed:23612973, ECO:0000305|PubMed:31519760}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/292/STK11"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry; CC URL="https://en.wikipedia.org/wiki/PJS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63333; AAB05809.1; -; mRNA. DR EMBL; AF035625; AAC39527.1; -; mRNA. DR EMBL; AF032984; AAB97833.1; -; Genomic_DNA. DR EMBL; AF055327; AAC15742.1; -; Genomic_DNA. DR EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AK314858; BAG37374.1; -; mRNA. DR EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471139; EAW69540.1; -; Genomic_DNA. DR EMBL; BC007981; AAH07981.1; -; mRNA. DR EMBL; BC019334; AAH19334.1; -; mRNA. DR CCDS; CCDS45896.1; -. [Q15831-1] DR RefSeq; NP_000446.1; NM_000455.5. [Q15831-1] DR RefSeq; NP_001394184.1; NM_001407255.1. [Q15831-2] DR PDB; 2WTK; X-ray; 2.65 A; C/F=43-347. DR PDB; 4ZDR; X-ray; 2.90 A; A/B=333-340. DR PDB; 5WXN; X-ray; 2.93 A; C/D=331-343. DR PDB; 8VSU; EM; 2.86 A; C=1-433. DR PDBsum; 2WTK; -. DR PDBsum; 4ZDR; -. DR PDBsum; 5WXN; -. DR PDBsum; 8VSU; -. DR AlphaFoldDB; Q15831; -. DR EMDB; EMD-43506; -. DR SMR; Q15831; -. DR BioGRID; 112670; 322. DR ComplexPortal; CPX-2431; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADA variant. DR ComplexPortal; CPX-2845; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADA variant. DR ComplexPortal; CPX-2868; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADB variant. DR ComplexPortal; CPX-2869; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADB variant. DR CORUM; Q15831; -. DR DIP; DIP-31317N; -. DR FunCoup; Q15831; 3083. DR IntAct; Q15831; 222. DR MINT; Q15831; -. DR STRING; 9606.ENSP00000324856; -. DR BindingDB; Q15831; -. DR ChEMBL; CHEMBL5606; -. DR DrugCentral; Q15831; -. DR GlyGen; Q15831; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q15831; -. DR PhosphoSitePlus; Q15831; -. DR BioMuta; STK11; -. DR DMDM; 3024670; -. DR CPTAC; CPTAC-2999; -. DR CPTAC; CPTAC-3000; -. DR jPOST; Q15831; -. DR MassIVE; Q15831; -. DR PaxDb; 9606-ENSP00000324856; -. DR PeptideAtlas; Q15831; -. DR ProteomicsDB; 60780; -. [Q15831-1] DR ProteomicsDB; 60781; -. [Q15831-2] DR Pumba; Q15831; -. DR Antibodypedia; 2048; 1357 antibodies from 44 providers. DR CPTC; Q15831; 1 antibody. DR DNASU; 6794; -. DR Ensembl; ENST00000326873.12; ENSP00000324856.6; ENSG00000118046.19. [Q15831-1] DR Ensembl; ENST00000585465.3; ENSP00000490268.2; ENSG00000118046.19. [Q15831-2] DR Ensembl; ENST00000652231.1; ENSP00000498804.1; ENSG00000118046.19. [Q15831-2] DR GeneID; 6794; -. DR KEGG; hsa:6794; -. DR MANE-Select; ENST00000326873.12; ENSP00000324856.6; NM_000455.5; NP_000446.1. DR UCSC; uc002lrl.2; human. [Q15831-1] DR AGR; HGNC:11389; -. DR CIViC; 6794; 20 evidence items across 8 molecular profiles. DR ClinPGx; PA36198; -. DR CTD; 6794; -. DR DisGeNET; 6794; -. DR GeneCards; STK11; -. DR GeneReviews; STK11; -. DR HGNC; HGNC:11389; STK11. DR HPA; ENSG00000118046; Low tissue specificity. DR MalaCards; STK11; -. DR MIM; 175200; phenotype. DR MIM; 273300; phenotype. DR MIM; 602216; gene. DR OpenTargets; ENSG00000118046; -. DR Orphanet; 2869; Peutz-Jeghers syndrome. DR VEuPathDB; HostDB:ENSG00000118046; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000158050; -. DR HOGENOM; CLU_000288_1_2_1; -. DR InParanoid; Q15831; -. DR OMA; AYHYGSE; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q15831; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q15831; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15831; -. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes. DR SignaLink; Q15831; -. DR SIGNOR; Q15831; -. DR Agora; ENSG00000118046; -. DR BioGRID-ORCS; 6794; 153 hits in 1229 CRISPR screens. DR ChiTaRS; STK11; human. DR EvolutionaryTrace; Q15831; -. DR GeneWiki; STK11; -. DR GenomeRNAi; 6794; -. DR Pharos; Q15831; Tchem. DR PRO; PR:Q15831; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q15831; protein. DR Bgee; ENSG00000118046; Expressed in left testis and 156 other cell types or tissues. DR ExpressionAtlas; Q15831; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0140535; C:intracellular protein-containing complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:1902554; C:serine/threonine protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI. DR GO; GO:0043276; P:anoikis; IMP:BHF-UCL. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; IEA:Ensembl. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0097484; P:dendrite extension; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IMP:UniProtKB. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0030010; P:establishment of cell polarity; IMP:UniProtKB. DR GO; GO:0070314; P:G1 to G0 transition; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0051645; P:Golgi localization; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0060770; P:negative regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:1901610; P:positive regulation of vesicle transport along microtubule; IMP:UniProtKB. DR GO; GO:0045059; P:positive thymic T cell selection; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006470; P:protein dephosphorylation; IMP:UniProtKB. DR GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome. DR GO; GO:0001558; P:regulation of cell growth; ISS:UniProtKB. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0030111; P:regulation of Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0001944; P:vasculature development; ISS:UniProtKB. DR CDD; cd14119; STKc_LKB1; 1. DR FunFam; 1.10.510.10:FF:000245; serine/threonine-protein kinase STK11; 1. DR FunFam; 3.30.200.20:FF:000235; serine/threonine-protein kinase STK11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00613; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR039154; LKB1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF94; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Autophagy; Cell cycle; Cytoplasm; Differentiation; Disease variant; KW DNA damage; Kinase; Lipoprotein; Magnesium; Manganese; Membrane; KW Metal-binding; Methylation; Mitochondrion; Nucleotide-binding; Nucleus; KW Palmitate; Phosphoprotein; Prenylation; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Spermatogenesis; KW Transferase; Tumor suppressor. FT CHAIN 1..430 FT /note="Serine/threonine-protein kinase STK11" FT /id="PRO_0000086699" FT PROPEP 431..433 FT /note="Removed in mature form" FT /evidence="ECO:0000250" FT /id="PRO_0000422300" FT DOMAIN 49..309 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 45..90 FT /note="Sufficient for interaction with SIRT1" FT /evidence="ECO:0000269|PubMed:18687677" FT REGION 312..331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 397..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..326 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..433 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 176 FT /note="Proton acceptor" FT BINDING 55..63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 78 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 31 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 44 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 48 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 96 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 97 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 189 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11430832" FT MOD_RES 296 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 311 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9WTK7" FT MOD_RES 336 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 363 FT /note="Phosphothreonine; by ATM and autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 401 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 416 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 423 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 428 FT /note="Phosphoserine; by autocatalysis, PKA, PKC/PRKCZ and FT RPS6KA1" FT /evidence="ECO:0000269|PubMed:18854309" FT MOD_RES 430 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000250" FT MOD_RES 431 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT LIPID 418 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000250" FT LIPID 430 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000250" FT VAR_SEQ 371..433 FT /note="QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAPNPARKACSASS FT KIRRLSACKQQ -> GEEASEAGLRAERGLQKSEGSDLSGEEASRPAPQ (in FT isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_041746" FT VARIANT 14 FT /note="E -> K (in cervical cancer; somatic mutation; FT dbSNP:rs2145404557)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065627" FT VARIANT 16 FT /note="E -> G (in PJS; dbSNP:rs2145404592)" FT /evidence="ECO:0000269|PubMed:21411391" FT /id="VAR_065628" FT VARIANT 49 FT /note="Y -> D (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853080)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033138" FT VARIANT 50..53 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071057" FT VARIANT 66 FT /note="V -> M (in cervical carcinoma; somatic mutation; FT dbSNP:rs1599915144)" FT /evidence="ECO:0000269|PubMed:12533684, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065629" FT VARIANT 67 FT /note="L -> P (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs137853077)" FT /evidence="ECO:0000269|PubMed:9428765, FT ECO:0000269|PubMed:9837816" FT /id="VAR_006202" FT VARIANT 86 FT /note="R -> G (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1057520039)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065630" FT VARIANT 87 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1568690463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041139" FT VARIANT 123 FT /note="Q -> R (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs764449808)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065631" FT VARIANT 135 FT /note="G -> R (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853081)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033139" FT VARIANT 157 FT /note="F -> S (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145424124)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065632" FT VARIANT 160 FT /note="L -> P (in cervical cancer; somatic mutation; FT dbSNP:rs2145424155)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065633" FT VARIANT 162..164 FT /note="DGL -> NDM (in PJS)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007920" FT VARIANT 163 FT /note="G -> D (in TGCT; a tumor with seminoma and teratoma FT components; somatic mutation; severely impaired but FT detectable kinase activity; impairs heterotrimeric complex FT assembly with STRADA and CAB39; predominantly nuclear FT localization; dbSNP:rs137853078)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330" FT /id="VAR_033140" FT VARIANT 170 FT /note="Q -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs876659972)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065634" FT VARIANT 171 FT /note="G -> S (in colorectal cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1599926499)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9731485" FT /id="VAR_065635" FT VARIANT 174 FT /note="H -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065636" FT VARIANT 176 FT /note="D -> N (in PJS; loss of kinase activity, leading to FT greatly reduced autophosphorylation; fails to phosphorylate FT PTEN in vitro; no significant effect on nucleocytoplasmic FT localization; dbSNP:rs730881979)" FT /evidence="ECO:0000269|PubMed:15987703, FT ECO:0000269|PubMed:9837816" FT /id="VAR_071058" FT VARIANT 176 FT /note="D -> Y (in sporadic cancer; somatic mutation; Loss FT of kinase activity)" FT /evidence="ECO:0000269|PubMed:12805220, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065637" FT VARIANT 177 FT /note="I -> N (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520041)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065638" FT VARIANT 181 FT /note="N -> E (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; requires 2 nucleotide substitutions; FT dbSNP:rs1568707668)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065639" FT VARIANT 194 FT /note="D -> N (in PJS; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007921" FT VARIANT 194 FT /note="D -> V (in lung cancer; somatic mutation; FT dbSNP:rs121913316)" FT /evidence="ECO:0000269|PubMed:10079245" FT /id="VAR_065640" FT VARIANT 194 FT /note="D -> Y (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10208439" FT /id="VAR_033141" FT VARIANT 199 FT /note="E -> K (in colorectal cancer; somatic mutation; FT impaired kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065641" FT VARIANT 199 FT /note="E -> Q (in sporadic cancer; somatic mutation; does FT not affect kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065642" FT VARIANT 205 FT /note="A -> T (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs730881981)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065643" FT VARIANT 208 FT /note="D -> N (in colorectal cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738372)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065644" FT VARIANT 215 FT /note="G -> D (in colorectal cancer; somatic mutation; FT dbSNP:rs1057520038)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065645" FT VARIANT 216 FT /note="S -> F (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520017)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065646" FT VARIANT 223 FT /note="E -> V (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2080776621)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065647" FT VARIANT 230 FT /note="T -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425367)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065648" FT VARIANT 231 FT /note="F -> L (in cervical cancer; somatic mutation; FT dbSNP:rs929783669)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065649" FT VARIANT 232 FT /note="S -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425398)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065650" FT VARIANT 239 FT /note="W -> C (in PJS; late onset suggests reduced FT penetrance; dbSNP:rs137853082)" FT /evidence="ECO:0000269|PubMed:12372054" FT /id="VAR_033142" FT VARIANT 245 FT /note="L -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065651" FT VARIANT 247 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9760200" FT /id="VAR_006203" FT VARIANT 250 FT /note="T -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1568709142)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065652" FT VARIANT 272 FT /note="Y -> H (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs2145427076)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065653" FT VARIANT 277 FT /note="D -> Y (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1555738692)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065654" FT VARIANT 281 FT /note="P -> L (in ovarian carcinoma; somatic mutation; FT dbSNP:rs121913322)" FT /evidence="ECO:0000269|PubMed:10429654" FT /id="VAR_065655" FT VARIANT 285 FT /note="L -> Q (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738724)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065656" FT VARIANT 297 FT /note="R -> K (in PJS; dbSNP:rs1568710381)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007922" FT VARIANT 303..306 FT /note="IRQH -> N (in PJS)" FT /id="VAR_033143" FT VARIANT 308 FT /note="W -> C (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs1057520042)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071059" FT VARIANT 314 FT /note="P -> H (in colorectal cancer; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs1064795752)" FT /evidence="ECO:0000269|PubMed:9809980" FT /id="VAR_065657" FT VARIANT 315 FT /note="P -> S (in PJS; uncertain significance; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs786202431)" FT /evidence="ECO:0000269|PubMed:12372054, FT ECO:0000269|PubMed:19892943" FT /id="VAR_033144" FT VARIANT 324 FT /note="P -> L (in gastric carcinoma; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs367807476)" FT /evidence="ECO:0000269|PubMed:9683800" FT /id="VAR_065658" FT VARIANT 354 FT /note="F -> L (in colorectal cancer; somatic mutation; FT dbSNP:rs59912467)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065659" FT VARIANT 367 FT /note="T -> M (in colorectal cancer; somatic mutation; FT dbSNP:rs587782835)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065660" FT MUTAGEN 44 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->Q: No effect on basal nucleocytoplasmic FT localization, but fails to translocate to the cytoplasm FT when coexpressed with SIRT1." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->R: Enhanced phosphorylation at Thr-336 and Ser- FT 428, enhanced cytoplasmic localization and increased kinase FT activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 74 FT /note="R->A: Impaired formation of a heterotrimeric complex FT with STRADA and CAB39; when associated with A-204." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 78 FT /note="K->I: Loss of kinase activity, leading to greatly FT reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 78 FT /note="K->M: Loss of kinase activity, leading to reduced FT autophosphorylation and acting as a dominant-negative FT mutant." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 96 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 97 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 189 FT /note="T->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:11430832" FT MUTAGEN 194 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14517248, FT ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943" FT MUTAGEN 204 FT /note="F->A: No effect. Impaired formation of a FT heterotrimeric complex with STRADA and CAB39; when FT associated with A-74." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 428 FT /note="S->A,E: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18854309" FT STRAND 54..57 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 62..68 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 69..71 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 74..80 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 82..87 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 91..102 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 120..123 FT /evidence="ECO:0007829|PDB:8VSU" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 136..142 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 150..169 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 231..233 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 234..250 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 260..269 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 280..289 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 294..296 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 300..305 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 307..310 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 326..328 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4ZDR" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:2WTK" FT MOD_RES Q15831-2:399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:23612973" SQ SEQUENCE 433 AA; 48636 MW; 6DF4C37AB7A89569 CRC64; MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA SSKIRRLSAC KQQ // ID TAF1_HUMAN Reviewed; 1893 AA. AC P21675; A5CVC8; A5CVC9; A5CVD0; A5CVD1; B1Q2X3; Q59FZ3; Q6IUZ1; Q70Q86; AC Q70Q87; Q70T00; Q70T01; Q70T02; Q70T03; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 08-NOV-2023, sequence version 3. DT 28-JAN-2026, entry version 249. DE RecName: Full=Transcription initiation factor TFIID subunit 1 {ECO:0000305}; DE EC=2.3.1.48 {ECO:0000269|PubMed:15870300}; DE EC=2.7.11.1; DE AltName: Full=Cell cycle gene 1 protein; DE AltName: Full=TBP-associated factor 250 kDa; DE Short=p250; DE AltName: Full=Transcription initiation factor TFIID 250 kDa subunit; DE Short=TAF(II)250; DE Short=TAFII-250; DE Short=TAFII250; GN Name=TAF1 {ECO:0000312|HGNC:HGNC:11535}; Synonyms=BA2R, CCG1, CCGS, TAF2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION. RC TISSUE=Laryngeal carcinoma; RX PubMed=2038334; DOI=10.1128/mcb.11.6.3317-3325.1991; RA Sekiguchi T., Nohiro Y., Nakamura Y., Hisamoto N., Nishimoto T.; RT "The human CCG1 gene, essential for progression of the G1 phase, encodes a RT 210-kilodalton nuclear DNA-binding protein."; RL Mol. Cell. Biol. 11:3317-3325(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TBP AND TAFS. RX PubMed=7680771; DOI=10.1038/362175a0; RA Ruppert S., Wang E.H., Tjian R.; RT "Cloning and expression of human TAFII250: a TBP-associated factor RT implicated in cell-cycle regulation."; RL Nature 362:175-179(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N-TAF1), AND INVOLVEMENT IN DYT3. RC TISSUE=Brain; RX PubMed=17273961; DOI=10.1086/512129; RA Makino S., Kaji R., Ando S., Tomizawa M., Yasuno K., Goto S., Matsumoto S., RA Tabuena M.D., Maranon E., Dantes M., Lee L.V., Ogasawara K., Tooyama I., RA Akatsu H., Nishimura M., Tamiya G.; RT "Reduced neuron-specific expression of the TAF1 gene is associated with X- RT linked dystonia-parkinsonism."; RL Am. J. Hum. Genet. 80:393-406(2007). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT VAL-290. RG NIEHS SNPs program; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 61-1604 (ISOFORM 1). RX PubMed=3169001; DOI=10.1002/j.1460-2075.1988.tb02996.x; RA Sekiguchi T., Miyata T., Nishimoto T.; RT "Molecular cloning of the cDNA of human X chromosomal gene (CCG1) which RT complements the temperature-sensitive G1 mutants, tsBN462 and ts13, of the RT BHK cell line."; RL EMBO J. 7:1683-1687(1988). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 858-1893 (ISOFORM 4). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1368-1893 (ISOFORMS 2A; 2C; 2D AND 2E), RP NUCLEOTIDE SEQUENCE [MRNA] OF 1519-1893 (ISOFORM 16), NUCLEOTIDE SEQUENCE RP [MRNA] OF 1749-1893 (ISOFORM 15), AND INVOLVEMENT IN DYT3. RC TISSUE=Fetal brain; RX PubMed=12928496; DOI=10.1073/pnas.1831949100; RA Nolte D., Niemann S., Muller U.; RT "Specific sequence changes in multiple transcript system DYT3 are RT associated with X-linked dystonia parkinsonism."; RL Proc. Natl. Acad. Sci. U.S.A. 100:10347-10352(2003). RN [9] RP SEQUENCE REVISION (ISOFORMS 2A; 2C; 2D AND 2E), NUCLEOTIDE SEQUENCE [MRNA] RP OF 1368-1893 (ISOFORMS 2E; 2G; 2H AND 2I), AND ALTERNATIVE SPLICING. RX PubMed=17952504; DOI=10.1007/s00335-007-9063-z; RA Herzfeld T., Nolte D., Muller U.; RT "Structural and functional analysis of the human TAF1/DYT3 multiple RT transcript system."; RL Mamm. Genome 18:787-795(2007). RN [10] RP FUNCTION. RX PubMed=8450888; DOI=10.1038/362179a0; RA Hisatake K., Hasegawa S., Takada R., Nakatani Y., Horikoshi M., RA Roeder R.G.; RT "The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle RT regulatory protein CCG1."; RL Nature 362:179-181(1993). RN [11] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-137 AND SER-328, AND RP ATP-BINDING. RX PubMed=8625415; DOI=10.1016/s0092-8674(00)81055-7; RA Dikstein R., Ruppert S., Tjian R.; RT "TAFII250 is a bipartite protein kinase that phosphorylates the base RT transcription factor RAP74."; RL Cell 84:781-790(1996). RN [12] RP INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION). RX PubMed=8647434; DOI=10.1101/gad.10.11.1369; RA Damania B., Alwine J.C.; RT "TAF-like function of SV40 large T antigen."; RL Genes Dev. 10:1369-1381(1996). RN [13] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4 (MICROBIAL INFECTION). RX PubMed=8649420; DOI=10.1128/mcb.16.6.3085; RA Carrozza M.J., DeLuca N.A.; RT "Interaction of the viral activator protein ICP4 with TFIID through RT TAF250."; RL Mol. Cell. Biol. 16:3085-3093(1996). RN [14] RP FUNCTION, AND MUTAGENESIS. RX PubMed=9660973; DOI=10.1016/s1097-2765(00)80089-1; RA O'Brien T., Tjian R.; RT "Functional analysis of the human TAFII250 N-terminal kinase domain."; RL Mol. Cell 1:905-911(1998). RN [15] RP FUNCTION, ACTIVITY REGULATION, INTERACTION WITH RB1, AND ATP-BINDING. RX PubMed=9858607; DOI=10.1128/mcb.19.1.846; RA Siegert J.L., Robbins P.D.; RT "Rb inhibits the intrinsic kinase activity of TATA-binding protein- RT associated factor TAFII250."; RL Mol. Cell. Biol. 19:846-854(1999). RN [16] RP INTERACTION WITH ASF1A. RX PubMed=10759893; DOI=10.1046/j.1365-2443.2000.00319.x; RA Munakata T., Adachi N., Yokoyama N., Kuzuhara T., Horikoshi M.; RT "A human homologue of yeast anti-silencing factor has histone chaperone RT activity."; RL Genes Cells 5:221-233(2000). RN [17] RP FUNCTION. RX PubMed=11278496; DOI=10.1074/jbc.m009385200; RA Solow S., Salunek M., Ryan R., Lieberman P.M.; RT "Taf(II) 250 phosphorylates human transcription factor IIA on serine RT residues important for TBP binding and transcription activity."; RL J. Biol. Chem. 276:15886-15892(2001). RN [18] RP ACTIVITY REGULATION, AND INTERACTION WITH TAF7. RX PubMed=11592977; DOI=10.1073/pnas.211444798; RA Gegonne A., Weissman J.D., Singer D.S.; RT "TAFII55 binding to TAFII250 inhibits its acetyltransferase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 98:12432-12437(2001). RN [19] RP INTERACTION WITH ASF1A. RX PubMed=12093919; DOI=10.1073/pnas.142627899; RA Chimura T., Kuzuhara T., Horikoshi M.; RT "Identification and characterization of CIA/ASF1 as an interactor of RT bromodomains associated with TFIID."; RL Proc. Natl. Acad. Sci. U.S.A. 99:9334-9339(2002). RN [20] RP INTERACTION WITH ASF1A AND ASF1B. RX PubMed=12842904; DOI=10.1074/jbc.m303549200; RA Umehara T., Horikoshi M.; RT "Transcription initiation factor IID-interactive histone chaperone CIA-II RT implicated in mammalian spermatogenesis."; RL J. Biol. Chem. 278:35660-35667(2003). RN [21] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [22] RP IDENTIFICATION IN THE MLL1/MLL COMPLEX. RX PubMed=15960975; DOI=10.1016/j.cell.2005.04.031; RA Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., RA Allis C.D., Chait B.T., Hess J.L., Roeder R.G.; RT "Physical association and coordinate function of the H3 K4 RT methyltransferase MLL1 and the H4 K16 acetyltransferase MOF."; RL Cell 121:873-885(2005). RN [23] RP HISTONE ACETYLTRANSFERASE ACTIVITY, AND MUTAGENESIS OF GLU-742 AND RP 848-MET--ASP-850. RX PubMed=15870300; DOI=10.1128/mcb.25.10.4321-4332.2005; RA Hilton T.L., Li Y., Dunphy E.L., Wang E.H.; RT "TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 RT promoter."; RL Mol. Cell. Biol. 25:4321-4332(2005). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1847, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1721 (ISOFORMS 2A AND 4), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1723 (ISOFORM 2G), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1718 (ISOFORM 16), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [27] RP ACTIVITY REGULATION. RX PubMed=22711989; DOI=10.1128/mcb.00416-12; RA Kloet S.L., Whiting J.L., Gafken P., Ranish J., Wang E.H.; RT "Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene RT transcription by TFIID subunits TAF1 and TAF7."; RL Mol. Cell. Biol. 32:3358-3369(2012). RN [28] RP MISCELLANEOUS. RX PubMed=23184149; DOI=10.1093/hmg/dds499; RA Herzfeld T., Nolte D., Grznarova M., Hofmann A., Schultze J.L., Muller U.; RT "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific RT sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and RT dopamine metabolism."; RL Hum. Mol. Genet. 22:941-951(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [31] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-570 AND LYS-583, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1380-1659. RX PubMed=10827952; DOI=10.1126/science.288.5470.1422; RA Jacobson R.H., Ladurner A.G., King D.S., Tjian R.; RT "Structure and function of a human TAFII250 double bromodomain module."; RL Science 288:1422-1425(2000). RN [33] RP X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 1522-1656, AND SUBUNIT. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 600-1236 IN COMPLEX WITH TAF7, RP FUNCTION, AND INTERACTION WITH TAF7. RX PubMed=25412659; DOI=10.1038/cr.2014.148; RA Wang H., Curran E.C., Hinds T.R., Wang E.H., Zheng N.; RT "Crystal structure of a TAF1-TAF7 complex in human transcription factor IID RT reveals a promoter binding module."; RL Cell Res. 24:1433-1444(2014). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1518-1659 IN COMPLEX WITH RP CROTONYLATED OR BUTYRYLATED HISTONE H4. RX PubMed=26365797; DOI=10.1016/j.str.2015.08.004; RA Flynn E.M., Huang O.W., Poy F., Oppikofer M., Bellon S.F., Tang Y., RA Cochran A.G.; RT "A subset of human bromodomains recognizes butyryllysine and crotonyllysine RT histone peptide modifications."; RL Structure 23:1801-1814(2015). RN [36] RP STRUCTURE BY ELECTRON MICROSCOPY (8.50 ANGSTROMS), AND SUBCELLULAR RP LOCATION. RX PubMed=27007846; DOI=10.1038/nature17394; RA Louder R.K., He Y., Lopez-Blanco J.R., Fang J., Chacon P., Nogales E.; RT "Structure of promoter-bound TFIID and model of human pre-initiation RT complex assembly."; RL Nature 531:604-609(2016). RN [37] {ECO:0007744|PDB:6FIC} RP X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 1380-1659. RA Mathea S., Suh J.L., Salah E., Tallant C., Siejka P., Pike A.C.W., RA von Delft F., Arrowsmith C.H., Edwards A.M., Bountra C., James L.I., RA Frye S.V., Knapp S.; RT "Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem."; RL Submitted (JAN-2018) to the PDB data bank. RN [38] {ECO:0007744|PDB:6P39, ECO:0007744|PDB:6P3A} RP X-RAY CRYSTALLOGRAPHY (2.94 ANGSTROMS) OF 1521-1656. RA Seo H.-S., Dhe-Paganon S.; RT "Crystal Structure Analysis of TAF1 Bromodomain."; RL Submitted (MAY-2019) to the PDB data bank. RN [39] {ECO:0007744|PDB:7JJG} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT ATR kinase inhibitor AZ20."; RL Submitted (JUL-2020) to the PDB data bank. RN [40] {ECO:0007744|PDB:7JJH} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human RT TAF1."; RL Submitted (JUL-2020) to the PDB data bank. RN [41] {ECO:0007744|PDB:7JSP} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT the ATR kinase inhibitor AZD6738."; RL Submitted (AUG-2020) to the PDB data bank. RN [42] {ECO:0007744|PDB:7JTC} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT ZS1-322."; RL Submitted (AUG-2020) to the PDB data bank. RN [43] {ECO:0007744|PDB:7K03} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 RT bound to ATR kinase inhibitor AZD6738."; RL Submitted (SEP-2020) to the PDB data bank. RN [44] {ECO:0007744|PDB:7K0D} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to mTORC1/2 inhibitor AZD3147."; RL Submitted (SEP-2020) to the PDB data bank. RN [45] {ECO:0007744|PDB:7K0U} RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT PLK1 kinase inhibitor BI2536."; RL Submitted (SEP-2020) to the PDB data bank. RN [46] {ECO:0007744|PDB:7K1P} RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT bromosporine."; RL Submitted (SEP-2020) to the PDB data bank. RN [47] {ECO:0007744|PDB:7K27} RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ATR inhibitor AZ20."; RL Submitted (SEP-2020) to the PDB data bank. RN [48] {ECO:0007744|PDB:7K3O} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the unliganded second bromodomain (BD2) of human RT TAF1."; RL Submitted (SEP-2020) to the PDB data bank. RN [49] {ECO:0007744|PDB:7K42} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT dioxane."; RL Submitted (SEP-2020) to the PDB data bank. RN [50] {ECO:0007744|PDB:7K6F} RP X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 1394-1656. RA Karim M.R., Bikowitz M.J., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in RT complex with MES (2-(N-morpholino)ethanesulfonic acid)."; RL Submitted (SEP-2020) to the PDB data bank. RN [51] {ECO:0007744|PDB:7L6X} RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to GNE-371."; RL Submitted (DEC-2020) to the PDB data bank. RN [52] {ECO:0007744|PDB:7LB0} RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-295."; RL Submitted (JAN-2021) to the PDB data bank. RN [53] {ECO:0007744|PDB:7LB1} RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-585."; RL Submitted (JAN-2021) to the PDB data bank. RN [54] {ECO:0007744|PDB:7LB2} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-589."; RL Submitted (JAN-2021) to the PDB data bank. RN [55] {ECO:0007744|PDB:7N42} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound RT to ZS1-681."; RL Submitted (JUN-2021) to the PDB data bank. RN [56] {ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH} RP STRUCTURE BY ELECTRON MICROSCOPY (3.04 ANGSTROMS), FUNCTION, IDENTIFICATION RP IN THE TFIID COMPLEX, AND SUBUNIT. RX PubMed=33795473; DOI=10.1126/science.aba8490; RA Chen X., Qi Y., Wu Z., Wang X., Li J., Zhao D., Hou H., Li Y., Yu Z., RA Liu W., Wang M., Ren Y., Li Z., Yang H., Xu Y.; RT "Structural insights into preinitiation complex assembly on core RT promoters."; RL Science 372:0-0(2021). RN [57] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-290; GLY-318; ASP-474; LYS-672 AND RP ILE-712. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP INVOLVEMENT IN MRXS33, AND VARIANTS MRXS33 SER-596; ARG-807; HIS-976; RP TRP-1246; THR-1337; HIS-1452 AND HIS-1517. RX PubMed=26637982; DOI=10.1016/j.ajhg.2015.11.005; RA O'Rawe J.A., Wu Y., Doerfel M.J., Rope A.F., Au P.Y., Parboosingh J.S., RA Moon S., Kousi M., Kosma K., Smith C.S., Tzetis M., Schuette J.L., RA Hufnagel R.B., Prada C.E., Martinez F., Orellana C., Crain J., RA Caro-Llopis A., Oltra S., Monfort S., Jimenez-Barron L.T., Swensen J., RA Ellingwood S., Smith R., Fang H., Ospina S., Stegmann S., Den Hollander N., RA Mittelman D., Highnam G., Robison R., Yang E., Faivre L., Roubertie A., RA Riviere J.B., Monaghan K.G., Wang K., Davis E.E., Katsanis N., RA Kalscheuer V.M., Wang E.H., Metcalfe K., Kleefstra T., Innes A.M., RA Kitsiou-Tzeli S., Rosello M., Keegan C.E., Lyon G.J.; RT "TAF1 Variants Are Associated with Dysmorphic Features, Intellectual RT Disability, and Neurological Manifestations."; RL Am. J. Hum. Genet. 97:922-932(2015). RN [59] RP VARIANTS ASP-493 AND CYS-1190. RX PubMed=25644381; DOI=10.1038/mp.2014.193; RA Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P., RA Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T., Love M.I., RA Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M., Fischer U., RA Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N., Castelnau L., RA Rucci J., Montjean R., Dorseuil O., Billuart P., Stuhlmann T., Shaw M., RA Corbett M.A., Gardner A., Willis-Owen S., Tan C., Friend K.L., Belet S., RA van Roozendaal K.E., Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R., RA O'Keeffe S., Chenna R., van Boemmel A., Goeke J., Hackett A., Field M., RA Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G., RA Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B., RA Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P., RA Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M., RA Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B., RA Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R., RA Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H., RA Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.; RT "X-exome sequencing of 405 unresolved families identifies seven novel RT intellectual disability genes."; RL Mol. Psychiatry 21:133-148(2016). CC -!- FUNCTION: The TFIID basal transcription factor complex plays a major CC role in the initiation of RNA polymerase II (Pol II)-dependent CC transcription (PubMed:33795473). TFIID recognizes and binds promoters CC with or without a TATA box via its subunit TBP, a TATA-box-binding CC protein, and promotes assembly of the pre-initiation complex (PIC) CC (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated CC factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, CC TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF1 is CC the largest component and core scaffold of the TFIID complex, involved CC in nucleating complex assembly (PubMed:25412659, PubMed:27007846, CC PubMed:33795473). TAF1 forms a promoter DNA binding subcomplex of CC TFIID, together with TAF7 and TAF2 (PubMed:33795473). Contains novel CC N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or CC transphosphorylate other transcription factors (PubMed:25412659, CC PubMed:8625415). Phosphorylates TP53 on 'Thr-55' which leads to MDM2- CC mediated degradation of TP53 (PubMed:25412659). Phosphorylates GTF2A1 CC and GTF2F1 on Ser residues (PubMed:25412659). Possesses DNA-binding CC activity (PubMed:25412659). Essential for progression of the G1 phase CC of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334, CC PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607). CC Exhibits histone acetyltransferase activity towards histones H3 and H4 CC (PubMed:15870300). {ECO:0000269|PubMed:11278496, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15870300, CC ECO:0000269|PubMed:2038334, ECO:0000269|PubMed:25412659, CC ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473, CC ECO:0000269|PubMed:8450888, ECO:0000269|PubMed:8625415, CC ECO:0000269|PubMed:9660973, ECO:0000269|PubMed:9858607}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-lysyl-[protein] + acetyl-CoA = N(6)-acetyl-L-lysyl-[protein] CC + CoA + H(+); Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752, Rhea:RHEA- CC COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57287, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48; CC Evidence={ECO:0000269|PubMed:15870300}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Autophosphorylates on Ser residues CC (PubMed:8625415). Inhibited by retinoblastoma tumor suppressor protein, CC RB1 (PubMed:9858607). Binding to TAF7 or CIITA inhibits the histone CC acetyltransferase activity (PubMed:11592977, PubMed:22711989). CC {ECO:0000269|PubMed:11592977, ECO:0000269|PubMed:22711989, CC ECO:0000269|PubMed:8625415, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: Component of the TFIID basal transcription factor complex, CC composed of TATA-box-binding protein TBP, and a number of TBP- CC associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, CC TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473, CC PubMed:7680771). Interacts with TAF7; the interaction is direct CC (PubMed:11592977, PubMed:25412659). TAF1, when part of the TFIID CC complex, interacts with C-terminus of TP53 (PubMed:15053879). Part of a CC TFIID-containing RNA polymerase II pre-initiation complex that is CC composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, CC GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, CC TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 CC (PubMed:27007846). Component of some MLL1/MLL complex, at least CC composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and CC RBBP5, as well as the facultative components BACC1, CHD8, E2F6, HSP70, CC INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, KAT8/MOF, PELP1, PHF20, PRP31, CC RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 CC and TEX10 (PubMed:15960975). RB1 interacts with the N-terminal domain CC of TAF1 (PubMed:9858607). Interacts with ASF1A and ASF1B CC (PubMed:10759893, PubMed:12093919, PubMed:12842904). Interacts (via CC bromo domains) with acetylated lysine residues on the N-terminus of CC histone H1.4, H2A, H2B, H3 and H4 (in vitro) (PubMed:22464331). CC {ECO:0000269|PubMed:10759893, ECO:0000269|PubMed:11592977, CC ECO:0000269|PubMed:12093919, ECO:0000269|PubMed:12842904, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15960975, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:25412659, CC ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473, CC ECO:0000269|PubMed:7680771, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 Large T antigen. CC {ECO:0000269|PubMed:8647434}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC ICP4. {ECO:0000269|PubMed:8649420}. CC -!- INTERACTION: CC P21675; P35269: GTF2F1; NbExp=3; IntAct=EBI-491289, EBI-457886; CC P21675; P20226: TBP; NbExp=11; IntAct=EBI-491289, EBI-355371; CC P21675; P03255; Xeno; NbExp=3; IntAct=EBI-491289, EBI-2603114; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:2038334, CC ECO:0000269|PubMed:25593309, ECO:0000269|PubMed:27007846}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=15; CC Comment=the TAF1/DYT3 multiple transcript system is composed of 38 CC evolutionary conserved exons plus 5 downstream exons referred to as CC exons d1-d5 that are primate-specific. Multiple highly polymorphic CC variants can be generated by splicing exons d3 and d4 to various CC combinations of exons 1-37. {ECO:0000305|PubMed:17952504}; CC Name=2; CC IsoId=P21675-2; Sequence=Displayed; CC Name=1; CC IsoId=P21675-1; Sequence=VSP_061988; CC Name=13; CC IsoId=P21675-13; Sequence=VSP_061987, VSP_061988; CC Name=14; CC IsoId=P21675-14; Sequence=VSP_061987; CC Name=15; CC IsoId=P21675-15; Sequence=VSP_061999, VSP_062000; CC Name=16; CC IsoId=P21675-16; Sequence=VSP_061996, VSP_061998; CC Name=N-TAF1; Synonyms=TA14-391; CC IsoId=P21675-17; Sequence=VSP_061995; CC Name=2a; CC IsoId=P21675-18; Sequence=VSP_061997, VSP_061998; CC Name=2c; CC IsoId=P21675-19; Sequence=VSP_061998; CC Name=2d; CC IsoId=P21675-20; Sequence=VSP_061995, VSP_061998; CC Name=2e; CC IsoId=P21675-21; Sequence=VSP_061993, VSP_061994; CC Name=2g; CC IsoId=P21675-22; Sequence=VSP_061995, VSP_061997, VSP_061998; CC Name=2h; CC IsoId=P21675-23; Sequence=VSP_061990, VSP_061991; CC Name=2i; CC IsoId=P21675-24; Sequence=VSP_061989, VSP_061992; CC Name=4; CC IsoId=P21675-25; Sequence=VSP_061997; CC -!- DOMAIN: The Bromo domain mediates interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). The CC second domain also recognizes and binds histones that are butyrylated CC and crotonylated (PubMed:26365797). {ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:26365797}. CC -!- PTM: Phosphorylated by casein kinase II in vitro. CC {ECO:0000269|PubMed:8625415}. CC -!- DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: An X-linked CC dystonia-parkinsonism disorder. Dystonia is defined by the presence of CC sustained involuntary muscle contractions, often leading to abnormal CC postures. DYT3 is characterized by severe progressive torsion dystonia CC followed by parkinsonism. It has a well-defined pathology of extensive CC neuronal loss and mosaic gliosis in the striatum (caudate nucleus and CC putamen) which appears to resemble that in Huntington disease. CC {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intellectual developmental disorder, X-linked, syndromic 33 CC (MRXS33) [MIM:300966]: A syndrome characterized by intellectual CC deficit, delayed psychomotor development, delayed speech and language, CC and characteristic facial features. {ECO:0000269|PubMed:26637982}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: [Isoform 16]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 2a]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2c]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2d]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2e]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2h]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2i]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2g]: Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 15]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform N-TAF1]: Only detected in brain, highest CC expression in the caudate nucleus. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the TAF1 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA30073.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal and C-terminal part.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D90359; BAA14374.1; -; mRNA. DR EMBL; AB300418; BAG15901.1; -; mRNA. DR EMBL; AY623109; AAT38105.1; -; Genomic_DNA. DR EMBL; AL590762; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590763; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; X07024; CAA30073.1; ALT_SEQ; mRNA. DR EMBL; AB209316; BAD92553.1; -; mRNA. DR EMBL; AJ549247; CAD70490.1; -; mRNA. DR EMBL; AJ549248; CAD70491.3; -; mRNA. DR EMBL; AJ549249; CAD70492.2; -; mRNA. DR EMBL; AJ549250; CAD70493.3; -; mRNA. DR EMBL; AJ555148; CAD87527.2; -; mRNA. DR EMBL; AJ555149; CAD87528.2; -; mRNA. DR EMBL; AM711892; CAM98555.1; -; mRNA. DR EMBL; AM711893; CAM98556.1; -; mRNA. DR EMBL; AM711894; CAM98557.1; -; mRNA. DR EMBL; AM711895; CAM98558.1; -; mRNA. DR CCDS; CCDS14412.2; -. [P21675-14] DR CCDS; CCDS35325.2; -. [P21675-13] DR PIR; A40262; A40262. DR RefSeq; NP_620278.2; NM_138923.4. [P21675-13] DR RefSeq; XP_047298351.1; XM_047442395.1. [P21675-14] DR RefSeq; XP_047298355.1; XM_047442399.1. [P21675-13] DR RefSeq; XP_054183607.1; XM_054327632.1. [P21675-14] DR RefSeq; XP_054183611.1; XM_054327636.1. [P21675-13] DR PDB; 1EQF; X-ray; 2.10 A; A=1380-1659. DR PDB; 3AAD; X-ray; 3.30 A; A=1363-1650. DR PDB; 3UV4; X-ray; 1.89 A; A/B=1522-1656. DR PDB; 3UV5; X-ray; 2.03 A; A=1394-1656. DR PDB; 4RGW; X-ray; 2.30 A; A=600-1236. DR PDB; 4YYM; X-ray; 1.50 A; A/B=1518-1659. DR PDB; 4YYN; X-ray; 1.85 A; A/B=1518-1659. DR PDB; 5FUR; EM; 8.50 A; G=1-1893. DR PDB; 5I1Q; X-ray; 1.50 A; A=1518-1659. DR PDB; 5I29; X-ray; 1.21 A; A=1518-1659. DR PDB; 5MG2; X-ray; 1.75 A; A=1522-1656. DR PDB; 6BQD; X-ray; 2.14 A; A/B=1522-1651. DR PDB; 6FIC; X-ray; 2.18 A; T=1380-1659. DR PDB; 6MZD; EM; 9.80 A; A=21-1893. DR PDB; 6MZL; EM; 23.00 A; A=1-1893. DR PDB; 6MZM; EM; 7.50 A; A=609-1104. DR PDB; 6P38; X-ray; 2.80 A; A=1522-1656. DR PDB; 6P39; X-ray; 2.94 A; A=1521-1656. DR PDB; 6P3A; X-ray; 2.99 A; A/B=1522-1656. DR PDB; 7EDX; EM; 4.50 A; A=1-1893. DR PDB; 7EG7; EM; 6.20 A; A=1-1893. DR PDB; 7EG8; EM; 7.40 A; A=1-1893. DR PDB; 7EG9; EM; 3.70 A; A=1-1893. DR PDB; 7EGA; EM; 4.10 A; A=1-1893. DR PDB; 7EGB; EM; 3.30 A; A=1-1893. DR PDB; 7EGC; EM; 3.90 A; A=1-1893. DR PDB; 7EGD; EM; 6.75 A; A=1-1893. DR PDB; 7EGE; EM; 9.00 A; A=1-1893. DR PDB; 7EGH; EM; 3.04 A; A=1-1893. DR PDB; 7EGI; EM; 9.82 A; A=1-1893. DR PDB; 7EGJ; EM; 8.64 A; A=1-1893. DR PDB; 7ENA; EM; 4.07 A; DA=1-1893. DR PDB; 7ENC; EM; 4.13 A; DA=1-1893. DR PDB; 7JJG; X-ray; 1.60 A; A=1522-1656. DR PDB; 7JJH; X-ray; 2.10 A; A=1394-1656. DR PDB; 7JSP; X-ray; 1.70 A; A=1522-1656. DR PDB; 7JTC; X-ray; 2.05 A; A=1522-1656. DR PDB; 7K03; X-ray; 1.60 A; A=1394-1656. DR PDB; 7K0D; X-ray; 2.20 A; A=1394-1656. DR PDB; 7K0U; X-ray; 2.52 A; A/B=1522-1656. DR PDB; 7K1P; X-ray; 2.45 A; A=1522-1656. DR PDB; 7K27; X-ray; 1.50 A; A=1394-1656. DR PDB; 7K3O; X-ray; 1.70 A; A/B=1522-1656. DR PDB; 7K42; X-ray; 1.70 A; A/B=1522-1656. DR PDB; 7K6F; X-ray; 1.86 A; A=1394-1656. DR PDB; 7L6X; X-ray; 2.75 A; A=1394-1656. DR PDB; 7LB0; X-ray; 2.33 A; A=1394-1656. DR PDB; 7LB1; X-ray; 1.35 A; A=1394-1656. DR PDB; 7LB2; X-ray; 1.70 A; A=1394-1656. DR PDB; 7LB3; X-ray; 1.90 A; A=1522-1656. DR PDB; 7N42; X-ray; 1.90 A; A=1394-1656. DR PDB; 7P4S; X-ray; 2.17 A; A=1522-1656. DR PDB; 7T2I; X-ray; 1.89 A; A=1394-1656. DR PDB; 7T36; X-ray; 1.65 A; A=1394-1656. DR PDB; 8GXQ; EM; 5.04 A; DA=1-1893. DR PDB; 8GXS; EM; 4.16 A; DA=1-1893. DR PDB; 8WAK; EM; 5.47 A; A=1-1872. DR PDB; 8WAL; EM; 8.52 A; A=1-1872. DR PDB; 8WAN; EM; 6.07 A; A=1-1872. DR PDB; 8WAO; EM; 6.40 A; A=1-1872. DR PDB; 8WAP; EM; 5.85 A; A=1-1872. DR PDB; 8WAQ; EM; 6.29 A; A=1-1872. DR PDB; 8WAR; EM; 7.20 A; A=1-1872. DR PDB; 8WAS; EM; 6.13 A; A=1-1872. DR PDBsum; 1EQF; -. DR PDBsum; 3AAD; -. DR PDBsum; 3UV4; -. DR PDBsum; 3UV5; -. DR PDBsum; 4RGW; -. DR PDBsum; 4YYM; -. DR PDBsum; 4YYN; -. DR PDBsum; 5FUR; -. DR PDBsum; 5I1Q; -. DR PDBsum; 5I29; -. DR PDBsum; 5MG2; -. DR PDBsum; 6BQD; -. DR PDBsum; 6FIC; -. DR PDBsum; 6MZD; -. DR PDBsum; 6MZL; -. DR PDBsum; 6MZM; -. DR PDBsum; 6P38; -. DR PDBsum; 6P39; -. DR PDBsum; 6P3A; -. DR PDBsum; 7EDX; -. DR PDBsum; 7EG7; -. DR PDBsum; 7EG8; -. DR PDBsum; 7EG9; -. DR PDBsum; 7EGA; -. DR PDBsum; 7EGB; -. DR PDBsum; 7EGC; -. DR PDBsum; 7EGD; -. DR PDBsum; 7EGE; -. DR PDBsum; 7EGH; -. DR PDBsum; 7EGI; -. DR PDBsum; 7EGJ; -. DR PDBsum; 7ENA; -. DR PDBsum; 7ENC; -. DR PDBsum; 7JJG; -. DR PDBsum; 7JJH; -. DR PDBsum; 7JSP; -. DR PDBsum; 7JTC; -. DR PDBsum; 7K03; -. DR PDBsum; 7K0D; -. DR PDBsum; 7K0U; -. DR PDBsum; 7K1P; -. DR PDBsum; 7K27; -. DR PDBsum; 7K3O; -. DR PDBsum; 7K42; -. DR PDBsum; 7K6F; -. DR PDBsum; 7L6X; -. DR PDBsum; 7LB0; -. DR PDBsum; 7LB1; -. DR PDBsum; 7LB2; -. DR PDBsum; 7LB3; -. DR PDBsum; 7N42; -. DR PDBsum; 7P4S; -. DR PDBsum; 7T2I; -. DR PDBsum; 7T36; -. DR PDBsum; 8GXQ; -. DR PDBsum; 8GXS; -. DR PDBsum; 8WAK; -. DR PDBsum; 8WAL; -. DR PDBsum; 8WAN; -. DR PDBsum; 8WAO; -. DR PDBsum; 8WAP; -. DR PDBsum; 8WAQ; -. DR PDBsum; 8WAR; -. DR PDBsum; 8WAS; -. DR AlphaFoldDB; P21675; -. DR EMDB; EMD-31075; -. DR EMDB; EMD-31107; -. DR EMDB; EMD-31108; -. DR EMDB; EMD-31109; -. DR EMDB; EMD-31110; -. DR EMDB; EMD-31111; -. DR EMDB; EMD-31112; -. DR EMDB; EMD-31113; -. DR EMDB; EMD-31114; -. DR EMDB; EMD-31117; -. DR EMDB; EMD-31118; -. DR EMDB; EMD-31119; -. DR EMDB; EMD-31204; -. DR EMDB; EMD-31207; -. DR EMDB; EMD-34359; -. DR EMDB; EMD-34360; -. DR EMDB; EMD-37395; -. DR EMDB; EMD-37396; -. DR EMDB; EMD-37398; -. DR EMDB; EMD-37399; -. DR EMDB; EMD-37400; -. DR EMDB; EMD-37401; -. DR EMDB; EMD-37402; -. DR EMDB; EMD-37403; -. DR EMDB; EMD-9302; -. DR EMDB; EMD-9305; -. DR EMDB; EMD-9306; -. DR SASBDB; P21675; -. DR SMR; P21675; -. DR BioGRID; 112735; 258. DR ComplexPortal; CPX-915; General transcription factor complex TFIID. DR ComplexPortal; CPX-930; General transcription factor complex TFIID, TAF4B variant. DR CORUM; P21675; -. DR DIP; DIP-147N; -. DR FunCoup; P21675; 3231. DR IntAct; P21675; 83. DR MINT; P21675; -. DR STRING; 9606.ENSP00000406549; -. DR BindingDB; P21675; -. DR ChEMBL; CHEMBL3217390; -. DR GuidetoPHARMACOLOGY; 2231; -. DR GlyCosmos; P21675; 1 site, 1 glycan. DR GlyGen; P21675; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P21675; -. DR PhosphoSitePlus; P21675; -. DR BioMuta; TAF1; -. DR DMDM; 115942; -. DR jPOST; P21675; -. DR MassIVE; P21675; -. DR PaxDb; 9606-ENSP00000406549; -. DR PeptideAtlas; P21675; -. DR ProteomicsDB; 3401; -. DR ProteomicsDB; 53886; -. [P21675-1] DR ProteomicsDB; 53887; -. [P21675-2] DR Pumba; P21675; -. DR ABCD; P21675; 1 sequenced antibody. DR Antibodypedia; 346; 301 antibodies from 39 providers. DR DNASU; 6872; -. DR Ensembl; ENST00000373790.9; ENSP00000362895.5; ENSG00000147133.19. [P21675-13] DR Ensembl; ENST00000423759.6; ENSP00000406549.2; ENSG00000147133.19. [P21675-14] DR Ensembl; ENST00000715246.1; ENSP00000520427.1; ENSG00000147133.19. [P21675-2] DR GeneID; 6872; -. DR KEGG; hsa:6872; -. DR MANE-Select; ENST00000423759.6; ENSP00000406549.2; NM_004606.5; NP_004597.3. [P21675-14] DR UCSC; uc004dzt.6; human. [P21675-2] DR AGR; HGNC:11535; -. DR ClinPGx; PA36310; -. DR CTD; 6872; -. DR DisGeNET; 6872; -. DR GeneCards; TAF1; -. DR GeneReviews; TAF1; -. DR HGNC; HGNC:11535; TAF1. DR HPA; ENSG00000147133; Low tissue specificity. DR MalaCards; TAF1; -. DR MIM; 300966; phenotype. DR MIM; 313650; gene. DR MIM; 314250; phenotype. DR OpenTargets; ENSG00000147133; -. DR Orphanet; 53351; X-linked dystonia-parkinsonism. DR Orphanet; 480907; X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome. DR VEuPathDB; HostDB:ENSG00000147133; -. DR eggNOG; KOG0008; Eukaryota. DR GeneTree; ENSGT00940000155242; -. DR HOGENOM; CLU_000572_3_0_1; -. DR InParanoid; P21675; -. DR OMA; PARIWYD; -. DR OrthoDB; 5752at2759; -. DR PAN-GO; P21675; 4 GO annotations based on evolutionary models. DR PhylomeDB; P21675; -. DR BRENDA; 2.3.1.48; 2681. DR PathwayCommons; P21675; -. DR Reactome; R-HSA-167161; HIV Transcription Initiation. DR Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape. DR Reactome; R-HSA-167172; Transcription of the HIV genome. DR Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape. DR Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening. DR Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation. DR Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance. DR SignaLink; P21675; -. DR SIGNOR; P21675; -. DR Agora; ENSG00000147133; -. DR BioGRID-ORCS; 6872; 343 hits in 821 CRISPR screens. DR ChiTaRS; TAF1; human. DR EvolutionaryTrace; P21675; -. DR GeneWiki; TAF1; -. DR GenomeRNAi; 6872; -. DR Pharos; P21675; Tchem. DR PRO; PR:P21675; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P21675; protein. DR Bgee; ENSG00000147133; Expressed in sural nerve and 182 other cell types or tissues. DR ExpressionAtlas; P21675; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL. DR GO; GO:0071339; C:MLL1 complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IPI:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB. DR GO; GO:0140046; F:histone H4K16ac reader activity; IDA:BHF-UCL. DR GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0016922; F:nuclear receptor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0001181; F:RNA polymerase I general transcription initiation factor activity; IDA:ARUK-UCL. DR GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IMP:ParkinsonsUK-UCL. DR GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:BHF-UCL. DR GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; ISS:BHF-UCL. DR GO; GO:0017025; F:TBP-class protein binding; IPI:BHF-UCL. DR GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0071318; P:cellular response to ATP; IDA:ParkinsonsUK-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:ParkinsonsUK-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:ParkinsonsUK-UCL. DR GO; GO:0030901; P:midbrain development; IGI:ParkinsonsUK-UCL. DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL. DR GO; GO:1905524; P:negative regulation of protein autoubiquitination; IDA:ParkinsonsUK-UCL. DR GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; IDA:ParkinsonsUK-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:ParkinsonsUK-UCL. DR GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL. DR GO; GO:0160207; P:positive regulation of androgen receptor signaling pathway; IDA:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL. DR GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0000209; P:protein polyubiquitination; IDA:ParkinsonsUK-UCL. DR GO; GO:0050821; P:protein stabilization; IDA:ParkinsonsUK-UCL. DR GO; GO:1902806; P:regulation of cell cycle G1/S phase transition; TAS:ParkinsonsUK-UCL. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IPI:ComplexPortal. DR GO; GO:0006366; P:transcription by RNA polymerase II; IGI:BHF-UCL. DR GO; GO:0006361; P:transcription initiation at RNA polymerase I promoter; IGI:ParkinsonsUK-UCL. DR GO; GO:0006367; P:transcription initiation at RNA polymerase II promoter; IDA:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL. DR CDD; cd05511; Bromo_TFIID; 2. DR DisProt; DP03451; -. [P21675-1] DR FunFam; 1.10.1100.10:FF:000001; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000019; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000020; Transcription initiation factor TFIID subunit; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR Gene3D; 1.10.1100.10; TAFII-230 TBP-binding domain; 1. DR IDEAL; IID00545; -. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR040240; TAF1. DR InterPro; IPR011177; TAF1_animal. DR InterPro; IPR022591; TAF1_HAT_dom. DR InterPro; IPR009067; TAF_II_230-bd. DR InterPro; IPR036741; TAFII-230_TBP-bd_sf. DR InterPro; IPR041670; Znf-CCHC_6. DR PANTHER; PTHR13900; TRANSCRIPTION INITIATION FACTOR TFIID; 1. DR PANTHER; PTHR13900:SF0; TRANSCRIPTION INITIATION FACTOR TFIID SUBUNIT 1; 1. DR Pfam; PF00439; Bromodomain; 2. DR Pfam; PF12157; DUF3591; 1. DR Pfam; PF09247; TBP-binding; 1. DR Pfam; PF15288; zf-CCHC_6; 1. DR PIRSF; PIRSF003047; TAF1_animal; 1. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR SUPFAM; SSF47055; TAF(II)230 TBP-binding fragment; 1. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Acyltransferase; Alternative initiation; KW Alternative splicing; ATP-binding; Bromodomain; Cell cycle; KW Disease variant; DNA-binding; Dystonia; Host-virus interaction; KW Intellectual disability; Isopeptide bond; Kinase; Nucleotide-binding; KW Nucleus; Parkinsonism; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Ubl conjugation. FT CHAIN 1..1893 FT /note="Transcription initiation factor TFIID subunit 1" FT /id="PRO_0000211215" FT DOMAIN 1..435 FT /note="Protein kinase 1" FT DOMAIN 1397..1505 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 1446..1893 FT /note="Protein kinase 2" FT DOMAIN 1519..1628 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DNA_BIND 1216..1294 FT /note="HMG box; involved in promoter binding" FT /evidence="ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, FT ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, FT ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, FT ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, FT ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH, FT ECO:0007744|PDB:7EGI, ECO:0007744|PDB:7EGJ" FT REGION 155..184 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 197..224 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 534..557 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 538..997 FT /note="Histone acetyltransferase (HAT)" FT REGION 990..1009 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1128..1148 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1158..1177 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1254..1278 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1363..1650 FT /note="Interaction with ASF1A and ASF1B" FT /evidence="ECO:0000269|PubMed:12842904" FT REGION 1651..1676 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1696..1893 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1372..1379 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 156..165 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 197..208 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 995..1004 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1139..1148 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1254..1270 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1659..1668 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1709..1723 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1741..1756 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1830..1840 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1846..1857 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1860..1869 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 137 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8625415" FT MOD_RES 328 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8625415, FT ECO:0007744|PubMed:24275569" FT MOD_RES 565 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1690 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1693 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1799 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1802 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1820 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1847 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT CROSSLNK 570 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 583 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..20 FT /note="Missing (in isoform 13 and isoform 14)" FT /id="VSP_061987" FT VAR_SEQ 178..198 FT /note="Missing (in isoform 1 and isoform 13)" FT /id="VSP_061988" FT VAR_SEQ 1546..1561 FT /note="SWPFHHPVNKKFVPDY -> VSCLCAKYFLAISSPS (in isoform FT 2i)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061989" FT VAR_SEQ 1546..1549 FT /note="SWPF -> IITK (in isoform 2h)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061990" FT VAR_SEQ 1550..1893 FT /note="Missing (in isoform 2h)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061991" FT VAR_SEQ 1562..1893 FT /note="Missing (in isoform 2i)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061992" FT VAR_SEQ 1606..1613 FT /note="PESQYTKT -> YMCTTCRT (in isoform 2e)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061993" FT VAR_SEQ 1614..1893 FT /note="Missing (in isoform 2e)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061994" FT VAR_SEQ 1666 FT /note="Q -> QAK (in isoform N-TAF1, isoform 2d and isoform FT 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17273961, ECO:0000303|PubMed:17952504" FT /id="VSP_061995" FT VAR_SEQ 1706..1708 FT /note="VTQ -> MRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in FT isoform 16)" FT /evidence="ECO:0000303|PubMed:12928496" FT /id="VSP_061996" FT VAR_SEQ 1708 FT /note="Q -> QMRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in isoform FT 4, isoform 2a and isoform 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504, ECO:0000303|Ref.7" FT /id="VSP_061997" FT VAR_SEQ 1820..1893 FT /note="SYGSYEEPDPKSNTQDTSFSSIGGYEVSEEEEDEEEEEQRSGPSVLSQVHLS FT EDEEDSEDFHSIAGDSDLDSDE -> RYQ (in isoform 2a, isoform 16, FT isoform 2c, isoform 2d and isoform 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061998" FT VAR_SEQ 1820 FT /note="S -> R (in isoform 15)" FT /id="VSP_061999" FT VAR_SEQ 1821..1893 FT /note="Missing (in isoform 15)" FT /id="VSP_062000" FT VARIANT 290 FT /note="L -> V (in dbSNP:rs28382158)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_020678" FT VARIANT 318 FT /note="A -> G (in dbSNP:rs35317750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041930" FT VARIANT 474 FT /note="G -> D (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041931" FT VARIANT 493 FT /note="N -> D (found in a patient with X-linked FT intellectual disability; uncertain significance; FT dbSNP:rs200177996)" FT /evidence="ECO:0000269|PubMed:25644381" FT /id="VAR_077838" FT VARIANT 596 FT /note="P -> S (in MRXS33; dbSNP:rs864321630)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076394" FT VARIANT 672 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041932" FT VARIANT 712 FT /note="M -> I (in a lung bronchoalveolar carcinoma sample; FT somatic mutation; dbSNP:rs2148297629)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041933" FT VARIANT 807 FT /note="C -> R (in MRXS33; dbSNP:rs864321628)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076395" FT VARIANT 976 FT /note="D -> H (in MRXS33; dbSNP:rs864321631)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076396" FT VARIANT 1190 FT /note="R -> C (found in a patient with X-linked FT intellectual disability; uncertain significance; FT dbSNP:rs1569301036)" FT /evidence="ECO:0000269|PubMed:25644381" FT /id="VAR_077839" FT VARIANT 1246 FT /note="R -> W (in MRXS33; dbSNP:rs864321629)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076397" FT VARIANT 1337 FT /note="I -> T (in MRXS33; dbSNP:rs864321627)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076398" FT VARIANT 1404 FT /note="V -> I (in dbSNP:rs7050748)" FT /id="VAR_048433" FT VARIANT 1452 FT /note="R -> H (in MRXS33; uncertain significance; FT dbSNP:rs2148488251)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076399" FT VARIANT 1517 FT /note="N -> H (in MRXS33; uncertain significance; FT dbSNP:rs1602624914)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076400" FT MUTAGEN 137 FT /note="S->A: No decrease in kinase activity." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 145 FT /note="D->A: Reduces kinase activity; when associated with FT A-147; A-149; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 147 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-149; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 149 FT /note="E->A: Reduces kinase activity; when associated with FT A-145; A-147; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 150 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 152 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-150 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 154 FT /note="K->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-150 and A-152." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 326 FT /note="C->A: Reduces kinase activity; when associated with FT A-328; A-329; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 328 FT /note="S->A: Reduces kinase activity; when associated with FT A-326; A-329; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 329 FT /note="D->A: Reduces kinase activity; when associated with FT A-326; A-328; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 330 FT /note="D->A: Reduces kinase activity; when associated with FT A-326; A-328; A-329 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 331 FT /note="E->A: Reduces kinase activity; when associated with FT A-326; A-328; A-329 and A-330." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 742 FT /note="E->Q: 25% decrease in histone acetylation." FT /evidence="ECO:0000269|PubMed:15870300" FT MUTAGEN 848..850 FT /note="Missing: Dramatic decrease in histone acetylation." FT /evidence="ECO:0000269|PubMed:15870300" FT STRAND 363..365 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 368..374 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 420..423 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 431..434 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 494..498 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 501..504 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 509..511 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 525..527 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 614..617 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 621..623 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 630..634 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 648..650 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 651..653 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 655..659 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 661..676 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 689..692 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 696..706 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 718..725 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 739..745 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 760..777 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 782..788 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 799..803 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 818..838 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 841..843 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 845..847 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 848..854 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 860..868 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 871..874 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 877..879 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 882..885 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 894..900 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 903..921 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 946..949 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 952..963 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 968..973 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 979..983 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 985..989 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 1014..1018 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1020..1031 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1035..1039 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1043..1055 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1076..1099 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 1186..1191 FT /evidence="ECO:0007829|PDB:7EGH" FT TURN 1195..1197 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 1201..1206 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1209..1224 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1238..1262 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1402..1418 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1424..1426 FT /evidence="ECO:0007829|PDB:7LB1" FT STRAND 1427..1429 FT /evidence="ECO:0007829|PDB:3AAD" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1438..1441 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1448..1456 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1463..1480 FT /evidence="ECO:0007829|PDB:7LB1" FT STRAND 1483..1485 FT /evidence="ECO:0007829|PDB:3AAD" FT HELIX 1486..1504 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1506..1516 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1518..1521 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1523..1538 FT /evidence="ECO:0007829|PDB:5I29" FT TURN 1539..1542 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1547..1549 FT /evidence="ECO:0007829|PDB:5I29" FT TURN 1555..1557 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1558..1560 FT /evidence="ECO:0007829|PDB:6P3A" FT HELIX 1561..1564 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1565..1567 FT /evidence="ECO:0007829|PDB:6P3A" FT HELIX 1571..1579 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1586..1604 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:7K6F" FT HELIX 1609..1627 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1629..1655 FT /evidence="ECO:0007829|PDB:5I29" FT MOD_RES P21675-16:1718 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-18:1721 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-22:1723 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-25:1721 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" SQ SEQUENCE 1893 AA; 214714 MW; AE148C222B418BB4 CRC64; MGPGCDLLLR TAATITAAAI MSDTDSDEDS AGGGPFSLAG FLFGNINGAG QLEGESVLDD ECKKHLAGLG ALGLGSLITE LTANEELTGT DGALVNDEGW VRSTEDAVDY SDINEVAEDE SRRYQQTMGS LQPLCHSDYD EDDYDADCED IDCKLMPPPP PPPGPMKKDK DQDSITGVSE NGEGIILPSI IAPSSLASEK VDFSSSSDSE SEMGPQEATQ AESEDGKLTL PLAGIMQHDA TKLLPSVTEL FPEFRPGKVL RFLRLFGPGK NVPSVWRSAR RKRKKKHREL IQEEQIQEVE CSVESEVSQK SLWNYDYAPP PPPEQCLSDD EITMMAPVES KFSQSTGDID KVTDTKPRVA EWRYGPARLW YDMLGVPEDG SGFDYGFKLR KTEHEPVIKS RMIEEFRKLE ENNGTDLLAD ENFLMVTQLH WEDDIIWDGE DVKHKGTKPQ RASLAGWLPS SMTRNAMAYN VQQGFAATLD DDKPWYSIFP IDNEDLVYGR WEDNIIWDAQ AMPRLLEPPV LTLDPNDENL ILEIPDEKEE ATSNSPSKES KKESSLKKSR ILLGKTGVIK EEPQQNMSQP EVKDPWNLSN DEYYYPKQQG LRGTFGGNII QHSIPAVELR QPFFPTHMGP IKLRQFHRPP LKKYSFGALS QPGPHSVQPL LKHIKKKAKM REQERQASGG GEMFFMRTPQ DLTGKDGDLI LAEYSEENGP LMMQVGMATK IKNYYKRKPG KDPGAPDCKY GETVYCHTSP FLGSLHPGQL LQAFENNLFR APIYLHKMPE TDFLIIRTRQ GYYIRELVDI FVVGQQCPLF EVPGPNSKRA NTHIRDFLQV FIYRLFWKSK DRPRRIRMED IKKAFPSHSE SSIRKRLKLC ADFKRTGMDS NWWVLKSDFR LPTEEEIRAM VSPEQCCAYY SMIAAEQRLK DAGYGEKSFF APEEENEEDF QMKIDDEVRT APWNTTRAFI AAMKGKCLLE VTGVADPTGC GEGFSYVKIP NKPTQQKDDK EPQPVKKTVT GTDADLRRLS LKNAKQLLRK FGVPEEEIKK LSRWEVIDVV RTMSTEQARS GEGPMSKFAR GSRFSVAEHQ ERYKEECQRI FDLQNKVLSS TEVLSTDTDS SSAEDSDFEE MGKNIENMLQ NKKTSSQLSR EREEQERKEL QRMLLAAGSA ASGNNHRDDD TASVTSLNSS ATGRCLKIYR TFRDEEGKEY VRCETVRKPA VIDAYVRIRT TKDEEFIRKF ALFDEQHREE MRKERRRIQE QLRRLKRNQE KEKLKGPPEK KPKKMKERPD LKLKCGACGA IGHMRTNKFC PLYYQTNAPP SNPVAMTEEQ EEELEKTVIH NDNEELIKVE GTKIVLGKQL IESADEVRRK SLVLKFPKQQ LPPKKKRRVG TTVHCDYLNR PHKSIHRRRT DPMVTLSSIL ESIINDMRDL PNTYPFHTPV NAKVVKDYYK IITRPMDLQT LRENVRKRLY PSREEFREHL ELIVKNSATY NGPKHSLTQI SQSMLDLCDE KLKEKEDKLA RLEKAINPLL DDDDQVAFSF ILDNIVTQKM MAVPDSWPFH HPVNKKFVPD YYKVIVNPMD LETIRKNISK HKYQSRESFL DDVNLILANS VKYNGPESQY TKTAQEIVNV CYQTLTEYDE HLTQLEKDIC TAKEAALEEA ELESLDPMTP GPYTPQPPDL YDTNTSLSMS RDASVFQDES NMSVLDIPSA TPEKQVTQEG EDGDGDLADE EEGTVQQPQA SVLYEDLLMS EGEDDEEDAG SDEEGDNPFS AIQLSESGSD SDVGSGGIRP KQPRMLQENT RMDMENEESM MSYEGDGGEA SHGLEDSNIS YGSYEEPDPK SNTQDTSFSS IGGYEVSEEE EDEEEEEQRS GPSVLSQVHL SEDEEDSEDF HSIAGDSDLD SDE // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TRRAP_HUMAN Reviewed; 3859 AA. AC Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 226. DE RecName: Full=Transformation/transcription domain-associated protein; DE AltName: Full=350/400 kDa PCAF-associated factor; DE Short=PAF350/400; DE AltName: Full=STAF40; DE AltName: Full=Tra1 homolog; GN Name=TRRAP; Synonyms=PAF400; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION, RP SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1. RC TISSUE=Cervix carcinoma; RX PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8; RA McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.; RT "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc RT and E2F oncoproteins."; RL Cell 94:363-374(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344; RP 369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820; RP 1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726; RP 2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND RP IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L; RP TAF10; SUPT3H; TAF12 AND TAF9. RC TISSUE=Fetal heart; RX PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9; RA Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., RA Nakatani Y.; RT "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the RT ATM superfamily."; RL Mol. Cell 2:869-875(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [6] RP SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H; RP GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001; RA Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M., RA Kundu T.K., Chait B.T., Roeder R.G.; RT "Human STAGA complex is a chromatin-acetylating transcription coactivator RT that interacts with pre-mRNA splicing and DNA damage-binding factors in RT vivo."; RL Mol. Cell. Biol. 21:6782-6795(2001). RN [7] RP IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H; RP TAF2; TAF4; TAF5; GCN5L2 AND TAF10. RX PubMed=10373431; DOI=10.1074/jbc.274.26.18285; RA Brand M., Yamamoto K., Staub A., Tora L.; RT "Identification of TATA-binding protein-free TAFII-containing complex RT subunits suggests a role in nucleosome acetylation and signal RT transduction."; RL J. Biol. Chem. 274:18285-18289(1999). RN [8] RP IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2. RX PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9; RA Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., RA Scully R., Qin J., Nakatani Y.; RT "Involvement of the TIP60 histone acetylase complex in DNA repair and RT apoptosis."; RL Cell 102:463-473(2000). RN [9] RP INTERACTION WITH GCN5L2. RX PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000; RA McMahon S.B., Wood M.A., Cole M.D.; RT "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 RT to c-Myc."; RL Mol. Cell. Biol. 20:556-562(2000). RN [10] RP INTERACTION WITH E2F1 AND E2F4, AND FUNCTION. RX PubMed=11418595; DOI=10.1074/jbc.m102067200; RA Lang S.E., McMahon S.B., Cole M.D., Hearing P.; RT "E2F transcriptional activation requires TRRAP and GCN5 cofactors."; RL J. Biol. Chem. 276:32627-32634(2001). RN [11] RP DOMAIN. RX PubMed=11445536; DOI=10.1101/gad.900101; RA Park J., Kunjibettu S., McMahon S.B., Cole M.D.; RT "The ATM-related domain of TRRAP is required for histone acetyltransferase RT recruitment and Myc-dependent oncogenesis."; RL Genes Dev. 15:1619-1624(2001). RN [12] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002; RA Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E., RA McMahon S.B.; RT "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP RT acetyltransferase complexes."; RL Mol. Cell. Biol. 22:5650-5661(2002). RN [13] RP IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4. RX PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002; RA Park J., Wood M.A., Cole M.D.; RT "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc- RT interacting nuclear cofactor for oncogenic transformation."; RL Mol. Cell. Biol. 22:1307-1316(2002). RN [14] RP FUNCTION. RX PubMed=12743606; DOI=10.1038/sj.onc.1206376; RA Lang S.E., Hearing P.; RT "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone RT acetyltransferase complex."; RL Oncogene 22:2836-2841(2003). RN [15] RP FUNCTION. RX PubMed=12660246; DOI=10.1074/jbc.m211795200; RA Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.; RT "c-Myc transformation domain recruits the human STAGA complex and requires RT TRRAP and GCN5 acetylase activity for transcription activation."; RL J. Biol. Chem. 278:20405-20412(2003). RN [16] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE RP NUA4 COMPLEX. RX PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004; RA Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.; RT "Structural and functional conservation of the NuA4 histone RT acetyltransferase complex from yeast to humans."; RL Mol. Cell. Biol. 24:1884-1896(2004). RN [17] RP IDENTIFICATION IN STAGA COMPLEX. RX PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011; RA Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S., RA Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G., RA Schuele R., Takeyama K., Kato S., Tora L., Devys D.; RT "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, RT coactivates nuclear receptors, and counteracts heterochromatin silencing."; RL Mol. Cell 29:92-101(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT. RX PubMed=17967892; DOI=10.1128/mcb.00607-07; RA DeRan M., Pulvino M., Greene E., Su C., Zhao J.; RT "Transcriptional activation of histone genes requires NPAT-dependent RT recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S RT phase transition."; RL Mol. Cell. Biol. 28:435-447(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [22] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF RP VARIANT PHE-722. RX PubMed=21499247; DOI=10.1038/ng.810; RA Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S., RA Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S., RA Rosenberg S.A., Samuels Y.; RT "Exome sequencing identifies GRIN2A as frequently mutated in melanoma."; RL Nat. Genet. 43:442-446(2011). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [29] RP FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX. RX PubMed=24463511; DOI=10.1038/nature12922; RA Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., RA Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C., RA Hamiche A.; RT "ANP32E is a histone chaperone that removes H2A.Z from chromatin."; RL Nature 505:648-653(2014). RN [30] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724; RP VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690; RP ASP-2750; GLU-2801 AND MET-2931. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [32] RP INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004. RX PubMed=30424743; DOI=10.1186/s12881-018-0711-9; RA Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S., RA Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J., RA Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.; RT "De novo variant of TRRAP in a patient with very early onset psychosis in RT the context of non-verbal learning disability and obsessive-compulsive RT disorder: a case report."; RL BMC Med. Genet. 19:197-197(2018). RN [33] RP VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037; RP THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866; RP ARG-1866; ARG-1883; LEU-1932 AND GLN-3757. RX PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010; RG CAUSES Study; RG Deciphering Developmental Disorders study; RA Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T., RA Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R., RA Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A., RA Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T., RA Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M., RA Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H., RA Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P., RA Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J., RA Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A., RA Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E., RA Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R., RA Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N., RA Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A., RA Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X., RA Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K., RA Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R., RA Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S., RA Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S., RA Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B., RA Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y., RA Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S., RA Campeau P.M.; RT "Missense Variants in the Histone Acetyltransferase Complex Component Gene RT TRRAP Cause Autism and Syndromic Intellectual Disability."; RL Am. J. Hum. Genet. 104:530-541(2019). RN [34] RP VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN RP DFNA75. RX PubMed=31231791; DOI=10.1111/cge.13590; RA Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.; RT "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing RT loss."; RL Clin. Genet. 96:300-308(2019). CC -!- FUNCTION: Adapter protein, which is found in various multiprotein CC chromatin complexes with histone acetyltransferase activity (HAT), CC which gives a specific tag for epigenetic transcription activation. CC Component of the NuA4 histone acetyltransferase complex which is CC responsible for acetylation of nucleosomal histones H4 and H2A. Plays a CC central role in MYC transcription activation, and also participates in CC cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4- CC mediated transcription activation. Also involved in transcription CC activation mediated by the adenovirus E1A, a viral oncoprotein that CC deregulates transcription of key genes. Probably acts by linking CC transcription factors such as E1A, MYC or E2F1 to HAT complexes such as CC STAGA thereby allowing transcription activation. Probably not required CC in the steps following histone acetylation in processes of CC transcription activation. May be required for the mitotic checkpoint CC and normal cell cycle progression. Component of a SWR1-like complex CC that specifically mediates the removal of histone H2A.Z/H2AZ1 from the CC nucleosome. May play a role in the formation and maintenance of the CC auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}. CC -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors. CC Interacts directly with p53/TP53. Interacts with GCN5L2. Component of CC various HAT complexes. Component of the PCAF complex, at least composed CC of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65- CC alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component CC of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L, CC SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5, CC TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase CC complex which contains the catalytic subunit KAT5/TIP60 and the CC subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, CC RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, CC MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of CC the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L, CC TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core CC complex is associated with a subcomplex required for histone CC deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the CC BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and CC TRRAP, which preferentially acetylates histone H4 (and H2A) within CC nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1. CC Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431, CC ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738, CC ECO:0000269|PubMed:9885574}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:9708738}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9Y4A5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103; CC -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT CC complexes, and the MYC-dependent transactivation. Although it is CC strongly related to the PI3/PI4-kinase family, it lacks the typical CC motifs that constitute the catalytic site of PI3/PI4-kinase proteins, CC and lacks such activity. {ECO:0000269|PubMed:11445536}. CC -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in CC cutaneous malignant melanoma, suggesting that TRRAP may play a role in CC the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}. CC -!- DISEASE: Developmental delay with or without dysmorphic facies and CC autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental CC disorder apparent from infancy or early childhood. Some patients CC present with intellectual disability and renal, cardiac, genitourinary CC systems, as well as structural brain abnormalities. In some cases, the CC phenotype is less severe, has no systemic involvement and is CC characterized by autism spectrum disorder and/or intellectual CC disability, sometimes associated with epilepsy. Affected individuals CC manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743, CC ECO:0000269|PubMed:30827496}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form CC of non-syndromic deafness characterized by late-onset hearing loss that CC involves mid and high frequencies, and progresses to encompass all CC frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF076974; AAD09420.1; -; mRNA. DR EMBL; AF110377; AAD04629.1; -; mRNA. DR EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA. DR EMBL; AC004991; AAC27675.2; -; Genomic_DNA. DR EMBL; CH471091; EAW76694.1; -; Genomic_DNA. DR EMBL; CH236956; EAL23887.1; -; Genomic_DNA. DR CCDS; CCDS5659.1; -. [Q9Y4A5-2] DR CCDS; CCDS59066.1; -. [Q9Y4A5-1] DR PIR; T02632; T02632. DR RefSeq; NP_001231509.1; NM_001244580.2. [Q9Y4A5-1] DR RefSeq; NP_003487.1; NM_003496.4. [Q9Y4A5-2] DR PDB; 7KTR; EM; 2.93 A; A=369-3859. DR PDB; 8H7G; EM; 3.70 A; C=1-3859. DR PDB; 8QRI; EM; 3.50 A; C=1-3859. DR PDB; 8XVG; EM; 9.40 A; L=1-3859. DR PDB; 8XVV; EM; 3.20 A; L=1-3859. DR PDB; 9C47; EM; 3.40 A; C=1-3859. DR PDB; 9CAD; EM; 3.05 A; D=1-3859. DR PDB; 9CAF; EM; 2.35 A; D=1-3859. DR PDBsum; 7KTR; -. DR PDBsum; 8H7G; -. DR PDBsum; 8QRI; -. DR PDBsum; 8XVG; -. DR PDBsum; 8XVV; -. DR PDBsum; 9C47; -. DR PDBsum; 9CAD; -. DR PDBsum; 9CAF; -. DR EMDB; EMD-18612; -. DR EMDB; EMD-18613; -. DR EMDB; EMD-18618; -. DR EMDB; EMD-18619; -. DR EMDB; EMD-34520; -. DR EMDB; EMD-38703; -. DR EMDB; EMD-38720; -. DR EMDB; EMD-45176; -. DR EMDB; EMD-45387; -. DR EMDB; EMD-45389; -. DR SMR; Q9Y4A5; -. DR BioGRID; 113900; 797. DR ComplexPortal; CPX-6802; SAGA complex, KAT2B variant. DR ComplexPortal; CPX-900; SAGA complex, KAT2A variant. DR ComplexPortal; CPX-903; TFTC histone acetylation complex. DR ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex. DR ComplexPortal; CPX-989; PCAF histone acetylase complex. DR CORUM; Q9Y4A5; -. DR DIP; DIP-28149N; -. DR FunCoup; Q9Y4A5; 1798. DR MINT; Q9Y4A5; -. DR STRING; 9606.ENSP00000352925; -. DR GlyGen; Q9Y4A5; 9 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (5 sites). DR iPTMnet; Q9Y4A5; -. DR MetOSite; Q9Y4A5; -. DR PhosphoSitePlus; Q9Y4A5; -. DR SwissPalm; Q9Y4A5; -. DR BioMuta; TRRAP; -. DR DMDM; 116242829; -. DR jPOST; Q9Y4A5; -. DR MassIVE; Q9Y4A5; -. DR PaxDb; 9606-ENSP00000352925; -. DR PeptideAtlas; Q9Y4A5; -. DR ProteomicsDB; 86142; -. [Q9Y4A5-1] DR ProteomicsDB; 86143; -. [Q9Y4A5-2] DR Pumba; Q9Y4A5; -. DR Antibodypedia; 16027; 189 antibodies from 23 providers. DR DNASU; 8295; -. DR Ensembl; ENST00000355540.7; ENSP00000347733.3; ENSG00000196367.15. [Q9Y4A5-2] DR Ensembl; ENST00000359863.8; ENSP00000352925.4; ENSG00000196367.15. [Q9Y4A5-1] DR GeneID; 8295; -. DR KEGG; hsa:8295; -. DR UCSC; uc003upp.3; human. [Q9Y4A5-1] DR AGR; HGNC:12347; -. DR ClinPGx; PA37020; -. DR CTD; 8295; -. DR DisGeNET; 8295; -. DR GeneCards; TRRAP; -. DR HGNC; HGNC:12347; TRRAP. DR HPA; ENSG00000196367; Low tissue specificity. DR MalaCards; TRRAP; -. DR MIM; 603015; gene. DR MIM; 618454; phenotype. DR MIM; 618778; phenotype. DR OpenTargets; ENSG00000196367; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000196367; -. DR eggNOG; KOG0889; Eukaryota. DR GeneTree; ENSGT00390000017961; -. DR InParanoid; Q9Y4A5; -. DR OrthoDB; 5570127at2759; -. DR PAN-GO; Q9Y4A5; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y4A5; -. DR PathwayCommons; Q9Y4A5; -. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3214847; HATs acetylate histones. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR SignaLink; Q9Y4A5; -. DR SIGNOR; Q9Y4A5; -. DR Agora; ENSG00000196367; -. DR BioGRID-ORCS; 8295; 773 hits in 1197 CRISPR screens. DR ChiTaRS; TRRAP; human. DR GenomeRNAi; 8295; -. DR Pharos; Q9Y4A5; Tbio. DR PRO; PR:Q9Y4A5; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9Y4A5; protein. DR Bgee; ENSG00000196367; Expressed in ventricular zone and 156 other cell types or tissues. DR ExpressionAtlas; Q9Y4A5; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000786; C:nucleosome; IDA:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000124; C:SAGA complex; IDA:UniProtKB. DR GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB. DR GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB. DR GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB. DR GO; GO:0140861; P:DNA repair-dependent chromatin remodeling; IBA:GO_Central. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal. DR GO; GO:0042981; P:regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0043484; P:regulation of RNA splicing; NAS:ComplexPortal. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd05163; PIKK_TRRAP; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR046807; Tra1_central. DR InterPro; IPR046805; Tra1_ring. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF1; TRANSFORMATION_TRANSCRIPTION DOMAIN-ASSOCIATED PROTEIN; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF20175; Tra1_central; 1. DR Pfam; PF20206; Tra1_ring; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Autism spectrum disorder; Chromatin regulator; Deafness; KW Direct protein sequencing; Disease variant; Intellectual disability; KW Isopeptide bond; Non-syndromic deafness; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3859 FT /note="Transformation/transcription domain-associated FT protein" FT /id="PRO_0000088851" FT DOMAIN 2692..3275 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 3500..3823 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3827..3859 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 491..541 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2010..2388 FT /note="Interaction with TP53" FT /evidence="ECO:0000269|PubMed:12138177" FT REGION 2023..2044 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2543..2578 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3506..3512 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3687..3695 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3707..3732 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 2047..2062 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 491..526 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 529..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2033..2044 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2543..2554 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 1628 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2051 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163" FT MOD_RES 2077 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3078 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 2543 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1492..1509 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009102" FT VAR_SEQ 3001..3012 FT /note="GKPTWSGMHSSS -> A (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009103" FT VARIANT 171 FT /note="R -> C (in DFNA75; uncertain significance; FT dbSNP:rs200157211)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083794" FT VARIANT 394 FT /note="D -> N (in DFNA75; uncertain significance; FT dbSNP:rs1554407965)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083795" FT VARIANT 722 FT /note="S -> F (found in a cutaneous malignant melanoma FT sample; somatic mutation; induces cell transformation and FT confers resistance to apoptosis; dbSNP:rs147405090)" FT /evidence="ECO:0000269|PubMed:21499247" FT /id="VAR_067754" FT VARIANT 805 FT /note="L -> F (in DEDDFA; uncertain significance; FT dbSNP:rs1562940289)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082969" FT VARIANT 860 FT /note="F -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082970" FT VARIANT 878 FT /note="R -> L (in dbSNP:rs17161510)" FT /id="VAR_028359" FT VARIANT 893 FT /note="R -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041658" FT VARIANT 893 FT /note="R -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082971" FT VARIANT 1031 FT /note="I -> M (in DEDDFA; dbSNP:rs1187165148)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082972" FT VARIANT 1035 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs2116495143)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082973" FT VARIANT 1037 FT /note="S -> R (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082974" FT VARIANT 1043 FT /note="A -> T (in DEDDFA; dbSNP:rs1562945106)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082975" FT VARIANT 1070 FT /note="S -> G (in dbSNP:rs55920979)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041659" FT VARIANT 1104 FT /note="E -> G (in DEDDFA; dbSNP:rs1790257064)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082976" FT VARIANT 1106 FT /note="E -> K (in DEDDFA; dbSNP:rs1584324956)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082977" FT VARIANT 1111 FT /note="G -> W (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082978" FT VARIANT 1159 FT /note="G -> R (in DEDDFA; dbSNP:rs1790288810)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082979" FT VARIANT 1669 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373632999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041660" FT VARIANT 1724 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs782203759)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041661" FT VARIANT 1859 FT /note="R -> C (in DEDDFA; dbSNP:rs1791432323)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082980" FT VARIANT 1866 FT /note="W -> C (in DEDDFA; uncertain significance; FT dbSNP:rs1562957576)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082981" FT VARIANT 1866 FT /note="W -> R (in DEDDFA; dbSNP:rs1562957569)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082982" FT VARIANT 1883 FT /note="G -> R (in DEDDFA)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082983" FT VARIANT 1925 FT /note="A -> V (in dbSNP:rs56197298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041662" FT VARIANT 1932 FT /note="P -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:30827496" FT /id="VAR_041663" FT VARIANT 1947 FT /note="R -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041664" FT VARIANT 2004 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs1562959030)" FT /evidence="ECO:0000269|PubMed:30424743" FT /id="VAR_082984" FT VARIANT 2139 FT /note="W -> G (in dbSNP:rs34185633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041665" FT VARIANT 2302 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs528967912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041666" FT VARIANT 2433 FT /note="S -> G (in dbSNP:rs35634065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041667" FT VARIANT 2690 FT /note="P -> L (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs753661271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041668" FT VARIANT 2750 FT /note="E -> D (in dbSNP:rs55755466)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:31231791" FT /id="VAR_041669" FT VARIANT 2801 FT /note="K -> E (in dbSNP:rs56341061)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041670" FT VARIANT 2931 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1294404368)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041671" FT VARIANT 3757 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs987263983)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082985" FT CONFLICT 660 FT /note="E -> D (in Ref. 2; AAD04629)" FT /evidence="ECO:0000305" FT HELIX 20..26 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 30..33 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 37..50 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 55..57 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 59..74 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 80..84 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 85..99 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 128..139 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 148..171 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 214..227 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 244..254 FT /evidence="ECO:0007829|PDB:9C47" FT TURN 255..259 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 276..293 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 294..298 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 307..319 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 325..338 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 342..345 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 347..351 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 365..367 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 371..385 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 387..389 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 392..406 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 413..434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 442..469 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 535..564 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 583..599 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 600..604 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 605..607 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 613..615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 627..639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 657..664 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 669..677 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 679..681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 682..695 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 698..702 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 704..723 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 725..732 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 736..747 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 774..779 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 780..782 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 783..795 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 821..827 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 828..835 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 839..855 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 858..865 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 869..879 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 885..898 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 899..903 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 923..927 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 934..938 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 940..951 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 952..955 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 957..973 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 981..988 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 992..995 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1005..1007 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1013..1029 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1032..1034 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1035..1057 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1058..1061 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1064..1066 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1067..1069 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1074..1076 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1080..1082 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1085..1087 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1091..1101 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1102..1104 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1107..1126 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1129..1132 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1136..1146 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1147..1150 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1151..1153 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1154..1170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1173..1193 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1194..1196 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1199..1201 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1202..1218 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1223..1225 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1228..1248 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1254..1271 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1275..1279 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1280..1285 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1287..1289 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1297..1299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1302..1315 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1317..1320 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1327..1329 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1330..1344 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1347..1351 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1354..1357 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1360..1362 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1363..1375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1376..1378 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1380..1382 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1383..1394 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1399..1413 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1415..1418 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1420..1431 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1435..1437 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1442..1454 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1456..1458 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1461..1484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1511..1523 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1524..1526 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1529..1531 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1532..1546 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1549..1551 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1555..1562 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1576..1579 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1582..1592 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1594..1596 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1598..1605 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1609..1612 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1613..1615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1638..1653 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1657..1659 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1661..1672 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1674..1681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1692..1706 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1707..1709 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1710..1715 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1716..1718 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1723..1725 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1728..1738 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1740..1743 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1746..1748 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1749..1758 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1760..1766 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1770..1773 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1774..1776 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1777..1786 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1804..1813 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1818..1820 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1828..1841 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1846..1853 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1854..1859 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1861..1870 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1877..1893 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1900..1911 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1913..1915 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1921..1925 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1928..1931 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1950..1964 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1966..1970 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1972..1974 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1976..1985 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1990..2000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2003..2016 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2021..2026 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2031..2042 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2045..2060 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2064..2073 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2077..2088 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2096..2099 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2105..2111 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2114..2118 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2120..2133 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2139..2141 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2146..2154 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2155..2157 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2158..2161 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2165..2182 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2184..2189 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2191..2200 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 2201..2203 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2205..2207 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 2212..2219 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2226..2232 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2233..2235 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2240..2251 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2257..2273 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2278..2286 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2287..2290 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2292..2294 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2295..2299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2301..2312 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2320..2331 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2340..2357 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2361..2375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2382..2384 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2389..2406 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2411..2426 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2429..2434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2435..2439 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2440..2448 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2452..2464 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2470..2478 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2483..2486 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2492..2500 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2506..2508 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2514..2516 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2523..2527 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2530..2538 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2586..2602 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2607..2618 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2622..2639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2642..2656 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2659..2666 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2671..2679 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2682..2684 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2690..2699 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2703..2714 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2718..2720 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2728..2730 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2742..2755 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2758..2768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2772..2781 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2782..2784 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2786..2806 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2811..2813 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2814..2830 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2834..2841 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2844..2847 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2849..2856 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2857..2859 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2862..2872 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2873..2875 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2878..2880 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2881..2894 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2904..2919 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2928..2930 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2931..2952 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2955..2957 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2961..2976 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2985..3000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3012..3020 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3028..3051 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3054..3062 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3063..3066 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3072..3089 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3090..3092 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3095..3106 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3115..3131 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3132..3134 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3135..3148 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3153..3170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3173..3186 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3192..3195 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3196..3205 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3206..3208 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3214..3222 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3224..3226 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 3228..3234 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3235..3242 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3247..3260 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3262..3283 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3284..3286 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3295..3310 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3312..3324 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3325..3328 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3332..3354 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3355..3358 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3365..3376 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3396..3407 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3411..3423 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3429..3432 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3434..3452 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3457..3460 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3461..3463 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3466..3470 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3473..3475 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3481..3484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3489..3491 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3495..3499 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3501..3507 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3509..3520 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3525..3531 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3536..3552 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3553..3557 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3562..3565 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3574..3578 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3581..3585 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3588..3592 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3593..3604 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3610..3625 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3631..3644 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3650..3658 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3662..3685 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3693..3695 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3696..3699 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3700..3702 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3705..3708 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3716..3718 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3719..3721 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3726..3729 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3733..3739 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3741..3745 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3747..3759 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3762..3764 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3766..3789 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3798..3800 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3804..3826 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3829..3831 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3834..3842 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3845..3848 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3853..3855 FT /evidence="ECO:0007829|PDB:7KTR" SQ SEQUENCE 3859 AA; 437600 MW; 391E467C0047B00B CRC64; MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA AANSLDNLCR MDPAWHPWL //